id,llm_model_name,edge,context_input_data,schema_dep_validity,verb,num_options,correct,prompt,reasoning,evidences,answer,answer_choice_probablities,critique_consistent,critique_answer,critique_reasoning
0,gpt-4o,"Location_of_Lymph_Nodes_3,N_State_1","""{'NODE1': {'id': 'Location_of_Lymph_Nodes_3', 'label': 'Location of Lymph Nodes', 'description': 'This node represents the presence or absence of lymph nodes in a specific location, which is crucial for cancer diagnosis and staging. The detection of lymph nodes can indicate the spread of cancer and affect treatment decisions.', 'type': 'Patient Situation', 'observability': 'Unobserved', 'states': [{'state_name': 'present', 'state_description': 'Lymph nodes are detected in the specified location, which may indicate the spread of cancer and is important for staging and treatment planning.'}, {'state_name': 'absent', 'state_description': 'Lymph nodes are not detected in the specified location, which may suggest no spread of cancer to this area and is important for staging and treatment planning.'}]}, 'NODE2': {'id': 'N_State_1', 'label': 'Nearby Lymph Nodes Cancer State', 'description': 'This node represents the clinical situation regarding the presence or absence of cancer in nearby lymph nodes. It is a critical factor in cancer staging and prognosis, as the involvement of lymph nodes can indicate the spread of cancer and affect treatment decisions.', 'type': 'Decision Node', 'observability': 'Needs to be Predicted', 'states': [{'state_name': 'present', 'state_description': 'Cancer is present in the nearby lymph nodes, indicating potential metastasis and a more advanced stage of cancer.'}, {'state_name': 'absent', 'state_description': 'Cancer is absent in the nearby lymph nodes, suggesting that the cancer has not spread to these nodes and may be in an earlier stage.'}]}, 'EDGE1': {'edges_ids': ['Location_of_Lymph_Nodes_3', 'N_State_1'], 'edge': '(Location_of_Lymph_Nodes_3) causes (N_State_1)', 'explanation': ['The edge represents the relationship between the presence of lymph nodes in a specific location and the state of cancer in nearby lymph nodes.', 'The presence of lymph nodes in a specific location can indicate the spread of cancer, which directly affects the state of cancer in nearby lymph nodes.', 'This relationship is important for cancer staging and treatment decisions, as the involvement of lymph nodes is a critical factor in determining the stage and prognosis of cancer.'], 'causal_direction': 'positive', 'causal_factor': {'necessary': False, 'sufficient': False}, 'causal_distance': 'Proximal'}, 'EDGE2': {'edges_ids': ['N_State_1', 'Location_of_Lymph_Nodes_3'], 'edge': '(N_State_1) causes (Location_of_Lymph_Nodes_3)', 'explanation': ['The edge suggests that the cancer state of nearby lymph nodes (N_State_1) causes the presence or absence of lymph nodes in a specific location (Location_of_Lymph_Nodes_3).', 'However, the anatomical presence of lymph nodes in a specific location is not caused by the cancer state of nearby lymph nodes.', 'The cancer state might influence clinical decisions or the interpretation of lymph node findings, but it does not cause the anatomical presence or absence of lymph nodes.', 'Thus, the edge is not valid as a causal relationship.'], 'causal_direction': 'Unknown', 'causal_factor': {'necessary': False, 'sufficient': False}, 'causal_distance': 'Unknown'}, 'ENTITIES_MATCHING_PAGES_INFO': {'102': {'matching_entities': [{'LYMPHATIC SYSTEM': 0.95855314}, {'LYMPHATIC STRUCTURE': 0.9469132}, {'METASTASIS': 0.9401313}, {'CANCER STAGING': 0.93824553}, {'TUMOR': 0.9323624}, {'STAGING': 0.9208425}], 'count': 6}, '55': {'matching_entities': [{'MALIGNANT NEOPLASTIC DISEASE': 0.97725874}, {'METASTASIS': 0.9401313}, {'CANCER': 0.9363244}, {'METASTATIC NEOPLASM': 0.9314138}, {'NEOPLASM METASTASIS': 0.9250777}, {'LARYNGEAL NEOPLASMS': 0.9236878}], 'count': 6}, '51': {'matching_entities': [{'MALIGNANT NEOPLASM': 0.9774111}, {'CANCER STAGING': 0.93824553}, {'CANCER': 0.9363244}, {'LARYNGEAL NEOPLASMS': 0.9236878}, {'NEOPLASM INVASIVENESS': 0.92347366}], 'count': 5}, '130': {'matching_entities': [{'LYMPH NODE STRUCTURE': 0.99134904}, {'LYMPH NODE': 0.98570025}, {'LYMPH NODES': 0.97445965}, {'METASTASIS': 0.9401313}, {'NEOPLASM METASTASIS': 0.9250777}], 'count': 5}, '47': {'matching_entities': [{'MALIGNANT NEOPLASM': 0.9774111}, {'LARYNGEAL CANCER': 0.95521915}, {'CANCER': 0.9363244}, {'LARYNGEAL NEOPLASMS': 0.9236878}], 'count': 4}}, 'GUIDELINE_PAGES_INFO': '--------------------------------------------------\\nPage Number: 102\\n\\nSection Name: Head and Neck Cancers - Principles of Surgery\\n====================\\nEntities:-\\nSurgical Procedures, Operative : Manual or operative procedures used in the treatment of disease, injuries, or deformities.\\nLymphatic System : Part of the circulatory system and a vital part of the immune system, comprising a network of lymphatic vessels that carry a clear fluid called lymph.\\nNeoplasms : New abnormal growth of tissue in animals or plants; a tumor.\\nNeck Dissection : A surgical procedure for control of neck lymph node metastasis from squamous cell carcinoma of the head and neck.\\nNeoplasm Staging : Methods which attempt to express in replicable terms the extent of the neoplasm in the patient.\\nMetastasis : The spread of a cancer or other disease from one organ or part of the body to another not directly connected with it.\\nSurgical Procedure : A procedure involving an incision with instruments; performed to repair damage or arrest disease in a living body.\\nLymphatic Structure : Anatomical structure that is part of the lymphatic system.\\nTumor : An abnormal mass of tissue that results when cells divide more than they should or do not die when they should.\\nStaging : The process of determining the size and spread of cancer within the body.\\nSurgery : Medical specialty that uses operative manual and instrumental techniques on a patient to investigate or treat a pathological condition such as disease or injury.\\nCancer Staging : The process of determining the extent to which a cancer has developed by growing and spreading.\\n\\nRelationships:-\\n1. Entity1: \""surgical management\"", Entity2: \""regional lymphatics\"", Relationship: \""dictated by tumor staging\""\\n2. Entity1: \""neck dissections\"", Entity2: \""primary tumor\"", Relationship: \""part of treatment\""\\n3. Entity1: \""surgery\"", Entity2: \""ipsilateral side of the neck\"", Relationship: \""risk for metastases\""\\n\\nCausalities:-\\n<C> The extent of the tumor at initial tumor staging </C> <E> dictates the surgical management of regional lymphatics </E>. These guidelines apply to the performance of neck dissections as part of treatment of the primary tumor. <CO> Patients undergoing surgery for resection of the primary tumor </CO> <A> will undergo dissection of the ipsilateral side of the neck that is at greatest risk for metastases </A>.\\n\\nSection Name: Neck Management\\n====================\\nEntities:-\\nTongue : A muscular organ in the mouth that is involved in tasting, swallowing, and speech.\\nPalate : The roof of the mouth, separating the oral and nasal cavities.\\nLarynx : An organ in the top of the neck involved in breathing, producing sound, and protecting the trachea.\\nHypopharynx : The bottom part of the pharynx, which is the cavity behind the nose and mouth.\\nNasopharynx : The upper part of the pharynx, connecting with the nasal cavity above the soft palate.\\nNeck Dissection : A surgical procedure for control of neck lymph node metastasis from squamous cell carcinoma of the head and neck.\\nMetastasis : The spread of a cancer or other disease from one organ or part of the body to another not directly connected with it.\\nSquamous Cell Carcinoma : A type of cancer that begins in the squamous cells, which are thin, flat cells that look like fish scales.\\nBiopsy : The removal of cells or tissues for examination under a microscope.\\n\\nRelationships:-\\n1. Entity1: \""Tumor sites\"", Entity2: \""Bilateral lymphatic drainage\"", Relationship: \""associated with\""\\n2. Entity1: \""Elective neck dissection\"", Entity2: \""Risk of occult metastasis\"", Relationship: \""based on\""\\n3. Entity1: \""SLN biopsy\"", Entity2: \""Elective neck dissection\"", Relationship: \""guides decision-making for\""\\n\\nCausalities:-\\n- **<C> Tumor sites that frequently have bilateral lymphatic drainage </C>** (e.g., base of tongue, palate, supraglottic larynx, hypopharynx, nasopharynx, deep pre-epiglottic space involvement) <E> often should have both sides of the neck dissected </E> with the extent of dissection determined as suggested below. For those patients with tumors at or approaching the midline, <CO> both sides of the neck are at risk for metastases </CO>, and <A> bilateral neck dissections should be performed </A>.\\n\\n- <CO> Patients with advanced lesions involving the anterior tongue, floor of the mouth, or alveolus that approximate or cross the midline </CO> <A> should undergo contralateral selective/modified neck dissection </A> as necessary to achieve adequate tumor resection.\\n\\n- **<C> Elective neck dissection </C>** <A> should be based on risk of occult metastasis in the appropriate nodal basin </A>. For oral cavity squamous cell carcinoma, <C> SLN biopsy or the primary tumor depth of invasion </C> is currently <E> the best predictor of occult metastatic disease </E> and <A> should be used to guide decision-making </A>. <CO> For tumors with a depth greater than 3 mm </CO>, <A> elective dissection should be strongly considered if RT is not already planned </A>. Recent randomized trial evidence supports the effectiveness of elective neck dissection in patients with oral cavity cancers greater than 3 mm in depth of invasion.\\n\\n  - <CO> For a depth less than 2 mm </CO>, <A> elective dissection is only indicated in highly selective situations </A>. <CO> For a depth of 2\u20134 mm </CO>, <A> clinical judgment (as to reliability of follow-up, clinical suspicion, and other factors) must be utilized to determine appropriateness of elective dissection </A>. Elective dissections are generally selective, preserving all major structures, unless operative findings dictate otherwise.\\n\\nSection Name: Types of Neck Dissection\\n====================\\nEntities:-\\nNeck Dissection : A surgical procedure for control of neck lymph node metastasis from squamous cell carcinoma of the head and neck.\\nLarynx : An organ in the top of the neck involved in breathing, producing sound, and protecting the trachea.\\n\\nRelationships:-\\n1. Entity1: \""N0\"", Entity2: \""Selective neck dissection\"", Relationship: \""associated with\""\\n2. Entity1: \""N3\"", Entity2: \""Comprehensive neck dissection\"", Relationship: \""associated with\""\\n3. Entity1: \""Level VI neck dissection\"", Entity2: \""Larynx\"", Relationship: \""performed for\""\\n4. Entity1: \""Level VI neck dissection\"", Entity2: \""Hypopharynx\"", Relationship: \""performed for\""\\n\\nCausalities:-\\n- **The type of neck dissection (comprehensive or selective)** is defined according to <CO> preoperative clinical staging </CO>, is determined at the discretion of the surgeon, and is based on the initial preoperative staging as follows:\\n  - **N0:** <A> Selective neck dissection </A>\\n    - Oral cavity at least levels I\u2013III\\n    - Oropharynx at least levels II\u2013IV\\n    - Hypopharynx at least levels II\u2013IV and level VI when appropriate\\n    - Larynx at least levels II\u2013IV and level VI when appropriate\\n  - **N1\u2013N2a\u2013c:** <A> Selective or comprehensive neck dissection </A> (Discussion)\\n  - **N3:** <A> Comprehensive neck dissection </A>\\n\\n- <C> Level VI neck dissections are performed for certain primary sites (such as the larynx and hypopharynx) </C> <E> as required to resect the primary tumor and any clinically evident neck nodes </E>. <CO> Elective dissection depends on primary tumor extent and site </CO>. <CO> For advanced glottic and hypopharyngeal cancers treated with primary surgery </CO>, <A> a level VI dissection (including pretracheal lymph nodes, the Delphian lymph node, and unilateral or bilateral paratracheal lymph nodes) and hemithyroidectomy to total thyroidectomy are appropriate </A>.\\n\\n- <CO> For primary subglottic tumors or glottic cancers with significant subglottic extension </CO>, <A> a level VI dissection with unilateral or total thyroidectomy is considered appropriate </A> based on the extent of the primary tumor. <CO> For example, a T4a glottic tumor with extension through the cricothyroid membrane and subglottic extension </CO> <A> should include thyroidectomy and pretracheal and bilateral paratracheal lymph node dissection </A>. <A> Parathyroid glands should be preserved in situ or auto transplanted as indicated </A>.\\n--------------------------------------------------\\nPage Number: 55\\n\\nSection Name: General Information\\n====================\\nEntities:-\\nNational Comprehensive Cancer Network : An alliance of 32 cancer centers in the United States, dedicated to improving the quality, effectiveness, and efficiency of cancer care.\\nNccn Guidelines : Clinical practice guidelines in oncology developed by the National Comprehensive Cancer Network.\\n\\nRelationships:-\\n1. Entity1: \""NCCN Guidelines\"", Entity2: \""National Comprehensive Cancer Network\"", Relationship: \""produced by\""\\n\\nSection Name: Important Notes\\n====================\\nEntities:-\\nClinical Trials As Topic : Works about research studies that evaluate the effectiveness and safety of medical, surgical, or behavioral interventions.\\nClinical Trial : A type of research that studies new tests and treatments and evaluates their effects on human health outcomes.\\nNational Comprehensive Cancer Network : An alliance of 32 cancer centers in the United States, dedicated to improving the quality, effectiveness, and efficiency of cancer care.\\nNeoplasms : New abnormal growth of tissue that can be benign or malignant.\\nMalignant Neoplastic Disease : A disease resulting from the growth of malignant neoplasms.\\nCancer : A group of diseases involving abnormal cell growth with the potential to invade or spread to other parts of the body.\\n\\nRelationships:-\\n1. Entity1: \""Clinical Trials\"", Entity2: \""Cancer\"", Relationship: \""recommended for\""\\n2. Entity1: \""NCCN\"", Entity2: \""Clinical Trials\"", Relationship: \""encourages participation in\""\\n\\nCausalities:-\\n<C> NCCN believes that the best management of any patient with cancer is in a clinical trial </C>. <A> Participation in clinical trials is especially encouraged </A>.\\n\\nSection Name: Principles\\n====================\\nEntities:-\\nSurgical Procedures, Operative : Surgical procedures involve the use of operative manual and instrumental techniques on a patient to investigate or treat a pathological condition such as disease or injury.\\nRadiation Therapy : Therapy using ionizing radiation, generally as part of cancer treatment to control or kill malignant cells.\\nChemotherapy : A type of cancer treatment that uses one or more anti-cancer drugs as part of a standardized chemotherapy regimen.\\n\\nRelationships:-\\n1. Entity1: \""Principles of Surgery\"", Entity2: \""Principles of Radiation Therapy\"", Relationship: \""Both are principles of cancer treatment methods.\""\\n2. Entity1: \""Principles of Surgery\"", Entity2: \""Principles of Systemic Therapy for Non-Nasopharyngeal Cancers\"", Relationship: \""Both are principles of cancer treatment methods.\""\\n3. Entity1: \""Principles of Radiation Therapy\"", Entity2: \""Principles of Systemic Therapy for Non-Nasopharyngeal Cancers\"", Relationship: \""Both are principles of cancer treatment methods.\""\\n\\nCausalities:-\\n### Principles\\n\\n- **Principles of Surgery (SURG-A)**\\n- **Principles of Radiation Therapy (SUPRA-A)**\\n- **Principles of Systemic Therapy for Non-Nasopharyngeal Cancers (SYST-A)**\\n\\nSection Name: Adverse Pathologic Features\\n====================\\nEntities:-\\nExtranodal Extension : The spread of cancer cells beyond the lymph node capsule into the surrounding tissues.\\nPositive Surgical Margin : The presence of cancer cells at the edge of the tissue removed during surgery, indicating that some cancer may have been left behind.\\nPerineural Invasion : The presence of cancer cells surrounding or tracking along a nerve within the perineural space.\\nVascular Invasion : The invasion of cancer cells into blood vessels.\\nLymphatic Invasion : The invasion of cancer cells into lymphatic vessels.\\n\\nRelationships:-\\n1. Entity1: \""Extranodal extension\"", Entity2: \""Adverse Pathologic Features\"", Relationship: \""is a type of\""\\n2. Entity1: \""Positive margins\"", Entity2: \""Adverse Pathologic Features\"", Relationship: \""is a type of\""\\n3. Entity1: \""Close margins\"", Entity2: \""Adverse Pathologic Features\"", Relationship: \""is a type of\""\\n4. Entity1: \""pT3 or pT4 primary\"", Entity2: \""Adverse Pathologic Features\"", Relationship: \""is a type of\""\\n5. Entity1: \""pN2 or pN3 nodal disease\"", Entity2: \""Adverse Pathologic Features\"", Relationship: \""is a type of\""\\n6. Entity1: \""Perineural invasion\"", Entity2: \""Adverse Pathologic Features\"", Relationship: \""is a type of\""\\n7. Entity1: \""Vascular invasion\"", Entity2: \""Adverse Pathologic Features\"", Relationship: \""is a type of\""\\n8. Entity1: \""Lymphatic invasion\"", Entity2: \""Adverse Pathologic Features\"", Relationship: \""is a type of\""\\n\\nCausalities:-\\n<C> Extranodal extension </C>\\n<C> Positive margins </C>\\n<C> Close margins </C>\\n<C> pT3 or pT4 primary </C>\\n<C> pN2 or pN3 nodal disease </C>\\n<C> Perineural invasion </C>\\n<C> Vascular invasion </C>\\n<C> Lymphatic invasion </C>\\n\\nSection Name: Response Assessment\\n====================\\nEntities:-\\nChemotherapy, Induction : Initial chemotherapy treatment to shrink a tumor before the main treatment.\\nPrimary Site : The original location where a tumor or cancer begins.\\nComplete Remission : The disappearance of all signs of cancer in response to treatment.\\nPartial Remission : A decrease in the size of a tumor, or in the extent of cancer in the body, in response to treatment.\\nRadiotherapy : The use of high-energy radiation to kill cancer cells and shrink tumors.\\nSurgical Procedures, Operative : Surgical procedures involve the use of operative manual and instrumental techniques on a patient to investigate or treat a pathological condition such as disease or injury.\\n\\nRelationships:-\\n1. Entity1: \""induction chemotherapy\"", Entity2: \""Primary site\"", Relationship: \""treatment outcome\""\\n2. Entity1: \""Definitive RT\"", Entity2: \""Primary site\"", Relationship: \""treatment option\""\\n3. Entity1: \""RT\"", Entity2: \""Primary site\"", Relationship: \""treatment option\""\\n4. Entity1: \""Surgery\"", Entity2: \""unresectable nodal disease\"", Relationship: \""treatment option\""\\n\\nCausalities:-\\n<C> Response after induction chemotherapy </C>: <E> Primary site: CR </E> <E> Primary site: PR </E> <E> Primary site: < PR </E> <A> Definitive RT </A> (category 1) <A> RT </A> (category 1) or <A> systemic therapy/RT </A> (category 2B) <A> Surgery </A> or <A> unresectable nodal disease </A>\\n\\nSection Name: Follow-up\\n====================\\nEntities:-\\nFollow-Up Studies : Studies in which individuals are followed over time to determine the outcome of exposures, treatments, or interventions.\\nFollow-Up Procedure : A procedure where a patient is monitored over time to assess the progress of a condition or the effects of treatment.\\nFollow-Up (Medicine) : The process of monitoring a patient\\'s health over time after treatment or diagnosis.\\nDisease Recurrence : The return of a sign, symptom, or disease after a remission.\\nRecurrent Disease : A disease that returns after a period of remission.\\nRecurrence (Medicine) : The return of a disease or condition after a period of improvement.\\n\\nRelationships:-\\n1. Entity1: \""Follow-up\"", Entity2: \""Recurrent or persistent disease\"", Relationship: \""monitoring\""\\n\\nCausalities:-\\n### Follow-up\\n\\n- **Follow-up** (FOLL-A, 1 of 2)\\n- **Recurrent or persistent disease** (ADV-3)\\n\\nSection Name: Risk Features\\n====================\\nEntities:-\\nRadiotherapy : The use of high-energy radiation to kill cancer cells and shrink tumors.\\nExtranodal Extension : The spread of cancer cells beyond the lymph node capsule into the surrounding tissues.\\nPositive Surgical Margin : The presence of cancer cells at the edge of the tissue removed during surgery, indicating that some cancer may have been left behind.\\nSystemic Therapy : Systemic therapy refers to treatment using substances that travel through the bloodstream, reaching and affecting cells all over the body.\\n\\nRelationships:-\\n1. Entity1: \""Adverse pathologic features\"", Entity2: \""RT\"", Relationship: \""Consideration for treatment\""\\n2. Entity1: \""Adverse pathologic features\"", Entity2: \""Systemic therapy\"", Relationship: \""Consideration for treatment\""\\n\\nCausalities:-\\n- **No adverse pathologic features**\\n- **Other risk features**\\n- **Adverse pathologic features**:\\n  - <C> Extranodal extension and/or positive margin </C>\\n  - <A> RT or consider systemic therapy/RT </A>\\n\\nSection Name: Post-Therapy Evaluation\\n====================\\nEntities:-\\nSystemic Therapy : Systemic therapy refers to treatment using substances that travel through the bloodstream, reaching and affecting cells all over the body.\\nRadiation Therapy : Therapy using ionizing radiation, generally as part of cancer treatment to control or kill malignant cells.\\nNeck : The neck is the part of the body that separates the head from the torso and provides the mobility and movements of the head.\\n\\nRelationships:-\\n1. Entity1: \""Systemic Therapy\"", Entity2: \""Neck Evaluation\"", Relationship: \""evaluated in\""\\n2. Entity1: \""RT\"", Entity2: \""Neck Evaluation\"", Relationship: \""evaluated in\""\\n\\nCausalities:-\\n<CO> Post Systemic Therapy/RT or RT Neck </CO> <A> Evaluation </A>\\n\\nSection Name: Flowchart Overview\\n====================\\nEntities:-\\nLaryngeal Neoplasms : Tumors or cancer of the larynx, which may affect the supraglottic, glottic, or subglottic regions.\\nSupraglottic Larynx : The part of the larynx located above the vocal cords, including the epiglottis and aryepiglottic folds.\\nNational Comprehensive Cancer Network : An alliance of 32 cancer centers in the United States, dedicated to improving the quality, effectiveness, and efficiency of cancer care.\\n\\nRelationships:-\\n1. Entity1: \""NCCN Guidelines\"", Entity2: \""cancer of the supraglottic larynx\"", Relationship: \""guides management of\""\\n2. Entity1: \""NCCN Guidelines\"", Entity2: \""healthcare professionals\"", Relationship: \""used by\""\\n\\nCausalities:-\\n<C> cancer of the supraglottic larynx </C> <E> evaluate patient responses following treatment </E> <CO> based on observed outcomes </CO> <A> evaluation of the primary site and determining subsequent steps </A>.\\n\\nSection Name: Assessment and Treatment Decisions\\n====================\\nEntities:-\\nInduction Chemotherapy : Initial chemotherapy treatment to shrink a tumor before the main treatment.\\nComplete Response : The disappearance of all signs of cancer in response to treatment.\\nPartial Response : A decrease in the size of a tumor, or in the extent of cancer in the body, in response to treatment.\\nRadiation Therapy : Therapy using ionizing radiation, generally as part of cancer treatment to control or kill malignant cells.\\nSurgery : Medical specialty that uses operative manual and instrumental techniques on a patient to investigate or treat a pathological condition such as disease or injury.\\nSystemic Therapy : Systemic therapy refers to treatment using substances that travel through the bloodstream, reaching and affecting cells all over the body.\\n\\nRelationships:-\\n1. Entity1: \""Complete Response\"", Entity2: \""Radiation Therapy\"", Relationship: \""leads to\""\\n2. Entity1: \""Complete Response\"", Entity2: \""Surgery\"", Relationship: \""leads to\""\\n3. Entity1: \""Partial Response\"", Entity2: \""Systemic Therapy\"", Relationship: \""leads to\""\\n4. Entity1: \""Partial Response\"", Entity2: \""Radiation Therapy\"", Relationship: \""leads to\""\\n\\nCausalities:-\\n<C> responses to initial treatments such as induction chemotherapy </C> <E> Three main response categories are recognized: Complete Response (CR), Partial Response (PR), and less than Partial Response (< PR) </E>. These categories are pivotal in determining the next steps. <C> CR </C> <E> indicates full resolution of the disease at the primary site </E>, <A> leading to the consideration of definitive radiation therapy or the likelihood of surgery </A>. Conversely, <C> PR </C> <E> suggests that the disease has improved but not completely resolved </E>, <A> which directs the pathway towards either systemic therapy or continued radiation therapy </A>, <A> with further evaluation necessary </A>.\\n\\nSection Name: Adverse Pathologic Features and Follow-up\\n====================\\nEntities:-\\nRadiation Therapy : Therapy using ionizing radiation, generally as part of cancer treatment to control or kill malignant cells.\\nSurgical Procedures, Operative : Surgical procedures involve the use of operative manual and instrumental techniques on a patient to investigate or treat a pathological condition such as disease or injury.\\nNeoplasm Recurrence, Local : The return of a tumor or cancer, at the original site, after it has been treated.\\nNeoplasm Metastasis : The transfer of a neoplasm from one organ or part of the body to another remote from the primary site.\\nSurgical Procedure : A medical procedure involving an incision with instruments; performed to repair damage or arrest disease in a living body.\\nRecurrent Neoplasm : A neoplasm that has returned after treatment.\\nMetastatic Neoplasm : A neoplasm that has spread from its original site to one or more other places in the body.\\nSurgery : Medical specialty that uses operative manual and instrumental techniques on a patient to investigate or treat a pathological condition such as disease or injury.\\nCancer Recurrence : The return of cancer after treatment and after a period of time during which the cancer was undetectable.\\nMetastasis : Spread of a cancer or other disease from one organ or part to another not directly connected with it.\\n\\nRelationships:-\\n1. Entity1: \""Adverse pathologic features\"", Entity2: \""Treatment decisions\"", Relationship: \""Influence\""\\n2. Entity1: \""Adverse features\"", Entity2: \""Surgical intervention\"", Relationship: \""Recommendation\""\\n3. Entity1: \""Absence of adverse features\"", Entity2: \""Radiation therapy\"", Relationship: \""Pathway\""\\n4. Entity1: \""Follow-up process\"", Entity2: \""Recurrent or persistent disease\"", Relationship: \""Detection\""\\n5. Entity1: \""Recurrent or persistent disease\"", Entity2: \""Advanced disease management\"", Relationship: \""Necessity\""\\n\\nCausalities:-\\n<C> The presence of adverse pathologic features \u2014 such as extranodal extension or positive margins </C> <E> can directly influence treatment decisions </E>. <CO> If adverse features are found </CO>, <A> surgical intervention is recommended </A>. <CO> In cases where there are no adverse features </CO>, the patient may proceed directly to radiation therapy or continued systemic treatment, emphasizing the tailored approach based on the individual patient\\'s disease characteristics.\\n\\nFurthermore, the chart includes a section addressing the follow-up process after initial treatment. <CO> If there are signs of recurrent or persistent disease </CO>, <A> additional evaluations and treatment modalities may be necessary </A>. These evaluations <E> lead to specific recommendations for advanced disease management, denoted as ADV-3 on the chart </E>, emphasizing the importance of continuous monitoring and assessment in cancer care.\\n--------------------------------------------------\\nPage Number: 51\\n\\nSection Name: Introduction\\n====================\\nEntities:-\\nLaryngeal Neoplasms : Tumors or cancer of the larynx, which may affect the supraglottic, glottic, or subglottic regions.\\nMalignant Neoplasm Of Supraglottis : A malignant tumor located in the supraglottic region of the larynx.\\nSupraglottic Laryngeal Cancer : A type of cancer that occurs in the supraglottic region of the larynx, which is above the vocal cords.\\n\\nRelationships:-\\n1. Entity1: \""National Comprehensive Cancer Network (NCCN)\"", Entity2: \""cancer of the supraglottic larynx\"", Relationship: \""provides guidelines for\""\\n2. Entity1: \""healthcare professionals\"", Entity2: \""cancer of the supraglottic larynx\"", Relationship: \""manage\""\\n\\nCausalities:-\\nThe provided image is a detailed flowchart from the National Comprehensive Cancer Network (NCCN) guidelines regarding the <C> clinical staging and treatment protocols for cancer of the supraglottic larynx </C>. This flowchart is structured to <A> guide healthcare professionals through the stages of treatment </A> based on <CO> clinical findings </CO>, emphasizing the <E> complexity and systematic approach required in managing this type of cancer </E>.\\n\\nSection Name: Clinical Staging\\n====================\\nEntities:-\\nLaryngectomy : A surgical procedure involving the removal of the larynx, usually to treat cancer of the larynx.\\nTotal Laryngectomy : A surgical procedure to remove the entire larynx, often used in the treatment of advanced laryngeal cancer.\\nNeoplasm Staging : Methods used for staging neoplasms, including clinical and pathological staging.\\nCancer Staging : The process of determining the extent of cancer in the body, often using the TNM system.\\nTnm Staging System : A cancer staging system that describes the extent of cancer using Tumor size (T), Node involvement (N), and Metastasis (M).\\n\\nRelationships:-\\n1. Entity1: \""Clinical staging criteria\"", Entity2: \""Total laryngectomy\"", Relationship: \""determines necessity of\""\\n2. Entity1: \""T3, N0\"", Entity2: \""Clinical staging criteria\"", Relationship: \""is a categorization of\""\\n\\nCausalities:-\\nThe flowchart begins with the <C> clinical staging criteria </C>, specifically focusing on <CO> cases that require total laryngectomy, denoted as requiring (amenable to) total laryngectomy (T3, N0) </CO>. This <A> categorization </A> is crucial as it <E> forms the basis for determining the appropriate treatment strategy </E>.\\n\\nSection Name: Treatment of Primary and Neck\\n====================\\nEntities:-\\nNeoplasm Staging : Methods used for staging neoplasms, including clinical and pathological staging.\\nSystemic Therapy : Treatment using substances that travel through the bloodstream, reaching and affecting cells all over the body.\\nRadiotherapy : The use of high-energy radiation from x-rays, gamma rays, neutrons, protons, and other sources to kill cancer cells and shrink tumors.\\nLaryngectomy : A surgical procedure involving the removal of the larynx, usually to treat cancer of the larynx.\\nThyroidectomy : A surgical procedure to remove all or part of the thyroid gland.\\nNeck Dissection : Surgical procedure to remove lymph nodes and surrounding tissue to treat or prevent cancer spread.\\nLymphatic Metastasis : Transfer of a neoplasm from one organ or part of the body to another remote from the primary site.\\n\\nRelationships:-\\n1. Entity1: \""Systemic Therapy\"", Entity2: \""Radiation Therapy\"", Relationship: \""combined with\""\\n2. Entity1: \""Laryngectomy\"", Entity2: \""Lymph Node Involvement\"", Relationship: \""considered based on\""\\n3. Entity1: \""Thyroidectomy\"", Entity2: \""Lymph Node Involvement\"", Relationship: \""considered based on\""\\n4. Entity1: \""Neck Dissection\"", Entity2: \""Lymph Node Involvement\"", Relationship: \""considered based on\""\\n\\nCausalities:-\\n<CO> Once clinical staging is established </CO>, the chart outlines various treatment options. <A> The initial step may involve either concurrent systemic therapy combined with radiation therapy (RT) or opting for RT alone </A>, <CO> especially if the patient is not a medical candidate for both therapies </CO>. <A> Laryngectomy, thyroidectomy, and neck dissection are considered </A> <CO> based on the extent of lymph node involvement </CO>.\\n\\nSection Name: Surgical Options\\n====================\\nEntities:-\\nLaryngectomy : A surgical procedure involving the removal of the larynx, usually to treat cancer of the larynx.\\nThyroidectomy : A surgical procedure to remove all or part of the thyroid gland.\\nLymph Node Excision : Surgical removal of one or more lymph nodes.\\nLymphadenectomy : Surgical removal of one or more groups of lymph nodes.\\nSurgical Procedures, Operative : Operations carried out for the correction of deformities and defects, repair of injuries, and diagnosis and cure of certain diseases.\\nSurgical Procedure : A medical procedure involving an incision with instruments; performed to repair damage or arrest disease in a living body.\\nSurgery : Medical specialty that uses operative manual and instrumental techniques on a patient to investigate or treat a pathological condition such as a disease or injury.\\n\\nRelationships:-\\n1. Entity1: \""Laryngectomy\"", Entity2: \""Thyroidectomy\"", Relationship: \""combined with\""\\n2. Entity1: \""Lymph Node Dissection\"", Entity2: \""Surgical Intervention\"", Relationship: \""extent of\""\\n3. Entity1: \""Surgical Intervention\"", Entity2: \""Advanced Cases\"", Relationship: \""management option for\""\\n\\nCausalities:-\\n<CO> If concurrent therapies are not suitable </CO>, <A> the chart presents laryngectomy combined with thyroidectomy </A>, <CO> depending on the extent of lymph node dissection required </CO>. <E> This highlights surgical intervention as a viable option in the management of advanced cases </E>.\\n\\nSection Name: Induction Chemotherapy\\n====================\\nEntities:-\\nInduction Chemotherapy : Initial chemotherapy treatment used to shrink a tumor before the main treatment, which is usually surgery.\\nSurgical Procedure : A medical procedure involving an incision with instruments; performed to repair damage or arrest disease in a living body.\\nTherapeutic Approach : A method or strategy used in the treatment of disease or injury.\\n\\nRelationships:-\\n1. Entity1: \""Induction Chemotherapy\"", Entity2: \""Surgical Intervention\"", Relationship: \""alternative or sequential treatment option\""\\n\\nCausalities:-\\n<C> immediate surgical intervention is either not feasible or considered insufficient </C> <E> The flowchart also considers the option of induction chemotherapy </E> <CO> in cases where immediate surgical intervention is either not feasible or considered insufficient </CO>. <A> tailoring therapeutic approaches tailored to individual patient needs </A>.\\n\\nSection Name: Adjuvant Treatment\\n====================\\nEntities:-\\nAdjuvant Chemotherapy : Chemotherapy given in addition to the primary treatment to maximize its effectiveness.\\nRadiotherapy : The use of high-energy radiation from x-rays, gamma rays, neutrons, protons, and other sources to kill cancer cells and shrink tumors.\\nNeoplasm Recurrence, Local : The return of a cancer, at the same site, after it has been treated.\\nDisease Progression : The worsening of a disease over time.\\n\\nRelationships:-\\n1. Entity1: \""Primary Treatment\"", Entity2: \""Adjuvant Treatment\"", Relationship: \""followed by\""\\n2. Entity1: \""Adjuvant Treatment\"", Entity2: \""Systemic Therapy\"", Relationship: \""includes\""\\n3. Entity1: \""Adjuvant Treatment\"", Entity2: \""Radiotherapy\"", Relationship: \""includes\""\\n4. Entity1: \""Follow-up Assessments\"", Entity2: \""Treatment Efficacy\"", Relationship: \""used to evaluate\""\\n\\nCausalities:-\\n<C> Following primary treatment </C>, <E> the flowchart addresses the potential for adjuvant treatment pathways </E>. This may include systemic therapy, RT, or further evaluations based on <CO> the patient\\'s response and any recurrence or persistent disease </CO>. It emphasizes <A> the need for follow-up assessments to evaluate treatment efficacy </A>.\\n\\nSection Name: Risk Features and Response Assessment\\n====================\\nEntities:-\\nNeoplasm Invasiveness : The property of a neoplasm to infiltrate and destroy surrounding tissue.\\nSurgical Margins : The edge or border of the tissue removed in cancer surgery.\\nNeoplasms : Neoplasms are abnormal growths of tissue, which can be cancerous or non-cancerous.\\nExtramural Extension : Extension of a tumor beyond the wall of an organ.\\nPositive Surgical Margin : Cancer cells are present at the edge of the tissue removed during surgery.\\nCancer Management : The process of planning and coordinating the treatment of cancer.\\nCancer : Cancer is a group of diseases involving abnormal cell growth with the potential to invade or spread to other parts of the body.\\n\\nRelationships:-\\n1. Entity1: \""Extramural extension\"", Entity2: \""Treatment decisions\"", Relationship: \""influences\""\\n2. Entity1: \""Positive surgical margin\"", Entity2: \""Treatment decisions\"", Relationship: \""influences\""\\n3. Entity1: \""Ongoing assessment\"", Entity2: \""Response evaluation\"", Relationship: \""leads to\""\\n4. Entity1: \""Response evaluation\"", Entity2: \""Adjustments to treatment\"", Relationship: \""leads to\""\\n5. Entity1: \""Management of cancer\"", Entity2: \""Treatment decisions\"", Relationship: \""involves\""\\n6. Entity1: \""Management of cancer\"", Entity2: \""Ongoing assessment\"", Relationship: \""involves\""\\n7. Entity1: \""Management of cancer\"", Entity2: \""Adjustments to treatment\"", Relationship: \""involves\""\\n\\nCausalities:-\\nThe chart incorporates a segment that takes into account <CO> adverse pathologic features, such as extramural extension or positive margins </CO>, <E> which could influence subsequent treatment decisions </E>. This highlights the importance of <A> ongoing assessment in the management of cancer, leading to response evaluation and adjustments to treatment as necessary </A>.\\n\\nSection Name: NCCN Guidelines Version 4.2024\\n====================\\nEntities:-\\nClinical Trials : Clinical trials are research studies performed in people that are aimed at evaluating a medical, surgical, or behavioral intervention.\\nNeoplasms : Neoplasms are abnormal growths of tissue, which can be cancerous or non-cancerous.\\nClinical Trial : A clinical trial is a research study that prospectively assigns human participants or groups of humans to one or more health-related interventions to evaluate the effects on health outcomes.\\nMalignant Neoplasm : A malignant neoplasm is a cancerous growth that has the potential to invade and destroy nearby tissue and spread to other parts of the body.\\nNational Comprehensive Cancer Network : The National Comprehensive Cancer Network (NCCN) is an alliance of 31 cancer centers in the United States, dedicated to improving the quality, effectiveness, and efficiency of cancer care.\\nCancer : Cancer is a group of diseases involving abnormal cell growth with the potential to invade or spread to other parts of the body.\\n\\nRelationships:-\\n1. Entity1: \""National Comprehensive Cancer Network\"", Entity2: \""NCCN Guidelines\"", Relationship: \""provides\""\\n2. Entity1: \""NCCN Guidelines\"", Entity2: \""Clinical Trials\"", Relationship: \""recommend\""\\n3. Entity1: \""NCCN Guidelines\"", Entity2: \""Cancer\"", Relationship: \""related to management of\""\\n\\nCausalities:-\\n<CO> any patient with cancer </CO> <A> the best management is in a clinical trial </A>. <A> Participation in clinical trials is especially encouraged </A>.\\n\\nSection Name: SUPRA-3\\n====================\\nEntities:-\\nLaryngectomy : A surgical procedure involving the removal of the larynx, usually to treat cancer of the larynx.\\nThyroidectomy : A surgical procedure to remove all or part of the thyroid gland.\\nNeck Dissection : Surgical procedure to remove lymph nodes and surrounding tissue to treat or prevent cancer spread.\\nChemotherapy, Induction : Initial chemotherapy treatment to shrink a tumor before the main treatment.\\nClinical Trials As Topic : Research studies that prospectively assign human participants or groups of humans to one or more health-related interventions to evaluate the effects on health outcomes.\\nInduction Chemotherapy : Initial chemotherapy treatment used to shrink a tumor before the main treatment, which is usually surgery.\\nClinical Trial : A clinical trial is a research study that prospectively assigns human participants or groups of humans to one or more health-related interventions to evaluate the effects on health outcomes.\\n\\nRelationships:-\\n1. Entity1: \""Total laryngectomy\"", Entity2: \""Laryngectomy\"", Relationship: \""is a type of\""\\n2. Entity1: \""Systemic therapy\"", Entity2: \""RT\"", Relationship: \""concurrent treatment option\""\\n3. Entity1: \""Induction chemotherapy\"", Entity2: \""Other treatments\"", Relationship: \""initial treatment option before\""\\n\\nCausalities:-\\n<CO> Requiring (amenable to) total laryngectomy (T3,N0) </CO>\\n  - <A> Concurrent systemic therapy/RT </A> or <A> RT if patient not medical candidate for concurrent systemic therapy/RT </A>\\n  - <A> Laryngectomy, thyroidectomy and with ipsilateral, central, or bilateral neck dissection </A>\\n  - or\\n  - <A> Induction chemotherapy </A>\\n  - or\\n  - <A> Clinical trials </A>\\n\\nSection Name: Follow-up\\n====================\\nEntities:-\\nFollow-Up Studies : Studies in which individuals are followed over time to determine the outcome of exposures, treatments, or interventions.\\nFollow-Up Procedure : A procedure performed to monitor the progress of a patient\\'s condition after initial treatment.\\nFollow-Up : Medical care given to a patient over time after initial treatment.\\nDisease Recurrence : The return of a sign, symptom, or disease after a remission.\\nRecurrent Disease : The reappearance of a disease after a period of improvement.\\n\\nRelationships:-\\n1. Entity1: \""Follow-up\"", Entity2: \""Recurrent or persistent disease\"", Relationship: \""monitoring\""\\n\\nCausalities:-\\n- **Follow-up (FOLL-A, 1 of 2)**\\n  - <CO> Recurrent or persistent disease </CO> (ADV-3)\\n\\nSection Name: Adverse Pathologic Features\\n====================\\nEntities:-\\nRadiotherapy : The use of high-energy radiation from x-rays, gamma rays, neutrons, protons, and other sources to kill cancer cells and shrink tumors.\\nExtranodal Extension : The spread of cancer beyond the lymph node capsule.\\nPositive Surgical Margin : Cancer cells are present at the edge of the tissue removed during surgery.\\nSystemic Therapy : Treatment using substances that travel through the bloodstream, reaching and affecting cells all over the body.\\n\\nRelationships:-\\n1. Entity1: \""pN1\"", Entity2: \""Radiotherapy\"", Relationship: \""Consideration for treatment\""\\n2. Entity1: \""Extranodal extension\"", Entity2: \""Systemic Therapy\"", Relationship: \""Treatment option\""\\n3. Entity1: \""Extranodal extension\"", Entity2: \""Radiotherapy\"", Relationship: \""Treatment option\""\\n4. Entity1: \""Positive surgical margin\"", Entity2: \""Systemic Therapy\"", Relationship: \""Treatment option\""\\n5. Entity1: \""Positive surgical margin\"", Entity2: \""Radiotherapy\"", Relationship: \""Treatment option\""\\n\\nCausalities:-\\n- <CO>pN1 without other risk features</CO>\\n  - <C>Adverse pathologic features</C>\\n  - <A>Consider RT</A>\\n  - <CO>Extranodal extension and/or positive margin</CO>\\n  - <CO>Other risk features</CO>\\n  - <A>Systemic therapy/RT (category 1)</A>\\n  - <A>RT or Consider systemic therapy/RT</A>\\n\\nSection Name: Response Assessment\\n====================\\nEntities:-\\nResponse Evaluation : The process of assessing the response of a disease to treatment, often used in clinical trials to determine the effectiveness of a therapy.\\nResponse To Treatment : A clinical finding indicating the response of a condition to a therapeutic intervention.\\n\\nRelationships:-\\n\\nSection Name: Principles of Surgery and Radiation Therapy\\n====================\\nEntities:-\\nSurgical Procedures, Operative : Operations carried out for the correction of deformities and defects, repair of injuries, and diagnosis and cure of certain diseases.\\nSurgical Procedure : A medical procedure involving an incision with instruments; performed to repair damage or arrest disease in a living body.\\nSurgery : Medical specialty that uses operative manual and instrumental techniques on a patient to investigate or treat a pathological condition such as a disease or injury.\\nRadiotherapy : The use of high-energy radiation from x-rays, gamma rays, neutrons, protons, and other sources to kill cancer cells and shrink tumors.\\nRadiation Therapy : Radiation therapy is a therapy using ionizing radiation, generally as part of cancer treatment to control or kill malignant cells.\\n\\nRelationships:-\\n1. Entity1: \""Principles of Surgery\"", Entity2: \""Principles of Radiation Therapy\"", Relationship: \""complementary treatments\""\\n\\nCausalities:-\\n**Principles of Surgery (SURG-A).**\\n\\n**Principles of Radiation Therapy (SUPRA-A).**\\n\\nSection Name: Principles of Systemic Therapy\\n====================\\nEntities:-\\nCisplatin : An inorganic and water-soluble platinum complex, cisplatin is an antineoplastic agent that is used in the treatment of various cancers.\\nRadiotherapy : The use of high-energy radiation from x-rays, gamma rays, neutrons, protons, and other sources to kill cancer cells and shrink tumors.\\nRadiation Therapy : Radiation therapy is a therapy using ionizing radiation, generally as part of cancer treatment to control or kill malignant cells.\\n\\nRelationships:-\\n1. Entity1: \""Cisplatin\"", Entity2: \""Systemic Therapy for Non-Nasopharyngeal Cancers\"", Relationship: \""preferred agent\""\\n2. Entity1: \""Cisplatin\"", Entity2: \""Concurrent Systemic Therapy/RT\"", Relationship: \""used in\""\\n\\nCausalities:-\\n<CO> When using concurrent systemic therapy/RT </CO>, <A> the preferred agent is cisplatin (category 1) </A>.\\n--------------------------------------------------\\nPage Number: 130\\n\\nSection Name: Pathological N (pN)\\n====================\\nEntities:-\\nLymph Nodes : Small, bean-shaped structures that are part of the body\\'s lymphatic system. They filter lymph fluid and store white blood cells that help fight infection.\\nNeoplasm Metastasis : The transfer of a neoplasm from one organ or part of the body to another remote from the primary site.\\nTnm Staging : A system used to describe the size and spread of cancer in a standardized way. T refers to the size of the tumor, N to the involvement of lymph nodes, and M to metastasis.\\nLymph Node Structure : A structure that is part of the lymphatic system, involved in the immune response.\\nMetastasis : The spread of a cancer or other disease from one organ or part to another not directly connected with it.\\nTnm Staging System : A cancer staging notation system that describes the extent of cancer in a patient\\'s body.\\nLymph Node : An organ of the lymphatic system and the adaptive immune system.\\n\\nRelationships:-\\n1. Entity1: \""Lymph Nodes\"", Entity2: \""Neoplasm Metastasis\"", Relationship: \""involved in\""\\n2. Entity1: \""TNM Staging\"", Entity2: \""Lymph Nodes\"", Relationship: \""includes\""\\n3. Entity1: \""TNM Staging\"", Entity2: \""Neoplasm Metastasis\"", Relationship: \""describes\""\\n\\nCausalities:-\\n<CO> NX: Regional lymph nodes cannot be assessed </CO>\\n<CO> N0: No regional lymph node metastasis </CO>\\n<CO> N1: Metastasis in a single ipsilateral lymph node, 3 cm or smaller in greatest dimension ENE(\u2013) </CO>\\n<CO> N2: Metastasis in a single ipsilateral lymph node, 3 cm or smaller in greatest dimension and ENE(+); or larger than 3 cm but not larger than 6 cm in greatest dimension and ENE(\u2212); or metastases in multiple ipsilateral lymph nodes, none larger than 6 cm in greatest dimension and ENE(\u2212); or in bilateral or contralateral lymph node(s), none larger than 6 cm in greatest dimension and ENE(\u2212) </CO>\\n<CO> N2a: Metastasis in a single ipsilateral node, 3 cm or smaller in greatest dimension and ENE(+); or metastasis in a single ipsilateral node, larger than 3 cm but not larger than 6 cm in greatest dimension and ENE(\u2212) </CO>\\n<CO> N2b: Metastases in multiple ipsilateral nodes, none larger than 6 cm in greatest dimension and ENE(\u2212) </CO>\\n<CO> N2c: Metastases in bilateral or contralateral lymph node(s), none larger than 6 cm in greatest dimension and ENE(\u2212) </CO>\\n<CO> N3: Metastasis in a lymph node, larger than 6 cm in greatest dimension and ENE(\u2212); or metastasis in a single ipsilateral node, larger than 3 cm in greatest dimension and ENE(+); or multiple ipsilateral, contralateral, or bilateral lymph nodes and any with ENE(+); or a single contralateral node of any size and ENE(+) </CO>\\n<CO> N3a: Metastasis in a lymph node, larger than 6 cm in greatest dimension and ENE(\u2212) </CO>\\n<CO> N3b: Metastasis in a single ipsilateral node, larger than 3 cm in greatest dimension and ENE(+); or multiple ipsilateral, contralateral, or bilateral lymph nodes any with ENE(+); or a single contralateral node of any size and ENE(+) </CO>\\n<CO> Note: A designation of \u201cU\u201d or \u201cL\u201d may be used for any N category to indicate metastasis above the lower border of the cricoid (U) or below the lower border of the cricoid (L). Similarly, clinical and pathological ENE should be recorded as ENE(\u2212) or ENE(+). </CO>\\n\\nSection Name: Distant Metastasis (M)\\n====================\\nEntities:-\\nNeoplasm Metastasis : The transfer of a neoplasm from one organ or part of the body to another remote from the primary site.\\nMetastasis : The spread of a cancer or other disease from one organ or part to another not directly connected with it.\\n\\nRelationships:-\\n1. Entity1: \""M0\"", Entity2: \""Distant Metastasis\"", Relationship: \""is a category of\""\\n2. Entity1: \""M1\"", Entity2: \""Distant Metastasis\"", Relationship: \""is a category of\""\\n\\nCausalities:-\\n### Distant Metastasis (M)\\n\\n- **M0**: No distant metastasis\\n- **M1**: Distant metastasis\\n\\nSection Name: Histologic Grade (G)\\n====================\\nEntities:-\\nNeoplasm Grading : A system of classifying cancer cells in terms of how abnormal they look under a microscope and how quickly the tumor is likely to grow and spread.\\nHistologic Grade : A measure of how much tumor cells differ from healthy cells, used to assess the aggressiveness of cancer.\\n\\nRelationships:-\\n1. Entity1: \""GX\"", Entity2: \""Grade cannot be assessed\"", Relationship: \""is described as\""\\n2. Entity1: \""G1\"", Entity2: \""Well differentiated\"", Relationship: \""is described as\""\\n3. Entity1: \""G2\"", Entity2: \""Moderately differentiated\"", Relationship: \""is described as\""\\n4. Entity1: \""G3\"", Entity2: \""Poorly differentiated\"", Relationship: \""is described as\""\\n\\nCausalities:-\\n<CO>GX</CO>: <E>Grade cannot be assessed</E>\\n<CO>G1</CO>: <E>Well differentiated</E>\\n<CO>G2</CO>: <E>Moderately differentiated</E>\\n<CO>G3</CO>: <E>Poorly differentiated</E>\\n\\nSection Name: Prognostic Stage Groups\\n====================\\nEntities:-\\nNeoplasm Staging : Methods and systems of classifying neoplasms according to extent of disease.\\nTumor Staging : A system for describing the size and spread of cancer within the body.\\nTnm Staging System : A cancer staging notation system that describes the extent of cancer in a patient\\'s body.\\n\\nRelationships:-\\n1. Entity1: \""Stage 0\"", Entity2: \""Tis N0 M0\"", Relationship: \""defined by\""\\n2. Entity1: \""Stage I\"", Entity2: \""T1 N0 M0\"", Relationship: \""defined by\""\\n3. Entity1: \""Stage II\"", Entity2: \""T2 N0 M0\"", Relationship: \""defined by\""\\n4. Entity1: \""Stage III\"", Entity2: \""T3 N0 M0, T1 N1 M0, T2 N1 M0, T3 N1 M0\"", Relationship: \""defined by\""\\n5. Entity1: \""Stage IVA\"", Entity2: \""T1 N2 M0, T2 N2 M0, T3 N2 M0, T4a N0,N1,N2 M0\"", Relationship: \""defined by\""\\n6. Entity1: \""Stage IVB\"", Entity2: \""Any T N3 M0, T4b Any N M0\"", Relationship: \""defined by\""\\n7. Entity1: \""Stage IVC\"", Entity2: \""Any T Any N M1\"", Relationship: \""defined by\""\\n--------------------------------------------------\\nPage Number: 47\\n\\nSection Name: Overview of Radiation Therapy Guidelines\\n====================\\nEntities:-\\nRadiation Therapy : The medical use of ionizing radiation, generally as part of cancer treatment to control or kill malignant cells.\\nCancer : A group of diseases involving abnormal cell growth with the potential to invade or spread to other parts of the body.\\nMalignant Neoplasm : A disease characterized by uncontrolled, abnormal growth of cells that can invade and destroy nearby tissue and spread to other parts of the body.\\nLaryngeal Neoplasms : Tumors or cancer of the larynx, which may affect the glottis, supraglottis, or subglottis.\\nGlottic Larynx Cancer : A malignant neoplasm located in the glottic region of the larynx.\\nLaryngeal Cancer : Cancer that occurs in the larynx, or voice box, which may include the glottic region.\\nNational Comprehensive Cancer Network : The National Comprehensive Cancer Network (NCCN) is an alliance of 30 cancer centers in the United States, dedicated to improving the quality, effectiveness, and efficiency of cancer care.\\n\\nRelationships:-\\n1. Entity1: \""Radiation Therapy\"", Entity2: \""Cancer\"", Relationship: \""treats\""\\n2. Entity1: \""NCCN Guidelines\"", Entity2: \""Cancer\"", Relationship: \""guides treatment for\""\\n3. Entity1: \""NCCN Guidelines\"", Entity2: \""Radiation Therapy\"", Relationship: \""specifies use of\""\\n\\nCausalities:-\\nThe image presents a detailed flowchart outlining the principles of radiation therapy specifically for the <C> treatment of cancer in the glottic larynx </C>, <CO> as per the National Comprehensive Cancer Network (NCCN) guidelines (version 2.2024) </CO>. <E> This structured guidance delineates various treatment protocols </E>, <A> stratified by risk levels and therapeutic approaches </A>.\\n\\nSection Name: Principles of Radiation Therapy\\n====================\\nEntities:-\\nRadiation Therapy : The medical use of ionizing radiation, generally as part of cancer treatment to control or kill malignant cells.\\nGy : Gray, a unit of ionizing radiation dose in the International System of Units (SI), defined as the absorption of one joule of radiation energy per kilogram of matter.\\nGray (Unit) : A unit of absorbed radiation dose of ionizing radiation, defined as the absorption of one joule of radiation energy per kilogram of matter.\\n\\nRelationships:-\\n1. Entity1: \""Tis, N0\"", Entity2: \""60.75 Gy (2.25 Gy/fraction) to 66 Gy (2.0 Gy/fraction)\"", Relationship: \""treatment protocol\""\\n2. Entity1: \""T1, N0\"", Entity2: \""63 Gy (2.25 Gy/fraction) to 66 Gy (2.0 Gy/fraction) or 50 Gy (3.12 Gy/fraction) to 52 Gy (3.28 Gy/fraction)\"", Relationship: \""treatment protocol\""\\n3. Entity1: \""T2, N0\"", Entity2: \""65.25 Gy (2.25 Gy/fraction) to 70 Gy (2.0 Gy/fraction)\"", Relationship: \""treatment protocol\""\\n4. Entity1: \""\u2265T2, N1 (PTV High risk)\"", Entity2: \""66 Gy (2.2 Gy/fraction) to 70 Gy (2.0 Gy/fraction)\"", Relationship: \""treatment protocol\""\\n5. Entity1: \""\u2265T2, N1 (Low to intermediate risk)\"", Entity2: \""44\u201350 Gy (2.0 Gy/fraction) to 54\u201363 Gy (1.6\u20131.8 Gy/fraction)\"", Relationship: \""treatment protocol\""\\n\\nCausalities:-\\n<CO>Tis, N0</CO>: <A>60.75 Gy (2.25 Gy/fraction) to 66 Gy (2.0 Gy/fraction)</A>\\n<CO>T1, N0</CO>: <A>63 Gy (2.25 Gy/fraction, preferred) to 66 Gy (2.0 Gy/fraction) or 50 Gy (3.12 Gy/fraction) to 52 Gy (3.28 Gy/fraction)</A>\\n<CO>T2, N0</CO>: <A>65.25 (2.25 Gy/fraction) to 70 Gy (2.0 Gy/fraction)</A>\\n<CO>\u2265T2, N1</CO>: <A>PTV High risk: Primary tumor and involved lymph nodes (includes possible local subclinical infiltration at the primary site and at the high-risk level lymph node(s))</A>\\n<A>Fractionation: 66 Gy (2.2 Gy/fraction) to 70 Gy (2.0 Gy/fraction); daily Monday\u2013Friday in 6\u20137 weeks</A>\\n<A>Concomitant boost accelerated RT: 72 Gy/6 weeks (1.8 Gy/fraction, large field; 1.5 Gy boost as second daily fraction during last 12 treatment days)</A>\\n<A>66\u201370 Gy (2.0 Gy/fraction; 6 fractions/wk accelerated)</A>\\n<A>Hyperfractionation: 79.2\u201381.6 Gy/7 weeks (1.2 Gy/fraction, twice daily)</A>\\n<CO>Low to intermediate risk</CO>: <A>Sites of suspected subclinical spread</A>\\n<A>44\u201350 Gy (2.0 Gy/fraction) to 54\u201363 Gy (1.6\u20131.8 Gy/fraction)</A>\\n\\nSection Name: Concurrent Systemic Therapy/RT\\n====================\\nEntities:-\\nCisplatin : A platinum-containing antineoplastic agent used in the treatment of various cancers.\\nCarboplatin : An organoplatinum compound that possesses antineoplastic activity.\\nFluorouracil : A chemotherapy drug used to treat various types of cancer.\\n\\nRelationships:-\\n1. Entity1: \""concurrent systemic therapy/RT\"", Entity2: \""cisplatin\"", Relationship: \""uses\""\\n2. Entity1: \""concurrent systemic therapy/RT\"", Entity2: \""carboplatin and 5-FU\"", Relationship: \""uses\""\\n3. Entity1: \""multiagent chemotherapy\"", Entity2: \""toxicity burden\"", Relationship: \""increases\""\\n\\nCausalities:-\\n<CO>Based on published data</CO>, <A>concurrent systemic therapy/RT most commonly uses conventional fractionation at 2.0 Gy per fraction to a typical dose of 70 Gy in 7 weeks with single-agent cisplatin given every 3 weeks at 100 mg/m\u00b2</A>; <CO>2\u20133 cycles of chemotherapy are used depending on the radiation fractionation scheme (RTOG 0129)</CO>. <CO>When carboplatin and 5-FU are used</CO>, <A>the recommended regimen is standard fractionation plus 3 cycles of chemotherapy</A>. <CO>Other fraction sizes (e.g., 1.8 Gy, conventional), multiagent chemotherapy, other dosing schedules of cisplatin, or altered fractionation with chemotherapy</CO> <E>are efficacious</E>, and <C>there is no consensus on the optimal approach</C>. <C>In general, the use of concurrent systemic therapy/RT</C> <E>carries a high toxicity burden</E>; <C>multiagent chemotherapy</C> <E>will likely further increase the toxicity burden</E>. <A>For any systemic therapy/RT approach, close attention should be paid to published reports for the specific chemotherapy agent, dose, and schedule of administration</A>. <A>Systemic therapy/RT should be performed by an experienced team and should include substantial supportive care</A>.\\n\\nSection Name: Treatment Modalities\\n====================\\nEntities:-\\nIntensity-Modulated Radiotherapy : A type of conformal radiotherapy that uses computer-controlled linear accelerators to deliver precise radiation doses to a malignant tumor or specific areas within the tumor.\\nIntensity Modulated Radiation Therapy : A type of conformal radiotherapy that uses computer-controlled linear accelerators to deliver precise radiation doses to a malignant tumor or specific areas within the tumor.\\nIntensity-Modulated Radiation Therapy : An advanced type of high-precision radiotherapy that uses computer-controlled linear accelerators to deliver precise radiation doses to a malignant tumor or specific areas within the tumor.\\nRadiotherapy, Conformal : A type of radiotherapy that uses imaging to conform the radiation dose to the shape of the tumor.\\n3D Conformal Radiation Therapy : A technique in radiotherapy that uses imaging to conform the radiation dose to the shape of the tumor.\\nChemotherapy, Adjuvant : Treatment with drugs that kill cancer cells, often used in conjunction with other therapies.\\nChemotherapy : The treatment of disease by the use of chemical substances, especially the treatment of cancer by cytotoxic and other drugs.\\nDrug Therapy, Combination : The use of two or more drugs to achieve a therapeutic effect.\\nSystemic Therapy : A type of therapy that uses substances that travel through the bloodstream, reaching and affecting cells all over the body.\\n\\nRelationships:-\\n1. Entity1: \""Intensity-Modulated Radiation Therapy (IMRT)\"", Entity2: \""3D Conformal Radiation Therapy (3D-CRT)\"", Relationship: \""are delivery methods for radiation therapy\""\\n2. Entity1: \""Chemotherapy\"", Entity2: \""Radiation Therapy\"", Relationship: \""is integrated with for aggressive or advanced cancer cases\""\\n\\nCausalities:-\\n<CO> contingent upon patient-specific considerations </CO> <A> suggests either Intensity-Modulated Radiation Therapy (IMRT) or 3D Conformal Radiation Therapy (3D-CRT) as delivery methods </A>. <A> These advanced techniques are employed to optimize treatment accuracy </A>, <E> preserving surrounding healthy tissue and improving overall patient outcomes </E>. <A> a focus on concurrent systemic therapies underlines the importance of integrating chemotherapy </A>, particularly <CO> for patients with more aggressive forms of cancer or those demonstrating advanced disease characteristics </CO>.\\n\\nSection Name: Additional Information\\n====================\\nEntities:-\\nClinical Trials : Clinical trials are research studies performed in people that are aimed at evaluating a medical, surgical, or behavioral intervention.\\nClinical Trial : A clinical trial is a research study in which one or more human subjects are prospectively assigned to one or more interventions to evaluate the effects of those interventions on health-related biomedical or behavioral outcomes.\\nNational Comprehensive Cancer Network : The National Comprehensive Cancer Network (NCCN) is an alliance of 30 cancer centers in the United States, dedicated to improving the quality, effectiveness, and efficiency of cancer care.\\nIntensity-Modulated Radiation Therapy : An advanced type of high-precision radiotherapy that uses computer-controlled linear accelerators to deliver precise radiation doses to a malignant tumor or specific areas within the tumor.\\nIntensity Modulated Radiation Therapy : A type of conformal radiotherapy that uses computer-controlled linear accelerators to deliver precise radiation doses to a malignant tumor or specific areas within the tumor.\\nThree-Dimensional Conformal Radiation Therapy : A type of external beam radiation therapy that uses a computer to create a 3-dimensional picture of the tumor so that multiple radiation beams can be shaped exactly to the contour of the treatment area.\\n\\nRelationships:-\\n1. Entity1: \""National Comprehensive Cancer Network\"", Entity2: \""Clinical trial\"", Relationship: \""encourages participation in\""\\n2. Entity1: \""Intensity-Modulated Radiation Therapy\"", Entity2: \""Three-Dimensional Conformal Radiation Therapy\"", Relationship: \""recommended alternatives\""\\n\\nCausalities:-\\n<A> Participation in clinical trials </A> is especially encouraged. <A> Either IMRT (preferred) or 3D-CRT is recommended. </A>\\n\\nSection Name: Conclusion\\n====================\\nEntities:-\\nLaryngeal Neoplasms : Tumors or cancer of the larynx, which may affect the glottis, supraglottis, or subglottis.\\nMalignant Neoplasm Of Glottis : A malignant tumor located in the glottic region of the larynx.\\nLaryngeal Cancer : Cancer that occurs in the larynx, or voice box, which may include the glottic region.\\nPrognosis : A medical term for predicting the likely or expected development of a disease.\\nEvidence-Based Practice : Healthcare practices that are based on scientific evidence and research.\\nEvidence-Based Medicine : An approach to medical practice intended to optimize decision-making by emphasizing the use of evidence from well-designed and conducted research.\\n\\nRelationships:-\\n1. Entity1: \""treatment paradigms\"", Entity2: \""glottic larynx cancer\"", Relationship: \""encapsulates\""\\n2. Entity1: \""personalized treatment plans\"", Entity2: \""prognosis\"", Relationship: \""improves\""\\n\\nCausalities:-\\n<C> glottic larynx cancer </C>. <CO> the nuances of each patient\\'s condition </CO>. <A> personalized treatment plans </A> <E> promoting effective management and improved prognosis </E>. <A> deliver clear, evidence-based interventions </A> <CO> considering the complexities involved in cancer treatment </CO>.\\n'}""",valid,increases risk,2,B,"edge - The edge which needs to be verified.
explanation - Explanation of what the edge represents and its validity.
causal_direction - Either Positive or Negative or Unknown. A positive influence direction indicates that both factors change in the same direction (e.g. an increase causes an increase effect). A negative influence direction indicates the opposite changes (e.g. an increase causes a decrease effect).
causal_factor - Is necessary or sufficient condition for an effect to occur. Exposure is a term commonly used in epidemiology to denote any condition that is considered as a possible cause of disease. Exposure is considered necessary when it always precedes the effects (e.g. symptoms) and always presents when the effects occur. A sufficient cause is a causal factor whose presence or occurrence guarantees the occurrence of symptom.
causal_distance - Either Distal or Proximal or Unknown. The distal factors lie towards the beginning of causal chain (i.e. indirect causal factors). The the proximal factors lie towards the end of the chain (i.e. cause directly or almost directly the effect).

Causality Tags:
<A> for action, <C> for cause, <CO> for condition and <E> for effect.
Cause (C): The reason or origin that leads to an effect. Causes often involve disease conditions, risk factors, or underlying mechanisms.
Effect (E): The outcome or result of a cause. Effects usually represent clinical outcomes, complications, or results of a specific cause.
Condition (CO): The circumstance or prerequisite required for an action or effect to occur. Conditions may include patient characteristics, clinical scenarios, or specific diagnostic criteria.
Action (A): The recommended or described response or activity to address a cause or condition. Actions typically involve clinical interventions, diagnostic procedures, or treatment recommendations.


`NODE1`:
id: Location_of_Lymph_Nodes_3
label: Location of Lymph Nodes
description: This node represents the presence or absence of lymph nodes in a specific location, which is crucial for cancer diagnosis and staging. The detection of lymph nodes can indicate the spread of cancer and affect treatment decisions.
type: Patient Situation
observability: Unobserved
states: [{'state_name': 'present', 'state_description': 'Lymph nodes are detected in the specified location, which may indicate the spread of cancer and is important for staging and treatment planning.'}, {'state_name': 'absent', 'state_description': 'Lymph nodes are not detected in the specified location, which may suggest no spread of cancer to this area and is important for staging and treatment planning.'}]

`NODE2`:
id: N_State_1
label: Nearby Lymph Nodes Cancer State
description: This node represents the clinical situation regarding the presence or absence of cancer in nearby lymph nodes. It is a critical factor in cancer staging and prognosis, as the involvement of lymph nodes can indicate the spread of cancer and affect treatment decisions.
type: Decision Node
observability: Needs to be Predicted
states: [{'state_name': 'present', 'state_description': 'Cancer is present in the nearby lymph nodes, indicating potential metastasis and a more advanced stage of cancer.'}, {'state_name': 'absent', 'state_description': 'Cancer is absent in the nearby lymph nodes, suggesting that the cancer has not spread to these nodes and may be in an earlier stage.'}]

`EDGE1`:
{'edges_ids': ['Location_of_Lymph_Nodes_3', 'N_State_1'], 'edge': '(Location_of_Lymph_Nodes_3) causes (N_State_1)', 'explanation': ['The edge represents the relationship between the presence of lymph nodes in a specific location and the state of cancer in nearby lymph nodes.', 'The presence of lymph nodes in a specific location can indicate the spread of cancer, which directly affects the state of cancer in nearby lymph nodes.', 'This relationship is important for cancer staging and treatment decisions, as the involvement of lymph nodes is a critical factor in determining the stage and prognosis of cancer.'], 'causal_direction': 'positive', 'causal_factor': {'necessary': False, 'sufficient': False}, 'causal_distance': 'Proximal'}

`EDGE2`:
{'edges_ids': ['N_State_1', 'Location_of_Lymph_Nodes_3'], 'edge': '(N_State_1) causes (Location_of_Lymph_Nodes_3)', 'explanation': ['The edge suggests that the cancer state of nearby lymph nodes (N_State_1) causes the presence or absence of lymph nodes in a specific location (Location_of_Lymph_Nodes_3).', 'However, the anatomical presence of lymph nodes in a specific location is not caused by the cancer state of nearby lymph nodes.', 'The cancer state might influence clinical decisions or the interpretation of lymph node findings, but it does not cause the anatomical presence or absence of lymph nodes.', 'Thus, the edge is not valid as a causal relationship.'], 'causal_direction': 'Unknown', 'causal_factor': {'necessary': False, 'sufficient': False}, 'causal_distance': 'Unknown'}

`INFORMATION FROM KNOWLEDGE BASE`:
--------------------------------------------------
Page Number: 102

Section Name: Head and Neck Cancers - Principles of Surgery
====================
Entities:-
Surgical Procedures, Operative : Manual or operative procedures used in the treatment of disease, injuries, or deformities.
Lymphatic System : Part of the circulatory system and a vital part of the immune system, comprising a network of lymphatic vessels that carry a clear fluid called lymph.
Neoplasms : New abnormal growth of tissue in animals or plants; a tumor.
Neck Dissection : A surgical procedure for control of neck lymph node metastasis from squamous cell carcinoma of the head and neck.
Neoplasm Staging : Methods which attempt to express in replicable terms the extent of the neoplasm in the patient.
Metastasis : The spread of a cancer or other disease from one organ or part of the body to another not directly connected with it.
Surgical Procedure : A procedure involving an incision with instruments; performed to repair damage or arrest disease in a living body.
Lymphatic Structure : Anatomical structure that is part of the lymphatic system.
Tumor : An abnormal mass of tissue that results when cells divide more than they should or do not die when they should.
Staging : The process of determining the size and spread of cancer within the body.
Surgery : Medical specialty that uses operative manual and instrumental techniques on a patient to investigate or treat a pathological condition such as disease or injury.
Cancer Staging : The process of determining the extent to which a cancer has developed by growing and spreading.

Relationships:-
1. Entity1: ""surgical management"", Entity2: ""regional lymphatics"", Relationship: ""dictated by tumor staging""
2. Entity1: ""neck dissections"", Entity2: ""primary tumor"", Relationship: ""part of treatment""
3. Entity1: ""surgery"", Entity2: ""ipsilateral side of the neck"", Relationship: ""risk for metastases""

Causalities:-
<C> The extent of the tumor at initial tumor staging </C> <E> dictates the surgical management of regional lymphatics </E>. These guidelines apply to the performance of neck dissections as part of treatment of the primary tumor. <CO> Patients undergoing surgery for resection of the primary tumor </CO> <A> will undergo dissection of the ipsilateral side of the neck that is at greatest risk for metastases </A>.

Section Name: Neck Management
====================
Entities:-
Tongue : A muscular organ in the mouth that is involved in tasting, swallowing, and speech.
Palate : The roof of the mouth, separating the oral and nasal cavities.
Larynx : An organ in the top of the neck involved in breathing, producing sound, and protecting the trachea.
Hypopharynx : The bottom part of the pharynx, which is the cavity behind the nose and mouth.
Nasopharynx : The upper part of the pharynx, connecting with the nasal cavity above the soft palate.
Neck Dissection : A surgical procedure for control of neck lymph node metastasis from squamous cell carcinoma of the head and neck.
Metastasis : The spread of a cancer or other disease from one organ or part of the body to another not directly connected with it.
Squamous Cell Carcinoma : A type of cancer that begins in the squamous cells, which are thin, flat cells that look like fish scales.
Biopsy : The removal of cells or tissues for examination under a microscope.

Relationships:-
1. Entity1: ""Tumor sites"", Entity2: ""Bilateral lymphatic drainage"", Relationship: ""associated with""
2. Entity1: ""Elective neck dissection"", Entity2: ""Risk of occult metastasis"", Relationship: ""based on""
3. Entity1: ""SLN biopsy"", Entity2: ""Elective neck dissection"", Relationship: ""guides decision-making for""

Causalities:-
- **<C> Tumor sites that frequently have bilateral lymphatic drainage </C>** (e.g., base of tongue, palate, supraglottic larynx, hypopharynx, nasopharynx, deep pre-epiglottic space involvement) <E> often should have both sides of the neck dissected </E> with the extent of dissection determined as suggested below. For those patients with tumors at or approaching the midline, <CO> both sides of the neck are at risk for metastases </CO>, and <A> bilateral neck dissections should be performed </A>.

- <CO> Patients with advanced lesions involving the anterior tongue, floor of the mouth, or alveolus that approximate or cross the midline </CO> <A> should undergo contralateral selective/modified neck dissection </A> as necessary to achieve adequate tumor resection.

- **<C> Elective neck dissection </C>** <A> should be based on risk of occult metastasis in the appropriate nodal basin </A>. For oral cavity squamous cell carcinoma, <C> SLN biopsy or the primary tumor depth of invasion </C> is currently <E> the best predictor of occult metastatic disease </E> and <A> should be used to guide decision-making </A>. <CO> For tumors with a depth greater than 3 mm </CO>, <A> elective dissection should be strongly considered if RT is not already planned </A>. Recent randomized trial evidence supports the effectiveness of elective neck dissection in patients with oral cavity cancers greater than 3 mm in depth of invasion.

  - <CO> For a depth less than 2 mm </CO>, <A> elective dissection is only indicated in highly selective situations </A>. <CO> For a depth of 2–4 mm </CO>, <A> clinical judgment (as to reliability of follow-up, clinical suspicion, and other factors) must be utilized to determine appropriateness of elective dissection </A>. Elective dissections are generally selective, preserving all major structures, unless operative findings dictate otherwise.

Section Name: Types of Neck Dissection
====================
Entities:-
Neck Dissection : A surgical procedure for control of neck lymph node metastasis from squamous cell carcinoma of the head and neck.
Larynx : An organ in the top of the neck involved in breathing, producing sound, and protecting the trachea.

Relationships:-
1. Entity1: ""N0"", Entity2: ""Selective neck dissection"", Relationship: ""associated with""
2. Entity1: ""N3"", Entity2: ""Comprehensive neck dissection"", Relationship: ""associated with""
3. Entity1: ""Level VI neck dissection"", Entity2: ""Larynx"", Relationship: ""performed for""
4. Entity1: ""Level VI neck dissection"", Entity2: ""Hypopharynx"", Relationship: ""performed for""

Causalities:-
- **The type of neck dissection (comprehensive or selective)** is defined according to <CO> preoperative clinical staging </CO>, is determined at the discretion of the surgeon, and is based on the initial preoperative staging as follows:
  - **N0:** <A> Selective neck dissection </A>
    - Oral cavity at least levels I–III
    - Oropharynx at least levels II–IV
    - Hypopharynx at least levels II–IV and level VI when appropriate
    - Larynx at least levels II–IV and level VI when appropriate
  - **N1–N2a–c:** <A> Selective or comprehensive neck dissection </A> (Discussion)
  - **N3:** <A> Comprehensive neck dissection </A>

- <C> Level VI neck dissections are performed for certain primary sites (such as the larynx and hypopharynx) </C> <E> as required to resect the primary tumor and any clinically evident neck nodes </E>. <CO> Elective dissection depends on primary tumor extent and site </CO>. <CO> For advanced glottic and hypopharyngeal cancers treated with primary surgery </CO>, <A> a level VI dissection (including pretracheal lymph nodes, the Delphian lymph node, and unilateral or bilateral paratracheal lymph nodes) and hemithyroidectomy to total thyroidectomy are appropriate </A>.

- <CO> For primary subglottic tumors or glottic cancers with significant subglottic extension </CO>, <A> a level VI dissection with unilateral or total thyroidectomy is considered appropriate </A> based on the extent of the primary tumor. <CO> For example, a T4a glottic tumor with extension through the cricothyroid membrane and subglottic extension </CO> <A> should include thyroidectomy and pretracheal and bilateral paratracheal lymph node dissection </A>. <A> Parathyroid glands should be preserved in situ or auto transplanted as indicated </A>.
--------------------------------------------------
Page Number: 55

Section Name: General Information
====================
Entities:-
National Comprehensive Cancer Network : An alliance of 32 cancer centers in the United States, dedicated to improving the quality, effectiveness, and efficiency of cancer care.
Nccn Guidelines : Clinical practice guidelines in oncology developed by the National Comprehensive Cancer Network.

Relationships:-
1. Entity1: ""NCCN Guidelines"", Entity2: ""National Comprehensive Cancer Network"", Relationship: ""produced by""

Section Name: Important Notes
====================
Entities:-
Clinical Trials As Topic : Works about research studies that evaluate the effectiveness and safety of medical, surgical, or behavioral interventions.
Clinical Trial : A type of research that studies new tests and treatments and evaluates their effects on human health outcomes.
National Comprehensive Cancer Network : An alliance of 32 cancer centers in the United States, dedicated to improving the quality, effectiveness, and efficiency of cancer care.
Neoplasms : New abnormal growth of tissue that can be benign or malignant.
Malignant Neoplastic Disease : A disease resulting from the growth of malignant neoplasms.
Cancer : A group of diseases involving abnormal cell growth with the potential to invade or spread to other parts of the body.

Relationships:-
1. Entity1: ""Clinical Trials"", Entity2: ""Cancer"", Relationship: ""recommended for""
2. Entity1: ""NCCN"", Entity2: ""Clinical Trials"", Relationship: ""encourages participation in""

Causalities:-
<C> NCCN believes that the best management of any patient with cancer is in a clinical trial </C>. <A> Participation in clinical trials is especially encouraged </A>.

Section Name: Principles
====================
Entities:-
Surgical Procedures, Operative : Surgical procedures involve the use of operative manual and instrumental techniques on a patient to investigate or treat a pathological condition such as disease or injury.
Radiation Therapy : Therapy using ionizing radiation, generally as part of cancer treatment to control or kill malignant cells.
Chemotherapy : A type of cancer treatment that uses one or more anti-cancer drugs as part of a standardized chemotherapy regimen.

Relationships:-
1. Entity1: ""Principles of Surgery"", Entity2: ""Principles of Radiation Therapy"", Relationship: ""Both are principles of cancer treatment methods.""
2. Entity1: ""Principles of Surgery"", Entity2: ""Principles of Systemic Therapy for Non-Nasopharyngeal Cancers"", Relationship: ""Both are principles of cancer treatment methods.""
3. Entity1: ""Principles of Radiation Therapy"", Entity2: ""Principles of Systemic Therapy for Non-Nasopharyngeal Cancers"", Relationship: ""Both are principles of cancer treatment methods.""

Causalities:-
### Principles

- **Principles of Surgery (SURG-A)**
- **Principles of Radiation Therapy (SUPRA-A)**
- **Principles of Systemic Therapy for Non-Nasopharyngeal Cancers (SYST-A)**

Section Name: Adverse Pathologic Features
====================
Entities:-
Extranodal Extension : The spread of cancer cells beyond the lymph node capsule into the surrounding tissues.
Positive Surgical Margin : The presence of cancer cells at the edge of the tissue removed during surgery, indicating that some cancer may have been left behind.
Perineural Invasion : The presence of cancer cells surrounding or tracking along a nerve within the perineural space.
Vascular Invasion : The invasion of cancer cells into blood vessels.
Lymphatic Invasion : The invasion of cancer cells into lymphatic vessels.

Relationships:-
1. Entity1: ""Extranodal extension"", Entity2: ""Adverse Pathologic Features"", Relationship: ""is a type of""
2. Entity1: ""Positive margins"", Entity2: ""Adverse Pathologic Features"", Relationship: ""is a type of""
3. Entity1: ""Close margins"", Entity2: ""Adverse Pathologic Features"", Relationship: ""is a type of""
4. Entity1: ""pT3 or pT4 primary"", Entity2: ""Adverse Pathologic Features"", Relationship: ""is a type of""
5. Entity1: ""pN2 or pN3 nodal disease"", Entity2: ""Adverse Pathologic Features"", Relationship: ""is a type of""
6. Entity1: ""Perineural invasion"", Entity2: ""Adverse Pathologic Features"", Relationship: ""is a type of""
7. Entity1: ""Vascular invasion"", Entity2: ""Adverse Pathologic Features"", Relationship: ""is a type of""
8. Entity1: ""Lymphatic invasion"", Entity2: ""Adverse Pathologic Features"", Relationship: ""is a type of""

Causalities:-
<C> Extranodal extension </C>
<C> Positive margins </C>
<C> Close margins </C>
<C> pT3 or pT4 primary </C>
<C> pN2 or pN3 nodal disease </C>
<C> Perineural invasion </C>
<C> Vascular invasion </C>
<C> Lymphatic invasion </C>

Section Name: Response Assessment
====================
Entities:-
Chemotherapy, Induction : Initial chemotherapy treatment to shrink a tumor before the main treatment.
Primary Site : The original location where a tumor or cancer begins.
Complete Remission : The disappearance of all signs of cancer in response to treatment.
Partial Remission : A decrease in the size of a tumor, or in the extent of cancer in the body, in response to treatment.
Radiotherapy : The use of high-energy radiation to kill cancer cells and shrink tumors.
Surgical Procedures, Operative : Surgical procedures involve the use of operative manual and instrumental techniques on a patient to investigate or treat a pathological condition such as disease or injury.

Relationships:-
1. Entity1: ""induction chemotherapy"", Entity2: ""Primary site"", Relationship: ""treatment outcome""
2. Entity1: ""Definitive RT"", Entity2: ""Primary site"", Relationship: ""treatment option""
3. Entity1: ""RT"", Entity2: ""Primary site"", Relationship: ""treatment option""
4. Entity1: ""Surgery"", Entity2: ""unresectable nodal disease"", Relationship: ""treatment option""

Causalities:-
<C> Response after induction chemotherapy </C>: <E> Primary site: CR </E> <E> Primary site: PR </E> <E> Primary site: < PR </E> <A> Definitive RT </A> (category 1) <A> RT </A> (category 1) or <A> systemic therapy/RT </A> (category 2B) <A> Surgery </A> or <A> unresectable nodal disease </A>

Section Name: Follow-up
====================
Entities:-
Follow-Up Studies : Studies in which individuals are followed over time to determine the outcome of exposures, treatments, or interventions.
Follow-Up Procedure : A procedure where a patient is monitored over time to assess the progress of a condition or the effects of treatment.
Follow-Up (Medicine) : The process of monitoring a patient's health over time after treatment or diagnosis.
Disease Recurrence : The return of a sign, symptom, or disease after a remission.
Recurrent Disease : A disease that returns after a period of remission.
Recurrence (Medicine) : The return of a disease or condition after a period of improvement.

Relationships:-
1. Entity1: ""Follow-up"", Entity2: ""Recurrent or persistent disease"", Relationship: ""monitoring""

Causalities:-
### Follow-up

- **Follow-up** (FOLL-A, 1 of 2)
- **Recurrent or persistent disease** (ADV-3)

Section Name: Risk Features
====================
Entities:-
Radiotherapy : The use of high-energy radiation to kill cancer cells and shrink tumors.
Extranodal Extension : The spread of cancer cells beyond the lymph node capsule into the surrounding tissues.
Positive Surgical Margin : The presence of cancer cells at the edge of the tissue removed during surgery, indicating that some cancer may have been left behind.
Systemic Therapy : Systemic therapy refers to treatment using substances that travel through the bloodstream, reaching and affecting cells all over the body.

Relationships:-
1. Entity1: ""Adverse pathologic features"", Entity2: ""RT"", Relationship: ""Consideration for treatment""
2. Entity1: ""Adverse pathologic features"", Entity2: ""Systemic therapy"", Relationship: ""Consideration for treatment""

Causalities:-
- **No adverse pathologic features**
- **Other risk features**
- **Adverse pathologic features**:
  - <C> Extranodal extension and/or positive margin </C>
  - <A> RT or consider systemic therapy/RT </A>

Section Name: Post-Therapy Evaluation
====================
Entities:-
Systemic Therapy : Systemic therapy refers to treatment using substances that travel through the bloodstream, reaching and affecting cells all over the body.
Radiation Therapy : Therapy using ionizing radiation, generally as part of cancer treatment to control or kill malignant cells.
Neck : The neck is the part of the body that separates the head from the torso and provides the mobility and movements of the head.

Relationships:-
1. Entity1: ""Systemic Therapy"", Entity2: ""Neck Evaluation"", Relationship: ""evaluated in""
2. Entity1: ""RT"", Entity2: ""Neck Evaluation"", Relationship: ""evaluated in""

Causalities:-
<CO> Post Systemic Therapy/RT or RT Neck </CO> <A> Evaluation </A>

Section Name: Flowchart Overview
====================
Entities:-
Laryngeal Neoplasms : Tumors or cancer of the larynx, which may affect the supraglottic, glottic, or subglottic regions.
Supraglottic Larynx : The part of the larynx located above the vocal cords, including the epiglottis and aryepiglottic folds.
National Comprehensive Cancer Network : An alliance of 32 cancer centers in the United States, dedicated to improving the quality, effectiveness, and efficiency of cancer care.

Relationships:-
1. Entity1: ""NCCN Guidelines"", Entity2: ""cancer of the supraglottic larynx"", Relationship: ""guides management of""
2. Entity1: ""NCCN Guidelines"", Entity2: ""healthcare professionals"", Relationship: ""used by""

Causalities:-
<C> cancer of the supraglottic larynx </C> <E> evaluate patient responses following treatment </E> <CO> based on observed outcomes </CO> <A> evaluation of the primary site and determining subsequent steps </A>.

Section Name: Assessment and Treatment Decisions
====================
Entities:-
Induction Chemotherapy : Initial chemotherapy treatment to shrink a tumor before the main treatment.
Complete Response : The disappearance of all signs of cancer in response to treatment.
Partial Response : A decrease in the size of a tumor, or in the extent of cancer in the body, in response to treatment.
Radiation Therapy : Therapy using ionizing radiation, generally as part of cancer treatment to control or kill malignant cells.
Surgery : Medical specialty that uses operative manual and instrumental techniques on a patient to investigate or treat a pathological condition such as disease or injury.
Systemic Therapy : Systemic therapy refers to treatment using substances that travel through the bloodstream, reaching and affecting cells all over the body.

Relationships:-
1. Entity1: ""Complete Response"", Entity2: ""Radiation Therapy"", Relationship: ""leads to""
2. Entity1: ""Complete Response"", Entity2: ""Surgery"", Relationship: ""leads to""
3. Entity1: ""Partial Response"", Entity2: ""Systemic Therapy"", Relationship: ""leads to""
4. Entity1: ""Partial Response"", Entity2: ""Radiation Therapy"", Relationship: ""leads to""

Causalities:-
<C> responses to initial treatments such as induction chemotherapy </C> <E> Three main response categories are recognized: Complete Response (CR), Partial Response (PR), and less than Partial Response (< PR) </E>. These categories are pivotal in determining the next steps. <C> CR </C> <E> indicates full resolution of the disease at the primary site </E>, <A> leading to the consideration of definitive radiation therapy or the likelihood of surgery </A>. Conversely, <C> PR </C> <E> suggests that the disease has improved but not completely resolved </E>, <A> which directs the pathway towards either systemic therapy or continued radiation therapy </A>, <A> with further evaluation necessary </A>.

Section Name: Adverse Pathologic Features and Follow-up
====================
Entities:-
Radiation Therapy : Therapy using ionizing radiation, generally as part of cancer treatment to control or kill malignant cells.
Surgical Procedures, Operative : Surgical procedures involve the use of operative manual and instrumental techniques on a patient to investigate or treat a pathological condition such as disease or injury.
Neoplasm Recurrence, Local : The return of a tumor or cancer, at the original site, after it has been treated.
Neoplasm Metastasis : The transfer of a neoplasm from one organ or part of the body to another remote from the primary site.
Surgical Procedure : A medical procedure involving an incision with instruments; performed to repair damage or arrest disease in a living body.
Recurrent Neoplasm : A neoplasm that has returned after treatment.
Metastatic Neoplasm : A neoplasm that has spread from its original site to one or more other places in the body.
Surgery : Medical specialty that uses operative manual and instrumental techniques on a patient to investigate or treat a pathological condition such as disease or injury.
Cancer Recurrence : The return of cancer after treatment and after a period of time during which the cancer was undetectable.
Metastasis : Spread of a cancer or other disease from one organ or part to another not directly connected with it.

Relationships:-
1. Entity1: ""Adverse pathologic features"", Entity2: ""Treatment decisions"", Relationship: ""Influence""
2. Entity1: ""Adverse features"", Entity2: ""Surgical intervention"", Relationship: ""Recommendation""
3. Entity1: ""Absence of adverse features"", Entity2: ""Radiation therapy"", Relationship: ""Pathway""
4. Entity1: ""Follow-up process"", Entity2: ""Recurrent or persistent disease"", Relationship: ""Detection""
5. Entity1: ""Recurrent or persistent disease"", Entity2: ""Advanced disease management"", Relationship: ""Necessity""

Causalities:-
<C> The presence of adverse pathologic features — such as extranodal extension or positive margins </C> <E> can directly influence treatment decisions </E>. <CO> If adverse features are found </CO>, <A> surgical intervention is recommended </A>. <CO> In cases where there are no adverse features </CO>, the patient may proceed directly to radiation therapy or continued systemic treatment, emphasizing the tailored approach based on the individual patient's disease characteristics.

Furthermore, the chart includes a section addressing the follow-up process after initial treatment. <CO> If there are signs of recurrent or persistent disease </CO>, <A> additional evaluations and treatment modalities may be necessary </A>. These evaluations <E> lead to specific recommendations for advanced disease management, denoted as ADV-3 on the chart </E>, emphasizing the importance of continuous monitoring and assessment in cancer care.
--------------------------------------------------
Page Number: 51

Section Name: Introduction
====================
Entities:-
Laryngeal Neoplasms : Tumors or cancer of the larynx, which may affect the supraglottic, glottic, or subglottic regions.
Malignant Neoplasm Of Supraglottis : A malignant tumor located in the supraglottic region of the larynx.
Supraglottic Laryngeal Cancer : A type of cancer that occurs in the supraglottic region of the larynx, which is above the vocal cords.

Relationships:-
1. Entity1: ""National Comprehensive Cancer Network (NCCN)"", Entity2: ""cancer of the supraglottic larynx"", Relationship: ""provides guidelines for""
2. Entity1: ""healthcare professionals"", Entity2: ""cancer of the supraglottic larynx"", Relationship: ""manage""

Causalities:-
The provided image is a detailed flowchart from the National Comprehensive Cancer Network (NCCN) guidelines regarding the <C> clinical staging and treatment protocols for cancer of the supraglottic larynx </C>. This flowchart is structured to <A> guide healthcare professionals through the stages of treatment </A> based on <CO> clinical findings </CO>, emphasizing the <E> complexity and systematic approach required in managing this type of cancer </E>.

Section Name: Clinical Staging
====================
Entities:-
Laryngectomy : A surgical procedure involving the removal of the larynx, usually to treat cancer of the larynx.
Total Laryngectomy : A surgical procedure to remove the entire larynx, often used in the treatment of advanced laryngeal cancer.
Neoplasm Staging : Methods used for staging neoplasms, including clinical and pathological staging.
Cancer Staging : The process of determining the extent of cancer in the body, often using the TNM system.
Tnm Staging System : A cancer staging system that describes the extent of cancer using Tumor size (T), Node involvement (N), and Metastasis (M).

Relationships:-
1. Entity1: ""Clinical staging criteria"", Entity2: ""Total laryngectomy"", Relationship: ""determines necessity of""
2. Entity1: ""T3, N0"", Entity2: ""Clinical staging criteria"", Relationship: ""is a categorization of""

Causalities:-
The flowchart begins with the <C> clinical staging criteria </C>, specifically focusing on <CO> cases that require total laryngectomy, denoted as requiring (amenable to) total laryngectomy (T3, N0) </CO>. This <A> categorization </A> is crucial as it <E> forms the basis for determining the appropriate treatment strategy </E>.

Section Name: Treatment of Primary and Neck
====================
Entities:-
Neoplasm Staging : Methods used for staging neoplasms, including clinical and pathological staging.
Systemic Therapy : Treatment using substances that travel through the bloodstream, reaching and affecting cells all over the body.
Radiotherapy : The use of high-energy radiation from x-rays, gamma rays, neutrons, protons, and other sources to kill cancer cells and shrink tumors.
Laryngectomy : A surgical procedure involving the removal of the larynx, usually to treat cancer of the larynx.
Thyroidectomy : A surgical procedure to remove all or part of the thyroid gland.
Neck Dissection : Surgical procedure to remove lymph nodes and surrounding tissue to treat or prevent cancer spread.
Lymphatic Metastasis : Transfer of a neoplasm from one organ or part of the body to another remote from the primary site.

Relationships:-
1. Entity1: ""Systemic Therapy"", Entity2: ""Radiation Therapy"", Relationship: ""combined with""
2. Entity1: ""Laryngectomy"", Entity2: ""Lymph Node Involvement"", Relationship: ""considered based on""
3. Entity1: ""Thyroidectomy"", Entity2: ""Lymph Node Involvement"", Relationship: ""considered based on""
4. Entity1: ""Neck Dissection"", Entity2: ""Lymph Node Involvement"", Relationship: ""considered based on""

Causalities:-
<CO> Once clinical staging is established </CO>, the chart outlines various treatment options. <A> The initial step may involve either concurrent systemic therapy combined with radiation therapy (RT) or opting for RT alone </A>, <CO> especially if the patient is not a medical candidate for both therapies </CO>. <A> Laryngectomy, thyroidectomy, and neck dissection are considered </A> <CO> based on the extent of lymph node involvement </CO>.

Section Name: Surgical Options
====================
Entities:-
Laryngectomy : A surgical procedure involving the removal of the larynx, usually to treat cancer of the larynx.
Thyroidectomy : A surgical procedure to remove all or part of the thyroid gland.
Lymph Node Excision : Surgical removal of one or more lymph nodes.
Lymphadenectomy : Surgical removal of one or more groups of lymph nodes.
Surgical Procedures, Operative : Operations carried out for the correction of deformities and defects, repair of injuries, and diagnosis and cure of certain diseases.
Surgical Procedure : A medical procedure involving an incision with instruments; performed to repair damage or arrest disease in a living body.
Surgery : Medical specialty that uses operative manual and instrumental techniques on a patient to investigate or treat a pathological condition such as a disease or injury.

Relationships:-
1. Entity1: ""Laryngectomy"", Entity2: ""Thyroidectomy"", Relationship: ""combined with""
2. Entity1: ""Lymph Node Dissection"", Entity2: ""Surgical Intervention"", Relationship: ""extent of""
3. Entity1: ""Surgical Intervention"", Entity2: ""Advanced Cases"", Relationship: ""management option for""

Causalities:-
<CO> If concurrent therapies are not suitable </CO>, <A> the chart presents laryngectomy combined with thyroidectomy </A>, <CO> depending on the extent of lymph node dissection required </CO>. <E> This highlights surgical intervention as a viable option in the management of advanced cases </E>.

Section Name: Induction Chemotherapy
====================
Entities:-
Induction Chemotherapy : Initial chemotherapy treatment used to shrink a tumor before the main treatment, which is usually surgery.
Surgical Procedure : A medical procedure involving an incision with instruments; performed to repair damage or arrest disease in a living body.
Therapeutic Approach : A method or strategy used in the treatment of disease or injury.

Relationships:-
1. Entity1: ""Induction Chemotherapy"", Entity2: ""Surgical Intervention"", Relationship: ""alternative or sequential treatment option""

Causalities:-
<C> immediate surgical intervention is either not feasible or considered insufficient </C> <E> The flowchart also considers the option of induction chemotherapy </E> <CO> in cases where immediate surgical intervention is either not feasible or considered insufficient </CO>. <A> tailoring therapeutic approaches tailored to individual patient needs </A>.

Section Name: Adjuvant Treatment
====================
Entities:-
Adjuvant Chemotherapy : Chemotherapy given in addition to the primary treatment to maximize its effectiveness.
Radiotherapy : The use of high-energy radiation from x-rays, gamma rays, neutrons, protons, and other sources to kill cancer cells and shrink tumors.
Neoplasm Recurrence, Local : The return of a cancer, at the same site, after it has been treated.
Disease Progression : The worsening of a disease over time.

Relationships:-
1. Entity1: ""Primary Treatment"", Entity2: ""Adjuvant Treatment"", Relationship: ""followed by""
2. Entity1: ""Adjuvant Treatment"", Entity2: ""Systemic Therapy"", Relationship: ""includes""
3. Entity1: ""Adjuvant Treatment"", Entity2: ""Radiotherapy"", Relationship: ""includes""
4. Entity1: ""Follow-up Assessments"", Entity2: ""Treatment Efficacy"", Relationship: ""used to evaluate""

Causalities:-
<C> Following primary treatment </C>, <E> the flowchart addresses the potential for adjuvant treatment pathways </E>. This may include systemic therapy, RT, or further evaluations based on <CO> the patient's response and any recurrence or persistent disease </CO>. It emphasizes <A> the need for follow-up assessments to evaluate treatment efficacy </A>.

Section Name: Risk Features and Response Assessment
====================
Entities:-
Neoplasm Invasiveness : The property of a neoplasm to infiltrate and destroy surrounding tissue.
Surgical Margins : The edge or border of the tissue removed in cancer surgery.
Neoplasms : Neoplasms are abnormal growths of tissue, which can be cancerous or non-cancerous.
Extramural Extension : Extension of a tumor beyond the wall of an organ.
Positive Surgical Margin : Cancer cells are present at the edge of the tissue removed during surgery.
Cancer Management : The process of planning and coordinating the treatment of cancer.
Cancer : Cancer is a group of diseases involving abnormal cell growth with the potential to invade or spread to other parts of the body.

Relationships:-
1. Entity1: ""Extramural extension"", Entity2: ""Treatment decisions"", Relationship: ""influences""
2. Entity1: ""Positive surgical margin"", Entity2: ""Treatment decisions"", Relationship: ""influences""
3. Entity1: ""Ongoing assessment"", Entity2: ""Response evaluation"", Relationship: ""leads to""
4. Entity1: ""Response evaluation"", Entity2: ""Adjustments to treatment"", Relationship: ""leads to""
5. Entity1: ""Management of cancer"", Entity2: ""Treatment decisions"", Relationship: ""involves""
6. Entity1: ""Management of cancer"", Entity2: ""Ongoing assessment"", Relationship: ""involves""
7. Entity1: ""Management of cancer"", Entity2: ""Adjustments to treatment"", Relationship: ""involves""

Causalities:-
The chart incorporates a segment that takes into account <CO> adverse pathologic features, such as extramural extension or positive margins </CO>, <E> which could influence subsequent treatment decisions </E>. This highlights the importance of <A> ongoing assessment in the management of cancer, leading to response evaluation and adjustments to treatment as necessary </A>.

Section Name: NCCN Guidelines Version 4.2024
====================
Entities:-
Clinical Trials : Clinical trials are research studies performed in people that are aimed at evaluating a medical, surgical, or behavioral intervention.
Neoplasms : Neoplasms are abnormal growths of tissue, which can be cancerous or non-cancerous.
Clinical Trial : A clinical trial is a research study that prospectively assigns human participants or groups of humans to one or more health-related interventions to evaluate the effects on health outcomes.
Malignant Neoplasm : A malignant neoplasm is a cancerous growth that has the potential to invade and destroy nearby tissue and spread to other parts of the body.
National Comprehensive Cancer Network : The National Comprehensive Cancer Network (NCCN) is an alliance of 31 cancer centers in the United States, dedicated to improving the quality, effectiveness, and efficiency of cancer care.
Cancer : Cancer is a group of diseases involving abnormal cell growth with the potential to invade or spread to other parts of the body.

Relationships:-
1. Entity1: ""National Comprehensive Cancer Network"", Entity2: ""NCCN Guidelines"", Relationship: ""provides""
2. Entity1: ""NCCN Guidelines"", Entity2: ""Clinical Trials"", Relationship: ""recommend""
3. Entity1: ""NCCN Guidelines"", Entity2: ""Cancer"", Relationship: ""related to management of""

Causalities:-
<CO> any patient with cancer </CO> <A> the best management is in a clinical trial </A>. <A> Participation in clinical trials is especially encouraged </A>.

Section Name: SUPRA-3
====================
Entities:-
Laryngectomy : A surgical procedure involving the removal of the larynx, usually to treat cancer of the larynx.
Thyroidectomy : A surgical procedure to remove all or part of the thyroid gland.
Neck Dissection : Surgical procedure to remove lymph nodes and surrounding tissue to treat or prevent cancer spread.
Chemotherapy, Induction : Initial chemotherapy treatment to shrink a tumor before the main treatment.
Clinical Trials As Topic : Research studies that prospectively assign human participants or groups of humans to one or more health-related interventions to evaluate the effects on health outcomes.
Induction Chemotherapy : Initial chemotherapy treatment used to shrink a tumor before the main treatment, which is usually surgery.
Clinical Trial : A clinical trial is a research study that prospectively assigns human participants or groups of humans to one or more health-related interventions to evaluate the effects on health outcomes.

Relationships:-
1. Entity1: ""Total laryngectomy"", Entity2: ""Laryngectomy"", Relationship: ""is a type of""
2. Entity1: ""Systemic therapy"", Entity2: ""RT"", Relationship: ""concurrent treatment option""
3. Entity1: ""Induction chemotherapy"", Entity2: ""Other treatments"", Relationship: ""initial treatment option before""

Causalities:-
<CO> Requiring (amenable to) total laryngectomy (T3,N0) </CO>
  - <A> Concurrent systemic therapy/RT </A> or <A> RT if patient not medical candidate for concurrent systemic therapy/RT </A>
  - <A> Laryngectomy, thyroidectomy and with ipsilateral, central, or bilateral neck dissection </A>
  - or
  - <A> Induction chemotherapy </A>
  - or
  - <A> Clinical trials </A>

Section Name: Follow-up
====================
Entities:-
Follow-Up Studies : Studies in which individuals are followed over time to determine the outcome of exposures, treatments, or interventions.
Follow-Up Procedure : A procedure performed to monitor the progress of a patient's condition after initial treatment.
Follow-Up : Medical care given to a patient over time after initial treatment.
Disease Recurrence : The return of a sign, symptom, or disease after a remission.
Recurrent Disease : The reappearance of a disease after a period of improvement.

Relationships:-
1. Entity1: ""Follow-up"", Entity2: ""Recurrent or persistent disease"", Relationship: ""monitoring""

Causalities:-
- **Follow-up (FOLL-A, 1 of 2)**
  - <CO> Recurrent or persistent disease </CO> (ADV-3)

Section Name: Adverse Pathologic Features
====================
Entities:-
Radiotherapy : The use of high-energy radiation from x-rays, gamma rays, neutrons, protons, and other sources to kill cancer cells and shrink tumors.
Extranodal Extension : The spread of cancer beyond the lymph node capsule.
Positive Surgical Margin : Cancer cells are present at the edge of the tissue removed during surgery.
Systemic Therapy : Treatment using substances that travel through the bloodstream, reaching and affecting cells all over the body.

Relationships:-
1. Entity1: ""pN1"", Entity2: ""Radiotherapy"", Relationship: ""Consideration for treatment""
2. Entity1: ""Extranodal extension"", Entity2: ""Systemic Therapy"", Relationship: ""Treatment option""
3. Entity1: ""Extranodal extension"", Entity2: ""Radiotherapy"", Relationship: ""Treatment option""
4. Entity1: ""Positive surgical margin"", Entity2: ""Systemic Therapy"", Relationship: ""Treatment option""
5. Entity1: ""Positive surgical margin"", Entity2: ""Radiotherapy"", Relationship: ""Treatment option""

Causalities:-
- <CO>pN1 without other risk features</CO>
  - <C>Adverse pathologic features</C>
  - <A>Consider RT</A>
  - <CO>Extranodal extension and/or positive margin</CO>
  - <CO>Other risk features</CO>
  - <A>Systemic therapy/RT (category 1)</A>
  - <A>RT or Consider systemic therapy/RT</A>

Section Name: Response Assessment
====================
Entities:-
Response Evaluation : The process of assessing the response of a disease to treatment, often used in clinical trials to determine the effectiveness of a therapy.
Response To Treatment : A clinical finding indicating the response of a condition to a therapeutic intervention.

Relationships:-

Section Name: Principles of Surgery and Radiation Therapy
====================
Entities:-
Surgical Procedures, Operative : Operations carried out for the correction of deformities and defects, repair of injuries, and diagnosis and cure of certain diseases.
Surgical Procedure : A medical procedure involving an incision with instruments; performed to repair damage or arrest disease in a living body.
Surgery : Medical specialty that uses operative manual and instrumental techniques on a patient to investigate or treat a pathological condition such as a disease or injury.
Radiotherapy : The use of high-energy radiation from x-rays, gamma rays, neutrons, protons, and other sources to kill cancer cells and shrink tumors.
Radiation Therapy : Radiation therapy is a therapy using ionizing radiation, generally as part of cancer treatment to control or kill malignant cells.

Relationships:-
1. Entity1: ""Principles of Surgery"", Entity2: ""Principles of Radiation Therapy"", Relationship: ""complementary treatments""

Causalities:-
**Principles of Surgery (SURG-A).**

**Principles of Radiation Therapy (SUPRA-A).**

Section Name: Principles of Systemic Therapy
====================
Entities:-
Cisplatin : An inorganic and water-soluble platinum complex, cisplatin is an antineoplastic agent that is used in the treatment of various cancers.
Radiotherapy : The use of high-energy radiation from x-rays, gamma rays, neutrons, protons, and other sources to kill cancer cells and shrink tumors.
Radiation Therapy : Radiation therapy is a therapy using ionizing radiation, generally as part of cancer treatment to control or kill malignant cells.

Relationships:-
1. Entity1: ""Cisplatin"", Entity2: ""Systemic Therapy for Non-Nasopharyngeal Cancers"", Relationship: ""preferred agent""
2. Entity1: ""Cisplatin"", Entity2: ""Concurrent Systemic Therapy/RT"", Relationship: ""used in""

Causalities:-
<CO> When using concurrent systemic therapy/RT </CO>, <A> the preferred agent is cisplatin (category 1) </A>.
--------------------------------------------------
Page Number: 130

Section Name: Pathological N (pN)
====================
Entities:-
Lymph Nodes : Small, bean-shaped structures that are part of the body's lymphatic system. They filter lymph fluid and store white blood cells that help fight infection.
Neoplasm Metastasis : The transfer of a neoplasm from one organ or part of the body to another remote from the primary site.
Tnm Staging : A system used to describe the size and spread of cancer in a standardized way. T refers to the size of the tumor, N to the involvement of lymph nodes, and M to metastasis.
Lymph Node Structure : A structure that is part of the lymphatic system, involved in the immune response.
Metastasis : The spread of a cancer or other disease from one organ or part to another not directly connected with it.
Tnm Staging System : A cancer staging notation system that describes the extent of cancer in a patient's body.
Lymph Node : An organ of the lymphatic system and the adaptive immune system.

Relationships:-
1. Entity1: ""Lymph Nodes"", Entity2: ""Neoplasm Metastasis"", Relationship: ""involved in""
2. Entity1: ""TNM Staging"", Entity2: ""Lymph Nodes"", Relationship: ""includes""
3. Entity1: ""TNM Staging"", Entity2: ""Neoplasm Metastasis"", Relationship: ""describes""

Causalities:-
<CO> NX: Regional lymph nodes cannot be assessed </CO>
<CO> N0: No regional lymph node metastasis </CO>
<CO> N1: Metastasis in a single ipsilateral lymph node, 3 cm or smaller in greatest dimension ENE(–) </CO>
<CO> N2: Metastasis in a single ipsilateral lymph node, 3 cm or smaller in greatest dimension and ENE(+); or larger than 3 cm but not larger than 6 cm in greatest dimension and ENE(−); or metastases in multiple ipsilateral lymph nodes, none larger than 6 cm in greatest dimension and ENE(−); or in bilateral or contralateral lymph node(s), none larger than 6 cm in greatest dimension and ENE(−) </CO>
<CO> N2a: Metastasis in a single ipsilateral node, 3 cm or smaller in greatest dimension and ENE(+); or metastasis in a single ipsilateral node, larger than 3 cm but not larger than 6 cm in greatest dimension and ENE(−) </CO>
<CO> N2b: Metastases in multiple ipsilateral nodes, none larger than 6 cm in greatest dimension and ENE(−) </CO>
<CO> N2c: Metastases in bilateral or contralateral lymph node(s), none larger than 6 cm in greatest dimension and ENE(−) </CO>
<CO> N3: Metastasis in a lymph node, larger than 6 cm in greatest dimension and ENE(−); or metastasis in a single ipsilateral node, larger than 3 cm in greatest dimension and ENE(+); or multiple ipsilateral, contralateral, or bilateral lymph nodes and any with ENE(+); or a single contralateral node of any size and ENE(+) </CO>
<CO> N3a: Metastasis in a lymph node, larger than 6 cm in greatest dimension and ENE(−) </CO>
<CO> N3b: Metastasis in a single ipsilateral node, larger than 3 cm in greatest dimension and ENE(+); or multiple ipsilateral, contralateral, or bilateral lymph nodes any with ENE(+); or a single contralateral node of any size and ENE(+) </CO>
<CO> Note: A designation of “U” or “L” may be used for any N category to indicate metastasis above the lower border of the cricoid (U) or below the lower border of the cricoid (L). Similarly, clinical and pathological ENE should be recorded as ENE(−) or ENE(+). </CO>

Section Name: Distant Metastasis (M)
====================
Entities:-
Neoplasm Metastasis : The transfer of a neoplasm from one organ or part of the body to another remote from the primary site.
Metastasis : The spread of a cancer or other disease from one organ or part to another not directly connected with it.

Relationships:-
1. Entity1: ""M0"", Entity2: ""Distant Metastasis"", Relationship: ""is a category of""
2. Entity1: ""M1"", Entity2: ""Distant Metastasis"", Relationship: ""is a category of""

Causalities:-
### Distant Metastasis (M)

- **M0**: No distant metastasis
- **M1**: Distant metastasis

Section Name: Histologic Grade (G)
====================
Entities:-
Neoplasm Grading : A system of classifying cancer cells in terms of how abnormal they look under a microscope and how quickly the tumor is likely to grow and spread.
Histologic Grade : A measure of how much tumor cells differ from healthy cells, used to assess the aggressiveness of cancer.

Relationships:-
1. Entity1: ""GX"", Entity2: ""Grade cannot be assessed"", Relationship: ""is described as""
2. Entity1: ""G1"", Entity2: ""Well differentiated"", Relationship: ""is described as""
3. Entity1: ""G2"", Entity2: ""Moderately differentiated"", Relationship: ""is described as""
4. Entity1: ""G3"", Entity2: ""Poorly differentiated"", Relationship: ""is described as""

Causalities:-
<CO>GX</CO>: <E>Grade cannot be assessed</E>
<CO>G1</CO>: <E>Well differentiated</E>
<CO>G2</CO>: <E>Moderately differentiated</E>
<CO>G3</CO>: <E>Poorly differentiated</E>

Section Name: Prognostic Stage Groups
====================
Entities:-
Neoplasm Staging : Methods and systems of classifying neoplasms according to extent of disease.
Tumor Staging : A system for describing the size and spread of cancer within the body.
Tnm Staging System : A cancer staging notation system that describes the extent of cancer in a patient's body.

Relationships:-
1. Entity1: ""Stage 0"", Entity2: ""Tis N0 M0"", Relationship: ""defined by""
2. Entity1: ""Stage I"", Entity2: ""T1 N0 M0"", Relationship: ""defined by""
3. Entity1: ""Stage II"", Entity2: ""T2 N0 M0"", Relationship: ""defined by""
4. Entity1: ""Stage III"", Entity2: ""T3 N0 M0, T1 N1 M0, T2 N1 M0, T3 N1 M0"", Relationship: ""defined by""
5. Entity1: ""Stage IVA"", Entity2: ""T1 N2 M0, T2 N2 M0, T3 N2 M0, T4a N0,N1,N2 M0"", Relationship: ""defined by""
6. Entity1: ""Stage IVB"", Entity2: ""Any T N3 M0, T4b Any N M0"", Relationship: ""defined by""
7. Entity1: ""Stage IVC"", Entity2: ""Any T Any N M1"", Relationship: ""defined by""
--------------------------------------------------
Page Number: 47

Section Name: Overview of Radiation Therapy Guidelines
====================
Entities:-
Radiation Therapy : The medical use of ionizing radiation, generally as part of cancer treatment to control or kill malignant cells.
Cancer : A group of diseases involving abnormal cell growth with the potential to invade or spread to other parts of the body.
Malignant Neoplasm : A disease characterized by uncontrolled, abnormal growth of cells that can invade and destroy nearby tissue and spread to other parts of the body.
Laryngeal Neoplasms : Tumors or cancer of the larynx, which may affect the glottis, supraglottis, or subglottis.
Glottic Larynx Cancer : A malignant neoplasm located in the glottic region of the larynx.
Laryngeal Cancer : Cancer that occurs in the larynx, or voice box, which may include the glottic region.
National Comprehensive Cancer Network : The National Comprehensive Cancer Network (NCCN) is an alliance of 30 cancer centers in the United States, dedicated to improving the quality, effectiveness, and efficiency of cancer care.

Relationships:-
1. Entity1: ""Radiation Therapy"", Entity2: ""Cancer"", Relationship: ""treats""
2. Entity1: ""NCCN Guidelines"", Entity2: ""Cancer"", Relationship: ""guides treatment for""
3. Entity1: ""NCCN Guidelines"", Entity2: ""Radiation Therapy"", Relationship: ""specifies use of""

Causalities:-
The image presents a detailed flowchart outlining the principles of radiation therapy specifically for the <C> treatment of cancer in the glottic larynx </C>, <CO> as per the National Comprehensive Cancer Network (NCCN) guidelines (version 2.2024) </CO>. <E> This structured guidance delineates various treatment protocols </E>, <A> stratified by risk levels and therapeutic approaches </A>.

Section Name: Principles of Radiation Therapy
====================
Entities:-
Radiation Therapy : The medical use of ionizing radiation, generally as part of cancer treatment to control or kill malignant cells.
Gy : Gray, a unit of ionizing radiation dose in the International System of Units (SI), defined as the absorption of one joule of radiation energy per kilogram of matter.
Gray (Unit) : A unit of absorbed radiation dose of ionizing radiation, defined as the absorption of one joule of radiation energy per kilogram of matter.

Relationships:-
1. Entity1: ""Tis, N0"", Entity2: ""60.75 Gy (2.25 Gy/fraction) to 66 Gy (2.0 Gy/fraction)"", Relationship: ""treatment protocol""
2. Entity1: ""T1, N0"", Entity2: ""63 Gy (2.25 Gy/fraction) to 66 Gy (2.0 Gy/fraction) or 50 Gy (3.12 Gy/fraction) to 52 Gy (3.28 Gy/fraction)"", Relationship: ""treatment protocol""
3. Entity1: ""T2, N0"", Entity2: ""65.25 Gy (2.25 Gy/fraction) to 70 Gy (2.0 Gy/fraction)"", Relationship: ""treatment protocol""
4. Entity1: ""≥T2, N1 (PTV High risk)"", Entity2: ""66 Gy (2.2 Gy/fraction) to 70 Gy (2.0 Gy/fraction)"", Relationship: ""treatment protocol""
5. Entity1: ""≥T2, N1 (Low to intermediate risk)"", Entity2: ""44–50 Gy (2.0 Gy/fraction) to 54–63 Gy (1.6–1.8 Gy/fraction)"", Relationship: ""treatment protocol""

Causalities:-
<CO>Tis, N0</CO>: <A>60.75 Gy (2.25 Gy/fraction) to 66 Gy (2.0 Gy/fraction)</A>
<CO>T1, N0</CO>: <A>63 Gy (2.25 Gy/fraction, preferred) to 66 Gy (2.0 Gy/fraction) or 50 Gy (3.12 Gy/fraction) to 52 Gy (3.28 Gy/fraction)</A>
<CO>T2, N0</CO>: <A>65.25 (2.25 Gy/fraction) to 70 Gy (2.0 Gy/fraction)</A>
<CO>≥T2, N1</CO>: <A>PTV High risk: Primary tumor and involved lymph nodes (includes possible local subclinical infiltration at the primary site and at the high-risk level lymph node(s))</A>
<A>Fractionation: 66 Gy (2.2 Gy/fraction) to 70 Gy (2.0 Gy/fraction); daily Monday–Friday in 6–7 weeks</A>
<A>Concomitant boost accelerated RT: 72 Gy/6 weeks (1.8 Gy/fraction, large field; 1.5 Gy boost as second daily fraction during last 12 treatment days)</A>
<A>66–70 Gy (2.0 Gy/fraction; 6 fractions/wk accelerated)</A>
<A>Hyperfractionation: 79.2–81.6 Gy/7 weeks (1.2 Gy/fraction, twice daily)</A>
<CO>Low to intermediate risk</CO>: <A>Sites of suspected subclinical spread</A>
<A>44–50 Gy (2.0 Gy/fraction) to 54–63 Gy (1.6–1.8 Gy/fraction)</A>

Section Name: Concurrent Systemic Therapy/RT
====================
Entities:-
Cisplatin : A platinum-containing antineoplastic agent used in the treatment of various cancers.
Carboplatin : An organoplatinum compound that possesses antineoplastic activity.
Fluorouracil : A chemotherapy drug used to treat various types of cancer.

Relationships:-
1. Entity1: ""concurrent systemic therapy/RT"", Entity2: ""cisplatin"", Relationship: ""uses""
2. Entity1: ""concurrent systemic therapy/RT"", Entity2: ""carboplatin and 5-FU"", Relationship: ""uses""
3. Entity1: ""multiagent chemotherapy"", Entity2: ""toxicity burden"", Relationship: ""increases""

Causalities:-
<CO>Based on published data</CO>, <A>concurrent systemic therapy/RT most commonly uses conventional fractionation at 2.0 Gy per fraction to a typical dose of 70 Gy in 7 weeks with single-agent cisplatin given every 3 weeks at 100 mg/m²</A>; <CO>2–3 cycles of chemotherapy are used depending on the radiation fractionation scheme (RTOG 0129)</CO>. <CO>When carboplatin and 5-FU are used</CO>, <A>the recommended regimen is standard fractionation plus 3 cycles of chemotherapy</A>. <CO>Other fraction sizes (e.g., 1.8 Gy, conventional), multiagent chemotherapy, other dosing schedules of cisplatin, or altered fractionation with chemotherapy</CO> <E>are efficacious</E>, and <C>there is no consensus on the optimal approach</C>. <C>In general, the use of concurrent systemic therapy/RT</C> <E>carries a high toxicity burden</E>; <C>multiagent chemotherapy</C> <E>will likely further increase the toxicity burden</E>. <A>For any systemic therapy/RT approach, close attention should be paid to published reports for the specific chemotherapy agent, dose, and schedule of administration</A>. <A>Systemic therapy/RT should be performed by an experienced team and should include substantial supportive care</A>.

Section Name: Treatment Modalities
====================
Entities:-
Intensity-Modulated Radiotherapy : A type of conformal radiotherapy that uses computer-controlled linear accelerators to deliver precise radiation doses to a malignant tumor or specific areas within the tumor.
Intensity Modulated Radiation Therapy : A type of conformal radiotherapy that uses computer-controlled linear accelerators to deliver precise radiation doses to a malignant tumor or specific areas within the tumor.
Intensity-Modulated Radiation Therapy : An advanced type of high-precision radiotherapy that uses computer-controlled linear accelerators to deliver precise radiation doses to a malignant tumor or specific areas within the tumor.
Radiotherapy, Conformal : A type of radiotherapy that uses imaging to conform the radiation dose to the shape of the tumor.
3D Conformal Radiation Therapy : A technique in radiotherapy that uses imaging to conform the radiation dose to the shape of the tumor.
Chemotherapy, Adjuvant : Treatment with drugs that kill cancer cells, often used in conjunction with other therapies.
Chemotherapy : The treatment of disease by the use of chemical substances, especially the treatment of cancer by cytotoxic and other drugs.
Drug Therapy, Combination : The use of two or more drugs to achieve a therapeutic effect.
Systemic Therapy : A type of therapy that uses substances that travel through the bloodstream, reaching and affecting cells all over the body.

Relationships:-
1. Entity1: ""Intensity-Modulated Radiation Therapy (IMRT)"", Entity2: ""3D Conformal Radiation Therapy (3D-CRT)"", Relationship: ""are delivery methods for radiation therapy""
2. Entity1: ""Chemotherapy"", Entity2: ""Radiation Therapy"", Relationship: ""is integrated with for aggressive or advanced cancer cases""

Causalities:-
<CO> contingent upon patient-specific considerations </CO> <A> suggests either Intensity-Modulated Radiation Therapy (IMRT) or 3D Conformal Radiation Therapy (3D-CRT) as delivery methods </A>. <A> These advanced techniques are employed to optimize treatment accuracy </A>, <E> preserving surrounding healthy tissue and improving overall patient outcomes </E>. <A> a focus on concurrent systemic therapies underlines the importance of integrating chemotherapy </A>, particularly <CO> for patients with more aggressive forms of cancer or those demonstrating advanced disease characteristics </CO>.

Section Name: Additional Information
====================
Entities:-
Clinical Trials : Clinical trials are research studies performed in people that are aimed at evaluating a medical, surgical, or behavioral intervention.
Clinical Trial : A clinical trial is a research study in which one or more human subjects are prospectively assigned to one or more interventions to evaluate the effects of those interventions on health-related biomedical or behavioral outcomes.
National Comprehensive Cancer Network : The National Comprehensive Cancer Network (NCCN) is an alliance of 30 cancer centers in the United States, dedicated to improving the quality, effectiveness, and efficiency of cancer care.
Intensity-Modulated Radiation Therapy : An advanced type of high-precision radiotherapy that uses computer-controlled linear accelerators to deliver precise radiation doses to a malignant tumor or specific areas within the tumor.
Intensity Modulated Radiation Therapy : A type of conformal radiotherapy that uses computer-controlled linear accelerators to deliver precise radiation doses to a malignant tumor or specific areas within the tumor.
Three-Dimensional Conformal Radiation Therapy : A type of external beam radiation therapy that uses a computer to create a 3-dimensional picture of the tumor so that multiple radiation beams can be shaped exactly to the contour of the treatment area.

Relationships:-
1. Entity1: ""National Comprehensive Cancer Network"", Entity2: ""Clinical trial"", Relationship: ""encourages participation in""
2. Entity1: ""Intensity-Modulated Radiation Therapy"", Entity2: ""Three-Dimensional Conformal Radiation Therapy"", Relationship: ""recommended alternatives""

Causalities:-
<A> Participation in clinical trials </A> is especially encouraged. <A> Either IMRT (preferred) or 3D-CRT is recommended. </A>

Section Name: Conclusion
====================
Entities:-
Laryngeal Neoplasms : Tumors or cancer of the larynx, which may affect the glottis, supraglottis, or subglottis.
Malignant Neoplasm Of Glottis : A malignant tumor located in the glottic region of the larynx.
Laryngeal Cancer : Cancer that occurs in the larynx, or voice box, which may include the glottic region.
Prognosis : A medical term for predicting the likely or expected development of a disease.
Evidence-Based Practice : Healthcare practices that are based on scientific evidence and research.
Evidence-Based Medicine : An approach to medical practice intended to optimize decision-making by emphasizing the use of evidence from well-designed and conducted research.

Relationships:-
1. Entity1: ""treatment paradigms"", Entity2: ""glottic larynx cancer"", Relationship: ""encapsulates""
2. Entity1: ""personalized treatment plans"", Entity2: ""prognosis"", Relationship: ""improves""

Causalities:-
<C> glottic larynx cancer </C>. <CO> the nuances of each patient's condition </CO>. <A> personalized treatment plans </A> <E> promoting effective management and improved prognosis </E>. <A> deliver clear, evidence-based interventions </A> <CO> considering the complexities involved in cancer treatment </CO>.


Among these two options which one is the most likely true:

(A) `Location_of_Lymph_Nodes_3` increases risk `N_State_1`
(B) `N_State_1` `increases risk `Location_of_Lymph_Nodes_3`

The answer is: ...

1. State the evidences in detail of the validity of option (A) or (B) by cross referencing
NCCN Clinical Practitioner’s Guidelines for Head and Neck Cancer.
2. If the evidences are obtained from `INFORMATION FROM KNOWLEDGE BASE`,
mention their corresponding Page Numbers, Section Name, entities, relationships and causalities.

DESIRED OUTPUT FORMAT:
<thinking>
...
</thinking>
<answer>
{
   ""thinking"": [""..."", ...],
   ""evidences"": [""..."", ...],
   ""answer"": ...
}
</answer>

Before providing the answer in <answer> tags, think step by step in detail in <thinking> tags and analyze every part.
Output inside <answer> tag in JSON format. Only output valid JSON.
DO NOT HALLUCINATE. DO NOT MAKE UP FACTUAL INFORMATION.
","1. The edge (Location_of_Lymph_Nodes_3) causes (N_State_1) suggests that the presence of lymph nodes in a specific location can indicate the spread of cancer, which directly affects the state of cancer in nearby lymph nodes.
2. The explanation for EDGE1 supports this causal relationship, indicating a positive causal direction and proximal causal distance, meaning the presence of lymph nodes is closely related to the state of cancer in nearby lymph nodes.
3. The edge (N_State_1) causes (Location_of_Lymph_Nodes_3) is deemed invalid as a causal relationship because the anatomical presence of lymph nodes is not caused by the cancer state of nearby lymph nodes.
4. The explanation for EDGE2 suggests that while the cancer state might influence clinical decisions, it does not cause the anatomical presence or absence of lymph nodes.
5. The NCCN Clinical Practitioner's Guidelines for Head and Neck Cancer emphasize the importance of lymph node involvement in cancer staging and prognosis, supporting the idea that the presence of lymph nodes can indicate cancer spread.
6. From the INFORMATION FROM KNOWLEDGE BASE, the section on 'Neck Management' (Page 102) discusses the relationship between tumor sites and lymphatic drainage, indicating that lymph node involvement is a critical factor in cancer management.
7. The causalities in the 'Neck Management' section highlight that tumor sites with bilateral lymphatic drainage often require neck dissection, emphasizing the role of lymph nodes in cancer spread.
","1. Page 102, Section Name: Neck Management, Entities: Tumor sites, Bilateral lymphatic drainage, Relationships: Tumor sites associated with bilateral lymphatic drainage, Causalities: Tumor sites with bilateral lymphatic drainage often require neck dissection.
2. Page 102, Section Name: Head and Neck Cancers - Principles of Surgery, Entities: Neoplasm Staging, Metastasis, Relationships: Surgical management dictated by tumor staging, Causalities: Extent of tumor at initial staging dictates surgical management of regional lymphatics.
",A,"{'A': 100.0, 'B': 0.0}",yes,A,"1. The AI assistant's reasoning for selecting option (A) is based on the explanation provided for EDGE1, which suggests a causal relationship where the presence of lymph nodes in a specific location can indicate the spread of cancer, affecting the state of cancer in nearby lymph nodes.
2. The assistant correctly identifies that EDGE2 is invalid as a causal relationship because the anatomical presence of lymph nodes is not caused by the cancer state of nearby lymph nodes, supporting the rejection of option (B).
3. The assistant references the NCCN Clinical Practitioner's Guidelines for Head and Neck Cancer, emphasizing the importance of lymph node involvement in cancer staging and prognosis, which aligns with the reasoning for option (A).
4. The assistant also cross-references the INFORMATION FROM KNOWLEDGE BASE, particularly the 'Neck Management' section, which discusses the relationship between tumor sites and lymphatic drainage, supporting the role of lymph nodes in cancer spread.
5. The causalities mentioned in the 'Neck Management' section further support the idea that lymph node involvement is a critical factor in cancer management, reinforcing the validity of option (A).
6. Overall, the assistant's reasoning is consistent with the provided explanations and external references, making the final answer (A) consistent with the reasoning.
"
1,gpt-4o,"Location_of_Lymph_Nodes_3,Sonographie_7","""{'NODE1': {'id': 'Location_of_Lymph_Nodes_3', 'label': 'Location of Lymph Nodes', 'description': 'This node represents the presence or absence of lymph nodes in a specific location, which is crucial for cancer diagnosis and staging. The detection of lymph nodes can indicate the spread of cancer and affect treatment decisions.', 'type': 'Patient Situation', 'observability': 'Unobserved', 'states': [{'state_name': 'present', 'state_description': 'Lymph nodes are detected in the specified location, which may indicate the spread of cancer and is important for staging and treatment planning.'}, {'state_name': 'absent', 'state_description': 'Lymph nodes are not detected in the specified location, which may suggest no spread of cancer to this area and is important for staging and treatment planning.'}]}, 'NODE2': {'id': 'Sonographie_7', 'label': 'Ultrasound Examination Result', 'description': 'This node represents the result of an ultrasound examination, which is a diagnostic imaging technique used to visualize internal organs and structures. The result can indicate whether certain findings are present or absent, which can aid in the diagnosis and management of various conditions.', 'type': 'Examination Result', 'observability': 'Observed', 'states': [{'state_name': 'present', 'state_description': 'The ultrasound examination has detected the presence of a specific finding or abnormality.'}, {'state_name': 'absent', 'state_description': 'The ultrasound examination has not detected the specific finding or abnormality, indicating its absence.'}]}, 'EDGE1': {'edges_ids': ['Location_of_Lymph_Nodes_3', 'Sonographie_7'], 'edge': '(Location_of_Lymph_Nodes_3) causes (Sonographie_7)', 'explanation': ['The edge represents the causal relationship where the presence or absence of lymph nodes in a specific location (Location_of_Lymph_Nodes_3) affects the result of an ultrasound examination (Sonographie_7).', 'In clinical practice, the presence of lymph nodes can be detected by ultrasound, making it a valid causal relationship.', 'The causal direction is positive because the presence of lymph nodes increases the likelihood of detection by ultrasound.', 'The presence of lymph nodes is a sufficient condition for the ultrasound to detect them, but not necessary, as ultrasounds can detect other findings.', 'The causal distance is proximal because the presence of lymph nodes directly affects the ultrasound result.'], 'causal_direction': 'positive', 'causal_factor': {'necessary': False, 'sufficient': True}, 'causal_distance': 'Proximal'}, 'EDGE2': {'edges_ids': ['Sonographie_7', 'Location_of_Lymph_Nodes_3'], 'edge': '(Sonographie_7) causes (Location_of_Lymph_Nodes_3)', 'explanation': ['The edge suggests that the result of an ultrasound examination (Sonographie_7) causes the presence or absence of lymph nodes in a specific location (Location_of_Lymph_Nodes_3).', 'However, the ultrasound examination is a diagnostic tool that detects the presence of lymph nodes; it does not cause them to be present or absent.', 'The presence of lymph nodes is a physical condition that exists independently of the ultrasound examination.', 'Therefore, the edge is not valid as there is no causal relationship where the ultrasound result causes the lymph nodes to be present or absent.'], 'causal_direction': 'Unknown', 'causal_factor': {'necessary': False, 'sufficient': False}, 'causal_distance': 'Unknown'}, 'ENTITIES_MATCHING_PAGES_INFO': {'53': {'matching_entities': [{'FOLLOW-UP EVALUATIONS': 0.92514485}, {'IMAGING': 0.9209789}, {'MAGNETIC RESONANCE IMAGING': 0.9202132}], 'count': 3}, '129': {'matching_entities': [{'LYMPH NODE STRUCTURE': 0.99134904}, {'LYMPH NODE': 0.98570025}, {'LYMPH NODES': 0.97445965}], 'count': 3}, '130': {'matching_entities': [{'LYMPH NODE STRUCTURE': 0.99134904}, {'LYMPH NODE': 0.98570025}, {'LYMPH NODES': 0.97445965}], 'count': 3}, '154': {'matching_entities': [{'LYMPH NODE STRUCTURE': 0.99134904}, {'LYMPH NODE': 0.98570025}, {'LYMPH NODES': 0.97445965}], 'count': 3}, '93': {'matching_entities': [{'ULTRASOUND': 0.9491661}, {'MAGNETIC RESONANCE IMAGING': 0.9202132}], 'count': 2}}, 'GUIDELINE_PAGES_INFO': '--------------------------------------------------\\nPage Number: 53\\n\\nSection Name: Introduction\\n====================\\nEntities:-\\nNational Comprehensive Cancer Network : The National Comprehensive Cancer Network (NCCN) is an alliance of 30 cancer centers in the United States, dedicated to improving the quality, effectiveness, and efficiency of cancer care so that patients can live better lives.\\nLaryngeal Neoplasms : Tumors or cancer of the larynx, which may affect the supraglottic, glottic, or subglottic regions.\\nMalignant Neoplasm Of Supraglottis : A malignant tumor located in the supraglottic region of the larynx.\\n\\nRelationships:-\\n1. Entity1: \""National Comprehensive Cancer Network\"", Entity2: \""Malignant neoplasm of supraglottis\"", Relationship: \""provides guidelines for\""\\n2. Entity1: \""clinical staging\"", Entity2: \""treatment strategies\"", Relationship: \""part of flowchart for\""\\n\\nCausalities:-\\nThe provided image is a flowchart outlining the <C> NCCN (National Comprehensive Cancer Network) guidelines </C> for the treatment of <CO> cancers of the supraglottic larynx </CO>. This flowchart <A> utilizes a highly structured approach to convey clinical staging and treatment strategies </A>, indicating the various pathways based on <CO> patient conditions and disease features </CO>.\\n\\nSection Name: NCCN Guidelines Version 4.2024\\n====================\\nEntities:-\\nLaryngeal Neoplasms : Tumors or cancer of the larynx, which may affect the supraglottic, glottic, or subglottic regions.\\nMalignant Neoplasm Of Supraglottis : A malignant tumor located in the supraglottic region of the larynx.\\nSupraglottic Cancer : Cancer that occurs in the supraglottic region of the larynx, above the vocal cords.\\nClinical Trials As Topic : Pre-planned studies of the safety, efficacy, or optimum dosage schedule of one or more diagnostic, therapeutic, or prophylactic drugs, devices, or techniques in humans selected according to predetermined criteria of eligibility and observed for predefined evidence of favorable and unfavorable effects.\\nClinical Trial : A type of research that studies new tests and treatments and evaluates their effects on human health outcomes.\\n\\nRelationships:-\\n1. Entity1: \""Cancer of the Supraglottic Larynx\"", Entity2: \""Clinical Trials\"", Relationship: \""recommended management strategy\""\\n\\nCausalities:-\\n- All recommendations are category 2A unless otherwise indicated.\\n- <A> Participation in clinical trials </A> is especially encouraged.\\n\\nSection Name: Key Components of the Flowchart\\n====================\\nEntities:-\\nNeoplasm Staging : Methods used for staging neoplasms, including clinical and pathological staging.\\nRadiotherapy : The use of ionizing radiation to treat cancer.\\nSurgical Procedures, Operative : Operations carried out for the correction of deformities and defects, repair of injuries, and diagnosis and cure of certain diseases.\\nAdjuvant Chemotherapy : Chemotherapy given in addition to the primary treatment to maximize its effectiveness.\\nNeoplasm Recurrence, Local : The return of a tumor at the original site after treatment.\\nClinical Trials As Topic : Pre-planned studies of the safety, efficacy, or optimum dosage schedule of one or more diagnostic, therapeutic, or prophylactic drugs, devices, or techniques in humans selected according to predetermined criteria of eligibility and observed for predefined evidence of favorable and unfavorable effects.\\n\\nRelationships:-\\n1. Entity1: \""Clinical Staging\"", Entity2: \""Treatment of Primary and Neck\"", Relationship: \""determines\""\\n2. Entity1: \""Evaluation and Follow-Up\"", Entity2: \""Adverse and No Adverse Features\"", Relationship: \""leads to decision based on\""\\n3. Entity1: \""Adjuvant Treatment\"", Entity2: \""Adverse pathologic features\"", Relationship: \""considered if present\""\\n4. Entity1: \""Clinical Trials\"", Entity2: \""Treatment Pathway\"", Relationship: \""part of\""\\n\\nCausalities:-\\n### Key Components of the Flowchart\\n\\n1. **Clinical Staging**: The flowchart starts with <A>clinical staging</A>, indicating that <CO>patients must first be evaluated to determine the extent of cancer</CO>. This is essential for <E>deciding on appropriate treatment options</E>.\\n\\n2. **Treatment of Primary and Neck**: The flowchart details multiple treatment strategies, including:\\n   - <A>**Concurrent systemic therapy/RT**</A>: This suggests a combination approach for <CO>patients eligible for such treatment</CO>.\\n   - <A>**Definitive Radiation Therapy (RT)**</A>: Recommended for <CO>low-volume diseases or patients who cannot tolerate systemic therapy</CO>.\\n   - <A>**Surgical Options**</A>: It highlights options such as endoscopic or open partial laryngectomy and neck dissection, which are <CO>contingent on clinical evaluations</CO>.\\n\\n3. **Evaluation and Follow-Up**: After initial treatment approaches, the chart directs clinicians to perform a <A>\""Post Systemic Therapy/RT or RT Neck Evaluation\""</A>. This step <E>assesses whether there are adverse pathologic features</E>, guiding subsequent treatment decisions.\\n\\n4. **Adverse and No Adverse Features**: The decision pathway diverges based on findings:\\n   - <CO>Patients with **adverse pathologic features**</CO> may have <A>additional diagnostic imaging (CT or MRI)</A> and may require <A>further systemic treatment</A>.\\n   - <CO>Patients with **no adverse features**</CO> may be directed towards <A>considerations for radiation therapy</A>.\\n\\n5. **Adjuvant Treatment and Recurrence**: The chart also addresses <E>management of any recurrent or persistent disease</E>, emphasizing the importance of <A>regular follow-up assessments</A>. Various options for <A>adjuvant treatment</A> are mentioned, focusing on tailored approaches towards ongoing management of the disease.\\n\\n6. **Clinical Trials**: The flowchart encourages <A>participation in clinical trials</A>, indicating a commitment to <E>exploring new treatments and improving patient outcomes</E>.\\n\\nSection Name: Principles\\n====================\\nEntities:-\\nImaging : The process of producing images of the body or parts of the body to diagnose or examine disease.\\nSurgical Procedure : A medical procedure involving an incision with instruments; performed to repair damage or arrest disease in a living body.\\nRadiation Therapy : The use of ionizing radiation to treat cancer and other diseases.\\nSystemic Therapy : Treatment using substances that travel through the bloodstream, reaching and affecting cells all over the body.\\n\\nRelationships:-\\n1. Entity1: \""Imaging\"", Entity2: \""Surgery\"", Relationship: \""Both are foundational principles in medical practice.\""\\n2. Entity1: \""Radiation therapy\"", Entity2: \""Systemic Therapy\"", Relationship: \""Both are treatment modalities for cancer.\""\\n\\nCausalities:-\\n#### Principles\\n- **Principles of Imaging (IMG-A)**\\n- **Principles of Surgery (SURG-A)**\\n- **Principles of Radiation Therapy (SUPRA-A)**\\n- **Principles of Systemic Therapy for Non-Nasopharyngeal Cancers (SYST-A)**\\n\\nSection Name: Adverse Pathologic Features\\n====================\\nEntities:-\\nExtranodal Extension : The spread of cancer cells beyond the lymph node capsule into the surrounding tissues.\\nPositive Surgical Margins : The presence of cancer cells at the edge of the tissue removed during surgery.\\nPerineural Invasion : Cancer cells found surrounding or tracking along a nerve within the perineural space.\\nVascular Invasion : The presence of cancer cells within blood vessels.\\nLymphatic Invasion : The presence of cancer cells within lymphatic vessels.\\n\\nRelationships:-\\n1. Entity1: \""Extranodal Extension\"", Entity2: \""Positive Surgical Margins\"", Relationship: \""Both indicate cancer spread beyond original site.\""\\n2. Entity1: \""Perineural Invasion\"", Entity2: \""Vascular Invasion\"", Relationship: \""Both are pathways for cancer spread.\""\\n3. Entity1: \""pT3 or pT4 primary\"", Entity2: \""pN2 or pN3 nodal disease\"", Relationship: \""Both indicate advanced cancer stages.\""\\n\\nCausalities:-\\n<C> Extranodal extension </C>\\n<C> Positive margins </C>\\n<C> Close margins </C>\\n<C> pT3 or pT4 primary </C>\\n<C> pN2 or pN3 nodal disease </C>\\n<C> Perineural invasion </C>\\n<C> Vascular invasion </C>\\n<C> Lymphatic invasion </C>\\n\\nSection Name: Clinical Staging and Treatment of Primary and Neck\\n====================\\nEntities:-\\nAdjuvant Chemotherapy : Chemotherapy given in addition to the primary treatment to maximize its effectiveness.\\nFollow-Up Procedure : A procedure performed to monitor the progress of a patient after treatment.\\nRecurrent Disease : A disease that returns after a period of remission.\\nLaryngectomy : Surgical removal of the larynx, often used to treat cancer.\\nRadiation Therapy : The use of ionizing radiation to treat cancer and other diseases.\\nClinical Trial : A type of research that studies new tests and treatments and evaluates their effects on human health outcomes.\\nNeck Dissection : Surgical procedure to remove lymph nodes and surrounding tissue to treat cancer.\\nChemotherapy : Treatment of disease by the use of chemical substances, especially cancer by cytotoxic drugs.\\n\\nRelationships:-\\n1. Entity1: \""Adjuvant Treatment\"", Entity2: \""Treatment of Primary and Neck\"", Relationship: \""part of\""\\n2. Entity1: \""Follow-up\"", Entity2: \""Treatment of Primary and Neck\"", Relationship: \""part of\""\\n3. Entity1: \""Recurrent or Persistent Disease\"", Entity2: \""Treatment of Primary and Neck\"", Relationship: \""part of\""\\n4. Entity1: \""Larynx-Preserving Surgery\"", Entity2: \""Treatment Options\"", Relationship: \""is a treatment option for\""\\n5. Entity1: \""Concurrent Systemic Therapy/RT\"", Entity2: \""Treatment Options\"", Relationship: \""is a treatment option for\""\\n6. Entity1: \""Clinical Trials or Definitive RT\"", Entity2: \""Treatment Options\"", Relationship: \""is a treatment option for\""\\n7. Entity1: \""Endoscopic or Open Partial Laryngectomy and Neck Dissection(s)\"", Entity2: \""Treatment Options\"", Relationship: \""is a treatment option for\""\\n8. Entity1: \""Induction Chemotherapy\"", Entity2: \""Treatment Options\"", Relationship: \""is a treatment option for\""\\n\\nCausalities:-\\n<A> Amenable to Larynx-Preserving (Conservation) Surgery </A>: <CO> T1\u20132, N+ and selected T3, N1 </CO>\\n<A> Concurrent Systemic Therapy/RT </A>: <CO> i, k, l </CO>\\n<A> Clinical Trials or Definitive RT </A>: <CO> i </CO>\\n<A> Endoscopic or Open Partial Laryngectomy and Neck Dissection(s) </A>: <CO> h </CO>\\n<A> Induction Chemotherapy </A>: <CO> k, m </CO>\\n\\nSection Name: Pathologic Features and Response Assessment\\n====================\\nEntities:-\\nRadiation Therapy : The use of ionizing radiation to treat cancer and other diseases.\\nExtranodal Extension : The spread of cancer cells beyond the lymph node capsule into the surrounding tissues.\\nPositive Surgical Margin : Cancer cells are found at the edge of the material removed during surgery, indicating that some cancer may have been left behind.\\nSystemic Therapy : Treatment using substances that travel through the bloodstream, reaching and affecting cells all over the body.\\n\\nRelationships:-\\n1. Entity1: \""Extranodal extension\"", Entity2: \""Adverse Pathologic Features\"", Relationship: \""is a type of\""\\n2. Entity1: \""Positive margin\"", Entity2: \""Adverse Pathologic Features\"", Relationship: \""is a type of\""\\n3. Entity1: \""Systemic Therapy\"", Entity2: \""Adverse Pathologic Features\"", Relationship: \""considered in response to\""\\n4. Entity1: \""Radiation Therapy\"", Entity2: \""Adverse Pathologic Features\"", Relationship: \""considered in response to\""\\n\\nCausalities:-\\n#### Pathologic Features\\n- **No Adverse Pathologic Features**: j\\n  - <A> Consider RT </A>: i\\n- **Adverse Pathologic Features**: j\\n  - <CO> Extranodal extension and/or positive margin </CO>: n\\n  - Other risk features\\n  - <A> Systemic therapy/RT </A>: i, k (category 1)\\n  - <A> Consider systemic therapy/RT </A>: i, k\\n\\n#### Response Assessment\\n- **Response Assessment** (SUPRA-7)\\n\\nSection Name: Imaging and Recurrent or Persistent Disease\\n====================\\nEntities:-\\nTomography, X-Ray Computed : A method of body imaging in which a thin X-ray beam rotates around the patient.\\nMagnetic Resonance Imaging : Medical imaging technique used in radiology to form pictures of the anatomy and the physiological processes of the body.\\nComputed Tomography : Medical imaging technique used in radiology to obtain detailed internal images of the body.\\n\\nRelationships:-\\n1. Entity1: \""CT\"", Entity2: \""primary and neck\"", Relationship: \""used for imaging\""\\n2. Entity1: \""MRI\"", Entity2: \""primary and neck\"", Relationship: \""used for imaging\""\\n3. Entity1: \""Post Systemic Therapy/RT\"", Entity2: \""Recurrent or Persistent Disease\"", Relationship: \""evaluation after treatment\""\\n4. Entity1: \""RT Neck Evaluation\"", Entity2: \""Recurrent or Persistent Disease\"", Relationship: \""evaluation after treatment\""\\n\\nCausalities:-\\n<A> CT (with contrast) or MRI (with and without contrast) of primary and neck </A>\\n\\n<CO> Recurrent or Persistent Disease </CO>\\n\\n<CO> Post Systemic Therapy/RT or RT Neck Evaluation </CO>\\n\\nSection Name: Conclusion\\n====================\\nEntities:-\\nOncologists : Medical doctors who specialize in the diagnosis and treatment of cancer.\\nSupraglottic Larynx Cancer : A type of cancer that occurs in the supraglottic region of the larynx, which is the area above the vocal cords.\\nClinical Staging : The process of determining the extent of cancer in the body, usually based on physical examination, imaging tests, and biopsies.\\nTreatment Strategies : Plans or methods developed to treat diseases, including cancer, which may involve surgery, chemotherapy, radiation therapy, or other modalities.\\nFollow-Up Evaluations : Medical assessments conducted after initial treatment to monitor a patient\\'s progress and detect any recurrence of disease.\\nClinical Efficacy : The ability of a treatment to produce the desired therapeutic effect in clinical settings.\\nResearch : Systematic investigation and study conducted to establish facts and reach new conclusions.\\nTreatment Paradigms : Standard models or patterns of treatment used in medical practice, often based on clinical guidelines and research findings.\\n\\nRelationships:-\\n1. Entity1: \""Oncologists\"", Entity2: \""Supraglottic Larynx Cancer\"", Relationship: \""use flowchart for decision-making\""\\n2. Entity1: \""Clinical Staging\"", Entity2: \""Treatment Strategies\"", Relationship: \""part of management process\""\\n3. Entity1: \""Treatment Strategies\"", Entity2: \""Follow-Up Evaluations\"", Relationship: \""part of management process\""\\n\\nCausalities:-\\n<A> The flowchart serves as a comprehensive guide for oncologists and healthcare providers </A>, <A> facilitating informed decision-making in the treatment of supraglottic larynx cancer </A>. <A> By visualizing the complex interactions between clinical staging, treatment strategies, and follow-up evaluations </A>, <E> it streamlines the management process </E>, <E> ensuring that patients receive appropriate care tailored to their specific needs </E>. <E> The detailed pathways not only enhance clinical efficacy </E> but also <E> underscore the importance of ongoing research and adaptation of treatment paradigms in oncology </E>.\\n--------------------------------------------------\\nPage Number: 129\\n\\nSection Name: TNM Staging System for the Larynx - Regional Lymph Nodes (N)\\n====================\\nEntities:-\\nLymph Nodes : Small, bean-shaped structures that are part of the body\\'s immune system. They filter substances that travel through the lymphatic fluid, and they contain lymphocytes (white blood cells) that help the body fight infection and disease.\\nLymph Node Structure : A structure that is part of the lymphatic system, involved in the filtration of lymph and the production of lymphocytes.\\nLymph Node : An organ of the lymphatic system and the adaptive immune system that is widely present throughout the body.\\n\\nRelationships:-\\n1. Entity1: \""NCCN Guidelines\"", Entity2: \""Regional Lymph Nodes\"", Relationship: \""provides classification for\""\\n2. Entity1: \""AJCC TNM Staging System\"", Entity2: \""Regional Lymph Nodes\"", Relationship: \""provides classification for\""\\n3. Entity1: \""Clinical N\"", Entity2: \""Regional Lymph Nodes\"", Relationship: \""is a classification of\""\\n\\nCausalities:-\\nThe <C> classification of the Regional Lymph Nodes (N) for head and neck cancers </C> is crucial for <E> determining the presence and extent of lymph node metastases </E>, which are critical in <E> establishing the severity and appropriate treatment strategies </E>. <A> Clinicians use this structured classification for accurate staging and subsequent treatment planning in patients diagnosed with head and neck cancers </A>.\\n\\nSection Name: NCCN Guidelines Version 4.2024\\n====================\\nEntities:-\\nHead And Neck Neoplasms : Cancers that occur in the head or neck region, including the nasal cavity, sinuses, lips, mouth, salivary glands, throat, or larynx.\\nMalignant Neoplasm Of Head And Neck : A malignant tumor located in the head and neck region.\\nNational Comprehensive Cancer Network : An alliance of cancer centers in the United States, dedicated to improving the quality, effectiveness, and efficiency of cancer care.\\n\\nRelationships:-\\n1. Entity1: \""NCCN Guidelines\"", Entity2: \""Head and Neck Cancers\"", Relationship: \""guidelines for\""\\n2. Entity1: \""NCCN Guidelines\"", Entity2: \""National Comprehensive Cancer Network\"", Relationship: \""published by\""\\n\\nCausalities:-\\nThe provided text does not contain any clinical causes, effects, conditions, or actions to extract.\\n--------------------------------------------------\\nPage Number: 130\\n\\nSection Name: Pathological N (pN)\\n====================\\nEntities:-\\nLymph Nodes : Small, bean-shaped structures that are part of the body\\'s lymphatic system. They filter lymph fluid and store white blood cells that help fight infection.\\nNeoplasm Metastasis : The transfer of a neoplasm from one organ or part of the body to another remote from the primary site.\\nTnm Staging : A system used to describe the size and spread of cancer in a standardized way. T refers to the size of the tumor, N to the involvement of lymph nodes, and M to metastasis.\\nLymph Node Structure : A structure that is part of the lymphatic system, involved in the immune response.\\nMetastasis : The spread of a cancer or other disease from one organ or part to another not directly connected with it.\\nTnm Staging System : A cancer staging notation system that describes the extent of cancer in a patient\\'s body.\\nLymph Node : An organ of the lymphatic system and the adaptive immune system.\\n\\nRelationships:-\\n1. Entity1: \""Lymph Nodes\"", Entity2: \""Neoplasm Metastasis\"", Relationship: \""involved in\""\\n2. Entity1: \""TNM Staging\"", Entity2: \""Lymph Nodes\"", Relationship: \""includes\""\\n3. Entity1: \""TNM Staging\"", Entity2: \""Neoplasm Metastasis\"", Relationship: \""describes\""\\n\\nCausalities:-\\n<CO> NX: Regional lymph nodes cannot be assessed </CO>\\n<CO> N0: No regional lymph node metastasis </CO>\\n<CO> N1: Metastasis in a single ipsilateral lymph node, 3 cm or smaller in greatest dimension ENE(\u2013) </CO>\\n<CO> N2: Metastasis in a single ipsilateral lymph node, 3 cm or smaller in greatest dimension and ENE(+); or larger than 3 cm but not larger than 6 cm in greatest dimension and ENE(\u2212); or metastases in multiple ipsilateral lymph nodes, none larger than 6 cm in greatest dimension and ENE(\u2212); or in bilateral or contralateral lymph node(s), none larger than 6 cm in greatest dimension and ENE(\u2212) </CO>\\n<CO> N2a: Metastasis in a single ipsilateral node, 3 cm or smaller in greatest dimension and ENE(+); or metastasis in a single ipsilateral node, larger than 3 cm but not larger than 6 cm in greatest dimension and ENE(\u2212) </CO>\\n<CO> N2b: Metastases in multiple ipsilateral nodes, none larger than 6 cm in greatest dimension and ENE(\u2212) </CO>\\n<CO> N2c: Metastases in bilateral or contralateral lymph node(s), none larger than 6 cm in greatest dimension and ENE(\u2212) </CO>\\n<CO> N3: Metastasis in a lymph node, larger than 6 cm in greatest dimension and ENE(\u2212); or metastasis in a single ipsilateral node, larger than 3 cm in greatest dimension and ENE(+); or multiple ipsilateral, contralateral, or bilateral lymph nodes and any with ENE(+); or a single contralateral node of any size and ENE(+) </CO>\\n<CO> N3a: Metastasis in a lymph node, larger than 6 cm in greatest dimension and ENE(\u2212) </CO>\\n<CO> N3b: Metastasis in a single ipsilateral node, larger than 3 cm in greatest dimension and ENE(+); or multiple ipsilateral, contralateral, or bilateral lymph nodes any with ENE(+); or a single contralateral node of any size and ENE(+) </CO>\\n<CO> Note: A designation of \u201cU\u201d or \u201cL\u201d may be used for any N category to indicate metastasis above the lower border of the cricoid (U) or below the lower border of the cricoid (L). Similarly, clinical and pathological ENE should be recorded as ENE(\u2212) or ENE(+). </CO>\\n\\nSection Name: Distant Metastasis (M)\\n====================\\nEntities:-\\nNeoplasm Metastasis : The transfer of a neoplasm from one organ or part of the body to another remote from the primary site.\\nMetastasis : The spread of a cancer or other disease from one organ or part to another not directly connected with it.\\n\\nRelationships:-\\n1. Entity1: \""M0\"", Entity2: \""Distant Metastasis\"", Relationship: \""is a category of\""\\n2. Entity1: \""M1\"", Entity2: \""Distant Metastasis\"", Relationship: \""is a category of\""\\n\\nCausalities:-\\n### Distant Metastasis (M)\\n\\n- **M0**: No distant metastasis\\n- **M1**: Distant metastasis\\n\\nSection Name: Histologic Grade (G)\\n====================\\nEntities:-\\nNeoplasm Grading : A system of classifying cancer cells in terms of how abnormal they look under a microscope and how quickly the tumor is likely to grow and spread.\\nHistologic Grade : A measure of how much tumor cells differ from healthy cells, used to assess the aggressiveness of cancer.\\n\\nRelationships:-\\n1. Entity1: \""GX\"", Entity2: \""Grade cannot be assessed\"", Relationship: \""is described as\""\\n2. Entity1: \""G1\"", Entity2: \""Well differentiated\"", Relationship: \""is described as\""\\n3. Entity1: \""G2\"", Entity2: \""Moderately differentiated\"", Relationship: \""is described as\""\\n4. Entity1: \""G3\"", Entity2: \""Poorly differentiated\"", Relationship: \""is described as\""\\n\\nCausalities:-\\n<CO>GX</CO>: <E>Grade cannot be assessed</E>\\n<CO>G1</CO>: <E>Well differentiated</E>\\n<CO>G2</CO>: <E>Moderately differentiated</E>\\n<CO>G3</CO>: <E>Poorly differentiated</E>\\n\\nSection Name: Prognostic Stage Groups\\n====================\\nEntities:-\\nNeoplasm Staging : Methods and systems of classifying neoplasms according to extent of disease.\\nTumor Staging : A system for describing the size and spread of cancer within the body.\\nTnm Staging System : A cancer staging notation system that describes the extent of cancer in a patient\\'s body.\\n\\nRelationships:-\\n1. Entity1: \""Stage 0\"", Entity2: \""Tis N0 M0\"", Relationship: \""defined by\""\\n2. Entity1: \""Stage I\"", Entity2: \""T1 N0 M0\"", Relationship: \""defined by\""\\n3. Entity1: \""Stage II\"", Entity2: \""T2 N0 M0\"", Relationship: \""defined by\""\\n4. Entity1: \""Stage III\"", Entity2: \""T3 N0 M0, T1 N1 M0, T2 N1 M0, T3 N1 M0\"", Relationship: \""defined by\""\\n5. Entity1: \""Stage IVA\"", Entity2: \""T1 N2 M0, T2 N2 M0, T3 N2 M0, T4a N0,N1,N2 M0\"", Relationship: \""defined by\""\\n6. Entity1: \""Stage IVB\"", Entity2: \""Any T N3 M0, T4b Any N M0\"", Relationship: \""defined by\""\\n7. Entity1: \""Stage IVC\"", Entity2: \""Any T Any N M1\"", Relationship: \""defined by\""\\n--------------------------------------------------\\nPage Number: 154\\n\\nSection Name: NCCN Guidelines Version 4.2024\\n====================\\nEntities:-\\nNccn Guidelines : The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) are a comprehensive set of guidelines detailing the sequential management decisions and interventions that apply to 97% of cancers affecting patients in the United States.\\n\\nRelationships:-\\n\\nCausalities:-\\n# NCCN Guidelines Version 4.2024\\n\\nSection Name: Head and Neck Cancers\\n====================\\nEntities:-\\nHead And Neck Neoplasms : Tumors or cancer of the head and neck region, including the nasal cavity, sinuses, lips, mouth, salivary glands, throat, or larynx.\\nRadiation Therapy : The medical use of ionizing radiation, generally as part of cancer treatment to control or kill malignant cells.\\nQuad Shot Regimen : A palliative radiation therapy regimen consisting of 44.4 Gy delivered in 12 fractions over three cycles, used for patients with limited life expectancy.\\n\\nRelationships:-\\n1. Entity1: \""Head and Neck Neoplasms\"", Entity2: \""70 Gy\"", Relationship: \""treatment dosage\""\\n2. Entity1: \""QUAD SHOT regimen\"", Entity2: \""Palliative Treatment\"", Relationship: \""purpose\""\\n\\nCausalities:-\\nThe College of Radiology describes basic technical specifications [here](http://www.acr.org/Quality-Safety). Furthermore, major consensus contouring guidelines for the treatment of head and neck (H&N) cancers are available for reference, especially for patients who are treated without surgery. [143,144]\\n\\nWhen radiation is given with definitive intent, <A> the dosages prescribed for gross disease are fairly standard, usually in the range of 70 Gy (at approximately 2 Gy/fraction/day) </A> for the following sites: <CO> lip, oral cavity, nasopharynx, oropharynx, hypopharynx, glottic larynx, supraglottic larynx, occult primary, salivary gland tumors, and MM </CO>. A second dose (often approximately 60 Gy, but varies) may be used to cover volumes considered at the highest risk for microscopic spread, while a lower dose (often approximately 50 Gy, but varies) is used for volumes treated electively with low risk for microscopic spread.\\n\\nAlthough several palliative RT regimens are provided, no single regimen is preferred [145,146]; specific regimens vary widely among NCCN Member Institutions. <A> Any palliative RT regimen that might cause severe toxicities should be avoided </A>. <A> More hypofractionated regimens may be useful </A> for <CO> patients with limited life expectancy, such as a few months </CO>. For example, <A> a common version of the QUAD SHOT regimen consists of a dose of 44.4 Gy, delivered in 12 fractions over three cycles, with each cycle separated by 2 to 3 weeks </A>. [147]\\n\\nSection Name: Radiation Doses\\n====================\\nEntities:-\\nRadiation Dosage : The amount of radiation absorbed by an object or person.\\nNeoplasms : New abnormal growth of tissue that can be benign or malignant.\\nLymph Nodes : Small, bean-shaped structures that are part of the body\\'s immune system.\\nRadiotherapy : The treatment of disease, especially cancer, using X-rays or similar forms of radiation.\\nChemotherapy : The use of chemical substances, especially the treatment of cancer by cytotoxic and other drugs.\\nRadiation Therapy : The medical use of ionizing radiation, generally as part of cancer treatment to control or kill malignant cells.\\nLymph Node Structure : A structure that is part of the lymphatic system, involved in the immune response.\\nNeoplasm : An abnormal mass of tissue as a result of neoplasia.\\nLymph Node : An organ of the lymphatic system and the adaptive immune system.\\nTumor : A mass of tissue that\\'s formed by an accumulation of abnormal cells.\\n\\nRelationships:-\\n1. Entity1: \""Radiation Dosage\"", Entity2: \""Neoplasms\"", Relationship: \""depends on\""\\n2. Entity1: \""Radiation Dosage\"", Entity2: \""Organs at risk\"", Relationship: \""may need to be decreased if close to\""\\n3. Entity1: \""Radiotherapy\"", Entity2: \""IMRT\"", Relationship: \""uses\""\\n4. Entity1: \""Radiotherapy\"", Entity2: \""Chemotherapy\"", Relationship: \""can be used with\""\\n\\nCausalities:-\\n<C> Selection of an exact radiation dose prescription and schedule of delivery </C> <E> depends on the primary tumor and neck node size, whether altered fractionation is used, and clinical circumstances, including whether concurrent systemic therapy will be used </E>. <CO> if it is prescribed very close to adjacent organs at risk </CO> <A> The dose may need to be decreased </A>. <CO> Anatomical changes (e.g., rapidly shrinking tumors, changes in air cavities, significant weight loss) </CO> <A> may necessitate repeat imaging and treatment replanning </A>. <CO> when the tumor is abutting brain or optic structures </CO> <A> hyperfractionation has been used </A>. <CO> if prescribed doses exceed 72 Gy using conventional fractionation </CO> <E> this may lead to unacceptable rates of normal tissue injury </E>. <A> Care must be taken </A>.\\n--------------------------------------------------\\nPage Number: 93\\n\\nSection Name: PRINCIPLES OF IMAGING\\n====================\\nEntities:-\\nImaging, Diagnostic : The production of a visual representation of parts of the body, for the purpose of clinical analysis and medical intervention.\\nHead And Neck Neoplasms : Tumors or cancer of the head and neck region, including the nasal cavity, sinuses, lips, mouth, salivary glands, throat, or larynx.\\nTomography, X-Ray Computed : An imaging procedure that uses special x-ray equipment to create detailed pictures, or scans, of areas inside the body.\\nMagnetic Resonance Imaging : A noninvasive diagnostic technique that uses magnetic fields and radio waves to produce a detailed image of the body\\'s soft tissue and bones.\\nContrast Media : Substances used to enhance the contrast of structures or fluids within the body in medical imaging.\\n\\nRelationships:-\\n1. Entity1: \""Imaging, Diagnostic\"", Entity2: \""Head and Neck Neoplasms\"", Relationship: \""used for\""\\n2. Entity1: \""Tomography, X-Ray Computed\"", Entity2: \""Contrast Media\"", Relationship: \""uses\""\\n3. Entity1: \""Magnetic Resonance Imaging\"", Entity2: \""Contrast Media\"", Relationship: \""uses\""\\n\\nCausalities:-\\n<C> Imaging </C> plays an essential role in the clinical care of patients with head and neck cancer. <A> The proper selection and utilization of imaging studies </A> is critical in caring for patients with head and neck cancer. <A> CT is performed with contrast </A>, while <A> CT imaging of the chest can be performed with or without contrast </A>, <CO> as clinically indicated </CO>. <A> MRI is performed with and without contrast </A>, <CO> unless contraindicated </CO>.\\n\\nSection Name: Initial Workup - Primary Site\\n====================\\nEntities:-\\nTomography, X-Ray Computed : An imaging procedure that uses special x-ray equipment to create detailed pictures, or scans, of areas inside the body.\\nMagnetic Resonance Imaging : A noninvasive diagnostic technique that uses magnetic fields and radio waves to produce a detailed image of the body\\'s soft tissue and bones.\\nHead And Neck Neoplasms : Tumors or cancer of the head and neck region, including the nasal cavity, sinuses, lips, mouth, salivary glands, throat, or larynx.\\nNeck Structure : The anatomical structure of the neck, which is the part of the body that connects the head to the torso.\\nSkull Base : The bottom part of the skull, which separates the brain from other facial structures.\\nThoracic Inlet : The opening at the top of the thoracic cavity, through which pass the trachea, esophagus, and major blood vessels.\\n\\nRelationships:-\\n1. Entity1: \""CT\"", Entity2: \""MRI\"", Relationship: \""complementary in imaging head and neck cancers\""\\n2. Entity1: \""CT\"", Entity2: \""Head and Neck Neoplasms\"", Relationship: \""used to evaluate\""\\n3. Entity1: \""MRI\"", Entity2: \""Head and Neck Neoplasms\"", Relationship: \""preferred for evaluating\""\\n4. Entity1: \""Skull base\"", Entity2: \""Thoracic inlet\"", Relationship: \""imaging range for evaluation\""\\n\\nCausalities:-\\n<A>Imaging assessment of the primary site</A> can be performed with <A>CT of the soft tissues of the neck</A> or <A>MRI of the neck</A>. <C>CT is complementary to MRI for head and neck cancers</C>. <A>It is utilized to evaluate cortical bone erosion or periosteal invasion, cartilage invasion, and bony erosion or destruction</A>. <CO>in certain conditions, such as evaluating the extent of bone marrow invasion or in patients with extensive dental amalgam obscuring anatomy on CT, assessing skull base invasion and cranial nerve involvement, and differentiating tumor from obstructed sinuses</CO>, <A>MRI is preferred over CT</A>. <CO>when involved lymph nodes or upper mediastinal cancers are present</CO>, <A>Complete evaluation of primary and nodal disease requires imaging from the skull base to the thoracic inlet, extending to the carina</A>.\\n\\nSection Name: PET/CT and Biopsy\\n====================\\nEntities:-\\nPositron Emission Tomography Computed Tomography : A medical imaging technique that combines PET and CT capabilities to provide detailed images of the body.\\nExamination Under Anesthesia : A procedure where a patient is examined while under anesthesia to allow for a more thorough examination.\\nBiopsy : A medical test involving the extraction of sample cells or tissues for examination to determine the presence or extent of a disease.\\nTonsillectomy : A surgical procedure to remove the tonsils, often performed to treat recurrent tonsillitis or sleep apnea.\\nFine Needle Aspiration : A type of biopsy procedure that uses a thin, hollow needle to extract cells from a lump or mass for examination.\\nUltrasound : A medical imaging technique that uses high-frequency sound waves to visualize internal organs and structures.\\nComputed Tomography : A diagnostic imaging procedure that uses a combination of X-rays and computer technology to produce cross-sectional images of the body.\\n\\nRelationships:-\\n1. Entity1: \""PET/CT\"", Entity2: \""EUA\"", Relationship: \""recommended before\""\\n2. Entity1: \""Fine Needle Aspiration (FNA)\"", Entity2: \""metastatic nodes\"", Relationship: \""used for biopsy of\""\\n3. Entity1: \""Image-guided needle biopsy\"", Entity2: \""cystic neck nodes\"", Relationship: \""recommended for initial diagnosis of\""\\n\\nCausalities:-\\n<CO> If imaging does not reveal an obvious primary cancer </CO>, <A> a PET/CT should be ordered before EUA, biopsies, and tonsillectomy </A>. <E> This helps identify potential primary sites </E> before any interventions take place. Additionally, <A> Fine Needle Aspiration (FNA) biopsy of metastatic nodes </A> <E> may provide pathologically informative results </E>. <CO> For initial diagnosis in cystic neck nodes </CO>, <A> image-guided needle biopsy (ultrasound or CT) </A> <E> may yield better results than FNA by palpation alone </E>.\\n\\nSection Name: Postoperative Imaging Advice\\n====================\\nEntities:-\\nPanoramic Radiography : A type of dental x-ray that provides a wide view of the upper and lower jaws, teeth, temporomandibular joints, and sinuses.\\nOral Cavity : The cavity of the mouth, including the lips, the lining inside the cheeks and lips, the front two-thirds of the tongue, the gums, the floor of the mouth under the tongue, the hard palate, and the small area of the gum behind the wisdom teeth.\\nRadiotherapy : The treatment of disease, especially cancer, using X-rays or similar forms of radiation.\\nMandibulotomy : A surgical procedure involving the cutting of the mandible.\\nMandibulectomy : A surgical procedure involving the removal of part or all of the mandible.\\nOropharynx : The part of the throat at the back of the mouth behind the oral cavity.\\n\\nRelationships:-\\n1. Entity1: \""panoramic dental x-ray\"", Entity2: \""oral cavity cancers\"", Relationship: \""recommended for\""\\n2. Entity1: \""panoramic dental x-ray\"", Entity2: \""postoperative radiotherapy\"", Relationship: \""essential for pre-radiation evaluation\""\\n3. Entity1: \""pre-radiation dental evaluation\"", Entity2: \""dental procedures or extractions\"", Relationship: \""determine necessity of\""\\n\\nCausalities:-\\n<A> A panoramic dental x-ray is recommended </A> <C> for oral cavity cancers requiring mandibulotomy and/or mandibulectomy </C>. <CO> When postoperative radiotherapy (RT) is anticipated for areas like the lip, oral cavity subsites, or oropharynx </CO>, <A> panoramic x-ray is essential for a comprehensive pre-radiation dental evaluation </A> <E> to assess the health of affected teeth and determine if pre-radiation dental procedures or extractions are necessary </E>.\\n\\nSection Name: NCCN Guidelines Note\\n====================\\nEntities:-\\nNeoplasms : Neoplasms are abnormal growths of tissue, which can be cancerous or non-cancerous.\\nMalignant Neoplastic Disease : A disease characterized by uncontrolled, abnormal growth of cells that can invade or spread to other parts of the body.\\nCancer : A group of diseases involving abnormal cell growth with the potential to invade or spread to other parts of the body.\\nClinical Trials As Topic : Pre-planned studies of the safety, efficacy, or optimum dosage schedule of one or more diagnostic, therapeutic, or prophylactic drugs, devices, or techniques in humans selected according to predetermined criteria of eligibility and observed for predefined evidence of favorable and unfavorable effects.\\nClinical Trial : A research study that prospectively assigns human participants or groups of humans to one or more health-related interventions to evaluate the effects on health outcomes.\\n\\nRelationships:-\\n1. Entity1: \""NCCN\"", Entity2: \""Clinical Trials\"", Relationship: \""encourages participation in\""\\n2. Entity1: \""NCCN\"", Entity2: \""Cancer\"", Relationship: \""recommends clinical trials for\""\\n\\nCausalities:-\\n<A> NCCN believes that the best management of any patient with cancer is through participation in clinical trials </A>, <A> which is especially encouraged </A>.\\n'}""",valid,increases risk,2,B,"edge - The edge which needs to be verified.
explanation - Explanation of what the edge represents and its validity.
causal_direction - Either Positive or Negative or Unknown. A positive influence direction indicates that both factors change in the same direction (e.g. an increase causes an increase effect). A negative influence direction indicates the opposite changes (e.g. an increase causes a decrease effect).
causal_factor - Is necessary or sufficient condition for an effect to occur. Exposure is a term commonly used in epidemiology to denote any condition that is considered as a possible cause of disease. Exposure is considered necessary when it always precedes the effects (e.g. symptoms) and always presents when the effects occur. A sufficient cause is a causal factor whose presence or occurrence guarantees the occurrence of symptom.
causal_distance - Either Distal or Proximal or Unknown. The distal factors lie towards the beginning of causal chain (i.e. indirect causal factors). The the proximal factors lie towards the end of the chain (i.e. cause directly or almost directly the effect).

Causality Tags:
<A> for action, <C> for cause, <CO> for condition and <E> for effect.
Cause (C): The reason or origin that leads to an effect. Causes often involve disease conditions, risk factors, or underlying mechanisms.
Effect (E): The outcome or result of a cause. Effects usually represent clinical outcomes, complications, or results of a specific cause.
Condition (CO): The circumstance or prerequisite required for an action or effect to occur. Conditions may include patient characteristics, clinical scenarios, or specific diagnostic criteria.
Action (A): The recommended or described response or activity to address a cause or condition. Actions typically involve clinical interventions, diagnostic procedures, or treatment recommendations.


`NODE1`:
id: Location_of_Lymph_Nodes_3
label: Location of Lymph Nodes
description: This node represents the presence or absence of lymph nodes in a specific location, which is crucial for cancer diagnosis and staging. The detection of lymph nodes can indicate the spread of cancer and affect treatment decisions.
type: Patient Situation
observability: Unobserved
states: [{'state_name': 'present', 'state_description': 'Lymph nodes are detected in the specified location, which may indicate the spread of cancer and is important for staging and treatment planning.'}, {'state_name': 'absent', 'state_description': 'Lymph nodes are not detected in the specified location, which may suggest no spread of cancer to this area and is important for staging and treatment planning.'}]

`NODE2`:
id: Sonographie_7
label: Ultrasound Examination Result
description: This node represents the result of an ultrasound examination, which is a diagnostic imaging technique used to visualize internal organs and structures. The result can indicate whether certain findings are present or absent, which can aid in the diagnosis and management of various conditions.
type: Examination Result
observability: Observed
states: [{'state_name': 'present', 'state_description': 'The ultrasound examination has detected the presence of a specific finding or abnormality.'}, {'state_name': 'absent', 'state_description': 'The ultrasound examination has not detected the specific finding or abnormality, indicating its absence.'}]

`EDGE1`:
{'edges_ids': ['Location_of_Lymph_Nodes_3', 'Sonographie_7'], 'edge': '(Location_of_Lymph_Nodes_3) causes (Sonographie_7)', 'explanation': ['The edge represents the causal relationship where the presence or absence of lymph nodes in a specific location (Location_of_Lymph_Nodes_3) affects the result of an ultrasound examination (Sonographie_7).', 'In clinical practice, the presence of lymph nodes can be detected by ultrasound, making it a valid causal relationship.', 'The causal direction is positive because the presence of lymph nodes increases the likelihood of detection by ultrasound.', 'The presence of lymph nodes is a sufficient condition for the ultrasound to detect them, but not necessary, as ultrasounds can detect other findings.', 'The causal distance is proximal because the presence of lymph nodes directly affects the ultrasound result.'], 'causal_direction': 'positive', 'causal_factor': {'necessary': False, 'sufficient': True}, 'causal_distance': 'Proximal'}

`EDGE2`:
{'edges_ids': ['Sonographie_7', 'Location_of_Lymph_Nodes_3'], 'edge': '(Sonographie_7) causes (Location_of_Lymph_Nodes_3)', 'explanation': ['The edge suggests that the result of an ultrasound examination (Sonographie_7) causes the presence or absence of lymph nodes in a specific location (Location_of_Lymph_Nodes_3).', 'However, the ultrasound examination is a diagnostic tool that detects the presence of lymph nodes; it does not cause them to be present or absent.', 'The presence of lymph nodes is a physical condition that exists independently of the ultrasound examination.', 'Therefore, the edge is not valid as there is no causal relationship where the ultrasound result causes the lymph nodes to be present or absent.'], 'causal_direction': 'Unknown', 'causal_factor': {'necessary': False, 'sufficient': False}, 'causal_distance': 'Unknown'}

`INFORMATION FROM KNOWLEDGE BASE`:
--------------------------------------------------
Page Number: 53

Section Name: Introduction
====================
Entities:-
National Comprehensive Cancer Network : The National Comprehensive Cancer Network (NCCN) is an alliance of 30 cancer centers in the United States, dedicated to improving the quality, effectiveness, and efficiency of cancer care so that patients can live better lives.
Laryngeal Neoplasms : Tumors or cancer of the larynx, which may affect the supraglottic, glottic, or subglottic regions.
Malignant Neoplasm Of Supraglottis : A malignant tumor located in the supraglottic region of the larynx.

Relationships:-
1. Entity1: ""National Comprehensive Cancer Network"", Entity2: ""Malignant neoplasm of supraglottis"", Relationship: ""provides guidelines for""
2. Entity1: ""clinical staging"", Entity2: ""treatment strategies"", Relationship: ""part of flowchart for""

Causalities:-
The provided image is a flowchart outlining the <C> NCCN (National Comprehensive Cancer Network) guidelines </C> for the treatment of <CO> cancers of the supraglottic larynx </CO>. This flowchart <A> utilizes a highly structured approach to convey clinical staging and treatment strategies </A>, indicating the various pathways based on <CO> patient conditions and disease features </CO>.

Section Name: NCCN Guidelines Version 4.2024
====================
Entities:-
Laryngeal Neoplasms : Tumors or cancer of the larynx, which may affect the supraglottic, glottic, or subglottic regions.
Malignant Neoplasm Of Supraglottis : A malignant tumor located in the supraglottic region of the larynx.
Supraglottic Cancer : Cancer that occurs in the supraglottic region of the larynx, above the vocal cords.
Clinical Trials As Topic : Pre-planned studies of the safety, efficacy, or optimum dosage schedule of one or more diagnostic, therapeutic, or prophylactic drugs, devices, or techniques in humans selected according to predetermined criteria of eligibility and observed for predefined evidence of favorable and unfavorable effects.
Clinical Trial : A type of research that studies new tests and treatments and evaluates their effects on human health outcomes.

Relationships:-
1. Entity1: ""Cancer of the Supraglottic Larynx"", Entity2: ""Clinical Trials"", Relationship: ""recommended management strategy""

Causalities:-
- All recommendations are category 2A unless otherwise indicated.
- <A> Participation in clinical trials </A> is especially encouraged.

Section Name: Key Components of the Flowchart
====================
Entities:-
Neoplasm Staging : Methods used for staging neoplasms, including clinical and pathological staging.
Radiotherapy : The use of ionizing radiation to treat cancer.
Surgical Procedures, Operative : Operations carried out for the correction of deformities and defects, repair of injuries, and diagnosis and cure of certain diseases.
Adjuvant Chemotherapy : Chemotherapy given in addition to the primary treatment to maximize its effectiveness.
Neoplasm Recurrence, Local : The return of a tumor at the original site after treatment.
Clinical Trials As Topic : Pre-planned studies of the safety, efficacy, or optimum dosage schedule of one or more diagnostic, therapeutic, or prophylactic drugs, devices, or techniques in humans selected according to predetermined criteria of eligibility and observed for predefined evidence of favorable and unfavorable effects.

Relationships:-
1. Entity1: ""Clinical Staging"", Entity2: ""Treatment of Primary and Neck"", Relationship: ""determines""
2. Entity1: ""Evaluation and Follow-Up"", Entity2: ""Adverse and No Adverse Features"", Relationship: ""leads to decision based on""
3. Entity1: ""Adjuvant Treatment"", Entity2: ""Adverse pathologic features"", Relationship: ""considered if present""
4. Entity1: ""Clinical Trials"", Entity2: ""Treatment Pathway"", Relationship: ""part of""

Causalities:-
### Key Components of the Flowchart

1. **Clinical Staging**: The flowchart starts with <A>clinical staging</A>, indicating that <CO>patients must first be evaluated to determine the extent of cancer</CO>. This is essential for <E>deciding on appropriate treatment options</E>.

2. **Treatment of Primary and Neck**: The flowchart details multiple treatment strategies, including:
   - <A>**Concurrent systemic therapy/RT**</A>: This suggests a combination approach for <CO>patients eligible for such treatment</CO>.
   - <A>**Definitive Radiation Therapy (RT)**</A>: Recommended for <CO>low-volume diseases or patients who cannot tolerate systemic therapy</CO>.
   - <A>**Surgical Options**</A>: It highlights options such as endoscopic or open partial laryngectomy and neck dissection, which are <CO>contingent on clinical evaluations</CO>.

3. **Evaluation and Follow-Up**: After initial treatment approaches, the chart directs clinicians to perform a <A>""Post Systemic Therapy/RT or RT Neck Evaluation""</A>. This step <E>assesses whether there are adverse pathologic features</E>, guiding subsequent treatment decisions.

4. **Adverse and No Adverse Features**: The decision pathway diverges based on findings:
   - <CO>Patients with **adverse pathologic features**</CO> may have <A>additional diagnostic imaging (CT or MRI)</A> and may require <A>further systemic treatment</A>.
   - <CO>Patients with **no adverse features**</CO> may be directed towards <A>considerations for radiation therapy</A>.

5. **Adjuvant Treatment and Recurrence**: The chart also addresses <E>management of any recurrent or persistent disease</E>, emphasizing the importance of <A>regular follow-up assessments</A>. Various options for <A>adjuvant treatment</A> are mentioned, focusing on tailored approaches towards ongoing management of the disease.

6. **Clinical Trials**: The flowchart encourages <A>participation in clinical trials</A>, indicating a commitment to <E>exploring new treatments and improving patient outcomes</E>.

Section Name: Principles
====================
Entities:-
Imaging : The process of producing images of the body or parts of the body to diagnose or examine disease.
Surgical Procedure : A medical procedure involving an incision with instruments; performed to repair damage or arrest disease in a living body.
Radiation Therapy : The use of ionizing radiation to treat cancer and other diseases.
Systemic Therapy : Treatment using substances that travel through the bloodstream, reaching and affecting cells all over the body.

Relationships:-
1. Entity1: ""Imaging"", Entity2: ""Surgery"", Relationship: ""Both are foundational principles in medical practice.""
2. Entity1: ""Radiation therapy"", Entity2: ""Systemic Therapy"", Relationship: ""Both are treatment modalities for cancer.""

Causalities:-
#### Principles
- **Principles of Imaging (IMG-A)**
- **Principles of Surgery (SURG-A)**
- **Principles of Radiation Therapy (SUPRA-A)**
- **Principles of Systemic Therapy for Non-Nasopharyngeal Cancers (SYST-A)**

Section Name: Adverse Pathologic Features
====================
Entities:-
Extranodal Extension : The spread of cancer cells beyond the lymph node capsule into the surrounding tissues.
Positive Surgical Margins : The presence of cancer cells at the edge of the tissue removed during surgery.
Perineural Invasion : Cancer cells found surrounding or tracking along a nerve within the perineural space.
Vascular Invasion : The presence of cancer cells within blood vessels.
Lymphatic Invasion : The presence of cancer cells within lymphatic vessels.

Relationships:-
1. Entity1: ""Extranodal Extension"", Entity2: ""Positive Surgical Margins"", Relationship: ""Both indicate cancer spread beyond original site.""
2. Entity1: ""Perineural Invasion"", Entity2: ""Vascular Invasion"", Relationship: ""Both are pathways for cancer spread.""
3. Entity1: ""pT3 or pT4 primary"", Entity2: ""pN2 or pN3 nodal disease"", Relationship: ""Both indicate advanced cancer stages.""

Causalities:-
<C> Extranodal extension </C>
<C> Positive margins </C>
<C> Close margins </C>
<C> pT3 or pT4 primary </C>
<C> pN2 or pN3 nodal disease </C>
<C> Perineural invasion </C>
<C> Vascular invasion </C>
<C> Lymphatic invasion </C>

Section Name: Clinical Staging and Treatment of Primary and Neck
====================
Entities:-
Adjuvant Chemotherapy : Chemotherapy given in addition to the primary treatment to maximize its effectiveness.
Follow-Up Procedure : A procedure performed to monitor the progress of a patient after treatment.
Recurrent Disease : A disease that returns after a period of remission.
Laryngectomy : Surgical removal of the larynx, often used to treat cancer.
Radiation Therapy : The use of ionizing radiation to treat cancer and other diseases.
Clinical Trial : A type of research that studies new tests and treatments and evaluates their effects on human health outcomes.
Neck Dissection : Surgical procedure to remove lymph nodes and surrounding tissue to treat cancer.
Chemotherapy : Treatment of disease by the use of chemical substances, especially cancer by cytotoxic drugs.

Relationships:-
1. Entity1: ""Adjuvant Treatment"", Entity2: ""Treatment of Primary and Neck"", Relationship: ""part of""
2. Entity1: ""Follow-up"", Entity2: ""Treatment of Primary and Neck"", Relationship: ""part of""
3. Entity1: ""Recurrent or Persistent Disease"", Entity2: ""Treatment of Primary and Neck"", Relationship: ""part of""
4. Entity1: ""Larynx-Preserving Surgery"", Entity2: ""Treatment Options"", Relationship: ""is a treatment option for""
5. Entity1: ""Concurrent Systemic Therapy/RT"", Entity2: ""Treatment Options"", Relationship: ""is a treatment option for""
6. Entity1: ""Clinical Trials or Definitive RT"", Entity2: ""Treatment Options"", Relationship: ""is a treatment option for""
7. Entity1: ""Endoscopic or Open Partial Laryngectomy and Neck Dissection(s)"", Entity2: ""Treatment Options"", Relationship: ""is a treatment option for""
8. Entity1: ""Induction Chemotherapy"", Entity2: ""Treatment Options"", Relationship: ""is a treatment option for""

Causalities:-
<A> Amenable to Larynx-Preserving (Conservation) Surgery </A>: <CO> T1–2, N+ and selected T3, N1 </CO>
<A> Concurrent Systemic Therapy/RT </A>: <CO> i, k, l </CO>
<A> Clinical Trials or Definitive RT </A>: <CO> i </CO>
<A> Endoscopic or Open Partial Laryngectomy and Neck Dissection(s) </A>: <CO> h </CO>
<A> Induction Chemotherapy </A>: <CO> k, m </CO>

Section Name: Pathologic Features and Response Assessment
====================
Entities:-
Radiation Therapy : The use of ionizing radiation to treat cancer and other diseases.
Extranodal Extension : The spread of cancer cells beyond the lymph node capsule into the surrounding tissues.
Positive Surgical Margin : Cancer cells are found at the edge of the material removed during surgery, indicating that some cancer may have been left behind.
Systemic Therapy : Treatment using substances that travel through the bloodstream, reaching and affecting cells all over the body.

Relationships:-
1. Entity1: ""Extranodal extension"", Entity2: ""Adverse Pathologic Features"", Relationship: ""is a type of""
2. Entity1: ""Positive margin"", Entity2: ""Adverse Pathologic Features"", Relationship: ""is a type of""
3. Entity1: ""Systemic Therapy"", Entity2: ""Adverse Pathologic Features"", Relationship: ""considered in response to""
4. Entity1: ""Radiation Therapy"", Entity2: ""Adverse Pathologic Features"", Relationship: ""considered in response to""

Causalities:-
#### Pathologic Features
- **No Adverse Pathologic Features**: j
  - <A> Consider RT </A>: i
- **Adverse Pathologic Features**: j
  - <CO> Extranodal extension and/or positive margin </CO>: n
  - Other risk features
  - <A> Systemic therapy/RT </A>: i, k (category 1)
  - <A> Consider systemic therapy/RT </A>: i, k

#### Response Assessment
- **Response Assessment** (SUPRA-7)

Section Name: Imaging and Recurrent or Persistent Disease
====================
Entities:-
Tomography, X-Ray Computed : A method of body imaging in which a thin X-ray beam rotates around the patient.
Magnetic Resonance Imaging : Medical imaging technique used in radiology to form pictures of the anatomy and the physiological processes of the body.
Computed Tomography : Medical imaging technique used in radiology to obtain detailed internal images of the body.

Relationships:-
1. Entity1: ""CT"", Entity2: ""primary and neck"", Relationship: ""used for imaging""
2. Entity1: ""MRI"", Entity2: ""primary and neck"", Relationship: ""used for imaging""
3. Entity1: ""Post Systemic Therapy/RT"", Entity2: ""Recurrent or Persistent Disease"", Relationship: ""evaluation after treatment""
4. Entity1: ""RT Neck Evaluation"", Entity2: ""Recurrent or Persistent Disease"", Relationship: ""evaluation after treatment""

Causalities:-
<A> CT (with contrast) or MRI (with and without contrast) of primary and neck </A>

<CO> Recurrent or Persistent Disease </CO>

<CO> Post Systemic Therapy/RT or RT Neck Evaluation </CO>

Section Name: Conclusion
====================
Entities:-
Oncologists : Medical doctors who specialize in the diagnosis and treatment of cancer.
Supraglottic Larynx Cancer : A type of cancer that occurs in the supraglottic region of the larynx, which is the area above the vocal cords.
Clinical Staging : The process of determining the extent of cancer in the body, usually based on physical examination, imaging tests, and biopsies.
Treatment Strategies : Plans or methods developed to treat diseases, including cancer, which may involve surgery, chemotherapy, radiation therapy, or other modalities.
Follow-Up Evaluations : Medical assessments conducted after initial treatment to monitor a patient's progress and detect any recurrence of disease.
Clinical Efficacy : The ability of a treatment to produce the desired therapeutic effect in clinical settings.
Research : Systematic investigation and study conducted to establish facts and reach new conclusions.
Treatment Paradigms : Standard models or patterns of treatment used in medical practice, often based on clinical guidelines and research findings.

Relationships:-
1. Entity1: ""Oncologists"", Entity2: ""Supraglottic Larynx Cancer"", Relationship: ""use flowchart for decision-making""
2. Entity1: ""Clinical Staging"", Entity2: ""Treatment Strategies"", Relationship: ""part of management process""
3. Entity1: ""Treatment Strategies"", Entity2: ""Follow-Up Evaluations"", Relationship: ""part of management process""

Causalities:-
<A> The flowchart serves as a comprehensive guide for oncologists and healthcare providers </A>, <A> facilitating informed decision-making in the treatment of supraglottic larynx cancer </A>. <A> By visualizing the complex interactions between clinical staging, treatment strategies, and follow-up evaluations </A>, <E> it streamlines the management process </E>, <E> ensuring that patients receive appropriate care tailored to their specific needs </E>. <E> The detailed pathways not only enhance clinical efficacy </E> but also <E> underscore the importance of ongoing research and adaptation of treatment paradigms in oncology </E>.
--------------------------------------------------
Page Number: 129

Section Name: TNM Staging System for the Larynx - Regional Lymph Nodes (N)
====================
Entities:-
Lymph Nodes : Small, bean-shaped structures that are part of the body's immune system. They filter substances that travel through the lymphatic fluid, and they contain lymphocytes (white blood cells) that help the body fight infection and disease.
Lymph Node Structure : A structure that is part of the lymphatic system, involved in the filtration of lymph and the production of lymphocytes.
Lymph Node : An organ of the lymphatic system and the adaptive immune system that is widely present throughout the body.

Relationships:-
1. Entity1: ""NCCN Guidelines"", Entity2: ""Regional Lymph Nodes"", Relationship: ""provides classification for""
2. Entity1: ""AJCC TNM Staging System"", Entity2: ""Regional Lymph Nodes"", Relationship: ""provides classification for""
3. Entity1: ""Clinical N"", Entity2: ""Regional Lymph Nodes"", Relationship: ""is a classification of""

Causalities:-
The <C> classification of the Regional Lymph Nodes (N) for head and neck cancers </C> is crucial for <E> determining the presence and extent of lymph node metastases </E>, which are critical in <E> establishing the severity and appropriate treatment strategies </E>. <A> Clinicians use this structured classification for accurate staging and subsequent treatment planning in patients diagnosed with head and neck cancers </A>.

Section Name: NCCN Guidelines Version 4.2024
====================
Entities:-
Head And Neck Neoplasms : Cancers that occur in the head or neck region, including the nasal cavity, sinuses, lips, mouth, salivary glands, throat, or larynx.
Malignant Neoplasm Of Head And Neck : A malignant tumor located in the head and neck region.
National Comprehensive Cancer Network : An alliance of cancer centers in the United States, dedicated to improving the quality, effectiveness, and efficiency of cancer care.

Relationships:-
1. Entity1: ""NCCN Guidelines"", Entity2: ""Head and Neck Cancers"", Relationship: ""guidelines for""
2. Entity1: ""NCCN Guidelines"", Entity2: ""National Comprehensive Cancer Network"", Relationship: ""published by""

Causalities:-
The provided text does not contain any clinical causes, effects, conditions, or actions to extract.
--------------------------------------------------
Page Number: 130

Section Name: Pathological N (pN)
====================
Entities:-
Lymph Nodes : Small, bean-shaped structures that are part of the body's lymphatic system. They filter lymph fluid and store white blood cells that help fight infection.
Neoplasm Metastasis : The transfer of a neoplasm from one organ or part of the body to another remote from the primary site.
Tnm Staging : A system used to describe the size and spread of cancer in a standardized way. T refers to the size of the tumor, N to the involvement of lymph nodes, and M to metastasis.
Lymph Node Structure : A structure that is part of the lymphatic system, involved in the immune response.
Metastasis : The spread of a cancer or other disease from one organ or part to another not directly connected with it.
Tnm Staging System : A cancer staging notation system that describes the extent of cancer in a patient's body.
Lymph Node : An organ of the lymphatic system and the adaptive immune system.

Relationships:-
1. Entity1: ""Lymph Nodes"", Entity2: ""Neoplasm Metastasis"", Relationship: ""involved in""
2. Entity1: ""TNM Staging"", Entity2: ""Lymph Nodes"", Relationship: ""includes""
3. Entity1: ""TNM Staging"", Entity2: ""Neoplasm Metastasis"", Relationship: ""describes""

Causalities:-
<CO> NX: Regional lymph nodes cannot be assessed </CO>
<CO> N0: No regional lymph node metastasis </CO>
<CO> N1: Metastasis in a single ipsilateral lymph node, 3 cm or smaller in greatest dimension ENE(–) </CO>
<CO> N2: Metastasis in a single ipsilateral lymph node, 3 cm or smaller in greatest dimension and ENE(+); or larger than 3 cm but not larger than 6 cm in greatest dimension and ENE(−); or metastases in multiple ipsilateral lymph nodes, none larger than 6 cm in greatest dimension and ENE(−); or in bilateral or contralateral lymph node(s), none larger than 6 cm in greatest dimension and ENE(−) </CO>
<CO> N2a: Metastasis in a single ipsilateral node, 3 cm or smaller in greatest dimension and ENE(+); or metastasis in a single ipsilateral node, larger than 3 cm but not larger than 6 cm in greatest dimension and ENE(−) </CO>
<CO> N2b: Metastases in multiple ipsilateral nodes, none larger than 6 cm in greatest dimension and ENE(−) </CO>
<CO> N2c: Metastases in bilateral or contralateral lymph node(s), none larger than 6 cm in greatest dimension and ENE(−) </CO>
<CO> N3: Metastasis in a lymph node, larger than 6 cm in greatest dimension and ENE(−); or metastasis in a single ipsilateral node, larger than 3 cm in greatest dimension and ENE(+); or multiple ipsilateral, contralateral, or bilateral lymph nodes and any with ENE(+); or a single contralateral node of any size and ENE(+) </CO>
<CO> N3a: Metastasis in a lymph node, larger than 6 cm in greatest dimension and ENE(−) </CO>
<CO> N3b: Metastasis in a single ipsilateral node, larger than 3 cm in greatest dimension and ENE(+); or multiple ipsilateral, contralateral, or bilateral lymph nodes any with ENE(+); or a single contralateral node of any size and ENE(+) </CO>
<CO> Note: A designation of “U” or “L” may be used for any N category to indicate metastasis above the lower border of the cricoid (U) or below the lower border of the cricoid (L). Similarly, clinical and pathological ENE should be recorded as ENE(−) or ENE(+). </CO>

Section Name: Distant Metastasis (M)
====================
Entities:-
Neoplasm Metastasis : The transfer of a neoplasm from one organ or part of the body to another remote from the primary site.
Metastasis : The spread of a cancer or other disease from one organ or part to another not directly connected with it.

Relationships:-
1. Entity1: ""M0"", Entity2: ""Distant Metastasis"", Relationship: ""is a category of""
2. Entity1: ""M1"", Entity2: ""Distant Metastasis"", Relationship: ""is a category of""

Causalities:-
### Distant Metastasis (M)

- **M0**: No distant metastasis
- **M1**: Distant metastasis

Section Name: Histologic Grade (G)
====================
Entities:-
Neoplasm Grading : A system of classifying cancer cells in terms of how abnormal they look under a microscope and how quickly the tumor is likely to grow and spread.
Histologic Grade : A measure of how much tumor cells differ from healthy cells, used to assess the aggressiveness of cancer.

Relationships:-
1. Entity1: ""GX"", Entity2: ""Grade cannot be assessed"", Relationship: ""is described as""
2. Entity1: ""G1"", Entity2: ""Well differentiated"", Relationship: ""is described as""
3. Entity1: ""G2"", Entity2: ""Moderately differentiated"", Relationship: ""is described as""
4. Entity1: ""G3"", Entity2: ""Poorly differentiated"", Relationship: ""is described as""

Causalities:-
<CO>GX</CO>: <E>Grade cannot be assessed</E>
<CO>G1</CO>: <E>Well differentiated</E>
<CO>G2</CO>: <E>Moderately differentiated</E>
<CO>G3</CO>: <E>Poorly differentiated</E>

Section Name: Prognostic Stage Groups
====================
Entities:-
Neoplasm Staging : Methods and systems of classifying neoplasms according to extent of disease.
Tumor Staging : A system for describing the size and spread of cancer within the body.
Tnm Staging System : A cancer staging notation system that describes the extent of cancer in a patient's body.

Relationships:-
1. Entity1: ""Stage 0"", Entity2: ""Tis N0 M0"", Relationship: ""defined by""
2. Entity1: ""Stage I"", Entity2: ""T1 N0 M0"", Relationship: ""defined by""
3. Entity1: ""Stage II"", Entity2: ""T2 N0 M0"", Relationship: ""defined by""
4. Entity1: ""Stage III"", Entity2: ""T3 N0 M0, T1 N1 M0, T2 N1 M0, T3 N1 M0"", Relationship: ""defined by""
5. Entity1: ""Stage IVA"", Entity2: ""T1 N2 M0, T2 N2 M0, T3 N2 M0, T4a N0,N1,N2 M0"", Relationship: ""defined by""
6. Entity1: ""Stage IVB"", Entity2: ""Any T N3 M0, T4b Any N M0"", Relationship: ""defined by""
7. Entity1: ""Stage IVC"", Entity2: ""Any T Any N M1"", Relationship: ""defined by""
--------------------------------------------------
Page Number: 154

Section Name: NCCN Guidelines Version 4.2024
====================
Entities:-
Nccn Guidelines : The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) are a comprehensive set of guidelines detailing the sequential management decisions and interventions that apply to 97% of cancers affecting patients in the United States.

Relationships:-

Causalities:-
# NCCN Guidelines Version 4.2024

Section Name: Head and Neck Cancers
====================
Entities:-
Head And Neck Neoplasms : Tumors or cancer of the head and neck region, including the nasal cavity, sinuses, lips, mouth, salivary glands, throat, or larynx.
Radiation Therapy : The medical use of ionizing radiation, generally as part of cancer treatment to control or kill malignant cells.
Quad Shot Regimen : A palliative radiation therapy regimen consisting of 44.4 Gy delivered in 12 fractions over three cycles, used for patients with limited life expectancy.

Relationships:-
1. Entity1: ""Head and Neck Neoplasms"", Entity2: ""70 Gy"", Relationship: ""treatment dosage""
2. Entity1: ""QUAD SHOT regimen"", Entity2: ""Palliative Treatment"", Relationship: ""purpose""

Causalities:-
The College of Radiology describes basic technical specifications [here](http://www.acr.org/Quality-Safety). Furthermore, major consensus contouring guidelines for the treatment of head and neck (H&N) cancers are available for reference, especially for patients who are treated without surgery. [143,144]

When radiation is given with definitive intent, <A> the dosages prescribed for gross disease are fairly standard, usually in the range of 70 Gy (at approximately 2 Gy/fraction/day) </A> for the following sites: <CO> lip, oral cavity, nasopharynx, oropharynx, hypopharynx, glottic larynx, supraglottic larynx, occult primary, salivary gland tumors, and MM </CO>. A second dose (often approximately 60 Gy, but varies) may be used to cover volumes considered at the highest risk for microscopic spread, while a lower dose (often approximately 50 Gy, but varies) is used for volumes treated electively with low risk for microscopic spread.

Although several palliative RT regimens are provided, no single regimen is preferred [145,146]; specific regimens vary widely among NCCN Member Institutions. <A> Any palliative RT regimen that might cause severe toxicities should be avoided </A>. <A> More hypofractionated regimens may be useful </A> for <CO> patients with limited life expectancy, such as a few months </CO>. For example, <A> a common version of the QUAD SHOT regimen consists of a dose of 44.4 Gy, delivered in 12 fractions over three cycles, with each cycle separated by 2 to 3 weeks </A>. [147]

Section Name: Radiation Doses
====================
Entities:-
Radiation Dosage : The amount of radiation absorbed by an object or person.
Neoplasms : New abnormal growth of tissue that can be benign or malignant.
Lymph Nodes : Small, bean-shaped structures that are part of the body's immune system.
Radiotherapy : The treatment of disease, especially cancer, using X-rays or similar forms of radiation.
Chemotherapy : The use of chemical substances, especially the treatment of cancer by cytotoxic and other drugs.
Radiation Therapy : The medical use of ionizing radiation, generally as part of cancer treatment to control or kill malignant cells.
Lymph Node Structure : A structure that is part of the lymphatic system, involved in the immune response.
Neoplasm : An abnormal mass of tissue as a result of neoplasia.
Lymph Node : An organ of the lymphatic system and the adaptive immune system.
Tumor : A mass of tissue that's formed by an accumulation of abnormal cells.

Relationships:-
1. Entity1: ""Radiation Dosage"", Entity2: ""Neoplasms"", Relationship: ""depends on""
2. Entity1: ""Radiation Dosage"", Entity2: ""Organs at risk"", Relationship: ""may need to be decreased if close to""
3. Entity1: ""Radiotherapy"", Entity2: ""IMRT"", Relationship: ""uses""
4. Entity1: ""Radiotherapy"", Entity2: ""Chemotherapy"", Relationship: ""can be used with""

Causalities:-
<C> Selection of an exact radiation dose prescription and schedule of delivery </C> <E> depends on the primary tumor and neck node size, whether altered fractionation is used, and clinical circumstances, including whether concurrent systemic therapy will be used </E>. <CO> if it is prescribed very close to adjacent organs at risk </CO> <A> The dose may need to be decreased </A>. <CO> Anatomical changes (e.g., rapidly shrinking tumors, changes in air cavities, significant weight loss) </CO> <A> may necessitate repeat imaging and treatment replanning </A>. <CO> when the tumor is abutting brain or optic structures </CO> <A> hyperfractionation has been used </A>. <CO> if prescribed doses exceed 72 Gy using conventional fractionation </CO> <E> this may lead to unacceptable rates of normal tissue injury </E>. <A> Care must be taken </A>.
--------------------------------------------------
Page Number: 93

Section Name: PRINCIPLES OF IMAGING
====================
Entities:-
Imaging, Diagnostic : The production of a visual representation of parts of the body, for the purpose of clinical analysis and medical intervention.
Head And Neck Neoplasms : Tumors or cancer of the head and neck region, including the nasal cavity, sinuses, lips, mouth, salivary glands, throat, or larynx.
Tomography, X-Ray Computed : An imaging procedure that uses special x-ray equipment to create detailed pictures, or scans, of areas inside the body.
Magnetic Resonance Imaging : A noninvasive diagnostic technique that uses magnetic fields and radio waves to produce a detailed image of the body's soft tissue and bones.
Contrast Media : Substances used to enhance the contrast of structures or fluids within the body in medical imaging.

Relationships:-
1. Entity1: ""Imaging, Diagnostic"", Entity2: ""Head and Neck Neoplasms"", Relationship: ""used for""
2. Entity1: ""Tomography, X-Ray Computed"", Entity2: ""Contrast Media"", Relationship: ""uses""
3. Entity1: ""Magnetic Resonance Imaging"", Entity2: ""Contrast Media"", Relationship: ""uses""

Causalities:-
<C> Imaging </C> plays an essential role in the clinical care of patients with head and neck cancer. <A> The proper selection and utilization of imaging studies </A> is critical in caring for patients with head and neck cancer. <A> CT is performed with contrast </A>, while <A> CT imaging of the chest can be performed with or without contrast </A>, <CO> as clinically indicated </CO>. <A> MRI is performed with and without contrast </A>, <CO> unless contraindicated </CO>.

Section Name: Initial Workup - Primary Site
====================
Entities:-
Tomography, X-Ray Computed : An imaging procedure that uses special x-ray equipment to create detailed pictures, or scans, of areas inside the body.
Magnetic Resonance Imaging : A noninvasive diagnostic technique that uses magnetic fields and radio waves to produce a detailed image of the body's soft tissue and bones.
Head And Neck Neoplasms : Tumors or cancer of the head and neck region, including the nasal cavity, sinuses, lips, mouth, salivary glands, throat, or larynx.
Neck Structure : The anatomical structure of the neck, which is the part of the body that connects the head to the torso.
Skull Base : The bottom part of the skull, which separates the brain from other facial structures.
Thoracic Inlet : The opening at the top of the thoracic cavity, through which pass the trachea, esophagus, and major blood vessels.

Relationships:-
1. Entity1: ""CT"", Entity2: ""MRI"", Relationship: ""complementary in imaging head and neck cancers""
2. Entity1: ""CT"", Entity2: ""Head and Neck Neoplasms"", Relationship: ""used to evaluate""
3. Entity1: ""MRI"", Entity2: ""Head and Neck Neoplasms"", Relationship: ""preferred for evaluating""
4. Entity1: ""Skull base"", Entity2: ""Thoracic inlet"", Relationship: ""imaging range for evaluation""

Causalities:-
<A>Imaging assessment of the primary site</A> can be performed with <A>CT of the soft tissues of the neck</A> or <A>MRI of the neck</A>. <C>CT is complementary to MRI for head and neck cancers</C>. <A>It is utilized to evaluate cortical bone erosion or periosteal invasion, cartilage invasion, and bony erosion or destruction</A>. <CO>in certain conditions, such as evaluating the extent of bone marrow invasion or in patients with extensive dental amalgam obscuring anatomy on CT, assessing skull base invasion and cranial nerve involvement, and differentiating tumor from obstructed sinuses</CO>, <A>MRI is preferred over CT</A>. <CO>when involved lymph nodes or upper mediastinal cancers are present</CO>, <A>Complete evaluation of primary and nodal disease requires imaging from the skull base to the thoracic inlet, extending to the carina</A>.

Section Name: PET/CT and Biopsy
====================
Entities:-
Positron Emission Tomography Computed Tomography : A medical imaging technique that combines PET and CT capabilities to provide detailed images of the body.
Examination Under Anesthesia : A procedure where a patient is examined while under anesthesia to allow for a more thorough examination.
Biopsy : A medical test involving the extraction of sample cells or tissues for examination to determine the presence or extent of a disease.
Tonsillectomy : A surgical procedure to remove the tonsils, often performed to treat recurrent tonsillitis or sleep apnea.
Fine Needle Aspiration : A type of biopsy procedure that uses a thin, hollow needle to extract cells from a lump or mass for examination.
Ultrasound : A medical imaging technique that uses high-frequency sound waves to visualize internal organs and structures.
Computed Tomography : A diagnostic imaging procedure that uses a combination of X-rays and computer technology to produce cross-sectional images of the body.

Relationships:-
1. Entity1: ""PET/CT"", Entity2: ""EUA"", Relationship: ""recommended before""
2. Entity1: ""Fine Needle Aspiration (FNA)"", Entity2: ""metastatic nodes"", Relationship: ""used for biopsy of""
3. Entity1: ""Image-guided needle biopsy"", Entity2: ""cystic neck nodes"", Relationship: ""recommended for initial diagnosis of""

Causalities:-
<CO> If imaging does not reveal an obvious primary cancer </CO>, <A> a PET/CT should be ordered before EUA, biopsies, and tonsillectomy </A>. <E> This helps identify potential primary sites </E> before any interventions take place. Additionally, <A> Fine Needle Aspiration (FNA) biopsy of metastatic nodes </A> <E> may provide pathologically informative results </E>. <CO> For initial diagnosis in cystic neck nodes </CO>, <A> image-guided needle biopsy (ultrasound or CT) </A> <E> may yield better results than FNA by palpation alone </E>.

Section Name: Postoperative Imaging Advice
====================
Entities:-
Panoramic Radiography : A type of dental x-ray that provides a wide view of the upper and lower jaws, teeth, temporomandibular joints, and sinuses.
Oral Cavity : The cavity of the mouth, including the lips, the lining inside the cheeks and lips, the front two-thirds of the tongue, the gums, the floor of the mouth under the tongue, the hard palate, and the small area of the gum behind the wisdom teeth.
Radiotherapy : The treatment of disease, especially cancer, using X-rays or similar forms of radiation.
Mandibulotomy : A surgical procedure involving the cutting of the mandible.
Mandibulectomy : A surgical procedure involving the removal of part or all of the mandible.
Oropharynx : The part of the throat at the back of the mouth behind the oral cavity.

Relationships:-
1. Entity1: ""panoramic dental x-ray"", Entity2: ""oral cavity cancers"", Relationship: ""recommended for""
2. Entity1: ""panoramic dental x-ray"", Entity2: ""postoperative radiotherapy"", Relationship: ""essential for pre-radiation evaluation""
3. Entity1: ""pre-radiation dental evaluation"", Entity2: ""dental procedures or extractions"", Relationship: ""determine necessity of""

Causalities:-
<A> A panoramic dental x-ray is recommended </A> <C> for oral cavity cancers requiring mandibulotomy and/or mandibulectomy </C>. <CO> When postoperative radiotherapy (RT) is anticipated for areas like the lip, oral cavity subsites, or oropharynx </CO>, <A> panoramic x-ray is essential for a comprehensive pre-radiation dental evaluation </A> <E> to assess the health of affected teeth and determine if pre-radiation dental procedures or extractions are necessary </E>.

Section Name: NCCN Guidelines Note
====================
Entities:-
Neoplasms : Neoplasms are abnormal growths of tissue, which can be cancerous or non-cancerous.
Malignant Neoplastic Disease : A disease characterized by uncontrolled, abnormal growth of cells that can invade or spread to other parts of the body.
Cancer : A group of diseases involving abnormal cell growth with the potential to invade or spread to other parts of the body.
Clinical Trials As Topic : Pre-planned studies of the safety, efficacy, or optimum dosage schedule of one or more diagnostic, therapeutic, or prophylactic drugs, devices, or techniques in humans selected according to predetermined criteria of eligibility and observed for predefined evidence of favorable and unfavorable effects.
Clinical Trial : A research study that prospectively assigns human participants or groups of humans to one or more health-related interventions to evaluate the effects on health outcomes.

Relationships:-
1. Entity1: ""NCCN"", Entity2: ""Clinical Trials"", Relationship: ""encourages participation in""
2. Entity1: ""NCCN"", Entity2: ""Cancer"", Relationship: ""recommends clinical trials for""

Causalities:-
<A> NCCN believes that the best management of any patient with cancer is through participation in clinical trials </A>, <A> which is especially encouraged </A>.


Among these two options which one is the most likely true:

(A) `Location_of_Lymph_Nodes_3` increases risk `Sonographie_7`
(B) `Sonographie_7` `increases risk `Location_of_Lymph_Nodes_3`

The answer is: ...

1. State the evidences in detail of the validity of option (A) or (B) by cross referencing
NCCN Clinical Practitioner’s Guidelines for Head and Neck Cancer.
2. If the evidences are obtained from `INFORMATION FROM KNOWLEDGE BASE`,
mention their corresponding Page Numbers, Section Name, entities, relationships and causalities.

DESIRED OUTPUT FORMAT:
<thinking>
...
</thinking>
<answer>
{
   ""thinking"": [""..."", ...],
   ""evidences"": [""..."", ...],
   ""answer"": ...
}
</answer>

Before providing the answer in <answer> tags, think step by step in detail in <thinking> tags and analyze every part.
Output inside <answer> tag in JSON format. Only output valid JSON.
DO NOT HALLUCINATE. DO NOT MAKE UP FACTUAL INFORMATION.
","1. The edge (A) suggests that the presence of lymph nodes in a specific location increases the likelihood of detection by ultrasound, which aligns with clinical practice where ultrasound is used to detect lymph nodes.
2. The edge (B) suggests that the result of an ultrasound examination causes the presence or absence of lymph nodes, which is not valid as ultrasound is a diagnostic tool and does not influence the physical presence of lymph nodes.
3. The causal direction for edge (A) is positive, indicating that the presence of lymph nodes increases the likelihood of detection by ultrasound, which is a valid causal relationship.
4. The causal factor for edge (A) is sufficient but not necessary, as the presence of lymph nodes is sufficient for ultrasound detection, but ultrasound can detect other findings as well.
5. The causal distance for edge (A) is proximal, as the presence of lymph nodes directly affects the ultrasound result.
6. The NCCN Guidelines for Head and Neck Cancer emphasize the importance of imaging, including ultrasound, for detecting lymph nodes and assessing cancer spread, supporting the validity of edge (A).
7. The NCCN Guidelines do not support the notion that ultrasound results cause the presence of lymph nodes, invalidating edge (B).
","1. Page Number: 93, Section Name: PRINCIPLES OF IMAGING, Entities: Imaging, Diagnostic, Head And Neck Neoplasms, Relationships: Imaging, Diagnostic used for Head and Neck Neoplasms, Causalities: Imaging plays an essential role in the clinical care of patients with head and neck cancer.
2. Page Number: 129, Section Name: TNM Staging System for the Larynx - Regional Lymph Nodes (N), Entities: Lymph Nodes, Relationships: NCCN Guidelines provides classification for Regional Lymph Nodes, Causalities: Classification of the Regional Lymph Nodes (N) is crucial for determining the presence and extent of lymph node metastases.
",A,"{'A': 100.0, 'B': 0.0}",yes,A,"1. The AI assistant's reasoning for option (A) is consistent with the explanation provided in the EDGE1 description. The assistant correctly identifies that the presence of lymph nodes can be detected by ultrasound, which aligns with the clinical practice of using ultrasound to visualize lymph nodes. This supports the causal relationship described in EDGE1, where the presence of lymph nodes affects the ultrasound result.
2. The assistant's reasoning for option (B) is also consistent with the explanation provided in the EDGE2 description. The assistant correctly identifies that the ultrasound examination is a diagnostic tool and does not cause the presence or absence of lymph nodes, which invalidates the causal relationship described in EDGE2.
3. The assistant's analysis of the causal direction, causal factor, and causal distance for EDGE1 is consistent with the information provided in the EDGE1 description. The assistant correctly identifies the causal direction as positive, the causal factor as sufficient but not necessary, and the causal distance as proximal.
4. The assistant's reference to the NCCN Guidelines for Head and Neck Cancer supports the validity of EDGE1, as the guidelines emphasize the importance of imaging, including ultrasound, for detecting lymph nodes and assessing cancer spread. This aligns with the explanation provided in EDGE1.
5. The assistant's reference to the NCCN Guidelines does not support the notion that ultrasound results cause the presence of lymph nodes, which aligns with the explanation provided in EDGE2 and invalidates the causal relationship described in EDGE2.
"
2,gpt-4o,"Location_of_Lymph_Nodes_3,CT_8","""{'NODE1': {'id': 'Location_of_Lymph_Nodes_3', 'label': 'Location of Lymph Nodes', 'description': 'This node represents the presence or absence of lymph nodes in a specific location, which is crucial for cancer diagnosis and staging. The detection of lymph nodes can indicate the spread of cancer and affect treatment decisions.', 'type': 'Patient Situation', 'observability': 'Unobserved', 'states': [{'state_name': 'present', 'state_description': 'Lymph nodes are detected in the specified location, which may indicate the spread of cancer and is important for staging and treatment planning.'}, {'state_name': 'absent', 'state_description': 'Lymph nodes are not detected in the specified location, which may suggest no spread of cancer to this area and is important for staging and treatment planning.'}]}, 'NODE2': {'id': 'CT_8', 'label': 'Computed Tomography Examination Result', 'description': 'This node represents the result of a CT scan examination, which is used to diagnose or assess medical conditions by providing detailed imaging of internal structures.', 'type': 'Examination Result', 'observability': 'Observed', 'states': [{'state_name': 'present', 'state_description': 'The finding or condition being assessed by the CT scan is present.'}, {'state_name': 'absent', 'state_description': 'The finding or condition being assessed by the CT scan is absent.'}]}, 'EDGE1': {'edges_ids': ['Location_of_Lymph_Nodes_3', 'CT_8'], 'edge': '(Location_of_Lymph_Nodes_3) causes (CT_8)', 'explanation': ['The edge represents the causal relationship where the presence of lymph nodes in a specific location (Location_of_Lymph_Nodes_3) affects the results of a CT scan (CT_8).', 'If lymph nodes are present, the CT scan is more likely to detect them, indicating a positive causal direction.', 'The presence of lymph nodes is neither a necessary nor a sufficient condition for the CT scan to show results, as CT scans can detect other conditions and may not always detect lymph nodes even if they are present.', 'The causal distance is proximal because the presence of lymph nodes directly influences the CT scan results.'], 'causal_direction': 'positive', 'causal_factor': {'necessary': False, 'sufficient': False}, 'causal_distance': 'Proximal'}, 'EDGE2': {'edges_ids': ['CT_8', 'Location_of_Lymph_Nodes_3'], 'edge': '(CT_8) causes (Location_of_Lymph_Nodes_3)', 'explanation': ['The edge `(CT_8) causes (Location_of_Lymph_Nodes_3)` is not valid because a CT scan result does not cause lymph nodes to be present or absent.', 'CT_8 represents the result of a CT scan, which is used to observe and diagnose conditions, including the detection of lymph nodes.', 'Location_of_Lymph_Nodes_3 represents the presence or absence of lymph nodes in a specific location, which is a biological condition.', 'A CT scan can detect lymph nodes but does not influence their presence or absence. It is a diagnostic tool, not a causal factor.', 'Therefore, the relationship is observational, not causal.'], 'causal_direction': 'Unknown', 'causal_factor': {'necessary': False, 'sufficient': False}, 'causal_distance': 'Unknown'}, 'ENTITIES_MATCHING_PAGES_INFO': {'93': {'matching_entities': [{'TOMOGRAPHY, X-RAY COMPUTED': 0.9942913}, {'COMPUTED TOMOGRAPHY': 0.9552146}, {'POSITRON EMISSION TOMOGRAPHY COMPUTED TOMOGRAPHY': 0.9421292}, {'MAGNETIC RESONANCE IMAGING': 0.92989886}], 'count': 4}, '94': {'matching_entities': [{'TOMOGRAPHY, X-RAY COMPUTED': 0.9942913}, {'COMPUTED TOMOGRAPHY': 0.9552146}, {'POSITRON EMISSION TOMOGRAPHY COMPUTED TOMOGRAPHY': 0.9421292}, {'MAGNETIC RESONANCE IMAGING': 0.92989886}], 'count': 4}, '46': {'matching_entities': [{'COMPUTED TOMOGRAPHY': 0.9552146}, {'COMPUTED TOMOGRAPHY (CT)': 0.9533483}, {'MAGNETIC RESONANCE IMAGING (MRI)': 0.9313307}, {'MAGNETIC RESONANCE IMAGING': 0.92989886}], 'count': 4}, '53': {'matching_entities': [{'TOMOGRAPHY, X-RAY COMPUTED': 0.9942913}, {'COMPUTED TOMOGRAPHY': 0.9552146}, {'MAGNETIC RESONANCE IMAGING': 0.92989886}, {'IMAGING': 0.922603}], 'count': 4}, '41': {'matching_entities': [{'COMPUTED TOMOGRAPHY (CT)': 0.9533483}, {'MAGNETIC RESONANCE IMAGING (MRI)': 0.9313307}, {'IMAGING': 0.922603}], 'count': 3}}, 'GUIDELINE_PAGES_INFO': '--------------------------------------------------\\nPage Number: 93\\n\\nSection Name: PRINCIPLES OF IMAGING\\n====================\\nEntities:-\\nImaging, Diagnostic : The production of a visual representation of parts of the body, for the purpose of clinical analysis and medical intervention.\\nHead And Neck Neoplasms : Tumors or cancer of the head and neck region, including the nasal cavity, sinuses, lips, mouth, salivary glands, throat, or larynx.\\nTomography, X-Ray Computed : An imaging procedure that uses special x-ray equipment to create detailed pictures, or scans, of areas inside the body.\\nMagnetic Resonance Imaging : A noninvasive diagnostic technique that uses magnetic fields and radio waves to produce a detailed image of the body\\'s soft tissue and bones.\\nContrast Media : Substances used to enhance the contrast of structures or fluids within the body in medical imaging.\\n\\nRelationships:-\\n1. Entity1: \""Imaging, Diagnostic\"", Entity2: \""Head and Neck Neoplasms\"", Relationship: \""used for\""\\n2. Entity1: \""Tomography, X-Ray Computed\"", Entity2: \""Contrast Media\"", Relationship: \""uses\""\\n3. Entity1: \""Magnetic Resonance Imaging\"", Entity2: \""Contrast Media\"", Relationship: \""uses\""\\n\\nCausalities:-\\n<C> Imaging </C> plays an essential role in the clinical care of patients with head and neck cancer. <A> The proper selection and utilization of imaging studies </A> is critical in caring for patients with head and neck cancer. <A> CT is performed with contrast </A>, while <A> CT imaging of the chest can be performed with or without contrast </A>, <CO> as clinically indicated </CO>. <A> MRI is performed with and without contrast </A>, <CO> unless contraindicated </CO>.\\n\\nSection Name: Initial Workup - Primary Site\\n====================\\nEntities:-\\nTomography, X-Ray Computed : An imaging procedure that uses special x-ray equipment to create detailed pictures, or scans, of areas inside the body.\\nMagnetic Resonance Imaging : A noninvasive diagnostic technique that uses magnetic fields and radio waves to produce a detailed image of the body\\'s soft tissue and bones.\\nHead And Neck Neoplasms : Tumors or cancer of the head and neck region, including the nasal cavity, sinuses, lips, mouth, salivary glands, throat, or larynx.\\nNeck Structure : The anatomical structure of the neck, which is the part of the body that connects the head to the torso.\\nSkull Base : The bottom part of the skull, which separates the brain from other facial structures.\\nThoracic Inlet : The opening at the top of the thoracic cavity, through which pass the trachea, esophagus, and major blood vessels.\\n\\nRelationships:-\\n1. Entity1: \""CT\"", Entity2: \""MRI\"", Relationship: \""complementary in imaging head and neck cancers\""\\n2. Entity1: \""CT\"", Entity2: \""Head and Neck Neoplasms\"", Relationship: \""used to evaluate\""\\n3. Entity1: \""MRI\"", Entity2: \""Head and Neck Neoplasms\"", Relationship: \""preferred for evaluating\""\\n4. Entity1: \""Skull base\"", Entity2: \""Thoracic inlet\"", Relationship: \""imaging range for evaluation\""\\n\\nCausalities:-\\n<A>Imaging assessment of the primary site</A> can be performed with <A>CT of the soft tissues of the neck</A> or <A>MRI of the neck</A>. <C>CT is complementary to MRI for head and neck cancers</C>. <A>It is utilized to evaluate cortical bone erosion or periosteal invasion, cartilage invasion, and bony erosion or destruction</A>. <CO>in certain conditions, such as evaluating the extent of bone marrow invasion or in patients with extensive dental amalgam obscuring anatomy on CT, assessing skull base invasion and cranial nerve involvement, and differentiating tumor from obstructed sinuses</CO>, <A>MRI is preferred over CT</A>. <CO>when involved lymph nodes or upper mediastinal cancers are present</CO>, <A>Complete evaluation of primary and nodal disease requires imaging from the skull base to the thoracic inlet, extending to the carina</A>.\\n\\nSection Name: PET/CT and Biopsy\\n====================\\nEntities:-\\nPositron Emission Tomography Computed Tomography : A medical imaging technique that combines PET and CT capabilities to provide detailed images of the body.\\nExamination Under Anesthesia : A procedure where a patient is examined while under anesthesia to allow for a more thorough examination.\\nBiopsy : A medical test involving the extraction of sample cells or tissues for examination to determine the presence or extent of a disease.\\nTonsillectomy : A surgical procedure to remove the tonsils, often performed to treat recurrent tonsillitis or sleep apnea.\\nFine Needle Aspiration : A type of biopsy procedure that uses a thin, hollow needle to extract cells from a lump or mass for examination.\\nUltrasound : A medical imaging technique that uses high-frequency sound waves to visualize internal organs and structures.\\nComputed Tomography : A diagnostic imaging procedure that uses a combination of X-rays and computer technology to produce cross-sectional images of the body.\\n\\nRelationships:-\\n1. Entity1: \""PET/CT\"", Entity2: \""EUA\"", Relationship: \""recommended before\""\\n2. Entity1: \""Fine Needle Aspiration (FNA)\"", Entity2: \""metastatic nodes\"", Relationship: \""used for biopsy of\""\\n3. Entity1: \""Image-guided needle biopsy\"", Entity2: \""cystic neck nodes\"", Relationship: \""recommended for initial diagnosis of\""\\n\\nCausalities:-\\n<CO> If imaging does not reveal an obvious primary cancer </CO>, <A> a PET/CT should be ordered before EUA, biopsies, and tonsillectomy </A>. <E> This helps identify potential primary sites </E> before any interventions take place. Additionally, <A> Fine Needle Aspiration (FNA) biopsy of metastatic nodes </A> <E> may provide pathologically informative results </E>. <CO> For initial diagnosis in cystic neck nodes </CO>, <A> image-guided needle biopsy (ultrasound or CT) </A> <E> may yield better results than FNA by palpation alone </E>.\\n\\nSection Name: Postoperative Imaging Advice\\n====================\\nEntities:-\\nPanoramic Radiography : A type of dental x-ray that provides a wide view of the upper and lower jaws, teeth, temporomandibular joints, and sinuses.\\nOral Cavity : The cavity of the mouth, including the lips, the lining inside the cheeks and lips, the front two-thirds of the tongue, the gums, the floor of the mouth under the tongue, the hard palate, and the small area of the gum behind the wisdom teeth.\\nRadiotherapy : The treatment of disease, especially cancer, using X-rays or similar forms of radiation.\\nMandibulotomy : A surgical procedure involving the cutting of the mandible.\\nMandibulectomy : A surgical procedure involving the removal of part or all of the mandible.\\nOropharynx : The part of the throat at the back of the mouth behind the oral cavity.\\n\\nRelationships:-\\n1. Entity1: \""panoramic dental x-ray\"", Entity2: \""oral cavity cancers\"", Relationship: \""recommended for\""\\n2. Entity1: \""panoramic dental x-ray\"", Entity2: \""postoperative radiotherapy\"", Relationship: \""essential for pre-radiation evaluation\""\\n3. Entity1: \""pre-radiation dental evaluation\"", Entity2: \""dental procedures or extractions\"", Relationship: \""determine necessity of\""\\n\\nCausalities:-\\n<A> A panoramic dental x-ray is recommended </A> <C> for oral cavity cancers requiring mandibulotomy and/or mandibulectomy </C>. <CO> When postoperative radiotherapy (RT) is anticipated for areas like the lip, oral cavity subsites, or oropharynx </CO>, <A> panoramic x-ray is essential for a comprehensive pre-radiation dental evaluation </A> <E> to assess the health of affected teeth and determine if pre-radiation dental procedures or extractions are necessary </E>.\\n\\nSection Name: NCCN Guidelines Note\\n====================\\nEntities:-\\nNeoplasms : Neoplasms are abnormal growths of tissue, which can be cancerous or non-cancerous.\\nMalignant Neoplastic Disease : A disease characterized by uncontrolled, abnormal growth of cells that can invade or spread to other parts of the body.\\nCancer : A group of diseases involving abnormal cell growth with the potential to invade or spread to other parts of the body.\\nClinical Trials As Topic : Pre-planned studies of the safety, efficacy, or optimum dosage schedule of one or more diagnostic, therapeutic, or prophylactic drugs, devices, or techniques in humans selected according to predetermined criteria of eligibility and observed for predefined evidence of favorable and unfavorable effects.\\nClinical Trial : A research study that prospectively assigns human participants or groups of humans to one or more health-related interventions to evaluate the effects on health outcomes.\\n\\nRelationships:-\\n1. Entity1: \""NCCN\"", Entity2: \""Clinical Trials\"", Relationship: \""encourages participation in\""\\n2. Entity1: \""NCCN\"", Entity2: \""Cancer\"", Relationship: \""recommends clinical trials for\""\\n\\nCausalities:-\\n<A> NCCN believes that the best management of any patient with cancer is through participation in clinical trials </A>, <A> which is especially encouraged </A>.\\n--------------------------------------------------\\nPage Number: 94\\n\\nSection Name: Head and Neck Cancers - Principles of Imaging\\n====================\\nEntities:-\\nPositron Emission Tomography Computed Tomography : A medical imaging technique combining PET and CT capabilities to provide detailed information about the body\\'s function and structure.\\nPositron Emission Tomography : A nuclear medicine functional imaging technique that is used to observe metabolic processes in the body.\\nComputed Tomography : A diagnostic imaging procedure that uses a combination of X-rays and computer technology to produce cross-sectional images of the body.\\nHead And Neck Neoplasms : Cancers that arise in the head or neck region, including the nasal cavity, sinuses, lips, mouth, salivary glands, throat, or larynx.\\n\\nRelationships:-\\n1. Entity1: \""PET/CT\"", Entity2: \""PET scan\"", Relationship: \""preferred over\""\\n2. Entity1: \""PET-CT\"", Entity2: \""head neck cancers\"", Relationship: \""used in study of\""\\n\\nCausalities:-\\n<A> PET/CT is preferred over PET scan alone (i.e., without superimposed CT scan) </A>. <C> PET/CT provides more accurate anatomical localization of abnormalities </C> <E> more accurate anatomical localization of abnormalities </E>.\\n\\nSection Name: Initial Workup - Nodal Metastases\\n====================\\nEntities:-\\nLymphatic Metastasis : The transfer of a neoplasm from one organ or part of the body to another remote from the primary site via the lymphatic system.\\nTomography, X-Ray Computed : A method of body imaging in which a thin X-ray beam rotates around the patient, producing signals that are processed by the machine\\'s computer to generate cross-sectional images.\\nMagnetic Resonance Imaging : A non-invasive imaging technique that uses magnetic fields and radio waves to create detailed images of the organs and tissues within the body.\\nPositron-Emission Tomography : An imaging technique that uses radioactive substances to visualize and measure changes in metabolic processes, and in other physiological activities including blood flow, regional chemical composition, and absorption.\\nLymph Node Metastasis : The spread of cancer cells to lymph nodes, which are part of the lymphatic system.\\nCt Of Neck : A computed tomography scan of the neck region.\\nMri Of Neck : A magnetic resonance imaging scan of the neck region.\\nFdg-Pet Scan : A type of positron emission tomography using fluorodeoxyglucose to assess metabolic activity.\\nComputed Tomography : A diagnostic imaging procedure that uses a combination of X-rays and computer technology to produce cross-sectional images of the body.\\nPositron Emission Tomography : A nuclear medicine functional imaging technique that is used to observe metabolic processes in the body.\\n\\nRelationships:-\\n1. Entity1: \""CT\"", Entity2: \""lymph node metastases\"", Relationship: \""used to evaluate\""\\n2. Entity1: \""MRI\"", Entity2: \""lymph node metastases\"", Relationship: \""used to evaluate\""\\n3. Entity1: \""FDG-PET/CT\"", Entity2: \""lymph node metastases\"", Relationship: \""used for detection\""\\n4. Entity1: \""FDG-PET/CT\"", Entity2: \""surgical primary approach\"", Relationship: \""used to determine\""\\n5. Entity1: \""FDG-PET/CT\"", Entity2: \""definitive RT approach\"", Relationship: \""used to identify\""\\n\\nCausalities:-\\n<A> Evaluation of lymph node metastases should be conducted with CT or MRI of the neck </A>, using whichever imaging study is suitable for primary site evaluation (IMG-A, 1 of 4).\\n<CO> For patients with multistation or lower neck nodal involvement or high-grade tumor histology </CO>, <A> consider CT of the chest to assess for mediastinal lymph node metastases or FDG-PET/CT </A>, <C> which is associated with higher sensitivity for both nodal and distant metastases </C>.\\n<CO> For patients who are under consideration for a surgical primary approach </CO>, <A> the higher sensitivity of FDG-PET/CT is warranted for tumors approaching the midline, to determine the surgical approach to the contralateral neck </A>. <CO> Similarly, patients who are scheduled for a definitive RT approach </CO> <A> may benefit from the higher sensitivity of FDG-PET/CT for identifying involved lymph nodes </A>.\\n\\nSection Name: Initial Workup - Distant Metastases\\n====================\\nEntities:-\\nPositron-Emission Tomography : An imaging technique that uses radioactive substances to visualize and measure changes in metabolic processes, and in other physiological activities including blood flow, regional chemical composition, and absorption.\\nMagnetic Resonance Imaging : A non-invasive imaging technique that uses magnetic fields and radio waves to create detailed images of the organs and tissues within the body.\\nTomography, X-Ray Computed : A method of body imaging in which a thin X-ray beam rotates around the patient, producing signals that are processed by the machine\\'s computer to generate cross-sectional images.\\nNeoplasm Metastasis : The transfer of a neoplasm from one organ or part of the body to another remote from the primary site.\\nLung Neoplasms : Tumors or cancer of the lung.\\nSmoking : The inhalation of the smoke of burning tobacco encased in cigarettes, pipes, and cigars.\\n\\nRelationships:-\\n1. Entity1: \""FDG-PET/CT\"", Entity2: \""Distant Metastases\"", Relationship: \""used to evaluate\""\\n2. Entity1: \""Contrast-enhanced brain MRI\"", Entity2: \""Brain Metastasis\"", Relationship: \""recommended for evaluation\""\\n3. Entity1: \""CT of the chest\"", Entity2: \""Pulmonary Metastases\"", Relationship: \""performed to assess\""\\n4. Entity1: \""Non-contrast CT of the chest\"", Entity2: \""Lung Parenchymal Metastases\"", Relationship: \""used to screen\""\\n5. Entity1: \""Annual CT screening\"", Entity2: \""Lung Metastasis\"", Relationship: \""considered for high risk\""\\n6. Entity1: \""Directed CT or MRI\"", Entity2: \""Distant Disease\"", Relationship: \""used for assessment\""\\n7. Entity1: \""FDG-PET/CT\"", Entity2: \""Recurrent Disease\"", Relationship: \""used for staging\""\\n\\nCausalities:-\\n<C> Patients with locoregionally advanced cancer (e.g., T3\u2013T4 primary or \u2265N1 nodal staging) </C>, <A> FDG-PET/CT is preferred to evaluate for distant disease and thoracic metastases </A>. <CO> For cancers where brain metastasis is a concern, such as mucosal melanoma or high-grade neuroendocrine carcinomas or adenocarcinomas </CO>, <A> contrast-enhanced brain MRI should be additionally obtained </A>.\\n<CO> If FDG-PET/CT is not performed </CO>, <A> CT of the chest should be performed to assess for presence of pulmonary metastases as well as mediastinal lymph node involvement </A>.\\n<CO> Non-contrast CT of the chest can be sufficient to screen for lung parenchymal metastases </CO> but <CO> is not adequate for assessment of mediastinal adenopathy </CO>. <CO> This is an appropriate lung cancer screening intervention for patients with a history of smoking </CO>.\\n<CO> Following primary definitive treatment (surgery, RT, or systemic therapy/RT) </CO> the role of annual CT screening for lung metastasis is controversial. <E> While this approach does detect early metastasis </E>, <CO> further study is needed to determine the extent of the positive effect and/or cost-effectiveness of this approach in specific subpopulations and timepoints post-treatment </CO>. <CO> For patients with a substantial smoking history or who are at high risk for lung metastases </CO>, <A> annual chest CT can be considered </A>.\\n<CO> If clinical concern for metastatic disease is confined to a specific anatomical area </CO>, <A> the assessment of distant disease can be performed with directed CT or MRI examination </A>.\\n<CO> FDG-PET/CT may complement or replace other imaging modalities when staging recurrent disease before any therapy for relapsed/refractory disease </CO> <A> in order to explore distant disease or second primaries that may significantly impact choice of therapy </A>.\\n--------------------------------------------------\\nPage Number: 46\\n\\nSection Name: Introduction\\n====================\\nEntities:-\\nLaryngeal Neoplasms : Tumors or cancer of the larynx, including the glottis.\\nMalignant Neoplasm Of Glottis : A malignant tumor located in the glottis, part of the larynx.\\nNational Comprehensive Cancer Network : The National Comprehensive Cancer Network (NCCN) is an alliance of 30 cancer centers in the United States, dedicated to improving the quality, effectiveness, and efficiency of cancer care.\\nAdjuvant Chemotherapy : Chemotherapy given in addition to the primary treatment to maximize its effectiveness, often used in cancer treatment.\\nAdjuvant Therapy : Treatment given in addition to the primary (main) treatment to enhance its effectiveness.\\n\\nRelationships:-\\n1. Entity1: \""National Comprehensive Cancer Network\"", Entity2: \""Laryngeal Neoplasms\"", Relationship: \""provides treatment guidelines for\""\\n2. Entity1: \""treatment guidelines\"", Entity2: \""Adjuvant therapy\"", Relationship: \""guide clinical decision-making for\""\\n\\nCausalities:-\\n<C> cancer of the glottic larynx </C> <E> treatment guidelines </E> <CO> based on various clinical stages and specific patient conditions </CO> <A> guide healthcare professionals through clinical decision-making </A>.\\n\\nSection Name: NCCN Guidelines Version 4.2024\\n====================\\nEntities:-\\nClinical Trials : Clinical trials are research studies performed in people that are aimed at evaluating a medical, surgical, or behavioral intervention.\\nNational Comprehensive Cancer Network : The National Comprehensive Cancer Network (NCCN) is an alliance of 30 cancer centers in the United States, dedicated to improving the quality, effectiveness, and efficiency of cancer care.\\n\\nRelationships:-\\n1. Entity1: \""National Comprehensive Cancer Network\"", Entity2: \""Clinical Trials\"", Relationship: \""encourages participation in\""\\n\\nCausalities:-\\n<A>Participation in clinical trials</A> is especially encouraged.\\n\\nSection Name: Clinical Staging and Treatment\\n====================\\nEntities:-\\nNeoplasm Staging : Methods used for staging of neoplasms based on extent of tumor spread.\\nT4A : A clinical stage indicating a tumor that has grown into nearby structures.\\nN0\u20133 : A range of clinical stages indicating the extent of regional lymph node involvement.\\nSurgical Procedures, Operative : Operations carried out for the correction of deformities and defects, repair of injuries, and diagnosis and cure of certain diseases.\\nNeck Dissection : Surgical procedure to remove lymph nodes and surrounding tissue in the neck.\\nPathology : The study of the nature and cause of disease which involves changes in structure and function.\\nAntineoplastic Combined Chemotherapy Protocols : The use of drug combinations to treat cancer.\\nRadiotherapy : The use of ionizing radiation to treat cancer.\\nClinical Trials As Topic : Works about research studies that evaluate the effectiveness and safety of medications or medical devices by monitoring their effects on large groups of people.\\n\\nRelationships:-\\n1. Entity1: \""Clinical Staging\"", Entity2: \""Surgical Intervention\"", Relationship: \""determines\""\\n2. Entity1: \""T4a\"", Entity2: \""Surgical Intervention\"", Relationship: \""relates to\""\\n3. Entity1: \""Systemic Therapy\"", Entity2: \""Radiotherapy\"", Relationship: \""considered with\""\\n4. Entity1: \""Clinical Trials\"", Entity2: \""Treatment of Primary and Neck\"", Relationship: \""option for\""\\n\\nCausalities:-\\n<CO> Clinical staging indicator labeled \""T4a,N0\u20133\"" </CO> <A> emphasizes the importance of surgical intervention </A>, highlighting procedures such as bilateral neck dissection and the need to address certain pathologic features. <CO> Selected T4a patients who decline surgery </CO> <A> consider concurrent systemic therapy/RT or clinical trial for function-preserving surgical or RT management or induction chemotherapy </A>.\\n\\nSection Name: Principles of Treatment\\n====================\\nEntities:-\\nThyroidectomy : Surgical removal of the thyroid gland.\\nExtranodal Extension : Spread of cancer beyond the lymph node capsule.\\nRadiation Therapy : Medical use of ionizing radiation to treat cancer.\\n\\nRelationships:-\\n1. Entity1: \""Surgery\"", Entity2: \""Thyroidectomy\"", Relationship: \""involves\""\\n2. Entity1: \""Radiation therapy\"", Entity2: \""Adverse pathologic features\"", Relationship: \""treats\""\\n\\nCausalities:-\\n- **Principles of Radiation Therapy (GLOT-A):**  \\n  - <C> Adverse pathologic features: extranodal extension, positive margins, close margins, pT4 primary, pN2 or pN3 nodal disease, perineural invasion, vascular invasion, lymphatic invasion, and subglottic extension </C> (Discussion).  \\n\\n- **Principles of Surgery (SURG-A):**  \\n  - <A> Surgery, including ipsilateral or bilateral neck dissection; thyroidectomy to clear central compartment nodes </A>, <CO> especially when there is thyroid cartilage with gross invasion of the thyroid gland and significant subglottic extension </CO>.\\n\\nSection Name: Adjuvant Treatment and Follow-up\\n====================\\nEntities:-\\nSystemic Therapy : Treatment using substances that travel through the bloodstream, reaching and affecting cells all over the body.\\nClinical Trial : A research study that prospectively assigns human participants or groups of humans to one or more health-related interventions to evaluate the effects on health outcomes.\\nComputed Tomography (Ct) : A medical imaging technique used in radiology to obtain detailed internal images of the body noninvasively for diagnostic purposes.\\nMagnetic Resonance Imaging (Mri) : A noninvasive medical test that physicians use to diagnose and treat medical conditions.\\nRecurrent Disease : A disease that has returned after a period of remission.\\nRadiation Therapy (Rt) : The use of ionizing radiation to treat cancer and other diseases.\\n\\nRelationships:-\\n1. Entity1: \""Adverse Features\"", Entity2: \""Specific Treatments\"", Relationship: \""Suggests\""\\n2. Entity1: \""Systemic Therapy\"", Entity2: \""Patients who decline surgery\"", Relationship: \""Option for\""\\n3. Entity1: \""CT or MRI\"", Entity2: \""Primary and Neck\"", Relationship: \""Used for imaging\""\\n4. Entity1: \""Recurrent or Persistent Disease\"", Entity2: \""Follow-up\"", Relationship: \""Condition for\""\\n5. Entity1: \""pN1 without other risk features\"", Entity2: \""RT\"", Relationship: \""Suggests considering\""\\n\\nCausalities:-\\n<C> adverse features such as extralateral extension or positive margins </C> <E> specific treatments are suggested </E>. The guidelines recommend <A> considering options like concurrent systemic therapy or clinical trials </A> <CO> for patients who decline surgery </CO>.\\n\\n- **Adjuvant Treatment:**  \\n  - <A> CT (with contrast) or MRI (with and without contrast) of primary and neck </A>.  \\n\\n- **Follow-up (FOLL-A, 1 of 2):**  \\n  - <CO> Recurrent or persistent disease (ADV-3) </CO>.  \\n\\n- **Post Systemic Therapy/RT or RT Neck Evaluation (FOLL-A, 2 of 2):**  \\n  - <CO> pN1 without other risk features </CO>: <A> Consider RT </A>.\\n\\nSection Name: Response Assessment\\n====================\\nEntities:-\\nAdjuvant Chemotherapy : Chemotherapy given in addition to the primary treatment to maximize its effectiveness, often used in cancer treatment.\\nComputed Tomography : A diagnostic imaging procedure that uses a combination of X-rays and computer technology to produce cross-sectional images of the body.\\nMagnetic Resonance Imaging : A medical imaging technique used in radiology to form pictures of the anatomy and the physiological processes of the body.\\nNeoplasm Recurrence, Local : The return of a cancer, at the same site as the original (primary) tumor, after it had disappeared.\\n\\nRelationships:-\\n1. Entity1: \""Adjuvant treatment\"", Entity2: \""Treatment responses\"", Relationship: \""affects\""\\n2. Entity1: \""Follow-up assessments\"", Entity2: \""CT or MRI scans\"", Relationship: \""conducted using\""\\n3. Entity1: \""Response Assessment (GLOT-5)\"", Entity2: \""Recurrent or persistent disease (ADV-3)\"", Relationship: \""determines\""\\n\\nCausalities:-\\nAs the flowchart progresses to the adjuvant treatment section, it depicts further decision points based on treatment responses and disease recurrence. The inclusion of references to follow-up assessments, such as CT or MRI scans, underscores the emphasis on continuous monitoring and evaluation of treatment efficacy.  - **Response Assessment (GLOT-5):**   - <C>Recurrent or persistent disease (ADV-3)</C>.\\n--------------------------------------------------\\nPage Number: 53\\n\\nSection Name: Introduction\\n====================\\nEntities:-\\nNational Comprehensive Cancer Network : The National Comprehensive Cancer Network (NCCN) is an alliance of 30 cancer centers in the United States, dedicated to improving the quality, effectiveness, and efficiency of cancer care so that patients can live better lives.\\nLaryngeal Neoplasms : Tumors or cancer of the larynx, which may affect the supraglottic, glottic, or subglottic regions.\\nMalignant Neoplasm Of Supraglottis : A malignant tumor located in the supraglottic region of the larynx.\\n\\nRelationships:-\\n1. Entity1: \""National Comprehensive Cancer Network\"", Entity2: \""Malignant neoplasm of supraglottis\"", Relationship: \""provides guidelines for\""\\n2. Entity1: \""clinical staging\"", Entity2: \""treatment strategies\"", Relationship: \""part of flowchart for\""\\n\\nCausalities:-\\nThe provided image is a flowchart outlining the <C> NCCN (National Comprehensive Cancer Network) guidelines </C> for the treatment of <CO> cancers of the supraglottic larynx </CO>. This flowchart <A> utilizes a highly structured approach to convey clinical staging and treatment strategies </A>, indicating the various pathways based on <CO> patient conditions and disease features </CO>.\\n\\nSection Name: NCCN Guidelines Version 4.2024\\n====================\\nEntities:-\\nLaryngeal Neoplasms : Tumors or cancer of the larynx, which may affect the supraglottic, glottic, or subglottic regions.\\nMalignant Neoplasm Of Supraglottis : A malignant tumor located in the supraglottic region of the larynx.\\nSupraglottic Cancer : Cancer that occurs in the supraglottic region of the larynx, above the vocal cords.\\nClinical Trials As Topic : Pre-planned studies of the safety, efficacy, or optimum dosage schedule of one or more diagnostic, therapeutic, or prophylactic drugs, devices, or techniques in humans selected according to predetermined criteria of eligibility and observed for predefined evidence of favorable and unfavorable effects.\\nClinical Trial : A type of research that studies new tests and treatments and evaluates their effects on human health outcomes.\\n\\nRelationships:-\\n1. Entity1: \""Cancer of the Supraglottic Larynx\"", Entity2: \""Clinical Trials\"", Relationship: \""recommended management strategy\""\\n\\nCausalities:-\\n- All recommendations are category 2A unless otherwise indicated.\\n- <A> Participation in clinical trials </A> is especially encouraged.\\n\\nSection Name: Key Components of the Flowchart\\n====================\\nEntities:-\\nNeoplasm Staging : Methods used for staging neoplasms, including clinical and pathological staging.\\nRadiotherapy : The use of ionizing radiation to treat cancer.\\nSurgical Procedures, Operative : Operations carried out for the correction of deformities and defects, repair of injuries, and diagnosis and cure of certain diseases.\\nAdjuvant Chemotherapy : Chemotherapy given in addition to the primary treatment to maximize its effectiveness.\\nNeoplasm Recurrence, Local : The return of a tumor at the original site after treatment.\\nClinical Trials As Topic : Pre-planned studies of the safety, efficacy, or optimum dosage schedule of one or more diagnostic, therapeutic, or prophylactic drugs, devices, or techniques in humans selected according to predetermined criteria of eligibility and observed for predefined evidence of favorable and unfavorable effects.\\n\\nRelationships:-\\n1. Entity1: \""Clinical Staging\"", Entity2: \""Treatment of Primary and Neck\"", Relationship: \""determines\""\\n2. Entity1: \""Evaluation and Follow-Up\"", Entity2: \""Adverse and No Adverse Features\"", Relationship: \""leads to decision based on\""\\n3. Entity1: \""Adjuvant Treatment\"", Entity2: \""Adverse pathologic features\"", Relationship: \""considered if present\""\\n4. Entity1: \""Clinical Trials\"", Entity2: \""Treatment Pathway\"", Relationship: \""part of\""\\n\\nCausalities:-\\n### Key Components of the Flowchart\\n\\n1. **Clinical Staging**: The flowchart starts with <A>clinical staging</A>, indicating that <CO>patients must first be evaluated to determine the extent of cancer</CO>. This is essential for <E>deciding on appropriate treatment options</E>.\\n\\n2. **Treatment of Primary and Neck**: The flowchart details multiple treatment strategies, including:\\n   - <A>**Concurrent systemic therapy/RT**</A>: This suggests a combination approach for <CO>patients eligible for such treatment</CO>.\\n   - <A>**Definitive Radiation Therapy (RT)**</A>: Recommended for <CO>low-volume diseases or patients who cannot tolerate systemic therapy</CO>.\\n   - <A>**Surgical Options**</A>: It highlights options such as endoscopic or open partial laryngectomy and neck dissection, which are <CO>contingent on clinical evaluations</CO>.\\n\\n3. **Evaluation and Follow-Up**: After initial treatment approaches, the chart directs clinicians to perform a <A>\""Post Systemic Therapy/RT or RT Neck Evaluation\""</A>. This step <E>assesses whether there are adverse pathologic features</E>, guiding subsequent treatment decisions.\\n\\n4. **Adverse and No Adverse Features**: The decision pathway diverges based on findings:\\n   - <CO>Patients with **adverse pathologic features**</CO> may have <A>additional diagnostic imaging (CT or MRI)</A> and may require <A>further systemic treatment</A>.\\n   - <CO>Patients with **no adverse features**</CO> may be directed towards <A>considerations for radiation therapy</A>.\\n\\n5. **Adjuvant Treatment and Recurrence**: The chart also addresses <E>management of any recurrent or persistent disease</E>, emphasizing the importance of <A>regular follow-up assessments</A>. Various options for <A>adjuvant treatment</A> are mentioned, focusing on tailored approaches towards ongoing management of the disease.\\n\\n6. **Clinical Trials**: The flowchart encourages <A>participation in clinical trials</A>, indicating a commitment to <E>exploring new treatments and improving patient outcomes</E>.\\n\\nSection Name: Principles\\n====================\\nEntities:-\\nImaging : The process of producing images of the body or parts of the body to diagnose or examine disease.\\nSurgical Procedure : A medical procedure involving an incision with instruments; performed to repair damage or arrest disease in a living body.\\nRadiation Therapy : The use of ionizing radiation to treat cancer and other diseases.\\nSystemic Therapy : Treatment using substances that travel through the bloodstream, reaching and affecting cells all over the body.\\n\\nRelationships:-\\n1. Entity1: \""Imaging\"", Entity2: \""Surgery\"", Relationship: \""Both are foundational principles in medical practice.\""\\n2. Entity1: \""Radiation therapy\"", Entity2: \""Systemic Therapy\"", Relationship: \""Both are treatment modalities for cancer.\""\\n\\nCausalities:-\\n#### Principles\\n- **Principles of Imaging (IMG-A)**\\n- **Principles of Surgery (SURG-A)**\\n- **Principles of Radiation Therapy (SUPRA-A)**\\n- **Principles of Systemic Therapy for Non-Nasopharyngeal Cancers (SYST-A)**\\n\\nSection Name: Adverse Pathologic Features\\n====================\\nEntities:-\\nExtranodal Extension : The spread of cancer cells beyond the lymph node capsule into the surrounding tissues.\\nPositive Surgical Margins : The presence of cancer cells at the edge of the tissue removed during surgery.\\nPerineural Invasion : Cancer cells found surrounding or tracking along a nerve within the perineural space.\\nVascular Invasion : The presence of cancer cells within blood vessels.\\nLymphatic Invasion : The presence of cancer cells within lymphatic vessels.\\n\\nRelationships:-\\n1. Entity1: \""Extranodal Extension\"", Entity2: \""Positive Surgical Margins\"", Relationship: \""Both indicate cancer spread beyond original site.\""\\n2. Entity1: \""Perineural Invasion\"", Entity2: \""Vascular Invasion\"", Relationship: \""Both are pathways for cancer spread.\""\\n3. Entity1: \""pT3 or pT4 primary\"", Entity2: \""pN2 or pN3 nodal disease\"", Relationship: \""Both indicate advanced cancer stages.\""\\n\\nCausalities:-\\n<C> Extranodal extension </C>\\n<C> Positive margins </C>\\n<C> Close margins </C>\\n<C> pT3 or pT4 primary </C>\\n<C> pN2 or pN3 nodal disease </C>\\n<C> Perineural invasion </C>\\n<C> Vascular invasion </C>\\n<C> Lymphatic invasion </C>\\n\\nSection Name: Clinical Staging and Treatment of Primary and Neck\\n====================\\nEntities:-\\nAdjuvant Chemotherapy : Chemotherapy given in addition to the primary treatment to maximize its effectiveness.\\nFollow-Up Procedure : A procedure performed to monitor the progress of a patient after treatment.\\nRecurrent Disease : A disease that returns after a period of remission.\\nLaryngectomy : Surgical removal of the larynx, often used to treat cancer.\\nRadiation Therapy : The use of ionizing radiation to treat cancer and other diseases.\\nClinical Trial : A type of research that studies new tests and treatments and evaluates their effects on human health outcomes.\\nNeck Dissection : Surgical procedure to remove lymph nodes and surrounding tissue to treat cancer.\\nChemotherapy : Treatment of disease by the use of chemical substances, especially cancer by cytotoxic drugs.\\n\\nRelationships:-\\n1. Entity1: \""Adjuvant Treatment\"", Entity2: \""Treatment of Primary and Neck\"", Relationship: \""part of\""\\n2. Entity1: \""Follow-up\"", Entity2: \""Treatment of Primary and Neck\"", Relationship: \""part of\""\\n3. Entity1: \""Recurrent or Persistent Disease\"", Entity2: \""Treatment of Primary and Neck\"", Relationship: \""part of\""\\n4. Entity1: \""Larynx-Preserving Surgery\"", Entity2: \""Treatment Options\"", Relationship: \""is a treatment option for\""\\n5. Entity1: \""Concurrent Systemic Therapy/RT\"", Entity2: \""Treatment Options\"", Relationship: \""is a treatment option for\""\\n6. Entity1: \""Clinical Trials or Definitive RT\"", Entity2: \""Treatment Options\"", Relationship: \""is a treatment option for\""\\n7. Entity1: \""Endoscopic or Open Partial Laryngectomy and Neck Dissection(s)\"", Entity2: \""Treatment Options\"", Relationship: \""is a treatment option for\""\\n8. Entity1: \""Induction Chemotherapy\"", Entity2: \""Treatment Options\"", Relationship: \""is a treatment option for\""\\n\\nCausalities:-\\n<A> Amenable to Larynx-Preserving (Conservation) Surgery </A>: <CO> T1\u20132, N+ and selected T3, N1 </CO>\\n<A> Concurrent Systemic Therapy/RT </A>: <CO> i, k, l </CO>\\n<A> Clinical Trials or Definitive RT </A>: <CO> i </CO>\\n<A> Endoscopic or Open Partial Laryngectomy and Neck Dissection(s) </A>: <CO> h </CO>\\n<A> Induction Chemotherapy </A>: <CO> k, m </CO>\\n\\nSection Name: Pathologic Features and Response Assessment\\n====================\\nEntities:-\\nRadiation Therapy : The use of ionizing radiation to treat cancer and other diseases.\\nExtranodal Extension : The spread of cancer cells beyond the lymph node capsule into the surrounding tissues.\\nPositive Surgical Margin : Cancer cells are found at the edge of the material removed during surgery, indicating that some cancer may have been left behind.\\nSystemic Therapy : Treatment using substances that travel through the bloodstream, reaching and affecting cells all over the body.\\n\\nRelationships:-\\n1. Entity1: \""Extranodal extension\"", Entity2: \""Adverse Pathologic Features\"", Relationship: \""is a type of\""\\n2. Entity1: \""Positive margin\"", Entity2: \""Adverse Pathologic Features\"", Relationship: \""is a type of\""\\n3. Entity1: \""Systemic Therapy\"", Entity2: \""Adverse Pathologic Features\"", Relationship: \""considered in response to\""\\n4. Entity1: \""Radiation Therapy\"", Entity2: \""Adverse Pathologic Features\"", Relationship: \""considered in response to\""\\n\\nCausalities:-\\n#### Pathologic Features\\n- **No Adverse Pathologic Features**: j\\n  - <A> Consider RT </A>: i\\n- **Adverse Pathologic Features**: j\\n  - <CO> Extranodal extension and/or positive margin </CO>: n\\n  - Other risk features\\n  - <A> Systemic therapy/RT </A>: i, k (category 1)\\n  - <A> Consider systemic therapy/RT </A>: i, k\\n\\n#### Response Assessment\\n- **Response Assessment** (SUPRA-7)\\n\\nSection Name: Imaging and Recurrent or Persistent Disease\\n====================\\nEntities:-\\nTomography, X-Ray Computed : A method of body imaging in which a thin X-ray beam rotates around the patient.\\nMagnetic Resonance Imaging : Medical imaging technique used in radiology to form pictures of the anatomy and the physiological processes of the body.\\nComputed Tomography : Medical imaging technique used in radiology to obtain detailed internal images of the body.\\n\\nRelationships:-\\n1. Entity1: \""CT\"", Entity2: \""primary and neck\"", Relationship: \""used for imaging\""\\n2. Entity1: \""MRI\"", Entity2: \""primary and neck\"", Relationship: \""used for imaging\""\\n3. Entity1: \""Post Systemic Therapy/RT\"", Entity2: \""Recurrent or Persistent Disease\"", Relationship: \""evaluation after treatment\""\\n4. Entity1: \""RT Neck Evaluation\"", Entity2: \""Recurrent or Persistent Disease\"", Relationship: \""evaluation after treatment\""\\n\\nCausalities:-\\n<A> CT (with contrast) or MRI (with and without contrast) of primary and neck </A>\\n\\n<CO> Recurrent or Persistent Disease </CO>\\n\\n<CO> Post Systemic Therapy/RT or RT Neck Evaluation </CO>\\n\\nSection Name: Conclusion\\n====================\\nEntities:-\\nOncologists : Medical doctors who specialize in the diagnosis and treatment of cancer.\\nSupraglottic Larynx Cancer : A type of cancer that occurs in the supraglottic region of the larynx, which is the area above the vocal cords.\\nClinical Staging : The process of determining the extent of cancer in the body, usually based on physical examination, imaging tests, and biopsies.\\nTreatment Strategies : Plans or methods developed to treat diseases, including cancer, which may involve surgery, chemotherapy, radiation therapy, or other modalities.\\nFollow-Up Evaluations : Medical assessments conducted after initial treatment to monitor a patient\\'s progress and detect any recurrence of disease.\\nClinical Efficacy : The ability of a treatment to produce the desired therapeutic effect in clinical settings.\\nResearch : Systematic investigation and study conducted to establish facts and reach new conclusions.\\nTreatment Paradigms : Standard models or patterns of treatment used in medical practice, often based on clinical guidelines and research findings.\\n\\nRelationships:-\\n1. Entity1: \""Oncologists\"", Entity2: \""Supraglottic Larynx Cancer\"", Relationship: \""use flowchart for decision-making\""\\n2. Entity1: \""Clinical Staging\"", Entity2: \""Treatment Strategies\"", Relationship: \""part of management process\""\\n3. Entity1: \""Treatment Strategies\"", Entity2: \""Follow-Up Evaluations\"", Relationship: \""part of management process\""\\n\\nCausalities:-\\n<A> The flowchart serves as a comprehensive guide for oncologists and healthcare providers </A>, <A> facilitating informed decision-making in the treatment of supraglottic larynx cancer </A>. <A> By visualizing the complex interactions between clinical staging, treatment strategies, and follow-up evaluations </A>, <E> it streamlines the management process </E>, <E> ensuring that patients receive appropriate care tailored to their specific needs </E>. <E> The detailed pathways not only enhance clinical efficacy </E> but also <E> underscore the importance of ongoing research and adaptation of treatment paradigms in oncology </E>.\\n--------------------------------------------------\\nPage Number: 41\\n\\nSection Name: Workup\\n====================\\nEntities:-\\nLaryngeal Neoplasms : Tumors or cancer of the larynx, which may affect the glottis, supraglottis, or subglottis.\\nHistory And Physical Examination : A comprehensive assessment of a patient\\'s medical history and physical condition.\\nTobacco Smoking : The act of smoking tobacco products, which is a risk factor for many diseases.\\nAlcohol Drinking : The consumption of beverages containing ethyl alcohol.\\nSmoking Cessation : The process of discontinuing tobacco smoking.\\nBiopsy : A medical test involving the extraction of sample cells or tissues for examination.\\nLaryngoscopy : A procedure to examine the larynx, often using a scope.\\nComputed Tomography (Ct) : A diagnostic imaging procedure that uses computer-processed combinations of many X-ray measurements taken from different angles to produce cross-sectional images of specific areas of a scanned object.\\nMagnetic Resonance Imaging (Mri) : A medical imaging technique used in radiology to form pictures of the anatomy and the physiological processes of the body.\\nPositron-Emission Tomography : A type of nuclear medicine imaging that measures metabolic activity of the cells of body tissues.\\nPulmonary Function Test : Tests that measure how well the lungs are working.\\nDental Examination : An evaluation of the teeth and gums to assess oral health.\\nNutritional Support : Therapies to provide nutrition to patients who cannot obtain nutrition by mouth.\\nSpeech Therapy : Therapy to improve speech and communication skills.\\nSwallowing Therapy : Therapy to help individuals with swallowing difficulties.\\nMultidisciplinary Care Team : A group of healthcare professionals from different specialties working together to manage patient care.\\n\\nRelationships:-\\n1. Entity1: \""glottic larynx cancer\"", Entity2: \""history and physical examination\"", Relationship: \""initial diagnostic step\""\\n2. Entity1: \""glottic larynx cancer\"", Entity2: \""biopsy\"", Relationship: \""required diagnostic procedure\""\\n3. Entity1: \""glottic larynx cancer\"", Entity2: \""direct laryngoscopy\"", Relationship: \""recommended procedure\""\\n4. Entity1: \""glottic larynx cancer\"", Entity2: \""CT scans\"", Relationship: \""imaging study\""\\n5. Entity1: \""glottic larynx cancer\"", Entity2: \""MRI\"", Relationship: \""imaging study\""\\n6. Entity1: \""glottic larynx cancer\"", Entity2: \""multidisciplinary consultation\"", Relationship: \""advised as clinically indicated\""\\n\\nCausalities:-\\nThe workup section outlines the initial steps for diagnosing <C>glottic larynx cancer</C>. It includes <A>a comprehensive history and physical examination (H&P)</A>, which should document tobacco and alcohol use, and provide counseling for smoking cessation. <A>A biopsy of the primary site is required</A>, and <A>direct laryngoscopy under anesthesia is generally recommended</A>. <A>Imaging studies such as CT scans with contrast and possibly MRI are used to evaluate the larynx and neck</A>. Additional evaluations may include <A>chest CT, FDG-PET/CT, pulmonary function tests, dental evaluation, and nutrition, speech, and swallowing therapy</A>. <A>Multidisciplinary consultation is advised</A> <CO>as clinically indicated</CO>.\\n\\nSection Name: Clinical Staging\\n====================\\nEntities:-\\nCancer : A group of diseases involving abnormal cell growth with the potential to invade or spread to other parts of the body.\\nCarcinoma In Situ : A lesion with cytological characteristics of cancer but which has not invaded the basement membrane.\\nBiopsy : A medical test involving the extraction of sample cells or tissues for examination.\\nLaryngectomy : A surgical procedure to remove the larynx.\\n\\nRelationships:-\\n1. Entity1: \""Clinical staging\"", Entity2: \""Cancer\"", Relationship: \""involves\""\\n2. Entity1: \""Carcinoma in situ\"", Entity2: \""Stages T1-T4\"", Relationship: \""is a stage of\""\\n3. Entity1: \""Biopsy\"", Entity2: \""Cancer\"", Relationship: \""used in staging\""\\n4. Entity1: \""Larynx-preserving surgeries\"", Entity2: \""Stages T1-T2\"", Relationship: \""considered for\""\\n5. Entity1: \""Total laryngectomy\"", Entity2: \""Stages T3-T4\"", Relationship: \""required for\""\\n\\nCausalities:-\\n<C> Clinical staging involves categorizing the cancer based on its aggressiveness </C>. It starts with carcinoma in situ, which is non-invasive, and progresses through stages T1-T4. <CO> Staging is based on H&P, biopsy, and imaging studies </CO>. <CO> For T1-T2 </CO>, <A> larynx-preserving surgeries are considered </A>, while <CO> more advanced stages like T3 or T4 </CO> <A> may require total laryngectomy </A>. <A> Additional evaluations such as videostrobe, audiogram, and fertility counseling may be considered </A>.\\n\\nSection Name: Treatment\\n====================\\nEntities:-\\nCarcinoma In Situ : A lesion with cytological characteristics of cancer but which has not invaded the basement membrane.\\nLaryngectomy : A surgical procedure to remove the larynx.\\nMetastasis : The transfer of a disease from one organ or part to another not directly connected with it.\\nClinical Trials As Topic : Works about research studies that evaluate the effectiveness and safety of medications or medical devices by monitoring their effects on large groups of people.\\n\\nRelationships:-\\n1. Entity1: \""Carcinoma in situ\"", Entity2: \""Larynx-preserving surgery\"", Relationship: \""treated with\""\\n2. Entity1: \""T1-T2 stages\"", Entity2: \""Conservation surgery\"", Relationship: \""treated with\""\\n3. Entity1: \""T3 stages\"", Entity2: \""Total laryngectomy\"", Relationship: \""may require\""\\n4. Entity1: \""T4a disease\"", Entity2: \""Complex interventions\"", Relationship: \""require\""\\n5. Entity1: \""Guidelines\"", Entity2: \""Multidisciplinary consultations\"", Relationship: \""emphasize importance of\""\\n6. Entity1: \""Guidelines\"", Entity2: \""Clinical trials\"", Relationship: \""consider as best option\""\\n\\nCausalities:-\\n<CO>Treatment recommendations vary by stage</CO>. <CO>Carcinoma in situ</CO> <A>may be treated with larynx-preserving surgery</A>. <CO>T1-T2 stages</CO> <A>may also be amenable to conservation surgery</A>. <CO>T3 stages</CO> <A>may require total laryngectomy</A>, <CO>especially if nodal involvement is present</CO>. <CO>T4a disease and unresectable or metastatic cases</CO> <A>require more complex interventions</A>. <A>The guidelines emphasize the importance of multidisciplinary consultations</A> and <A>consider clinical trials as the best management option</A>.\\n\\nSection Name: Additional Notes\\n====================\\nEntities:-\\nBiopsy, Needle : A procedure to remove a small sample of tissue for examination under a microscope.\\nImage-Guided Biopsy : A biopsy procedure that uses imaging techniques to guide the needle to the precise location of the tissue to be sampled.\\nBiopsy : A medical test involving the extraction of sample cells or tissues for examination.\\nDiagnostic Techniques And Procedures : Methods and procedures for the diagnosis of disease or dysfunction.\\nImaging : The process of producing images of the body for clinical purposes.\\nDental Care : The total of dental diagnostic, preventive, and corrective procedures.\\nNutritional Physiological Phenomena : The functions and properties of nutrients in living organisms.\\nFertility : The capacity to conceive or induce conception.\\nReproductive Health : A state of physical, mental, and social well-being in all matters relating to the reproductive system.\\nLymphatic Metastasis : The transfer of a neoplasm from one organ or part of the body to another remote from the primary site.\\nGlottis : The part of the larynx consisting of the vocal cords and the opening between them.\\n\\nRelationships:-\\n1. Entity1: \""image-guided needle biopsy\"", Entity2: \""diagnostic yield\"", Relationship: \""used for\""\\n2. Entity1: \""nodal disease\"", Entity2: \""glottic tumors\"", Relationship: \""is rare in\""\\n\\nCausalities:-\\n<A> use of image-guided needle biopsy </A> for <E> better diagnostic yield </E>, principles of imaging, dental evaluation, and nutrition management. The guidelines also address fertility and reproductive considerations, and note that <CO> nodal disease in glottic tumors is rare </CO>.\\n'}""",valid,increases risk,2,B,"edge - The edge which needs to be verified.
explanation - Explanation of what the edge represents and its validity.
causal_direction - Either Positive or Negative or Unknown. A positive influence direction indicates that both factors change in the same direction (e.g. an increase causes an increase effect). A negative influence direction indicates the opposite changes (e.g. an increase causes a decrease effect).
causal_factor - Is necessary or sufficient condition for an effect to occur. Exposure is a term commonly used in epidemiology to denote any condition that is considered as a possible cause of disease. Exposure is considered necessary when it always precedes the effects (e.g. symptoms) and always presents when the effects occur. A sufficient cause is a causal factor whose presence or occurrence guarantees the occurrence of symptom.
causal_distance - Either Distal or Proximal or Unknown. The distal factors lie towards the beginning of causal chain (i.e. indirect causal factors). The the proximal factors lie towards the end of the chain (i.e. cause directly or almost directly the effect).

Causality Tags:
<A> for action, <C> for cause, <CO> for condition and <E> for effect.
Cause (C): The reason or origin that leads to an effect. Causes often involve disease conditions, risk factors, or underlying mechanisms.
Effect (E): The outcome or result of a cause. Effects usually represent clinical outcomes, complications, or results of a specific cause.
Condition (CO): The circumstance or prerequisite required for an action or effect to occur. Conditions may include patient characteristics, clinical scenarios, or specific diagnostic criteria.
Action (A): The recommended or described response or activity to address a cause or condition. Actions typically involve clinical interventions, diagnostic procedures, or treatment recommendations.


`NODE1`:
id: Location_of_Lymph_Nodes_3
label: Location of Lymph Nodes
description: This node represents the presence or absence of lymph nodes in a specific location, which is crucial for cancer diagnosis and staging. The detection of lymph nodes can indicate the spread of cancer and affect treatment decisions.
type: Patient Situation
observability: Unobserved
states: [{'state_name': 'present', 'state_description': 'Lymph nodes are detected in the specified location, which may indicate the spread of cancer and is important for staging and treatment planning.'}, {'state_name': 'absent', 'state_description': 'Lymph nodes are not detected in the specified location, which may suggest no spread of cancer to this area and is important for staging and treatment planning.'}]

`NODE2`:
id: CT_8
label: Computed Tomography Examination Result
description: This node represents the result of a CT scan examination, which is used to diagnose or assess medical conditions by providing detailed imaging of internal structures.
type: Examination Result
observability: Observed
states: [{'state_name': 'present', 'state_description': 'The finding or condition being assessed by the CT scan is present.'}, {'state_name': 'absent', 'state_description': 'The finding or condition being assessed by the CT scan is absent.'}]

`EDGE1`:
{'edges_ids': ['Location_of_Lymph_Nodes_3', 'CT_8'], 'edge': '(Location_of_Lymph_Nodes_3) causes (CT_8)', 'explanation': ['The edge represents the causal relationship where the presence of lymph nodes in a specific location (Location_of_Lymph_Nodes_3) affects the results of a CT scan (CT_8).', 'If lymph nodes are present, the CT scan is more likely to detect them, indicating a positive causal direction.', 'The presence of lymph nodes is neither a necessary nor a sufficient condition for the CT scan to show results, as CT scans can detect other conditions and may not always detect lymph nodes even if they are present.', 'The causal distance is proximal because the presence of lymph nodes directly influences the CT scan results.'], 'causal_direction': 'positive', 'causal_factor': {'necessary': False, 'sufficient': False}, 'causal_distance': 'Proximal'}

`EDGE2`:
{'edges_ids': ['CT_8', 'Location_of_Lymph_Nodes_3'], 'edge': '(CT_8) causes (Location_of_Lymph_Nodes_3)', 'explanation': ['The edge `(CT_8) causes (Location_of_Lymph_Nodes_3)` is not valid because a CT scan result does not cause lymph nodes to be present or absent.', 'CT_8 represents the result of a CT scan, which is used to observe and diagnose conditions, including the detection of lymph nodes.', 'Location_of_Lymph_Nodes_3 represents the presence or absence of lymph nodes in a specific location, which is a biological condition.', 'A CT scan can detect lymph nodes but does not influence their presence or absence. It is a diagnostic tool, not a causal factor.', 'Therefore, the relationship is observational, not causal.'], 'causal_direction': 'Unknown', 'causal_factor': {'necessary': False, 'sufficient': False}, 'causal_distance': 'Unknown'}

`INFORMATION FROM KNOWLEDGE BASE`:
--------------------------------------------------
Page Number: 93

Section Name: PRINCIPLES OF IMAGING
====================
Entities:-
Imaging, Diagnostic : The production of a visual representation of parts of the body, for the purpose of clinical analysis and medical intervention.
Head And Neck Neoplasms : Tumors or cancer of the head and neck region, including the nasal cavity, sinuses, lips, mouth, salivary glands, throat, or larynx.
Tomography, X-Ray Computed : An imaging procedure that uses special x-ray equipment to create detailed pictures, or scans, of areas inside the body.
Magnetic Resonance Imaging : A noninvasive diagnostic technique that uses magnetic fields and radio waves to produce a detailed image of the body's soft tissue and bones.
Contrast Media : Substances used to enhance the contrast of structures or fluids within the body in medical imaging.

Relationships:-
1. Entity1: ""Imaging, Diagnostic"", Entity2: ""Head and Neck Neoplasms"", Relationship: ""used for""
2. Entity1: ""Tomography, X-Ray Computed"", Entity2: ""Contrast Media"", Relationship: ""uses""
3. Entity1: ""Magnetic Resonance Imaging"", Entity2: ""Contrast Media"", Relationship: ""uses""

Causalities:-
<C> Imaging </C> plays an essential role in the clinical care of patients with head and neck cancer. <A> The proper selection and utilization of imaging studies </A> is critical in caring for patients with head and neck cancer. <A> CT is performed with contrast </A>, while <A> CT imaging of the chest can be performed with or without contrast </A>, <CO> as clinically indicated </CO>. <A> MRI is performed with and without contrast </A>, <CO> unless contraindicated </CO>.

Section Name: Initial Workup - Primary Site
====================
Entities:-
Tomography, X-Ray Computed : An imaging procedure that uses special x-ray equipment to create detailed pictures, or scans, of areas inside the body.
Magnetic Resonance Imaging : A noninvasive diagnostic technique that uses magnetic fields and radio waves to produce a detailed image of the body's soft tissue and bones.
Head And Neck Neoplasms : Tumors or cancer of the head and neck region, including the nasal cavity, sinuses, lips, mouth, salivary glands, throat, or larynx.
Neck Structure : The anatomical structure of the neck, which is the part of the body that connects the head to the torso.
Skull Base : The bottom part of the skull, which separates the brain from other facial structures.
Thoracic Inlet : The opening at the top of the thoracic cavity, through which pass the trachea, esophagus, and major blood vessels.

Relationships:-
1. Entity1: ""CT"", Entity2: ""MRI"", Relationship: ""complementary in imaging head and neck cancers""
2. Entity1: ""CT"", Entity2: ""Head and Neck Neoplasms"", Relationship: ""used to evaluate""
3. Entity1: ""MRI"", Entity2: ""Head and Neck Neoplasms"", Relationship: ""preferred for evaluating""
4. Entity1: ""Skull base"", Entity2: ""Thoracic inlet"", Relationship: ""imaging range for evaluation""

Causalities:-
<A>Imaging assessment of the primary site</A> can be performed with <A>CT of the soft tissues of the neck</A> or <A>MRI of the neck</A>. <C>CT is complementary to MRI for head and neck cancers</C>. <A>It is utilized to evaluate cortical bone erosion or periosteal invasion, cartilage invasion, and bony erosion or destruction</A>. <CO>in certain conditions, such as evaluating the extent of bone marrow invasion or in patients with extensive dental amalgam obscuring anatomy on CT, assessing skull base invasion and cranial nerve involvement, and differentiating tumor from obstructed sinuses</CO>, <A>MRI is preferred over CT</A>. <CO>when involved lymph nodes or upper mediastinal cancers are present</CO>, <A>Complete evaluation of primary and nodal disease requires imaging from the skull base to the thoracic inlet, extending to the carina</A>.

Section Name: PET/CT and Biopsy
====================
Entities:-
Positron Emission Tomography Computed Tomography : A medical imaging technique that combines PET and CT capabilities to provide detailed images of the body.
Examination Under Anesthesia : A procedure where a patient is examined while under anesthesia to allow for a more thorough examination.
Biopsy : A medical test involving the extraction of sample cells or tissues for examination to determine the presence or extent of a disease.
Tonsillectomy : A surgical procedure to remove the tonsils, often performed to treat recurrent tonsillitis or sleep apnea.
Fine Needle Aspiration : A type of biopsy procedure that uses a thin, hollow needle to extract cells from a lump or mass for examination.
Ultrasound : A medical imaging technique that uses high-frequency sound waves to visualize internal organs and structures.
Computed Tomography : A diagnostic imaging procedure that uses a combination of X-rays and computer technology to produce cross-sectional images of the body.

Relationships:-
1. Entity1: ""PET/CT"", Entity2: ""EUA"", Relationship: ""recommended before""
2. Entity1: ""Fine Needle Aspiration (FNA)"", Entity2: ""metastatic nodes"", Relationship: ""used for biopsy of""
3. Entity1: ""Image-guided needle biopsy"", Entity2: ""cystic neck nodes"", Relationship: ""recommended for initial diagnosis of""

Causalities:-
<CO> If imaging does not reveal an obvious primary cancer </CO>, <A> a PET/CT should be ordered before EUA, biopsies, and tonsillectomy </A>. <E> This helps identify potential primary sites </E> before any interventions take place. Additionally, <A> Fine Needle Aspiration (FNA) biopsy of metastatic nodes </A> <E> may provide pathologically informative results </E>. <CO> For initial diagnosis in cystic neck nodes </CO>, <A> image-guided needle biopsy (ultrasound or CT) </A> <E> may yield better results than FNA by palpation alone </E>.

Section Name: Postoperative Imaging Advice
====================
Entities:-
Panoramic Radiography : A type of dental x-ray that provides a wide view of the upper and lower jaws, teeth, temporomandibular joints, and sinuses.
Oral Cavity : The cavity of the mouth, including the lips, the lining inside the cheeks and lips, the front two-thirds of the tongue, the gums, the floor of the mouth under the tongue, the hard palate, and the small area of the gum behind the wisdom teeth.
Radiotherapy : The treatment of disease, especially cancer, using X-rays or similar forms of radiation.
Mandibulotomy : A surgical procedure involving the cutting of the mandible.
Mandibulectomy : A surgical procedure involving the removal of part or all of the mandible.
Oropharynx : The part of the throat at the back of the mouth behind the oral cavity.

Relationships:-
1. Entity1: ""panoramic dental x-ray"", Entity2: ""oral cavity cancers"", Relationship: ""recommended for""
2. Entity1: ""panoramic dental x-ray"", Entity2: ""postoperative radiotherapy"", Relationship: ""essential for pre-radiation evaluation""
3. Entity1: ""pre-radiation dental evaluation"", Entity2: ""dental procedures or extractions"", Relationship: ""determine necessity of""

Causalities:-
<A> A panoramic dental x-ray is recommended </A> <C> for oral cavity cancers requiring mandibulotomy and/or mandibulectomy </C>. <CO> When postoperative radiotherapy (RT) is anticipated for areas like the lip, oral cavity subsites, or oropharynx </CO>, <A> panoramic x-ray is essential for a comprehensive pre-radiation dental evaluation </A> <E> to assess the health of affected teeth and determine if pre-radiation dental procedures or extractions are necessary </E>.

Section Name: NCCN Guidelines Note
====================
Entities:-
Neoplasms : Neoplasms are abnormal growths of tissue, which can be cancerous or non-cancerous.
Malignant Neoplastic Disease : A disease characterized by uncontrolled, abnormal growth of cells that can invade or spread to other parts of the body.
Cancer : A group of diseases involving abnormal cell growth with the potential to invade or spread to other parts of the body.
Clinical Trials As Topic : Pre-planned studies of the safety, efficacy, or optimum dosage schedule of one or more diagnostic, therapeutic, or prophylactic drugs, devices, or techniques in humans selected according to predetermined criteria of eligibility and observed for predefined evidence of favorable and unfavorable effects.
Clinical Trial : A research study that prospectively assigns human participants or groups of humans to one or more health-related interventions to evaluate the effects on health outcomes.

Relationships:-
1. Entity1: ""NCCN"", Entity2: ""Clinical Trials"", Relationship: ""encourages participation in""
2. Entity1: ""NCCN"", Entity2: ""Cancer"", Relationship: ""recommends clinical trials for""

Causalities:-
<A> NCCN believes that the best management of any patient with cancer is through participation in clinical trials </A>, <A> which is especially encouraged </A>.
--------------------------------------------------
Page Number: 94

Section Name: Head and Neck Cancers - Principles of Imaging
====================
Entities:-
Positron Emission Tomography Computed Tomography : A medical imaging technique combining PET and CT capabilities to provide detailed information about the body's function and structure.
Positron Emission Tomography : A nuclear medicine functional imaging technique that is used to observe metabolic processes in the body.
Computed Tomography : A diagnostic imaging procedure that uses a combination of X-rays and computer technology to produce cross-sectional images of the body.
Head And Neck Neoplasms : Cancers that arise in the head or neck region, including the nasal cavity, sinuses, lips, mouth, salivary glands, throat, or larynx.

Relationships:-
1. Entity1: ""PET/CT"", Entity2: ""PET scan"", Relationship: ""preferred over""
2. Entity1: ""PET-CT"", Entity2: ""head neck cancers"", Relationship: ""used in study of""

Causalities:-
<A> PET/CT is preferred over PET scan alone (i.e., without superimposed CT scan) </A>. <C> PET/CT provides more accurate anatomical localization of abnormalities </C> <E> more accurate anatomical localization of abnormalities </E>.

Section Name: Initial Workup - Nodal Metastases
====================
Entities:-
Lymphatic Metastasis : The transfer of a neoplasm from one organ or part of the body to another remote from the primary site via the lymphatic system.
Tomography, X-Ray Computed : A method of body imaging in which a thin X-ray beam rotates around the patient, producing signals that are processed by the machine's computer to generate cross-sectional images.
Magnetic Resonance Imaging : A non-invasive imaging technique that uses magnetic fields and radio waves to create detailed images of the organs and tissues within the body.
Positron-Emission Tomography : An imaging technique that uses radioactive substances to visualize and measure changes in metabolic processes, and in other physiological activities including blood flow, regional chemical composition, and absorption.
Lymph Node Metastasis : The spread of cancer cells to lymph nodes, which are part of the lymphatic system.
Ct Of Neck : A computed tomography scan of the neck region.
Mri Of Neck : A magnetic resonance imaging scan of the neck region.
Fdg-Pet Scan : A type of positron emission tomography using fluorodeoxyglucose to assess metabolic activity.
Computed Tomography : A diagnostic imaging procedure that uses a combination of X-rays and computer technology to produce cross-sectional images of the body.
Positron Emission Tomography : A nuclear medicine functional imaging technique that is used to observe metabolic processes in the body.

Relationships:-
1. Entity1: ""CT"", Entity2: ""lymph node metastases"", Relationship: ""used to evaluate""
2. Entity1: ""MRI"", Entity2: ""lymph node metastases"", Relationship: ""used to evaluate""
3. Entity1: ""FDG-PET/CT"", Entity2: ""lymph node metastases"", Relationship: ""used for detection""
4. Entity1: ""FDG-PET/CT"", Entity2: ""surgical primary approach"", Relationship: ""used to determine""
5. Entity1: ""FDG-PET/CT"", Entity2: ""definitive RT approach"", Relationship: ""used to identify""

Causalities:-
<A> Evaluation of lymph node metastases should be conducted with CT or MRI of the neck </A>, using whichever imaging study is suitable for primary site evaluation (IMG-A, 1 of 4).
<CO> For patients with multistation or lower neck nodal involvement or high-grade tumor histology </CO>, <A> consider CT of the chest to assess for mediastinal lymph node metastases or FDG-PET/CT </A>, <C> which is associated with higher sensitivity for both nodal and distant metastases </C>.
<CO> For patients who are under consideration for a surgical primary approach </CO>, <A> the higher sensitivity of FDG-PET/CT is warranted for tumors approaching the midline, to determine the surgical approach to the contralateral neck </A>. <CO> Similarly, patients who are scheduled for a definitive RT approach </CO> <A> may benefit from the higher sensitivity of FDG-PET/CT for identifying involved lymph nodes </A>.

Section Name: Initial Workup - Distant Metastases
====================
Entities:-
Positron-Emission Tomography : An imaging technique that uses radioactive substances to visualize and measure changes in metabolic processes, and in other physiological activities including blood flow, regional chemical composition, and absorption.
Magnetic Resonance Imaging : A non-invasive imaging technique that uses magnetic fields and radio waves to create detailed images of the organs and tissues within the body.
Tomography, X-Ray Computed : A method of body imaging in which a thin X-ray beam rotates around the patient, producing signals that are processed by the machine's computer to generate cross-sectional images.
Neoplasm Metastasis : The transfer of a neoplasm from one organ or part of the body to another remote from the primary site.
Lung Neoplasms : Tumors or cancer of the lung.
Smoking : The inhalation of the smoke of burning tobacco encased in cigarettes, pipes, and cigars.

Relationships:-
1. Entity1: ""FDG-PET/CT"", Entity2: ""Distant Metastases"", Relationship: ""used to evaluate""
2. Entity1: ""Contrast-enhanced brain MRI"", Entity2: ""Brain Metastasis"", Relationship: ""recommended for evaluation""
3. Entity1: ""CT of the chest"", Entity2: ""Pulmonary Metastases"", Relationship: ""performed to assess""
4. Entity1: ""Non-contrast CT of the chest"", Entity2: ""Lung Parenchymal Metastases"", Relationship: ""used to screen""
5. Entity1: ""Annual CT screening"", Entity2: ""Lung Metastasis"", Relationship: ""considered for high risk""
6. Entity1: ""Directed CT or MRI"", Entity2: ""Distant Disease"", Relationship: ""used for assessment""
7. Entity1: ""FDG-PET/CT"", Entity2: ""Recurrent Disease"", Relationship: ""used for staging""

Causalities:-
<C> Patients with locoregionally advanced cancer (e.g., T3–T4 primary or ≥N1 nodal staging) </C>, <A> FDG-PET/CT is preferred to evaluate for distant disease and thoracic metastases </A>. <CO> For cancers where brain metastasis is a concern, such as mucosal melanoma or high-grade neuroendocrine carcinomas or adenocarcinomas </CO>, <A> contrast-enhanced brain MRI should be additionally obtained </A>.
<CO> If FDG-PET/CT is not performed </CO>, <A> CT of the chest should be performed to assess for presence of pulmonary metastases as well as mediastinal lymph node involvement </A>.
<CO> Non-contrast CT of the chest can be sufficient to screen for lung parenchymal metastases </CO> but <CO> is not adequate for assessment of mediastinal adenopathy </CO>. <CO> This is an appropriate lung cancer screening intervention for patients with a history of smoking </CO>.
<CO> Following primary definitive treatment (surgery, RT, or systemic therapy/RT) </CO> the role of annual CT screening for lung metastasis is controversial. <E> While this approach does detect early metastasis </E>, <CO> further study is needed to determine the extent of the positive effect and/or cost-effectiveness of this approach in specific subpopulations and timepoints post-treatment </CO>. <CO> For patients with a substantial smoking history or who are at high risk for lung metastases </CO>, <A> annual chest CT can be considered </A>.
<CO> If clinical concern for metastatic disease is confined to a specific anatomical area </CO>, <A> the assessment of distant disease can be performed with directed CT or MRI examination </A>.
<CO> FDG-PET/CT may complement or replace other imaging modalities when staging recurrent disease before any therapy for relapsed/refractory disease </CO> <A> in order to explore distant disease or second primaries that may significantly impact choice of therapy </A>.
--------------------------------------------------
Page Number: 46

Section Name: Introduction
====================
Entities:-
Laryngeal Neoplasms : Tumors or cancer of the larynx, including the glottis.
Malignant Neoplasm Of Glottis : A malignant tumor located in the glottis, part of the larynx.
National Comprehensive Cancer Network : The National Comprehensive Cancer Network (NCCN) is an alliance of 30 cancer centers in the United States, dedicated to improving the quality, effectiveness, and efficiency of cancer care.
Adjuvant Chemotherapy : Chemotherapy given in addition to the primary treatment to maximize its effectiveness, often used in cancer treatment.
Adjuvant Therapy : Treatment given in addition to the primary (main) treatment to enhance its effectiveness.

Relationships:-
1. Entity1: ""National Comprehensive Cancer Network"", Entity2: ""Laryngeal Neoplasms"", Relationship: ""provides treatment guidelines for""
2. Entity1: ""treatment guidelines"", Entity2: ""Adjuvant therapy"", Relationship: ""guide clinical decision-making for""

Causalities:-
<C> cancer of the glottic larynx </C> <E> treatment guidelines </E> <CO> based on various clinical stages and specific patient conditions </CO> <A> guide healthcare professionals through clinical decision-making </A>.

Section Name: NCCN Guidelines Version 4.2024
====================
Entities:-
Clinical Trials : Clinical trials are research studies performed in people that are aimed at evaluating a medical, surgical, or behavioral intervention.
National Comprehensive Cancer Network : The National Comprehensive Cancer Network (NCCN) is an alliance of 30 cancer centers in the United States, dedicated to improving the quality, effectiveness, and efficiency of cancer care.

Relationships:-
1. Entity1: ""National Comprehensive Cancer Network"", Entity2: ""Clinical Trials"", Relationship: ""encourages participation in""

Causalities:-
<A>Participation in clinical trials</A> is especially encouraged.

Section Name: Clinical Staging and Treatment
====================
Entities:-
Neoplasm Staging : Methods used for staging of neoplasms based on extent of tumor spread.
T4A : A clinical stage indicating a tumor that has grown into nearby structures.
N0–3 : A range of clinical stages indicating the extent of regional lymph node involvement.
Surgical Procedures, Operative : Operations carried out for the correction of deformities and defects, repair of injuries, and diagnosis and cure of certain diseases.
Neck Dissection : Surgical procedure to remove lymph nodes and surrounding tissue in the neck.
Pathology : The study of the nature and cause of disease which involves changes in structure and function.
Antineoplastic Combined Chemotherapy Protocols : The use of drug combinations to treat cancer.
Radiotherapy : The use of ionizing radiation to treat cancer.
Clinical Trials As Topic : Works about research studies that evaluate the effectiveness and safety of medications or medical devices by monitoring their effects on large groups of people.

Relationships:-
1. Entity1: ""Clinical Staging"", Entity2: ""Surgical Intervention"", Relationship: ""determines""
2. Entity1: ""T4a"", Entity2: ""Surgical Intervention"", Relationship: ""relates to""
3. Entity1: ""Systemic Therapy"", Entity2: ""Radiotherapy"", Relationship: ""considered with""
4. Entity1: ""Clinical Trials"", Entity2: ""Treatment of Primary and Neck"", Relationship: ""option for""

Causalities:-
<CO> Clinical staging indicator labeled ""T4a,N0–3"" </CO> <A> emphasizes the importance of surgical intervention </A>, highlighting procedures such as bilateral neck dissection and the need to address certain pathologic features. <CO> Selected T4a patients who decline surgery </CO> <A> consider concurrent systemic therapy/RT or clinical trial for function-preserving surgical or RT management or induction chemotherapy </A>.

Section Name: Principles of Treatment
====================
Entities:-
Thyroidectomy : Surgical removal of the thyroid gland.
Extranodal Extension : Spread of cancer beyond the lymph node capsule.
Radiation Therapy : Medical use of ionizing radiation to treat cancer.

Relationships:-
1. Entity1: ""Surgery"", Entity2: ""Thyroidectomy"", Relationship: ""involves""
2. Entity1: ""Radiation therapy"", Entity2: ""Adverse pathologic features"", Relationship: ""treats""

Causalities:-
- **Principles of Radiation Therapy (GLOT-A):**  
  - <C> Adverse pathologic features: extranodal extension, positive margins, close margins, pT4 primary, pN2 or pN3 nodal disease, perineural invasion, vascular invasion, lymphatic invasion, and subglottic extension </C> (Discussion).  

- **Principles of Surgery (SURG-A):**  
  - <A> Surgery, including ipsilateral or bilateral neck dissection; thyroidectomy to clear central compartment nodes </A>, <CO> especially when there is thyroid cartilage with gross invasion of the thyroid gland and significant subglottic extension </CO>.

Section Name: Adjuvant Treatment and Follow-up
====================
Entities:-
Systemic Therapy : Treatment using substances that travel through the bloodstream, reaching and affecting cells all over the body.
Clinical Trial : A research study that prospectively assigns human participants or groups of humans to one or more health-related interventions to evaluate the effects on health outcomes.
Computed Tomography (Ct) : A medical imaging technique used in radiology to obtain detailed internal images of the body noninvasively for diagnostic purposes.
Magnetic Resonance Imaging (Mri) : A noninvasive medical test that physicians use to diagnose and treat medical conditions.
Recurrent Disease : A disease that has returned after a period of remission.
Radiation Therapy (Rt) : The use of ionizing radiation to treat cancer and other diseases.

Relationships:-
1. Entity1: ""Adverse Features"", Entity2: ""Specific Treatments"", Relationship: ""Suggests""
2. Entity1: ""Systemic Therapy"", Entity2: ""Patients who decline surgery"", Relationship: ""Option for""
3. Entity1: ""CT or MRI"", Entity2: ""Primary and Neck"", Relationship: ""Used for imaging""
4. Entity1: ""Recurrent or Persistent Disease"", Entity2: ""Follow-up"", Relationship: ""Condition for""
5. Entity1: ""pN1 without other risk features"", Entity2: ""RT"", Relationship: ""Suggests considering""

Causalities:-
<C> adverse features such as extralateral extension or positive margins </C> <E> specific treatments are suggested </E>. The guidelines recommend <A> considering options like concurrent systemic therapy or clinical trials </A> <CO> for patients who decline surgery </CO>.

- **Adjuvant Treatment:**  
  - <A> CT (with contrast) or MRI (with and without contrast) of primary and neck </A>.  

- **Follow-up (FOLL-A, 1 of 2):**  
  - <CO> Recurrent or persistent disease (ADV-3) </CO>.  

- **Post Systemic Therapy/RT or RT Neck Evaluation (FOLL-A, 2 of 2):**  
  - <CO> pN1 without other risk features </CO>: <A> Consider RT </A>.

Section Name: Response Assessment
====================
Entities:-
Adjuvant Chemotherapy : Chemotherapy given in addition to the primary treatment to maximize its effectiveness, often used in cancer treatment.
Computed Tomography : A diagnostic imaging procedure that uses a combination of X-rays and computer technology to produce cross-sectional images of the body.
Magnetic Resonance Imaging : A medical imaging technique used in radiology to form pictures of the anatomy and the physiological processes of the body.
Neoplasm Recurrence, Local : The return of a cancer, at the same site as the original (primary) tumor, after it had disappeared.

Relationships:-
1. Entity1: ""Adjuvant treatment"", Entity2: ""Treatment responses"", Relationship: ""affects""
2. Entity1: ""Follow-up assessments"", Entity2: ""CT or MRI scans"", Relationship: ""conducted using""
3. Entity1: ""Response Assessment (GLOT-5)"", Entity2: ""Recurrent or persistent disease (ADV-3)"", Relationship: ""determines""

Causalities:-
As the flowchart progresses to the adjuvant treatment section, it depicts further decision points based on treatment responses and disease recurrence. The inclusion of references to follow-up assessments, such as CT or MRI scans, underscores the emphasis on continuous monitoring and evaluation of treatment efficacy.  - **Response Assessment (GLOT-5):**   - <C>Recurrent or persistent disease (ADV-3)</C>.
--------------------------------------------------
Page Number: 53

Section Name: Introduction
====================
Entities:-
National Comprehensive Cancer Network : The National Comprehensive Cancer Network (NCCN) is an alliance of 30 cancer centers in the United States, dedicated to improving the quality, effectiveness, and efficiency of cancer care so that patients can live better lives.
Laryngeal Neoplasms : Tumors or cancer of the larynx, which may affect the supraglottic, glottic, or subglottic regions.
Malignant Neoplasm Of Supraglottis : A malignant tumor located in the supraglottic region of the larynx.

Relationships:-
1. Entity1: ""National Comprehensive Cancer Network"", Entity2: ""Malignant neoplasm of supraglottis"", Relationship: ""provides guidelines for""
2. Entity1: ""clinical staging"", Entity2: ""treatment strategies"", Relationship: ""part of flowchart for""

Causalities:-
The provided image is a flowchart outlining the <C> NCCN (National Comprehensive Cancer Network) guidelines </C> for the treatment of <CO> cancers of the supraglottic larynx </CO>. This flowchart <A> utilizes a highly structured approach to convey clinical staging and treatment strategies </A>, indicating the various pathways based on <CO> patient conditions and disease features </CO>.

Section Name: NCCN Guidelines Version 4.2024
====================
Entities:-
Laryngeal Neoplasms : Tumors or cancer of the larynx, which may affect the supraglottic, glottic, or subglottic regions.
Malignant Neoplasm Of Supraglottis : A malignant tumor located in the supraglottic region of the larynx.
Supraglottic Cancer : Cancer that occurs in the supraglottic region of the larynx, above the vocal cords.
Clinical Trials As Topic : Pre-planned studies of the safety, efficacy, or optimum dosage schedule of one or more diagnostic, therapeutic, or prophylactic drugs, devices, or techniques in humans selected according to predetermined criteria of eligibility and observed for predefined evidence of favorable and unfavorable effects.
Clinical Trial : A type of research that studies new tests and treatments and evaluates their effects on human health outcomes.

Relationships:-
1. Entity1: ""Cancer of the Supraglottic Larynx"", Entity2: ""Clinical Trials"", Relationship: ""recommended management strategy""

Causalities:-
- All recommendations are category 2A unless otherwise indicated.
- <A> Participation in clinical trials </A> is especially encouraged.

Section Name: Key Components of the Flowchart
====================
Entities:-
Neoplasm Staging : Methods used for staging neoplasms, including clinical and pathological staging.
Radiotherapy : The use of ionizing radiation to treat cancer.
Surgical Procedures, Operative : Operations carried out for the correction of deformities and defects, repair of injuries, and diagnosis and cure of certain diseases.
Adjuvant Chemotherapy : Chemotherapy given in addition to the primary treatment to maximize its effectiveness.
Neoplasm Recurrence, Local : The return of a tumor at the original site after treatment.
Clinical Trials As Topic : Pre-planned studies of the safety, efficacy, or optimum dosage schedule of one or more diagnostic, therapeutic, or prophylactic drugs, devices, or techniques in humans selected according to predetermined criteria of eligibility and observed for predefined evidence of favorable and unfavorable effects.

Relationships:-
1. Entity1: ""Clinical Staging"", Entity2: ""Treatment of Primary and Neck"", Relationship: ""determines""
2. Entity1: ""Evaluation and Follow-Up"", Entity2: ""Adverse and No Adverse Features"", Relationship: ""leads to decision based on""
3. Entity1: ""Adjuvant Treatment"", Entity2: ""Adverse pathologic features"", Relationship: ""considered if present""
4. Entity1: ""Clinical Trials"", Entity2: ""Treatment Pathway"", Relationship: ""part of""

Causalities:-
### Key Components of the Flowchart

1. **Clinical Staging**: The flowchart starts with <A>clinical staging</A>, indicating that <CO>patients must first be evaluated to determine the extent of cancer</CO>. This is essential for <E>deciding on appropriate treatment options</E>.

2. **Treatment of Primary and Neck**: The flowchart details multiple treatment strategies, including:
   - <A>**Concurrent systemic therapy/RT**</A>: This suggests a combination approach for <CO>patients eligible for such treatment</CO>.
   - <A>**Definitive Radiation Therapy (RT)**</A>: Recommended for <CO>low-volume diseases or patients who cannot tolerate systemic therapy</CO>.
   - <A>**Surgical Options**</A>: It highlights options such as endoscopic or open partial laryngectomy and neck dissection, which are <CO>contingent on clinical evaluations</CO>.

3. **Evaluation and Follow-Up**: After initial treatment approaches, the chart directs clinicians to perform a <A>""Post Systemic Therapy/RT or RT Neck Evaluation""</A>. This step <E>assesses whether there are adverse pathologic features</E>, guiding subsequent treatment decisions.

4. **Adverse and No Adverse Features**: The decision pathway diverges based on findings:
   - <CO>Patients with **adverse pathologic features**</CO> may have <A>additional diagnostic imaging (CT or MRI)</A> and may require <A>further systemic treatment</A>.
   - <CO>Patients with **no adverse features**</CO> may be directed towards <A>considerations for radiation therapy</A>.

5. **Adjuvant Treatment and Recurrence**: The chart also addresses <E>management of any recurrent or persistent disease</E>, emphasizing the importance of <A>regular follow-up assessments</A>. Various options for <A>adjuvant treatment</A> are mentioned, focusing on tailored approaches towards ongoing management of the disease.

6. **Clinical Trials**: The flowchart encourages <A>participation in clinical trials</A>, indicating a commitment to <E>exploring new treatments and improving patient outcomes</E>.

Section Name: Principles
====================
Entities:-
Imaging : The process of producing images of the body or parts of the body to diagnose or examine disease.
Surgical Procedure : A medical procedure involving an incision with instruments; performed to repair damage or arrest disease in a living body.
Radiation Therapy : The use of ionizing radiation to treat cancer and other diseases.
Systemic Therapy : Treatment using substances that travel through the bloodstream, reaching and affecting cells all over the body.

Relationships:-
1. Entity1: ""Imaging"", Entity2: ""Surgery"", Relationship: ""Both are foundational principles in medical practice.""
2. Entity1: ""Radiation therapy"", Entity2: ""Systemic Therapy"", Relationship: ""Both are treatment modalities for cancer.""

Causalities:-
#### Principles
- **Principles of Imaging (IMG-A)**
- **Principles of Surgery (SURG-A)**
- **Principles of Radiation Therapy (SUPRA-A)**
- **Principles of Systemic Therapy for Non-Nasopharyngeal Cancers (SYST-A)**

Section Name: Adverse Pathologic Features
====================
Entities:-
Extranodal Extension : The spread of cancer cells beyond the lymph node capsule into the surrounding tissues.
Positive Surgical Margins : The presence of cancer cells at the edge of the tissue removed during surgery.
Perineural Invasion : Cancer cells found surrounding or tracking along a nerve within the perineural space.
Vascular Invasion : The presence of cancer cells within blood vessels.
Lymphatic Invasion : The presence of cancer cells within lymphatic vessels.

Relationships:-
1. Entity1: ""Extranodal Extension"", Entity2: ""Positive Surgical Margins"", Relationship: ""Both indicate cancer spread beyond original site.""
2. Entity1: ""Perineural Invasion"", Entity2: ""Vascular Invasion"", Relationship: ""Both are pathways for cancer spread.""
3. Entity1: ""pT3 or pT4 primary"", Entity2: ""pN2 or pN3 nodal disease"", Relationship: ""Both indicate advanced cancer stages.""

Causalities:-
<C> Extranodal extension </C>
<C> Positive margins </C>
<C> Close margins </C>
<C> pT3 or pT4 primary </C>
<C> pN2 or pN3 nodal disease </C>
<C> Perineural invasion </C>
<C> Vascular invasion </C>
<C> Lymphatic invasion </C>

Section Name: Clinical Staging and Treatment of Primary and Neck
====================
Entities:-
Adjuvant Chemotherapy : Chemotherapy given in addition to the primary treatment to maximize its effectiveness.
Follow-Up Procedure : A procedure performed to monitor the progress of a patient after treatment.
Recurrent Disease : A disease that returns after a period of remission.
Laryngectomy : Surgical removal of the larynx, often used to treat cancer.
Radiation Therapy : The use of ionizing radiation to treat cancer and other diseases.
Clinical Trial : A type of research that studies new tests and treatments and evaluates their effects on human health outcomes.
Neck Dissection : Surgical procedure to remove lymph nodes and surrounding tissue to treat cancer.
Chemotherapy : Treatment of disease by the use of chemical substances, especially cancer by cytotoxic drugs.

Relationships:-
1. Entity1: ""Adjuvant Treatment"", Entity2: ""Treatment of Primary and Neck"", Relationship: ""part of""
2. Entity1: ""Follow-up"", Entity2: ""Treatment of Primary and Neck"", Relationship: ""part of""
3. Entity1: ""Recurrent or Persistent Disease"", Entity2: ""Treatment of Primary and Neck"", Relationship: ""part of""
4. Entity1: ""Larynx-Preserving Surgery"", Entity2: ""Treatment Options"", Relationship: ""is a treatment option for""
5. Entity1: ""Concurrent Systemic Therapy/RT"", Entity2: ""Treatment Options"", Relationship: ""is a treatment option for""
6. Entity1: ""Clinical Trials or Definitive RT"", Entity2: ""Treatment Options"", Relationship: ""is a treatment option for""
7. Entity1: ""Endoscopic or Open Partial Laryngectomy and Neck Dissection(s)"", Entity2: ""Treatment Options"", Relationship: ""is a treatment option for""
8. Entity1: ""Induction Chemotherapy"", Entity2: ""Treatment Options"", Relationship: ""is a treatment option for""

Causalities:-
<A> Amenable to Larynx-Preserving (Conservation) Surgery </A>: <CO> T1–2, N+ and selected T3, N1 </CO>
<A> Concurrent Systemic Therapy/RT </A>: <CO> i, k, l </CO>
<A> Clinical Trials or Definitive RT </A>: <CO> i </CO>
<A> Endoscopic or Open Partial Laryngectomy and Neck Dissection(s) </A>: <CO> h </CO>
<A> Induction Chemotherapy </A>: <CO> k, m </CO>

Section Name: Pathologic Features and Response Assessment
====================
Entities:-
Radiation Therapy : The use of ionizing radiation to treat cancer and other diseases.
Extranodal Extension : The spread of cancer cells beyond the lymph node capsule into the surrounding tissues.
Positive Surgical Margin : Cancer cells are found at the edge of the material removed during surgery, indicating that some cancer may have been left behind.
Systemic Therapy : Treatment using substances that travel through the bloodstream, reaching and affecting cells all over the body.

Relationships:-
1. Entity1: ""Extranodal extension"", Entity2: ""Adverse Pathologic Features"", Relationship: ""is a type of""
2. Entity1: ""Positive margin"", Entity2: ""Adverse Pathologic Features"", Relationship: ""is a type of""
3. Entity1: ""Systemic Therapy"", Entity2: ""Adverse Pathologic Features"", Relationship: ""considered in response to""
4. Entity1: ""Radiation Therapy"", Entity2: ""Adverse Pathologic Features"", Relationship: ""considered in response to""

Causalities:-
#### Pathologic Features
- **No Adverse Pathologic Features**: j
  - <A> Consider RT </A>: i
- **Adverse Pathologic Features**: j
  - <CO> Extranodal extension and/or positive margin </CO>: n
  - Other risk features
  - <A> Systemic therapy/RT </A>: i, k (category 1)
  - <A> Consider systemic therapy/RT </A>: i, k

#### Response Assessment
- **Response Assessment** (SUPRA-7)

Section Name: Imaging and Recurrent or Persistent Disease
====================
Entities:-
Tomography, X-Ray Computed : A method of body imaging in which a thin X-ray beam rotates around the patient.
Magnetic Resonance Imaging : Medical imaging technique used in radiology to form pictures of the anatomy and the physiological processes of the body.
Computed Tomography : Medical imaging technique used in radiology to obtain detailed internal images of the body.

Relationships:-
1. Entity1: ""CT"", Entity2: ""primary and neck"", Relationship: ""used for imaging""
2. Entity1: ""MRI"", Entity2: ""primary and neck"", Relationship: ""used for imaging""
3. Entity1: ""Post Systemic Therapy/RT"", Entity2: ""Recurrent or Persistent Disease"", Relationship: ""evaluation after treatment""
4. Entity1: ""RT Neck Evaluation"", Entity2: ""Recurrent or Persistent Disease"", Relationship: ""evaluation after treatment""

Causalities:-
<A> CT (with contrast) or MRI (with and without contrast) of primary and neck </A>

<CO> Recurrent or Persistent Disease </CO>

<CO> Post Systemic Therapy/RT or RT Neck Evaluation </CO>

Section Name: Conclusion
====================
Entities:-
Oncologists : Medical doctors who specialize in the diagnosis and treatment of cancer.
Supraglottic Larynx Cancer : A type of cancer that occurs in the supraglottic region of the larynx, which is the area above the vocal cords.
Clinical Staging : The process of determining the extent of cancer in the body, usually based on physical examination, imaging tests, and biopsies.
Treatment Strategies : Plans or methods developed to treat diseases, including cancer, which may involve surgery, chemotherapy, radiation therapy, or other modalities.
Follow-Up Evaluations : Medical assessments conducted after initial treatment to monitor a patient's progress and detect any recurrence of disease.
Clinical Efficacy : The ability of a treatment to produce the desired therapeutic effect in clinical settings.
Research : Systematic investigation and study conducted to establish facts and reach new conclusions.
Treatment Paradigms : Standard models or patterns of treatment used in medical practice, often based on clinical guidelines and research findings.

Relationships:-
1. Entity1: ""Oncologists"", Entity2: ""Supraglottic Larynx Cancer"", Relationship: ""use flowchart for decision-making""
2. Entity1: ""Clinical Staging"", Entity2: ""Treatment Strategies"", Relationship: ""part of management process""
3. Entity1: ""Treatment Strategies"", Entity2: ""Follow-Up Evaluations"", Relationship: ""part of management process""

Causalities:-
<A> The flowchart serves as a comprehensive guide for oncologists and healthcare providers </A>, <A> facilitating informed decision-making in the treatment of supraglottic larynx cancer </A>. <A> By visualizing the complex interactions between clinical staging, treatment strategies, and follow-up evaluations </A>, <E> it streamlines the management process </E>, <E> ensuring that patients receive appropriate care tailored to their specific needs </E>. <E> The detailed pathways not only enhance clinical efficacy </E> but also <E> underscore the importance of ongoing research and adaptation of treatment paradigms in oncology </E>.
--------------------------------------------------
Page Number: 41

Section Name: Workup
====================
Entities:-
Laryngeal Neoplasms : Tumors or cancer of the larynx, which may affect the glottis, supraglottis, or subglottis.
History And Physical Examination : A comprehensive assessment of a patient's medical history and physical condition.
Tobacco Smoking : The act of smoking tobacco products, which is a risk factor for many diseases.
Alcohol Drinking : The consumption of beverages containing ethyl alcohol.
Smoking Cessation : The process of discontinuing tobacco smoking.
Biopsy : A medical test involving the extraction of sample cells or tissues for examination.
Laryngoscopy : A procedure to examine the larynx, often using a scope.
Computed Tomography (Ct) : A diagnostic imaging procedure that uses computer-processed combinations of many X-ray measurements taken from different angles to produce cross-sectional images of specific areas of a scanned object.
Magnetic Resonance Imaging (Mri) : A medical imaging technique used in radiology to form pictures of the anatomy and the physiological processes of the body.
Positron-Emission Tomography : A type of nuclear medicine imaging that measures metabolic activity of the cells of body tissues.
Pulmonary Function Test : Tests that measure how well the lungs are working.
Dental Examination : An evaluation of the teeth and gums to assess oral health.
Nutritional Support : Therapies to provide nutrition to patients who cannot obtain nutrition by mouth.
Speech Therapy : Therapy to improve speech and communication skills.
Swallowing Therapy : Therapy to help individuals with swallowing difficulties.
Multidisciplinary Care Team : A group of healthcare professionals from different specialties working together to manage patient care.

Relationships:-
1. Entity1: ""glottic larynx cancer"", Entity2: ""history and physical examination"", Relationship: ""initial diagnostic step""
2. Entity1: ""glottic larynx cancer"", Entity2: ""biopsy"", Relationship: ""required diagnostic procedure""
3. Entity1: ""glottic larynx cancer"", Entity2: ""direct laryngoscopy"", Relationship: ""recommended procedure""
4. Entity1: ""glottic larynx cancer"", Entity2: ""CT scans"", Relationship: ""imaging study""
5. Entity1: ""glottic larynx cancer"", Entity2: ""MRI"", Relationship: ""imaging study""
6. Entity1: ""glottic larynx cancer"", Entity2: ""multidisciplinary consultation"", Relationship: ""advised as clinically indicated""

Causalities:-
The workup section outlines the initial steps for diagnosing <C>glottic larynx cancer</C>. It includes <A>a comprehensive history and physical examination (H&P)</A>, which should document tobacco and alcohol use, and provide counseling for smoking cessation. <A>A biopsy of the primary site is required</A>, and <A>direct laryngoscopy under anesthesia is generally recommended</A>. <A>Imaging studies such as CT scans with contrast and possibly MRI are used to evaluate the larynx and neck</A>. Additional evaluations may include <A>chest CT, FDG-PET/CT, pulmonary function tests, dental evaluation, and nutrition, speech, and swallowing therapy</A>. <A>Multidisciplinary consultation is advised</A> <CO>as clinically indicated</CO>.

Section Name: Clinical Staging
====================
Entities:-
Cancer : A group of diseases involving abnormal cell growth with the potential to invade or spread to other parts of the body.
Carcinoma In Situ : A lesion with cytological characteristics of cancer but which has not invaded the basement membrane.
Biopsy : A medical test involving the extraction of sample cells or tissues for examination.
Laryngectomy : A surgical procedure to remove the larynx.

Relationships:-
1. Entity1: ""Clinical staging"", Entity2: ""Cancer"", Relationship: ""involves""
2. Entity1: ""Carcinoma in situ"", Entity2: ""Stages T1-T4"", Relationship: ""is a stage of""
3. Entity1: ""Biopsy"", Entity2: ""Cancer"", Relationship: ""used in staging""
4. Entity1: ""Larynx-preserving surgeries"", Entity2: ""Stages T1-T2"", Relationship: ""considered for""
5. Entity1: ""Total laryngectomy"", Entity2: ""Stages T3-T4"", Relationship: ""required for""

Causalities:-
<C> Clinical staging involves categorizing the cancer based on its aggressiveness </C>. It starts with carcinoma in situ, which is non-invasive, and progresses through stages T1-T4. <CO> Staging is based on H&P, biopsy, and imaging studies </CO>. <CO> For T1-T2 </CO>, <A> larynx-preserving surgeries are considered </A>, while <CO> more advanced stages like T3 or T4 </CO> <A> may require total laryngectomy </A>. <A> Additional evaluations such as videostrobe, audiogram, and fertility counseling may be considered </A>.

Section Name: Treatment
====================
Entities:-
Carcinoma In Situ : A lesion with cytological characteristics of cancer but which has not invaded the basement membrane.
Laryngectomy : A surgical procedure to remove the larynx.
Metastasis : The transfer of a disease from one organ or part to another not directly connected with it.
Clinical Trials As Topic : Works about research studies that evaluate the effectiveness and safety of medications or medical devices by monitoring their effects on large groups of people.

Relationships:-
1. Entity1: ""Carcinoma in situ"", Entity2: ""Larynx-preserving surgery"", Relationship: ""treated with""
2. Entity1: ""T1-T2 stages"", Entity2: ""Conservation surgery"", Relationship: ""treated with""
3. Entity1: ""T3 stages"", Entity2: ""Total laryngectomy"", Relationship: ""may require""
4. Entity1: ""T4a disease"", Entity2: ""Complex interventions"", Relationship: ""require""
5. Entity1: ""Guidelines"", Entity2: ""Multidisciplinary consultations"", Relationship: ""emphasize importance of""
6. Entity1: ""Guidelines"", Entity2: ""Clinical trials"", Relationship: ""consider as best option""

Causalities:-
<CO>Treatment recommendations vary by stage</CO>. <CO>Carcinoma in situ</CO> <A>may be treated with larynx-preserving surgery</A>. <CO>T1-T2 stages</CO> <A>may also be amenable to conservation surgery</A>. <CO>T3 stages</CO> <A>may require total laryngectomy</A>, <CO>especially if nodal involvement is present</CO>. <CO>T4a disease and unresectable or metastatic cases</CO> <A>require more complex interventions</A>. <A>The guidelines emphasize the importance of multidisciplinary consultations</A> and <A>consider clinical trials as the best management option</A>.

Section Name: Additional Notes
====================
Entities:-
Biopsy, Needle : A procedure to remove a small sample of tissue for examination under a microscope.
Image-Guided Biopsy : A biopsy procedure that uses imaging techniques to guide the needle to the precise location of the tissue to be sampled.
Biopsy : A medical test involving the extraction of sample cells or tissues for examination.
Diagnostic Techniques And Procedures : Methods and procedures for the diagnosis of disease or dysfunction.
Imaging : The process of producing images of the body for clinical purposes.
Dental Care : The total of dental diagnostic, preventive, and corrective procedures.
Nutritional Physiological Phenomena : The functions and properties of nutrients in living organisms.
Fertility : The capacity to conceive or induce conception.
Reproductive Health : A state of physical, mental, and social well-being in all matters relating to the reproductive system.
Lymphatic Metastasis : The transfer of a neoplasm from one organ or part of the body to another remote from the primary site.
Glottis : The part of the larynx consisting of the vocal cords and the opening between them.

Relationships:-
1. Entity1: ""image-guided needle biopsy"", Entity2: ""diagnostic yield"", Relationship: ""used for""
2. Entity1: ""nodal disease"", Entity2: ""glottic tumors"", Relationship: ""is rare in""

Causalities:-
<A> use of image-guided needle biopsy </A> for <E> better diagnostic yield </E>, principles of imaging, dental evaluation, and nutrition management. The guidelines also address fertility and reproductive considerations, and note that <CO> nodal disease in glottic tumors is rare </CO>.


Among these two options which one is the most likely true:

(A) `Location_of_Lymph_Nodes_3` increases risk `CT_8`
(B) `CT_8` `increases risk `Location_of_Lymph_Nodes_3`

The answer is: ...

1. State the evidences in detail of the validity of option (A) or (B) by cross referencing
NCCN Clinical Practitioner’s Guidelines for Head and Neck Cancer.
2. If the evidences are obtained from `INFORMATION FROM KNOWLEDGE BASE`,
mention their corresponding Page Numbers, Section Name, entities, relationships and causalities.

DESIRED OUTPUT FORMAT:
<thinking>
...
</thinking>
<answer>
{
   ""thinking"": [""..."", ...],
   ""evidences"": [""..."", ...],
   ""answer"": ...
}
</answer>

Before providing the answer in <answer> tags, think step by step in detail in <thinking> tags and analyze every part.
Output inside <answer> tag in JSON format. Only output valid JSON.
DO NOT HALLUCINATE. DO NOT MAKE UP FACTUAL INFORMATION.
","1. The edge (Location_of_Lymph_Nodes_3) causes (CT_8) suggests that the presence of lymph nodes in a specific location affects the results of a CT scan.
2. The explanation for EDGE1 indicates a positive causal direction, meaning the presence of lymph nodes increases the likelihood of detection by CT scan.
3. The causal factor is neither necessary nor sufficient, as CT scans can detect other conditions and may not always detect lymph nodes even if present.
4. The causal distance is proximal, indicating a direct influence on the CT scan results.
5. The edge (CT_8) causes (Location_of_Lymph_Nodes_3) is not valid because a CT scan result does not cause lymph nodes to be present or absent.
6. CT scans are diagnostic tools used to observe and diagnose conditions, not to influence the presence of lymph nodes.
7. The relationship in EDGE2 is observational, not causal, as CT scans detect lymph nodes but do not affect their presence.
8. The NCCN guidelines emphasize the role of imaging, including CT scans, in diagnosing and staging cancer, but do not suggest that imaging results cause biological changes like lymph node presence.
","1. Page 93, Section: PRINCIPLES OF IMAGING - Imaging is used for clinical analysis and medical intervention, not as a causal factor for biological changes.
2. Page 94, Section: Head and Neck Cancers - Principles of Imaging - CT is used to evaluate head and neck neoplasms, indicating its role as a diagnostic tool.
3. Page 41, Section: Workup - CT scans are used to evaluate the larynx and neck, supporting their role in diagnosis rather than causing biological changes.
",A,"{'A': 100.0, 'B': 0.0}",yes,A,"1. The AI assistant's reasoning for selecting option (A) is based on the explanation provided for EDGE1, which states that the presence of lymph nodes affects the results of a CT scan, indicating a positive causal direction.
2. The assistant correctly identifies that the causal factor is neither necessary nor sufficient, as CT scans can detect other conditions and may not always detect lymph nodes even if present.
3. The assistant also notes that the causal distance is proximal, meaning the presence of lymph nodes directly influences the CT scan results.
4. For EDGE2, the assistant correctly identifies that a CT scan result does not cause lymph nodes to be present or absent, as CT scans are diagnostic tools used to observe and diagnose conditions, not to influence the presence of lymph nodes.
5. The assistant's reasoning aligns with the information from the NCCN guidelines, which emphasize the role of imaging, including CT scans, in diagnosing and staging cancer, but do not suggest that imaging results cause biological changes like lymph node presence.
6. The evidences provided from the NCCN guidelines support the assistant's reasoning, as they highlight the diagnostic role of CT scans in evaluating head and neck neoplasms and the larynx and neck, rather than causing biological changes.
"
3,gpt-4o,"Location_of_Lymph_Nodes_3,MRT_9","""{'NODE1': {'id': 'Location_of_Lymph_Nodes_3', 'label': 'Location of Lymph Nodes', 'description': 'This node represents the presence or absence of lymph nodes in a specific location, which is crucial for cancer diagnosis and staging. The detection of lymph nodes can indicate the spread of cancer and affect treatment decisions.', 'type': 'Patient Situation', 'observability': 'Unobserved', 'states': [{'state_name': 'present', 'state_description': 'Lymph nodes are detected in the specified location, which may indicate the spread of cancer and is important for staging and treatment planning.'}, {'state_name': 'absent', 'state_description': 'Lymph nodes are not detected in the specified location, which may suggest no spread of cancer to this area and is important for staging and treatment planning.'}]}, 'NODE2': {'id': 'MRT_9', 'label': 'Magnetresonanztomographie Examination Result', 'description': 'This node represents the result of a Magnetresonanztomographie (MRI) examination. It indicates whether a particular finding or condition is present or absent based on the MRI scan. MRI is a crucial imaging technique used to diagnose and monitor various medical conditions by providing detailed images of the organs and tissues within the body.', 'type': 'Examination Result', 'observability': 'Observed', 'states': [{'state_name': 'present', 'state_description': \""The 'present' state indicates that the MRI examination has detected the specific finding or condition in question. This could mean the presence of a lesion, abnormality, or other clinically significant feature that was being investigated.\""}, {'state_name': 'absent', 'state_description': \""The 'absent' state indicates that the MRI examination did not detect the specific finding or condition in question. This suggests that there is no evidence of the lesion, abnormality, or feature that was being investigated, based on the MRI scan.\""}]}, 'EDGE1': {'edges_ids': ['Location_of_Lymph_Nodes_3', 'MRT_9'], 'edge': '(Location_of_Lymph_Nodes_3) causes (MRT_9)', 'explanation': ['The edge `(Location_of_Lymph_Nodes_3) causes (MRT_9)` is not valid as a causal relationship.', 'The `Location_of_Lymph_Nodes_3` node represents the presence or absence of lymph nodes, which is a condition that can be observed by an MRI scan, represented by the 'MRT_9' node.', \""The MRI result ('MRT_9') is an observation of the state of the lymph nodes ('Location_of_Lymph_Nodes_3'), not a result caused by them.\"", 'Therefore, the relationship is observational rather than causal.'], 'causal_direction': 'Unknown', 'causal_factor': {'necessary': False, 'sufficient': False}, 'causal_distance': 'Proximal'}, 'EDGE2': {'edges_ids': ['MRT_9', 'Location_of_Lymph_Nodes_3'], 'edge': '(MRT_9) causes (Location_of_Lymph_Nodes_3)', 'explanation': ['The edge `(MRT_9) causes (Location_of_Lymph_Nodes_3)` is not valid because an MRI examination result does not cause the presence or absence of lymph nodes.', 'MRT_9 represents the findings from an MRI scan, which can detect the presence of lymph nodes but does not influence their presence or absence.', 'Location_of_Lymph_Nodes_3 represents whether lymph nodes are present in a specific location, which is a condition observed by the MRI, not caused by it.', 'The relationship is observational, where the MRI detects the state of lymph nodes, rather than causal.'], 'causal_direction': 'Unknown', 'causal_factor': {'necessary': False, 'sufficient': False}, 'causal_distance': 'Unknown'}, 'ENTITIES_MATCHING_PAGES_INFO': {'46': {'matching_entities': [{'MAGNETIC RESONANCE IMAGING': 0.9692417}, {'MAGNETIC RESONANCE IMAGING (MRI)': 0.94132537}, {'COMPUTED TOMOGRAPHY (CT)': 0.9349672}, {'COMPUTED TOMOGRAPHY': 0.9228411}], 'count': 4}, '53': {'matching_entities': [{'MAGNETIC RESONANCE IMAGING': 0.9692417}, {'COMPUTED TOMOGRAPHY': 0.9228411}, {'IMAGING': 0.9221975}, {'TOMOGRAPHY, X-RAY COMPUTED': 0.9212845}], 'count': 4}, '93': {'matching_entities': [{'MAGNETIC RESONANCE IMAGING': 0.9692417}, {'COMPUTED TOMOGRAPHY': 0.9228411}, {'TOMOGRAPHY, X-RAY COMPUTED': 0.9212845}], 'count': 3}, '41': {'matching_entities': [{'MAGNETIC RESONANCE IMAGING (MRI)': 0.94132537}, {'COMPUTED TOMOGRAPHY (CT)': 0.9349672}, {'IMAGING': 0.9221975}], 'count': 3}, '44': {'matching_entities': [{'MAGNETIC RESONANCE IMAGING': 0.9692417}, {'COMPUTED TOMOGRAPHY': 0.9228411}, {'TOMOGRAPHY, X-RAY COMPUTED': 0.9212845}], 'count': 3}}, 'GUIDELINE_PAGES_INFO': '--------------------------------------------------\\nPage Number: 46\\n\\nSection Name: Introduction\\n====================\\nEntities:-\\nLaryngeal Neoplasms : Tumors or cancer of the larynx, including the glottis.\\nMalignant Neoplasm Of Glottis : A malignant tumor located in the glottis, part of the larynx.\\nNational Comprehensive Cancer Network : The National Comprehensive Cancer Network (NCCN) is an alliance of 30 cancer centers in the United States, dedicated to improving the quality, effectiveness, and efficiency of cancer care.\\nAdjuvant Chemotherapy : Chemotherapy given in addition to the primary treatment to maximize its effectiveness, often used in cancer treatment.\\nAdjuvant Therapy : Treatment given in addition to the primary (main) treatment to enhance its effectiveness.\\n\\nRelationships:-\\n1. Entity1: \""National Comprehensive Cancer Network\"", Entity2: \""Laryngeal Neoplasms\"", Relationship: \""provides treatment guidelines for\""\\n2. Entity1: \""treatment guidelines\"", Entity2: \""Adjuvant therapy\"", Relationship: \""guide clinical decision-making for\""\\n\\nCausalities:-\\n<C> cancer of the glottic larynx </C> <E> treatment guidelines </E> <CO> based on various clinical stages and specific patient conditions </CO> <A> guide healthcare professionals through clinical decision-making </A>.\\n\\nSection Name: NCCN Guidelines Version 4.2024\\n====================\\nEntities:-\\nClinical Trials : Clinical trials are research studies performed in people that are aimed at evaluating a medical, surgical, or behavioral intervention.\\nNational Comprehensive Cancer Network : The National Comprehensive Cancer Network (NCCN) is an alliance of 30 cancer centers in the United States, dedicated to improving the quality, effectiveness, and efficiency of cancer care.\\n\\nRelationships:-\\n1. Entity1: \""National Comprehensive Cancer Network\"", Entity2: \""Clinical Trials\"", Relationship: \""encourages participation in\""\\n\\nCausalities:-\\n<A>Participation in clinical trials</A> is especially encouraged.\\n\\nSection Name: Clinical Staging and Treatment\\n====================\\nEntities:-\\nNeoplasm Staging : Methods used for staging of neoplasms based on extent of tumor spread.\\nT4A : A clinical stage indicating a tumor that has grown into nearby structures.\\nN0\u20133 : A range of clinical stages indicating the extent of regional lymph node involvement.\\nSurgical Procedures, Operative : Operations carried out for the correction of deformities and defects, repair of injuries, and diagnosis and cure of certain diseases.\\nNeck Dissection : Surgical procedure to remove lymph nodes and surrounding tissue in the neck.\\nPathology : The study of the nature and cause of disease which involves changes in structure and function.\\nAntineoplastic Combined Chemotherapy Protocols : The use of drug combinations to treat cancer.\\nRadiotherapy : The use of ionizing radiation to treat cancer.\\nClinical Trials As Topic : Works about research studies that evaluate the effectiveness and safety of medications or medical devices by monitoring their effects on large groups of people.\\n\\nRelationships:-\\n1. Entity1: \""Clinical Staging\"", Entity2: \""Surgical Intervention\"", Relationship: \""determines\""\\n2. Entity1: \""T4a\"", Entity2: \""Surgical Intervention\"", Relationship: \""relates to\""\\n3. Entity1: \""Systemic Therapy\"", Entity2: \""Radiotherapy\"", Relationship: \""considered with\""\\n4. Entity1: \""Clinical Trials\"", Entity2: \""Treatment of Primary and Neck\"", Relationship: \""option for\""\\n\\nCausalities:-\\n<CO> Clinical staging indicator labeled \""T4a,N0\u20133\"" </CO> <A> emphasizes the importance of surgical intervention </A>, highlighting procedures such as bilateral neck dissection and the need to address certain pathologic features. <CO> Selected T4a patients who decline surgery </CO> <A> consider concurrent systemic therapy/RT or clinical trial for function-preserving surgical or RT management or induction chemotherapy </A>.\\n\\nSection Name: Principles of Treatment\\n====================\\nEntities:-\\nThyroidectomy : Surgical removal of the thyroid gland.\\nExtranodal Extension : Spread of cancer beyond the lymph node capsule.\\nRadiation Therapy : Medical use of ionizing radiation to treat cancer.\\n\\nRelationships:-\\n1. Entity1: \""Surgery\"", Entity2: \""Thyroidectomy\"", Relationship: \""involves\""\\n2. Entity1: \""Radiation therapy\"", Entity2: \""Adverse pathologic features\"", Relationship: \""treats\""\\n\\nCausalities:-\\n- **Principles of Radiation Therapy (GLOT-A):**  \\n  - <C> Adverse pathologic features: extranodal extension, positive margins, close margins, pT4 primary, pN2 or pN3 nodal disease, perineural invasion, vascular invasion, lymphatic invasion, and subglottic extension </C> (Discussion).  \\n\\n- **Principles of Surgery (SURG-A):**  \\n  - <A> Surgery, including ipsilateral or bilateral neck dissection; thyroidectomy to clear central compartment nodes </A>, <CO> especially when there is thyroid cartilage with gross invasion of the thyroid gland and significant subglottic extension </CO>.\\n\\nSection Name: Adjuvant Treatment and Follow-up\\n====================\\nEntities:-\\nSystemic Therapy : Treatment using substances that travel through the bloodstream, reaching and affecting cells all over the body.\\nClinical Trial : A research study that prospectively assigns human participants or groups of humans to one or more health-related interventions to evaluate the effects on health outcomes.\\nComputed Tomography (Ct) : A medical imaging technique used in radiology to obtain detailed internal images of the body noninvasively for diagnostic purposes.\\nMagnetic Resonance Imaging (Mri) : A noninvasive medical test that physicians use to diagnose and treat medical conditions.\\nRecurrent Disease : A disease that has returned after a period of remission.\\nRadiation Therapy (Rt) : The use of ionizing radiation to treat cancer and other diseases.\\n\\nRelationships:-\\n1. Entity1: \""Adverse Features\"", Entity2: \""Specific Treatments\"", Relationship: \""Suggests\""\\n2. Entity1: \""Systemic Therapy\"", Entity2: \""Patients who decline surgery\"", Relationship: \""Option for\""\\n3. Entity1: \""CT or MRI\"", Entity2: \""Primary and Neck\"", Relationship: \""Used for imaging\""\\n4. Entity1: \""Recurrent or Persistent Disease\"", Entity2: \""Follow-up\"", Relationship: \""Condition for\""\\n5. Entity1: \""pN1 without other risk features\"", Entity2: \""RT\"", Relationship: \""Suggests considering\""\\n\\nCausalities:-\\n<C> adverse features such as extralateral extension or positive margins </C> <E> specific treatments are suggested </E>. The guidelines recommend <A> considering options like concurrent systemic therapy or clinical trials </A> <CO> for patients who decline surgery </CO>.\\n\\n- **Adjuvant Treatment:**  \\n  - <A> CT (with contrast) or MRI (with and without contrast) of primary and neck </A>.  \\n\\n- **Follow-up (FOLL-A, 1 of 2):**  \\n  - <CO> Recurrent or persistent disease (ADV-3) </CO>.  \\n\\n- **Post Systemic Therapy/RT or RT Neck Evaluation (FOLL-A, 2 of 2):**  \\n  - <CO> pN1 without other risk features </CO>: <A> Consider RT </A>.\\n\\nSection Name: Response Assessment\\n====================\\nEntities:-\\nAdjuvant Chemotherapy : Chemotherapy given in addition to the primary treatment to maximize its effectiveness, often used in cancer treatment.\\nComputed Tomography : A diagnostic imaging procedure that uses a combination of X-rays and computer technology to produce cross-sectional images of the body.\\nMagnetic Resonance Imaging : A medical imaging technique used in radiology to form pictures of the anatomy and the physiological processes of the body.\\nNeoplasm Recurrence, Local : The return of a cancer, at the same site as the original (primary) tumor, after it had disappeared.\\n\\nRelationships:-\\n1. Entity1: \""Adjuvant treatment\"", Entity2: \""Treatment responses\"", Relationship: \""affects\""\\n2. Entity1: \""Follow-up assessments\"", Entity2: \""CT or MRI scans\"", Relationship: \""conducted using\""\\n3. Entity1: \""Response Assessment (GLOT-5)\"", Entity2: \""Recurrent or persistent disease (ADV-3)\"", Relationship: \""determines\""\\n\\nCausalities:-\\nAs the flowchart progresses to the adjuvant treatment section, it depicts further decision points based on treatment responses and disease recurrence. The inclusion of references to follow-up assessments, such as CT or MRI scans, underscores the emphasis on continuous monitoring and evaluation of treatment efficacy.  - **Response Assessment (GLOT-5):**   - <C>Recurrent or persistent disease (ADV-3)</C>.\\n--------------------------------------------------\\nPage Number: 53\\n\\nSection Name: Introduction\\n====================\\nEntities:-\\nNational Comprehensive Cancer Network : The National Comprehensive Cancer Network (NCCN) is an alliance of 30 cancer centers in the United States, dedicated to improving the quality, effectiveness, and efficiency of cancer care so that patients can live better lives.\\nLaryngeal Neoplasms : Tumors or cancer of the larynx, which may affect the supraglottic, glottic, or subglottic regions.\\nMalignant Neoplasm Of Supraglottis : A malignant tumor located in the supraglottic region of the larynx.\\n\\nRelationships:-\\n1. Entity1: \""National Comprehensive Cancer Network\"", Entity2: \""Malignant neoplasm of supraglottis\"", Relationship: \""provides guidelines for\""\\n2. Entity1: \""clinical staging\"", Entity2: \""treatment strategies\"", Relationship: \""part of flowchart for\""\\n\\nCausalities:-\\nThe provided image is a flowchart outlining the <C> NCCN (National Comprehensive Cancer Network) guidelines </C> for the treatment of <CO> cancers of the supraglottic larynx </CO>. This flowchart <A> utilizes a highly structured approach to convey clinical staging and treatment strategies </A>, indicating the various pathways based on <CO> patient conditions and disease features </CO>.\\n\\nSection Name: NCCN Guidelines Version 4.2024\\n====================\\nEntities:-\\nLaryngeal Neoplasms : Tumors or cancer of the larynx, which may affect the supraglottic, glottic, or subglottic regions.\\nMalignant Neoplasm Of Supraglottis : A malignant tumor located in the supraglottic region of the larynx.\\nSupraglottic Cancer : Cancer that occurs in the supraglottic region of the larynx, above the vocal cords.\\nClinical Trials As Topic : Pre-planned studies of the safety, efficacy, or optimum dosage schedule of one or more diagnostic, therapeutic, or prophylactic drugs, devices, or techniques in humans selected according to predetermined criteria of eligibility and observed for predefined evidence of favorable and unfavorable effects.\\nClinical Trial : A type of research that studies new tests and treatments and evaluates their effects on human health outcomes.\\n\\nRelationships:-\\n1. Entity1: \""Cancer of the Supraglottic Larynx\"", Entity2: \""Clinical Trials\"", Relationship: \""recommended management strategy\""\\n\\nCausalities:-\\n- All recommendations are category 2A unless otherwise indicated.\\n- <A> Participation in clinical trials </A> is especially encouraged.\\n\\nSection Name: Key Components of the Flowchart\\n====================\\nEntities:-\\nNeoplasm Staging : Methods used for staging neoplasms, including clinical and pathological staging.\\nRadiotherapy : The use of ionizing radiation to treat cancer.\\nSurgical Procedures, Operative : Operations carried out for the correction of deformities and defects, repair of injuries, and diagnosis and cure of certain diseases.\\nAdjuvant Chemotherapy : Chemotherapy given in addition to the primary treatment to maximize its effectiveness.\\nNeoplasm Recurrence, Local : The return of a tumor at the original site after treatment.\\nClinical Trials As Topic : Pre-planned studies of the safety, efficacy, or optimum dosage schedule of one or more diagnostic, therapeutic, or prophylactic drugs, devices, or techniques in humans selected according to predetermined criteria of eligibility and observed for predefined evidence of favorable and unfavorable effects.\\n\\nRelationships:-\\n1. Entity1: \""Clinical Staging\"", Entity2: \""Treatment of Primary and Neck\"", Relationship: \""determines\""\\n2. Entity1: \""Evaluation and Follow-Up\"", Entity2: \""Adverse and No Adverse Features\"", Relationship: \""leads to decision based on\""\\n3. Entity1: \""Adjuvant Treatment\"", Entity2: \""Adverse pathologic features\"", Relationship: \""considered if present\""\\n4. Entity1: \""Clinical Trials\"", Entity2: \""Treatment Pathway\"", Relationship: \""part of\""\\n\\nCausalities:-\\n### Key Components of the Flowchart\\n\\n1. **Clinical Staging**: The flowchart starts with <A>clinical staging</A>, indicating that <CO>patients must first be evaluated to determine the extent of cancer</CO>. This is essential for <E>deciding on appropriate treatment options</E>.\\n\\n2. **Treatment of Primary and Neck**: The flowchart details multiple treatment strategies, including:\\n   - <A>**Concurrent systemic therapy/RT**</A>: This suggests a combination approach for <CO>patients eligible for such treatment</CO>.\\n   - <A>**Definitive Radiation Therapy (RT)**</A>: Recommended for <CO>low-volume diseases or patients who cannot tolerate systemic therapy</CO>.\\n   - <A>**Surgical Options**</A>: It highlights options such as endoscopic or open partial laryngectomy and neck dissection, which are <CO>contingent on clinical evaluations</CO>.\\n\\n3. **Evaluation and Follow-Up**: After initial treatment approaches, the chart directs clinicians to perform a <A>\""Post Systemic Therapy/RT or RT Neck Evaluation\""</A>. This step <E>assesses whether there are adverse pathologic features</E>, guiding subsequent treatment decisions.\\n\\n4. **Adverse and No Adverse Features**: The decision pathway diverges based on findings:\\n   - <CO>Patients with **adverse pathologic features**</CO> may have <A>additional diagnostic imaging (CT or MRI)</A> and may require <A>further systemic treatment</A>.\\n   - <CO>Patients with **no adverse features**</CO> may be directed towards <A>considerations for radiation therapy</A>.\\n\\n5. **Adjuvant Treatment and Recurrence**: The chart also addresses <E>management of any recurrent or persistent disease</E>, emphasizing the importance of <A>regular follow-up assessments</A>. Various options for <A>adjuvant treatment</A> are mentioned, focusing on tailored approaches towards ongoing management of the disease.\\n\\n6. **Clinical Trials**: The flowchart encourages <A>participation in clinical trials</A>, indicating a commitment to <E>exploring new treatments and improving patient outcomes</E>.\\n\\nSection Name: Principles\\n====================\\nEntities:-\\nImaging : The process of producing images of the body or parts of the body to diagnose or examine disease.\\nSurgical Procedure : A medical procedure involving an incision with instruments; performed to repair damage or arrest disease in a living body.\\nRadiation Therapy : The use of ionizing radiation to treat cancer and other diseases.\\nSystemic Therapy : Treatment using substances that travel through the bloodstream, reaching and affecting cells all over the body.\\n\\nRelationships:-\\n1. Entity1: \""Imaging\"", Entity2: \""Surgery\"", Relationship: \""Both are foundational principles in medical practice.\""\\n2. Entity1: \""Radiation therapy\"", Entity2: \""Systemic Therapy\"", Relationship: \""Both are treatment modalities for cancer.\""\\n\\nCausalities:-\\n#### Principles\\n- **Principles of Imaging (IMG-A)**\\n- **Principles of Surgery (SURG-A)**\\n- **Principles of Radiation Therapy (SUPRA-A)**\\n- **Principles of Systemic Therapy for Non-Nasopharyngeal Cancers (SYST-A)**\\n\\nSection Name: Adverse Pathologic Features\\n====================\\nEntities:-\\nExtranodal Extension : The spread of cancer cells beyond the lymph node capsule into the surrounding tissues.\\nPositive Surgical Margins : The presence of cancer cells at the edge of the tissue removed during surgery.\\nPerineural Invasion : Cancer cells found surrounding or tracking along a nerve within the perineural space.\\nVascular Invasion : The presence of cancer cells within blood vessels.\\nLymphatic Invasion : The presence of cancer cells within lymphatic vessels.\\n\\nRelationships:-\\n1. Entity1: \""Extranodal Extension\"", Entity2: \""Positive Surgical Margins\"", Relationship: \""Both indicate cancer spread beyond original site.\""\\n2. Entity1: \""Perineural Invasion\"", Entity2: \""Vascular Invasion\"", Relationship: \""Both are pathways for cancer spread.\""\\n3. Entity1: \""pT3 or pT4 primary\"", Entity2: \""pN2 or pN3 nodal disease\"", Relationship: \""Both indicate advanced cancer stages.\""\\n\\nCausalities:-\\n<C> Extranodal extension </C>\\n<C> Positive margins </C>\\n<C> Close margins </C>\\n<C> pT3 or pT4 primary </C>\\n<C> pN2 or pN3 nodal disease </C>\\n<C> Perineural invasion </C>\\n<C> Vascular invasion </C>\\n<C> Lymphatic invasion </C>\\n\\nSection Name: Clinical Staging and Treatment of Primary and Neck\\n====================\\nEntities:-\\nAdjuvant Chemotherapy : Chemotherapy given in addition to the primary treatment to maximize its effectiveness.\\nFollow-Up Procedure : A procedure performed to monitor the progress of a patient after treatment.\\nRecurrent Disease : A disease that returns after a period of remission.\\nLaryngectomy : Surgical removal of the larynx, often used to treat cancer.\\nRadiation Therapy : The use of ionizing radiation to treat cancer and other diseases.\\nClinical Trial : A type of research that studies new tests and treatments and evaluates their effects on human health outcomes.\\nNeck Dissection : Surgical procedure to remove lymph nodes and surrounding tissue to treat cancer.\\nChemotherapy : Treatment of disease by the use of chemical substances, especially cancer by cytotoxic drugs.\\n\\nRelationships:-\\n1. Entity1: \""Adjuvant Treatment\"", Entity2: \""Treatment of Primary and Neck\"", Relationship: \""part of\""\\n2. Entity1: \""Follow-up\"", Entity2: \""Treatment of Primary and Neck\"", Relationship: \""part of\""\\n3. Entity1: \""Recurrent or Persistent Disease\"", Entity2: \""Treatment of Primary and Neck\"", Relationship: \""part of\""\\n4. Entity1: \""Larynx-Preserving Surgery\"", Entity2: \""Treatment Options\"", Relationship: \""is a treatment option for\""\\n5. Entity1: \""Concurrent Systemic Therapy/RT\"", Entity2: \""Treatment Options\"", Relationship: \""is a treatment option for\""\\n6. Entity1: \""Clinical Trials or Definitive RT\"", Entity2: \""Treatment Options\"", Relationship: \""is a treatment option for\""\\n7. Entity1: \""Endoscopic or Open Partial Laryngectomy and Neck Dissection(s)\"", Entity2: \""Treatment Options\"", Relationship: \""is a treatment option for\""\\n8. Entity1: \""Induction Chemotherapy\"", Entity2: \""Treatment Options\"", Relationship: \""is a treatment option for\""\\n\\nCausalities:-\\n<A> Amenable to Larynx-Preserving (Conservation) Surgery </A>: <CO> T1\u20132, N+ and selected T3, N1 </CO>\\n<A> Concurrent Systemic Therapy/RT </A>: <CO> i, k, l </CO>\\n<A> Clinical Trials or Definitive RT </A>: <CO> i </CO>\\n<A> Endoscopic or Open Partial Laryngectomy and Neck Dissection(s) </A>: <CO> h </CO>\\n<A> Induction Chemotherapy </A>: <CO> k, m </CO>\\n\\nSection Name: Pathologic Features and Response Assessment\\n====================\\nEntities:-\\nRadiation Therapy : The use of ionizing radiation to treat cancer and other diseases.\\nExtranodal Extension : The spread of cancer cells beyond the lymph node capsule into the surrounding tissues.\\nPositive Surgical Margin : Cancer cells are found at the edge of the material removed during surgery, indicating that some cancer may have been left behind.\\nSystemic Therapy : Treatment using substances that travel through the bloodstream, reaching and affecting cells all over the body.\\n\\nRelationships:-\\n1. Entity1: \""Extranodal extension\"", Entity2: \""Adverse Pathologic Features\"", Relationship: \""is a type of\""\\n2. Entity1: \""Positive margin\"", Entity2: \""Adverse Pathologic Features\"", Relationship: \""is a type of\""\\n3. Entity1: \""Systemic Therapy\"", Entity2: \""Adverse Pathologic Features\"", Relationship: \""considered in response to\""\\n4. Entity1: \""Radiation Therapy\"", Entity2: \""Adverse Pathologic Features\"", Relationship: \""considered in response to\""\\n\\nCausalities:-\\n#### Pathologic Features\\n- **No Adverse Pathologic Features**: j\\n  - <A> Consider RT </A>: i\\n- **Adverse Pathologic Features**: j\\n  - <CO> Extranodal extension and/or positive margin </CO>: n\\n  - Other risk features\\n  - <A> Systemic therapy/RT </A>: i, k (category 1)\\n  - <A> Consider systemic therapy/RT </A>: i, k\\n\\n#### Response Assessment\\n- **Response Assessment** (SUPRA-7)\\n\\nSection Name: Imaging and Recurrent or Persistent Disease\\n====================\\nEntities:-\\nTomography, X-Ray Computed : A method of body imaging in which a thin X-ray beam rotates around the patient.\\nMagnetic Resonance Imaging : Medical imaging technique used in radiology to form pictures of the anatomy and the physiological processes of the body.\\nComputed Tomography : Medical imaging technique used in radiology to obtain detailed internal images of the body.\\n\\nRelationships:-\\n1. Entity1: \""CT\"", Entity2: \""primary and neck\"", Relationship: \""used for imaging\""\\n2. Entity1: \""MRI\"", Entity2: \""primary and neck\"", Relationship: \""used for imaging\""\\n3. Entity1: \""Post Systemic Therapy/RT\"", Entity2: \""Recurrent or Persistent Disease\"", Relationship: \""evaluation after treatment\""\\n4. Entity1: \""RT Neck Evaluation\"", Entity2: \""Recurrent or Persistent Disease\"", Relationship: \""evaluation after treatment\""\\n\\nCausalities:-\\n<A> CT (with contrast) or MRI (with and without contrast) of primary and neck </A>\\n\\n<CO> Recurrent or Persistent Disease </CO>\\n\\n<CO> Post Systemic Therapy/RT or RT Neck Evaluation </CO>\\n\\nSection Name: Conclusion\\n====================\\nEntities:-\\nOncologists : Medical doctors who specialize in the diagnosis and treatment of cancer.\\nSupraglottic Larynx Cancer : A type of cancer that occurs in the supraglottic region of the larynx, which is the area above the vocal cords.\\nClinical Staging : The process of determining the extent of cancer in the body, usually based on physical examination, imaging tests, and biopsies.\\nTreatment Strategies : Plans or methods developed to treat diseases, including cancer, which may involve surgery, chemotherapy, radiation therapy, or other modalities.\\nFollow-Up Evaluations : Medical assessments conducted after initial treatment to monitor a patient\\'s progress and detect any recurrence of disease.\\nClinical Efficacy : The ability of a treatment to produce the desired therapeutic effect in clinical settings.\\nResearch : Systematic investigation and study conducted to establish facts and reach new conclusions.\\nTreatment Paradigms : Standard models or patterns of treatment used in medical practice, often based on clinical guidelines and research findings.\\n\\nRelationships:-\\n1. Entity1: \""Oncologists\"", Entity2: \""Supraglottic Larynx Cancer\"", Relationship: \""use flowchart for decision-making\""\\n2. Entity1: \""Clinical Staging\"", Entity2: \""Treatment Strategies\"", Relationship: \""part of management process\""\\n3. Entity1: \""Treatment Strategies\"", Entity2: \""Follow-Up Evaluations\"", Relationship: \""part of management process\""\\n\\nCausalities:-\\n<A> The flowchart serves as a comprehensive guide for oncologists and healthcare providers </A>, <A> facilitating informed decision-making in the treatment of supraglottic larynx cancer </A>. <A> By visualizing the complex interactions between clinical staging, treatment strategies, and follow-up evaluations </A>, <E> it streamlines the management process </E>, <E> ensuring that patients receive appropriate care tailored to their specific needs </E>. <E> The detailed pathways not only enhance clinical efficacy </E> but also <E> underscore the importance of ongoing research and adaptation of treatment paradigms in oncology </E>.\\n--------------------------------------------------\\nPage Number: 93\\n\\nSection Name: PRINCIPLES OF IMAGING\\n====================\\nEntities:-\\nImaging, Diagnostic : The production of a visual representation of parts of the body, for the purpose of clinical analysis and medical intervention.\\nHead And Neck Neoplasms : Tumors or cancer of the head and neck region, including the nasal cavity, sinuses, lips, mouth, salivary glands, throat, or larynx.\\nTomography, X-Ray Computed : An imaging procedure that uses special x-ray equipment to create detailed pictures, or scans, of areas inside the body.\\nMagnetic Resonance Imaging : A noninvasive diagnostic technique that uses magnetic fields and radio waves to produce a detailed image of the body\\'s soft tissue and bones.\\nContrast Media : Substances used to enhance the contrast of structures or fluids within the body in medical imaging.\\n\\nRelationships:-\\n1. Entity1: \""Imaging, Diagnostic\"", Entity2: \""Head and Neck Neoplasms\"", Relationship: \""used for\""\\n2. Entity1: \""Tomography, X-Ray Computed\"", Entity2: \""Contrast Media\"", Relationship: \""uses\""\\n3. Entity1: \""Magnetic Resonance Imaging\"", Entity2: \""Contrast Media\"", Relationship: \""uses\""\\n\\nCausalities:-\\n<C> Imaging </C> plays an essential role in the clinical care of patients with head and neck cancer. <A> The proper selection and utilization of imaging studies </A> is critical in caring for patients with head and neck cancer. <A> CT is performed with contrast </A>, while <A> CT imaging of the chest can be performed with or without contrast </A>, <CO> as clinically indicated </CO>. <A> MRI is performed with and without contrast </A>, <CO> unless contraindicated </CO>.\\n\\nSection Name: Initial Workup - Primary Site\\n====================\\nEntities:-\\nTomography, X-Ray Computed : An imaging procedure that uses special x-ray equipment to create detailed pictures, or scans, of areas inside the body.\\nMagnetic Resonance Imaging : A noninvasive diagnostic technique that uses magnetic fields and radio waves to produce a detailed image of the body\\'s soft tissue and bones.\\nHead And Neck Neoplasms : Tumors or cancer of the head and neck region, including the nasal cavity, sinuses, lips, mouth, salivary glands, throat, or larynx.\\nNeck Structure : The anatomical structure of the neck, which is the part of the body that connects the head to the torso.\\nSkull Base : The bottom part of the skull, which separates the brain from other facial structures.\\nThoracic Inlet : The opening at the top of the thoracic cavity, through which pass the trachea, esophagus, and major blood vessels.\\n\\nRelationships:-\\n1. Entity1: \""CT\"", Entity2: \""MRI\"", Relationship: \""complementary in imaging head and neck cancers\""\\n2. Entity1: \""CT\"", Entity2: \""Head and Neck Neoplasms\"", Relationship: \""used to evaluate\""\\n3. Entity1: \""MRI\"", Entity2: \""Head and Neck Neoplasms\"", Relationship: \""preferred for evaluating\""\\n4. Entity1: \""Skull base\"", Entity2: \""Thoracic inlet\"", Relationship: \""imaging range for evaluation\""\\n\\nCausalities:-\\n<A>Imaging assessment of the primary site</A> can be performed with <A>CT of the soft tissues of the neck</A> or <A>MRI of the neck</A>. <C>CT is complementary to MRI for head and neck cancers</C>. <A>It is utilized to evaluate cortical bone erosion or periosteal invasion, cartilage invasion, and bony erosion or destruction</A>. <CO>in certain conditions, such as evaluating the extent of bone marrow invasion or in patients with extensive dental amalgam obscuring anatomy on CT, assessing skull base invasion and cranial nerve involvement, and differentiating tumor from obstructed sinuses</CO>, <A>MRI is preferred over CT</A>. <CO>when involved lymph nodes or upper mediastinal cancers are present</CO>, <A>Complete evaluation of primary and nodal disease requires imaging from the skull base to the thoracic inlet, extending to the carina</A>.\\n\\nSection Name: PET/CT and Biopsy\\n====================\\nEntities:-\\nPositron Emission Tomography Computed Tomography : A medical imaging technique that combines PET and CT capabilities to provide detailed images of the body.\\nExamination Under Anesthesia : A procedure where a patient is examined while under anesthesia to allow for a more thorough examination.\\nBiopsy : A medical test involving the extraction of sample cells or tissues for examination to determine the presence or extent of a disease.\\nTonsillectomy : A surgical procedure to remove the tonsils, often performed to treat recurrent tonsillitis or sleep apnea.\\nFine Needle Aspiration : A type of biopsy procedure that uses a thin, hollow needle to extract cells from a lump or mass for examination.\\nUltrasound : A medical imaging technique that uses high-frequency sound waves to visualize internal organs and structures.\\nComputed Tomography : A diagnostic imaging procedure that uses a combination of X-rays and computer technology to produce cross-sectional images of the body.\\n\\nRelationships:-\\n1. Entity1: \""PET/CT\"", Entity2: \""EUA\"", Relationship: \""recommended before\""\\n2. Entity1: \""Fine Needle Aspiration (FNA)\"", Entity2: \""metastatic nodes\"", Relationship: \""used for biopsy of\""\\n3. Entity1: \""Image-guided needle biopsy\"", Entity2: \""cystic neck nodes\"", Relationship: \""recommended for initial diagnosis of\""\\n\\nCausalities:-\\n<CO> If imaging does not reveal an obvious primary cancer </CO>, <A> a PET/CT should be ordered before EUA, biopsies, and tonsillectomy </A>. <E> This helps identify potential primary sites </E> before any interventions take place. Additionally, <A> Fine Needle Aspiration (FNA) biopsy of metastatic nodes </A> <E> may provide pathologically informative results </E>. <CO> For initial diagnosis in cystic neck nodes </CO>, <A> image-guided needle biopsy (ultrasound or CT) </A> <E> may yield better results than FNA by palpation alone </E>.\\n\\nSection Name: Postoperative Imaging Advice\\n====================\\nEntities:-\\nPanoramic Radiography : A type of dental x-ray that provides a wide view of the upper and lower jaws, teeth, temporomandibular joints, and sinuses.\\nOral Cavity : The cavity of the mouth, including the lips, the lining inside the cheeks and lips, the front two-thirds of the tongue, the gums, the floor of the mouth under the tongue, the hard palate, and the small area of the gum behind the wisdom teeth.\\nRadiotherapy : The treatment of disease, especially cancer, using X-rays or similar forms of radiation.\\nMandibulotomy : A surgical procedure involving the cutting of the mandible.\\nMandibulectomy : A surgical procedure involving the removal of part or all of the mandible.\\nOropharynx : The part of the throat at the back of the mouth behind the oral cavity.\\n\\nRelationships:-\\n1. Entity1: \""panoramic dental x-ray\"", Entity2: \""oral cavity cancers\"", Relationship: \""recommended for\""\\n2. Entity1: \""panoramic dental x-ray\"", Entity2: \""postoperative radiotherapy\"", Relationship: \""essential for pre-radiation evaluation\""\\n3. Entity1: \""pre-radiation dental evaluation\"", Entity2: \""dental procedures or extractions\"", Relationship: \""determine necessity of\""\\n\\nCausalities:-\\n<A> A panoramic dental x-ray is recommended </A> <C> for oral cavity cancers requiring mandibulotomy and/or mandibulectomy </C>. <CO> When postoperative radiotherapy (RT) is anticipated for areas like the lip, oral cavity subsites, or oropharynx </CO>, <A> panoramic x-ray is essential for a comprehensive pre-radiation dental evaluation </A> <E> to assess the health of affected teeth and determine if pre-radiation dental procedures or extractions are necessary </E>.\\n\\nSection Name: NCCN Guidelines Note\\n====================\\nEntities:-\\nNeoplasms : Neoplasms are abnormal growths of tissue, which can be cancerous or non-cancerous.\\nMalignant Neoplastic Disease : A disease characterized by uncontrolled, abnormal growth of cells that can invade or spread to other parts of the body.\\nCancer : A group of diseases involving abnormal cell growth with the potential to invade or spread to other parts of the body.\\nClinical Trials As Topic : Pre-planned studies of the safety, efficacy, or optimum dosage schedule of one or more diagnostic, therapeutic, or prophylactic drugs, devices, or techniques in humans selected according to predetermined criteria of eligibility and observed for predefined evidence of favorable and unfavorable effects.\\nClinical Trial : A research study that prospectively assigns human participants or groups of humans to one or more health-related interventions to evaluate the effects on health outcomes.\\n\\nRelationships:-\\n1. Entity1: \""NCCN\"", Entity2: \""Clinical Trials\"", Relationship: \""encourages participation in\""\\n2. Entity1: \""NCCN\"", Entity2: \""Cancer\"", Relationship: \""recommends clinical trials for\""\\n\\nCausalities:-\\n<A> NCCN believes that the best management of any patient with cancer is through participation in clinical trials </A>, <A> which is especially encouraged </A>.\\n--------------------------------------------------\\nPage Number: 41\\n\\nSection Name: Workup\\n====================\\nEntities:-\\nLaryngeal Neoplasms : Tumors or cancer of the larynx, which may affect the glottis, supraglottis, or subglottis.\\nHistory And Physical Examination : A comprehensive assessment of a patient\\'s medical history and physical condition.\\nTobacco Smoking : The act of smoking tobacco products, which is a risk factor for many diseases.\\nAlcohol Drinking : The consumption of beverages containing ethyl alcohol.\\nSmoking Cessation : The process of discontinuing tobacco smoking.\\nBiopsy : A medical test involving the extraction of sample cells or tissues for examination.\\nLaryngoscopy : A procedure to examine the larynx, often using a scope.\\nComputed Tomography (Ct) : A diagnostic imaging procedure that uses computer-processed combinations of many X-ray measurements taken from different angles to produce cross-sectional images of specific areas of a scanned object.\\nMagnetic Resonance Imaging (Mri) : A medical imaging technique used in radiology to form pictures of the anatomy and the physiological processes of the body.\\nPositron-Emission Tomography : A type of nuclear medicine imaging that measures metabolic activity of the cells of body tissues.\\nPulmonary Function Test : Tests that measure how well the lungs are working.\\nDental Examination : An evaluation of the teeth and gums to assess oral health.\\nNutritional Support : Therapies to provide nutrition to patients who cannot obtain nutrition by mouth.\\nSpeech Therapy : Therapy to improve speech and communication skills.\\nSwallowing Therapy : Therapy to help individuals with swallowing difficulties.\\nMultidisciplinary Care Team : A group of healthcare professionals from different specialties working together to manage patient care.\\n\\nRelationships:-\\n1. Entity1: \""glottic larynx cancer\"", Entity2: \""history and physical examination\"", Relationship: \""initial diagnostic step\""\\n2. Entity1: \""glottic larynx cancer\"", Entity2: \""biopsy\"", Relationship: \""required diagnostic procedure\""\\n3. Entity1: \""glottic larynx cancer\"", Entity2: \""direct laryngoscopy\"", Relationship: \""recommended procedure\""\\n4. Entity1: \""glottic larynx cancer\"", Entity2: \""CT scans\"", Relationship: \""imaging study\""\\n5. Entity1: \""glottic larynx cancer\"", Entity2: \""MRI\"", Relationship: \""imaging study\""\\n6. Entity1: \""glottic larynx cancer\"", Entity2: \""multidisciplinary consultation\"", Relationship: \""advised as clinically indicated\""\\n\\nCausalities:-\\nThe workup section outlines the initial steps for diagnosing <C>glottic larynx cancer</C>. It includes <A>a comprehensive history and physical examination (H&P)</A>, which should document tobacco and alcohol use, and provide counseling for smoking cessation. <A>A biopsy of the primary site is required</A>, and <A>direct laryngoscopy under anesthesia is generally recommended</A>. <A>Imaging studies such as CT scans with contrast and possibly MRI are used to evaluate the larynx and neck</A>. Additional evaluations may include <A>chest CT, FDG-PET/CT, pulmonary function tests, dental evaluation, and nutrition, speech, and swallowing therapy</A>. <A>Multidisciplinary consultation is advised</A> <CO>as clinically indicated</CO>.\\n\\nSection Name: Clinical Staging\\n====================\\nEntities:-\\nCancer : A group of diseases involving abnormal cell growth with the potential to invade or spread to other parts of the body.\\nCarcinoma In Situ : A lesion with cytological characteristics of cancer but which has not invaded the basement membrane.\\nBiopsy : A medical test involving the extraction of sample cells or tissues for examination.\\nLaryngectomy : A surgical procedure to remove the larynx.\\n\\nRelationships:-\\n1. Entity1: \""Clinical staging\"", Entity2: \""Cancer\"", Relationship: \""involves\""\\n2. Entity1: \""Carcinoma in situ\"", Entity2: \""Stages T1-T4\"", Relationship: \""is a stage of\""\\n3. Entity1: \""Biopsy\"", Entity2: \""Cancer\"", Relationship: \""used in staging\""\\n4. Entity1: \""Larynx-preserving surgeries\"", Entity2: \""Stages T1-T2\"", Relationship: \""considered for\""\\n5. Entity1: \""Total laryngectomy\"", Entity2: \""Stages T3-T4\"", Relationship: \""required for\""\\n\\nCausalities:-\\n<C> Clinical staging involves categorizing the cancer based on its aggressiveness </C>. It starts with carcinoma in situ, which is non-invasive, and progresses through stages T1-T4. <CO> Staging is based on H&P, biopsy, and imaging studies </CO>. <CO> For T1-T2 </CO>, <A> larynx-preserving surgeries are considered </A>, while <CO> more advanced stages like T3 or T4 </CO> <A> may require total laryngectomy </A>. <A> Additional evaluations such as videostrobe, audiogram, and fertility counseling may be considered </A>.\\n\\nSection Name: Treatment\\n====================\\nEntities:-\\nCarcinoma In Situ : A lesion with cytological characteristics of cancer but which has not invaded the basement membrane.\\nLaryngectomy : A surgical procedure to remove the larynx.\\nMetastasis : The transfer of a disease from one organ or part to another not directly connected with it.\\nClinical Trials As Topic : Works about research studies that evaluate the effectiveness and safety of medications or medical devices by monitoring their effects on large groups of people.\\n\\nRelationships:-\\n1. Entity1: \""Carcinoma in situ\"", Entity2: \""Larynx-preserving surgery\"", Relationship: \""treated with\""\\n2. Entity1: \""T1-T2 stages\"", Entity2: \""Conservation surgery\"", Relationship: \""treated with\""\\n3. Entity1: \""T3 stages\"", Entity2: \""Total laryngectomy\"", Relationship: \""may require\""\\n4. Entity1: \""T4a disease\"", Entity2: \""Complex interventions\"", Relationship: \""require\""\\n5. Entity1: \""Guidelines\"", Entity2: \""Multidisciplinary consultations\"", Relationship: \""emphasize importance of\""\\n6. Entity1: \""Guidelines\"", Entity2: \""Clinical trials\"", Relationship: \""consider as best option\""\\n\\nCausalities:-\\n<CO>Treatment recommendations vary by stage</CO>. <CO>Carcinoma in situ</CO> <A>may be treated with larynx-preserving surgery</A>. <CO>T1-T2 stages</CO> <A>may also be amenable to conservation surgery</A>. <CO>T3 stages</CO> <A>may require total laryngectomy</A>, <CO>especially if nodal involvement is present</CO>. <CO>T4a disease and unresectable or metastatic cases</CO> <A>require more complex interventions</A>. <A>The guidelines emphasize the importance of multidisciplinary consultations</A> and <A>consider clinical trials as the best management option</A>.\\n\\nSection Name: Additional Notes\\n====================\\nEntities:-\\nBiopsy, Needle : A procedure to remove a small sample of tissue for examination under a microscope.\\nImage-Guided Biopsy : A biopsy procedure that uses imaging techniques to guide the needle to the precise location of the tissue to be sampled.\\nBiopsy : A medical test involving the extraction of sample cells or tissues for examination.\\nDiagnostic Techniques And Procedures : Methods and procedures for the diagnosis of disease or dysfunction.\\nImaging : The process of producing images of the body for clinical purposes.\\nDental Care : The total of dental diagnostic, preventive, and corrective procedures.\\nNutritional Physiological Phenomena : The functions and properties of nutrients in living organisms.\\nFertility : The capacity to conceive or induce conception.\\nReproductive Health : A state of physical, mental, and social well-being in all matters relating to the reproductive system.\\nLymphatic Metastasis : The transfer of a neoplasm from one organ or part of the body to another remote from the primary site.\\nGlottis : The part of the larynx consisting of the vocal cords and the opening between them.\\n\\nRelationships:-\\n1. Entity1: \""image-guided needle biopsy\"", Entity2: \""diagnostic yield\"", Relationship: \""used for\""\\n2. Entity1: \""nodal disease\"", Entity2: \""glottic tumors\"", Relationship: \""is rare in\""\\n\\nCausalities:-\\n<A> use of image-guided needle biopsy </A> for <E> better diagnostic yield </E>, principles of imaging, dental evaluation, and nutrition management. The guidelines also address fertility and reproductive considerations, and note that <CO> nodal disease in glottic tumors is rare </CO>.\\n--------------------------------------------------\\nPage Number: 44\\n\\nSection Name: Flowchart Structure\\n====================\\nEntities:-\\nNeoplasm Staging : Methods used for staging neoplasms based on extent of tumor spread according to standardized criteria.\\nLaryngectomy : Surgical procedure to remove the larynx, often used to treat laryngeal cancer.\\nChemotherapy, Adjuvant : Drug therapy given in addition to the primary treatment to enhance its effectiveness.\\nRadiotherapy : The use of radiation, usually high-energy X-rays, to damage cancer cells and treat cancer.\\nTomography, X-Ray Computed : An imaging procedure that uses special x-ray equipment to create detailed pictures, or scans, of areas inside the body.\\nMagnetic Resonance Imaging : A noninvasive diagnostic technique that uses magnetic fields and radio waves to produce a detailed image of the body\\'s soft tissue and bones.\\nNeoplasm Recurrence, Local : The return of a tumor at the original site after treatment.\\n\\nRelationships:-\\n1. Entity1: \""Clinical Staging\"", Entity2: \""T3 tumors\"", Relationship: \""determines treatment approach\""\\n2. Entity1: \""Adverse Pathologic Features\"", Entity2: \""Systemic Therapy\"", Relationship: \""directs to\""\\n3. Entity1: \""Adverse Pathologic Features\"", Entity2: \""Radiation Treatment\"", Relationship: \""directs to\""\\n4. Entity1: \""Induction Chemotherapy\"", Entity2: \""Imaging (CT or MRI)\"", Relationship: \""leads to\""\\n\\nCausalities:-\\n1. <A> The flow begins with the clinical staging of T3 tumors </A> <C> that require total laryngectomy (N2\u20133) </C>. <CO> This staging </CO> <E> is crucial for determining the appropriate therapeutic approach </E>.\\n\\n2. The flowchart provides multiple pathways for treatment, indicating that <CO> patients </CO> <A> may undergo either \""Concurrent systemic therapy/RT\"" or \""Surgery\"" </A>. There is also an <A> option for \""Induction chemotherapy,\"" leading to further imaging (CT or MRI) to assess the primary site and neck status </A>.\\n\\n3. For <CO> patients who have surgery </CO>, the flowchart distinguishes between those with adverse pathologic features and those without. <CO> Patients with adverse features\u2014such as extranodal extension or positive margins </CO>\u2014are <A> directed toward systemic therapy or radiation treatment </A>, while those without may follow a different management path.\\n\\n4. The flowchart concludes by <A> outlining follow-up procedures for recurrent or persistent disease </A>, suggesting additional assessments and treatments based on the risk features identified during earlier stages.\\n\\nSection Name: Detailed Explanation\\n====================\\nEntities:-\\nLaryngeal Neoplasms : Tumors or cancer of the larynx, which may affect the glottis, supraglottis, or subglottis.\\nAdverse Pathological Feature : A pathological feature that indicates a worse prognosis or outcome.\\nRadiation Therapy : The use of high-energy radiation from x-rays, gamma rays, neutrons, protons, and other sources to kill cancer cells and shrink tumors.\\nClinical Trials As Topic : Works about research studies that evaluate the effectiveness and safety of medications or medical devices by monitoring their effects on large groups of people.\\n\\nRelationships:-\\n1. Entity1: \""Systemic therapy\"", Entity2: \""Radiation\"", Relationship: \""Concurrent treatment\""\\n2. Entity1: \""Clinical trials\"", Entity2: \""Personalized treatment plans\"", Relationship: \""Development of\""\\n\\nCausalities:-\\n<A> The flowchart is designed to provide healthcare professionals with a systematic pathway for managing glottic larynx cancer </A>. Each step is meticulously organized to ensure that important factors are considered, such as <C> the presence of adverse pathological features </C>, which <E> strongly influence treatment decisions </E>.\\n\\n<A> The emphasis on concurrent treatments, such as systemic therapy combined with radiation </A>, reflects current best practices in oncology, where multimodal approaches are often necessary to achieve better outcomes. <A> The inclusion of clinical trials </A> indicates an emphasis on maintaining up-to-date practices and personalized treatment plans as part of patient management strategies.\\n\\nFurthermore, <A> the chart\\'s organization into treatment and follow-up segments </A> allows for a straightforward interpretation, guiding oncologists through complex decisions in a logical manner. This can <E> improve consistency in care and enhance patient safety through meticulous monitoring and responses to treatment efficacy or disease progression </E>.\\n\\nIn summary, <E> this flowchart serves as an essential resource for oncologists, facilitating a better understanding of treatment protocols for glottic larynx cancer while promoting a patient-centered approach to oncological care </E>.\\n\\nSection Name: NCCN Guidelines Version 4.2024\\n====================\\nEntities:-\\nClinical Trials As Topic : Works about research studies that evaluate the effectiveness and safety of medications or medical devices by monitoring their effects on large groups of people.\\nClinical Trial : A research study that prospectively assigns human participants or groups of humans to one or more health-related interventions to evaluate the effects on health outcomes.\\nNeoplasms : New abnormal growth of tissue that may be benign or malignant.\\nMalignant Neoplastic Disease : A disease in which abnormal cells divide uncontrollably and destroy body tissue.\\nCancer : A group of diseases involving abnormal cell growth with the potential to invade or spread to other parts of the body.\\nNational Comprehensive Cancer Network : An alliance of 31 cancer centers in the United States, dedicated to improving the quality, effectiveness, and efficiency of cancer care.\\n\\nRelationships:-\\n1. Entity1: \""National Comprehensive Cancer Network\"", Entity2: \""NCCN Guidelines\"", Relationship: \""publishes\""\\n2. Entity1: \""Clinical trial\"", Entity2: \""Cancer\"", Relationship: \""manages\""\\n\\nCausalities:-\\n<C> any patient with cancer </C> <E> the best management is in a clinical trial </E>. <A> Participation in clinical trials is especially encouraged </A>.\\n\\nSection Name: Principles of Treatment\\n====================\\nEntities:-\\nRadiation Therapy : The use of high-energy radiation from x-rays, gamma rays, neutrons, protons, and other sources to kill cancer cells and shrink tumors.\\nSurgical Procedures, Operative : Operations carried out for the correction of deformities and defects, repair of injuries, and diagnosis and cure of certain diseases.\\nExtranodal Extension : The spread of cancer beyond the lymph node capsule into the surrounding tissues.\\nPositive Surgical Margins : Cancer cells are found at the edge of the material removed during surgery, indicating that some cancer may have been left behind.\\nPerineural Invasion : Cancer cells are found surrounding or tracking along a nerve within the perineural space.\\nVascular Invasion : The presence of cancer cells within blood vessels.\\nLymphatic Metastasis : The spread of cancer cells through the lymphatic system to distant sites.\\n\\nRelationships:-\\n1. Entity1: \""Principles of Radiation Therapy\"", Entity2: \""Extranodal Extension\"", Relationship: \""management of\""\\n2. Entity1: \""Principles of Surgery\"", Entity2: \""Positive Surgical Margins\"", Relationship: \""concerned with avoiding\""\\n3. Entity1: \""Principles of Radiation Therapy\"", Entity2: \""Perineural Invasion\"", Relationship: \""consideration in treatment planning\""\\n\\nCausalities:-\\n<C> Extranodal extension </C> <C> Positive margins </C> <C> Close margins </C> <C> pT4 primary </C> <C> pN2 or pN3 nodal disease </C> <C> Perineural invasion </C> <C> Vascular invasion </C> <C> Lymphatic invasion </C> <C> Subglottic extension </C>\\n\\nSection Name: Clinical Staging\\n====================\\nEntities:-\\nAdjuvant Chemotherapy : Chemotherapy given in addition to the primary treatment to enhance its effectiveness.\\nAdjuvant Therapy : A therapy given in addition to the primary or initial therapy to maximize its effectiveness.\\nFollow-Up Studies : Studies that continue to monitor patients after treatment to assess long-term outcomes.\\nFollow-Up Procedure : A procedure performed to monitor the progress of a patient after initial treatment.\\nFollow-Up : The act of monitoring a patient\\'s health over time after treatment.\\nNeoplasm Recurrence, Local : The return of a tumor at the original site after treatment.\\nRecurrent Disease : A disease that has returned after a period of remission.\\n\\nRelationships:-\\n1. Entity1: \""Adjuvant Treatment\"", Entity2: \""Recurrent or Persistent Disease\"", Relationship: \""prevention\""\\n2. Entity1: \""Follow-up\"", Entity2: \""Recurrent or Persistent Disease\"", Relationship: \""monitoring\""\\n\\nSection Name: Treatment Options\\n====================\\nEntities:-\\nLaryngectomy : Surgical procedure to remove the larynx, often used to treat laryngeal cancer.\\nTotal Laryngectomy : A surgical procedure to remove the entire larynx.\\nChemotherapy, Adjuvant : Drug therapy given in addition to the primary treatment to enhance its effectiveness.\\nInduction Chemotherapy : Chemotherapy given as a first step to shrink a tumor before the main treatment.\\nClinical Trials As Topic : Works about research studies that evaluate the effectiveness and safety of medications or medical devices by monitoring their effects on large groups of people.\\nClinical Trial : A research study that prospectively assigns human participants or groups of humans to one or more health-related interventions to evaluate the effects on health outcomes.\\n\\nRelationships:-\\n1. Entity1: \""T3 requiring total laryngectomy\"", Entity2: \""Concurrent systemic therapy/RT\"", Relationship: \""treatment option\""\\n2. Entity1: \""T3 requiring total laryngectomy\"", Entity2: \""Induction chemotherapy\"", Relationship: \""treatment option\""\\n3. Entity1: \""T3 requiring total laryngectomy\"", Entity2: \""Clinical trials\"", Relationship: \""research option\""\\n\\nCausalities:-\\n<CO> T3 requiring (amenable to) total laryngectomy (N2\u20133) </CO> <A> Concurrent systemic therapy/RT </A> <A> Surgery </A> <A> Induction chemotherapy </A> <A> Clinical trials </A>\\n\\nSection Name: Surgical Considerations\\n====================\\nEntities:-\\nLaryngectomy : Surgical procedure to remove the larynx, often used to treat laryngeal cancer.\\nThyroidectomy : Surgical removal of all or part of the thyroid gland.\\nNeck Dissection : Surgical procedure to remove lymph nodes and surrounding tissue in the neck.\\nLymph Node Excision : Surgical removal of one or more lymph nodes.\\nLymph Node Dissection : A surgical procedure to remove lymph nodes.\\nLymphadenectomy : Surgical removal of one or more groups of lymph nodes.\\n\\nRelationships:-\\n1. Entity1: \""Laryngectomy\"", Entity2: \""Thyroidectomy\"", Relationship: \""performed with\""\\n2. Entity1: \""Neck Dissection\"", Entity2: \""Lymph Node Excision\"", Relationship: \""includes\""\\n3. Entity1: \""Neck Dissection\"", Entity2: \""Lymph Node Excision\"", Relationship: \""includes specific types\""\\n\\nCausalities:-\\n<A> Laryngectomy with thyroidectomy as indicated, ipsilateral or bilateral neck dissection, and pretracheal and ipsilateral paratracheal lymph node dissection </A>\\n\\nSection Name: Pathologic Features\\n====================\\nEntities:-\\nExtranodal Extension : The spread of cancer beyond the lymph node capsule into the surrounding tissues.\\nPositive Surgical Margins : Cancer cells are found at the edge of the material removed during surgery, indicating that some cancer may have been left behind.\\nPositive Margin : A surgical margin that contains residual tumor cells.\\n\\nRelationships:-\\n1. Entity1: \""Adverse pathologic features\"", Entity2: \""Extranodal extension\"", Relationship: \""includes\""\\n2. Entity1: \""Adverse pathologic features\"", Entity2: \""Positive margin\"", Relationship: \""includes\""\\n\\nCausalities:-\\n- **No adverse pathologic features**\\n- **Adverse pathologic features**\\n  - <C> Extranodal extension and/or positive margin </C>\\n  - Other risk features\\n\\nSection Name: Systemic Therapy\\n====================\\nEntities:-\\nAntineoplastic Agents : Drugs used to treat cancer by inhibiting the growth of cancerous cells.\\nSystemic Therapy : A treatment using substances that travel through the bloodstream, reaching and affecting cells all over the body.\\nRadiotherapy : The use of radiation, usually high-energy X-rays, to damage cancer cells and treat cancer.\\nRadiation Therapy : The use of high-energy radiation from x-rays, gamma rays, neutrons, protons, and other sources to kill cancer cells and shrink tumors.\\n\\nRelationships:-\\n1. Entity1: \""Systemic therapy\"", Entity2: \""RT\"", Relationship: \""Consideration\""\\n\\nCausalities:-\\n<A> Systemic therapy/RT (category 1) </A>\\n<A> RT </A>\\n<A> Consider systemic therapy/RT </A>\\n\\nSection Name: Imaging\\n====================\\nEntities:-\\nTomography, X-Ray Computed : An imaging procedure that uses special x-ray equipment to create detailed pictures, or scans, of areas inside the body.\\nMagnetic Resonance Imaging : A noninvasive diagnostic technique that uses magnetic fields and radio waves to produce a detailed image of the body\\'s soft tissue and bones.\\nNeck : Part of the body, on many terrestrial or secondarily aquatic vertebrates, that distinguishes the head from the torso or trunk.\\nComputed Tomography : A diagnostic imaging procedure that uses a combination of X-rays and computer technology to produce cross-sectional images (often called slices), both horizontally and vertically, of the body.\\nNeck Structure : The anatomical structure that connects the head to the torso.\\n\\nRelationships:-\\n1. Entity1: \""CT\"", Entity2: \""Neck\"", Relationship: \""imaging of\""\\n2. Entity1: \""MRI\"", Entity2: \""Neck\"", Relationship: \""imaging of\""\\n\\nCausalities:-\\n<A> CT (with contrast) or MRI (with and without contrast) of primary and neck </A>\\n\\nSection Name: Post-Treatment Evaluation\\n====================\\nEntities:-\\nRadiotherapy : The use of radiation, usually high-energy X-rays, to damage cancer cells and treat cancer.\\nPn1 Category : A pathological classification indicating regional lymph node metastasis in cancer staging.\\nRadiation Therapy : The use of high-energy radiation from x-rays, gamma rays, neutrons, protons, and other sources to kill cancer cells and shrink tumors.\\n\\nRelationships:-\\n1. Entity1: \""Post Systemic Therapy/RT or RT Neck Evaluation\"", Entity2: \""pN1\"", Relationship: \""evaluation of cancer staging\""\\n2. Entity1: \""pN1\"", Entity2: \""Consider RT\"", Relationship: \""treatment recommendation\""\\n\\nCausalities:-\\n<CO> pN1 without other risk features </CO> <A> Consider RT </A>\\n\\nSection Name: Additional Notes\\n====================\\nEntities:-\\nAntineoplastic Combined Chemotherapy Protocols : Protocols for the administration of more than one antineoplastic agent in combination to treat malignant neoplasms.\\nCisplatin : A platinum-containing antineoplastic agent used in the treatment of various cancers.\\n\\nRelationships:-\\n1. Entity1: \""Systemic Therapy\"", Entity2: \""Non-Nasopharyngeal Cancers\"", Relationship: \""used for\""\\n2. Entity1: \""Cisplatin\"", Entity2: \""Systemic Therapy\"", Relationship: \""preferred agent in\""\\n3. Entity1: \""Induction Chemotherapy\"", Entity2: \""Systemic Therapy\"", Relationship: \""discussed in context of\""\\n\\nCausalities:-\\n- **Principles of Systemic Therapy for Non-Nasopharyngeal Cancers (SYST-A)**\\n- **<CO> When using concurrent systemic therapy/RT </CO>, <A> the preferred agent is cisplatin (category 1) </A>. See Principles of Systemic Therapy for Non-Nasopharyngeal Cancers (SYST-A).**\\n- **<A> See Discussion on induction chemotherapy. </A>**\\n'}""",valid,increases risk,2,B,"edge - The edge which needs to be verified.
explanation - Explanation of what the edge represents and its validity.
causal_direction - Either Positive or Negative or Unknown. A positive influence direction indicates that both factors change in the same direction (e.g. an increase causes an increase effect). A negative influence direction indicates the opposite changes (e.g. an increase causes a decrease effect).
causal_factor - Is necessary or sufficient condition for an effect to occur. Exposure is a term commonly used in epidemiology to denote any condition that is considered as a possible cause of disease. Exposure is considered necessary when it always precedes the effects (e.g. symptoms) and always presents when the effects occur. A sufficient cause is a causal factor whose presence or occurrence guarantees the occurrence of symptom.
causal_distance - Either Distal or Proximal or Unknown. The distal factors lie towards the beginning of causal chain (i.e. indirect causal factors). The the proximal factors lie towards the end of the chain (i.e. cause directly or almost directly the effect).

Causality Tags:
<A> for action, <C> for cause, <CO> for condition and <E> for effect.
Cause (C): The reason or origin that leads to an effect. Causes often involve disease conditions, risk factors, or underlying mechanisms.
Effect (E): The outcome or result of a cause. Effects usually represent clinical outcomes, complications, or results of a specific cause.
Condition (CO): The circumstance or prerequisite required for an action or effect to occur. Conditions may include patient characteristics, clinical scenarios, or specific diagnostic criteria.
Action (A): The recommended or described response or activity to address a cause or condition. Actions typically involve clinical interventions, diagnostic procedures, or treatment recommendations.


`NODE1`:
id: Location_of_Lymph_Nodes_3
label: Location of Lymph Nodes
description: This node represents the presence or absence of lymph nodes in a specific location, which is crucial for cancer diagnosis and staging. The detection of lymph nodes can indicate the spread of cancer and affect treatment decisions.
type: Patient Situation
observability: Unobserved
states: [{'state_name': 'present', 'state_description': 'Lymph nodes are detected in the specified location, which may indicate the spread of cancer and is important for staging and treatment planning.'}, {'state_name': 'absent', 'state_description': 'Lymph nodes are not detected in the specified location, which may suggest no spread of cancer to this area and is important for staging and treatment planning.'}]

`NODE2`:
id: MRT_9
label: Magnetresonanztomographie Examination Result
description: This node represents the result of a Magnetresonanztomographie (MRI) examination. It indicates whether a particular finding or condition is present or absent based on the MRI scan. MRI is a crucial imaging technique used to diagnose and monitor various medical conditions by providing detailed images of the organs and tissues within the body.
type: Examination Result
observability: Observed
states: [{'state_name': 'present', 'state_description': ""The 'present' state indicates that the MRI examination has detected the specific finding or condition in question. This could mean the presence of a lesion, abnormality, or other clinically significant feature that was being investigated.""}, {'state_name': 'absent', 'state_description': ""The 'absent' state indicates that the MRI examination did not detect the specific finding or condition in question. This suggests that there is no evidence of the lesion, abnormality, or feature that was being investigated, based on the MRI scan.""}]

`EDGE1`:
{'edges_ids': ['Location_of_Lymph_Nodes_3', 'MRT_9'], 'edge': '(Location_of_Lymph_Nodes_3) causes (MRT_9)', 'explanation': ['The edge `(Location_of_Lymph_Nodes_3) causes (MRT_9)` is not valid as a causal relationship.', 'The `Location_of_Lymph_Nodes_3` node represents the presence or absence of lymph nodes, which is a condition that can be observed by an MRI scan, represented by the `MRT_9` node.', 'The MRI result (`MRT_9`) is an observation of the state of the lymph nodes (`Location_of_Lymph_Nodes_3`), not a result caused by them.', 'Therefore, the relationship is observational rather than causal.'], 'causal_direction': 'Unknown', 'causal_factor': {'necessary': False, 'sufficient': False}, 'causal_distance': 'Proximal'}

`EDGE2`:
{'edges_ids': ['MRT_9', 'Location_of_Lymph_Nodes_3'], 'edge': '(MRT_9) causes (Location_of_Lymph_Nodes_3)', 'explanation': ['The edge `(MRT_9) causes (Location_of_Lymph_Nodes_3)` is not valid because an MRI examination result does not cause the presence or absence of lymph nodes.', 'MRT_9 represents the findings from an MRI scan, which can detect the presence of lymph nodes but does not influence their presence or absence.', 'Location_of_Lymph_Nodes_3 represents whether lymph nodes are present in a specific location, which is a condition observed by the MRI, not caused by it.', 'The relationship is observational, where the MRI detects the state of lymph nodes, rather than causal.'], 'causal_direction': 'Unknown', 'causal_factor': {'necessary': False, 'sufficient': False}, 'causal_distance': 'Unknown'}

`INFORMATION FROM KNOWLEDGE BASE`:
--------------------------------------------------
Page Number: 46

Section Name: Introduction
====================
Entities:-
Laryngeal Neoplasms : Tumors or cancer of the larynx, including the glottis.
Malignant Neoplasm Of Glottis : A malignant tumor located in the glottis, part of the larynx.
National Comprehensive Cancer Network : The National Comprehensive Cancer Network (NCCN) is an alliance of 30 cancer centers in the United States, dedicated to improving the quality, effectiveness, and efficiency of cancer care.
Adjuvant Chemotherapy : Chemotherapy given in addition to the primary treatment to maximize its effectiveness, often used in cancer treatment.
Adjuvant Therapy : Treatment given in addition to the primary (main) treatment to enhance its effectiveness.

Relationships:-
1. Entity1: ""National Comprehensive Cancer Network"", Entity2: ""Laryngeal Neoplasms"", Relationship: ""provides treatment guidelines for""
2. Entity1: ""treatment guidelines"", Entity2: ""Adjuvant therapy"", Relationship: ""guide clinical decision-making for""

Causalities:-
<C> cancer of the glottic larynx </C> <E> treatment guidelines </E> <CO> based on various clinical stages and specific patient conditions </CO> <A> guide healthcare professionals through clinical decision-making </A>.

Section Name: NCCN Guidelines Version 4.2024
====================
Entities:-
Clinical Trials : Clinical trials are research studies performed in people that are aimed at evaluating a medical, surgical, or behavioral intervention.
National Comprehensive Cancer Network : The National Comprehensive Cancer Network (NCCN) is an alliance of 30 cancer centers in the United States, dedicated to improving the quality, effectiveness, and efficiency of cancer care.

Relationships:-
1. Entity1: ""National Comprehensive Cancer Network"", Entity2: ""Clinical Trials"", Relationship: ""encourages participation in""

Causalities:-
<A>Participation in clinical trials</A> is especially encouraged.

Section Name: Clinical Staging and Treatment
====================
Entities:-
Neoplasm Staging : Methods used for staging of neoplasms based on extent of tumor spread.
T4A : A clinical stage indicating a tumor that has grown into nearby structures.
N0–3 : A range of clinical stages indicating the extent of regional lymph node involvement.
Surgical Procedures, Operative : Operations carried out for the correction of deformities and defects, repair of injuries, and diagnosis and cure of certain diseases.
Neck Dissection : Surgical procedure to remove lymph nodes and surrounding tissue in the neck.
Pathology : The study of the nature and cause of disease which involves changes in structure and function.
Antineoplastic Combined Chemotherapy Protocols : The use of drug combinations to treat cancer.
Radiotherapy : The use of ionizing radiation to treat cancer.
Clinical Trials As Topic : Works about research studies that evaluate the effectiveness and safety of medications or medical devices by monitoring their effects on large groups of people.

Relationships:-
1. Entity1: ""Clinical Staging"", Entity2: ""Surgical Intervention"", Relationship: ""determines""
2. Entity1: ""T4a"", Entity2: ""Surgical Intervention"", Relationship: ""relates to""
3. Entity1: ""Systemic Therapy"", Entity2: ""Radiotherapy"", Relationship: ""considered with""
4. Entity1: ""Clinical Trials"", Entity2: ""Treatment of Primary and Neck"", Relationship: ""option for""

Causalities:-
<CO> Clinical staging indicator labeled ""T4a,N0–3"" </CO> <A> emphasizes the importance of surgical intervention </A>, highlighting procedures such as bilateral neck dissection and the need to address certain pathologic features. <CO> Selected T4a patients who decline surgery </CO> <A> consider concurrent systemic therapy/RT or clinical trial for function-preserving surgical or RT management or induction chemotherapy </A>.

Section Name: Principles of Treatment
====================
Entities:-
Thyroidectomy : Surgical removal of the thyroid gland.
Extranodal Extension : Spread of cancer beyond the lymph node capsule.
Radiation Therapy : Medical use of ionizing radiation to treat cancer.

Relationships:-
1. Entity1: ""Surgery"", Entity2: ""Thyroidectomy"", Relationship: ""involves""
2. Entity1: ""Radiation therapy"", Entity2: ""Adverse pathologic features"", Relationship: ""treats""

Causalities:-
- **Principles of Radiation Therapy (GLOT-A):**  
  - <C> Adverse pathologic features: extranodal extension, positive margins, close margins, pT4 primary, pN2 or pN3 nodal disease, perineural invasion, vascular invasion, lymphatic invasion, and subglottic extension </C> (Discussion).  

- **Principles of Surgery (SURG-A):**  
  - <A> Surgery, including ipsilateral or bilateral neck dissection; thyroidectomy to clear central compartment nodes </A>, <CO> especially when there is thyroid cartilage with gross invasion of the thyroid gland and significant subglottic extension </CO>.

Section Name: Adjuvant Treatment and Follow-up
====================
Entities:-
Systemic Therapy : Treatment using substances that travel through the bloodstream, reaching and affecting cells all over the body.
Clinical Trial : A research study that prospectively assigns human participants or groups of humans to one or more health-related interventions to evaluate the effects on health outcomes.
Computed Tomography (Ct) : A medical imaging technique used in radiology to obtain detailed internal images of the body noninvasively for diagnostic purposes.
Magnetic Resonance Imaging (Mri) : A noninvasive medical test that physicians use to diagnose and treat medical conditions.
Recurrent Disease : A disease that has returned after a period of remission.
Radiation Therapy (Rt) : The use of ionizing radiation to treat cancer and other diseases.

Relationships:-
1. Entity1: ""Adverse Features"", Entity2: ""Specific Treatments"", Relationship: ""Suggests""
2. Entity1: ""Systemic Therapy"", Entity2: ""Patients who decline surgery"", Relationship: ""Option for""
3. Entity1: ""CT or MRI"", Entity2: ""Primary and Neck"", Relationship: ""Used for imaging""
4. Entity1: ""Recurrent or Persistent Disease"", Entity2: ""Follow-up"", Relationship: ""Condition for""
5. Entity1: ""pN1 without other risk features"", Entity2: ""RT"", Relationship: ""Suggests considering""

Causalities:-
<C> adverse features such as extralateral extension or positive margins </C> <E> specific treatments are suggested </E>. The guidelines recommend <A> considering options like concurrent systemic therapy or clinical trials </A> <CO> for patients who decline surgery </CO>.

- **Adjuvant Treatment:**  
  - <A> CT (with contrast) or MRI (with and without contrast) of primary and neck </A>.  

- **Follow-up (FOLL-A, 1 of 2):**  
  - <CO> Recurrent or persistent disease (ADV-3) </CO>.  

- **Post Systemic Therapy/RT or RT Neck Evaluation (FOLL-A, 2 of 2):**  
  - <CO> pN1 without other risk features </CO>: <A> Consider RT </A>.

Section Name: Response Assessment
====================
Entities:-
Adjuvant Chemotherapy : Chemotherapy given in addition to the primary treatment to maximize its effectiveness, often used in cancer treatment.
Computed Tomography : A diagnostic imaging procedure that uses a combination of X-rays and computer technology to produce cross-sectional images of the body.
Magnetic Resonance Imaging : A medical imaging technique used in radiology to form pictures of the anatomy and the physiological processes of the body.
Neoplasm Recurrence, Local : The return of a cancer, at the same site as the original (primary) tumor, after it had disappeared.

Relationships:-
1. Entity1: ""Adjuvant treatment"", Entity2: ""Treatment responses"", Relationship: ""affects""
2. Entity1: ""Follow-up assessments"", Entity2: ""CT or MRI scans"", Relationship: ""conducted using""
3. Entity1: ""Response Assessment (GLOT-5)"", Entity2: ""Recurrent or persistent disease (ADV-3)"", Relationship: ""determines""

Causalities:-
As the flowchart progresses to the adjuvant treatment section, it depicts further decision points based on treatment responses and disease recurrence. The inclusion of references to follow-up assessments, such as CT or MRI scans, underscores the emphasis on continuous monitoring and evaluation of treatment efficacy.  - **Response Assessment (GLOT-5):**   - <C>Recurrent or persistent disease (ADV-3)</C>.
--------------------------------------------------
Page Number: 53

Section Name: Introduction
====================
Entities:-
National Comprehensive Cancer Network : The National Comprehensive Cancer Network (NCCN) is an alliance of 30 cancer centers in the United States, dedicated to improving the quality, effectiveness, and efficiency of cancer care so that patients can live better lives.
Laryngeal Neoplasms : Tumors or cancer of the larynx, which may affect the supraglottic, glottic, or subglottic regions.
Malignant Neoplasm Of Supraglottis : A malignant tumor located in the supraglottic region of the larynx.

Relationships:-
1. Entity1: ""National Comprehensive Cancer Network"", Entity2: ""Malignant neoplasm of supraglottis"", Relationship: ""provides guidelines for""
2. Entity1: ""clinical staging"", Entity2: ""treatment strategies"", Relationship: ""part of flowchart for""

Causalities:-
The provided image is a flowchart outlining the <C> NCCN (National Comprehensive Cancer Network) guidelines </C> for the treatment of <CO> cancers of the supraglottic larynx </CO>. This flowchart <A> utilizes a highly structured approach to convey clinical staging and treatment strategies </A>, indicating the various pathways based on <CO> patient conditions and disease features </CO>.

Section Name: NCCN Guidelines Version 4.2024
====================
Entities:-
Laryngeal Neoplasms : Tumors or cancer of the larynx, which may affect the supraglottic, glottic, or subglottic regions.
Malignant Neoplasm Of Supraglottis : A malignant tumor located in the supraglottic region of the larynx.
Supraglottic Cancer : Cancer that occurs in the supraglottic region of the larynx, above the vocal cords.
Clinical Trials As Topic : Pre-planned studies of the safety, efficacy, or optimum dosage schedule of one or more diagnostic, therapeutic, or prophylactic drugs, devices, or techniques in humans selected according to predetermined criteria of eligibility and observed for predefined evidence of favorable and unfavorable effects.
Clinical Trial : A type of research that studies new tests and treatments and evaluates their effects on human health outcomes.

Relationships:-
1. Entity1: ""Cancer of the Supraglottic Larynx"", Entity2: ""Clinical Trials"", Relationship: ""recommended management strategy""

Causalities:-
- All recommendations are category 2A unless otherwise indicated.
- <A> Participation in clinical trials </A> is especially encouraged.

Section Name: Key Components of the Flowchart
====================
Entities:-
Neoplasm Staging : Methods used for staging neoplasms, including clinical and pathological staging.
Radiotherapy : The use of ionizing radiation to treat cancer.
Surgical Procedures, Operative : Operations carried out for the correction of deformities and defects, repair of injuries, and diagnosis and cure of certain diseases.
Adjuvant Chemotherapy : Chemotherapy given in addition to the primary treatment to maximize its effectiveness.
Neoplasm Recurrence, Local : The return of a tumor at the original site after treatment.
Clinical Trials As Topic : Pre-planned studies of the safety, efficacy, or optimum dosage schedule of one or more diagnostic, therapeutic, or prophylactic drugs, devices, or techniques in humans selected according to predetermined criteria of eligibility and observed for predefined evidence of favorable and unfavorable effects.

Relationships:-
1. Entity1: ""Clinical Staging"", Entity2: ""Treatment of Primary and Neck"", Relationship: ""determines""
2. Entity1: ""Evaluation and Follow-Up"", Entity2: ""Adverse and No Adverse Features"", Relationship: ""leads to decision based on""
3. Entity1: ""Adjuvant Treatment"", Entity2: ""Adverse pathologic features"", Relationship: ""considered if present""
4. Entity1: ""Clinical Trials"", Entity2: ""Treatment Pathway"", Relationship: ""part of""

Causalities:-
### Key Components of the Flowchart

1. **Clinical Staging**: The flowchart starts with <A>clinical staging</A>, indicating that <CO>patients must first be evaluated to determine the extent of cancer</CO>. This is essential for <E>deciding on appropriate treatment options</E>.

2. **Treatment of Primary and Neck**: The flowchart details multiple treatment strategies, including:
   - <A>**Concurrent systemic therapy/RT**</A>: This suggests a combination approach for <CO>patients eligible for such treatment</CO>.
   - <A>**Definitive Radiation Therapy (RT)**</A>: Recommended for <CO>low-volume diseases or patients who cannot tolerate systemic therapy</CO>.
   - <A>**Surgical Options**</A>: It highlights options such as endoscopic or open partial laryngectomy and neck dissection, which are <CO>contingent on clinical evaluations</CO>.

3. **Evaluation and Follow-Up**: After initial treatment approaches, the chart directs clinicians to perform a <A>""Post Systemic Therapy/RT or RT Neck Evaluation""</A>. This step <E>assesses whether there are adverse pathologic features</E>, guiding subsequent treatment decisions.

4. **Adverse and No Adverse Features**: The decision pathway diverges based on findings:
   - <CO>Patients with **adverse pathologic features**</CO> may have <A>additional diagnostic imaging (CT or MRI)</A> and may require <A>further systemic treatment</A>.
   - <CO>Patients with **no adverse features**</CO> may be directed towards <A>considerations for radiation therapy</A>.

5. **Adjuvant Treatment and Recurrence**: The chart also addresses <E>management of any recurrent or persistent disease</E>, emphasizing the importance of <A>regular follow-up assessments</A>. Various options for <A>adjuvant treatment</A> are mentioned, focusing on tailored approaches towards ongoing management of the disease.

6. **Clinical Trials**: The flowchart encourages <A>participation in clinical trials</A>, indicating a commitment to <E>exploring new treatments and improving patient outcomes</E>.

Section Name: Principles
====================
Entities:-
Imaging : The process of producing images of the body or parts of the body to diagnose or examine disease.
Surgical Procedure : A medical procedure involving an incision with instruments; performed to repair damage or arrest disease in a living body.
Radiation Therapy : The use of ionizing radiation to treat cancer and other diseases.
Systemic Therapy : Treatment using substances that travel through the bloodstream, reaching and affecting cells all over the body.

Relationships:-
1. Entity1: ""Imaging"", Entity2: ""Surgery"", Relationship: ""Both are foundational principles in medical practice.""
2. Entity1: ""Radiation therapy"", Entity2: ""Systemic Therapy"", Relationship: ""Both are treatment modalities for cancer.""

Causalities:-
#### Principles
- **Principles of Imaging (IMG-A)**
- **Principles of Surgery (SURG-A)**
- **Principles of Radiation Therapy (SUPRA-A)**
- **Principles of Systemic Therapy for Non-Nasopharyngeal Cancers (SYST-A)**

Section Name: Adverse Pathologic Features
====================
Entities:-
Extranodal Extension : The spread of cancer cells beyond the lymph node capsule into the surrounding tissues.
Positive Surgical Margins : The presence of cancer cells at the edge of the tissue removed during surgery.
Perineural Invasion : Cancer cells found surrounding or tracking along a nerve within the perineural space.
Vascular Invasion : The presence of cancer cells within blood vessels.
Lymphatic Invasion : The presence of cancer cells within lymphatic vessels.

Relationships:-
1. Entity1: ""Extranodal Extension"", Entity2: ""Positive Surgical Margins"", Relationship: ""Both indicate cancer spread beyond original site.""
2. Entity1: ""Perineural Invasion"", Entity2: ""Vascular Invasion"", Relationship: ""Both are pathways for cancer spread.""
3. Entity1: ""pT3 or pT4 primary"", Entity2: ""pN2 or pN3 nodal disease"", Relationship: ""Both indicate advanced cancer stages.""

Causalities:-
<C> Extranodal extension </C>
<C> Positive margins </C>
<C> Close margins </C>
<C> pT3 or pT4 primary </C>
<C> pN2 or pN3 nodal disease </C>
<C> Perineural invasion </C>
<C> Vascular invasion </C>
<C> Lymphatic invasion </C>

Section Name: Clinical Staging and Treatment of Primary and Neck
====================
Entities:-
Adjuvant Chemotherapy : Chemotherapy given in addition to the primary treatment to maximize its effectiveness.
Follow-Up Procedure : A procedure performed to monitor the progress of a patient after treatment.
Recurrent Disease : A disease that returns after a period of remission.
Laryngectomy : Surgical removal of the larynx, often used to treat cancer.
Radiation Therapy : The use of ionizing radiation to treat cancer and other diseases.
Clinical Trial : A type of research that studies new tests and treatments and evaluates their effects on human health outcomes.
Neck Dissection : Surgical procedure to remove lymph nodes and surrounding tissue to treat cancer.
Chemotherapy : Treatment of disease by the use of chemical substances, especially cancer by cytotoxic drugs.

Relationships:-
1. Entity1: ""Adjuvant Treatment"", Entity2: ""Treatment of Primary and Neck"", Relationship: ""part of""
2. Entity1: ""Follow-up"", Entity2: ""Treatment of Primary and Neck"", Relationship: ""part of""
3. Entity1: ""Recurrent or Persistent Disease"", Entity2: ""Treatment of Primary and Neck"", Relationship: ""part of""
4. Entity1: ""Larynx-Preserving Surgery"", Entity2: ""Treatment Options"", Relationship: ""is a treatment option for""
5. Entity1: ""Concurrent Systemic Therapy/RT"", Entity2: ""Treatment Options"", Relationship: ""is a treatment option for""
6. Entity1: ""Clinical Trials or Definitive RT"", Entity2: ""Treatment Options"", Relationship: ""is a treatment option for""
7. Entity1: ""Endoscopic or Open Partial Laryngectomy and Neck Dissection(s)"", Entity2: ""Treatment Options"", Relationship: ""is a treatment option for""
8. Entity1: ""Induction Chemotherapy"", Entity2: ""Treatment Options"", Relationship: ""is a treatment option for""

Causalities:-
<A> Amenable to Larynx-Preserving (Conservation) Surgery </A>: <CO> T1–2, N+ and selected T3, N1 </CO>
<A> Concurrent Systemic Therapy/RT </A>: <CO> i, k, l </CO>
<A> Clinical Trials or Definitive RT </A>: <CO> i </CO>
<A> Endoscopic or Open Partial Laryngectomy and Neck Dissection(s) </A>: <CO> h </CO>
<A> Induction Chemotherapy </A>: <CO> k, m </CO>

Section Name: Pathologic Features and Response Assessment
====================
Entities:-
Radiation Therapy : The use of ionizing radiation to treat cancer and other diseases.
Extranodal Extension : The spread of cancer cells beyond the lymph node capsule into the surrounding tissues.
Positive Surgical Margin : Cancer cells are found at the edge of the material removed during surgery, indicating that some cancer may have been left behind.
Systemic Therapy : Treatment using substances that travel through the bloodstream, reaching and affecting cells all over the body.

Relationships:-
1. Entity1: ""Extranodal extension"", Entity2: ""Adverse Pathologic Features"", Relationship: ""is a type of""
2. Entity1: ""Positive margin"", Entity2: ""Adverse Pathologic Features"", Relationship: ""is a type of""
3. Entity1: ""Systemic Therapy"", Entity2: ""Adverse Pathologic Features"", Relationship: ""considered in response to""
4. Entity1: ""Radiation Therapy"", Entity2: ""Adverse Pathologic Features"", Relationship: ""considered in response to""

Causalities:-
#### Pathologic Features
- **No Adverse Pathologic Features**: j
  - <A> Consider RT </A>: i
- **Adverse Pathologic Features**: j
  - <CO> Extranodal extension and/or positive margin </CO>: n
  - Other risk features
  - <A> Systemic therapy/RT </A>: i, k (category 1)
  - <A> Consider systemic therapy/RT </A>: i, k

#### Response Assessment
- **Response Assessment** (SUPRA-7)

Section Name: Imaging and Recurrent or Persistent Disease
====================
Entities:-
Tomography, X-Ray Computed : A method of body imaging in which a thin X-ray beam rotates around the patient.
Magnetic Resonance Imaging : Medical imaging technique used in radiology to form pictures of the anatomy and the physiological processes of the body.
Computed Tomography : Medical imaging technique used in radiology to obtain detailed internal images of the body.

Relationships:-
1. Entity1: ""CT"", Entity2: ""primary and neck"", Relationship: ""used for imaging""
2. Entity1: ""MRI"", Entity2: ""primary and neck"", Relationship: ""used for imaging""
3. Entity1: ""Post Systemic Therapy/RT"", Entity2: ""Recurrent or Persistent Disease"", Relationship: ""evaluation after treatment""
4. Entity1: ""RT Neck Evaluation"", Entity2: ""Recurrent or Persistent Disease"", Relationship: ""evaluation after treatment""

Causalities:-
<A> CT (with contrast) or MRI (with and without contrast) of primary and neck </A>

<CO> Recurrent or Persistent Disease </CO>

<CO> Post Systemic Therapy/RT or RT Neck Evaluation </CO>

Section Name: Conclusion
====================
Entities:-
Oncologists : Medical doctors who specialize in the diagnosis and treatment of cancer.
Supraglottic Larynx Cancer : A type of cancer that occurs in the supraglottic region of the larynx, which is the area above the vocal cords.
Clinical Staging : The process of determining the extent of cancer in the body, usually based on physical examination, imaging tests, and biopsies.
Treatment Strategies : Plans or methods developed to treat diseases, including cancer, which may involve surgery, chemotherapy, radiation therapy, or other modalities.
Follow-Up Evaluations : Medical assessments conducted after initial treatment to monitor a patient's progress and detect any recurrence of disease.
Clinical Efficacy : The ability of a treatment to produce the desired therapeutic effect in clinical settings.
Research : Systematic investigation and study conducted to establish facts and reach new conclusions.
Treatment Paradigms : Standard models or patterns of treatment used in medical practice, often based on clinical guidelines and research findings.

Relationships:-
1. Entity1: ""Oncologists"", Entity2: ""Supraglottic Larynx Cancer"", Relationship: ""use flowchart for decision-making""
2. Entity1: ""Clinical Staging"", Entity2: ""Treatment Strategies"", Relationship: ""part of management process""
3. Entity1: ""Treatment Strategies"", Entity2: ""Follow-Up Evaluations"", Relationship: ""part of management process""

Causalities:-
<A> The flowchart serves as a comprehensive guide for oncologists and healthcare providers </A>, <A> facilitating informed decision-making in the treatment of supraglottic larynx cancer </A>. <A> By visualizing the complex interactions between clinical staging, treatment strategies, and follow-up evaluations </A>, <E> it streamlines the management process </E>, <E> ensuring that patients receive appropriate care tailored to their specific needs </E>. <E> The detailed pathways not only enhance clinical efficacy </E> but also <E> underscore the importance of ongoing research and adaptation of treatment paradigms in oncology </E>.
--------------------------------------------------
Page Number: 93

Section Name: PRINCIPLES OF IMAGING
====================
Entities:-
Imaging, Diagnostic : The production of a visual representation of parts of the body, for the purpose of clinical analysis and medical intervention.
Head And Neck Neoplasms : Tumors or cancer of the head and neck region, including the nasal cavity, sinuses, lips, mouth, salivary glands, throat, or larynx.
Tomography, X-Ray Computed : An imaging procedure that uses special x-ray equipment to create detailed pictures, or scans, of areas inside the body.
Magnetic Resonance Imaging : A noninvasive diagnostic technique that uses magnetic fields and radio waves to produce a detailed image of the body's soft tissue and bones.
Contrast Media : Substances used to enhance the contrast of structures or fluids within the body in medical imaging.

Relationships:-
1. Entity1: ""Imaging, Diagnostic"", Entity2: ""Head and Neck Neoplasms"", Relationship: ""used for""
2. Entity1: ""Tomography, X-Ray Computed"", Entity2: ""Contrast Media"", Relationship: ""uses""
3. Entity1: ""Magnetic Resonance Imaging"", Entity2: ""Contrast Media"", Relationship: ""uses""

Causalities:-
<C> Imaging </C> plays an essential role in the clinical care of patients with head and neck cancer. <A> The proper selection and utilization of imaging studies </A> is critical in caring for patients with head and neck cancer. <A> CT is performed with contrast </A>, while <A> CT imaging of the chest can be performed with or without contrast </A>, <CO> as clinically indicated </CO>. <A> MRI is performed with and without contrast </A>, <CO> unless contraindicated </CO>.

Section Name: Initial Workup - Primary Site
====================
Entities:-
Tomography, X-Ray Computed : An imaging procedure that uses special x-ray equipment to create detailed pictures, or scans, of areas inside the body.
Magnetic Resonance Imaging : A noninvasive diagnostic technique that uses magnetic fields and radio waves to produce a detailed image of the body's soft tissue and bones.
Head And Neck Neoplasms : Tumors or cancer of the head and neck region, including the nasal cavity, sinuses, lips, mouth, salivary glands, throat, or larynx.
Neck Structure : The anatomical structure of the neck, which is the part of the body that connects the head to the torso.
Skull Base : The bottom part of the skull, which separates the brain from other facial structures.
Thoracic Inlet : The opening at the top of the thoracic cavity, through which pass the trachea, esophagus, and major blood vessels.

Relationships:-
1. Entity1: ""CT"", Entity2: ""MRI"", Relationship: ""complementary in imaging head and neck cancers""
2. Entity1: ""CT"", Entity2: ""Head and Neck Neoplasms"", Relationship: ""used to evaluate""
3. Entity1: ""MRI"", Entity2: ""Head and Neck Neoplasms"", Relationship: ""preferred for evaluating""
4. Entity1: ""Skull base"", Entity2: ""Thoracic inlet"", Relationship: ""imaging range for evaluation""

Causalities:-
<A>Imaging assessment of the primary site</A> can be performed with <A>CT of the soft tissues of the neck</A> or <A>MRI of the neck</A>. <C>CT is complementary to MRI for head and neck cancers</C>. <A>It is utilized to evaluate cortical bone erosion or periosteal invasion, cartilage invasion, and bony erosion or destruction</A>. <CO>in certain conditions, such as evaluating the extent of bone marrow invasion or in patients with extensive dental amalgam obscuring anatomy on CT, assessing skull base invasion and cranial nerve involvement, and differentiating tumor from obstructed sinuses</CO>, <A>MRI is preferred over CT</A>. <CO>when involved lymph nodes or upper mediastinal cancers are present</CO>, <A>Complete evaluation of primary and nodal disease requires imaging from the skull base to the thoracic inlet, extending to the carina</A>.

Section Name: PET/CT and Biopsy
====================
Entities:-
Positron Emission Tomography Computed Tomography : A medical imaging technique that combines PET and CT capabilities to provide detailed images of the body.
Examination Under Anesthesia : A procedure where a patient is examined while under anesthesia to allow for a more thorough examination.
Biopsy : A medical test involving the extraction of sample cells or tissues for examination to determine the presence or extent of a disease.
Tonsillectomy : A surgical procedure to remove the tonsils, often performed to treat recurrent tonsillitis or sleep apnea.
Fine Needle Aspiration : A type of biopsy procedure that uses a thin, hollow needle to extract cells from a lump or mass for examination.
Ultrasound : A medical imaging technique that uses high-frequency sound waves to visualize internal organs and structures.
Computed Tomography : A diagnostic imaging procedure that uses a combination of X-rays and computer technology to produce cross-sectional images of the body.

Relationships:-
1. Entity1: ""PET/CT"", Entity2: ""EUA"", Relationship: ""recommended before""
2. Entity1: ""Fine Needle Aspiration (FNA)"", Entity2: ""metastatic nodes"", Relationship: ""used for biopsy of""
3. Entity1: ""Image-guided needle biopsy"", Entity2: ""cystic neck nodes"", Relationship: ""recommended for initial diagnosis of""

Causalities:-
<CO> If imaging does not reveal an obvious primary cancer </CO>, <A> a PET/CT should be ordered before EUA, biopsies, and tonsillectomy </A>. <E> This helps identify potential primary sites </E> before any interventions take place. Additionally, <A> Fine Needle Aspiration (FNA) biopsy of metastatic nodes </A> <E> may provide pathologically informative results </E>. <CO> For initial diagnosis in cystic neck nodes </CO>, <A> image-guided needle biopsy (ultrasound or CT) </A> <E> may yield better results than FNA by palpation alone </E>.

Section Name: Postoperative Imaging Advice
====================
Entities:-
Panoramic Radiography : A type of dental x-ray that provides a wide view of the upper and lower jaws, teeth, temporomandibular joints, and sinuses.
Oral Cavity : The cavity of the mouth, including the lips, the lining inside the cheeks and lips, the front two-thirds of the tongue, the gums, the floor of the mouth under the tongue, the hard palate, and the small area of the gum behind the wisdom teeth.
Radiotherapy : The treatment of disease, especially cancer, using X-rays or similar forms of radiation.
Mandibulotomy : A surgical procedure involving the cutting of the mandible.
Mandibulectomy : A surgical procedure involving the removal of part or all of the mandible.
Oropharynx : The part of the throat at the back of the mouth behind the oral cavity.

Relationships:-
1. Entity1: ""panoramic dental x-ray"", Entity2: ""oral cavity cancers"", Relationship: ""recommended for""
2. Entity1: ""panoramic dental x-ray"", Entity2: ""postoperative radiotherapy"", Relationship: ""essential for pre-radiation evaluation""
3. Entity1: ""pre-radiation dental evaluation"", Entity2: ""dental procedures or extractions"", Relationship: ""determine necessity of""

Causalities:-
<A> A panoramic dental x-ray is recommended </A> <C> for oral cavity cancers requiring mandibulotomy and/or mandibulectomy </C>. <CO> When postoperative radiotherapy (RT) is anticipated for areas like the lip, oral cavity subsites, or oropharynx </CO>, <A> panoramic x-ray is essential for a comprehensive pre-radiation dental evaluation </A> <E> to assess the health of affected teeth and determine if pre-radiation dental procedures or extractions are necessary </E>.

Section Name: NCCN Guidelines Note
====================
Entities:-
Neoplasms : Neoplasms are abnormal growths of tissue, which can be cancerous or non-cancerous.
Malignant Neoplastic Disease : A disease characterized by uncontrolled, abnormal growth of cells that can invade or spread to other parts of the body.
Cancer : A group of diseases involving abnormal cell growth with the potential to invade or spread to other parts of the body.
Clinical Trials As Topic : Pre-planned studies of the safety, efficacy, or optimum dosage schedule of one or more diagnostic, therapeutic, or prophylactic drugs, devices, or techniques in humans selected according to predetermined criteria of eligibility and observed for predefined evidence of favorable and unfavorable effects.
Clinical Trial : A research study that prospectively assigns human participants or groups of humans to one or more health-related interventions to evaluate the effects on health outcomes.

Relationships:-
1. Entity1: ""NCCN"", Entity2: ""Clinical Trials"", Relationship: ""encourages participation in""
2. Entity1: ""NCCN"", Entity2: ""Cancer"", Relationship: ""recommends clinical trials for""

Causalities:-
<A> NCCN believes that the best management of any patient with cancer is through participation in clinical trials </A>, <A> which is especially encouraged </A>.
--------------------------------------------------
Page Number: 41

Section Name: Workup
====================
Entities:-
Laryngeal Neoplasms : Tumors or cancer of the larynx, which may affect the glottis, supraglottis, or subglottis.
History And Physical Examination : A comprehensive assessment of a patient's medical history and physical condition.
Tobacco Smoking : The act of smoking tobacco products, which is a risk factor for many diseases.
Alcohol Drinking : The consumption of beverages containing ethyl alcohol.
Smoking Cessation : The process of discontinuing tobacco smoking.
Biopsy : A medical test involving the extraction of sample cells or tissues for examination.
Laryngoscopy : A procedure to examine the larynx, often using a scope.
Computed Tomography (Ct) : A diagnostic imaging procedure that uses computer-processed combinations of many X-ray measurements taken from different angles to produce cross-sectional images of specific areas of a scanned object.
Magnetic Resonance Imaging (Mri) : A medical imaging technique used in radiology to form pictures of the anatomy and the physiological processes of the body.
Positron-Emission Tomography : A type of nuclear medicine imaging that measures metabolic activity of the cells of body tissues.
Pulmonary Function Test : Tests that measure how well the lungs are working.
Dental Examination : An evaluation of the teeth and gums to assess oral health.
Nutritional Support : Therapies to provide nutrition to patients who cannot obtain nutrition by mouth.
Speech Therapy : Therapy to improve speech and communication skills.
Swallowing Therapy : Therapy to help individuals with swallowing difficulties.
Multidisciplinary Care Team : A group of healthcare professionals from different specialties working together to manage patient care.

Relationships:-
1. Entity1: ""glottic larynx cancer"", Entity2: ""history and physical examination"", Relationship: ""initial diagnostic step""
2. Entity1: ""glottic larynx cancer"", Entity2: ""biopsy"", Relationship: ""required diagnostic procedure""
3. Entity1: ""glottic larynx cancer"", Entity2: ""direct laryngoscopy"", Relationship: ""recommended procedure""
4. Entity1: ""glottic larynx cancer"", Entity2: ""CT scans"", Relationship: ""imaging study""
5. Entity1: ""glottic larynx cancer"", Entity2: ""MRI"", Relationship: ""imaging study""
6. Entity1: ""glottic larynx cancer"", Entity2: ""multidisciplinary consultation"", Relationship: ""advised as clinically indicated""

Causalities:-
The workup section outlines the initial steps for diagnosing <C>glottic larynx cancer</C>. It includes <A>a comprehensive history and physical examination (H&P)</A>, which should document tobacco and alcohol use, and provide counseling for smoking cessation. <A>A biopsy of the primary site is required</A>, and <A>direct laryngoscopy under anesthesia is generally recommended</A>. <A>Imaging studies such as CT scans with contrast and possibly MRI are used to evaluate the larynx and neck</A>. Additional evaluations may include <A>chest CT, FDG-PET/CT, pulmonary function tests, dental evaluation, and nutrition, speech, and swallowing therapy</A>. <A>Multidisciplinary consultation is advised</A> <CO>as clinically indicated</CO>.

Section Name: Clinical Staging
====================
Entities:-
Cancer : A group of diseases involving abnormal cell growth with the potential to invade or spread to other parts of the body.
Carcinoma In Situ : A lesion with cytological characteristics of cancer but which has not invaded the basement membrane.
Biopsy : A medical test involving the extraction of sample cells or tissues for examination.
Laryngectomy : A surgical procedure to remove the larynx.

Relationships:-
1. Entity1: ""Clinical staging"", Entity2: ""Cancer"", Relationship: ""involves""
2. Entity1: ""Carcinoma in situ"", Entity2: ""Stages T1-T4"", Relationship: ""is a stage of""
3. Entity1: ""Biopsy"", Entity2: ""Cancer"", Relationship: ""used in staging""
4. Entity1: ""Larynx-preserving surgeries"", Entity2: ""Stages T1-T2"", Relationship: ""considered for""
5. Entity1: ""Total laryngectomy"", Entity2: ""Stages T3-T4"", Relationship: ""required for""

Causalities:-
<C> Clinical staging involves categorizing the cancer based on its aggressiveness </C>. It starts with carcinoma in situ, which is non-invasive, and progresses through stages T1-T4. <CO> Staging is based on H&P, biopsy, and imaging studies </CO>. <CO> For T1-T2 </CO>, <A> larynx-preserving surgeries are considered </A>, while <CO> more advanced stages like T3 or T4 </CO> <A> may require total laryngectomy </A>. <A> Additional evaluations such as videostrobe, audiogram, and fertility counseling may be considered </A>.

Section Name: Treatment
====================
Entities:-
Carcinoma In Situ : A lesion with cytological characteristics of cancer but which has not invaded the basement membrane.
Laryngectomy : A surgical procedure to remove the larynx.
Metastasis : The transfer of a disease from one organ or part to another not directly connected with it.
Clinical Trials As Topic : Works about research studies that evaluate the effectiveness and safety of medications or medical devices by monitoring their effects on large groups of people.

Relationships:-
1. Entity1: ""Carcinoma in situ"", Entity2: ""Larynx-preserving surgery"", Relationship: ""treated with""
2. Entity1: ""T1-T2 stages"", Entity2: ""Conservation surgery"", Relationship: ""treated with""
3. Entity1: ""T3 stages"", Entity2: ""Total laryngectomy"", Relationship: ""may require""
4. Entity1: ""T4a disease"", Entity2: ""Complex interventions"", Relationship: ""require""
5. Entity1: ""Guidelines"", Entity2: ""Multidisciplinary consultations"", Relationship: ""emphasize importance of""
6. Entity1: ""Guidelines"", Entity2: ""Clinical trials"", Relationship: ""consider as best option""

Causalities:-
<CO>Treatment recommendations vary by stage</CO>. <CO>Carcinoma in situ</CO> <A>may be treated with larynx-preserving surgery</A>. <CO>T1-T2 stages</CO> <A>may also be amenable to conservation surgery</A>. <CO>T3 stages</CO> <A>may require total laryngectomy</A>, <CO>especially if nodal involvement is present</CO>. <CO>T4a disease and unresectable or metastatic cases</CO> <A>require more complex interventions</A>. <A>The guidelines emphasize the importance of multidisciplinary consultations</A> and <A>consider clinical trials as the best management option</A>.

Section Name: Additional Notes
====================
Entities:-
Biopsy, Needle : A procedure to remove a small sample of tissue for examination under a microscope.
Image-Guided Biopsy : A biopsy procedure that uses imaging techniques to guide the needle to the precise location of the tissue to be sampled.
Biopsy : A medical test involving the extraction of sample cells or tissues for examination.
Diagnostic Techniques And Procedures : Methods and procedures for the diagnosis of disease or dysfunction.
Imaging : The process of producing images of the body for clinical purposes.
Dental Care : The total of dental diagnostic, preventive, and corrective procedures.
Nutritional Physiological Phenomena : The functions and properties of nutrients in living organisms.
Fertility : The capacity to conceive or induce conception.
Reproductive Health : A state of physical, mental, and social well-being in all matters relating to the reproductive system.
Lymphatic Metastasis : The transfer of a neoplasm from one organ or part of the body to another remote from the primary site.
Glottis : The part of the larynx consisting of the vocal cords and the opening between them.

Relationships:-
1. Entity1: ""image-guided needle biopsy"", Entity2: ""diagnostic yield"", Relationship: ""used for""
2. Entity1: ""nodal disease"", Entity2: ""glottic tumors"", Relationship: ""is rare in""

Causalities:-
<A> use of image-guided needle biopsy </A> for <E> better diagnostic yield </E>, principles of imaging, dental evaluation, and nutrition management. The guidelines also address fertility and reproductive considerations, and note that <CO> nodal disease in glottic tumors is rare </CO>.
--------------------------------------------------
Page Number: 44

Section Name: Flowchart Structure
====================
Entities:-
Neoplasm Staging : Methods used for staging neoplasms based on extent of tumor spread according to standardized criteria.
Laryngectomy : Surgical procedure to remove the larynx, often used to treat laryngeal cancer.
Chemotherapy, Adjuvant : Drug therapy given in addition to the primary treatment to enhance its effectiveness.
Radiotherapy : The use of radiation, usually high-energy X-rays, to damage cancer cells and treat cancer.
Tomography, X-Ray Computed : An imaging procedure that uses special x-ray equipment to create detailed pictures, or scans, of areas inside the body.
Magnetic Resonance Imaging : A noninvasive diagnostic technique that uses magnetic fields and radio waves to produce a detailed image of the body's soft tissue and bones.
Neoplasm Recurrence, Local : The return of a tumor at the original site after treatment.

Relationships:-
1. Entity1: ""Clinical Staging"", Entity2: ""T3 tumors"", Relationship: ""determines treatment approach""
2. Entity1: ""Adverse Pathologic Features"", Entity2: ""Systemic Therapy"", Relationship: ""directs to""
3. Entity1: ""Adverse Pathologic Features"", Entity2: ""Radiation Treatment"", Relationship: ""directs to""
4. Entity1: ""Induction Chemotherapy"", Entity2: ""Imaging (CT or MRI)"", Relationship: ""leads to""

Causalities:-
1. <A> The flow begins with the clinical staging of T3 tumors </A> <C> that require total laryngectomy (N2–3) </C>. <CO> This staging </CO> <E> is crucial for determining the appropriate therapeutic approach </E>.

2. The flowchart provides multiple pathways for treatment, indicating that <CO> patients </CO> <A> may undergo either ""Concurrent systemic therapy/RT"" or ""Surgery"" </A>. There is also an <A> option for ""Induction chemotherapy,"" leading to further imaging (CT or MRI) to assess the primary site and neck status </A>.

3. For <CO> patients who have surgery </CO>, the flowchart distinguishes between those with adverse pathologic features and those without. <CO> Patients with adverse features—such as extranodal extension or positive margins </CO>—are <A> directed toward systemic therapy or radiation treatment </A>, while those without may follow a different management path.

4. The flowchart concludes by <A> outlining follow-up procedures for recurrent or persistent disease </A>, suggesting additional assessments and treatments based on the risk features identified during earlier stages.

Section Name: Detailed Explanation
====================
Entities:-
Laryngeal Neoplasms : Tumors or cancer of the larynx, which may affect the glottis, supraglottis, or subglottis.
Adverse Pathological Feature : A pathological feature that indicates a worse prognosis or outcome.
Radiation Therapy : The use of high-energy radiation from x-rays, gamma rays, neutrons, protons, and other sources to kill cancer cells and shrink tumors.
Clinical Trials As Topic : Works about research studies that evaluate the effectiveness and safety of medications or medical devices by monitoring their effects on large groups of people.

Relationships:-
1. Entity1: ""Systemic therapy"", Entity2: ""Radiation"", Relationship: ""Concurrent treatment""
2. Entity1: ""Clinical trials"", Entity2: ""Personalized treatment plans"", Relationship: ""Development of""

Causalities:-
<A> The flowchart is designed to provide healthcare professionals with a systematic pathway for managing glottic larynx cancer </A>. Each step is meticulously organized to ensure that important factors are considered, such as <C> the presence of adverse pathological features </C>, which <E> strongly influence treatment decisions </E>.

<A> The emphasis on concurrent treatments, such as systemic therapy combined with radiation </A>, reflects current best practices in oncology, where multimodal approaches are often necessary to achieve better outcomes. <A> The inclusion of clinical trials </A> indicates an emphasis on maintaining up-to-date practices and personalized treatment plans as part of patient management strategies.

Furthermore, <A> the chart's organization into treatment and follow-up segments </A> allows for a straightforward interpretation, guiding oncologists through complex decisions in a logical manner. This can <E> improve consistency in care and enhance patient safety through meticulous monitoring and responses to treatment efficacy or disease progression </E>.

In summary, <E> this flowchart serves as an essential resource for oncologists, facilitating a better understanding of treatment protocols for glottic larynx cancer while promoting a patient-centered approach to oncological care </E>.

Section Name: NCCN Guidelines Version 4.2024
====================
Entities:-
Clinical Trials As Topic : Works about research studies that evaluate the effectiveness and safety of medications or medical devices by monitoring their effects on large groups of people.
Clinical Trial : A research study that prospectively assigns human participants or groups of humans to one or more health-related interventions to evaluate the effects on health outcomes.
Neoplasms : New abnormal growth of tissue that may be benign or malignant.
Malignant Neoplastic Disease : A disease in which abnormal cells divide uncontrollably and destroy body tissue.
Cancer : A group of diseases involving abnormal cell growth with the potential to invade or spread to other parts of the body.
National Comprehensive Cancer Network : An alliance of 31 cancer centers in the United States, dedicated to improving the quality, effectiveness, and efficiency of cancer care.

Relationships:-
1. Entity1: ""National Comprehensive Cancer Network"", Entity2: ""NCCN Guidelines"", Relationship: ""publishes""
2. Entity1: ""Clinical trial"", Entity2: ""Cancer"", Relationship: ""manages""

Causalities:-
<C> any patient with cancer </C> <E> the best management is in a clinical trial </E>. <A> Participation in clinical trials is especially encouraged </A>.

Section Name: Principles of Treatment
====================
Entities:-
Radiation Therapy : The use of high-energy radiation from x-rays, gamma rays, neutrons, protons, and other sources to kill cancer cells and shrink tumors.
Surgical Procedures, Operative : Operations carried out for the correction of deformities and defects, repair of injuries, and diagnosis and cure of certain diseases.
Extranodal Extension : The spread of cancer beyond the lymph node capsule into the surrounding tissues.
Positive Surgical Margins : Cancer cells are found at the edge of the material removed during surgery, indicating that some cancer may have been left behind.
Perineural Invasion : Cancer cells are found surrounding or tracking along a nerve within the perineural space.
Vascular Invasion : The presence of cancer cells within blood vessels.
Lymphatic Metastasis : The spread of cancer cells through the lymphatic system to distant sites.

Relationships:-
1. Entity1: ""Principles of Radiation Therapy"", Entity2: ""Extranodal Extension"", Relationship: ""management of""
2. Entity1: ""Principles of Surgery"", Entity2: ""Positive Surgical Margins"", Relationship: ""concerned with avoiding""
3. Entity1: ""Principles of Radiation Therapy"", Entity2: ""Perineural Invasion"", Relationship: ""consideration in treatment planning""

Causalities:-
<C> Extranodal extension </C> <C> Positive margins </C> <C> Close margins </C> <C> pT4 primary </C> <C> pN2 or pN3 nodal disease </C> <C> Perineural invasion </C> <C> Vascular invasion </C> <C> Lymphatic invasion </C> <C> Subglottic extension </C>

Section Name: Clinical Staging
====================
Entities:-
Adjuvant Chemotherapy : Chemotherapy given in addition to the primary treatment to enhance its effectiveness.
Adjuvant Therapy : A therapy given in addition to the primary or initial therapy to maximize its effectiveness.
Follow-Up Studies : Studies that continue to monitor patients after treatment to assess long-term outcomes.
Follow-Up Procedure : A procedure performed to monitor the progress of a patient after initial treatment.
Follow-Up : The act of monitoring a patient's health over time after treatment.
Neoplasm Recurrence, Local : The return of a tumor at the original site after treatment.
Recurrent Disease : A disease that has returned after a period of remission.

Relationships:-
1. Entity1: ""Adjuvant Treatment"", Entity2: ""Recurrent or Persistent Disease"", Relationship: ""prevention""
2. Entity1: ""Follow-up"", Entity2: ""Recurrent or Persistent Disease"", Relationship: ""monitoring""

Section Name: Treatment Options
====================
Entities:-
Laryngectomy : Surgical procedure to remove the larynx, often used to treat laryngeal cancer.
Total Laryngectomy : A surgical procedure to remove the entire larynx.
Chemotherapy, Adjuvant : Drug therapy given in addition to the primary treatment to enhance its effectiveness.
Induction Chemotherapy : Chemotherapy given as a first step to shrink a tumor before the main treatment.
Clinical Trials As Topic : Works about research studies that evaluate the effectiveness and safety of medications or medical devices by monitoring their effects on large groups of people.
Clinical Trial : A research study that prospectively assigns human participants or groups of humans to one or more health-related interventions to evaluate the effects on health outcomes.

Relationships:-
1. Entity1: ""T3 requiring total laryngectomy"", Entity2: ""Concurrent systemic therapy/RT"", Relationship: ""treatment option""
2. Entity1: ""T3 requiring total laryngectomy"", Entity2: ""Induction chemotherapy"", Relationship: ""treatment option""
3. Entity1: ""T3 requiring total laryngectomy"", Entity2: ""Clinical trials"", Relationship: ""research option""

Causalities:-
<CO> T3 requiring (amenable to) total laryngectomy (N2–3) </CO> <A> Concurrent systemic therapy/RT </A> <A> Surgery </A> <A> Induction chemotherapy </A> <A> Clinical trials </A>

Section Name: Surgical Considerations
====================
Entities:-
Laryngectomy : Surgical procedure to remove the larynx, often used to treat laryngeal cancer.
Thyroidectomy : Surgical removal of all or part of the thyroid gland.
Neck Dissection : Surgical procedure to remove lymph nodes and surrounding tissue in the neck.
Lymph Node Excision : Surgical removal of one or more lymph nodes.
Lymph Node Dissection : A surgical procedure to remove lymph nodes.
Lymphadenectomy : Surgical removal of one or more groups of lymph nodes.

Relationships:-
1. Entity1: ""Laryngectomy"", Entity2: ""Thyroidectomy"", Relationship: ""performed with""
2. Entity1: ""Neck Dissection"", Entity2: ""Lymph Node Excision"", Relationship: ""includes""
3. Entity1: ""Neck Dissection"", Entity2: ""Lymph Node Excision"", Relationship: ""includes specific types""

Causalities:-
<A> Laryngectomy with thyroidectomy as indicated, ipsilateral or bilateral neck dissection, and pretracheal and ipsilateral paratracheal lymph node dissection </A>

Section Name: Pathologic Features
====================
Entities:-
Extranodal Extension : The spread of cancer beyond the lymph node capsule into the surrounding tissues.
Positive Surgical Margins : Cancer cells are found at the edge of the material removed during surgery, indicating that some cancer may have been left behind.
Positive Margin : A surgical margin that contains residual tumor cells.

Relationships:-
1. Entity1: ""Adverse pathologic features"", Entity2: ""Extranodal extension"", Relationship: ""includes""
2. Entity1: ""Adverse pathologic features"", Entity2: ""Positive margin"", Relationship: ""includes""

Causalities:-
- **No adverse pathologic features**
- **Adverse pathologic features**
  - <C> Extranodal extension and/or positive margin </C>
  - Other risk features

Section Name: Systemic Therapy
====================
Entities:-
Antineoplastic Agents : Drugs used to treat cancer by inhibiting the growth of cancerous cells.
Systemic Therapy : A treatment using substances that travel through the bloodstream, reaching and affecting cells all over the body.
Radiotherapy : The use of radiation, usually high-energy X-rays, to damage cancer cells and treat cancer.
Radiation Therapy : The use of high-energy radiation from x-rays, gamma rays, neutrons, protons, and other sources to kill cancer cells and shrink tumors.

Relationships:-
1. Entity1: ""Systemic therapy"", Entity2: ""RT"", Relationship: ""Consideration""

Causalities:-
<A> Systemic therapy/RT (category 1) </A>
<A> RT </A>
<A> Consider systemic therapy/RT </A>

Section Name: Imaging
====================
Entities:-
Tomography, X-Ray Computed : An imaging procedure that uses special x-ray equipment to create detailed pictures, or scans, of areas inside the body.
Magnetic Resonance Imaging : A noninvasive diagnostic technique that uses magnetic fields and radio waves to produce a detailed image of the body's soft tissue and bones.
Neck : Part of the body, on many terrestrial or secondarily aquatic vertebrates, that distinguishes the head from the torso or trunk.
Computed Tomography : A diagnostic imaging procedure that uses a combination of X-rays and computer technology to produce cross-sectional images (often called slices), both horizontally and vertically, of the body.
Neck Structure : The anatomical structure that connects the head to the torso.

Relationships:-
1. Entity1: ""CT"", Entity2: ""Neck"", Relationship: ""imaging of""
2. Entity1: ""MRI"", Entity2: ""Neck"", Relationship: ""imaging of""

Causalities:-
<A> CT (with contrast) or MRI (with and without contrast) of primary and neck </A>

Section Name: Post-Treatment Evaluation
====================
Entities:-
Radiotherapy : The use of radiation, usually high-energy X-rays, to damage cancer cells and treat cancer.
Pn1 Category : A pathological classification indicating regional lymph node metastasis in cancer staging.
Radiation Therapy : The use of high-energy radiation from x-rays, gamma rays, neutrons, protons, and other sources to kill cancer cells and shrink tumors.

Relationships:-
1. Entity1: ""Post Systemic Therapy/RT or RT Neck Evaluation"", Entity2: ""pN1"", Relationship: ""evaluation of cancer staging""
2. Entity1: ""pN1"", Entity2: ""Consider RT"", Relationship: ""treatment recommendation""

Causalities:-
<CO> pN1 without other risk features </CO> <A> Consider RT </A>

Section Name: Additional Notes
====================
Entities:-
Antineoplastic Combined Chemotherapy Protocols : Protocols for the administration of more than one antineoplastic agent in combination to treat malignant neoplasms.
Cisplatin : A platinum-containing antineoplastic agent used in the treatment of various cancers.

Relationships:-
1. Entity1: ""Systemic Therapy"", Entity2: ""Non-Nasopharyngeal Cancers"", Relationship: ""used for""
2. Entity1: ""Cisplatin"", Entity2: ""Systemic Therapy"", Relationship: ""preferred agent in""
3. Entity1: ""Induction Chemotherapy"", Entity2: ""Systemic Therapy"", Relationship: ""discussed in context of""

Causalities:-
- **Principles of Systemic Therapy for Non-Nasopharyngeal Cancers (SYST-A)**
- **<CO> When using concurrent systemic therapy/RT </CO>, <A> the preferred agent is cisplatin (category 1) </A>. See Principles of Systemic Therapy for Non-Nasopharyngeal Cancers (SYST-A).**
- **<A> See Discussion on induction chemotherapy. </A>**


Among these two options which one is the most likely true:

(A) `Location_of_Lymph_Nodes_3` increases risk `MRT_9`
(B) `MRT_9` `increases risk `Location_of_Lymph_Nodes_3`

The answer is: ...

1. State the evidences in detail of the validity of option (A) or (B) by cross referencing
NCCN Clinical Practitioner’s Guidelines for Head and Neck Cancer.
2. If the evidences are obtained from `INFORMATION FROM KNOWLEDGE BASE`,
mention their corresponding Page Numbers, Section Name, entities, relationships and causalities.

DESIRED OUTPUT FORMAT:
<thinking>
...
</thinking>
<answer>
{
   ""thinking"": [""..."", ...],
   ""evidences"": [""..."", ...],
   ""answer"": ...
}
</answer>

Before providing the answer in <answer> tags, think step by step in detail in <thinking> tags and analyze every part.
Output inside <answer> tag in JSON format. Only output valid JSON.
DO NOT HALLUCINATE. DO NOT MAKE UP FACTUAL INFORMATION.
","1. The edge '(Location_of_Lymph_Nodes_3) causes (MRT_9)' is not valid as a causal relationship. The 'Location_of_Lymph_Nodes_3' node represents the presence or absence of lymph nodes, which is a condition that can be observed by an MRI scan, represented by the 'MRT_9' node. The MRI result ('MRT_9') is an observation of the state of the lymph nodes ('Location_of_Lymph_Nodes_3'), not a result caused by them. Therefore, the relationship is observational rather than causal.
2. The edge '(MRT_9) causes (Location_of_Lymph_Nodes_3)' is not valid because an MRI examination result does not cause the presence or absence of lymph nodes. MRT_9 represents the findings from an MRI scan, which can detect the presence of lymph nodes but does not influence their presence or absence. Location_of_Lymph_Nodes_3 represents whether lymph nodes are present in a specific location, which is a condition observed by the MRI, not caused by it. The relationship is observational, where the MRI detects the state of lymph nodes, rather than causal.
3. In the context of NCCN Clinical Practitioner's Guidelines for Head and Neck Cancer, imaging techniques like MRI are used to observe and diagnose conditions such as the presence of lymph nodes, but they do not influence the presence or absence of these nodes. This aligns with the explanation that the relationship between the nodes is observational rather than causal.
4. The causal direction for both edges is marked as 'Unknown', indicating that there is no established causal relationship between the presence of lymph nodes and the MRI results. This further supports the conclusion that neither option (A) nor (B) is valid as a causal relationship.
","1. Page Number: 93, Section Name: Principles of Imaging, Entities: Imaging, Diagnostic, Head And Neck Neoplasms, Tomography, X-Ray Computed, Magnetic Resonance Imaging, Contrast Media, Relationships: Imaging, Diagnostic used for Head and Neck Neoplasms, Tomography, X-Ray Computed uses Contrast Media, Magnetic Resonance Imaging uses Contrast Media, Causalities: Imaging plays an essential role in the clinical care of patients with head and neck cancer. The proper selection and utilization of imaging studies is critical in caring for patients with head and neck cancer. CT is performed with contrast, while CT imaging of the chest can be performed with or without contrast, as clinically indicated. MRI is performed with and without contrast, unless contraindicated.
",A,"{'A': 88.08, 'B': 11.92}",no,B,"1. The AI assistant's reasoning is based on the explanation provided for the edges between 'Location_of_Lymph_Nodes_3' and 'MRT_9'. It correctly identifies that the relationship is observational rather than causal, as the MRI (MRT_9) is used to detect the presence of lymph nodes (Location_of_Lymph_Nodes_3) but does not influence their presence or absence.
2. The assistant references the NCCN Clinical Practitioner's Guidelines for Head and Neck Cancer, which supports the notion that imaging techniques like MRI are used for observation and diagnosis rather than causing changes in the state of lymph nodes.
3. The causal direction for both edges is marked as 'Unknown', which aligns with the assistant's conclusion that neither option (A) nor (B) represents a valid causal relationship.
4. The assistant's final answer, option (A), is inconsistent with its reasoning. The reasoning clearly states that neither option (A) nor (B) is valid as a causal relationship, yet the answer provided is option (A). This indicates a discrepancy between the reasoning and the final answer.
"
4,gpt-4o,"Location_of_Lymph_Nodes_3,PET_10","""{'NODE1': {'id': 'Location_of_Lymph_Nodes_3', 'label': 'Location of Lymph Nodes', 'description': 'This node represents the presence or absence of lymph nodes in a specific location, which is crucial for cancer diagnosis and staging. The detection of lymph nodes can indicate the spread of cancer and affect treatment decisions.', 'type': 'Patient Situation', 'observability': 'Unobserved', 'states': [{'state_name': 'present', 'state_description': 'Lymph nodes are detected in the specified location, which may indicate the spread of cancer and is important for staging and treatment planning.'}, {'state_name': 'absent', 'state_description': 'Lymph nodes are not detected in the specified location, which may suggest no spread of cancer to this area and is important for staging and treatment planning.'}]}, 'NODE2': {'id': 'PET_10', 'label': 'Positron Emission Tomography Examination Result', 'description': 'This node represents the result of a Positron Emission Tomography (PET) scan, which is an imaging test that helps reveal how your tissues and organs are functioning. A PET scan uses a radioactive drug (tracer) to show this activity. This node indicates whether the PET scan detected any abnormal metabolic activity, which could suggest the presence of disease such as cancer.', 'type': 'Examination Result', 'observability': 'Observed', 'states': [{'state_name': 'present', 'state_description': \""The 'present' state indicates that the PET scan detected abnormal metabolic activity, suggesting the presence of disease such as cancer.\""}, {'state_name': 'absent', 'state_description': \""The 'absent' state indicates that the PET scan did not detect any abnormal metabolic activity, suggesting the absence of disease.\""}]}, 'EDGE1': {'edges_ids': ['Location_of_Lymph_Nodes_3', 'PET_10'], 'edge': '(Location_of_Lymph_Nodes_3) causes (PET_10)', 'explanation': ['The edge represents the causal relationship between the presence of lymph nodes in a specific location and the result of a PET scan.', 'The presence of lymph nodes in a specific location can indicate the spread of cancer, which may be detected as abnormal metabolic activity on a PET scan.', 'Therefore, the presence of lymph nodes could cause a positive PET scan result, indicating a valid causal relationship.'], 'causal_direction': 'positive', 'causal_factor': {'necessary': False, 'sufficient': True}, 'causal_distance': 'Proximal'}, 'EDGE2': {'edges_ids': ['PET_10', 'Location_of_Lymph_Nodes_3'], 'edge': '(PET_10) causes (Location_of_Lymph_Nodes_3)', 'explanation': ['The edge `(PET_10) causes (Location_of_Lymph_Nodes_3)` is not valid because the PET scan result does not directly cause the presence of lymph nodes in a specific location.', 'Both the PET scan result and the presence of lymph nodes are indicators of the underlying disease process, such as cancer, but one does not cause the other.', 'The PET scan result indicates abnormal metabolic activity, which suggests the presence of disease, but it does not directly influence the presence of lymph nodes.'], 'causal_direction': 'Unknown', 'causal_factor': {'necessary': False, 'sufficient': False}, 'causal_distance': 'Distal'}, 'ENTITIES_MATCHING_PAGES_INFO': {'92': {'matching_entities': [{'POSITRON EMISSION TOMOGRAPHY (PROCEDURE)': 0.9864658}, {'POSITRON-EMISSION TOMOGRAPHY': 0.9655257}, {'POSITRON EMISSION TOMOGRAPHY': 0.9552841}, {'MAGNETIC RESONANCE IMAGING': 0.9216922}], 'count': 4}, '94': {'matching_entities': [{'POSITRON-EMISSION TOMOGRAPHY': 0.9655257}, {'POSITRON EMISSION TOMOGRAPHY': 0.9552841}, {'POSITRON EMISSION TOMOGRAPHY COMPUTED TOMOGRAPHY': 0.94104874}, {'MAGNETIC RESONANCE IMAGING': 0.9216922}], 'count': 4}, '95': {'matching_entities': [{'POSITRON-EMISSION TOMOGRAPHY': 0.9655257}, {'POSITRON EMISSION TOMOGRAPHY': 0.9552841}, {'MAGNETIC RESONANCE IMAGING': 0.9216922}], 'count': 3}, '96': {'matching_entities': [{'POSITRON-EMISSION TOMOGRAPHY': 0.9655257}, {'POSITRON EMISSION TOMOGRAPHY': 0.9552841}, {'MAGNETIC RESONANCE IMAGING': 0.9216922}], 'count': 3}, '129': {'matching_entities': [{'LYMPH NODE STRUCTURE': 0.99134904}, {'LYMPH NODE': 0.98570025}, {'LYMPH NODES': 0.97445965}], 'count': 3}}, 'GUIDELINE_PAGES_INFO': '--------------------------------------------------\\nPage Number: 92\\n\\nSection Name: NCCN Guidelines Overview\\n====================\\nEntities:-\\nHead And Neck Neoplasms : Cancers that arise in the head or neck region, including the nasal cavity, sinuses, lips, mouth, salivary glands, throat, or larynx.\\nMalignant Neoplasm Of Head And Neck : A malignant tumor located in the head and neck region.\\nHead And Neck Cancer : A group of cancers that originate in the head and neck region.\\nAntineoplastic Agents : Drugs used to treat cancer by inhibiting the growth of cancerous cells.\\nSystemic Therapy : Treatment using substances that travel through the bloodstream, reaching and affecting cells all over the body.\\nRadiotherapy : The treatment of disease, especially cancer, using X-rays or similar forms of radiation.\\nRadiation Therapy : The treatment of disease, especially cancer, using X-rays or similar forms of radiation.\\n\\nRelationships:-\\n1. Entity1: \""Head and neck cancers\"", Entity2: \""Systemic therapy\"", Relationship: \""follow-up recommendations after\""\\n2. Entity1: \""Head and neck cancers\"", Entity2: \""Radiation therapy\"", Relationship: \""follow-up recommendations after\""\\n\\nCausalities:-\\nThe image presents a flowchart from the National Comprehensive Cancer Network (NCCN) Guidelines Version 2.2024, especially focusing on <A> follow-up recommendations </A> for <CO> patients with head and neck cancers after systemic therapy or radiation therapy (RT) </CO>. All recommendations are categorized as level A unless stated otherwise, highlighting the importance of clinical trials in cancer management.\\n\\nSection Name: Imaging and Assessment Protocols\\n====================\\nEntities:-\\nSystemic Therapy : Treatment using substances that travel through the bloodstream, reaching and affecting cells all over the body.\\nRadiotherapy : The treatment of disease, especially cancer, using X-rays or similar forms of radiation.\\nClinical Assessment : A systematic evaluation of a patient\\'s health status, often involving a physical examination and medical history.\\nPositron-Emission Tomography : An imaging technique using a radioactive substance called a tracer to look for disease in the body.\\nComputed Tomography : A medical imaging technique used in radiology to obtain detailed internal images of the body.\\nMagnetic Resonance Imaging : A medical imaging technique used in radiology to form pictures of the anatomy and the physiological processes of the body.\\nNeck Dissection : A surgical procedure for control of neck lymph node metastasis.\\nDisease : A disorder of structure or function in a human, animal, or plant, especially one that produces specific symptoms.\\nMetastasis : The spread of a cancer or other disease from one organ or part to another not directly connected with it.\\nResidual Neoplasm : Remaining cancer cells after treatment.\\n\\nRelationships:-\\n1. Entity1: \""Systemic Therapy\"", Entity2: \""Clinical Assessment\"", Relationship: \""occurs before\""\\n2. Entity1: \""FDG-PET/CT Scan\"", Entity2: \""Distant Metastases\"", Relationship: \""assesses\""\\n3. Entity1: \""FDG-PET/CT Scan\"", Entity2: \""Observation\"", Relationship: \""leads to if negative\""\\n4. Entity1: \""FDG-PET/CT Scan\"", Entity2: \""CT Scan\"", Relationship: \""leads to if strongly positive\""\\n5. Entity1: \""CT Scan\"", Entity2: \""Neck Dissection\"", Relationship: \""leads to if positive\""\\n\\nCausalities:-\\n<CO> After systemic therapy or RT </CO>, <A> a clinical assessment should occur 4 to 8 weeks later </A>. <CO> If there is a response </CO>, <A> it is necessary to assess the extent of disease or distant metastases, preferably through a FDG-PET/CT scan at a minimum of 12 weeks post-treatment </A>. <CO> If the FDG-PET/CT results are negative </CO>, <A> the patient may continue with monitoring through observation </A>. <CO> In cases where the results are equivocal </CO>, <A> observation or repeat FDG-PET/CT within 3 to 6 months is prescribed </A>.\\n\\n<CO> In cases where the FDG-PET/CT results are strongly positive </CO>, <A> further imaging via CT scan with contrast of the primary site and neck, or MRI with and without contrast, becomes necessary </A>. <CO> If these imaging results confirm positive findings </CO>, <A> neck dissection may be considered, depending on the evidence of residual or persistent disease </A>. <CO> If the imaging findings are negative </CO>, <A> the patient might continue in observation </A>.\\n\\nSection Name: Outcomes Based on Disease Resectability\\n====================\\nEntities:-\\nDisease : A disorder of structure or function in a human, animal, or plant, especially one that produces specific symptoms.\\nResectable : Capable of being surgically removed.\\nNeck Dissection : A surgical procedure for control of neck lymph node metastasis.\\n\\nRelationships:-\\n1. Entity1: \""Disease\"", Entity2: \""Resectable\"", Relationship: \""Classification\""\\n2. Entity1: \""Unresectable\"", Entity2: \""Treatment plans (ADV-3)\"", Relationship: \""Treatment recommendation\""\\n3. Entity1: \""Resectable\"", Entity2: \""Resection and/or Neck dissection\"", Relationship: \""Surgical procedure\""\\n\\nCausalities:-\\n<CO> If there is confirmed residual or persistent disease </CO>, the options split into two pathways: \\'Unresectable\\' or \\'Resectable.\\' <CO> If the disease is classified as unresectable </CO>, <A> advances in treatment plans (labeled ADV-3) are called for </A>. Conversely, <CO> if it is deemed resectable </CO>, <A> a resection of the primary and/or neck dissection may occur </A>, <CO> contingent upon the disease status </CO>.\\n\\nSection Name: Important Notes\\n====================\\nEntities:-\\nClinical Trials As Topic : Works about research studies that evaluate the effectiveness and safety of medications or medical devices by monitoring their effects on large groups of people.\\nClinical Trial : A type of research that studies new tests and treatments and evaluates their effects on human health outcomes.\\nPositron-Emission Tomography : An imaging technique using a radioactive substance called a tracer to look for disease in the body.\\nPositron Emission Tomography (Procedure) : A diagnostic imaging procedure that uses a radioactive tracer to visualize and measure changes in metabolic processes.\\nPositron Emission Tomography : A nuclear medicine functional imaging technique used to observe metabolic processes in the body.\\nNeoplasms : New abnormal growth of tissue in animals or plants; a tumor.\\nMalignant Neoplasm : A cancerous growth that has the potential to spread to other parts of the body.\\nCancer : A group of diseases involving abnormal cell growth with the potential to invade or spread to other parts of the body.\\n\\nRelationships:-\\n1. Entity1: \""NCCN\"", Entity2: \""Clinical trials\"", Relationship: \""emphasizes participation in\""\\n2. Entity1: \""FDG-PET/CT\"", Entity2: \""Persistent cancer\"", Relationship: \""used to detect\""\\n3. Entity1: \""FDG-PET/CT\"", Entity2: \""PET negative\"", Relationship: \""interpretation of results\""\\n4. Entity1: \""FDG-PET/CT\"", Entity2: \""PET positive\"", Relationship: \""interpretation of results\""\\n\\nCausalities:-\\n<A> NCCN emphasizes that the best management for any cancer patient is participation in clinical trials </A>, especially encouraged for all patients. Additional notes clarify that <CO> if the FDG-PET/CT is negative for persistent cancer </CO>, <A> further cross-sectional imaging is optional </A>. The interpretations define <CO> PET negative as no or low-grade uptake not suspicious for disease </CO>, while <CO> PET positive implies suspicion for disease </CO>.\\n--------------------------------------------------\\nPage Number: 94\\n\\nSection Name: Head and Neck Cancers - Principles of Imaging\\n====================\\nEntities:-\\nPositron Emission Tomography Computed Tomography : A medical imaging technique combining PET and CT capabilities to provide detailed information about the body\\'s function and structure.\\nPositron Emission Tomography : A nuclear medicine functional imaging technique that is used to observe metabolic processes in the body.\\nComputed Tomography : A diagnostic imaging procedure that uses a combination of X-rays and computer technology to produce cross-sectional images of the body.\\nHead And Neck Neoplasms : Cancers that arise in the head or neck region, including the nasal cavity, sinuses, lips, mouth, salivary glands, throat, or larynx.\\n\\nRelationships:-\\n1. Entity1: \""PET/CT\"", Entity2: \""PET scan\"", Relationship: \""preferred over\""\\n2. Entity1: \""PET-CT\"", Entity2: \""head neck cancers\"", Relationship: \""used in study of\""\\n\\nCausalities:-\\n<A> PET/CT is preferred over PET scan alone (i.e., without superimposed CT scan) </A>. <C> PET/CT provides more accurate anatomical localization of abnormalities </C> <E> more accurate anatomical localization of abnormalities </E>.\\n\\nSection Name: Initial Workup - Nodal Metastases\\n====================\\nEntities:-\\nLymphatic Metastasis : The transfer of a neoplasm from one organ or part of the body to another remote from the primary site via the lymphatic system.\\nTomography, X-Ray Computed : A method of body imaging in which a thin X-ray beam rotates around the patient, producing signals that are processed by the machine\\'s computer to generate cross-sectional images.\\nMagnetic Resonance Imaging : A non-invasive imaging technique that uses magnetic fields and radio waves to create detailed images of the organs and tissues within the body.\\nPositron-Emission Tomography : An imaging technique that uses radioactive substances to visualize and measure changes in metabolic processes, and in other physiological activities including blood flow, regional chemical composition, and absorption.\\nLymph Node Metastasis : The spread of cancer cells to lymph nodes, which are part of the lymphatic system.\\nCt Of Neck : A computed tomography scan of the neck region.\\nMri Of Neck : A magnetic resonance imaging scan of the neck region.\\nFdg-Pet Scan : A type of positron emission tomography using fluorodeoxyglucose to assess metabolic activity.\\nComputed Tomography : A diagnostic imaging procedure that uses a combination of X-rays and computer technology to produce cross-sectional images of the body.\\nPositron Emission Tomography : A nuclear medicine functional imaging technique that is used to observe metabolic processes in the body.\\n\\nRelationships:-\\n1. Entity1: \""CT\"", Entity2: \""lymph node metastases\"", Relationship: \""used to evaluate\""\\n2. Entity1: \""MRI\"", Entity2: \""lymph node metastases\"", Relationship: \""used to evaluate\""\\n3. Entity1: \""FDG-PET/CT\"", Entity2: \""lymph node metastases\"", Relationship: \""used for detection\""\\n4. Entity1: \""FDG-PET/CT\"", Entity2: \""surgical primary approach\"", Relationship: \""used to determine\""\\n5. Entity1: \""FDG-PET/CT\"", Entity2: \""definitive RT approach\"", Relationship: \""used to identify\""\\n\\nCausalities:-\\n<A> Evaluation of lymph node metastases should be conducted with CT or MRI of the neck </A>, using whichever imaging study is suitable for primary site evaluation (IMG-A, 1 of 4).\\n<CO> For patients with multistation or lower neck nodal involvement or high-grade tumor histology </CO>, <A> consider CT of the chest to assess for mediastinal lymph node metastases or FDG-PET/CT </A>, <C> which is associated with higher sensitivity for both nodal and distant metastases </C>.\\n<CO> For patients who are under consideration for a surgical primary approach </CO>, <A> the higher sensitivity of FDG-PET/CT is warranted for tumors approaching the midline, to determine the surgical approach to the contralateral neck </A>. <CO> Similarly, patients who are scheduled for a definitive RT approach </CO> <A> may benefit from the higher sensitivity of FDG-PET/CT for identifying involved lymph nodes </A>.\\n\\nSection Name: Initial Workup - Distant Metastases\\n====================\\nEntities:-\\nPositron-Emission Tomography : An imaging technique that uses radioactive substances to visualize and measure changes in metabolic processes, and in other physiological activities including blood flow, regional chemical composition, and absorption.\\nMagnetic Resonance Imaging : A non-invasive imaging technique that uses magnetic fields and radio waves to create detailed images of the organs and tissues within the body.\\nTomography, X-Ray Computed : A method of body imaging in which a thin X-ray beam rotates around the patient, producing signals that are processed by the machine\\'s computer to generate cross-sectional images.\\nNeoplasm Metastasis : The transfer of a neoplasm from one organ or part of the body to another remote from the primary site.\\nLung Neoplasms : Tumors or cancer of the lung.\\nSmoking : The inhalation of the smoke of burning tobacco encased in cigarettes, pipes, and cigars.\\n\\nRelationships:-\\n1. Entity1: \""FDG-PET/CT\"", Entity2: \""Distant Metastases\"", Relationship: \""used to evaluate\""\\n2. Entity1: \""Contrast-enhanced brain MRI\"", Entity2: \""Brain Metastasis\"", Relationship: \""recommended for evaluation\""\\n3. Entity1: \""CT of the chest\"", Entity2: \""Pulmonary Metastases\"", Relationship: \""performed to assess\""\\n4. Entity1: \""Non-contrast CT of the chest\"", Entity2: \""Lung Parenchymal Metastases\"", Relationship: \""used to screen\""\\n5. Entity1: \""Annual CT screening\"", Entity2: \""Lung Metastasis\"", Relationship: \""considered for high risk\""\\n6. Entity1: \""Directed CT or MRI\"", Entity2: \""Distant Disease\"", Relationship: \""used for assessment\""\\n7. Entity1: \""FDG-PET/CT\"", Entity2: \""Recurrent Disease\"", Relationship: \""used for staging\""\\n\\nCausalities:-\\n<C> Patients with locoregionally advanced cancer (e.g., T3\u2013T4 primary or \u2265N1 nodal staging) </C>, <A> FDG-PET/CT is preferred to evaluate for distant disease and thoracic metastases </A>. <CO> For cancers where brain metastasis is a concern, such as mucosal melanoma or high-grade neuroendocrine carcinomas or adenocarcinomas </CO>, <A> contrast-enhanced brain MRI should be additionally obtained </A>.\\n<CO> If FDG-PET/CT is not performed </CO>, <A> CT of the chest should be performed to assess for presence of pulmonary metastases as well as mediastinal lymph node involvement </A>.\\n<CO> Non-contrast CT of the chest can be sufficient to screen for lung parenchymal metastases </CO> but <CO> is not adequate for assessment of mediastinal adenopathy </CO>. <CO> This is an appropriate lung cancer screening intervention for patients with a history of smoking </CO>.\\n<CO> Following primary definitive treatment (surgery, RT, or systemic therapy/RT) </CO> the role of annual CT screening for lung metastasis is controversial. <E> While this approach does detect early metastasis </E>, <CO> further study is needed to determine the extent of the positive effect and/or cost-effectiveness of this approach in specific subpopulations and timepoints post-treatment </CO>. <CO> For patients with a substantial smoking history or who are at high risk for lung metastases </CO>, <A> annual chest CT can be considered </A>.\\n<CO> If clinical concern for metastatic disease is confined to a specific anatomical area </CO>, <A> the assessment of distant disease can be performed with directed CT or MRI examination </A>.\\n<CO> FDG-PET/CT may complement or replace other imaging modalities when staging recurrent disease before any therapy for relapsed/refractory disease </CO> <A> in order to explore distant disease or second primaries that may significantly impact choice of therapy </A>.\\n--------------------------------------------------\\nPage Number: 95\\n\\nSection Name: Head and Neck Cancers\\n====================\\nEntities:-\\nHead And Neck Neoplasms : Tumors or cancers located in the head or neck region, including the nasal cavity, sinuses, lips, mouth, salivary glands, throat, or larynx.\\nMalignant Neoplasm Of Head And Neck : A malignant tumor located in the head and neck region.\\nHead And Neck Cancer : A group of cancers that originate in the head and neck region.\\nClinical Trials As Topic : Pre-planned studies of the safety, efficacy, or optimum dosage schedule of one or more diagnostic, therapeutic, or prophylactic drugs, devices, or techniques in humans selected according to predetermined criteria of eligibility and observed for predefined evidence of favorable and unfavorable effects.\\nClinical Trial : A type of research that studies new tests and treatments and evaluates their effects on human health outcomes.\\n\\nRelationships:-\\n1. Entity1: \""NCCN Guidelines\"", Entity2: \""Head and Neck Cancers\"", Relationship: \""provides recommendations for\""\\n2. Entity1: \""Clinical Trials\"", Entity2: \""Head and Neck Cancers\"", Relationship: \""are encouraged for\""\\n\\nCausalities:-\\n<C> NCCN believes that the best management of any patient with cancer is in a clinical trial </C>. <A> Participation in clinical trials is especially encouraged </A>.\\n\\nSection Name: Locoregionally Advanced Disease: <6 Months Post-Treatment (Short-Term)\\n====================\\nEntities:-\\nNeoplasm Recurrence, Local : The return of a tumor at the original site after treatment.\\nAdjuvant Chemotherapy : Chemotherapy given in addition to the primary treatment to enhance its effectiveness.\\nTomography, X-Ray Computed : A method of body imaging in which a thin X-ray beam rotates around the patient.\\nMagnetic Resonance Imaging : A noninvasive diagnostic technique that produces computerized images of internal body tissues.\\nPositron-Emission Tomography : An imaging technique using radioactive substances to visualize and measure metabolic processes in the body.\\nRadiotherapy : The use of ionizing radiation to treat cancer.\\nCarcinoma, Squamous Cell : A type of cancer that begins in the squamous cells.\\nChemotherapy, Adjuvant : Treatment given in addition to the primary therapy to maximize its effectiveness.\\n\\nRelationships:-\\n1. Entity1: \""FDG-PET/CT\"", Entity2: \""locoregionally advanced cancer\"", Relationship: \""used for assessment of treatment response\""\\n2. Entity1: \""CT and MRI\"", Entity2: \""locoregionally advanced disease\"", Relationship: \""used to establish baseline\""\\n3. Entity1: \""Adjuvant postoperative therapy\"", Entity2: \""high risk of early recurrence\"", Relationship: \""recommended for\""\\n\\nCausalities:-\\n- Following surgery in <C> patients with locoregionally advanced cancer </C>, <A> short-term post-treatment imaging is recommended </A> <CO> for those who show signs of early recurrence or who are at high risk of early recurrence prior to starting adjuvant postoperative therapy </CO>.\\n- <A> Obtain CT and/or MRI within 3\u20134 months after surgical treatment </A> <CO> for patients with locoregionally advanced disease or with altered anatomy causing challenging physical exam assessment </CO>, <E> in order to establish a new baseline for future comparisons </E>.\\n- <CO> In cases of concern for incomplete response </CO>, <A> a CT or MRI scan may be obtained much earlier, such as 4\u20138 weeks post-treatment or even immediately based on the specific clinical situation </A>. <A> US of the neck for targeted sampling of any suspicious tissues may also be helpful </A>, <CO> but results can be variably interpreted depending on the specific clinical situation </CO>.\\n- <A> FDG-PET/CT should be performed within 3\u20136 months of definitive radiation or systemic therapy/RT </A> <E> for assessment of treatment response and to identify any residual tumor </E>.\\n  - <CO> Early FDG-PET/CT scans before 12 weeks are associated with significant false-positive rates </CO> and <A> should be avoided in the absence of signs of recurrence or progression </A>.\\n  - <E> The optimal timing of PET scans after radiation treatment appears to be at the 3- to 6-month window </E>. <E> A negative PET at this time point predicts improved overall survival at 2 years </E>.\\n- <CO> In patients receiving definitive RT-based treatment of mucosal squamous cell carcinoma with AJCC 7th edition N2\u2013N3 nodal disease </CO>, <E> FDG-PET/CT surveillance approach led to fewer neck dissections and considerable cost savings compared to a routine approach of planned post-treatment neck dissection </E>. The majority of cases studied were p16-positive oropharyngeal cancers.\\n- <CO> In the special case of patients who are treated initially with induction chemotherapy prior to the initiation of definitive therapy </CO>, <A> either CT or MRI has typically been obtained after 2\u20133 cycles of induction </A>. <CO> Chest CT and/or FDG-PET/CT (with diagnostic-quality imaging of the regions of the body at risk) may be obtained if there is concern for locoregional or distant metastatic progression </CO>.\\n\\nSection Name: PRINCIPLES OF IMAGING\\n====================\\nEntities:-\\nHead And Neck Neoplasms : Tumors or cancers located in the head or neck region, including the nasal cavity, sinuses, lips, mouth, salivary glands, throat, or larynx.\\nSquamous Cell Carcinoma Of Head And Neck : A type of cancer that occurs in the squamous cells of the head and neck region.\\nPositron Emission Tomography : A nuclear medicine functional imaging technique used to observe metabolic processes in the body.\\nRadiotherapy : The use of ionizing radiation to treat cancer.\\nNeck Dissection : A surgical procedure for control of neck lymph node metastasis.\\nComputed Tomography : A medical imaging technique used in radiology to obtain detailed internal images of the body.\\n\\nRelationships:-\\n1. Entity1: \""PET/CT\"", Entity2: \""Head and Neck Squamous Cell Carcinomas\"", Relationship: \""detects\""\\n2. Entity1: \""Surveillance Imaging\"", Entity2: \""Head and Neck Cancer\"", Relationship: \""performed after treatment\""\\n3. Entity1: \""PET-CT Surveillance\"", Entity2: \""Neck Dissection\"", Relationship: \""compared with\""\\n4. Entity1: \""Surveillance Imaging\"", Entity2: \""Definitive Radiotherapy\"", Relationship: \""useful in patients treated with\""\\n--------------------------------------------------\\nPage Number: 96\\n\\nSection Name: Head and Neck Cancers\\n====================\\nEntities:-\\nHead And Neck Neoplasms : Tumors or cancer of the head and neck region, including the nasal cavity, sinuses, lips, mouth, salivary glands, throat, or larynx.\\nPositron-Emission Tomography : An imaging technique that uses radioactive substances to visualize and measure changes in metabolic processes.\\nSurveillance : The ongoing systematic collection, analysis, and interpretation of health data essential to the planning, implementation, and evaluation of public health practice.\\nLocoregional Recurrence Of Tumor : The return of cancer in the original tumor location or nearby lymph nodes after treatment.\\nAsymptomatic : A condition or a person showing no symptoms of disease.\\nMagnetic Resonance Imaging : A medical imaging technique used in radiology to form pictures of the anatomy and the physiological processes of the body.\\nUltrasound : A medical imaging technique that uses high-frequency sound waves to visualize soft tissues such as muscles and internal organs.\\n\\nRelationships:-\\n1. Entity1: \""FDG-PET/CT\"", Entity2: \""Head and Neck Neoplasms\"", Relationship: \""used for surveillance imaging\""\\n2. Entity1: \""Recurrence\"", Entity2: \""Post-treatment period\"", Relationship: \""occurs within\""\\n3. Entity1: \""Imaging Modalities\"", Entity2: \""Surveillance\"", Relationship: \""used for\""\\n\\nCausalities:-\\n<C> The majority of recurrences after treatment of head and neck cancer occur in the first 2 years </C>. <C> Surveillance can be challenging </C> <C> because of altered anatomy and/or fibrosis from surgery, radiation, and/or chemotherapy </C>. <CO> There are no consensus guidelines on the frequency and modality of routine post-treatment imaging in the asymptomatic patient </CO>. <A> Practice varies widely across institutions </A>.\\n\\n<C> US, CT, MRI, and PET/CT all have unique advantages and disadvantages when used as surveillance imaging </C>. <C> There is evidence that FDG-PET/CT may be the most sensitive of these modalities </C>. <E> A 12-month PET has been shown to reveal recurrent or second primary cancers in approximately 10% of treated patients </E>; <E> a 24-month FDG-PET/CT imaging revealed these findings in approximately 5% of treated cases </E>. <CO> Most cases of asymptomatic FDG-PET/CT lesion localization occur at distant sites </CO>. <CO> Whether earlier detection leads to improved disease-specific survival is not established </CO>.\\n\\n<A> Standardized multi-institutional imaging-based trials are needed to clearly elucidate the value of routine imaging in the clinically asymptomatic patient </A>. <CO> There may be little proven benefit in further imaging if the initial 3-month FDG-PET/CT scan was negative </CO>. <C> Ho et al reported no significant difference in 3-year disease-free survival in patients undergoing imaging surveillance versus those only receiving clinical surveillance </C> <E> (41% vs. 46%, P = .91) in this setting </E>.\\n\\n<CO> If an FDG-PET/CT at 3 months post-treatment is negative </CO>, <CO> there are no data to support substantial benefit for further routine imaging in an asymptomatic patient with negative exam </CO>. <A> In the absence of multi-institutional prospective data, a tailored approach to surveillance with attention to tumor type, stage, prognostic factors, symptomatology, and physical exam changes or restrictions is appropriate </A>.\\n\\n<A> US of the neck is a well-established tool for nodal surveillance </A>. <C> US is generally widely available, safe, fast, inexpensive, and an accurate modality for examination of the neck for any suspicious nodal disease </C>.\\n\\n<CO> Additional post-treatment imaging is indicated for worrisome or equivocal signs/symptoms </CO>.\\n\\n<CO> Routine annual imaging (repeat use of pretreatment imaging modality) may be indicated to visualize areas inaccessible to routine clinical examination </CO> <CO> (deep-seated anatomic locations or areas obscured by extensive treatment change) </CO>.\\n\\nSection Name: Principles of Imaging\\n====================\\nEntities:-\\nHead And Neck Neoplasms : Tumors or cancer of the head and neck region, including the nasal cavity, sinuses, lips, mouth, salivary glands, throat, or larynx.\\nHead And Neck Cancer : A group of cancers that originate in the head and neck region.\\nPositron-Emission Tomography : An imaging technique that uses radioactive substances to visualize and measure changes in metabolic processes.\\nPositron Emission Tomography : A type of nuclear medicine imaging that uses small amounts of radioactive materials to diagnose or treat a variety of diseases.\\nTomography, X-Ray Computed : A method of body imaging in which a thin X-ray beam rotates around the patient, producing signals that are processed by the computer to generate cross-sectional images.\\nComputed Tomography : A diagnostic imaging procedure that uses a combination of X-rays and computer technology to produce cross-sectional images.\\nNeck : The part of the body on many vertebrates that separates the head from the torso or trunk.\\n\\nRelationships:-\\n1. Entity1: \""Surveillance imaging\"", Entity2: \""Head and neck cancer\"", Relationship: \""used for monitoring\""\\n2. Entity1: \""PET-CT\"", Entity2: \""Head and neck cancer\"", Relationship: \""used for detection\""\\n3. Entity1: \""Positron emission tomography/computed tomography\"", Entity2: \""Head and neck cancer\"", Relationship: \""used for surveillance\""\\n\\nSection Name: NCCN Guidelines\\n====================\\nEntities:-\\nNeoplasms : Neoplasms are abnormal growths of tissue, which can be cancerous or non-cancerous.\\nClinical Trial : A clinical trial is a research study conducted with patients to evaluate a new medical treatment, drug, or device.\\nNational Comprehensive Cancer Network : The National Comprehensive Cancer Network (NCCN) is an alliance of cancer centers in the United States, dedicated to improving the quality, effectiveness, and efficiency of cancer care.\\n\\nRelationships:-\\n1. Entity1: \""Neoplasms\"", Entity2: \""Clinical trial\"", Relationship: \""best management through\""\\n\\nCausalities:-\\n<C> NCCN believes that the best management of any patient with cancer is in a clinical trial </C>. <A> Participation in clinical trials is especially encouraged </A>.\\n--------------------------------------------------\\nPage Number: 129\\n\\nSection Name: TNM Staging System for the Larynx - Regional Lymph Nodes (N)\\n====================\\nEntities:-\\nLymph Nodes : Small, bean-shaped structures that are part of the body\\'s immune system. They filter substances that travel through the lymphatic fluid, and they contain lymphocytes (white blood cells) that help the body fight infection and disease.\\nLymph Node Structure : A structure that is part of the lymphatic system, involved in the filtration of lymph and the production of lymphocytes.\\nLymph Node : An organ of the lymphatic system and the adaptive immune system that is widely present throughout the body.\\n\\nRelationships:-\\n1. Entity1: \""NCCN Guidelines\"", Entity2: \""Regional Lymph Nodes\"", Relationship: \""provides classification for\""\\n2. Entity1: \""AJCC TNM Staging System\"", Entity2: \""Regional Lymph Nodes\"", Relationship: \""provides classification for\""\\n3. Entity1: \""Clinical N\"", Entity2: \""Regional Lymph Nodes\"", Relationship: \""is a classification of\""\\n\\nCausalities:-\\nThe <C> classification of the Regional Lymph Nodes (N) for head and neck cancers </C> is crucial for <E> determining the presence and extent of lymph node metastases </E>, which are critical in <E> establishing the severity and appropriate treatment strategies </E>. <A> Clinicians use this structured classification for accurate staging and subsequent treatment planning in patients diagnosed with head and neck cancers </A>.\\n\\nSection Name: NCCN Guidelines Version 4.2024\\n====================\\nEntities:-\\nHead And Neck Neoplasms : Cancers that occur in the head or neck region, including the nasal cavity, sinuses, lips, mouth, salivary glands, throat, or larynx.\\nMalignant Neoplasm Of Head And Neck : A malignant tumor located in the head and neck region.\\nNational Comprehensive Cancer Network : An alliance of cancer centers in the United States, dedicated to improving the quality, effectiveness, and efficiency of cancer care.\\n\\nRelationships:-\\n1. Entity1: \""NCCN Guidelines\"", Entity2: \""Head and Neck Cancers\"", Relationship: \""guidelines for\""\\n2. Entity1: \""NCCN Guidelines\"", Entity2: \""National Comprehensive Cancer Network\"", Relationship: \""published by\""\\n\\nCausalities:-\\nThe provided text does not contain any clinical causes, effects, conditions, or actions to extract.\\n'}""",valid,increases risk,2,B,"edge - The edge which needs to be verified.
explanation - Explanation of what the edge represents and its validity.
causal_direction - Either Positive or Negative or Unknown. A positive influence direction indicates that both factors change in the same direction (e.g. an increase causes an increase effect). A negative influence direction indicates the opposite changes (e.g. an increase causes a decrease effect).
causal_factor - Is necessary or sufficient condition for an effect to occur. Exposure is a term commonly used in epidemiology to denote any condition that is considered as a possible cause of disease. Exposure is considered necessary when it always precedes the effects (e.g. symptoms) and always presents when the effects occur. A sufficient cause is a causal factor whose presence or occurrence guarantees the occurrence of symptom.
causal_distance - Either Distal or Proximal or Unknown. The distal factors lie towards the beginning of causal chain (i.e. indirect causal factors). The the proximal factors lie towards the end of the chain (i.e. cause directly or almost directly the effect).

Causality Tags:
<A> for action, <C> for cause, <CO> for condition and <E> for effect.
Cause (C): The reason or origin that leads to an effect. Causes often involve disease conditions, risk factors, or underlying mechanisms.
Effect (E): The outcome or result of a cause. Effects usually represent clinical outcomes, complications, or results of a specific cause.
Condition (CO): The circumstance or prerequisite required for an action or effect to occur. Conditions may include patient characteristics, clinical scenarios, or specific diagnostic criteria.
Action (A): The recommended or described response or activity to address a cause or condition. Actions typically involve clinical interventions, diagnostic procedures, or treatment recommendations.


`NODE1`:
id: Location_of_Lymph_Nodes_3
label: Location of Lymph Nodes
description: This node represents the presence or absence of lymph nodes in a specific location, which is crucial for cancer diagnosis and staging. The detection of lymph nodes can indicate the spread of cancer and affect treatment decisions.
type: Patient Situation
observability: Unobserved
states: [{'state_name': 'present', 'state_description': 'Lymph nodes are detected in the specified location, which may indicate the spread of cancer and is important for staging and treatment planning.'}, {'state_name': 'absent', 'state_description': 'Lymph nodes are not detected in the specified location, which may suggest no spread of cancer to this area and is important for staging and treatment planning.'}]

`NODE2`:
id: PET_10
label: Positron Emission Tomography Examination Result
description: This node represents the result of a Positron Emission Tomography (PET) scan, which is an imaging test that helps reveal how your tissues and organs are functioning. A PET scan uses a radioactive drug (tracer) to show this activity. This node indicates whether the PET scan detected any abnormal metabolic activity, which could suggest the presence of disease such as cancer.
type: Examination Result
observability: Observed
states: [{'state_name': 'present', 'state_description': ""The 'present' state indicates that the PET scan detected abnormal metabolic activity, suggesting the presence of disease such as cancer.""}, {'state_name': 'absent', 'state_description': ""The 'absent' state indicates that the PET scan did not detect any abnormal metabolic activity, suggesting the absence of disease.""}]

`EDGE1`:
{'edges_ids': ['Location_of_Lymph_Nodes_3', 'PET_10'], 'edge': '(Location_of_Lymph_Nodes_3) causes (PET_10)', 'explanation': ['The edge represents the causal relationship between the presence of lymph nodes in a specific location and the result of a PET scan.', 'The presence of lymph nodes in a specific location can indicate the spread of cancer, which may be detected as abnormal metabolic activity on a PET scan.', 'Therefore, the presence of lymph nodes could cause a positive PET scan result, indicating a valid causal relationship.'], 'causal_direction': 'positive', 'causal_factor': {'necessary': False, 'sufficient': True}, 'causal_distance': 'Proximal'}

`EDGE2`:
{'edges_ids': ['PET_10', 'Location_of_Lymph_Nodes_3'], 'edge': '(PET_10) causes (Location_of_Lymph_Nodes_3)', 'explanation': ['The edge `(PET_10) causes (Location_of_Lymph_Nodes_3)` is not valid because the PET scan result does not directly cause the presence of lymph nodes in a specific location.', 'Both the PET scan result and the presence of lymph nodes are indicators of the underlying disease process, such as cancer, but one does not cause the other.', 'The PET scan result indicates abnormal metabolic activity, which suggests the presence of disease, but it does not directly influence the presence of lymph nodes.'], 'causal_direction': 'Unknown', 'causal_factor': {'necessary': False, 'sufficient': False}, 'causal_distance': 'Distal'}

`INFORMATION FROM KNOWLEDGE BASE`:
--------------------------------------------------
Page Number: 92

Section Name: NCCN Guidelines Overview
====================
Entities:-
Head And Neck Neoplasms : Cancers that arise in the head or neck region, including the nasal cavity, sinuses, lips, mouth, salivary glands, throat, or larynx.
Malignant Neoplasm Of Head And Neck : A malignant tumor located in the head and neck region.
Head And Neck Cancer : A group of cancers that originate in the head and neck region.
Antineoplastic Agents : Drugs used to treat cancer by inhibiting the growth of cancerous cells.
Systemic Therapy : Treatment using substances that travel through the bloodstream, reaching and affecting cells all over the body.
Radiotherapy : The treatment of disease, especially cancer, using X-rays or similar forms of radiation.
Radiation Therapy : The treatment of disease, especially cancer, using X-rays or similar forms of radiation.

Relationships:-
1. Entity1: ""Head and neck cancers"", Entity2: ""Systemic therapy"", Relationship: ""follow-up recommendations after""
2. Entity1: ""Head and neck cancers"", Entity2: ""Radiation therapy"", Relationship: ""follow-up recommendations after""

Causalities:-
The image presents a flowchart from the National Comprehensive Cancer Network (NCCN) Guidelines Version 2.2024, especially focusing on <A> follow-up recommendations </A> for <CO> patients with head and neck cancers after systemic therapy or radiation therapy (RT) </CO>. All recommendations are categorized as level A unless stated otherwise, highlighting the importance of clinical trials in cancer management.

Section Name: Imaging and Assessment Protocols
====================
Entities:-
Systemic Therapy : Treatment using substances that travel through the bloodstream, reaching and affecting cells all over the body.
Radiotherapy : The treatment of disease, especially cancer, using X-rays or similar forms of radiation.
Clinical Assessment : A systematic evaluation of a patient's health status, often involving a physical examination and medical history.
Positron-Emission Tomography : An imaging technique using a radioactive substance called a tracer to look for disease in the body.
Computed Tomography : A medical imaging technique used in radiology to obtain detailed internal images of the body.
Magnetic Resonance Imaging : A medical imaging technique used in radiology to form pictures of the anatomy and the physiological processes of the body.
Neck Dissection : A surgical procedure for control of neck lymph node metastasis.
Disease : A disorder of structure or function in a human, animal, or plant, especially one that produces specific symptoms.
Metastasis : The spread of a cancer or other disease from one organ or part to another not directly connected with it.
Residual Neoplasm : Remaining cancer cells after treatment.

Relationships:-
1. Entity1: ""Systemic Therapy"", Entity2: ""Clinical Assessment"", Relationship: ""occurs before""
2. Entity1: ""FDG-PET/CT Scan"", Entity2: ""Distant Metastases"", Relationship: ""assesses""
3. Entity1: ""FDG-PET/CT Scan"", Entity2: ""Observation"", Relationship: ""leads to if negative""
4. Entity1: ""FDG-PET/CT Scan"", Entity2: ""CT Scan"", Relationship: ""leads to if strongly positive""
5. Entity1: ""CT Scan"", Entity2: ""Neck Dissection"", Relationship: ""leads to if positive""

Causalities:-
<CO> After systemic therapy or RT </CO>, <A> a clinical assessment should occur 4 to 8 weeks later </A>. <CO> If there is a response </CO>, <A> it is necessary to assess the extent of disease or distant metastases, preferably through a FDG-PET/CT scan at a minimum of 12 weeks post-treatment </A>. <CO> If the FDG-PET/CT results are negative </CO>, <A> the patient may continue with monitoring through observation </A>. <CO> In cases where the results are equivocal </CO>, <A> observation or repeat FDG-PET/CT within 3 to 6 months is prescribed </A>.

<CO> In cases where the FDG-PET/CT results are strongly positive </CO>, <A> further imaging via CT scan with contrast of the primary site and neck, or MRI with and without contrast, becomes necessary </A>. <CO> If these imaging results confirm positive findings </CO>, <A> neck dissection may be considered, depending on the evidence of residual or persistent disease </A>. <CO> If the imaging findings are negative </CO>, <A> the patient might continue in observation </A>.

Section Name: Outcomes Based on Disease Resectability
====================
Entities:-
Disease : A disorder of structure or function in a human, animal, or plant, especially one that produces specific symptoms.
Resectable : Capable of being surgically removed.
Neck Dissection : A surgical procedure for control of neck lymph node metastasis.

Relationships:-
1. Entity1: ""Disease"", Entity2: ""Resectable"", Relationship: ""Classification""
2. Entity1: ""Unresectable"", Entity2: ""Treatment plans (ADV-3)"", Relationship: ""Treatment recommendation""
3. Entity1: ""Resectable"", Entity2: ""Resection and/or Neck dissection"", Relationship: ""Surgical procedure""

Causalities:-
<CO> If there is confirmed residual or persistent disease </CO>, the options split into two pathways: 'Unresectable' or 'Resectable.' <CO> If the disease is classified as unresectable </CO>, <A> advances in treatment plans (labeled ADV-3) are called for </A>. Conversely, <CO> if it is deemed resectable </CO>, <A> a resection of the primary and/or neck dissection may occur </A>, <CO> contingent upon the disease status </CO>.

Section Name: Important Notes
====================
Entities:-
Clinical Trials As Topic : Works about research studies that evaluate the effectiveness and safety of medications or medical devices by monitoring their effects on large groups of people.
Clinical Trial : A type of research that studies new tests and treatments and evaluates their effects on human health outcomes.
Positron-Emission Tomography : An imaging technique using a radioactive substance called a tracer to look for disease in the body.
Positron Emission Tomography (Procedure) : A diagnostic imaging procedure that uses a radioactive tracer to visualize and measure changes in metabolic processes.
Positron Emission Tomography : A nuclear medicine functional imaging technique used to observe metabolic processes in the body.
Neoplasms : New abnormal growth of tissue in animals or plants; a tumor.
Malignant Neoplasm : A cancerous growth that has the potential to spread to other parts of the body.
Cancer : A group of diseases involving abnormal cell growth with the potential to invade or spread to other parts of the body.

Relationships:-
1. Entity1: ""NCCN"", Entity2: ""Clinical trials"", Relationship: ""emphasizes participation in""
2. Entity1: ""FDG-PET/CT"", Entity2: ""Persistent cancer"", Relationship: ""used to detect""
3. Entity1: ""FDG-PET/CT"", Entity2: ""PET negative"", Relationship: ""interpretation of results""
4. Entity1: ""FDG-PET/CT"", Entity2: ""PET positive"", Relationship: ""interpretation of results""

Causalities:-
<A> NCCN emphasizes that the best management for any cancer patient is participation in clinical trials </A>, especially encouraged for all patients. Additional notes clarify that <CO> if the FDG-PET/CT is negative for persistent cancer </CO>, <A> further cross-sectional imaging is optional </A>. The interpretations define <CO> PET negative as no or low-grade uptake not suspicious for disease </CO>, while <CO> PET positive implies suspicion for disease </CO>.
--------------------------------------------------
Page Number: 94

Section Name: Head and Neck Cancers - Principles of Imaging
====================
Entities:-
Positron Emission Tomography Computed Tomography : A medical imaging technique combining PET and CT capabilities to provide detailed information about the body's function and structure.
Positron Emission Tomography : A nuclear medicine functional imaging technique that is used to observe metabolic processes in the body.
Computed Tomography : A diagnostic imaging procedure that uses a combination of X-rays and computer technology to produce cross-sectional images of the body.
Head And Neck Neoplasms : Cancers that arise in the head or neck region, including the nasal cavity, sinuses, lips, mouth, salivary glands, throat, or larynx.

Relationships:-
1. Entity1: ""PET/CT"", Entity2: ""PET scan"", Relationship: ""preferred over""
2. Entity1: ""PET-CT"", Entity2: ""head neck cancers"", Relationship: ""used in study of""

Causalities:-
<A> PET/CT is preferred over PET scan alone (i.e., without superimposed CT scan) </A>. <C> PET/CT provides more accurate anatomical localization of abnormalities </C> <E> more accurate anatomical localization of abnormalities </E>.

Section Name: Initial Workup - Nodal Metastases
====================
Entities:-
Lymphatic Metastasis : The transfer of a neoplasm from one organ or part of the body to another remote from the primary site via the lymphatic system.
Tomography, X-Ray Computed : A method of body imaging in which a thin X-ray beam rotates around the patient, producing signals that are processed by the machine's computer to generate cross-sectional images.
Magnetic Resonance Imaging : A non-invasive imaging technique that uses magnetic fields and radio waves to create detailed images of the organs and tissues within the body.
Positron-Emission Tomography : An imaging technique that uses radioactive substances to visualize and measure changes in metabolic processes, and in other physiological activities including blood flow, regional chemical composition, and absorption.
Lymph Node Metastasis : The spread of cancer cells to lymph nodes, which are part of the lymphatic system.
Ct Of Neck : A computed tomography scan of the neck region.
Mri Of Neck : A magnetic resonance imaging scan of the neck region.
Fdg-Pet Scan : A type of positron emission tomography using fluorodeoxyglucose to assess metabolic activity.
Computed Tomography : A diagnostic imaging procedure that uses a combination of X-rays and computer technology to produce cross-sectional images of the body.
Positron Emission Tomography : A nuclear medicine functional imaging technique that is used to observe metabolic processes in the body.

Relationships:-
1. Entity1: ""CT"", Entity2: ""lymph node metastases"", Relationship: ""used to evaluate""
2. Entity1: ""MRI"", Entity2: ""lymph node metastases"", Relationship: ""used to evaluate""
3. Entity1: ""FDG-PET/CT"", Entity2: ""lymph node metastases"", Relationship: ""used for detection""
4. Entity1: ""FDG-PET/CT"", Entity2: ""surgical primary approach"", Relationship: ""used to determine""
5. Entity1: ""FDG-PET/CT"", Entity2: ""definitive RT approach"", Relationship: ""used to identify""

Causalities:-
<A> Evaluation of lymph node metastases should be conducted with CT or MRI of the neck </A>, using whichever imaging study is suitable for primary site evaluation (IMG-A, 1 of 4).
<CO> For patients with multistation or lower neck nodal involvement or high-grade tumor histology </CO>, <A> consider CT of the chest to assess for mediastinal lymph node metastases or FDG-PET/CT </A>, <C> which is associated with higher sensitivity for both nodal and distant metastases </C>.
<CO> For patients who are under consideration for a surgical primary approach </CO>, <A> the higher sensitivity of FDG-PET/CT is warranted for tumors approaching the midline, to determine the surgical approach to the contralateral neck </A>. <CO> Similarly, patients who are scheduled for a definitive RT approach </CO> <A> may benefit from the higher sensitivity of FDG-PET/CT for identifying involved lymph nodes </A>.

Section Name: Initial Workup - Distant Metastases
====================
Entities:-
Positron-Emission Tomography : An imaging technique that uses radioactive substances to visualize and measure changes in metabolic processes, and in other physiological activities including blood flow, regional chemical composition, and absorption.
Magnetic Resonance Imaging : A non-invasive imaging technique that uses magnetic fields and radio waves to create detailed images of the organs and tissues within the body.
Tomography, X-Ray Computed : A method of body imaging in which a thin X-ray beam rotates around the patient, producing signals that are processed by the machine's computer to generate cross-sectional images.
Neoplasm Metastasis : The transfer of a neoplasm from one organ or part of the body to another remote from the primary site.
Lung Neoplasms : Tumors or cancer of the lung.
Smoking : The inhalation of the smoke of burning tobacco encased in cigarettes, pipes, and cigars.

Relationships:-
1. Entity1: ""FDG-PET/CT"", Entity2: ""Distant Metastases"", Relationship: ""used to evaluate""
2. Entity1: ""Contrast-enhanced brain MRI"", Entity2: ""Brain Metastasis"", Relationship: ""recommended for evaluation""
3. Entity1: ""CT of the chest"", Entity2: ""Pulmonary Metastases"", Relationship: ""performed to assess""
4. Entity1: ""Non-contrast CT of the chest"", Entity2: ""Lung Parenchymal Metastases"", Relationship: ""used to screen""
5. Entity1: ""Annual CT screening"", Entity2: ""Lung Metastasis"", Relationship: ""considered for high risk""
6. Entity1: ""Directed CT or MRI"", Entity2: ""Distant Disease"", Relationship: ""used for assessment""
7. Entity1: ""FDG-PET/CT"", Entity2: ""Recurrent Disease"", Relationship: ""used for staging""

Causalities:-
<C> Patients with locoregionally advanced cancer (e.g., T3–T4 primary or ≥N1 nodal staging) </C>, <A> FDG-PET/CT is preferred to evaluate for distant disease and thoracic metastases </A>. <CO> For cancers where brain metastasis is a concern, such as mucosal melanoma or high-grade neuroendocrine carcinomas or adenocarcinomas </CO>, <A> contrast-enhanced brain MRI should be additionally obtained </A>.
<CO> If FDG-PET/CT is not performed </CO>, <A> CT of the chest should be performed to assess for presence of pulmonary metastases as well as mediastinal lymph node involvement </A>.
<CO> Non-contrast CT of the chest can be sufficient to screen for lung parenchymal metastases </CO> but <CO> is not adequate for assessment of mediastinal adenopathy </CO>. <CO> This is an appropriate lung cancer screening intervention for patients with a history of smoking </CO>.
<CO> Following primary definitive treatment (surgery, RT, or systemic therapy/RT) </CO> the role of annual CT screening for lung metastasis is controversial. <E> While this approach does detect early metastasis </E>, <CO> further study is needed to determine the extent of the positive effect and/or cost-effectiveness of this approach in specific subpopulations and timepoints post-treatment </CO>. <CO> For patients with a substantial smoking history or who are at high risk for lung metastases </CO>, <A> annual chest CT can be considered </A>.
<CO> If clinical concern for metastatic disease is confined to a specific anatomical area </CO>, <A> the assessment of distant disease can be performed with directed CT or MRI examination </A>.
<CO> FDG-PET/CT may complement or replace other imaging modalities when staging recurrent disease before any therapy for relapsed/refractory disease </CO> <A> in order to explore distant disease or second primaries that may significantly impact choice of therapy </A>.
--------------------------------------------------
Page Number: 95

Section Name: Head and Neck Cancers
====================
Entities:-
Head And Neck Neoplasms : Tumors or cancers located in the head or neck region, including the nasal cavity, sinuses, lips, mouth, salivary glands, throat, or larynx.
Malignant Neoplasm Of Head And Neck : A malignant tumor located in the head and neck region.
Head And Neck Cancer : A group of cancers that originate in the head and neck region.
Clinical Trials As Topic : Pre-planned studies of the safety, efficacy, or optimum dosage schedule of one or more diagnostic, therapeutic, or prophylactic drugs, devices, or techniques in humans selected according to predetermined criteria of eligibility and observed for predefined evidence of favorable and unfavorable effects.
Clinical Trial : A type of research that studies new tests and treatments and evaluates their effects on human health outcomes.

Relationships:-
1. Entity1: ""NCCN Guidelines"", Entity2: ""Head and Neck Cancers"", Relationship: ""provides recommendations for""
2. Entity1: ""Clinical Trials"", Entity2: ""Head and Neck Cancers"", Relationship: ""are encouraged for""

Causalities:-
<C> NCCN believes that the best management of any patient with cancer is in a clinical trial </C>. <A> Participation in clinical trials is especially encouraged </A>.

Section Name: Locoregionally Advanced Disease: <6 Months Post-Treatment (Short-Term)
====================
Entities:-
Neoplasm Recurrence, Local : The return of a tumor at the original site after treatment.
Adjuvant Chemotherapy : Chemotherapy given in addition to the primary treatment to enhance its effectiveness.
Tomography, X-Ray Computed : A method of body imaging in which a thin X-ray beam rotates around the patient.
Magnetic Resonance Imaging : A noninvasive diagnostic technique that produces computerized images of internal body tissues.
Positron-Emission Tomography : An imaging technique using radioactive substances to visualize and measure metabolic processes in the body.
Radiotherapy : The use of ionizing radiation to treat cancer.
Carcinoma, Squamous Cell : A type of cancer that begins in the squamous cells.
Chemotherapy, Adjuvant : Treatment given in addition to the primary therapy to maximize its effectiveness.

Relationships:-
1. Entity1: ""FDG-PET/CT"", Entity2: ""locoregionally advanced cancer"", Relationship: ""used for assessment of treatment response""
2. Entity1: ""CT and MRI"", Entity2: ""locoregionally advanced disease"", Relationship: ""used to establish baseline""
3. Entity1: ""Adjuvant postoperative therapy"", Entity2: ""high risk of early recurrence"", Relationship: ""recommended for""

Causalities:-
- Following surgery in <C> patients with locoregionally advanced cancer </C>, <A> short-term post-treatment imaging is recommended </A> <CO> for those who show signs of early recurrence or who are at high risk of early recurrence prior to starting adjuvant postoperative therapy </CO>.
- <A> Obtain CT and/or MRI within 3–4 months after surgical treatment </A> <CO> for patients with locoregionally advanced disease or with altered anatomy causing challenging physical exam assessment </CO>, <E> in order to establish a new baseline for future comparisons </E>.
- <CO> In cases of concern for incomplete response </CO>, <A> a CT or MRI scan may be obtained much earlier, such as 4–8 weeks post-treatment or even immediately based on the specific clinical situation </A>. <A> US of the neck for targeted sampling of any suspicious tissues may also be helpful </A>, <CO> but results can be variably interpreted depending on the specific clinical situation </CO>.
- <A> FDG-PET/CT should be performed within 3–6 months of definitive radiation or systemic therapy/RT </A> <E> for assessment of treatment response and to identify any residual tumor </E>.
  - <CO> Early FDG-PET/CT scans before 12 weeks are associated with significant false-positive rates </CO> and <A> should be avoided in the absence of signs of recurrence or progression </A>.
  - <E> The optimal timing of PET scans after radiation treatment appears to be at the 3- to 6-month window </E>. <E> A negative PET at this time point predicts improved overall survival at 2 years </E>.
- <CO> In patients receiving definitive RT-based treatment of mucosal squamous cell carcinoma with AJCC 7th edition N2–N3 nodal disease </CO>, <E> FDG-PET/CT surveillance approach led to fewer neck dissections and considerable cost savings compared to a routine approach of planned post-treatment neck dissection </E>. The majority of cases studied were p16-positive oropharyngeal cancers.
- <CO> In the special case of patients who are treated initially with induction chemotherapy prior to the initiation of definitive therapy </CO>, <A> either CT or MRI has typically been obtained after 2–3 cycles of induction </A>. <CO> Chest CT and/or FDG-PET/CT (with diagnostic-quality imaging of the regions of the body at risk) may be obtained if there is concern for locoregional or distant metastatic progression </CO>.

Section Name: PRINCIPLES OF IMAGING
====================
Entities:-
Head And Neck Neoplasms : Tumors or cancers located in the head or neck region, including the nasal cavity, sinuses, lips, mouth, salivary glands, throat, or larynx.
Squamous Cell Carcinoma Of Head And Neck : A type of cancer that occurs in the squamous cells of the head and neck region.
Positron Emission Tomography : A nuclear medicine functional imaging technique used to observe metabolic processes in the body.
Radiotherapy : The use of ionizing radiation to treat cancer.
Neck Dissection : A surgical procedure for control of neck lymph node metastasis.
Computed Tomography : A medical imaging technique used in radiology to obtain detailed internal images of the body.

Relationships:-
1. Entity1: ""PET/CT"", Entity2: ""Head and Neck Squamous Cell Carcinomas"", Relationship: ""detects""
2. Entity1: ""Surveillance Imaging"", Entity2: ""Head and Neck Cancer"", Relationship: ""performed after treatment""
3. Entity1: ""PET-CT Surveillance"", Entity2: ""Neck Dissection"", Relationship: ""compared with""
4. Entity1: ""Surveillance Imaging"", Entity2: ""Definitive Radiotherapy"", Relationship: ""useful in patients treated with""
--------------------------------------------------
Page Number: 96

Section Name: Head and Neck Cancers
====================
Entities:-
Head And Neck Neoplasms : Tumors or cancer of the head and neck region, including the nasal cavity, sinuses, lips, mouth, salivary glands, throat, or larynx.
Positron-Emission Tomography : An imaging technique that uses radioactive substances to visualize and measure changes in metabolic processes.
Surveillance : The ongoing systematic collection, analysis, and interpretation of health data essential to the planning, implementation, and evaluation of public health practice.
Locoregional Recurrence Of Tumor : The return of cancer in the original tumor location or nearby lymph nodes after treatment.
Asymptomatic : A condition or a person showing no symptoms of disease.
Magnetic Resonance Imaging : A medical imaging technique used in radiology to form pictures of the anatomy and the physiological processes of the body.
Ultrasound : A medical imaging technique that uses high-frequency sound waves to visualize soft tissues such as muscles and internal organs.

Relationships:-
1. Entity1: ""FDG-PET/CT"", Entity2: ""Head and Neck Neoplasms"", Relationship: ""used for surveillance imaging""
2. Entity1: ""Recurrence"", Entity2: ""Post-treatment period"", Relationship: ""occurs within""
3. Entity1: ""Imaging Modalities"", Entity2: ""Surveillance"", Relationship: ""used for""

Causalities:-
<C> The majority of recurrences after treatment of head and neck cancer occur in the first 2 years </C>. <C> Surveillance can be challenging </C> <C> because of altered anatomy and/or fibrosis from surgery, radiation, and/or chemotherapy </C>. <CO> There are no consensus guidelines on the frequency and modality of routine post-treatment imaging in the asymptomatic patient </CO>. <A> Practice varies widely across institutions </A>.

<C> US, CT, MRI, and PET/CT all have unique advantages and disadvantages when used as surveillance imaging </C>. <C> There is evidence that FDG-PET/CT may be the most sensitive of these modalities </C>. <E> A 12-month PET has been shown to reveal recurrent or second primary cancers in approximately 10% of treated patients </E>; <E> a 24-month FDG-PET/CT imaging revealed these findings in approximately 5% of treated cases </E>. <CO> Most cases of asymptomatic FDG-PET/CT lesion localization occur at distant sites </CO>. <CO> Whether earlier detection leads to improved disease-specific survival is not established </CO>.

<A> Standardized multi-institutional imaging-based trials are needed to clearly elucidate the value of routine imaging in the clinically asymptomatic patient </A>. <CO> There may be little proven benefit in further imaging if the initial 3-month FDG-PET/CT scan was negative </CO>. <C> Ho et al reported no significant difference in 3-year disease-free survival in patients undergoing imaging surveillance versus those only receiving clinical surveillance </C> <E> (41% vs. 46%, P = .91) in this setting </E>.

<CO> If an FDG-PET/CT at 3 months post-treatment is negative </CO>, <CO> there are no data to support substantial benefit for further routine imaging in an asymptomatic patient with negative exam </CO>. <A> In the absence of multi-institutional prospective data, a tailored approach to surveillance with attention to tumor type, stage, prognostic factors, symptomatology, and physical exam changes or restrictions is appropriate </A>.

<A> US of the neck is a well-established tool for nodal surveillance </A>. <C> US is generally widely available, safe, fast, inexpensive, and an accurate modality for examination of the neck for any suspicious nodal disease </C>.

<CO> Additional post-treatment imaging is indicated for worrisome or equivocal signs/symptoms </CO>.

<CO> Routine annual imaging (repeat use of pretreatment imaging modality) may be indicated to visualize areas inaccessible to routine clinical examination </CO> <CO> (deep-seated anatomic locations or areas obscured by extensive treatment change) </CO>.

Section Name: Principles of Imaging
====================
Entities:-
Head And Neck Neoplasms : Tumors or cancer of the head and neck region, including the nasal cavity, sinuses, lips, mouth, salivary glands, throat, or larynx.
Head And Neck Cancer : A group of cancers that originate in the head and neck region.
Positron-Emission Tomography : An imaging technique that uses radioactive substances to visualize and measure changes in metabolic processes.
Positron Emission Tomography : A type of nuclear medicine imaging that uses small amounts of radioactive materials to diagnose or treat a variety of diseases.
Tomography, X-Ray Computed : A method of body imaging in which a thin X-ray beam rotates around the patient, producing signals that are processed by the computer to generate cross-sectional images.
Computed Tomography : A diagnostic imaging procedure that uses a combination of X-rays and computer technology to produce cross-sectional images.
Neck : The part of the body on many vertebrates that separates the head from the torso or trunk.

Relationships:-
1. Entity1: ""Surveillance imaging"", Entity2: ""Head and neck cancer"", Relationship: ""used for monitoring""
2. Entity1: ""PET-CT"", Entity2: ""Head and neck cancer"", Relationship: ""used for detection""
3. Entity1: ""Positron emission tomography/computed tomography"", Entity2: ""Head and neck cancer"", Relationship: ""used for surveillance""

Section Name: NCCN Guidelines
====================
Entities:-
Neoplasms : Neoplasms are abnormal growths of tissue, which can be cancerous or non-cancerous.
Clinical Trial : A clinical trial is a research study conducted with patients to evaluate a new medical treatment, drug, or device.
National Comprehensive Cancer Network : The National Comprehensive Cancer Network (NCCN) is an alliance of cancer centers in the United States, dedicated to improving the quality, effectiveness, and efficiency of cancer care.

Relationships:-
1. Entity1: ""Neoplasms"", Entity2: ""Clinical trial"", Relationship: ""best management through""

Causalities:-
<C> NCCN believes that the best management of any patient with cancer is in a clinical trial </C>. <A> Participation in clinical trials is especially encouraged </A>.
--------------------------------------------------
Page Number: 129

Section Name: TNM Staging System for the Larynx - Regional Lymph Nodes (N)
====================
Entities:-
Lymph Nodes : Small, bean-shaped structures that are part of the body's immune system. They filter substances that travel through the lymphatic fluid, and they contain lymphocytes (white blood cells) that help the body fight infection and disease.
Lymph Node Structure : A structure that is part of the lymphatic system, involved in the filtration of lymph and the production of lymphocytes.
Lymph Node : An organ of the lymphatic system and the adaptive immune system that is widely present throughout the body.

Relationships:-
1. Entity1: ""NCCN Guidelines"", Entity2: ""Regional Lymph Nodes"", Relationship: ""provides classification for""
2. Entity1: ""AJCC TNM Staging System"", Entity2: ""Regional Lymph Nodes"", Relationship: ""provides classification for""
3. Entity1: ""Clinical N"", Entity2: ""Regional Lymph Nodes"", Relationship: ""is a classification of""

Causalities:-
The <C> classification of the Regional Lymph Nodes (N) for head and neck cancers </C> is crucial for <E> determining the presence and extent of lymph node metastases </E>, which are critical in <E> establishing the severity and appropriate treatment strategies </E>. <A> Clinicians use this structured classification for accurate staging and subsequent treatment planning in patients diagnosed with head and neck cancers </A>.

Section Name: NCCN Guidelines Version 4.2024
====================
Entities:-
Head And Neck Neoplasms : Cancers that occur in the head or neck region, including the nasal cavity, sinuses, lips, mouth, salivary glands, throat, or larynx.
Malignant Neoplasm Of Head And Neck : A malignant tumor located in the head and neck region.
National Comprehensive Cancer Network : An alliance of cancer centers in the United States, dedicated to improving the quality, effectiveness, and efficiency of cancer care.

Relationships:-
1. Entity1: ""NCCN Guidelines"", Entity2: ""Head and Neck Cancers"", Relationship: ""guidelines for""
2. Entity1: ""NCCN Guidelines"", Entity2: ""National Comprehensive Cancer Network"", Relationship: ""published by""

Causalities:-
The provided text does not contain any clinical causes, effects, conditions, or actions to extract.


Among these two options which one is the most likely true:

(A) `Location_of_Lymph_Nodes_3` increases risk `PET_10`
(B) `PET_10` `increases risk `Location_of_Lymph_Nodes_3`

The answer is: ...

1. State the evidences in detail of the validity of option (A) or (B) by cross referencing
NCCN Clinical Practitioner’s Guidelines for Head and Neck Cancer.
2. If the evidences are obtained from `INFORMATION FROM KNOWLEDGE BASE`,
mention their corresponding Page Numbers, Section Name, entities, relationships and causalities.

DESIRED OUTPUT FORMAT:
<thinking>
...
</thinking>
<answer>
{
   ""thinking"": [""..."", ...],
   ""evidences"": [""..."", ...],
   ""answer"": ...
}
</answer>

Before providing the answer in <answer> tags, think step by step in detail in <thinking> tags and analyze every part.
Output inside <answer> tag in JSON format. Only output valid JSON.
DO NOT HALLUCINATE. DO NOT MAKE UP FACTUAL INFORMATION.
","1. The edge (Location_of_Lymph_Nodes_3) causes (PET_10) suggests that the presence of lymph nodes in a specific location can lead to a positive PET scan result due to the detection of abnormal metabolic activity, which is indicative of cancer spread.
2. The edge (PET_10) causes (Location_of_Lymph_Nodes_3) is not valid because a PET scan result does not directly cause the presence of lymph nodes. Instead, both are indicators of an underlying disease process.
3. The causal direction for EDGE1 is positive, indicating that the presence of lymph nodes and a positive PET scan result change in the same direction, supporting the idea that lymph node presence can lead to a positive PET scan.
4. The causal factor for EDGE1 is sufficient, meaning the presence of lymph nodes is enough to cause a positive PET scan result, but not necessary, as other factors could also lead to a positive result.
5. The causal distance for EDGE1 is proximal, indicating a direct or almost direct cause-effect relationship between lymph node presence and PET scan results.
6. The causal direction for EDGE2 is unknown, and the causal factor is neither necessary nor sufficient, further supporting the invalidity of this edge.
7. The NCCN Guidelines emphasize the use of PET/CT scans for detecting metabolic activity indicative of cancer spread, aligning with the explanation for EDGE1.
8. Page 94 of the NCCN Guidelines mentions the use of PET/CT in the study of head and neck cancers, supporting the role of PET scans in detecting cancer spread, which aligns with the explanation for EDGE1.
","1. Page 94, Section Name: Principles of Imaging, Entities: Positron Emission Tomography Computed Tomography, Head And Neck Neoplasms, Relationships: PET/CT used in study of head neck cancers.
2. Page 96, Section Name: Head and Neck Cancers, Entities: FDG-PET/CT, Head and Neck Neoplasms, Relationships: used for surveillance imaging, Causalities: FDG-PET/CT may be the most sensitive modality for detecting recurrences or second primary cancers.
",A,"{'A': 100.0, 'B': 0.0}",yes,A,"1. The AI assistant's reasoning for selecting option (A) is based on the causal relationship between the presence of lymph nodes and the results of a PET scan. The assistant correctly identifies that the presence of lymph nodes can lead to a positive PET scan result due to the detection of abnormal metabolic activity, which is indicative of cancer spread.
2. The assistant's analysis of EDGE1 is consistent with the explanation provided. It notes that the causal direction is positive, meaning both the presence of lymph nodes and a positive PET scan result change in the same direction. This supports the idea that lymph node presence can lead to a positive PET scan.
3. The assistant also correctly identifies that the causal factor for EDGE1 is sufficient, meaning the presence of lymph nodes is enough to cause a positive PET scan result, but not necessary, as other factors could also lead to a positive result.
4. The causal distance for EDGE1 is proximal, indicating a direct or almost direct cause-effect relationship between lymph node presence and PET scan results. This aligns with the explanation provided for EDGE1.
5. The assistant's analysis of EDGE2 is also consistent with the explanation provided. It notes that the causal direction is unknown, and the causal factor is neither necessary nor sufficient, further supporting the invalidity of this edge.
6. The assistant references the NCCN Guidelines, which emphasize the use of PET/CT scans for detecting metabolic activity indicative of cancer spread. This aligns with the explanation for EDGE1, supporting the validity of option (A).
7. The assistant provides evidence from the NCCN Guidelines, specifically from Page 94 and Page 96, which supports the role of PET scans in detecting cancer spread, aligning with the explanation for EDGE1.
"
5,gpt-4o,"Location_of_Lymph_Nodes_3,Examination_11","""{'NODE1': {'id': 'Location_of_Lymph_Nodes_3', 'label': 'Location of Lymph Nodes', 'description': 'This node represents the presence or absence of lymph nodes in a specific location, which is crucial for cancer diagnosis and staging. The detection of lymph nodes can indicate the spread of cancer and affect treatment decisions.', 'type': 'Patient Situation', 'observability': 'Unobserved', 'states': [{'state_name': 'present', 'state_description': 'Lymph nodes are detected in the specified location, which may indicate the spread of cancer and is important for staging and treatment planning.'}, {'state_name': 'absent', 'state_description': 'Lymph nodes are not detected in the specified location, which may suggest no spread of cancer to this area and is important for staging and treatment planning.'}]}, 'NODE2': {'id': 'Examination_11', 'label': 'Diagnostic Examination Result', 'description': 'This node represents the result of a specific diagnostic examination, which is observed and can indicate the presence or absence of a particular condition or finding.', 'type': 'Examination Result', 'observability': 'Observed', 'states': [{'state_name': 'present', 'state_description': 'The result of the examination indicates the presence of the condition or finding being tested for.'}, {'state_name': 'absent', 'state_description': 'The result of the examination indicates the absence of the condition or finding being tested for.'}]}, 'EDGE1': {'edges_ids': ['Location_of_Lymph_Nodes_3', 'Examination_11'], 'edge': '(Location_of_Lymph_Nodes_3) causes (Examination_11)', 'explanation': ['The edge represents a causal relationship where the presence or absence of lymph nodes in a specific location (`Location_of_Lymph_Nodes_3`) affects the result of a diagnostic examination (`Examination_11`).', \""If the examination is designed to detect lymph nodes or assess cancer spread, then the presence of lymph nodes would likely lead to a 'present' result in the examination.\"", 'The causal direction is positive because the presence of lymph nodes would lead to a positive finding in the examination if it is related to lymph nodes.', \""The causal factor is neither necessary nor sufficient because other factors could lead to a 'present' examination result, and the presence of lymph nodes alone does not guarantee a 'present' result unless the examination is specifically for that purpose.\"", 'The causal distance is proximal if the examination is directly related to detecting lymph nodes, as it would be a direct cause-effect relationship.'], 'causal_direction': 'positive', 'causal_factor': {'necessary': False, 'sufficient': False}, 'causal_distance': 'Proximal'}, 'EDGE2': {'edges_ids': ['Examination_11', 'Location_of_Lymph_Nodes_3'], 'edge': '(Examination_11) causes (Location_of_Lymph_Nodes_3)', 'explanation': ['The edge suggests that the result of a diagnostic examination (Examination_11) causes the presence or absence of lymph nodes in a specific location (Location_of_Lymph_Nodes_3).', \""However, the examination result is an observation of the lymph nodes' presence or absence, not a cause of it.\"", 'The presence of lymph nodes is a physical condition that might be detected by the examination, but the examination itself does not cause the lymph nodes to appear or disappear.', 'Therefore, the edge is not valid as a causal relationship.'], 'causal_direction': 'Unknown', 'causal_factor': {'necessary': False, 'sufficient': False}, 'causal_distance': 'Proximal'}, 'ENTITIES_MATCHING_PAGES_INFO': {'51': {'matching_entities': [{'CLINICAL TRIALS': 0.9367982}, {'CLINICAL TRIALS AS TOPIC': 0.9333815}, {'RESPONSE EVALUATION': 0.9307092}, {'FOLLOW-UP PROCEDURE': 0.9293796}, {'SURGICAL PROCEDURE': 0.9255254}, {'SURGERY': 0.9254029}, {'RESPONSE TO TREATMENT': 0.9204324}], 'count': 7}, '70': {'matching_entities': [{'CLINICAL TRIALS': 0.9367982}, {'CLINICAL TRIALS AS TOPIC': 0.9333815}, {'BIOMARKERS': 0.9266646}, {'BIOMARKER': 0.9259977}, {'SUPPORTIVE CARE': 0.92568463}, {'SURGICAL PROCEDURE': 0.9255254}, {'SURGERY': 0.9254029}], 'count': 7}, '53': {'matching_entities': [{'CLINICAL TRIALS AS TOPIC': 0.9333815}, {'FOLLOW-UP PROCEDURE': 0.9293796}, {'TREATMENT STRATEGIES': 0.92767245}, {'IMAGING': 0.9261862}, {'SURGICAL PROCEDURE': 0.9255254}, {'FOLLOW-UP EVALUATIONS': 0.9244507}], 'count': 6}, '68': {'matching_entities': [{'DIAGNOSIS': 0.9335496}, {'CLINICAL TRIALS AS TOPIC': 0.9333815}, {'SUPPORTIVE CARE': 0.92568463}, {'SURGICAL PROCEDURE': 0.9255254}, {'SURGERY': 0.9254029}], 'count': 5}, '69': {'matching_entities': [{'CLINICAL TRIALS AS TOPIC': 0.9333815}, {'BIOMARKERS': 0.9266646}, {'BIOMARKER': 0.9259977}, {'SURGICAL PROCEDURE': 0.9255254}, {'SURGERY': 0.9254029}], 'count': 5}}, 'GUIDELINE_PAGES_INFO': '--------------------------------------------------\\nPage Number: 51\\n\\nSection Name: Introduction\\n====================\\nEntities:-\\nLaryngeal Neoplasms : Tumors or cancer of the larynx, which may affect the supraglottic, glottic, or subglottic regions.\\nMalignant Neoplasm Of Supraglottis : A malignant tumor located in the supraglottic region of the larynx.\\nSupraglottic Laryngeal Cancer : A type of cancer that occurs in the supraglottic region of the larynx, which is above the vocal cords.\\n\\nRelationships:-\\n1. Entity1: \""National Comprehensive Cancer Network (NCCN)\"", Entity2: \""cancer of the supraglottic larynx\"", Relationship: \""provides guidelines for\""\\n2. Entity1: \""healthcare professionals\"", Entity2: \""cancer of the supraglottic larynx\"", Relationship: \""manage\""\\n\\nCausalities:-\\nThe provided image is a detailed flowchart from the National Comprehensive Cancer Network (NCCN) guidelines regarding the <C> clinical staging and treatment protocols for cancer of the supraglottic larynx </C>. This flowchart is structured to <A> guide healthcare professionals through the stages of treatment </A> based on <CO> clinical findings </CO>, emphasizing the <E> complexity and systematic approach required in managing this type of cancer </E>.\\n\\nSection Name: Clinical Staging\\n====================\\nEntities:-\\nLaryngectomy : A surgical procedure involving the removal of the larynx, usually to treat cancer of the larynx.\\nTotal Laryngectomy : A surgical procedure to remove the entire larynx, often used in the treatment of advanced laryngeal cancer.\\nNeoplasm Staging : Methods used for staging neoplasms, including clinical and pathological staging.\\nCancer Staging : The process of determining the extent of cancer in the body, often using the TNM system.\\nTnm Staging System : A cancer staging system that describes the extent of cancer using Tumor size (T), Node involvement (N), and Metastasis (M).\\n\\nRelationships:-\\n1. Entity1: \""Clinical staging criteria\"", Entity2: \""Total laryngectomy\"", Relationship: \""determines necessity of\""\\n2. Entity1: \""T3, N0\"", Entity2: \""Clinical staging criteria\"", Relationship: \""is a categorization of\""\\n\\nCausalities:-\\nThe flowchart begins with the <C> clinical staging criteria </C>, specifically focusing on <CO> cases that require total laryngectomy, denoted as requiring (amenable to) total laryngectomy (T3, N0) </CO>. This <A> categorization </A> is crucial as it <E> forms the basis for determining the appropriate treatment strategy </E>.\\n\\nSection Name: Treatment of Primary and Neck\\n====================\\nEntities:-\\nNeoplasm Staging : Methods used for staging neoplasms, including clinical and pathological staging.\\nSystemic Therapy : Treatment using substances that travel through the bloodstream, reaching and affecting cells all over the body.\\nRadiotherapy : The use of high-energy radiation from x-rays, gamma rays, neutrons, protons, and other sources to kill cancer cells and shrink tumors.\\nLaryngectomy : A surgical procedure involving the removal of the larynx, usually to treat cancer of the larynx.\\nThyroidectomy : A surgical procedure to remove all or part of the thyroid gland.\\nNeck Dissection : Surgical procedure to remove lymph nodes and surrounding tissue to treat or prevent cancer spread.\\nLymphatic Metastasis : Transfer of a neoplasm from one organ or part of the body to another remote from the primary site.\\n\\nRelationships:-\\n1. Entity1: \""Systemic Therapy\"", Entity2: \""Radiation Therapy\"", Relationship: \""combined with\""\\n2. Entity1: \""Laryngectomy\"", Entity2: \""Lymph Node Involvement\"", Relationship: \""considered based on\""\\n3. Entity1: \""Thyroidectomy\"", Entity2: \""Lymph Node Involvement\"", Relationship: \""considered based on\""\\n4. Entity1: \""Neck Dissection\"", Entity2: \""Lymph Node Involvement\"", Relationship: \""considered based on\""\\n\\nCausalities:-\\n<CO> Once clinical staging is established </CO>, the chart outlines various treatment options. <A> The initial step may involve either concurrent systemic therapy combined with radiation therapy (RT) or opting for RT alone </A>, <CO> especially if the patient is not a medical candidate for both therapies </CO>. <A> Laryngectomy, thyroidectomy, and neck dissection are considered </A> <CO> based on the extent of lymph node involvement </CO>.\\n\\nSection Name: Surgical Options\\n====================\\nEntities:-\\nLaryngectomy : A surgical procedure involving the removal of the larynx, usually to treat cancer of the larynx.\\nThyroidectomy : A surgical procedure to remove all or part of the thyroid gland.\\nLymph Node Excision : Surgical removal of one or more lymph nodes.\\nLymphadenectomy : Surgical removal of one or more groups of lymph nodes.\\nSurgical Procedures, Operative : Operations carried out for the correction of deformities and defects, repair of injuries, and diagnosis and cure of certain diseases.\\nSurgical Procedure : A medical procedure involving an incision with instruments; performed to repair damage or arrest disease in a living body.\\nSurgery : Medical specialty that uses operative manual and instrumental techniques on a patient to investigate or treat a pathological condition such as a disease or injury.\\n\\nRelationships:-\\n1. Entity1: \""Laryngectomy\"", Entity2: \""Thyroidectomy\"", Relationship: \""combined with\""\\n2. Entity1: \""Lymph Node Dissection\"", Entity2: \""Surgical Intervention\"", Relationship: \""extent of\""\\n3. Entity1: \""Surgical Intervention\"", Entity2: \""Advanced Cases\"", Relationship: \""management option for\""\\n\\nCausalities:-\\n<CO> If concurrent therapies are not suitable </CO>, <A> the chart presents laryngectomy combined with thyroidectomy </A>, <CO> depending on the extent of lymph node dissection required </CO>. <E> This highlights surgical intervention as a viable option in the management of advanced cases </E>.\\n\\nSection Name: Induction Chemotherapy\\n====================\\nEntities:-\\nInduction Chemotherapy : Initial chemotherapy treatment used to shrink a tumor before the main treatment, which is usually surgery.\\nSurgical Procedure : A medical procedure involving an incision with instruments; performed to repair damage or arrest disease in a living body.\\nTherapeutic Approach : A method or strategy used in the treatment of disease or injury.\\n\\nRelationships:-\\n1. Entity1: \""Induction Chemotherapy\"", Entity2: \""Surgical Intervention\"", Relationship: \""alternative or sequential treatment option\""\\n\\nCausalities:-\\n<C> immediate surgical intervention is either not feasible or considered insufficient </C> <E> The flowchart also considers the option of induction chemotherapy </E> <CO> in cases where immediate surgical intervention is either not feasible or considered insufficient </CO>. <A> tailoring therapeutic approaches tailored to individual patient needs </A>.\\n\\nSection Name: Adjuvant Treatment\\n====================\\nEntities:-\\nAdjuvant Chemotherapy : Chemotherapy given in addition to the primary treatment to maximize its effectiveness.\\nRadiotherapy : The use of high-energy radiation from x-rays, gamma rays, neutrons, protons, and other sources to kill cancer cells and shrink tumors.\\nNeoplasm Recurrence, Local : The return of a cancer, at the same site, after it has been treated.\\nDisease Progression : The worsening of a disease over time.\\n\\nRelationships:-\\n1. Entity1: \""Primary Treatment\"", Entity2: \""Adjuvant Treatment\"", Relationship: \""followed by\""\\n2. Entity1: \""Adjuvant Treatment\"", Entity2: \""Systemic Therapy\"", Relationship: \""includes\""\\n3. Entity1: \""Adjuvant Treatment\"", Entity2: \""Radiotherapy\"", Relationship: \""includes\""\\n4. Entity1: \""Follow-up Assessments\"", Entity2: \""Treatment Efficacy\"", Relationship: \""used to evaluate\""\\n\\nCausalities:-\\n<C> Following primary treatment </C>, <E> the flowchart addresses the potential for adjuvant treatment pathways </E>. This may include systemic therapy, RT, or further evaluations based on <CO> the patient\\'s response and any recurrence or persistent disease </CO>. It emphasizes <A> the need for follow-up assessments to evaluate treatment efficacy </A>.\\n\\nSection Name: Risk Features and Response Assessment\\n====================\\nEntities:-\\nNeoplasm Invasiveness : The property of a neoplasm to infiltrate and destroy surrounding tissue.\\nSurgical Margins : The edge or border of the tissue removed in cancer surgery.\\nNeoplasms : Neoplasms are abnormal growths of tissue, which can be cancerous or non-cancerous.\\nExtramural Extension : Extension of a tumor beyond the wall of an organ.\\nPositive Surgical Margin : Cancer cells are present at the edge of the tissue removed during surgery.\\nCancer Management : The process of planning and coordinating the treatment of cancer.\\nCancer : Cancer is a group of diseases involving abnormal cell growth with the potential to invade or spread to other parts of the body.\\n\\nRelationships:-\\n1. Entity1: \""Extramural extension\"", Entity2: \""Treatment decisions\"", Relationship: \""influences\""\\n2. Entity1: \""Positive surgical margin\"", Entity2: \""Treatment decisions\"", Relationship: \""influences\""\\n3. Entity1: \""Ongoing assessment\"", Entity2: \""Response evaluation\"", Relationship: \""leads to\""\\n4. Entity1: \""Response evaluation\"", Entity2: \""Adjustments to treatment\"", Relationship: \""leads to\""\\n5. Entity1: \""Management of cancer\"", Entity2: \""Treatment decisions\"", Relationship: \""involves\""\\n6. Entity1: \""Management of cancer\"", Entity2: \""Ongoing assessment\"", Relationship: \""involves\""\\n7. Entity1: \""Management of cancer\"", Entity2: \""Adjustments to treatment\"", Relationship: \""involves\""\\n\\nCausalities:-\\nThe chart incorporates a segment that takes into account <CO> adverse pathologic features, such as extramural extension or positive margins </CO>, <E> which could influence subsequent treatment decisions </E>. This highlights the importance of <A> ongoing assessment in the management of cancer, leading to response evaluation and adjustments to treatment as necessary </A>.\\n\\nSection Name: NCCN Guidelines Version 4.2024\\n====================\\nEntities:-\\nClinical Trials : Clinical trials are research studies performed in people that are aimed at evaluating a medical, surgical, or behavioral intervention.\\nNeoplasms : Neoplasms are abnormal growths of tissue, which can be cancerous or non-cancerous.\\nClinical Trial : A clinical trial is a research study that prospectively assigns human participants or groups of humans to one or more health-related interventions to evaluate the effects on health outcomes.\\nMalignant Neoplasm : A malignant neoplasm is a cancerous growth that has the potential to invade and destroy nearby tissue and spread to other parts of the body.\\nNational Comprehensive Cancer Network : The National Comprehensive Cancer Network (NCCN) is an alliance of 31 cancer centers in the United States, dedicated to improving the quality, effectiveness, and efficiency of cancer care.\\nCancer : Cancer is a group of diseases involving abnormal cell growth with the potential to invade or spread to other parts of the body.\\n\\nRelationships:-\\n1. Entity1: \""National Comprehensive Cancer Network\"", Entity2: \""NCCN Guidelines\"", Relationship: \""provides\""\\n2. Entity1: \""NCCN Guidelines\"", Entity2: \""Clinical Trials\"", Relationship: \""recommend\""\\n3. Entity1: \""NCCN Guidelines\"", Entity2: \""Cancer\"", Relationship: \""related to management of\""\\n\\nCausalities:-\\n<CO> any patient with cancer </CO> <A> the best management is in a clinical trial </A>. <A> Participation in clinical trials is especially encouraged </A>.\\n\\nSection Name: SUPRA-3\\n====================\\nEntities:-\\nLaryngectomy : A surgical procedure involving the removal of the larynx, usually to treat cancer of the larynx.\\nThyroidectomy : A surgical procedure to remove all or part of the thyroid gland.\\nNeck Dissection : Surgical procedure to remove lymph nodes and surrounding tissue to treat or prevent cancer spread.\\nChemotherapy, Induction : Initial chemotherapy treatment to shrink a tumor before the main treatment.\\nClinical Trials As Topic : Research studies that prospectively assign human participants or groups of humans to one or more health-related interventions to evaluate the effects on health outcomes.\\nInduction Chemotherapy : Initial chemotherapy treatment used to shrink a tumor before the main treatment, which is usually surgery.\\nClinical Trial : A clinical trial is a research study that prospectively assigns human participants or groups of humans to one or more health-related interventions to evaluate the effects on health outcomes.\\n\\nRelationships:-\\n1. Entity1: \""Total laryngectomy\"", Entity2: \""Laryngectomy\"", Relationship: \""is a type of\""\\n2. Entity1: \""Systemic therapy\"", Entity2: \""RT\"", Relationship: \""concurrent treatment option\""\\n3. Entity1: \""Induction chemotherapy\"", Entity2: \""Other treatments\"", Relationship: \""initial treatment option before\""\\n\\nCausalities:-\\n<CO> Requiring (amenable to) total laryngectomy (T3,N0) </CO>\\n  - <A> Concurrent systemic therapy/RT </A> or <A> RT if patient not medical candidate for concurrent systemic therapy/RT </A>\\n  - <A> Laryngectomy, thyroidectomy and with ipsilateral, central, or bilateral neck dissection </A>\\n  - or\\n  - <A> Induction chemotherapy </A>\\n  - or\\n  - <A> Clinical trials </A>\\n\\nSection Name: Follow-up\\n====================\\nEntities:-\\nFollow-Up Studies : Studies in which individuals are followed over time to determine the outcome of exposures, treatments, or interventions.\\nFollow-Up Procedure : A procedure performed to monitor the progress of a patient\\'s condition after initial treatment.\\nFollow-Up : Medical care given to a patient over time after initial treatment.\\nDisease Recurrence : The return of a sign, symptom, or disease after a remission.\\nRecurrent Disease : The reappearance of a disease after a period of improvement.\\n\\nRelationships:-\\n1. Entity1: \""Follow-up\"", Entity2: \""Recurrent or persistent disease\"", Relationship: \""monitoring\""\\n\\nCausalities:-\\n- **Follow-up (FOLL-A, 1 of 2)**\\n  - <CO> Recurrent or persistent disease </CO> (ADV-3)\\n\\nSection Name: Adverse Pathologic Features\\n====================\\nEntities:-\\nRadiotherapy : The use of high-energy radiation from x-rays, gamma rays, neutrons, protons, and other sources to kill cancer cells and shrink tumors.\\nExtranodal Extension : The spread of cancer beyond the lymph node capsule.\\nPositive Surgical Margin : Cancer cells are present at the edge of the tissue removed during surgery.\\nSystemic Therapy : Treatment using substances that travel through the bloodstream, reaching and affecting cells all over the body.\\n\\nRelationships:-\\n1. Entity1: \""pN1\"", Entity2: \""Radiotherapy\"", Relationship: \""Consideration for treatment\""\\n2. Entity1: \""Extranodal extension\"", Entity2: \""Systemic Therapy\"", Relationship: \""Treatment option\""\\n3. Entity1: \""Extranodal extension\"", Entity2: \""Radiotherapy\"", Relationship: \""Treatment option\""\\n4. Entity1: \""Positive surgical margin\"", Entity2: \""Systemic Therapy\"", Relationship: \""Treatment option\""\\n5. Entity1: \""Positive surgical margin\"", Entity2: \""Radiotherapy\"", Relationship: \""Treatment option\""\\n\\nCausalities:-\\n- <CO>pN1 without other risk features</CO>\\n  - <C>Adverse pathologic features</C>\\n  - <A>Consider RT</A>\\n  - <CO>Extranodal extension and/or positive margin</CO>\\n  - <CO>Other risk features</CO>\\n  - <A>Systemic therapy/RT (category 1)</A>\\n  - <A>RT or Consider systemic therapy/RT</A>\\n\\nSection Name: Response Assessment\\n====================\\nEntities:-\\nResponse Evaluation : The process of assessing the response of a disease to treatment, often used in clinical trials to determine the effectiveness of a therapy.\\nResponse To Treatment : A clinical finding indicating the response of a condition to a therapeutic intervention.\\n\\nRelationships:-\\n\\nSection Name: Principles of Surgery and Radiation Therapy\\n====================\\nEntities:-\\nSurgical Procedures, Operative : Operations carried out for the correction of deformities and defects, repair of injuries, and diagnosis and cure of certain diseases.\\nSurgical Procedure : A medical procedure involving an incision with instruments; performed to repair damage or arrest disease in a living body.\\nSurgery : Medical specialty that uses operative manual and instrumental techniques on a patient to investigate or treat a pathological condition such as a disease or injury.\\nRadiotherapy : The use of high-energy radiation from x-rays, gamma rays, neutrons, protons, and other sources to kill cancer cells and shrink tumors.\\nRadiation Therapy : Radiation therapy is a therapy using ionizing radiation, generally as part of cancer treatment to control or kill malignant cells.\\n\\nRelationships:-\\n1. Entity1: \""Principles of Surgery\"", Entity2: \""Principles of Radiation Therapy\"", Relationship: \""complementary treatments\""\\n\\nCausalities:-\\n**Principles of Surgery (SURG-A).**\\n\\n**Principles of Radiation Therapy (SUPRA-A).**\\n\\nSection Name: Principles of Systemic Therapy\\n====================\\nEntities:-\\nCisplatin : An inorganic and water-soluble platinum complex, cisplatin is an antineoplastic agent that is used in the treatment of various cancers.\\nRadiotherapy : The use of high-energy radiation from x-rays, gamma rays, neutrons, protons, and other sources to kill cancer cells and shrink tumors.\\nRadiation Therapy : Radiation therapy is a therapy using ionizing radiation, generally as part of cancer treatment to control or kill malignant cells.\\n\\nRelationships:-\\n1. Entity1: \""Cisplatin\"", Entity2: \""Systemic Therapy for Non-Nasopharyngeal Cancers\"", Relationship: \""preferred agent\""\\n2. Entity1: \""Cisplatin\"", Entity2: \""Concurrent Systemic Therapy/RT\"", Relationship: \""used in\""\\n\\nCausalities:-\\n<CO> When using concurrent systemic therapy/RT </CO>, <A> the preferred agent is cisplatin (category 1) </A>.\\n--------------------------------------------------\\nPage Number: 70\\n\\nSection Name: Diagnosis\\n====================\\nEntities:-\\nNeoplasm Metastasis : The transfer of a neoplasm from one organ or part of the body to another remote from the primary site.\\nClinical Trial : A research study that prospectively assigns human participants or groups of humans to one or more health-related interventions to evaluate the effects on health outcomes.\\nPersonalized Medicine : A medical model that proposes the customization of healthcare, with medical decisions, practices, and/or products being tailored to the individual patient.\\n\\nRelationships:-\\n1. Entity1: \""recurrent or persistent disease\"", Entity2: \""distant metastases\"", Relationship: \""has condition\""\\n2. Entity1: \""Clinical trials\"", Entity2: \""recurrent or persistent disease with distant metastases\"", Relationship: \""recommended for\""\\n3. Entity1: \""locoregional failure\"", Entity2: \""locoregional treatment\"", Relationship: \""treatment response to\""\\n\\nCausalities:-\\nIn the **Diagnosis** section, the focus is on <C> recurrent or persistent disease with distant metastases </C>. <A> Clinical trials are preferred </A> for <CO> patients diagnosed at this stage </CO>. <CO> If there is locoregional failure </CO>, <A> locoregional treatment should be considered based on the extent of the disease and symptoms presented </A>. This highlights the importance of personalized treatment approaches, taking into account the unique circumstances of each patient.\\n\\nSection Name: Treatment\\n====================\\nEntities:-\\nTherapeutics : The branch of medicine concerned with the treatment of disease and the action of remedial agents.\\nPerformance Status : A measure of how well a patient is able to perform ordinary tasks and carry out daily activities.\\nSystemic Therapy : A type of treatment that uses substances that travel through the bloodstream, reaching and affecting cells all over the body.\\nSurgical Procedures, Operative : Operations carried out for the correction of deformities and defects, repair of injuries, and diagnosis and cure of certain diseases.\\nPalliative Care : An interdisciplinary medical caregiving approach aimed at optimizing quality of life and mitigating suffering among people with serious, complex illness.\\nRadiation Therapy : The medical use of ionizing radiation, generally as part of cancer treatment to control or kill malignant cells.\\n\\nRelationships:-\\n1. Entity1: \""Performance Status\"", Entity2: \""Systemic Therapy\"", Relationship: \""Treatment option for PS 0-1, PS 2, and PS 3 patients\""\\n2. Entity1: \""Performance Status\"", Entity2: \""Surgery\"", Relationship: \""Treatment option for PS 0-1 patients\""\\n3. Entity1: \""Performance Status\"", Entity2: \""Best Supportive Care\"", Relationship: \""Treatment option for PS 0-1 and PS 3 patients\""\\n4. Entity1: \""Performance Status\"", Entity2: \""Palliative Treatments\"", Relationship: \""Treatment option for PS 2 and PS 3 patients\""\\n5. Entity1: \""Performance Status\"", Entity2: \""Radiation Therapy\"", Relationship: \""Consideration for PS 3 patients\""\\n\\nCausalities:-\\nThe <C> Treatment section </C> outlines pathways based on <C> performance status (PS) </C>. For <CO> PS 0-1 patients </CO>, <A> options include combination systemic therapy, single-agent systemic therapy, surgery, or best supportive care for those with limited metastases </A>. For <CO> PS 2 patients </CO>, <A> recommendations include single-agent systemic therapy, supportive care, or palliative treatments </A>. For <CO> PS 3 patients </CO>, <A> the focus is on single-agent therapy and best supportive care, with consideration of palliative radiation therapy (RT) and palliative surgery </A>. This section addresses the evolving needs of patients as their <C> performance status declines </C>.\\n\\nSection Name: Persistent Disease or Progression\\n====================\\nEntities:-\\nDisease Progression : The worsening of a disease over time.\\nSystemic Therapy : A type of treatment that uses substances that travel through the bloodstream, reaching and affecting cells all over the body.\\nClinical Trials : Research studies performed in people that are aimed at evaluating a medical, surgical, or behavioral intervention.\\nPalliative Care : An interdisciplinary medical caregiving approach aimed at optimizing quality of life and mitigating suffering among people with serious, complex illness.\\nQuality Of Life : An individual\\'s overall appraisal of their situation and well-being.\\nSupportive Care : Care given to improve the quality of life of patients who have a serious or life-threatening disease.\\n\\nRelationships:-\\n1. Entity1: \""Persistent Disease or Progression\"", Entity2: \""Systemic Therapy\"", Relationship: \""option for management\""\\n2. Entity1: \""Persistent Disease or Progression\"", Entity2: \""Clinical Trials\"", Relationship: \""option for management\""\\n3. Entity1: \""Persistent Disease or Progression\"", Entity2: \""Palliative Care\"", Relationship: \""option for management\""\\n4. Entity1: \""Best Supportive Care\"", Entity2: \""Quality of Life\"", Relationship: \""improves\""\\n5. Entity1: \""Best Supportive Care\"", Entity2: \""Advanced Illness\"", Relationship: \""applied in context of\""\\n\\nCausalities:-\\n<A> continued evaluation of treatment efficacy </A> is reiterated. <A> Options include systemic therapy, clinical trials, or palliative care </A> <CO> based on the specific patient condition </CO>. <A> Best supportive care is emphasized </A>, <E> prioritizing the patient\\'s quality of life </E>, <CO> particularly in the context of advanced illness </CO>.\\n\\nSection Name: NCCN Guidelines Overview\\n====================\\nEntities:-\\nClinical Trials As Topic : Works about research studies that evaluate the effectiveness and safety of medications or medical devices by monitoring their effects on large groups of people.\\nClinical Trial : A research study that prospectively assigns human participants or groups of humans to one or more health-related interventions to evaluate the effects on health outcomes.\\nNeoplasms : New abnormal growth of tissue that may be benign or malignant.\\nMalignant Neoplastic Disease : A disease in which abnormal cells divide uncontrollably and destroy body tissue.\\nCancer : A group of diseases involving abnormal cell growth with the potential to invade or spread to other parts of the body.\\n\\nRelationships:-\\n1. Entity1: \""cancer\"", Entity2: \""clinical trial\"", Relationship: \""best management through\""\\n\\nCausalities:-\\n<CO> any patient with cancer </CO> <A> Participation in clinical trials is especially encouraged </A>.\\n\\nSection Name: Principles and Considerations\\n====================\\nEntities:-\\nRadiation Therapy : The medical use of ionizing radiation, generally as part of cancer treatment to control or kill malignant cells.\\nSurgery : A medical specialty that uses operative manual and instrumental techniques on a patient to investigate or treat a pathological condition such as disease or injury.\\nSurgical Procedure : A procedure involving an incision with instruments; performed to repair damage or arrest disease in a living body.\\nGenomic Profiling : The measurement of the activity (the expression) of thousands of genes at once, to create a global picture of cellular function.\\nBiomarkers : Biological molecules found in blood, other body fluids, or tissues that are a sign of a normal or abnormal process, or of a condition or disease.\\nBiomarker : A biological molecule found in blood, other body fluids, or tissues that is a sign of a normal or abnormal process, or of a condition or disease.\\nPalliative Care : An interdisciplinary medical caregiving approach aimed at optimizing quality of life and mitigating suffering among people with serious, complex illness.\\nBone Neoplasms : Tumors or cancer of the bone.\\nBone Metastasis : The spread of cancer cells from their original site to a bone.\\n\\nRelationships:-\\n1. Entity1: \""Palliative RT\"", Entity2: \""Bone Metastases\"", Relationship: \""treatment for\""\\n\\nCausalities:-\\n- **Principles of Radiation Therapy (ADV-A).**\\n- **Principles of Surgery (SURG-A).**\\n<A> Consider NGS genomic profiling for biomarker identification. </A>\\n<A> Consider palliative RT </A> <CO> as clinically indicated (e.g., bone metastases) </CO> (RAD-A).\\n- See Principles of Systemic Therapy for Non-Nasopharyngeal Cancers (SYST-A) or Systemic Therapy for Nasopharyngeal Cancers (NASO-B).\\n--------------------------------------------------\\nPage Number: 53\\n\\nSection Name: Introduction\\n====================\\nEntities:-\\nNational Comprehensive Cancer Network : The National Comprehensive Cancer Network (NCCN) is an alliance of 30 cancer centers in the United States, dedicated to improving the quality, effectiveness, and efficiency of cancer care so that patients can live better lives.\\nLaryngeal Neoplasms : Tumors or cancer of the larynx, which may affect the supraglottic, glottic, or subglottic regions.\\nMalignant Neoplasm Of Supraglottis : A malignant tumor located in the supraglottic region of the larynx.\\n\\nRelationships:-\\n1. Entity1: \""National Comprehensive Cancer Network\"", Entity2: \""Malignant neoplasm of supraglottis\"", Relationship: \""provides guidelines for\""\\n2. Entity1: \""clinical staging\"", Entity2: \""treatment strategies\"", Relationship: \""part of flowchart for\""\\n\\nCausalities:-\\nThe provided image is a flowchart outlining the <C> NCCN (National Comprehensive Cancer Network) guidelines </C> for the treatment of <CO> cancers of the supraglottic larynx </CO>. This flowchart <A> utilizes a highly structured approach to convey clinical staging and treatment strategies </A>, indicating the various pathways based on <CO> patient conditions and disease features </CO>.\\n\\nSection Name: NCCN Guidelines Version 4.2024\\n====================\\nEntities:-\\nLaryngeal Neoplasms : Tumors or cancer of the larynx, which may affect the supraglottic, glottic, or subglottic regions.\\nMalignant Neoplasm Of Supraglottis : A malignant tumor located in the supraglottic region of the larynx.\\nSupraglottic Cancer : Cancer that occurs in the supraglottic region of the larynx, above the vocal cords.\\nClinical Trials As Topic : Pre-planned studies of the safety, efficacy, or optimum dosage schedule of one or more diagnostic, therapeutic, or prophylactic drugs, devices, or techniques in humans selected according to predetermined criteria of eligibility and observed for predefined evidence of favorable and unfavorable effects.\\nClinical Trial : A type of research that studies new tests and treatments and evaluates their effects on human health outcomes.\\n\\nRelationships:-\\n1. Entity1: \""Cancer of the Supraglottic Larynx\"", Entity2: \""Clinical Trials\"", Relationship: \""recommended management strategy\""\\n\\nCausalities:-\\n- All recommendations are category 2A unless otherwise indicated.\\n- <A> Participation in clinical trials </A> is especially encouraged.\\n\\nSection Name: Key Components of the Flowchart\\n====================\\nEntities:-\\nNeoplasm Staging : Methods used for staging neoplasms, including clinical and pathological staging.\\nRadiotherapy : The use of ionizing radiation to treat cancer.\\nSurgical Procedures, Operative : Operations carried out for the correction of deformities and defects, repair of injuries, and diagnosis and cure of certain diseases.\\nAdjuvant Chemotherapy : Chemotherapy given in addition to the primary treatment to maximize its effectiveness.\\nNeoplasm Recurrence, Local : The return of a tumor at the original site after treatment.\\nClinical Trials As Topic : Pre-planned studies of the safety, efficacy, or optimum dosage schedule of one or more diagnostic, therapeutic, or prophylactic drugs, devices, or techniques in humans selected according to predetermined criteria of eligibility and observed for predefined evidence of favorable and unfavorable effects.\\n\\nRelationships:-\\n1. Entity1: \""Clinical Staging\"", Entity2: \""Treatment of Primary and Neck\"", Relationship: \""determines\""\\n2. Entity1: \""Evaluation and Follow-Up\"", Entity2: \""Adverse and No Adverse Features\"", Relationship: \""leads to decision based on\""\\n3. Entity1: \""Adjuvant Treatment\"", Entity2: \""Adverse pathologic features\"", Relationship: \""considered if present\""\\n4. Entity1: \""Clinical Trials\"", Entity2: \""Treatment Pathway\"", Relationship: \""part of\""\\n\\nCausalities:-\\n### Key Components of the Flowchart\\n\\n1. **Clinical Staging**: The flowchart starts with <A>clinical staging</A>, indicating that <CO>patients must first be evaluated to determine the extent of cancer</CO>. This is essential for <E>deciding on appropriate treatment options</E>.\\n\\n2. **Treatment of Primary and Neck**: The flowchart details multiple treatment strategies, including:\\n   - <A>**Concurrent systemic therapy/RT**</A>: This suggests a combination approach for <CO>patients eligible for such treatment</CO>.\\n   - <A>**Definitive Radiation Therapy (RT)**</A>: Recommended for <CO>low-volume diseases or patients who cannot tolerate systemic therapy</CO>.\\n   - <A>**Surgical Options**</A>: It highlights options such as endoscopic or open partial laryngectomy and neck dissection, which are <CO>contingent on clinical evaluations</CO>.\\n\\n3. **Evaluation and Follow-Up**: After initial treatment approaches, the chart directs clinicians to perform a <A>\""Post Systemic Therapy/RT or RT Neck Evaluation\""</A>. This step <E>assesses whether there are adverse pathologic features</E>, guiding subsequent treatment decisions.\\n\\n4. **Adverse and No Adverse Features**: The decision pathway diverges based on findings:\\n   - <CO>Patients with **adverse pathologic features**</CO> may have <A>additional diagnostic imaging (CT or MRI)</A> and may require <A>further systemic treatment</A>.\\n   - <CO>Patients with **no adverse features**</CO> may be directed towards <A>considerations for radiation therapy</A>.\\n\\n5. **Adjuvant Treatment and Recurrence**: The chart also addresses <E>management of any recurrent or persistent disease</E>, emphasizing the importance of <A>regular follow-up assessments</A>. Various options for <A>adjuvant treatment</A> are mentioned, focusing on tailored approaches towards ongoing management of the disease.\\n\\n6. **Clinical Trials**: The flowchart encourages <A>participation in clinical trials</A>, indicating a commitment to <E>exploring new treatments and improving patient outcomes</E>.\\n\\nSection Name: Principles\\n====================\\nEntities:-\\nImaging : The process of producing images of the body or parts of the body to diagnose or examine disease.\\nSurgical Procedure : A medical procedure involving an incision with instruments; performed to repair damage or arrest disease in a living body.\\nRadiation Therapy : The use of ionizing radiation to treat cancer and other diseases.\\nSystemic Therapy : Treatment using substances that travel through the bloodstream, reaching and affecting cells all over the body.\\n\\nRelationships:-\\n1. Entity1: \""Imaging\"", Entity2: \""Surgery\"", Relationship: \""Both are foundational principles in medical practice.\""\\n2. Entity1: \""Radiation therapy\"", Entity2: \""Systemic Therapy\"", Relationship: \""Both are treatment modalities for cancer.\""\\n\\nCausalities:-\\n#### Principles\\n- **Principles of Imaging (IMG-A)**\\n- **Principles of Surgery (SURG-A)**\\n- **Principles of Radiation Therapy (SUPRA-A)**\\n- **Principles of Systemic Therapy for Non-Nasopharyngeal Cancers (SYST-A)**\\n\\nSection Name: Adverse Pathologic Features\\n====================\\nEntities:-\\nExtranodal Extension : The spread of cancer cells beyond the lymph node capsule into the surrounding tissues.\\nPositive Surgical Margins : The presence of cancer cells at the edge of the tissue removed during surgery.\\nPerineural Invasion : Cancer cells found surrounding or tracking along a nerve within the perineural space.\\nVascular Invasion : The presence of cancer cells within blood vessels.\\nLymphatic Invasion : The presence of cancer cells within lymphatic vessels.\\n\\nRelationships:-\\n1. Entity1: \""Extranodal Extension\"", Entity2: \""Positive Surgical Margins\"", Relationship: \""Both indicate cancer spread beyond original site.\""\\n2. Entity1: \""Perineural Invasion\"", Entity2: \""Vascular Invasion\"", Relationship: \""Both are pathways for cancer spread.\""\\n3. Entity1: \""pT3 or pT4 primary\"", Entity2: \""pN2 or pN3 nodal disease\"", Relationship: \""Both indicate advanced cancer stages.\""\\n\\nCausalities:-\\n<C> Extranodal extension </C>\\n<C> Positive margins </C>\\n<C> Close margins </C>\\n<C> pT3 or pT4 primary </C>\\n<C> pN2 or pN3 nodal disease </C>\\n<C> Perineural invasion </C>\\n<C> Vascular invasion </C>\\n<C> Lymphatic invasion </C>\\n\\nSection Name: Clinical Staging and Treatment of Primary and Neck\\n====================\\nEntities:-\\nAdjuvant Chemotherapy : Chemotherapy given in addition to the primary treatment to maximize its effectiveness.\\nFollow-Up Procedure : A procedure performed to monitor the progress of a patient after treatment.\\nRecurrent Disease : A disease that returns after a period of remission.\\nLaryngectomy : Surgical removal of the larynx, often used to treat cancer.\\nRadiation Therapy : The use of ionizing radiation to treat cancer and other diseases.\\nClinical Trial : A type of research that studies new tests and treatments and evaluates their effects on human health outcomes.\\nNeck Dissection : Surgical procedure to remove lymph nodes and surrounding tissue to treat cancer.\\nChemotherapy : Treatment of disease by the use of chemical substances, especially cancer by cytotoxic drugs.\\n\\nRelationships:-\\n1. Entity1: \""Adjuvant Treatment\"", Entity2: \""Treatment of Primary and Neck\"", Relationship: \""part of\""\\n2. Entity1: \""Follow-up\"", Entity2: \""Treatment of Primary and Neck\"", Relationship: \""part of\""\\n3. Entity1: \""Recurrent or Persistent Disease\"", Entity2: \""Treatment of Primary and Neck\"", Relationship: \""part of\""\\n4. Entity1: \""Larynx-Preserving Surgery\"", Entity2: \""Treatment Options\"", Relationship: \""is a treatment option for\""\\n5. Entity1: \""Concurrent Systemic Therapy/RT\"", Entity2: \""Treatment Options\"", Relationship: \""is a treatment option for\""\\n6. Entity1: \""Clinical Trials or Definitive RT\"", Entity2: \""Treatment Options\"", Relationship: \""is a treatment option for\""\\n7. Entity1: \""Endoscopic or Open Partial Laryngectomy and Neck Dissection(s)\"", Entity2: \""Treatment Options\"", Relationship: \""is a treatment option for\""\\n8. Entity1: \""Induction Chemotherapy\"", Entity2: \""Treatment Options\"", Relationship: \""is a treatment option for\""\\n\\nCausalities:-\\n<A> Amenable to Larynx-Preserving (Conservation) Surgery </A>: <CO> T1\u20132, N+ and selected T3, N1 </CO>\\n<A> Concurrent Systemic Therapy/RT </A>: <CO> i, k, l </CO>\\n<A> Clinical Trials or Definitive RT </A>: <CO> i </CO>\\n<A> Endoscopic or Open Partial Laryngectomy and Neck Dissection(s) </A>: <CO> h </CO>\\n<A> Induction Chemotherapy </A>: <CO> k, m </CO>\\n\\nSection Name: Pathologic Features and Response Assessment\\n====================\\nEntities:-\\nRadiation Therapy : The use of ionizing radiation to treat cancer and other diseases.\\nExtranodal Extension : The spread of cancer cells beyond the lymph node capsule into the surrounding tissues.\\nPositive Surgical Margin : Cancer cells are found at the edge of the material removed during surgery, indicating that some cancer may have been left behind.\\nSystemic Therapy : Treatment using substances that travel through the bloodstream, reaching and affecting cells all over the body.\\n\\nRelationships:-\\n1. Entity1: \""Extranodal extension\"", Entity2: \""Adverse Pathologic Features\"", Relationship: \""is a type of\""\\n2. Entity1: \""Positive margin\"", Entity2: \""Adverse Pathologic Features\"", Relationship: \""is a type of\""\\n3. Entity1: \""Systemic Therapy\"", Entity2: \""Adverse Pathologic Features\"", Relationship: \""considered in response to\""\\n4. Entity1: \""Radiation Therapy\"", Entity2: \""Adverse Pathologic Features\"", Relationship: \""considered in response to\""\\n\\nCausalities:-\\n#### Pathologic Features\\n- **No Adverse Pathologic Features**: j\\n  - <A> Consider RT </A>: i\\n- **Adverse Pathologic Features**: j\\n  - <CO> Extranodal extension and/or positive margin </CO>: n\\n  - Other risk features\\n  - <A> Systemic therapy/RT </A>: i, k (category 1)\\n  - <A> Consider systemic therapy/RT </A>: i, k\\n\\n#### Response Assessment\\n- **Response Assessment** (SUPRA-7)\\n\\nSection Name: Imaging and Recurrent or Persistent Disease\\n====================\\nEntities:-\\nTomography, X-Ray Computed : A method of body imaging in which a thin X-ray beam rotates around the patient.\\nMagnetic Resonance Imaging : Medical imaging technique used in radiology to form pictures of the anatomy and the physiological processes of the body.\\nComputed Tomography : Medical imaging technique used in radiology to obtain detailed internal images of the body.\\n\\nRelationships:-\\n1. Entity1: \""CT\"", Entity2: \""primary and neck\"", Relationship: \""used for imaging\""\\n2. Entity1: \""MRI\"", Entity2: \""primary and neck\"", Relationship: \""used for imaging\""\\n3. Entity1: \""Post Systemic Therapy/RT\"", Entity2: \""Recurrent or Persistent Disease\"", Relationship: \""evaluation after treatment\""\\n4. Entity1: \""RT Neck Evaluation\"", Entity2: \""Recurrent or Persistent Disease\"", Relationship: \""evaluation after treatment\""\\n\\nCausalities:-\\n<A> CT (with contrast) or MRI (with and without contrast) of primary and neck </A>\\n\\n<CO> Recurrent or Persistent Disease </CO>\\n\\n<CO> Post Systemic Therapy/RT or RT Neck Evaluation </CO>\\n\\nSection Name: Conclusion\\n====================\\nEntities:-\\nOncologists : Medical doctors who specialize in the diagnosis and treatment of cancer.\\nSupraglottic Larynx Cancer : A type of cancer that occurs in the supraglottic region of the larynx, which is the area above the vocal cords.\\nClinical Staging : The process of determining the extent of cancer in the body, usually based on physical examination, imaging tests, and biopsies.\\nTreatment Strategies : Plans or methods developed to treat diseases, including cancer, which may involve surgery, chemotherapy, radiation therapy, or other modalities.\\nFollow-Up Evaluations : Medical assessments conducted after initial treatment to monitor a patient\\'s progress and detect any recurrence of disease.\\nClinical Efficacy : The ability of a treatment to produce the desired therapeutic effect in clinical settings.\\nResearch : Systematic investigation and study conducted to establish facts and reach new conclusions.\\nTreatment Paradigms : Standard models or patterns of treatment used in medical practice, often based on clinical guidelines and research findings.\\n\\nRelationships:-\\n1. Entity1: \""Oncologists\"", Entity2: \""Supraglottic Larynx Cancer\"", Relationship: \""use flowchart for decision-making\""\\n2. Entity1: \""Clinical Staging\"", Entity2: \""Treatment Strategies\"", Relationship: \""part of management process\""\\n3. Entity1: \""Treatment Strategies\"", Entity2: \""Follow-Up Evaluations\"", Relationship: \""part of management process\""\\n\\nCausalities:-\\n<A> The flowchart serves as a comprehensive guide for oncologists and healthcare providers </A>, <A> facilitating informed decision-making in the treatment of supraglottic larynx cancer </A>. <A> By visualizing the complex interactions between clinical staging, treatment strategies, and follow-up evaluations </A>, <E> it streamlines the management process </E>, <E> ensuring that patients receive appropriate care tailored to their specific needs </E>. <E> The detailed pathways not only enhance clinical efficacy </E> but also <E> underscore the importance of ongoing research and adaptation of treatment paradigms in oncology </E>.\\n--------------------------------------------------\\nPage Number: 68\\n\\nSection Name: Diagnosis Section\\n====================\\nEntities:-\\nDiagnosis : The process of determining which disease or condition explains a person\\'s symptoms and signs.\\nMetastatic Disease : A disease in which cancer cells spread from the place where they first formed to another part of the body.\\nClinical Trial : A research study that prospectively assigns human participants or groups of humans to one or more health-related interventions to evaluate the effects on health outcomes.\\nLocoregional Therapy : Treatment that is directed to a specific area of the body, often used in cancer treatment.\\n\\nRelationships:-\\n1. Entity1: \""Diagnosis\"", Entity2: \""Decision-making process\"", Relationship: \""initiates\""\\n2. Entity1: \""Metastatic disease\"", Entity2: \""Clinical trial\"", Relationship: \""preferred pathway\""\\n3. Entity1: \""Locoregional treatment\"", Entity2: \""Primary site algorithms\"", Relationship: \""based on\""\\n\\nCausalities:-\\n<CO> for patients presenting with metastatic disease </CO>, <A> a clinical trial is the preferred pathway </A>, emphasizing the critical nature of innovative therapies in advanced cancer care. The option to <A> \""Consider locoregional treatment based on primary site algorithms\"" </A> suggests that specific treatment strategies may be tailored <CO> depending on the exact location and characteristics of the cancer </CO>.\\n\\nSection Name: Treatment Pathways\\n====================\\nEntities:-\\nPerformance Status : A measure of a patient\\'s general well-being and ability to perform ordinary tasks, often used in oncology to determine the appropriate treatment.\\nSystemic Therapy : A treatment using substances that travel through the bloodstream, reaching and affecting cells all over the body.\\nSurgery : A medical specialty that uses operative manual and instrumental techniques on a patient to investigate or treat a pathological condition such as disease or injury.\\nRadiation Therapy : The use of high-energy radiation from x-rays, gamma rays, neutrons, protons, and other sources to kill cancer cells and shrink tumors.\\nPalliative Care : Specialized medical care for people living with a serious illness, focused on providing relief from the symptoms and stress of the illness.\\nSupportive Care : Care given to improve the quality of life of patients who have a serious or life-threatening disease.\\n\\nRelationships:-\\n1. Entity1: \""Performance Status\"", Entity2: \""Systemic Therapy\"", Relationship: \""affects choice of\""\\n2. Entity1: \""Performance Status\"", Entity2: \""Surgery\"", Relationship: \""affects choice of\""\\n3. Entity1: \""Performance Status\"", Entity2: \""Radiation Therapy\"", Relationship: \""affects choice of\""\\n4. Entity1: \""Performance Status\"", Entity2: \""Palliative Care\"", Relationship: \""affects choice of\""\\n5. Entity1: \""Performance Status\"", Entity2: \""Supportive Care\"", Relationship: \""affects choice of\""\\n6. Entity1: \""PS 0-1 Patients\"", Entity2: \""Combination Systemic Therapy\"", Relationship: \""suitable for\""\\n7. Entity1: \""PS 2 Patients\"", Entity2: \""Palliative Radiation Therapy\"", Relationship: \""may receive\""\\n8. Entity1: \""PS 3 Patients\"", Entity2: \""Supportive Care\"", Relationship: \""recommended\""\\n\\nCausalities:-\\nThe treatment section branches into various pathways depending on <CO> the patient\u2019s performance status (PS) </CO>, which is a measure of their general well-being and ability to function. - **For PS 0-1 Patients:** The flowchart indicates several treatment options, including <A> combination systemic therapy, single-agent systemic therapy, surgery, and radiation therapy (RT) </A>. This group is highlighted as those who are most capable of handling intensive treatments and <E> may benefit significantly from combination therapies </E>. - **For PS 2 Patients:** The recommended approach varies slightly, with a continued emphasis on <A> systemic therapies, palliative radiation therapy, or best supportive care </A>. This indicates a level of compromise in treatment options, suggesting that while aggressive treatment is still possible, <E> the focus might shift more towards quality of life </E>. - **For PS 3 Patients:** The treatment options further narrow, still recommending <A> systemic therapy or supportive care </A> but highlighting palliative approaches, reflecting a recognition of <E> the more advanced disease and potentially limited treatment efficacy </E>.\\n\\nSection Name: Principles of Treatment\\n====================\\nEntities:-\\nAntineoplastic Combined Chemotherapy Protocols : Protocols for the administration of more than one antineoplastic agent in combination to treat malignant neoplasms.\\nRadiotherapy : The use of radiation, usually X-rays or gamma rays, to treat disease, especially cancer.\\nSurgical Procedures, Operative : Operations carried out for the correction of deformities and defects, repair of injuries, and diagnosis and cure of certain diseases.\\nSystemic Therapy : A treatment using substances that travel through the bloodstream, reaching and affecting cells all over the body.\\nRadiation Therapy : The use of high-energy radiation from x-rays, gamma rays, neutrons, protons, and other sources to kill cancer cells and shrink tumors.\\nSurgical Procedure : A procedure involving an incision with instruments; performed to repair damage or arrest disease in a living body.\\nChemotherapy : A type of cancer treatment that uses one or more anti-cancer drugs as part of a standardized chemotherapy regimen.\\nSurgery : A medical specialty that uses operative manual and instrumental techniques on a patient to investigate or treat a pathological condition such as disease or injury.\\n\\nRelationships:-\\n1. Entity1: \""Systemic Therapy\"", Entity2: \""Radiation Therapy\"", Relationship: \""Different modalities of cancer treatment\""\\n2. Entity1: \""Systemic Therapy\"", Entity2: \""Surgery\"", Relationship: \""Different modalities of cancer treatment\""\\n3. Entity1: \""Radiation Therapy\"", Entity2: \""Surgery\"", Relationship: \""Different modalities of cancer treatment\""\\n\\nCausalities:-\\n- **Principles of Systemic Therapy for Non-Nasopharyngeal Cancers (SYST-A)** - **Principles of Radiation Therapy (ADV-A)** - **Principles of Surgery (SURG-A)**\\n\\nSection Name: Diagnosis and Treatment of Head and Neck Cancer\\n====================\\nEntities:-\\nNeoplasm Metastasis : The transfer of a neoplasm from one organ or part of the body to another remote from the primary site.\\nMetastatic Malignant Neoplasm : A malignant neoplasm that has spread from its original site to a different site.\\nMetastasis : The spread of a cancer or other disease from one organ or part to another not directly connected with it.\\nClinical Trials As Topic : Works about research studies that evaluate the effectiveness and safety of medications or medical devices by monitoring their effects on large groups of people.\\nClinical Trial : A research study that prospectively assigns human participants or groups of humans to one or more health-related interventions to evaluate the effects on health outcomes.\\nPerformance Status : A measure of a patient\\'s general well-being and ability to perform ordinary tasks, often used in oncology to determine the appropriate treatment.\\n\\nRelationships:-\\n1. Entity1: \""Metastatic disease\"", Entity2: \""Clinical trial\"", Relationship: \""preferred treatment option\""\\n2. Entity1: \""Performance Status 0-1\"", Entity2: \""Combination systemic therapy\"", Relationship: \""treatment option\""\\n3. Entity1: \""Performance Status 2\"", Entity2: \""Single-agent systemic therapy\"", Relationship: \""treatment option\""\\n4. Entity1: \""Performance Status 3\"", Entity2: \""Systemic therapy\"", Relationship: \""treatment option\""\\n\\nCausalities:-\\n- <CO>Metastatic (M1) disease at initial presentation</CO>\\n  <A>Clinical trial preferred</A>\\n  <E>Distant metastases</E>\\n  <A>Consider locoregional treatment based on primary site algorithms (Table of Contents)</A>\\n\\n#### Performance Status (PS)\\n- <CO>PS 0\u20131</CO>\\n  <A>Combination systemic therapy</A> or <A>Single-agent systemic therapy</A> or <A>Surgery</A> or <A>RT</A> or <A>systemic therapy/RT for selected patients with limited metastases</A> or <A>Best supportive care</A>\\n- <CO>PS 2</CO>\\n  <A>Single-agent systemic therapy</A> or <A>Best supportive care \u00b1 Palliative RT</A> or <A>Palliative surgery</A>\\n- <CO>PS 3</CO>\\n  <A>Systemic therapy, clinical trial preferred</A> or <A>Palliative RT</A> or <A>Best supportive care</A>\\n\\nSection Name: Persistent Disease or Progression\\n====================\\nEntities:-\\nPalliative Care : Specialized medical care for people living with a serious illness, focused on providing relief from the symptoms and stress of the illness.\\nSupportive Care : Care given to improve the quality of life of patients who have a serious or life-threatening disease.\\nAntineoplastic Agents : Substances that inhibit or prevent the proliferation of neoplasms.\\nSystemic Therapy : A treatment using substances that travel through the bloodstream, reaching and affecting cells all over the body.\\nChemotherapy : A type of cancer treatment that uses one or more anti-cancer drugs as part of a standardized chemotherapy regimen.\\nRadiotherapy : The use of radiation, usually X-rays or gamma rays, to treat disease, especially cancer.\\nPalliative Radiotherapy : Radiotherapy given to relieve symptoms and reduce suffering caused by cancer.\\nRadiation Therapy : The use of high-energy radiation from x-rays, gamma rays, neutrons, protons, and other sources to kill cancer cells and shrink tumors.\\n\\nRelationships:-\\n1. Entity1: \""Best supportive care\"", Entity2: \""Alternate single-agent systemic therapy\"", Relationship: \""alternative treatment options\""\\n2. Entity1: \""Best supportive care\"", Entity2: \""Palliative RT\"", Relationship: \""alternative treatment options\""\\n3. Entity1: \""Alternate single-agent systemic therapy\"", Entity2: \""Palliative RT\"", Relationship: \""alternative treatment options\""\\n\\nCausalities:-\\n<A> Best supportive care </A> or <A> Alternate single-agent systemic therapy </A> or <A> Palliative RT </A>\\n--------------------------------------------------\\nPage Number: 69\\n\\nSection Name: Diagnosis\\n====================\\nEntities:-\\nHead And Neck Neoplasms : Tumors or cancer of the head and neck region, including the nasal cavity, sinuses, lips, mouth, salivary glands, throat, or larynx.\\nMalignant Neoplasm Of Head And Neck : A malignant tumor located in the head and neck region.\\nHead And Neck Cancer : Cancer that arises in the head or neck region, including the throat, larynx, nose, sinuses, and mouth.\\nRadiation Therapy : A therapy that uses ionizing radiation, generally as part of cancer treatment to control or kill malignant cells.\\nRadiotherapy : A treatment method that uses ionizing radiation, generally as part of cancer treatment to control or kill malignant cells.\\nSurgical Procedures, Operative : Operations carried out for the correction of deformities and defects, repair of injuries, and diagnosis and cure of certain diseases.\\nSurgical Procedure : A procedure involving an incision with instruments; performed to repair damage or arrest disease in a living body.\\nSurgery : A medical specialty that uses operative manual and instrumental techniques on a patient to investigate or treat a pathological condition such as disease or injury.\\nClinical Trials As Topic : Pre-planned studies of the safety, efficacy, or optimum dosage schedule of one or more diagnostic, therapeutic, or prophylactic drugs, devices, or techniques in humans selected according to predetermined criteria of eligibility and observed for predefined evidence of favorable and unfavorable effects.\\nClinical Trial : A research study that prospectively assigns human participants or groups of humans to one or more health-related interventions to evaluate the effects on health outcomes.\\n\\nRelationships:-\\n1. Entity1: \""head and neck cancer\"", Entity2: \""surgery\"", Relationship: \""preferred treatment if resectable\""\\n2. Entity1: \""head and neck cancer\"", Entity2: \""reirradiation\"", Relationship: \""treatment option if unresectable\""\\n3. Entity1: \""head and neck cancer\"", Entity2: \""clinical trials\"", Relationship: \""preferred for unresectable cases\""\\n\\nCausalities:-\\nThe diagnosis process for very advanced head and neck cancer involves <CO> categorizing patients based on their disease status </CO>. The guidelines differentiate between \\'Recurrent or persistent disease\\' and \\'Locoregional recurrence or persistent disease without prior RT (radiation therapy)\\'. This distinction is crucial <C> as it influences subsequent treatment decisions </C>. <CO> In cases of locoregional recurrence or persistent disease without prior RT </CO>, the disease can be classified as \\'Resectable\\' or \\'Unresectable\\'. <CO> If resectable </CO>, <A> surgery is the preferred treatment </A>. <CO> If unresectable </CO>, <A> options include reirradiation with or without systemic therapy, and clinical trials are preferred </A>.\\n\\nSection Name: Treatment of Very Advanced Head and Neck Cancer\\n====================\\nEntities:-\\nHead And Neck Neoplasms : Tumors or cancer of the head and neck region, including the nasal cavity, sinuses, lips, mouth, salivary glands, throat, or larynx.\\nMalignant Neoplasm Of Head And Neck : A malignant tumor located in the head and neck region.\\nHead And Neck Cancer : Cancer that arises in the head or neck region, including the throat, larynx, nose, sinuses, and mouth.\\nSurgical Procedures, Operative : Operations carried out for the correction of deformities and defects, repair of injuries, and diagnosis and cure of certain diseases.\\nSurgical Procedure : A procedure involving an incision with instruments; performed to repair damage or arrest disease in a living body.\\nSurgery : A medical specialty that uses operative manual and instrumental techniques on a patient to investigate or treat a pathological condition such as disease or injury.\\nRadiotherapy : A treatment method that uses ionizing radiation, generally as part of cancer treatment to control or kill malignant cells.\\nRadiation Therapy : A therapy that uses ionizing radiation, generally as part of cancer treatment to control or kill malignant cells.\\nClinical Trials As Topic : Pre-planned studies of the safety, efficacy, or optimum dosage schedule of one or more diagnostic, therapeutic, or prophylactic drugs, devices, or techniques in humans selected according to predetermined criteria of eligibility and observed for predefined evidence of favorable and unfavorable effects.\\nClinical Trial : A research study that prospectively assigns human participants or groups of humans to one or more health-related interventions to evaluate the effects on health outcomes.\\n\\nRelationships:-\\n1. Entity1: \""Surgery\"", Entity2: \""Resectable disease\"", Relationship: \""recommended for\""\\n2. Entity1: \""Reirradiation\"", Entity2: \""Unresectable disease\"", Relationship: \""considered for\""\\n3. Entity1: \""Systemic therapy\"", Entity2: \""Unresectable disease\"", Relationship: \""considered for\""\\n4. Entity1: \""Clinical trials\"", Entity2: \""Head and neck cancer\"", Relationship: \""preferred for management of\""\\n\\nCausalities:-\\n<CO> For resectable disease </CO>, <A> surgery with or without postoperative reirradiation is recommended </A>, and <A> systemic therapy or RT is considered </A>, with <A> clinical trials preferred </A>. <CO> For unresectable disease </CO>, <A> reirradiation with or without systemic therapy is recommended </A>, and <A> best supportive care is considered </A>. The guidelines emphasize the importance of <A> clinical trials </A> and suggest that <A> the best management of any patient with cancer is in a clinical trial </A>.\\n\\nSection Name: Pathologic Features\\n====================\\nEntities:-\\nPathologic Processes : The physiological processes and conditions that are characteristic of disease or injury.\\nRadiotherapy : A treatment method that uses ionizing radiation, generally as part of cancer treatment to control or kill malignant cells.\\nSystemic Therapy : A type of medical treatment that uses substances that travel through the bloodstream, reaching and affecting cells all over the body.\\nExtranodal Extension : The spread of cancer beyond the lymph node capsule into the surrounding tissues.\\nPositive Surgical Margin : A situation where cancer cells are found at the edge of the material removed during surgery, indicating that some cancer may have been left behind.\\nRadiation Therapy : A therapy that uses ionizing radiation, generally as part of cancer treatment to control or kill malignant cells.\\n\\nRelationships:-\\n1. Entity1: \""Adverse pathologic features\"", Entity2: \""Systemic therapy with RT\"", Relationship: \""leads to\""\\n2. Entity1: \""No adverse pathologic features\"", Entity2: \""Observation and follow-up\"", Relationship: \""leads to\""\\n3. Entity1: \""Other risk features\"", Entity2: \""RT or systemic therapy with RT\"", Relationship: \""may warrant\""\\n\\nCausalities:-\\n<C> Pathologic features </C> play a significant role in determining the treatment approach. <CO> If no adverse pathologic features are present </CO>, <A> observation and follow-up are recommended </A>. <CO> if adverse pathologic features such as extranodal extension or positive margins are present </CO>, <A> systemic therapy with RT is recommended </A>. <CO> Other risk features </CO> may also <A> warrant RT or systemic therapy with RT </A>. The guidelines highlight the importance of considering <C> these features </C> in treatment planning.\\n\\nSection Name: Therapy for Persistent Disease\\n====================\\nEntities:-\\nRadiotherapy : A treatment method that uses ionizing radiation, generally as part of cancer treatment to control or kill malignant cells.\\nSystemic Therapy : A type of medical treatment that uses substances that travel through the bloodstream, reaching and affecting cells all over the body.\\nNext-Generation Sequencing : High-throughput sequencing methods that allow for rapid sequencing of large stretches of DNA.\\nBiomarkers : Biological molecules that indicate a process, condition, or disease and can be used to assess the effect of treatment.\\nRadiation Therapy : A therapy that uses ionizing radiation, generally as part of cancer treatment to control or kill malignant cells.\\nBiomarker : A biological molecule found in blood, other body fluids, or tissues that is a sign of a normal or abnormal process, or of a condition or disease.\\n\\nRelationships:-\\n1. Entity1: \""Guidelines\"", Entity2: \""Therapy\"", Relationship: \""recommendation\""\\n2. Entity1: \""Next-Generation Sequencing\"", Entity2: \""Biomarker Identification\"", Relationship: \""used for\""\\n3. Entity1: \""Therapy\"", Entity2: \""Systemic Therapy\"", Relationship: \""can include\""\\n4. Entity1: \""Therapy\"", Entity2: \""Radiotherapy\"", Relationship: \""can include\""\\n\\nCausalities:-\\n<CO> For persistent disease </CO>, the guidelines <A> recommend therapy </A> <CO> as indicated by the specific clinical scenario </CO>. This may include <A> systemic therapy, RT, or a combination of both </A>, <CO> depending on the presence of adverse pathologic features and other risk factors </CO>. The guidelines also <A> suggest considering next-generation sequencing genomic profiling </A> <C> for biomarker identification </C> <A> to tailor treatment strategies </A>.\\n\\nSection Name: Conclusion\\n====================\\nEntities:-\\nHead And Neck Neoplasms : Tumors or cancer of the head and neck region, including the nasal cavity, sinuses, lips, mouth, salivary glands, throat, or larynx.\\nMalignant Neoplasm Of Head And Neck : A malignant tumor located in the head and neck region.\\nHead And Neck Cancer : Cancer that arises in the head or neck region, including the throat, larynx, nose, sinuses, and mouth.\\nClinical Trials As Topic : Pre-planned studies of the safety, efficacy, or optimum dosage schedule of one or more diagnostic, therapeutic, or prophylactic drugs, devices, or techniques in humans selected according to predetermined criteria of eligibility and observed for predefined evidence of favorable and unfavorable effects.\\nClinical Trial : A research study that prospectively assigns human participants or groups of humans to one or more health-related interventions to evaluate the effects on health outcomes.\\n\\nRelationships:-\\n1. Entity1: \""NCCN guidelines\"", Entity2: \""head and neck cancer\"", Relationship: \""used for diagnosis and treatment\""\\n2. Entity1: \""NCCN guidelines\"", Entity2: \""clinical trials\"", Relationship: \""emphasize importance\""\\n3. Entity1: \""NCCN guidelines\"", Entity2: \""healthcare providers\"", Relationship: \""serve as a resource for\""\\n\\nCausalities:-\\nThe NCCN guidelines <A> provide a comprehensive framework for the diagnosis and treatment of very advanced head and neck cancer </A>. <A> They emphasize evidence-based practices </A> and <A> the importance of clinical trials </A>, <A> advocating for an individualized approach to patient care </A>. The guidelines <E> serve as a critical resource for healthcare providers </E>, <E> ensuring that all potential treatment avenues are explored </E> while <CO> considering patient-specific factors </CO>.\\n'}""",valid,increases risk,2,B,"edge - The edge which needs to be verified.
explanation - Explanation of what the edge represents and its validity.
causal_direction - Either Positive or Negative or Unknown. A positive influence direction indicates that both factors change in the same direction (e.g. an increase causes an increase effect). A negative influence direction indicates the opposite changes (e.g. an increase causes a decrease effect).
causal_factor - Is necessary or sufficient condition for an effect to occur. Exposure is a term commonly used in epidemiology to denote any condition that is considered as a possible cause of disease. Exposure is considered necessary when it always precedes the effects (e.g. symptoms) and always presents when the effects occur. A sufficient cause is a causal factor whose presence or occurrence guarantees the occurrence of symptom.
causal_distance - Either Distal or Proximal or Unknown. The distal factors lie towards the beginning of causal chain (i.e. indirect causal factors). The the proximal factors lie towards the end of the chain (i.e. cause directly or almost directly the effect).

Causality Tags:
<A> for action, <C> for cause, <CO> for condition and <E> for effect.
Cause (C): The reason or origin that leads to an effect. Causes often involve disease conditions, risk factors, or underlying mechanisms.
Effect (E): The outcome or result of a cause. Effects usually represent clinical outcomes, complications, or results of a specific cause.
Condition (CO): The circumstance or prerequisite required for an action or effect to occur. Conditions may include patient characteristics, clinical scenarios, or specific diagnostic criteria.
Action (A): The recommended or described response or activity to address a cause or condition. Actions typically involve clinical interventions, diagnostic procedures, or treatment recommendations.


`NODE1`:
id: Location_of_Lymph_Nodes_3
label: Location of Lymph Nodes
description: This node represents the presence or absence of lymph nodes in a specific location, which is crucial for cancer diagnosis and staging. The detection of lymph nodes can indicate the spread of cancer and affect treatment decisions.
type: Patient Situation
observability: Unobserved
states: [{'state_name': 'present', 'state_description': 'Lymph nodes are detected in the specified location, which may indicate the spread of cancer and is important for staging and treatment planning.'}, {'state_name': 'absent', 'state_description': 'Lymph nodes are not detected in the specified location, which may suggest no spread of cancer to this area and is important for staging and treatment planning.'}]

`NODE2`:
id: Examination_11
label: Diagnostic Examination Result
description: This node represents the result of a specific diagnostic examination, which is observed and can indicate the presence or absence of a particular condition or finding.
type: Examination Result
observability: Observed
states: [{'state_name': 'present', 'state_description': 'The result of the examination indicates the presence of the condition or finding being tested for.'}, {'state_name': 'absent', 'state_description': 'The result of the examination indicates the absence of the condition or finding being tested for.'}]

`EDGE1`:
{'edges_ids': ['Location_of_Lymph_Nodes_3', 'Examination_11'], 'edge': '(Location_of_Lymph_Nodes_3) causes (Examination_11)', 'explanation': ['The edge represents a causal relationship where the presence or absence of lymph nodes in a specific location (`Location_of_Lymph_Nodes_3`) affects the result of a diagnostic examination (`Examination_11`).', 'If the examination is designed to detect lymph nodes or assess cancer spread, then the presence of lymph nodes would likely lead to a `present` result in the examination.', 'The causal direction is positive because the presence of lymph nodes would lead to a positive finding in the examination if it is related to lymph nodes.', 'The causal factor is neither necessary nor sufficient because other factors could lead to a `present` examination result, and the presence of lymph nodes alone does not guarantee a `present` result unless the examination is specifically for that purpose.', 'The causal distance is proximal if the examination is directly related to detecting lymph nodes, as it would be a direct cause-effect relationship.'], 'causal_direction': 'positive', 'causal_factor': {'necessary': False, 'sufficient': False}, 'causal_distance': 'Proximal'}

`EDGE2`:
{'edges_ids': ['Examination_11', 'Location_of_Lymph_Nodes_3'], 'edge': '(Examination_11) causes (Location_of_Lymph_Nodes_3)', 'explanation': ['The edge suggests that the result of a diagnostic examination (Examination_11) causes the presence or absence of lymph nodes in a specific location (Location_of_Lymph_Nodes_3).', ""However, the examination result is an observation of the lymph nodes presence or absence, not a cause of it."", 'The presence of lymph nodes is a physical condition that might be detected by the examination, but the examination itself does not cause the lymph nodes to appear or disappear.', 'Therefore, the edge is not valid as a causal relationship.'], 'causal_direction': 'Unknown', 'causal_factor': {'necessary': False, 'sufficient': False}, 'causal_distance': 'Proximal'}

`INFORMATION FROM KNOWLEDGE BASE`:
--------------------------------------------------
Page Number: 51

Section Name: Introduction
====================
Entities:-
Laryngeal Neoplasms : Tumors or cancer of the larynx, which may affect the supraglottic, glottic, or subglottic regions.
Malignant Neoplasm Of Supraglottis : A malignant tumor located in the supraglottic region of the larynx.
Supraglottic Laryngeal Cancer : A type of cancer that occurs in the supraglottic region of the larynx, which is above the vocal cords.

Relationships:-
1. Entity1: ""National Comprehensive Cancer Network (NCCN)"", Entity2: ""cancer of the supraglottic larynx"", Relationship: ""provides guidelines for""
2. Entity1: ""healthcare professionals"", Entity2: ""cancer of the supraglottic larynx"", Relationship: ""manage""

Causalities:-
The provided image is a detailed flowchart from the National Comprehensive Cancer Network (NCCN) guidelines regarding the <C> clinical staging and treatment protocols for cancer of the supraglottic larynx </C>. This flowchart is structured to <A> guide healthcare professionals through the stages of treatment </A> based on <CO> clinical findings </CO>, emphasizing the <E> complexity and systematic approach required in managing this type of cancer </E>.

Section Name: Clinical Staging
====================
Entities:-
Laryngectomy : A surgical procedure involving the removal of the larynx, usually to treat cancer of the larynx.
Total Laryngectomy : A surgical procedure to remove the entire larynx, often used in the treatment of advanced laryngeal cancer.
Neoplasm Staging : Methods used for staging neoplasms, including clinical and pathological staging.
Cancer Staging : The process of determining the extent of cancer in the body, often using the TNM system.
Tnm Staging System : A cancer staging system that describes the extent of cancer using Tumor size (T), Node involvement (N), and Metastasis (M).

Relationships:-
1. Entity1: ""Clinical staging criteria"", Entity2: ""Total laryngectomy"", Relationship: ""determines necessity of""
2. Entity1: ""T3, N0"", Entity2: ""Clinical staging criteria"", Relationship: ""is a categorization of""

Causalities:-
The flowchart begins with the <C> clinical staging criteria </C>, specifically focusing on <CO> cases that require total laryngectomy, denoted as requiring (amenable to) total laryngectomy (T3, N0) </CO>. This <A> categorization </A> is crucial as it <E> forms the basis for determining the appropriate treatment strategy </E>.

Section Name: Treatment of Primary and Neck
====================
Entities:-
Neoplasm Staging : Methods used for staging neoplasms, including clinical and pathological staging.
Systemic Therapy : Treatment using substances that travel through the bloodstream, reaching and affecting cells all over the body.
Radiotherapy : The use of high-energy radiation from x-rays, gamma rays, neutrons, protons, and other sources to kill cancer cells and shrink tumors.
Laryngectomy : A surgical procedure involving the removal of the larynx, usually to treat cancer of the larynx.
Thyroidectomy : A surgical procedure to remove all or part of the thyroid gland.
Neck Dissection : Surgical procedure to remove lymph nodes and surrounding tissue to treat or prevent cancer spread.
Lymphatic Metastasis : Transfer of a neoplasm from one organ or part of the body to another remote from the primary site.

Relationships:-
1. Entity1: ""Systemic Therapy"", Entity2: ""Radiation Therapy"", Relationship: ""combined with""
2. Entity1: ""Laryngectomy"", Entity2: ""Lymph Node Involvement"", Relationship: ""considered based on""
3. Entity1: ""Thyroidectomy"", Entity2: ""Lymph Node Involvement"", Relationship: ""considered based on""
4. Entity1: ""Neck Dissection"", Entity2: ""Lymph Node Involvement"", Relationship: ""considered based on""

Causalities:-
<CO> Once clinical staging is established </CO>, the chart outlines various treatment options. <A> The initial step may involve either concurrent systemic therapy combined with radiation therapy (RT) or opting for RT alone </A>, <CO> especially if the patient is not a medical candidate for both therapies </CO>. <A> Laryngectomy, thyroidectomy, and neck dissection are considered </A> <CO> based on the extent of lymph node involvement </CO>.

Section Name: Surgical Options
====================
Entities:-
Laryngectomy : A surgical procedure involving the removal of the larynx, usually to treat cancer of the larynx.
Thyroidectomy : A surgical procedure to remove all or part of the thyroid gland.
Lymph Node Excision : Surgical removal of one or more lymph nodes.
Lymphadenectomy : Surgical removal of one or more groups of lymph nodes.
Surgical Procedures, Operative : Operations carried out for the correction of deformities and defects, repair of injuries, and diagnosis and cure of certain diseases.
Surgical Procedure : A medical procedure involving an incision with instruments; performed to repair damage or arrest disease in a living body.
Surgery : Medical specialty that uses operative manual and instrumental techniques on a patient to investigate or treat a pathological condition such as a disease or injury.

Relationships:-
1. Entity1: ""Laryngectomy"", Entity2: ""Thyroidectomy"", Relationship: ""combined with""
2. Entity1: ""Lymph Node Dissection"", Entity2: ""Surgical Intervention"", Relationship: ""extent of""
3. Entity1: ""Surgical Intervention"", Entity2: ""Advanced Cases"", Relationship: ""management option for""

Causalities:-
<CO> If concurrent therapies are not suitable </CO>, <A> the chart presents laryngectomy combined with thyroidectomy </A>, <CO> depending on the extent of lymph node dissection required </CO>. <E> This highlights surgical intervention as a viable option in the management of advanced cases </E>.

Section Name: Induction Chemotherapy
====================
Entities:-
Induction Chemotherapy : Initial chemotherapy treatment used to shrink a tumor before the main treatment, which is usually surgery.
Surgical Procedure : A medical procedure involving an incision with instruments; performed to repair damage or arrest disease in a living body.
Therapeutic Approach : A method or strategy used in the treatment of disease or injury.

Relationships:-
1. Entity1: ""Induction Chemotherapy"", Entity2: ""Surgical Intervention"", Relationship: ""alternative or sequential treatment option""

Causalities:-
<C> immediate surgical intervention is either not feasible or considered insufficient </C> <E> The flowchart also considers the option of induction chemotherapy </E> <CO> in cases where immediate surgical intervention is either not feasible or considered insufficient </CO>. <A> tailoring therapeutic approaches tailored to individual patient needs </A>.

Section Name: Adjuvant Treatment
====================
Entities:-
Adjuvant Chemotherapy : Chemotherapy given in addition to the primary treatment to maximize its effectiveness.
Radiotherapy : The use of high-energy radiation from x-rays, gamma rays, neutrons, protons, and other sources to kill cancer cells and shrink tumors.
Neoplasm Recurrence, Local : The return of a cancer, at the same site, after it has been treated.
Disease Progression : The worsening of a disease over time.

Relationships:-
1. Entity1: ""Primary Treatment"", Entity2: ""Adjuvant Treatment"", Relationship: ""followed by""
2. Entity1: ""Adjuvant Treatment"", Entity2: ""Systemic Therapy"", Relationship: ""includes""
3. Entity1: ""Adjuvant Treatment"", Entity2: ""Radiotherapy"", Relationship: ""includes""
4. Entity1: ""Follow-up Assessments"", Entity2: ""Treatment Efficacy"", Relationship: ""used to evaluate""

Causalities:-
<C> Following primary treatment </C>, <E> the flowchart addresses the potential for adjuvant treatment pathways </E>. This may include systemic therapy, RT, or further evaluations based on <CO> the patient's response and any recurrence or persistent disease </CO>. It emphasizes <A> the need for follow-up assessments to evaluate treatment efficacy </A>.

Section Name: Risk Features and Response Assessment
====================
Entities:-
Neoplasm Invasiveness : The property of a neoplasm to infiltrate and destroy surrounding tissue.
Surgical Margins : The edge or border of the tissue removed in cancer surgery.
Neoplasms : Neoplasms are abnormal growths of tissue, which can be cancerous or non-cancerous.
Extramural Extension : Extension of a tumor beyond the wall of an organ.
Positive Surgical Margin : Cancer cells are present at the edge of the tissue removed during surgery.
Cancer Management : The process of planning and coordinating the treatment of cancer.
Cancer : Cancer is a group of diseases involving abnormal cell growth with the potential to invade or spread to other parts of the body.

Relationships:-
1. Entity1: ""Extramural extension"", Entity2: ""Treatment decisions"", Relationship: ""influences""
2. Entity1: ""Positive surgical margin"", Entity2: ""Treatment decisions"", Relationship: ""influences""
3. Entity1: ""Ongoing assessment"", Entity2: ""Response evaluation"", Relationship: ""leads to""
4. Entity1: ""Response evaluation"", Entity2: ""Adjustments to treatment"", Relationship: ""leads to""
5. Entity1: ""Management of cancer"", Entity2: ""Treatment decisions"", Relationship: ""involves""
6. Entity1: ""Management of cancer"", Entity2: ""Ongoing assessment"", Relationship: ""involves""
7. Entity1: ""Management of cancer"", Entity2: ""Adjustments to treatment"", Relationship: ""involves""

Causalities:-
The chart incorporates a segment that takes into account <CO> adverse pathologic features, such as extramural extension or positive margins </CO>, <E> which could influence subsequent treatment decisions </E>. This highlights the importance of <A> ongoing assessment in the management of cancer, leading to response evaluation and adjustments to treatment as necessary </A>.

Section Name: NCCN Guidelines Version 4.2024
====================
Entities:-
Clinical Trials : Clinical trials are research studies performed in people that are aimed at evaluating a medical, surgical, or behavioral intervention.
Neoplasms : Neoplasms are abnormal growths of tissue, which can be cancerous or non-cancerous.
Clinical Trial : A clinical trial is a research study that prospectively assigns human participants or groups of humans to one or more health-related interventions to evaluate the effects on health outcomes.
Malignant Neoplasm : A malignant neoplasm is a cancerous growth that has the potential to invade and destroy nearby tissue and spread to other parts of the body.
National Comprehensive Cancer Network : The National Comprehensive Cancer Network (NCCN) is an alliance of 31 cancer centers in the United States, dedicated to improving the quality, effectiveness, and efficiency of cancer care.
Cancer : Cancer is a group of diseases involving abnormal cell growth with the potential to invade or spread to other parts of the body.

Relationships:-
1. Entity1: ""National Comprehensive Cancer Network"", Entity2: ""NCCN Guidelines"", Relationship: ""provides""
2. Entity1: ""NCCN Guidelines"", Entity2: ""Clinical Trials"", Relationship: ""recommend""
3. Entity1: ""NCCN Guidelines"", Entity2: ""Cancer"", Relationship: ""related to management of""

Causalities:-
<CO> any patient with cancer </CO> <A> the best management is in a clinical trial </A>. <A> Participation in clinical trials is especially encouraged </A>.

Section Name: SUPRA-3
====================
Entities:-
Laryngectomy : A surgical procedure involving the removal of the larynx, usually to treat cancer of the larynx.
Thyroidectomy : A surgical procedure to remove all or part of the thyroid gland.
Neck Dissection : Surgical procedure to remove lymph nodes and surrounding tissue to treat or prevent cancer spread.
Chemotherapy, Induction : Initial chemotherapy treatment to shrink a tumor before the main treatment.
Clinical Trials As Topic : Research studies that prospectively assign human participants or groups of humans to one or more health-related interventions to evaluate the effects on health outcomes.
Induction Chemotherapy : Initial chemotherapy treatment used to shrink a tumor before the main treatment, which is usually surgery.
Clinical Trial : A clinical trial is a research study that prospectively assigns human participants or groups of humans to one or more health-related interventions to evaluate the effects on health outcomes.

Relationships:-
1. Entity1: ""Total laryngectomy"", Entity2: ""Laryngectomy"", Relationship: ""is a type of""
2. Entity1: ""Systemic therapy"", Entity2: ""RT"", Relationship: ""concurrent treatment option""
3. Entity1: ""Induction chemotherapy"", Entity2: ""Other treatments"", Relationship: ""initial treatment option before""

Causalities:-
<CO> Requiring (amenable to) total laryngectomy (T3,N0) </CO>
  - <A> Concurrent systemic therapy/RT </A> or <A> RT if patient not medical candidate for concurrent systemic therapy/RT </A>
  - <A> Laryngectomy, thyroidectomy and with ipsilateral, central, or bilateral neck dissection </A>
  - or
  - <A> Induction chemotherapy </A>
  - or
  - <A> Clinical trials </A>

Section Name: Follow-up
====================
Entities:-
Follow-Up Studies : Studies in which individuals are followed over time to determine the outcome of exposures, treatments, or interventions.
Follow-Up Procedure : A procedure performed to monitor the progress of a patient's condition after initial treatment.
Follow-Up : Medical care given to a patient over time after initial treatment.
Disease Recurrence : The return of a sign, symptom, or disease after a remission.
Recurrent Disease : The reappearance of a disease after a period of improvement.

Relationships:-
1. Entity1: ""Follow-up"", Entity2: ""Recurrent or persistent disease"", Relationship: ""monitoring""

Causalities:-
- **Follow-up (FOLL-A, 1 of 2)**
  - <CO> Recurrent or persistent disease </CO> (ADV-3)

Section Name: Adverse Pathologic Features
====================
Entities:-
Radiotherapy : The use of high-energy radiation from x-rays, gamma rays, neutrons, protons, and other sources to kill cancer cells and shrink tumors.
Extranodal Extension : The spread of cancer beyond the lymph node capsule.
Positive Surgical Margin : Cancer cells are present at the edge of the tissue removed during surgery.
Systemic Therapy : Treatment using substances that travel through the bloodstream, reaching and affecting cells all over the body.

Relationships:-
1. Entity1: ""pN1"", Entity2: ""Radiotherapy"", Relationship: ""Consideration for treatment""
2. Entity1: ""Extranodal extension"", Entity2: ""Systemic Therapy"", Relationship: ""Treatment option""
3. Entity1: ""Extranodal extension"", Entity2: ""Radiotherapy"", Relationship: ""Treatment option""
4. Entity1: ""Positive surgical margin"", Entity2: ""Systemic Therapy"", Relationship: ""Treatment option""
5. Entity1: ""Positive surgical margin"", Entity2: ""Radiotherapy"", Relationship: ""Treatment option""

Causalities:-
- <CO>pN1 without other risk features</CO>
  - <C>Adverse pathologic features</C>
  - <A>Consider RT</A>
  - <CO>Extranodal extension and/or positive margin</CO>
  - <CO>Other risk features</CO>
  - <A>Systemic therapy/RT (category 1)</A>
  - <A>RT or Consider systemic therapy/RT</A>

Section Name: Response Assessment
====================
Entities:-
Response Evaluation : The process of assessing the response of a disease to treatment, often used in clinical trials to determine the effectiveness of a therapy.
Response To Treatment : A clinical finding indicating the response of a condition to a therapeutic intervention.

Relationships:-

Section Name: Principles of Surgery and Radiation Therapy
====================
Entities:-
Surgical Procedures, Operative : Operations carried out for the correction of deformities and defects, repair of injuries, and diagnosis and cure of certain diseases.
Surgical Procedure : A medical procedure involving an incision with instruments; performed to repair damage or arrest disease in a living body.
Surgery : Medical specialty that uses operative manual and instrumental techniques on a patient to investigate or treat a pathological condition such as a disease or injury.
Radiotherapy : The use of high-energy radiation from x-rays, gamma rays, neutrons, protons, and other sources to kill cancer cells and shrink tumors.
Radiation Therapy : Radiation therapy is a therapy using ionizing radiation, generally as part of cancer treatment to control or kill malignant cells.

Relationships:-
1. Entity1: ""Principles of Surgery"", Entity2: ""Principles of Radiation Therapy"", Relationship: ""complementary treatments""

Causalities:-
**Principles of Surgery (SURG-A).**

**Principles of Radiation Therapy (SUPRA-A).**

Section Name: Principles of Systemic Therapy
====================
Entities:-
Cisplatin : An inorganic and water-soluble platinum complex, cisplatin is an antineoplastic agent that is used in the treatment of various cancers.
Radiotherapy : The use of high-energy radiation from x-rays, gamma rays, neutrons, protons, and other sources to kill cancer cells and shrink tumors.
Radiation Therapy : Radiation therapy is a therapy using ionizing radiation, generally as part of cancer treatment to control or kill malignant cells.

Relationships:-
1. Entity1: ""Cisplatin"", Entity2: ""Systemic Therapy for Non-Nasopharyngeal Cancers"", Relationship: ""preferred agent""
2. Entity1: ""Cisplatin"", Entity2: ""Concurrent Systemic Therapy/RT"", Relationship: ""used in""

Causalities:-
<CO> When using concurrent systemic therapy/RT </CO>, <A> the preferred agent is cisplatin (category 1) </A>.
--------------------------------------------------
Page Number: 70

Section Name: Diagnosis
====================
Entities:-
Neoplasm Metastasis : The transfer of a neoplasm from one organ or part of the body to another remote from the primary site.
Clinical Trial : A research study that prospectively assigns human participants or groups of humans to one or more health-related interventions to evaluate the effects on health outcomes.
Personalized Medicine : A medical model that proposes the customization of healthcare, with medical decisions, practices, and/or products being tailored to the individual patient.

Relationships:-
1. Entity1: ""recurrent or persistent disease"", Entity2: ""distant metastases"", Relationship: ""has condition""
2. Entity1: ""Clinical trials"", Entity2: ""recurrent or persistent disease with distant metastases"", Relationship: ""recommended for""
3. Entity1: ""locoregional failure"", Entity2: ""locoregional treatment"", Relationship: ""treatment response to""

Causalities:-
In the **Diagnosis** section, the focus is on <C> recurrent or persistent disease with distant metastases </C>. <A> Clinical trials are preferred </A> for <CO> patients diagnosed at this stage </CO>. <CO> If there is locoregional failure </CO>, <A> locoregional treatment should be considered based on the extent of the disease and symptoms presented </A>. This highlights the importance of personalized treatment approaches, taking into account the unique circumstances of each patient.

Section Name: Treatment
====================
Entities:-
Therapeutics : The branch of medicine concerned with the treatment of disease and the action of remedial agents.
Performance Status : A measure of how well a patient is able to perform ordinary tasks and carry out daily activities.
Systemic Therapy : A type of treatment that uses substances that travel through the bloodstream, reaching and affecting cells all over the body.
Surgical Procedures, Operative : Operations carried out for the correction of deformities and defects, repair of injuries, and diagnosis and cure of certain diseases.
Palliative Care : An interdisciplinary medical caregiving approach aimed at optimizing quality of life and mitigating suffering among people with serious, complex illness.
Radiation Therapy : The medical use of ionizing radiation, generally as part of cancer treatment to control or kill malignant cells.

Relationships:-
1. Entity1: ""Performance Status"", Entity2: ""Systemic Therapy"", Relationship: ""Treatment option for PS 0-1, PS 2, and PS 3 patients""
2. Entity1: ""Performance Status"", Entity2: ""Surgery"", Relationship: ""Treatment option for PS 0-1 patients""
3. Entity1: ""Performance Status"", Entity2: ""Best Supportive Care"", Relationship: ""Treatment option for PS 0-1 and PS 3 patients""
4. Entity1: ""Performance Status"", Entity2: ""Palliative Treatments"", Relationship: ""Treatment option for PS 2 and PS 3 patients""
5. Entity1: ""Performance Status"", Entity2: ""Radiation Therapy"", Relationship: ""Consideration for PS 3 patients""

Causalities:-
The <C> Treatment section </C> outlines pathways based on <C> performance status (PS) </C>. For <CO> PS 0-1 patients </CO>, <A> options include combination systemic therapy, single-agent systemic therapy, surgery, or best supportive care for those with limited metastases </A>. For <CO> PS 2 patients </CO>, <A> recommendations include single-agent systemic therapy, supportive care, or palliative treatments </A>. For <CO> PS 3 patients </CO>, <A> the focus is on single-agent therapy and best supportive care, with consideration of palliative radiation therapy (RT) and palliative surgery </A>. This section addresses the evolving needs of patients as their <C> performance status declines </C>.

Section Name: Persistent Disease or Progression
====================
Entities:-
Disease Progression : The worsening of a disease over time.
Systemic Therapy : A type of treatment that uses substances that travel through the bloodstream, reaching and affecting cells all over the body.
Clinical Trials : Research studies performed in people that are aimed at evaluating a medical, surgical, or behavioral intervention.
Palliative Care : An interdisciplinary medical caregiving approach aimed at optimizing quality of life and mitigating suffering among people with serious, complex illness.
Quality Of Life : An individual's overall appraisal of their situation and well-being.
Supportive Care : Care given to improve the quality of life of patients who have a serious or life-threatening disease.

Relationships:-
1. Entity1: ""Persistent Disease or Progression"", Entity2: ""Systemic Therapy"", Relationship: ""option for management""
2. Entity1: ""Persistent Disease or Progression"", Entity2: ""Clinical Trials"", Relationship: ""option for management""
3. Entity1: ""Persistent Disease or Progression"", Entity2: ""Palliative Care"", Relationship: ""option for management""
4. Entity1: ""Best Supportive Care"", Entity2: ""Quality of Life"", Relationship: ""improves""
5. Entity1: ""Best Supportive Care"", Entity2: ""Advanced Illness"", Relationship: ""applied in context of""

Causalities:-
<A> continued evaluation of treatment efficacy </A> is reiterated. <A> Options include systemic therapy, clinical trials, or palliative care </A> <CO> based on the specific patient condition </CO>. <A> Best supportive care is emphasized </A>, <E> prioritizing the patient's quality of life </E>, <CO> particularly in the context of advanced illness </CO>.

Section Name: NCCN Guidelines Overview
====================
Entities:-
Clinical Trials As Topic : Works about research studies that evaluate the effectiveness and safety of medications or medical devices by monitoring their effects on large groups of people.
Clinical Trial : A research study that prospectively assigns human participants or groups of humans to one or more health-related interventions to evaluate the effects on health outcomes.
Neoplasms : New abnormal growth of tissue that may be benign or malignant.
Malignant Neoplastic Disease : A disease in which abnormal cells divide uncontrollably and destroy body tissue.
Cancer : A group of diseases involving abnormal cell growth with the potential to invade or spread to other parts of the body.

Relationships:-
1. Entity1: ""cancer"", Entity2: ""clinical trial"", Relationship: ""best management through""

Causalities:-
<CO> any patient with cancer </CO> <A> Participation in clinical trials is especially encouraged </A>.

Section Name: Principles and Considerations
====================
Entities:-
Radiation Therapy : The medical use of ionizing radiation, generally as part of cancer treatment to control or kill malignant cells.
Surgery : A medical specialty that uses operative manual and instrumental techniques on a patient to investigate or treat a pathological condition such as disease or injury.
Surgical Procedure : A procedure involving an incision with instruments; performed to repair damage or arrest disease in a living body.
Genomic Profiling : The measurement of the activity (the expression) of thousands of genes at once, to create a global picture of cellular function.
Biomarkers : Biological molecules found in blood, other body fluids, or tissues that are a sign of a normal or abnormal process, or of a condition or disease.
Biomarker : A biological molecule found in blood, other body fluids, or tissues that is a sign of a normal or abnormal process, or of a condition or disease.
Palliative Care : An interdisciplinary medical caregiving approach aimed at optimizing quality of life and mitigating suffering among people with serious, complex illness.
Bone Neoplasms : Tumors or cancer of the bone.
Bone Metastasis : The spread of cancer cells from their original site to a bone.

Relationships:-
1. Entity1: ""Palliative RT"", Entity2: ""Bone Metastases"", Relationship: ""treatment for""

Causalities:-
- **Principles of Radiation Therapy (ADV-A).**
- **Principles of Surgery (SURG-A).**
<A> Consider NGS genomic profiling for biomarker identification. </A>
<A> Consider palliative RT </A> <CO> as clinically indicated (e.g., bone metastases) </CO> (RAD-A).
- See Principles of Systemic Therapy for Non-Nasopharyngeal Cancers (SYST-A) or Systemic Therapy for Nasopharyngeal Cancers (NASO-B).
--------------------------------------------------
Page Number: 53

Section Name: Introduction
====================
Entities:-
National Comprehensive Cancer Network : The National Comprehensive Cancer Network (NCCN) is an alliance of 30 cancer centers in the United States, dedicated to improving the quality, effectiveness, and efficiency of cancer care so that patients can live better lives.
Laryngeal Neoplasms : Tumors or cancer of the larynx, which may affect the supraglottic, glottic, or subglottic regions.
Malignant Neoplasm Of Supraglottis : A malignant tumor located in the supraglottic region of the larynx.

Relationships:-
1. Entity1: ""National Comprehensive Cancer Network"", Entity2: ""Malignant neoplasm of supraglottis"", Relationship: ""provides guidelines for""
2. Entity1: ""clinical staging"", Entity2: ""treatment strategies"", Relationship: ""part of flowchart for""

Causalities:-
The provided image is a flowchart outlining the <C> NCCN (National Comprehensive Cancer Network) guidelines </C> for the treatment of <CO> cancers of the supraglottic larynx </CO>. This flowchart <A> utilizes a highly structured approach to convey clinical staging and treatment strategies </A>, indicating the various pathways based on <CO> patient conditions and disease features </CO>.

Section Name: NCCN Guidelines Version 4.2024
====================
Entities:-
Laryngeal Neoplasms : Tumors or cancer of the larynx, which may affect the supraglottic, glottic, or subglottic regions.
Malignant Neoplasm Of Supraglottis : A malignant tumor located in the supraglottic region of the larynx.
Supraglottic Cancer : Cancer that occurs in the supraglottic region of the larynx, above the vocal cords.
Clinical Trials As Topic : Pre-planned studies of the safety, efficacy, or optimum dosage schedule of one or more diagnostic, therapeutic, or prophylactic drugs, devices, or techniques in humans selected according to predetermined criteria of eligibility and observed for predefined evidence of favorable and unfavorable effects.
Clinical Trial : A type of research that studies new tests and treatments and evaluates their effects on human health outcomes.

Relationships:-
1. Entity1: ""Cancer of the Supraglottic Larynx"", Entity2: ""Clinical Trials"", Relationship: ""recommended management strategy""

Causalities:-
- All recommendations are category 2A unless otherwise indicated.
- <A> Participation in clinical trials </A> is especially encouraged.

Section Name: Key Components of the Flowchart
====================
Entities:-
Neoplasm Staging : Methods used for staging neoplasms, including clinical and pathological staging.
Radiotherapy : The use of ionizing radiation to treat cancer.
Surgical Procedures, Operative : Operations carried out for the correction of deformities and defects, repair of injuries, and diagnosis and cure of certain diseases.
Adjuvant Chemotherapy : Chemotherapy given in addition to the primary treatment to maximize its effectiveness.
Neoplasm Recurrence, Local : The return of a tumor at the original site after treatment.
Clinical Trials As Topic : Pre-planned studies of the safety, efficacy, or optimum dosage schedule of one or more diagnostic, therapeutic, or prophylactic drugs, devices, or techniques in humans selected according to predetermined criteria of eligibility and observed for predefined evidence of favorable and unfavorable effects.

Relationships:-
1. Entity1: ""Clinical Staging"", Entity2: ""Treatment of Primary and Neck"", Relationship: ""determines""
2. Entity1: ""Evaluation and Follow-Up"", Entity2: ""Adverse and No Adverse Features"", Relationship: ""leads to decision based on""
3. Entity1: ""Adjuvant Treatment"", Entity2: ""Adverse pathologic features"", Relationship: ""considered if present""
4. Entity1: ""Clinical Trials"", Entity2: ""Treatment Pathway"", Relationship: ""part of""

Causalities:-
### Key Components of the Flowchart

1. **Clinical Staging**: The flowchart starts with <A>clinical staging</A>, indicating that <CO>patients must first be evaluated to determine the extent of cancer</CO>. This is essential for <E>deciding on appropriate treatment options</E>.

2. **Treatment of Primary and Neck**: The flowchart details multiple treatment strategies, including:
   - <A>**Concurrent systemic therapy/RT**</A>: This suggests a combination approach for <CO>patients eligible for such treatment</CO>.
   - <A>**Definitive Radiation Therapy (RT)**</A>: Recommended for <CO>low-volume diseases or patients who cannot tolerate systemic therapy</CO>.
   - <A>**Surgical Options**</A>: It highlights options such as endoscopic or open partial laryngectomy and neck dissection, which are <CO>contingent on clinical evaluations</CO>.

3. **Evaluation and Follow-Up**: After initial treatment approaches, the chart directs clinicians to perform a <A>""Post Systemic Therapy/RT or RT Neck Evaluation""</A>. This step <E>assesses whether there are adverse pathologic features</E>, guiding subsequent treatment decisions.

4. **Adverse and No Adverse Features**: The decision pathway diverges based on findings:
   - <CO>Patients with **adverse pathologic features**</CO> may have <A>additional diagnostic imaging (CT or MRI)</A> and may require <A>further systemic treatment</A>.
   - <CO>Patients with **no adverse features**</CO> may be directed towards <A>considerations for radiation therapy</A>.

5. **Adjuvant Treatment and Recurrence**: The chart also addresses <E>management of any recurrent or persistent disease</E>, emphasizing the importance of <A>regular follow-up assessments</A>. Various options for <A>adjuvant treatment</A> are mentioned, focusing on tailored approaches towards ongoing management of the disease.

6. **Clinical Trials**: The flowchart encourages <A>participation in clinical trials</A>, indicating a commitment to <E>exploring new treatments and improving patient outcomes</E>.

Section Name: Principles
====================
Entities:-
Imaging : The process of producing images of the body or parts of the body to diagnose or examine disease.
Surgical Procedure : A medical procedure involving an incision with instruments; performed to repair damage or arrest disease in a living body.
Radiation Therapy : The use of ionizing radiation to treat cancer and other diseases.
Systemic Therapy : Treatment using substances that travel through the bloodstream, reaching and affecting cells all over the body.

Relationships:-
1. Entity1: ""Imaging"", Entity2: ""Surgery"", Relationship: ""Both are foundational principles in medical practice.""
2. Entity1: ""Radiation therapy"", Entity2: ""Systemic Therapy"", Relationship: ""Both are treatment modalities for cancer.""

Causalities:-
#### Principles
- **Principles of Imaging (IMG-A)**
- **Principles of Surgery (SURG-A)**
- **Principles of Radiation Therapy (SUPRA-A)**
- **Principles of Systemic Therapy for Non-Nasopharyngeal Cancers (SYST-A)**

Section Name: Adverse Pathologic Features
====================
Entities:-
Extranodal Extension : The spread of cancer cells beyond the lymph node capsule into the surrounding tissues.
Positive Surgical Margins : The presence of cancer cells at the edge of the tissue removed during surgery.
Perineural Invasion : Cancer cells found surrounding or tracking along a nerve within the perineural space.
Vascular Invasion : The presence of cancer cells within blood vessels.
Lymphatic Invasion : The presence of cancer cells within lymphatic vessels.

Relationships:-
1. Entity1: ""Extranodal Extension"", Entity2: ""Positive Surgical Margins"", Relationship: ""Both indicate cancer spread beyond original site.""
2. Entity1: ""Perineural Invasion"", Entity2: ""Vascular Invasion"", Relationship: ""Both are pathways for cancer spread.""
3. Entity1: ""pT3 or pT4 primary"", Entity2: ""pN2 or pN3 nodal disease"", Relationship: ""Both indicate advanced cancer stages.""

Causalities:-
<C> Extranodal extension </C>
<C> Positive margins </C>
<C> Close margins </C>
<C> pT3 or pT4 primary </C>
<C> pN2 or pN3 nodal disease </C>
<C> Perineural invasion </C>
<C> Vascular invasion </C>
<C> Lymphatic invasion </C>

Section Name: Clinical Staging and Treatment of Primary and Neck
====================
Entities:-
Adjuvant Chemotherapy : Chemotherapy given in addition to the primary treatment to maximize its effectiveness.
Follow-Up Procedure : A procedure performed to monitor the progress of a patient after treatment.
Recurrent Disease : A disease that returns after a period of remission.
Laryngectomy : Surgical removal of the larynx, often used to treat cancer.
Radiation Therapy : The use of ionizing radiation to treat cancer and other diseases.
Clinical Trial : A type of research that studies new tests and treatments and evaluates their effects on human health outcomes.
Neck Dissection : Surgical procedure to remove lymph nodes and surrounding tissue to treat cancer.
Chemotherapy : Treatment of disease by the use of chemical substances, especially cancer by cytotoxic drugs.

Relationships:-
1. Entity1: ""Adjuvant Treatment"", Entity2: ""Treatment of Primary and Neck"", Relationship: ""part of""
2. Entity1: ""Follow-up"", Entity2: ""Treatment of Primary and Neck"", Relationship: ""part of""
3. Entity1: ""Recurrent or Persistent Disease"", Entity2: ""Treatment of Primary and Neck"", Relationship: ""part of""
4. Entity1: ""Larynx-Preserving Surgery"", Entity2: ""Treatment Options"", Relationship: ""is a treatment option for""
5. Entity1: ""Concurrent Systemic Therapy/RT"", Entity2: ""Treatment Options"", Relationship: ""is a treatment option for""
6. Entity1: ""Clinical Trials or Definitive RT"", Entity2: ""Treatment Options"", Relationship: ""is a treatment option for""
7. Entity1: ""Endoscopic or Open Partial Laryngectomy and Neck Dissection(s)"", Entity2: ""Treatment Options"", Relationship: ""is a treatment option for""
8. Entity1: ""Induction Chemotherapy"", Entity2: ""Treatment Options"", Relationship: ""is a treatment option for""

Causalities:-
<A> Amenable to Larynx-Preserving (Conservation) Surgery </A>: <CO> T1–2, N+ and selected T3, N1 </CO>
<A> Concurrent Systemic Therapy/RT </A>: <CO> i, k, l </CO>
<A> Clinical Trials or Definitive RT </A>: <CO> i </CO>
<A> Endoscopic or Open Partial Laryngectomy and Neck Dissection(s) </A>: <CO> h </CO>
<A> Induction Chemotherapy </A>: <CO> k, m </CO>

Section Name: Pathologic Features and Response Assessment
====================
Entities:-
Radiation Therapy : The use of ionizing radiation to treat cancer and other diseases.
Extranodal Extension : The spread of cancer cells beyond the lymph node capsule into the surrounding tissues.
Positive Surgical Margin : Cancer cells are found at the edge of the material removed during surgery, indicating that some cancer may have been left behind.
Systemic Therapy : Treatment using substances that travel through the bloodstream, reaching and affecting cells all over the body.

Relationships:-
1. Entity1: ""Extranodal extension"", Entity2: ""Adverse Pathologic Features"", Relationship: ""is a type of""
2. Entity1: ""Positive margin"", Entity2: ""Adverse Pathologic Features"", Relationship: ""is a type of""
3. Entity1: ""Systemic Therapy"", Entity2: ""Adverse Pathologic Features"", Relationship: ""considered in response to""
4. Entity1: ""Radiation Therapy"", Entity2: ""Adverse Pathologic Features"", Relationship: ""considered in response to""

Causalities:-
#### Pathologic Features
- **No Adverse Pathologic Features**: j
  - <A> Consider RT </A>: i
- **Adverse Pathologic Features**: j
  - <CO> Extranodal extension and/or positive margin </CO>: n
  - Other risk features
  - <A> Systemic therapy/RT </A>: i, k (category 1)
  - <A> Consider systemic therapy/RT </A>: i, k

#### Response Assessment
- **Response Assessment** (SUPRA-7)

Section Name: Imaging and Recurrent or Persistent Disease
====================
Entities:-
Tomography, X-Ray Computed : A method of body imaging in which a thin X-ray beam rotates around the patient.
Magnetic Resonance Imaging : Medical imaging technique used in radiology to form pictures of the anatomy and the physiological processes of the body.
Computed Tomography : Medical imaging technique used in radiology to obtain detailed internal images of the body.

Relationships:-
1. Entity1: ""CT"", Entity2: ""primary and neck"", Relationship: ""used for imaging""
2. Entity1: ""MRI"", Entity2: ""primary and neck"", Relationship: ""used for imaging""
3. Entity1: ""Post Systemic Therapy/RT"", Entity2: ""Recurrent or Persistent Disease"", Relationship: ""evaluation after treatment""
4. Entity1: ""RT Neck Evaluation"", Entity2: ""Recurrent or Persistent Disease"", Relationship: ""evaluation after treatment""

Causalities:-
<A> CT (with contrast) or MRI (with and without contrast) of primary and neck </A>

<CO> Recurrent or Persistent Disease </CO>

<CO> Post Systemic Therapy/RT or RT Neck Evaluation </CO>

Section Name: Conclusion
====================
Entities:-
Oncologists : Medical doctors who specialize in the diagnosis and treatment of cancer.
Supraglottic Larynx Cancer : A type of cancer that occurs in the supraglottic region of the larynx, which is the area above the vocal cords.
Clinical Staging : The process of determining the extent of cancer in the body, usually based on physical examination, imaging tests, and biopsies.
Treatment Strategies : Plans or methods developed to treat diseases, including cancer, which may involve surgery, chemotherapy, radiation therapy, or other modalities.
Follow-Up Evaluations : Medical assessments conducted after initial treatment to monitor a patient's progress and detect any recurrence of disease.
Clinical Efficacy : The ability of a treatment to produce the desired therapeutic effect in clinical settings.
Research : Systematic investigation and study conducted to establish facts and reach new conclusions.
Treatment Paradigms : Standard models or patterns of treatment used in medical practice, often based on clinical guidelines and research findings.

Relationships:-
1. Entity1: ""Oncologists"", Entity2: ""Supraglottic Larynx Cancer"", Relationship: ""use flowchart for decision-making""
2. Entity1: ""Clinical Staging"", Entity2: ""Treatment Strategies"", Relationship: ""part of management process""
3. Entity1: ""Treatment Strategies"", Entity2: ""Follow-Up Evaluations"", Relationship: ""part of management process""

Causalities:-
<A> The flowchart serves as a comprehensive guide for oncologists and healthcare providers </A>, <A> facilitating informed decision-making in the treatment of supraglottic larynx cancer </A>. <A> By visualizing the complex interactions between clinical staging, treatment strategies, and follow-up evaluations </A>, <E> it streamlines the management process </E>, <E> ensuring that patients receive appropriate care tailored to their specific needs </E>. <E> The detailed pathways not only enhance clinical efficacy </E> but also <E> underscore the importance of ongoing research and adaptation of treatment paradigms in oncology </E>.
--------------------------------------------------
Page Number: 68

Section Name: Diagnosis Section
====================
Entities:-
Diagnosis : The process of determining which disease or condition explains a person's symptoms and signs.
Metastatic Disease : A disease in which cancer cells spread from the place where they first formed to another part of the body.
Clinical Trial : A research study that prospectively assigns human participants or groups of humans to one or more health-related interventions to evaluate the effects on health outcomes.
Locoregional Therapy : Treatment that is directed to a specific area of the body, often used in cancer treatment.

Relationships:-
1. Entity1: ""Diagnosis"", Entity2: ""Decision-making process"", Relationship: ""initiates""
2. Entity1: ""Metastatic disease"", Entity2: ""Clinical trial"", Relationship: ""preferred pathway""
3. Entity1: ""Locoregional treatment"", Entity2: ""Primary site algorithms"", Relationship: ""based on""

Causalities:-
<CO> for patients presenting with metastatic disease </CO>, <A> a clinical trial is the preferred pathway </A>, emphasizing the critical nature of innovative therapies in advanced cancer care. The option to <A> ""Consider locoregional treatment based on primary site algorithms"" </A> suggests that specific treatment strategies may be tailored <CO> depending on the exact location and characteristics of the cancer </CO>.

Section Name: Treatment Pathways
====================
Entities:-
Performance Status : A measure of a patient's general well-being and ability to perform ordinary tasks, often used in oncology to determine the appropriate treatment.
Systemic Therapy : A treatment using substances that travel through the bloodstream, reaching and affecting cells all over the body.
Surgery : A medical specialty that uses operative manual and instrumental techniques on a patient to investigate or treat a pathological condition such as disease or injury.
Radiation Therapy : The use of high-energy radiation from x-rays, gamma rays, neutrons, protons, and other sources to kill cancer cells and shrink tumors.
Palliative Care : Specialized medical care for people living with a serious illness, focused on providing relief from the symptoms and stress of the illness.
Supportive Care : Care given to improve the quality of life of patients who have a serious or life-threatening disease.

Relationships:-
1. Entity1: ""Performance Status"", Entity2: ""Systemic Therapy"", Relationship: ""affects choice of""
2. Entity1: ""Performance Status"", Entity2: ""Surgery"", Relationship: ""affects choice of""
3. Entity1: ""Performance Status"", Entity2: ""Radiation Therapy"", Relationship: ""affects choice of""
4. Entity1: ""Performance Status"", Entity2: ""Palliative Care"", Relationship: ""affects choice of""
5. Entity1: ""Performance Status"", Entity2: ""Supportive Care"", Relationship: ""affects choice of""
6. Entity1: ""PS 0-1 Patients"", Entity2: ""Combination Systemic Therapy"", Relationship: ""suitable for""
7. Entity1: ""PS 2 Patients"", Entity2: ""Palliative Radiation Therapy"", Relationship: ""may receive""
8. Entity1: ""PS 3 Patients"", Entity2: ""Supportive Care"", Relationship: ""recommended""

Causalities:-
The treatment section branches into various pathways depending on <CO> the patient’s performance status (PS) </CO>, which is a measure of their general well-being and ability to function. - **For PS 0-1 Patients:** The flowchart indicates several treatment options, including <A> combination systemic therapy, single-agent systemic therapy, surgery, and radiation therapy (RT) </A>. This group is highlighted as those who are most capable of handling intensive treatments and <E> may benefit significantly from combination therapies </E>. - **For PS 2 Patients:** The recommended approach varies slightly, with a continued emphasis on <A> systemic therapies, palliative radiation therapy, or best supportive care </A>. This indicates a level of compromise in treatment options, suggesting that while aggressive treatment is still possible, <E> the focus might shift more towards quality of life </E>. - **For PS 3 Patients:** The treatment options further narrow, still recommending <A> systemic therapy or supportive care </A> but highlighting palliative approaches, reflecting a recognition of <E> the more advanced disease and potentially limited treatment efficacy </E>.

Section Name: Principles of Treatment
====================
Entities:-
Antineoplastic Combined Chemotherapy Protocols : Protocols for the administration of more than one antineoplastic agent in combination to treat malignant neoplasms.
Radiotherapy : The use of radiation, usually X-rays or gamma rays, to treat disease, especially cancer.
Surgical Procedures, Operative : Operations carried out for the correction of deformities and defects, repair of injuries, and diagnosis and cure of certain diseases.
Systemic Therapy : A treatment using substances that travel through the bloodstream, reaching and affecting cells all over the body.
Radiation Therapy : The use of high-energy radiation from x-rays, gamma rays, neutrons, protons, and other sources to kill cancer cells and shrink tumors.
Surgical Procedure : A procedure involving an incision with instruments; performed to repair damage or arrest disease in a living body.
Chemotherapy : A type of cancer treatment that uses one or more anti-cancer drugs as part of a standardized chemotherapy regimen.
Surgery : A medical specialty that uses operative manual and instrumental techniques on a patient to investigate or treat a pathological condition such as disease or injury.

Relationships:-
1. Entity1: ""Systemic Therapy"", Entity2: ""Radiation Therapy"", Relationship: ""Different modalities of cancer treatment""
2. Entity1: ""Systemic Therapy"", Entity2: ""Surgery"", Relationship: ""Different modalities of cancer treatment""
3. Entity1: ""Radiation Therapy"", Entity2: ""Surgery"", Relationship: ""Different modalities of cancer treatment""

Causalities:-
- **Principles of Systemic Therapy for Non-Nasopharyngeal Cancers (SYST-A)** - **Principles of Radiation Therapy (ADV-A)** - **Principles of Surgery (SURG-A)**

Section Name: Diagnosis and Treatment of Head and Neck Cancer
====================
Entities:-
Neoplasm Metastasis : The transfer of a neoplasm from one organ or part of the body to another remote from the primary site.
Metastatic Malignant Neoplasm : A malignant neoplasm that has spread from its original site to a different site.
Metastasis : The spread of a cancer or other disease from one organ or part to another not directly connected with it.
Clinical Trials As Topic : Works about research studies that evaluate the effectiveness and safety of medications or medical devices by monitoring their effects on large groups of people.
Clinical Trial : A research study that prospectively assigns human participants or groups of humans to one or more health-related interventions to evaluate the effects on health outcomes.
Performance Status : A measure of a patient's general well-being and ability to perform ordinary tasks, often used in oncology to determine the appropriate treatment.

Relationships:-
1. Entity1: ""Metastatic disease"", Entity2: ""Clinical trial"", Relationship: ""preferred treatment option""
2. Entity1: ""Performance Status 0-1"", Entity2: ""Combination systemic therapy"", Relationship: ""treatment option""
3. Entity1: ""Performance Status 2"", Entity2: ""Single-agent systemic therapy"", Relationship: ""treatment option""
4. Entity1: ""Performance Status 3"", Entity2: ""Systemic therapy"", Relationship: ""treatment option""

Causalities:-
- <CO>Metastatic (M1) disease at initial presentation</CO>
  <A>Clinical trial preferred</A>
  <E>Distant metastases</E>
  <A>Consider locoregional treatment based on primary site algorithms (Table of Contents)</A>

#### Performance Status (PS)
- <CO>PS 0–1</CO>
  <A>Combination systemic therapy</A> or <A>Single-agent systemic therapy</A> or <A>Surgery</A> or <A>RT</A> or <A>systemic therapy/RT for selected patients with limited metastases</A> or <A>Best supportive care</A>
- <CO>PS 2</CO>
  <A>Single-agent systemic therapy</A> or <A>Best supportive care ± Palliative RT</A> or <A>Palliative surgery</A>
- <CO>PS 3</CO>
  <A>Systemic therapy, clinical trial preferred</A> or <A>Palliative RT</A> or <A>Best supportive care</A>

Section Name: Persistent Disease or Progression
====================
Entities:-
Palliative Care : Specialized medical care for people living with a serious illness, focused on providing relief from the symptoms and stress of the illness.
Supportive Care : Care given to improve the quality of life of patients who have a serious or life-threatening disease.
Antineoplastic Agents : Substances that inhibit or prevent the proliferation of neoplasms.
Systemic Therapy : A treatment using substances that travel through the bloodstream, reaching and affecting cells all over the body.
Chemotherapy : A type of cancer treatment that uses one or more anti-cancer drugs as part of a standardized chemotherapy regimen.
Radiotherapy : The use of radiation, usually X-rays or gamma rays, to treat disease, especially cancer.
Palliative Radiotherapy : Radiotherapy given to relieve symptoms and reduce suffering caused by cancer.
Radiation Therapy : The use of high-energy radiation from x-rays, gamma rays, neutrons, protons, and other sources to kill cancer cells and shrink tumors.

Relationships:-
1. Entity1: ""Best supportive care"", Entity2: ""Alternate single-agent systemic therapy"", Relationship: ""alternative treatment options""
2. Entity1: ""Best supportive care"", Entity2: ""Palliative RT"", Relationship: ""alternative treatment options""
3. Entity1: ""Alternate single-agent systemic therapy"", Entity2: ""Palliative RT"", Relationship: ""alternative treatment options""

Causalities:-
<A> Best supportive care </A> or <A> Alternate single-agent systemic therapy </A> or <A> Palliative RT </A>
--------------------------------------------------
Page Number: 69

Section Name: Diagnosis
====================
Entities:-
Head And Neck Neoplasms : Tumors or cancer of the head and neck region, including the nasal cavity, sinuses, lips, mouth, salivary glands, throat, or larynx.
Malignant Neoplasm Of Head And Neck : A malignant tumor located in the head and neck region.
Head And Neck Cancer : Cancer that arises in the head or neck region, including the throat, larynx, nose, sinuses, and mouth.
Radiation Therapy : A therapy that uses ionizing radiation, generally as part of cancer treatment to control or kill malignant cells.
Radiotherapy : A treatment method that uses ionizing radiation, generally as part of cancer treatment to control or kill malignant cells.
Surgical Procedures, Operative : Operations carried out for the correction of deformities and defects, repair of injuries, and diagnosis and cure of certain diseases.
Surgical Procedure : A procedure involving an incision with instruments; performed to repair damage or arrest disease in a living body.
Surgery : A medical specialty that uses operative manual and instrumental techniques on a patient to investigate or treat a pathological condition such as disease or injury.
Clinical Trials As Topic : Pre-planned studies of the safety, efficacy, or optimum dosage schedule of one or more diagnostic, therapeutic, or prophylactic drugs, devices, or techniques in humans selected according to predetermined criteria of eligibility and observed for predefined evidence of favorable and unfavorable effects.
Clinical Trial : A research study that prospectively assigns human participants or groups of humans to one or more health-related interventions to evaluate the effects on health outcomes.

Relationships:-
1. Entity1: ""head and neck cancer"", Entity2: ""surgery"", Relationship: ""preferred treatment if resectable""
2. Entity1: ""head and neck cancer"", Entity2: ""reirradiation"", Relationship: ""treatment option if unresectable""
3. Entity1: ""head and neck cancer"", Entity2: ""clinical trials"", Relationship: ""preferred for unresectable cases""

Causalities:-
The diagnosis process for very advanced head and neck cancer involves <CO> categorizing patients based on their disease status </CO>. The guidelines differentiate between 'Recurrent or persistent disease' and 'Locoregional recurrence or persistent disease without prior RT (radiation therapy)'. This distinction is crucial <C> as it influences subsequent treatment decisions </C>. <CO> In cases of locoregional recurrence or persistent disease without prior RT </CO>, the disease can be classified as 'Resectable' or 'Unresectable'. <CO> If resectable </CO>, <A> surgery is the preferred treatment </A>. <CO> If unresectable </CO>, <A> options include reirradiation with or without systemic therapy, and clinical trials are preferred </A>.

Section Name: Treatment of Very Advanced Head and Neck Cancer
====================
Entities:-
Head And Neck Neoplasms : Tumors or cancer of the head and neck region, including the nasal cavity, sinuses, lips, mouth, salivary glands, throat, or larynx.
Malignant Neoplasm Of Head And Neck : A malignant tumor located in the head and neck region.
Head And Neck Cancer : Cancer that arises in the head or neck region, including the throat, larynx, nose, sinuses, and mouth.
Surgical Procedures, Operative : Operations carried out for the correction of deformities and defects, repair of injuries, and diagnosis and cure of certain diseases.
Surgical Procedure : A procedure involving an incision with instruments; performed to repair damage or arrest disease in a living body.
Surgery : A medical specialty that uses operative manual and instrumental techniques on a patient to investigate or treat a pathological condition such as disease or injury.
Radiotherapy : A treatment method that uses ionizing radiation, generally as part of cancer treatment to control or kill malignant cells.
Radiation Therapy : A therapy that uses ionizing radiation, generally as part of cancer treatment to control or kill malignant cells.
Clinical Trials As Topic : Pre-planned studies of the safety, efficacy, or optimum dosage schedule of one or more diagnostic, therapeutic, or prophylactic drugs, devices, or techniques in humans selected according to predetermined criteria of eligibility and observed for predefined evidence of favorable and unfavorable effects.
Clinical Trial : A research study that prospectively assigns human participants or groups of humans to one or more health-related interventions to evaluate the effects on health outcomes.

Relationships:-
1. Entity1: ""Surgery"", Entity2: ""Resectable disease"", Relationship: ""recommended for""
2. Entity1: ""Reirradiation"", Entity2: ""Unresectable disease"", Relationship: ""considered for""
3. Entity1: ""Systemic therapy"", Entity2: ""Unresectable disease"", Relationship: ""considered for""
4. Entity1: ""Clinical trials"", Entity2: ""Head and neck cancer"", Relationship: ""preferred for management of""

Causalities:-
<CO> For resectable disease </CO>, <A> surgery with or without postoperative reirradiation is recommended </A>, and <A> systemic therapy or RT is considered </A>, with <A> clinical trials preferred </A>. <CO> For unresectable disease </CO>, <A> reirradiation with or without systemic therapy is recommended </A>, and <A> best supportive care is considered </A>. The guidelines emphasize the importance of <A> clinical trials </A> and suggest that <A> the best management of any patient with cancer is in a clinical trial </A>.

Section Name: Pathologic Features
====================
Entities:-
Pathologic Processes : The physiological processes and conditions that are characteristic of disease or injury.
Radiotherapy : A treatment method that uses ionizing radiation, generally as part of cancer treatment to control or kill malignant cells.
Systemic Therapy : A type of medical treatment that uses substances that travel through the bloodstream, reaching and affecting cells all over the body.
Extranodal Extension : The spread of cancer beyond the lymph node capsule into the surrounding tissues.
Positive Surgical Margin : A situation where cancer cells are found at the edge of the material removed during surgery, indicating that some cancer may have been left behind.
Radiation Therapy : A therapy that uses ionizing radiation, generally as part of cancer treatment to control or kill malignant cells.

Relationships:-
1. Entity1: ""Adverse pathologic features"", Entity2: ""Systemic therapy with RT"", Relationship: ""leads to""
2. Entity1: ""No adverse pathologic features"", Entity2: ""Observation and follow-up"", Relationship: ""leads to""
3. Entity1: ""Other risk features"", Entity2: ""RT or systemic therapy with RT"", Relationship: ""may warrant""

Causalities:-
<C> Pathologic features </C> play a significant role in determining the treatment approach. <CO> If no adverse pathologic features are present </CO>, <A> observation and follow-up are recommended </A>. <CO> if adverse pathologic features such as extranodal extension or positive margins are present </CO>, <A> systemic therapy with RT is recommended </A>. <CO> Other risk features </CO> may also <A> warrant RT or systemic therapy with RT </A>. The guidelines highlight the importance of considering <C> these features </C> in treatment planning.

Section Name: Therapy for Persistent Disease
====================
Entities:-
Radiotherapy : A treatment method that uses ionizing radiation, generally as part of cancer treatment to control or kill malignant cells.
Systemic Therapy : A type of medical treatment that uses substances that travel through the bloodstream, reaching and affecting cells all over the body.
Next-Generation Sequencing : High-throughput sequencing methods that allow for rapid sequencing of large stretches of DNA.
Biomarkers : Biological molecules that indicate a process, condition, or disease and can be used to assess the effect of treatment.
Radiation Therapy : A therapy that uses ionizing radiation, generally as part of cancer treatment to control or kill malignant cells.
Biomarker : A biological molecule found in blood, other body fluids, or tissues that is a sign of a normal or abnormal process, or of a condition or disease.

Relationships:-
1. Entity1: ""Guidelines"", Entity2: ""Therapy"", Relationship: ""recommendation""
2. Entity1: ""Next-Generation Sequencing"", Entity2: ""Biomarker Identification"", Relationship: ""used for""
3. Entity1: ""Therapy"", Entity2: ""Systemic Therapy"", Relationship: ""can include""
4. Entity1: ""Therapy"", Entity2: ""Radiotherapy"", Relationship: ""can include""

Causalities:-
<CO> For persistent disease </CO>, the guidelines <A> recommend therapy </A> <CO> as indicated by the specific clinical scenario </CO>. This may include <A> systemic therapy, RT, or a combination of both </A>, <CO> depending on the presence of adverse pathologic features and other risk factors </CO>. The guidelines also <A> suggest considering next-generation sequencing genomic profiling </A> <C> for biomarker identification </C> <A> to tailor treatment strategies </A>.

Section Name: Conclusion
====================
Entities:-
Head And Neck Neoplasms : Tumors or cancer of the head and neck region, including the nasal cavity, sinuses, lips, mouth, salivary glands, throat, or larynx.
Malignant Neoplasm Of Head And Neck : A malignant tumor located in the head and neck region.
Head And Neck Cancer : Cancer that arises in the head or neck region, including the throat, larynx, nose, sinuses, and mouth.
Clinical Trials As Topic : Pre-planned studies of the safety, efficacy, or optimum dosage schedule of one or more diagnostic, therapeutic, or prophylactic drugs, devices, or techniques in humans selected according to predetermined criteria of eligibility and observed for predefined evidence of favorable and unfavorable effects.
Clinical Trial : A research study that prospectively assigns human participants or groups of humans to one or more health-related interventions to evaluate the effects on health outcomes.

Relationships:-
1. Entity1: ""NCCN guidelines"", Entity2: ""head and neck cancer"", Relationship: ""used for diagnosis and treatment""
2. Entity1: ""NCCN guidelines"", Entity2: ""clinical trials"", Relationship: ""emphasize importance""
3. Entity1: ""NCCN guidelines"", Entity2: ""healthcare providers"", Relationship: ""serve as a resource for""

Causalities:-
The NCCN guidelines <A> provide a comprehensive framework for the diagnosis and treatment of very advanced head and neck cancer </A>. <A> They emphasize evidence-based practices </A> and <A> the importance of clinical trials </A>, <A> advocating for an individualized approach to patient care </A>. The guidelines <E> serve as a critical resource for healthcare providers </E>, <E> ensuring that all potential treatment avenues are explored </E> while <CO> considering patient-specific factors </CO>.


Among these two options which one is the most likely true:

(A) `Location_of_Lymph_Nodes_3` increases risk `Examination_11`
(B) `Examination_11` `increases risk `Location_of_Lymph_Nodes_3`

The answer is: ...

1. State the evidences in detail of the validity of option (A) or (B) by cross referencing
NCCN Clinical Practitioner’s Guidelines for Head and Neck Cancer.
2. If the evidences are obtained from `INFORMATION FROM KNOWLEDGE BASE`,
mention their corresponding Page Numbers, Section Name, entities, relationships and causalities.

DESIRED OUTPUT FORMAT:
<thinking>
...
</thinking>
<answer>
{
   ""thinking"": [""..."", ...],
   ""evidences"": [""..."", ...],
   ""answer"": ...
}
</answer>

Before providing the answer in <answer> tags, think step by step in detail in <thinking> tags and analyze every part.
Output inside <answer> tag in JSON format. Only output valid JSON.
DO NOT HALLUCINATE. DO NOT MAKE UP FACTUAL INFORMATION.
","1. The edge (A) suggests that the presence of lymph nodes in a specific location affects the result of a diagnostic examination. This aligns with the understanding that lymph node involvement is a critical factor in cancer staging and diagnosis, as indicated in the NCCN guidelines.
2. The edge (B) suggests that the result of a diagnostic examination causes the presence or absence of lymph nodes, which is not a valid causal relationship. Diagnostic examinations are used to detect conditions, not cause them.
3. In the NCCN guidelines, lymph node involvement is a key factor in determining the stage and treatment of head and neck cancers, as seen in the sections discussing clinical staging and treatment strategies.
4. The causal direction for edge (A) is positive, indicating that the presence of lymph nodes would lead to a positive finding in the examination if it is related to lymph nodes.
5. The causal factor for edge (A) is neither necessary nor sufficient, as other factors could lead to a 'present' examination result, and the presence of lymph nodes alone does not guarantee a 'present' result unless the examination is specifically for that purpose.
6. The causal distance for edge (A) is proximal if the examination is directly related to detecting lymph nodes, as it would be a direct cause-effect relationship.
7. The NCCN guidelines emphasize the importance of lymph node involvement in cancer staging and treatment decisions, supporting the validity of edge (A).
","1. Page Number: 51, Section Name: Introduction, Entities: Laryngeal Neoplasms, Malignant Neoplasm Of Supraglottis, Supraglottic Laryngeal Cancer, Relationships: NCCN provides guidelines for cancer of the supraglottic larynx, Causalities: Clinical staging and treatment protocols for cancer of the supraglottic larynx.
2. Page Number: 53, Section Name: Introduction, Entities: National Comprehensive Cancer Network, Laryngeal Neoplasms, Malignant Neoplasm Of Supraglottis, Relationships: NCCN provides guidelines for malignant neoplasm of supraglottis, Causalities: NCCN guidelines for the treatment of cancers of the supraglottic larynx.
",A,"{'A': 100.0, 'B': 0.0}",yes,A,"1. The AI assistant's reasoning for option (A) is based on the understanding that lymph node involvement is a critical factor in cancer diagnosis and staging, which aligns with the NCCN guidelines. This is a valid interpretation as lymph nodes are often assessed to determine the spread of cancer, which can influence diagnostic examination results.
2. The assistant correctly identifies that option (B) is not a valid causal relationship because diagnostic examinations are used to detect conditions, not cause them. This aligns with the general understanding of medical diagnostics.
3. The assistant references the NCCN guidelines, which emphasize the importance of lymph node involvement in cancer staging and treatment decisions. This supports the validity of option (A) as lymph nodes are a key factor in determining the stage and treatment of cancers, particularly in the head and neck region.
4. The causal direction, factor, and distance for edge (A) are analyzed correctly. The assistant notes that the causal direction is positive, which is consistent with the idea that the presence of lymph nodes would lead to a positive finding in an examination designed to detect them.
5. The assistant's conclusion that option (A) is the most likely true is consistent with the reasoning provided, as it aligns with the understanding of lymph node involvement in cancer diagnosis and the NCCN guidelines.
"
6,gpt-4o,"Number_of_Lymph_Nodes_5,N_State_1","""{'NODE1': {'id': 'Number_of_Lymph_Nodes_5', 'label': 'Number of Lymph Nodes', 'description': 'This node represents the presence or absence of a specific number of lymph nodes, which can be clinically significant in assessing the spread of cancer or other diseases.', 'type': 'Patient Situation', 'observability': 'Unobserved', 'states': [{'state_name': 'present', 'state_description': \""The state 'present' indicates that the specific number of lymph nodes is detected or considered in the clinical assessment.\""}, {'state_name': 'absent', 'state_description': \""The state 'absent' indicates that the specific number of lymph nodes is not detected or considered in the clinical assessment.\""}]}, 'NODE2': {'id': 'N_State_1', 'label': 'Nearby Lymph Nodes Cancer State', 'description': 'This node represents the clinical situation regarding the presence or absence of cancer in nearby lymph nodes. It is a critical factor in cancer staging and prognosis, as the involvement of lymph nodes can indicate the spread of cancer and affect treatment decisions.', 'type': 'Decision Node', 'observability': 'Needs to be Predicted', 'states': [{'state_name': 'present', 'state_description': 'Cancer is present in the nearby lymph nodes, indicating potential metastasis and a more advanced stage of cancer.'}, {'state_name': 'absent', 'state_description': 'Cancer is absent in the nearby lymph nodes, suggesting that the cancer has not spread to these nodes and may be in an earlier stage.'}]}, 'EDGE1': {'edges_ids': ['Number_of_Lymph_Nodes_5', 'N_State_1'], 'edge': '(Number_of_Lymph_Nodes_5) causes (N_State_1)', 'explanation': ['The edge suggests that the number of lymph nodes (Number_of_Lymph_Nodes_5) causes the cancer state in nearby lymph nodes (N_State_1).', 'Clinically, the number of lymph nodes does not directly cause cancer to be present or absent in them.', 'The presence of cancer in lymph nodes is more directly related to the spread of cancer from a primary site, not the number of lymph nodes themselves.', 'Therefore, the edge is not valid as a direct causal relationship.'], 'causal_direction': 'Unknown', 'causal_factor': {'necessary': False, 'sufficient': False}, 'causal_distance': 'Distal'}, 'EDGE2': {'edges_ids': ['N_State_1', 'Number_of_Lymph_Nodes_5'], 'edge': '(N_State_1) causes (Number_of_Lymph_Nodes_5)', 'explanation': ['The edge suggests that the presence of cancer in nearby lymph nodes (N_State_1) causes a specific number of lymph nodes to be present or absent (Number_of_Lymph_Nodes_5).', 'This is not a valid causal relationship because the number of lymph nodes is a physical characteristic that is not directly caused by the presence of cancer.', 'The presence of cancer might be detected in a certain number of lymph nodes, but it does not cause the number of lymph nodes to change.'], 'causal_direction': 'Unknown', 'causal_factor': {'necessary': False, 'sufficient': False}, 'causal_distance': 'Unknown'}, 'ENTITIES_MATCHING_PAGES_INFO': {'102': {'matching_entities': [{'LYMPHATIC SYSTEM': 0.95855314}, {'LYMPHATIC STRUCTURE': 0.9469132}, {'METASTASIS': 0.9401313}, {'CANCER STAGING': 0.93824553}, {'TUMOR': 0.9323624}, {'STAGING': 0.9208425}], 'count': 6}, '55': {'matching_entities': [{'MALIGNANT NEOPLASTIC DISEASE': 0.97725874}, {'METASTASIS': 0.9401313}, {'CANCER': 0.9363244}, {'METASTATIC NEOPLASM': 0.9314138}, {'NEOPLASM METASTASIS': 0.9250777}, {'LARYNGEAL NEOPLASMS': 0.9236878}], 'count': 6}, '51': {'matching_entities': [{'MALIGNANT NEOPLASM': 0.9774111}, {'CANCER STAGING': 0.93824553}, {'CANCER': 0.9363244}, {'LARYNGEAL NEOPLASMS': 0.9236878}, {'NEOPLASM INVASIVENESS': 0.92347366}], 'count': 5}, '130': {'matching_entities': [{'LYMPH NODE STRUCTURE': 0.99134904}, {'LYMPH NODE': 0.98570025}, {'LYMPH NODES': 0.97445965}, {'METASTASIS': 0.9401313}, {'NEOPLASM METASTASIS': 0.9250777}], 'count': 5}, '47': {'matching_entities': [{'MALIGNANT NEOPLASM': 0.9774111}, {'LARYNGEAL CANCER': 0.95521915}, {'CANCER': 0.9363244}, {'LARYNGEAL NEOPLASMS': 0.9236878}], 'count': 4}}, 'GUIDELINE_PAGES_INFO': '--------------------------------------------------\\nPage Number: 102\\n\\nSection Name: Head and Neck Cancers - Principles of Surgery\\n====================\\nEntities:-\\nSurgical Procedures, Operative : Manual or operative procedures used in the treatment of disease, injuries, or deformities.\\nLymphatic System : Part of the circulatory system and a vital part of the immune system, comprising a network of lymphatic vessels that carry a clear fluid called lymph.\\nNeoplasms : New abnormal growth of tissue in animals or plants; a tumor.\\nNeck Dissection : A surgical procedure for control of neck lymph node metastasis from squamous cell carcinoma of the head and neck.\\nNeoplasm Staging : Methods which attempt to express in replicable terms the extent of the neoplasm in the patient.\\nMetastasis : The spread of a cancer or other disease from one organ or part of the body to another not directly connected with it.\\nSurgical Procedure : A procedure involving an incision with instruments; performed to repair damage or arrest disease in a living body.\\nLymphatic Structure : Anatomical structure that is part of the lymphatic system.\\nTumor : An abnormal mass of tissue that results when cells divide more than they should or do not die when they should.\\nStaging : The process of determining the size and spread of cancer within the body.\\nSurgery : Medical specialty that uses operative manual and instrumental techniques on a patient to investigate or treat a pathological condition such as disease or injury.\\nCancer Staging : The process of determining the extent to which a cancer has developed by growing and spreading.\\n\\nRelationships:-\\n1. Entity1: \""surgical management\"", Entity2: \""regional lymphatics\"", Relationship: \""dictated by tumor staging\""\\n2. Entity1: \""neck dissections\"", Entity2: \""primary tumor\"", Relationship: \""part of treatment\""\\n3. Entity1: \""surgery\"", Entity2: \""ipsilateral side of the neck\"", Relationship: \""risk for metastases\""\\n\\nCausalities:-\\n<C> The extent of the tumor at initial tumor staging </C> <E> dictates the surgical management of regional lymphatics </E>. These guidelines apply to the performance of neck dissections as part of treatment of the primary tumor. <CO> Patients undergoing surgery for resection of the primary tumor </CO> <A> will undergo dissection of the ipsilateral side of the neck that is at greatest risk for metastases </A>.\\n\\nSection Name: Neck Management\\n====================\\nEntities:-\\nTongue : A muscular organ in the mouth that is involved in tasting, swallowing, and speech.\\nPalate : The roof of the mouth, separating the oral and nasal cavities.\\nLarynx : An organ in the top of the neck involved in breathing, producing sound, and protecting the trachea.\\nHypopharynx : The bottom part of the pharynx, which is the cavity behind the nose and mouth.\\nNasopharynx : The upper part of the pharynx, connecting with the nasal cavity above the soft palate.\\nNeck Dissection : A surgical procedure for control of neck lymph node metastasis from squamous cell carcinoma of the head and neck.\\nMetastasis : The spread of a cancer or other disease from one organ or part of the body to another not directly connected with it.\\nSquamous Cell Carcinoma : A type of cancer that begins in the squamous cells, which are thin, flat cells that look like fish scales.\\nBiopsy : The removal of cells or tissues for examination under a microscope.\\n\\nRelationships:-\\n1. Entity1: \""Tumor sites\"", Entity2: \""Bilateral lymphatic drainage\"", Relationship: \""associated with\""\\n2. Entity1: \""Elective neck dissection\"", Entity2: \""Risk of occult metastasis\"", Relationship: \""based on\""\\n3. Entity1: \""SLN biopsy\"", Entity2: \""Elective neck dissection\"", Relationship: \""guides decision-making for\""\\n\\nCausalities:-\\n- **<C> Tumor sites that frequently have bilateral lymphatic drainage </C>** (e.g., base of tongue, palate, supraglottic larynx, hypopharynx, nasopharynx, deep pre-epiglottic space involvement) <E> often should have both sides of the neck dissected </E> with the extent of dissection determined as suggested below. For those patients with tumors at or approaching the midline, <CO> both sides of the neck are at risk for metastases </CO>, and <A> bilateral neck dissections should be performed </A>.\\n\\n- <CO> Patients with advanced lesions involving the anterior tongue, floor of the mouth, or alveolus that approximate or cross the midline </CO> <A> should undergo contralateral selective/modified neck dissection </A> as necessary to achieve adequate tumor resection.\\n\\n- **<C> Elective neck dissection </C>** <A> should be based on risk of occult metastasis in the appropriate nodal basin </A>. For oral cavity squamous cell carcinoma, <C> SLN biopsy or the primary tumor depth of invasion </C> is currently <E> the best predictor of occult metastatic disease </E> and <A> should be used to guide decision-making </A>. <CO> For tumors with a depth greater than 3 mm </CO>, <A> elective dissection should be strongly considered if RT is not already planned </A>. Recent randomized trial evidence supports the effectiveness of elective neck dissection in patients with oral cavity cancers greater than 3 mm in depth of invasion.\\n\\n  - <CO> For a depth less than 2 mm </CO>, <A> elective dissection is only indicated in highly selective situations </A>. <CO> For a depth of 2\u20134 mm </CO>, <A> clinical judgment (as to reliability of follow-up, clinical suspicion, and other factors) must be utilized to determine appropriateness of elective dissection </A>. Elective dissections are generally selective, preserving all major structures, unless operative findings dictate otherwise.\\n\\nSection Name: Types of Neck Dissection\\n====================\\nEntities:-\\nNeck Dissection : A surgical procedure for control of neck lymph node metastasis from squamous cell carcinoma of the head and neck.\\nLarynx : An organ in the top of the neck involved in breathing, producing sound, and protecting the trachea.\\n\\nRelationships:-\\n1. Entity1: \""N0\"", Entity2: \""Selective neck dissection\"", Relationship: \""associated with\""\\n2. Entity1: \""N3\"", Entity2: \""Comprehensive neck dissection\"", Relationship: \""associated with\""\\n3. Entity1: \""Level VI neck dissection\"", Entity2: \""Larynx\"", Relationship: \""performed for\""\\n4. Entity1: \""Level VI neck dissection\"", Entity2: \""Hypopharynx\"", Relationship: \""performed for\""\\n\\nCausalities:-\\n- **The type of neck dissection (comprehensive or selective)** is defined according to <CO> preoperative clinical staging </CO>, is determined at the discretion of the surgeon, and is based on the initial preoperative staging as follows:\\n  - **N0:** <A> Selective neck dissection </A>\\n    - Oral cavity at least levels I\u2013III\\n    - Oropharynx at least levels II\u2013IV\\n    - Hypopharynx at least levels II\u2013IV and level VI when appropriate\\n    - Larynx at least levels II\u2013IV and level VI when appropriate\\n  - **N1\u2013N2a\u2013c:** <A> Selective or comprehensive neck dissection </A> (Discussion)\\n  - **N3:** <A> Comprehensive neck dissection </A>\\n\\n- <C> Level VI neck dissections are performed for certain primary sites (such as the larynx and hypopharynx) </C> <E> as required to resect the primary tumor and any clinically evident neck nodes </E>. <CO> Elective dissection depends on primary tumor extent and site </CO>. <CO> For advanced glottic and hypopharyngeal cancers treated with primary surgery </CO>, <A> a level VI dissection (including pretracheal lymph nodes, the Delphian lymph node, and unilateral or bilateral paratracheal lymph nodes) and hemithyroidectomy to total thyroidectomy are appropriate </A>.\\n\\n- <CO> For primary subglottic tumors or glottic cancers with significant subglottic extension </CO>, <A> a level VI dissection with unilateral or total thyroidectomy is considered appropriate </A> based on the extent of the primary tumor. <CO> For example, a T4a glottic tumor with extension through the cricothyroid membrane and subglottic extension </CO> <A> should include thyroidectomy and pretracheal and bilateral paratracheal lymph node dissection </A>. <A> Parathyroid glands should be preserved in situ or auto transplanted as indicated </A>.\\n--------------------------------------------------\\nPage Number: 55\\n\\nSection Name: General Information\\n====================\\nEntities:-\\nNational Comprehensive Cancer Network : An alliance of 32 cancer centers in the United States, dedicated to improving the quality, effectiveness, and efficiency of cancer care.\\nNccn Guidelines : Clinical practice guidelines in oncology developed by the National Comprehensive Cancer Network.\\n\\nRelationships:-\\n1. Entity1: \""NCCN Guidelines\"", Entity2: \""National Comprehensive Cancer Network\"", Relationship: \""produced by\""\\n\\nSection Name: Important Notes\\n====================\\nEntities:-\\nClinical Trials As Topic : Works about research studies that evaluate the effectiveness and safety of medical, surgical, or behavioral interventions.\\nClinical Trial : A type of research that studies new tests and treatments and evaluates their effects on human health outcomes.\\nNational Comprehensive Cancer Network : An alliance of 32 cancer centers in the United States, dedicated to improving the quality, effectiveness, and efficiency of cancer care.\\nNeoplasms : New abnormal growth of tissue that can be benign or malignant.\\nMalignant Neoplastic Disease : A disease resulting from the growth of malignant neoplasms.\\nCancer : A group of diseases involving abnormal cell growth with the potential to invade or spread to other parts of the body.\\n\\nRelationships:-\\n1. Entity1: \""Clinical Trials\"", Entity2: \""Cancer\"", Relationship: \""recommended for\""\\n2. Entity1: \""NCCN\"", Entity2: \""Clinical Trials\"", Relationship: \""encourages participation in\""\\n\\nCausalities:-\\n<C> NCCN believes that the best management of any patient with cancer is in a clinical trial </C>. <A> Participation in clinical trials is especially encouraged </A>.\\n\\nSection Name: Principles\\n====================\\nEntities:-\\nSurgical Procedures, Operative : Surgical procedures involve the use of operative manual and instrumental techniques on a patient to investigate or treat a pathological condition such as disease or injury.\\nRadiation Therapy : Therapy using ionizing radiation, generally as part of cancer treatment to control or kill malignant cells.\\nChemotherapy : A type of cancer treatment that uses one or more anti-cancer drugs as part of a standardized chemotherapy regimen.\\n\\nRelationships:-\\n1. Entity1: \""Principles of Surgery\"", Entity2: \""Principles of Radiation Therapy\"", Relationship: \""Both are principles of cancer treatment methods.\""\\n2. Entity1: \""Principles of Surgery\"", Entity2: \""Principles of Systemic Therapy for Non-Nasopharyngeal Cancers\"", Relationship: \""Both are principles of cancer treatment methods.\""\\n3. Entity1: \""Principles of Radiation Therapy\"", Entity2: \""Principles of Systemic Therapy for Non-Nasopharyngeal Cancers\"", Relationship: \""Both are principles of cancer treatment methods.\""\\n\\nCausalities:-\\n### Principles\\n\\n- **Principles of Surgery (SURG-A)**\\n- **Principles of Radiation Therapy (SUPRA-A)**\\n- **Principles of Systemic Therapy for Non-Nasopharyngeal Cancers (SYST-A)**\\n\\nSection Name: Adverse Pathologic Features\\n====================\\nEntities:-\\nExtranodal Extension : The spread of cancer cells beyond the lymph node capsule into the surrounding tissues.\\nPositive Surgical Margin : The presence of cancer cells at the edge of the tissue removed during surgery, indicating that some cancer may have been left behind.\\nPerineural Invasion : The presence of cancer cells surrounding or tracking along a nerve within the perineural space.\\nVascular Invasion : The invasion of cancer cells into blood vessels.\\nLymphatic Invasion : The invasion of cancer cells into lymphatic vessels.\\n\\nRelationships:-\\n1. Entity1: \""Extranodal extension\"", Entity2: \""Adverse Pathologic Features\"", Relationship: \""is a type of\""\\n2. Entity1: \""Positive margins\"", Entity2: \""Adverse Pathologic Features\"", Relationship: \""is a type of\""\\n3. Entity1: \""Close margins\"", Entity2: \""Adverse Pathologic Features\"", Relationship: \""is a type of\""\\n4. Entity1: \""pT3 or pT4 primary\"", Entity2: \""Adverse Pathologic Features\"", Relationship: \""is a type of\""\\n5. Entity1: \""pN2 or pN3 nodal disease\"", Entity2: \""Adverse Pathologic Features\"", Relationship: \""is a type of\""\\n6. Entity1: \""Perineural invasion\"", Entity2: \""Adverse Pathologic Features\"", Relationship: \""is a type of\""\\n7. Entity1: \""Vascular invasion\"", Entity2: \""Adverse Pathologic Features\"", Relationship: \""is a type of\""\\n8. Entity1: \""Lymphatic invasion\"", Entity2: \""Adverse Pathologic Features\"", Relationship: \""is a type of\""\\n\\nCausalities:-\\n<C> Extranodal extension </C>\\n<C> Positive margins </C>\\n<C> Close margins </C>\\n<C> pT3 or pT4 primary </C>\\n<C> pN2 or pN3 nodal disease </C>\\n<C> Perineural invasion </C>\\n<C> Vascular invasion </C>\\n<C> Lymphatic invasion </C>\\n\\nSection Name: Response Assessment\\n====================\\nEntities:-\\nChemotherapy, Induction : Initial chemotherapy treatment to shrink a tumor before the main treatment.\\nPrimary Site : The original location where a tumor or cancer begins.\\nComplete Remission : The disappearance of all signs of cancer in response to treatment.\\nPartial Remission : A decrease in the size of a tumor, or in the extent of cancer in the body, in response to treatment.\\nRadiotherapy : The use of high-energy radiation to kill cancer cells and shrink tumors.\\nSurgical Procedures, Operative : Surgical procedures involve the use of operative manual and instrumental techniques on a patient to investigate or treat a pathological condition such as disease or injury.\\n\\nRelationships:-\\n1. Entity1: \""induction chemotherapy\"", Entity2: \""Primary site\"", Relationship: \""treatment outcome\""\\n2. Entity1: \""Definitive RT\"", Entity2: \""Primary site\"", Relationship: \""treatment option\""\\n3. Entity1: \""RT\"", Entity2: \""Primary site\"", Relationship: \""treatment option\""\\n4. Entity1: \""Surgery\"", Entity2: \""unresectable nodal disease\"", Relationship: \""treatment option\""\\n\\nCausalities:-\\n<C> Response after induction chemotherapy </C>: <E> Primary site: CR </E> <E> Primary site: PR </E> <E> Primary site: < PR </E> <A> Definitive RT </A> (category 1) <A> RT </A> (category 1) or <A> systemic therapy/RT </A> (category 2B) <A> Surgery </A> or <A> unresectable nodal disease </A>\\n\\nSection Name: Follow-up\\n====================\\nEntities:-\\nFollow-Up Studies : Studies in which individuals are followed over time to determine the outcome of exposures, treatments, or interventions.\\nFollow-Up Procedure : A procedure where a patient is monitored over time to assess the progress of a condition or the effects of treatment.\\nFollow-Up (Medicine) : The process of monitoring a patient\\'s health over time after treatment or diagnosis.\\nDisease Recurrence : The return of a sign, symptom, or disease after a remission.\\nRecurrent Disease : A disease that returns after a period of remission.\\nRecurrence (Medicine) : The return of a disease or condition after a period of improvement.\\n\\nRelationships:-\\n1. Entity1: \""Follow-up\"", Entity2: \""Recurrent or persistent disease\"", Relationship: \""monitoring\""\\n\\nCausalities:-\\n### Follow-up\\n\\n- **Follow-up** (FOLL-A, 1 of 2)\\n- **Recurrent or persistent disease** (ADV-3)\\n\\nSection Name: Risk Features\\n====================\\nEntities:-\\nRadiotherapy : The use of high-energy radiation to kill cancer cells and shrink tumors.\\nExtranodal Extension : The spread of cancer cells beyond the lymph node capsule into the surrounding tissues.\\nPositive Surgical Margin : The presence of cancer cells at the edge of the tissue removed during surgery, indicating that some cancer may have been left behind.\\nSystemic Therapy : Systemic therapy refers to treatment using substances that travel through the bloodstream, reaching and affecting cells all over the body.\\n\\nRelationships:-\\n1. Entity1: \""Adverse pathologic features\"", Entity2: \""RT\"", Relationship: \""Consideration for treatment\""\\n2. Entity1: \""Adverse pathologic features\"", Entity2: \""Systemic therapy\"", Relationship: \""Consideration for treatment\""\\n\\nCausalities:-\\n- **No adverse pathologic features**\\n- **Other risk features**\\n- **Adverse pathologic features**:\\n  - <C> Extranodal extension and/or positive margin </C>\\n  - <A> RT or consider systemic therapy/RT </A>\\n\\nSection Name: Post-Therapy Evaluation\\n====================\\nEntities:-\\nSystemic Therapy : Systemic therapy refers to treatment using substances that travel through the bloodstream, reaching and affecting cells all over the body.\\nRadiation Therapy : Therapy using ionizing radiation, generally as part of cancer treatment to control or kill malignant cells.\\nNeck : The neck is the part of the body that separates the head from the torso and provides the mobility and movements of the head.\\n\\nRelationships:-\\n1. Entity1: \""Systemic Therapy\"", Entity2: \""Neck Evaluation\"", Relationship: \""evaluated in\""\\n2. Entity1: \""RT\"", Entity2: \""Neck Evaluation\"", Relationship: \""evaluated in\""\\n\\nCausalities:-\\n<CO> Post Systemic Therapy/RT or RT Neck </CO> <A> Evaluation </A>\\n\\nSection Name: Flowchart Overview\\n====================\\nEntities:-\\nLaryngeal Neoplasms : Tumors or cancer of the larynx, which may affect the supraglottic, glottic, or subglottic regions.\\nSupraglottic Larynx : The part of the larynx located above the vocal cords, including the epiglottis and aryepiglottic folds.\\nNational Comprehensive Cancer Network : An alliance of 32 cancer centers in the United States, dedicated to improving the quality, effectiveness, and efficiency of cancer care.\\n\\nRelationships:-\\n1. Entity1: \""NCCN Guidelines\"", Entity2: \""cancer of the supraglottic larynx\"", Relationship: \""guides management of\""\\n2. Entity1: \""NCCN Guidelines\"", Entity2: \""healthcare professionals\"", Relationship: \""used by\""\\n\\nCausalities:-\\n<C> cancer of the supraglottic larynx </C> <E> evaluate patient responses following treatment </E> <CO> based on observed outcomes </CO> <A> evaluation of the primary site and determining subsequent steps </A>.\\n\\nSection Name: Assessment and Treatment Decisions\\n====================\\nEntities:-\\nInduction Chemotherapy : Initial chemotherapy treatment to shrink a tumor before the main treatment.\\nComplete Response : The disappearance of all signs of cancer in response to treatment.\\nPartial Response : A decrease in the size of a tumor, or in the extent of cancer in the body, in response to treatment.\\nRadiation Therapy : Therapy using ionizing radiation, generally as part of cancer treatment to control or kill malignant cells.\\nSurgery : Medical specialty that uses operative manual and instrumental techniques on a patient to investigate or treat a pathological condition such as disease or injury.\\nSystemic Therapy : Systemic therapy refers to treatment using substances that travel through the bloodstream, reaching and affecting cells all over the body.\\n\\nRelationships:-\\n1. Entity1: \""Complete Response\"", Entity2: \""Radiation Therapy\"", Relationship: \""leads to\""\\n2. Entity1: \""Complete Response\"", Entity2: \""Surgery\"", Relationship: \""leads to\""\\n3. Entity1: \""Partial Response\"", Entity2: \""Systemic Therapy\"", Relationship: \""leads to\""\\n4. Entity1: \""Partial Response\"", Entity2: \""Radiation Therapy\"", Relationship: \""leads to\""\\n\\nCausalities:-\\n<C> responses to initial treatments such as induction chemotherapy </C> <E> Three main response categories are recognized: Complete Response (CR), Partial Response (PR), and less than Partial Response (< PR) </E>. These categories are pivotal in determining the next steps. <C> CR </C> <E> indicates full resolution of the disease at the primary site </E>, <A> leading to the consideration of definitive radiation therapy or the likelihood of surgery </A>. Conversely, <C> PR </C> <E> suggests that the disease has improved but not completely resolved </E>, <A> which directs the pathway towards either systemic therapy or continued radiation therapy </A>, <A> with further evaluation necessary </A>.\\n\\nSection Name: Adverse Pathologic Features and Follow-up\\n====================\\nEntities:-\\nRadiation Therapy : Therapy using ionizing radiation, generally as part of cancer treatment to control or kill malignant cells.\\nSurgical Procedures, Operative : Surgical procedures involve the use of operative manual and instrumental techniques on a patient to investigate or treat a pathological condition such as disease or injury.\\nNeoplasm Recurrence, Local : The return of a tumor or cancer, at the original site, after it has been treated.\\nNeoplasm Metastasis : The transfer of a neoplasm from one organ or part of the body to another remote from the primary site.\\nSurgical Procedure : A medical procedure involving an incision with instruments; performed to repair damage or arrest disease in a living body.\\nRecurrent Neoplasm : A neoplasm that has returned after treatment.\\nMetastatic Neoplasm : A neoplasm that has spread from its original site to one or more other places in the body.\\nSurgery : Medical specialty that uses operative manual and instrumental techniques on a patient to investigate or treat a pathological condition such as disease or injury.\\nCancer Recurrence : The return of cancer after treatment and after a period of time during which the cancer was undetectable.\\nMetastasis : Spread of a cancer or other disease from one organ or part to another not directly connected with it.\\n\\nRelationships:-\\n1. Entity1: \""Adverse pathologic features\"", Entity2: \""Treatment decisions\"", Relationship: \""Influence\""\\n2. Entity1: \""Adverse features\"", Entity2: \""Surgical intervention\"", Relationship: \""Recommendation\""\\n3. Entity1: \""Absence of adverse features\"", Entity2: \""Radiation therapy\"", Relationship: \""Pathway\""\\n4. Entity1: \""Follow-up process\"", Entity2: \""Recurrent or persistent disease\"", Relationship: \""Detection\""\\n5. Entity1: \""Recurrent or persistent disease\"", Entity2: \""Advanced disease management\"", Relationship: \""Necessity\""\\n\\nCausalities:-\\n<C> The presence of adverse pathologic features \u2014 such as extranodal extension or positive margins </C> <E> can directly influence treatment decisions </E>. <CO> If adverse features are found </CO>, <A> surgical intervention is recommended </A>. <CO> In cases where there are no adverse features </CO>, the patient may proceed directly to radiation therapy or continued systemic treatment, emphasizing the tailored approach based on the individual patient\\'s disease characteristics.\\n\\nFurthermore, the chart includes a section addressing the follow-up process after initial treatment. <CO> If there are signs of recurrent or persistent disease </CO>, <A> additional evaluations and treatment modalities may be necessary </A>. These evaluations <E> lead to specific recommendations for advanced disease management, denoted as ADV-3 on the chart </E>, emphasizing the importance of continuous monitoring and assessment in cancer care.\\n--------------------------------------------------\\nPage Number: 51\\n\\nSection Name: Introduction\\n====================\\nEntities:-\\nLaryngeal Neoplasms : Tumors or cancer of the larynx, which may affect the supraglottic, glottic, or subglottic regions.\\nMalignant Neoplasm Of Supraglottis : A malignant tumor located in the supraglottic region of the larynx.\\nSupraglottic Laryngeal Cancer : A type of cancer that occurs in the supraglottic region of the larynx, which is above the vocal cords.\\n\\nRelationships:-\\n1. Entity1: \""National Comprehensive Cancer Network (NCCN)\"", Entity2: \""cancer of the supraglottic larynx\"", Relationship: \""provides guidelines for\""\\n2. Entity1: \""healthcare professionals\"", Entity2: \""cancer of the supraglottic larynx\"", Relationship: \""manage\""\\n\\nCausalities:-\\nThe provided image is a detailed flowchart from the National Comprehensive Cancer Network (NCCN) guidelines regarding the <C> clinical staging and treatment protocols for cancer of the supraglottic larynx </C>. This flowchart is structured to <A> guide healthcare professionals through the stages of treatment </A> based on <CO> clinical findings </CO>, emphasizing the <E> complexity and systematic approach required in managing this type of cancer </E>.\\n\\nSection Name: Clinical Staging\\n====================\\nEntities:-\\nLaryngectomy : A surgical procedure involving the removal of the larynx, usually to treat cancer of the larynx.\\nTotal Laryngectomy : A surgical procedure to remove the entire larynx, often used in the treatment of advanced laryngeal cancer.\\nNeoplasm Staging : Methods used for staging neoplasms, including clinical and pathological staging.\\nCancer Staging : The process of determining the extent of cancer in the body, often using the TNM system.\\nTnm Staging System : A cancer staging system that describes the extent of cancer using Tumor size (T), Node involvement (N), and Metastasis (M).\\n\\nRelationships:-\\n1. Entity1: \""Clinical staging criteria\"", Entity2: \""Total laryngectomy\"", Relationship: \""determines necessity of\""\\n2. Entity1: \""T3, N0\"", Entity2: \""Clinical staging criteria\"", Relationship: \""is a categorization of\""\\n\\nCausalities:-\\nThe flowchart begins with the <C> clinical staging criteria </C>, specifically focusing on <CO> cases that require total laryngectomy, denoted as requiring (amenable to) total laryngectomy (T3, N0) </CO>. This <A> categorization </A> is crucial as it <E> forms the basis for determining the appropriate treatment strategy </E>.\\n\\nSection Name: Treatment of Primary and Neck\\n====================\\nEntities:-\\nNeoplasm Staging : Methods used for staging neoplasms, including clinical and pathological staging.\\nSystemic Therapy : Treatment using substances that travel through the bloodstream, reaching and affecting cells all over the body.\\nRadiotherapy : The use of high-energy radiation from x-rays, gamma rays, neutrons, protons, and other sources to kill cancer cells and shrink tumors.\\nLaryngectomy : A surgical procedure involving the removal of the larynx, usually to treat cancer of the larynx.\\nThyroidectomy : A surgical procedure to remove all or part of the thyroid gland.\\nNeck Dissection : Surgical procedure to remove lymph nodes and surrounding tissue to treat or prevent cancer spread.\\nLymphatic Metastasis : Transfer of a neoplasm from one organ or part of the body to another remote from the primary site.\\n\\nRelationships:-\\n1. Entity1: \""Systemic Therapy\"", Entity2: \""Radiation Therapy\"", Relationship: \""combined with\""\\n2. Entity1: \""Laryngectomy\"", Entity2: \""Lymph Node Involvement\"", Relationship: \""considered based on\""\\n3. Entity1: \""Thyroidectomy\"", Entity2: \""Lymph Node Involvement\"", Relationship: \""considered based on\""\\n4. Entity1: \""Neck Dissection\"", Entity2: \""Lymph Node Involvement\"", Relationship: \""considered based on\""\\n\\nCausalities:-\\n<CO> Once clinical staging is established </CO>, the chart outlines various treatment options. <A> The initial step may involve either concurrent systemic therapy combined with radiation therapy (RT) or opting for RT alone </A>, <CO> especially if the patient is not a medical candidate for both therapies </CO>. <A> Laryngectomy, thyroidectomy, and neck dissection are considered </A> <CO> based on the extent of lymph node involvement </CO>.\\n\\nSection Name: Surgical Options\\n====================\\nEntities:-\\nLaryngectomy : A surgical procedure involving the removal of the larynx, usually to treat cancer of the larynx.\\nThyroidectomy : A surgical procedure to remove all or part of the thyroid gland.\\nLymph Node Excision : Surgical removal of one or more lymph nodes.\\nLymphadenectomy : Surgical removal of one or more groups of lymph nodes.\\nSurgical Procedures, Operative : Operations carried out for the correction of deformities and defects, repair of injuries, and diagnosis and cure of certain diseases.\\nSurgical Procedure : A medical procedure involving an incision with instruments; performed to repair damage or arrest disease in a living body.\\nSurgery : Medical specialty that uses operative manual and instrumental techniques on a patient to investigate or treat a pathological condition such as a disease or injury.\\n\\nRelationships:-\\n1. Entity1: \""Laryngectomy\"", Entity2: \""Thyroidectomy\"", Relationship: \""combined with\""\\n2. Entity1: \""Lymph Node Dissection\"", Entity2: \""Surgical Intervention\"", Relationship: \""extent of\""\\n3. Entity1: \""Surgical Intervention\"", Entity2: \""Advanced Cases\"", Relationship: \""management option for\""\\n\\nCausalities:-\\n<CO> If concurrent therapies are not suitable </CO>, <A> the chart presents laryngectomy combined with thyroidectomy </A>, <CO> depending on the extent of lymph node dissection required </CO>. <E> This highlights surgical intervention as a viable option in the management of advanced cases </E>.\\n\\nSection Name: Induction Chemotherapy\\n====================\\nEntities:-\\nInduction Chemotherapy : Initial chemotherapy treatment used to shrink a tumor before the main treatment, which is usually surgery.\\nSurgical Procedure : A medical procedure involving an incision with instruments; performed to repair damage or arrest disease in a living body.\\nTherapeutic Approach : A method or strategy used in the treatment of disease or injury.\\n\\nRelationships:-\\n1. Entity1: \""Induction Chemotherapy\"", Entity2: \""Surgical Intervention\"", Relationship: \""alternative or sequential treatment option\""\\n\\nCausalities:-\\n<C> immediate surgical intervention is either not feasible or considered insufficient </C> <E> The flowchart also considers the option of induction chemotherapy </E> <CO> in cases where immediate surgical intervention is either not feasible or considered insufficient </CO>. <A> tailoring therapeutic approaches tailored to individual patient needs </A>.\\n\\nSection Name: Adjuvant Treatment\\n====================\\nEntities:-\\nAdjuvant Chemotherapy : Chemotherapy given in addition to the primary treatment to maximize its effectiveness.\\nRadiotherapy : The use of high-energy radiation from x-rays, gamma rays, neutrons, protons, and other sources to kill cancer cells and shrink tumors.\\nNeoplasm Recurrence, Local : The return of a cancer, at the same site, after it has been treated.\\nDisease Progression : The worsening of a disease over time.\\n\\nRelationships:-\\n1. Entity1: \""Primary Treatment\"", Entity2: \""Adjuvant Treatment\"", Relationship: \""followed by\""\\n2. Entity1: \""Adjuvant Treatment\"", Entity2: \""Systemic Therapy\"", Relationship: \""includes\""\\n3. Entity1: \""Adjuvant Treatment\"", Entity2: \""Radiotherapy\"", Relationship: \""includes\""\\n4. Entity1: \""Follow-up Assessments\"", Entity2: \""Treatment Efficacy\"", Relationship: \""used to evaluate\""\\n\\nCausalities:-\\n<C> Following primary treatment </C>, <E> the flowchart addresses the potential for adjuvant treatment pathways </E>. This may include systemic therapy, RT, or further evaluations based on <CO> the patient\\'s response and any recurrence or persistent disease </CO>. It emphasizes <A> the need for follow-up assessments to evaluate treatment efficacy </A>.\\n\\nSection Name: Risk Features and Response Assessment\\n====================\\nEntities:-\\nNeoplasm Invasiveness : The property of a neoplasm to infiltrate and destroy surrounding tissue.\\nSurgical Margins : The edge or border of the tissue removed in cancer surgery.\\nNeoplasms : Neoplasms are abnormal growths of tissue, which can be cancerous or non-cancerous.\\nExtramural Extension : Extension of a tumor beyond the wall of an organ.\\nPositive Surgical Margin : Cancer cells are present at the edge of the tissue removed during surgery.\\nCancer Management : The process of planning and coordinating the treatment of cancer.\\nCancer : Cancer is a group of diseases involving abnormal cell growth with the potential to invade or spread to other parts of the body.\\n\\nRelationships:-\\n1. Entity1: \""Extramural extension\"", Entity2: \""Treatment decisions\"", Relationship: \""influences\""\\n2. Entity1: \""Positive surgical margin\"", Entity2: \""Treatment decisions\"", Relationship: \""influences\""\\n3. Entity1: \""Ongoing assessment\"", Entity2: \""Response evaluation\"", Relationship: \""leads to\""\\n4. Entity1: \""Response evaluation\"", Entity2: \""Adjustments to treatment\"", Relationship: \""leads to\""\\n5. Entity1: \""Management of cancer\"", Entity2: \""Treatment decisions\"", Relationship: \""involves\""\\n6. Entity1: \""Management of cancer\"", Entity2: \""Ongoing assessment\"", Relationship: \""involves\""\\n7. Entity1: \""Management of cancer\"", Entity2: \""Adjustments to treatment\"", Relationship: \""involves\""\\n\\nCausalities:-\\nThe chart incorporates a segment that takes into account <CO> adverse pathologic features, such as extramural extension or positive margins </CO>, <E> which could influence subsequent treatment decisions </E>. This highlights the importance of <A> ongoing assessment in the management of cancer, leading to response evaluation and adjustments to treatment as necessary </A>.\\n\\nSection Name: NCCN Guidelines Version 4.2024\\n====================\\nEntities:-\\nClinical Trials : Clinical trials are research studies performed in people that are aimed at evaluating a medical, surgical, or behavioral intervention.\\nNeoplasms : Neoplasms are abnormal growths of tissue, which can be cancerous or non-cancerous.\\nClinical Trial : A clinical trial is a research study that prospectively assigns human participants or groups of humans to one or more health-related interventions to evaluate the effects on health outcomes.\\nMalignant Neoplasm : A malignant neoplasm is a cancerous growth that has the potential to invade and destroy nearby tissue and spread to other parts of the body.\\nNational Comprehensive Cancer Network : The National Comprehensive Cancer Network (NCCN) is an alliance of 31 cancer centers in the United States, dedicated to improving the quality, effectiveness, and efficiency of cancer care.\\nCancer : Cancer is a group of diseases involving abnormal cell growth with the potential to invade or spread to other parts of the body.\\n\\nRelationships:-\\n1. Entity1: \""National Comprehensive Cancer Network\"", Entity2: \""NCCN Guidelines\"", Relationship: \""provides\""\\n2. Entity1: \""NCCN Guidelines\"", Entity2: \""Clinical Trials\"", Relationship: \""recommend\""\\n3. Entity1: \""NCCN Guidelines\"", Entity2: \""Cancer\"", Relationship: \""related to management of\""\\n\\nCausalities:-\\n<CO> any patient with cancer </CO> <A> the best management is in a clinical trial </A>. <A> Participation in clinical trials is especially encouraged </A>.\\n\\nSection Name: SUPRA-3\\n====================\\nEntities:-\\nLaryngectomy : A surgical procedure involving the removal of the larynx, usually to treat cancer of the larynx.\\nThyroidectomy : A surgical procedure to remove all or part of the thyroid gland.\\nNeck Dissection : Surgical procedure to remove lymph nodes and surrounding tissue to treat or prevent cancer spread.\\nChemotherapy, Induction : Initial chemotherapy treatment to shrink a tumor before the main treatment.\\nClinical Trials As Topic : Research studies that prospectively assign human participants or groups of humans to one or more health-related interventions to evaluate the effects on health outcomes.\\nInduction Chemotherapy : Initial chemotherapy treatment used to shrink a tumor before the main treatment, which is usually surgery.\\nClinical Trial : A clinical trial is a research study that prospectively assigns human participants or groups of humans to one or more health-related interventions to evaluate the effects on health outcomes.\\n\\nRelationships:-\\n1. Entity1: \""Total laryngectomy\"", Entity2: \""Laryngectomy\"", Relationship: \""is a type of\""\\n2. Entity1: \""Systemic therapy\"", Entity2: \""RT\"", Relationship: \""concurrent treatment option\""\\n3. Entity1: \""Induction chemotherapy\"", Entity2: \""Other treatments\"", Relationship: \""initial treatment option before\""\\n\\nCausalities:-\\n<CO> Requiring (amenable to) total laryngectomy (T3,N0) </CO>\\n  - <A> Concurrent systemic therapy/RT </A> or <A> RT if patient not medical candidate for concurrent systemic therapy/RT </A>\\n  - <A> Laryngectomy, thyroidectomy and with ipsilateral, central, or bilateral neck dissection </A>\\n  - or\\n  - <A> Induction chemotherapy </A>\\n  - or\\n  - <A> Clinical trials </A>\\n\\nSection Name: Follow-up\\n====================\\nEntities:-\\nFollow-Up Studies : Studies in which individuals are followed over time to determine the outcome of exposures, treatments, or interventions.\\nFollow-Up Procedure : A procedure performed to monitor the progress of a patient\\'s condition after initial treatment.\\nFollow-Up : Medical care given to a patient over time after initial treatment.\\nDisease Recurrence : The return of a sign, symptom, or disease after a remission.\\nRecurrent Disease : The reappearance of a disease after a period of improvement.\\n\\nRelationships:-\\n1. Entity1: \""Follow-up\"", Entity2: \""Recurrent or persistent disease\"", Relationship: \""monitoring\""\\n\\nCausalities:-\\n- **Follow-up (FOLL-A, 1 of 2)**\\n  - <CO> Recurrent or persistent disease </CO> (ADV-3)\\n\\nSection Name: Adverse Pathologic Features\\n====================\\nEntities:-\\nRadiotherapy : The use of high-energy radiation from x-rays, gamma rays, neutrons, protons, and other sources to kill cancer cells and shrink tumors.\\nExtranodal Extension : The spread of cancer beyond the lymph node capsule.\\nPositive Surgical Margin : Cancer cells are present at the edge of the tissue removed during surgery.\\nSystemic Therapy : Treatment using substances that travel through the bloodstream, reaching and affecting cells all over the body.\\n\\nRelationships:-\\n1. Entity1: \""pN1\"", Entity2: \""Radiotherapy\"", Relationship: \""Consideration for treatment\""\\n2. Entity1: \""Extranodal extension\"", Entity2: \""Systemic Therapy\"", Relationship: \""Treatment option\""\\n3. Entity1: \""Extranodal extension\"", Entity2: \""Radiotherapy\"", Relationship: \""Treatment option\""\\n4. Entity1: \""Positive surgical margin\"", Entity2: \""Systemic Therapy\"", Relationship: \""Treatment option\""\\n5. Entity1: \""Positive surgical margin\"", Entity2: \""Radiotherapy\"", Relationship: \""Treatment option\""\\n\\nCausalities:-\\n- <CO>pN1 without other risk features</CO>\\n  - <C>Adverse pathologic features</C>\\n  - <A>Consider RT</A>\\n  - <CO>Extranodal extension and/or positive margin</CO>\\n  - <CO>Other risk features</CO>\\n  - <A>Systemic therapy/RT (category 1)</A>\\n  - <A>RT or Consider systemic therapy/RT</A>\\n\\nSection Name: Response Assessment\\n====================\\nEntities:-\\nResponse Evaluation : The process of assessing the response of a disease to treatment, often used in clinical trials to determine the effectiveness of a therapy.\\nResponse To Treatment : A clinical finding indicating the response of a condition to a therapeutic intervention.\\n\\nRelationships:-\\n\\nSection Name: Principles of Surgery and Radiation Therapy\\n====================\\nEntities:-\\nSurgical Procedures, Operative : Operations carried out for the correction of deformities and defects, repair of injuries, and diagnosis and cure of certain diseases.\\nSurgical Procedure : A medical procedure involving an incision with instruments; performed to repair damage or arrest disease in a living body.\\nSurgery : Medical specialty that uses operative manual and instrumental techniques on a patient to investigate or treat a pathological condition such as a disease or injury.\\nRadiotherapy : The use of high-energy radiation from x-rays, gamma rays, neutrons, protons, and other sources to kill cancer cells and shrink tumors.\\nRadiation Therapy : Radiation therapy is a therapy using ionizing radiation, generally as part of cancer treatment to control or kill malignant cells.\\n\\nRelationships:-\\n1. Entity1: \""Principles of Surgery\"", Entity2: \""Principles of Radiation Therapy\"", Relationship: \""complementary treatments\""\\n\\nCausalities:-\\n**Principles of Surgery (SURG-A).**\\n\\n**Principles of Radiation Therapy (SUPRA-A).**\\n\\nSection Name: Principles of Systemic Therapy\\n====================\\nEntities:-\\nCisplatin : An inorganic and water-soluble platinum complex, cisplatin is an antineoplastic agent that is used in the treatment of various cancers.\\nRadiotherapy : The use of high-energy radiation from x-rays, gamma rays, neutrons, protons, and other sources to kill cancer cells and shrink tumors.\\nRadiation Therapy : Radiation therapy is a therapy using ionizing radiation, generally as part of cancer treatment to control or kill malignant cells.\\n\\nRelationships:-\\n1. Entity1: \""Cisplatin\"", Entity2: \""Systemic Therapy for Non-Nasopharyngeal Cancers\"", Relationship: \""preferred agent\""\\n2. Entity1: \""Cisplatin\"", Entity2: \""Concurrent Systemic Therapy/RT\"", Relationship: \""used in\""\\n\\nCausalities:-\\n<CO> When using concurrent systemic therapy/RT </CO>, <A> the preferred agent is cisplatin (category 1) </A>.\\n--------------------------------------------------\\nPage Number: 130\\n\\nSection Name: Pathological N (pN)\\n====================\\nEntities:-\\nLymph Nodes : Small, bean-shaped structures that are part of the body\\'s lymphatic system. They filter lymph fluid and store white blood cells that help fight infection.\\nNeoplasm Metastasis : The transfer of a neoplasm from one organ or part of the body to another remote from the primary site.\\nTnm Staging : A system used to describe the size and spread of cancer in a standardized way. T refers to the size of the tumor, N to the involvement of lymph nodes, and M to metastasis.\\nLymph Node Structure : A structure that is part of the lymphatic system, involved in the immune response.\\nMetastasis : The spread of a cancer or other disease from one organ or part to another not directly connected with it.\\nTnm Staging System : A cancer staging notation system that describes the extent of cancer in a patient\\'s body.\\nLymph Node : An organ of the lymphatic system and the adaptive immune system.\\n\\nRelationships:-\\n1. Entity1: \""Lymph Nodes\"", Entity2: \""Neoplasm Metastasis\"", Relationship: \""involved in\""\\n2. Entity1: \""TNM Staging\"", Entity2: \""Lymph Nodes\"", Relationship: \""includes\""\\n3. Entity1: \""TNM Staging\"", Entity2: \""Neoplasm Metastasis\"", Relationship: \""describes\""\\n\\nCausalities:-\\n<CO> NX: Regional lymph nodes cannot be assessed </CO>\\n<CO> N0: No regional lymph node metastasis </CO>\\n<CO> N1: Metastasis in a single ipsilateral lymph node, 3 cm or smaller in greatest dimension ENE(\u2013) </CO>\\n<CO> N2: Metastasis in a single ipsilateral lymph node, 3 cm or smaller in greatest dimension and ENE(+); or larger than 3 cm but not larger than 6 cm in greatest dimension and ENE(\u2212); or metastases in multiple ipsilateral lymph nodes, none larger than 6 cm in greatest dimension and ENE(\u2212); or in bilateral or contralateral lymph node(s), none larger than 6 cm in greatest dimension and ENE(\u2212) </CO>\\n<CO> N2a: Metastasis in a single ipsilateral node, 3 cm or smaller in greatest dimension and ENE(+); or metastasis in a single ipsilateral node, larger than 3 cm but not larger than 6 cm in greatest dimension and ENE(\u2212) </CO>\\n<CO> N2b: Metastases in multiple ipsilateral nodes, none larger than 6 cm in greatest dimension and ENE(\u2212) </CO>\\n<CO> N2c: Metastases in bilateral or contralateral lymph node(s), none larger than 6 cm in greatest dimension and ENE(\u2212) </CO>\\n<CO> N3: Metastasis in a lymph node, larger than 6 cm in greatest dimension and ENE(\u2212); or metastasis in a single ipsilateral node, larger than 3 cm in greatest dimension and ENE(+); or multiple ipsilateral, contralateral, or bilateral lymph nodes and any with ENE(+); or a single contralateral node of any size and ENE(+) </CO>\\n<CO> N3a: Metastasis in a lymph node, larger than 6 cm in greatest dimension and ENE(\u2212) </CO>\\n<CO> N3b: Metastasis in a single ipsilateral node, larger than 3 cm in greatest dimension and ENE(+); or multiple ipsilateral, contralateral, or bilateral lymph nodes any with ENE(+); or a single contralateral node of any size and ENE(+) </CO>\\n<CO> Note: A designation of \u201cU\u201d or \u201cL\u201d may be used for any N category to indicate metastasis above the lower border of the cricoid (U) or below the lower border of the cricoid (L). Similarly, clinical and pathological ENE should be recorded as ENE(\u2212) or ENE(+). </CO>\\n\\nSection Name: Distant Metastasis (M)\\n====================\\nEntities:-\\nNeoplasm Metastasis : The transfer of a neoplasm from one organ or part of the body to another remote from the primary site.\\nMetastasis : The spread of a cancer or other disease from one organ or part to another not directly connected with it.\\n\\nRelationships:-\\n1. Entity1: \""M0\"", Entity2: \""Distant Metastasis\"", Relationship: \""is a category of\""\\n2. Entity1: \""M1\"", Entity2: \""Distant Metastasis\"", Relationship: \""is a category of\""\\n\\nCausalities:-\\n### Distant Metastasis (M)\\n\\n- **M0**: No distant metastasis\\n- **M1**: Distant metastasis\\n\\nSection Name: Histologic Grade (G)\\n====================\\nEntities:-\\nNeoplasm Grading : A system of classifying cancer cells in terms of how abnormal they look under a microscope and how quickly the tumor is likely to grow and spread.\\nHistologic Grade : A measure of how much tumor cells differ from healthy cells, used to assess the aggressiveness of cancer.\\n\\nRelationships:-\\n1. Entity1: \""GX\"", Entity2: \""Grade cannot be assessed\"", Relationship: \""is described as\""\\n2. Entity1: \""G1\"", Entity2: \""Well differentiated\"", Relationship: \""is described as\""\\n3. Entity1: \""G2\"", Entity2: \""Moderately differentiated\"", Relationship: \""is described as\""\\n4. Entity1: \""G3\"", Entity2: \""Poorly differentiated\"", Relationship: \""is described as\""\\n\\nCausalities:-\\n<CO>GX</CO>: <E>Grade cannot be assessed</E>\\n<CO>G1</CO>: <E>Well differentiated</E>\\n<CO>G2</CO>: <E>Moderately differentiated</E>\\n<CO>G3</CO>: <E>Poorly differentiated</E>\\n\\nSection Name: Prognostic Stage Groups\\n====================\\nEntities:-\\nNeoplasm Staging : Methods and systems of classifying neoplasms according to extent of disease.\\nTumor Staging : A system for describing the size and spread of cancer within the body.\\nTnm Staging System : A cancer staging notation system that describes the extent of cancer in a patient\\'s body.\\n\\nRelationships:-\\n1. Entity1: \""Stage 0\"", Entity2: \""Tis N0 M0\"", Relationship: \""defined by\""\\n2. Entity1: \""Stage I\"", Entity2: \""T1 N0 M0\"", Relationship: \""defined by\""\\n3. Entity1: \""Stage II\"", Entity2: \""T2 N0 M0\"", Relationship: \""defined by\""\\n4. Entity1: \""Stage III\"", Entity2: \""T3 N0 M0, T1 N1 M0, T2 N1 M0, T3 N1 M0\"", Relationship: \""defined by\""\\n5. Entity1: \""Stage IVA\"", Entity2: \""T1 N2 M0, T2 N2 M0, T3 N2 M0, T4a N0,N1,N2 M0\"", Relationship: \""defined by\""\\n6. Entity1: \""Stage IVB\"", Entity2: \""Any T N3 M0, T4b Any N M0\"", Relationship: \""defined by\""\\n7. Entity1: \""Stage IVC\"", Entity2: \""Any T Any N M1\"", Relationship: \""defined by\""\\n--------------------------------------------------\\nPage Number: 47\\n\\nSection Name: Overview of Radiation Therapy Guidelines\\n====================\\nEntities:-\\nRadiation Therapy : The medical use of ionizing radiation, generally as part of cancer treatment to control or kill malignant cells.\\nCancer : A group of diseases involving abnormal cell growth with the potential to invade or spread to other parts of the body.\\nMalignant Neoplasm : A disease characterized by uncontrolled, abnormal growth of cells that can invade and destroy nearby tissue and spread to other parts of the body.\\nLaryngeal Neoplasms : Tumors or cancer of the larynx, which may affect the glottis, supraglottis, or subglottis.\\nGlottic Larynx Cancer : A malignant neoplasm located in the glottic region of the larynx.\\nLaryngeal Cancer : Cancer that occurs in the larynx, or voice box, which may include the glottic region.\\nNational Comprehensive Cancer Network : The National Comprehensive Cancer Network (NCCN) is an alliance of 30 cancer centers in the United States, dedicated to improving the quality, effectiveness, and efficiency of cancer care.\\n\\nRelationships:-\\n1. Entity1: \""Radiation Therapy\"", Entity2: \""Cancer\"", Relationship: \""treats\""\\n2. Entity1: \""NCCN Guidelines\"", Entity2: \""Cancer\"", Relationship: \""guides treatment for\""\\n3. Entity1: \""NCCN Guidelines\"", Entity2: \""Radiation Therapy\"", Relationship: \""specifies use of\""\\n\\nCausalities:-\\nThe image presents a detailed flowchart outlining the principles of radiation therapy specifically for the <C> treatment of cancer in the glottic larynx </C>, <CO> as per the National Comprehensive Cancer Network (NCCN) guidelines (version 2.2024) </CO>. <E> This structured guidance delineates various treatment protocols </E>, <A> stratified by risk levels and therapeutic approaches </A>.\\n\\nSection Name: Principles of Radiation Therapy\\n====================\\nEntities:-\\nRadiation Therapy : The medical use of ionizing radiation, generally as part of cancer treatment to control or kill malignant cells.\\nGy : Gray, a unit of ionizing radiation dose in the International System of Units (SI), defined as the absorption of one joule of radiation energy per kilogram of matter.\\nGray (Unit) : A unit of absorbed radiation dose of ionizing radiation, defined as the absorption of one joule of radiation energy per kilogram of matter.\\n\\nRelationships:-\\n1. Entity1: \""Tis, N0\"", Entity2: \""60.75 Gy (2.25 Gy/fraction) to 66 Gy (2.0 Gy/fraction)\"", Relationship: \""treatment protocol\""\\n2. Entity1: \""T1, N0\"", Entity2: \""63 Gy (2.25 Gy/fraction) to 66 Gy (2.0 Gy/fraction) or 50 Gy (3.12 Gy/fraction) to 52 Gy (3.28 Gy/fraction)\"", Relationship: \""treatment protocol\""\\n3. Entity1: \""T2, N0\"", Entity2: \""65.25 Gy (2.25 Gy/fraction) to 70 Gy (2.0 Gy/fraction)\"", Relationship: \""treatment protocol\""\\n4. Entity1: \""\u2265T2, N1 (PTV High risk)\"", Entity2: \""66 Gy (2.2 Gy/fraction) to 70 Gy (2.0 Gy/fraction)\"", Relationship: \""treatment protocol\""\\n5. Entity1: \""\u2265T2, N1 (Low to intermediate risk)\"", Entity2: \""44\u201350 Gy (2.0 Gy/fraction) to 54\u201363 Gy (1.6\u20131.8 Gy/fraction)\"", Relationship: \""treatment protocol\""\\n\\nCausalities:-\\n<CO>Tis, N0</CO>: <A>60.75 Gy (2.25 Gy/fraction) to 66 Gy (2.0 Gy/fraction)</A>\\n<CO>T1, N0</CO>: <A>63 Gy (2.25 Gy/fraction, preferred) to 66 Gy (2.0 Gy/fraction) or 50 Gy (3.12 Gy/fraction) to 52 Gy (3.28 Gy/fraction)</A>\\n<CO>T2, N0</CO>: <A>65.25 (2.25 Gy/fraction) to 70 Gy (2.0 Gy/fraction)</A>\\n<CO>\u2265T2, N1</CO>: <A>PTV High risk: Primary tumor and involved lymph nodes (includes possible local subclinical infiltration at the primary site and at the high-risk level lymph node(s))</A>\\n<A>Fractionation: 66 Gy (2.2 Gy/fraction) to 70 Gy (2.0 Gy/fraction); daily Monday\u2013Friday in 6\u20137 weeks</A>\\n<A>Concomitant boost accelerated RT: 72 Gy/6 weeks (1.8 Gy/fraction, large field; 1.5 Gy boost as second daily fraction during last 12 treatment days)</A>\\n<A>66\u201370 Gy (2.0 Gy/fraction; 6 fractions/wk accelerated)</A>\\n<A>Hyperfractionation: 79.2\u201381.6 Gy/7 weeks (1.2 Gy/fraction, twice daily)</A>\\n<CO>Low to intermediate risk</CO>: <A>Sites of suspected subclinical spread</A>\\n<A>44\u201350 Gy (2.0 Gy/fraction) to 54\u201363 Gy (1.6\u20131.8 Gy/fraction)</A>\\n\\nSection Name: Concurrent Systemic Therapy/RT\\n====================\\nEntities:-\\nCisplatin : A platinum-containing antineoplastic agent used in the treatment of various cancers.\\nCarboplatin : An organoplatinum compound that possesses antineoplastic activity.\\nFluorouracil : A chemotherapy drug used to treat various types of cancer.\\n\\nRelationships:-\\n1. Entity1: \""concurrent systemic therapy/RT\"", Entity2: \""cisplatin\"", Relationship: \""uses\""\\n2. Entity1: \""concurrent systemic therapy/RT\"", Entity2: \""carboplatin and 5-FU\"", Relationship: \""uses\""\\n3. Entity1: \""multiagent chemotherapy\"", Entity2: \""toxicity burden\"", Relationship: \""increases\""\\n\\nCausalities:-\\n<CO>Based on published data</CO>, <A>concurrent systemic therapy/RT most commonly uses conventional fractionation at 2.0 Gy per fraction to a typical dose of 70 Gy in 7 weeks with single-agent cisplatin given every 3 weeks at 100 mg/m\u00b2</A>; <CO>2\u20133 cycles of chemotherapy are used depending on the radiation fractionation scheme (RTOG 0129)</CO>. <CO>When carboplatin and 5-FU are used</CO>, <A>the recommended regimen is standard fractionation plus 3 cycles of chemotherapy</A>. <CO>Other fraction sizes (e.g., 1.8 Gy, conventional), multiagent chemotherapy, other dosing schedules of cisplatin, or altered fractionation with chemotherapy</CO> <E>are efficacious</E>, and <C>there is no consensus on the optimal approach</C>. <C>In general, the use of concurrent systemic therapy/RT</C> <E>carries a high toxicity burden</E>; <C>multiagent chemotherapy</C> <E>will likely further increase the toxicity burden</E>. <A>For any systemic therapy/RT approach, close attention should be paid to published reports for the specific chemotherapy agent, dose, and schedule of administration</A>. <A>Systemic therapy/RT should be performed by an experienced team and should include substantial supportive care</A>.\\n\\nSection Name: Treatment Modalities\\n====================\\nEntities:-\\nIntensity-Modulated Radiotherapy : A type of conformal radiotherapy that uses computer-controlled linear accelerators to deliver precise radiation doses to a malignant tumor or specific areas within the tumor.\\nIntensity Modulated Radiation Therapy : A type of conformal radiotherapy that uses computer-controlled linear accelerators to deliver precise radiation doses to a malignant tumor or specific areas within the tumor.\\nIntensity-Modulated Radiation Therapy : An advanced type of high-precision radiotherapy that uses computer-controlled linear accelerators to deliver precise radiation doses to a malignant tumor or specific areas within the tumor.\\nRadiotherapy, Conformal : A type of radiotherapy that uses imaging to conform the radiation dose to the shape of the tumor.\\n3D Conformal Radiation Therapy : A technique in radiotherapy that uses imaging to conform the radiation dose to the shape of the tumor.\\nChemotherapy, Adjuvant : Treatment with drugs that kill cancer cells, often used in conjunction with other therapies.\\nChemotherapy : The treatment of disease by the use of chemical substances, especially the treatment of cancer by cytotoxic and other drugs.\\nDrug Therapy, Combination : The use of two or more drugs to achieve a therapeutic effect.\\nSystemic Therapy : A type of therapy that uses substances that travel through the bloodstream, reaching and affecting cells all over the body.\\n\\nRelationships:-\\n1. Entity1: \""Intensity-Modulated Radiation Therapy (IMRT)\"", Entity2: \""3D Conformal Radiation Therapy (3D-CRT)\"", Relationship: \""are delivery methods for radiation therapy\""\\n2. Entity1: \""Chemotherapy\"", Entity2: \""Radiation Therapy\"", Relationship: \""is integrated with for aggressive or advanced cancer cases\""\\n\\nCausalities:-\\n<CO> contingent upon patient-specific considerations </CO> <A> suggests either Intensity-Modulated Radiation Therapy (IMRT) or 3D Conformal Radiation Therapy (3D-CRT) as delivery methods </A>. <A> These advanced techniques are employed to optimize treatment accuracy </A>, <E> preserving surrounding healthy tissue and improving overall patient outcomes </E>. <A> a focus on concurrent systemic therapies underlines the importance of integrating chemotherapy </A>, particularly <CO> for patients with more aggressive forms of cancer or those demonstrating advanced disease characteristics </CO>.\\n\\nSection Name: Additional Information\\n====================\\nEntities:-\\nClinical Trials : Clinical trials are research studies performed in people that are aimed at evaluating a medical, surgical, or behavioral intervention.\\nClinical Trial : A clinical trial is a research study in which one or more human subjects are prospectively assigned to one or more interventions to evaluate the effects of those interventions on health-related biomedical or behavioral outcomes.\\nNational Comprehensive Cancer Network : The National Comprehensive Cancer Network (NCCN) is an alliance of 30 cancer centers in the United States, dedicated to improving the quality, effectiveness, and efficiency of cancer care.\\nIntensity-Modulated Radiation Therapy : An advanced type of high-precision radiotherapy that uses computer-controlled linear accelerators to deliver precise radiation doses to a malignant tumor or specific areas within the tumor.\\nIntensity Modulated Radiation Therapy : A type of conformal radiotherapy that uses computer-controlled linear accelerators to deliver precise radiation doses to a malignant tumor or specific areas within the tumor.\\nThree-Dimensional Conformal Radiation Therapy : A type of external beam radiation therapy that uses a computer to create a 3-dimensional picture of the tumor so that multiple radiation beams can be shaped exactly to the contour of the treatment area.\\n\\nRelationships:-\\n1. Entity1: \""National Comprehensive Cancer Network\"", Entity2: \""Clinical trial\"", Relationship: \""encourages participation in\""\\n2. Entity1: \""Intensity-Modulated Radiation Therapy\"", Entity2: \""Three-Dimensional Conformal Radiation Therapy\"", Relationship: \""recommended alternatives\""\\n\\nCausalities:-\\n<A> Participation in clinical trials </A> is especially encouraged. <A> Either IMRT (preferred) or 3D-CRT is recommended. </A>\\n\\nSection Name: Conclusion\\n====================\\nEntities:-\\nLaryngeal Neoplasms : Tumors or cancer of the larynx, which may affect the glottis, supraglottis, or subglottis.\\nMalignant Neoplasm Of Glottis : A malignant tumor located in the glottic region of the larynx.\\nLaryngeal Cancer : Cancer that occurs in the larynx, or voice box, which may include the glottic region.\\nPrognosis : A medical term for predicting the likely or expected development of a disease.\\nEvidence-Based Practice : Healthcare practices that are based on scientific evidence and research.\\nEvidence-Based Medicine : An approach to medical practice intended to optimize decision-making by emphasizing the use of evidence from well-designed and conducted research.\\n\\nRelationships:-\\n1. Entity1: \""treatment paradigms\"", Entity2: \""glottic larynx cancer\"", Relationship: \""encapsulates\""\\n2. Entity1: \""personalized treatment plans\"", Entity2: \""prognosis\"", Relationship: \""improves\""\\n\\nCausalities:-\\n<C> glottic larynx cancer </C>. <CO> the nuances of each patient\\'s condition </CO>. <A> personalized treatment plans </A> <E> promoting effective management and improved prognosis </E>. <A> deliver clear, evidence-based interventions </A> <CO> considering the complexities involved in cancer treatment </CO>.\\n'}""",valid,increases risk,2,B,"edge - The edge which needs to be verified.
explanation - Explanation of what the edge represents and its validity.
causal_direction - Either Positive or Negative or Unknown. A positive influence direction indicates that both factors change in the same direction (e.g. an increase causes an increase effect). A negative influence direction indicates the opposite changes (e.g. an increase causes a decrease effect).
causal_factor - Is necessary or sufficient condition for an effect to occur. Exposure is a term commonly used in epidemiology to denote any condition that is considered as a possible cause of disease. Exposure is considered necessary when it always precedes the effects (e.g. symptoms) and always presents when the effects occur. A sufficient cause is a causal factor whose presence or occurrence guarantees the occurrence of symptom.
causal_distance - Either Distal or Proximal or Unknown. The distal factors lie towards the beginning of causal chain (i.e. indirect causal factors). The the proximal factors lie towards the end of the chain (i.e. cause directly or almost directly the effect).

Causality Tags:
<A> for action, <C> for cause, <CO> for condition and <E> for effect.
Cause (C): The reason or origin that leads to an effect. Causes often involve disease conditions, risk factors, or underlying mechanisms.
Effect (E): The outcome or result of a cause. Effects usually represent clinical outcomes, complications, or results of a specific cause.
Condition (CO): The circumstance or prerequisite required for an action or effect to occur. Conditions may include patient characteristics, clinical scenarios, or specific diagnostic criteria.
Action (A): The recommended or described response or activity to address a cause or condition. Actions typically involve clinical interventions, diagnostic procedures, or treatment recommendations.


`NODE1`:
id: Number_of_Lymph_Nodes_5
label: Number of Lymph Nodes
description: This node represents the presence or absence of a specific number of lymph nodes, which can be clinically significant in assessing the spread of cancer or other diseases.
type: Patient Situation
observability: Unobserved
states: [{'state_name': 'present', 'state_description': ""The state 'present' indicates that the specific number of lymph nodes is detected or considered in the clinical assessment.""}, {'state_name': 'absent', 'state_description': ""The state 'absent' indicates that the specific number of lymph nodes is not detected or considered in the clinical assessment.""}]

`NODE2`:
id: N_State_1
label: Nearby Lymph Nodes Cancer State
description: This node represents the clinical situation regarding the presence or absence of cancer in nearby lymph nodes. It is a critical factor in cancer staging and prognosis, as the involvement of lymph nodes can indicate the spread of cancer and affect treatment decisions.
type: Decision Node
observability: Needs to be Predicted
states: [{'state_name': 'present', 'state_description': 'Cancer is present in the nearby lymph nodes, indicating potential metastasis and a more advanced stage of cancer.'}, {'state_name': 'absent', 'state_description': 'Cancer is absent in the nearby lymph nodes, suggesting that the cancer has not spread to these nodes and may be in an earlier stage.'}]

`EDGE1`:
{'edges_ids': ['Number_of_Lymph_Nodes_5', 'N_State_1'], 'edge': '(Number_of_Lymph_Nodes_5) causes (N_State_1)', 'explanation': ['The edge suggests that the number of lymph nodes (Number_of_Lymph_Nodes_5) causes the cancer state in nearby lymph nodes (N_State_1).', 'Clinically, the number of lymph nodes does not directly cause cancer to be present or absent in them.', 'The presence of cancer in lymph nodes is more directly related to the spread of cancer from a primary site, not the number of lymph nodes themselves.', 'Therefore, the edge is not valid as a direct causal relationship.'], 'causal_direction': 'Unknown', 'causal_factor': {'necessary': False, 'sufficient': False}, 'causal_distance': 'Distal'}

`EDGE2`:
{'edges_ids': ['N_State_1', 'Number_of_Lymph_Nodes_5'], 'edge': '(N_State_1) causes (Number_of_Lymph_Nodes_5)', 'explanation': ['The edge suggests that the presence of cancer in nearby lymph nodes (N_State_1) causes a specific number of lymph nodes to be present or absent (Number_of_Lymph_Nodes_5).', 'This is not a valid causal relationship because the number of lymph nodes is a physical characteristic that is not directly caused by the presence of cancer.', 'The presence of cancer might be detected in a certain number of lymph nodes, but it does not cause the number of lymph nodes to change.'], 'causal_direction': 'Unknown', 'causal_factor': {'necessary': False, 'sufficient': False}, 'causal_distance': 'Unknown'}

`INFORMATION FROM KNOWLEDGE BASE`:
--------------------------------------------------
Page Number: 102

Section Name: Head and Neck Cancers - Principles of Surgery
====================
Entities:-
Surgical Procedures, Operative : Manual or operative procedures used in the treatment of disease, injuries, or deformities.
Lymphatic System : Part of the circulatory system and a vital part of the immune system, comprising a network of lymphatic vessels that carry a clear fluid called lymph.
Neoplasms : New abnormal growth of tissue in animals or plants; a tumor.
Neck Dissection : A surgical procedure for control of neck lymph node metastasis from squamous cell carcinoma of the head and neck.
Neoplasm Staging : Methods which attempt to express in replicable terms the extent of the neoplasm in the patient.
Metastasis : The spread of a cancer or other disease from one organ or part of the body to another not directly connected with it.
Surgical Procedure : A procedure involving an incision with instruments; performed to repair damage or arrest disease in a living body.
Lymphatic Structure : Anatomical structure that is part of the lymphatic system.
Tumor : An abnormal mass of tissue that results when cells divide more than they should or do not die when they should.
Staging : The process of determining the size and spread of cancer within the body.
Surgery : Medical specialty that uses operative manual and instrumental techniques on a patient to investigate or treat a pathological condition such as disease or injury.
Cancer Staging : The process of determining the extent to which a cancer has developed by growing and spreading.

Relationships:-
1. Entity1: ""surgical management"", Entity2: ""regional lymphatics"", Relationship: ""dictated by tumor staging""
2. Entity1: ""neck dissections"", Entity2: ""primary tumor"", Relationship: ""part of treatment""
3. Entity1: ""surgery"", Entity2: ""ipsilateral side of the neck"", Relationship: ""risk for metastases""

Causalities:-
<C> The extent of the tumor at initial tumor staging </C> <E> dictates the surgical management of regional lymphatics </E>. These guidelines apply to the performance of neck dissections as part of treatment of the primary tumor. <CO> Patients undergoing surgery for resection of the primary tumor </CO> <A> will undergo dissection of the ipsilateral side of the neck that is at greatest risk for metastases </A>.

Section Name: Neck Management
====================
Entities:-
Tongue : A muscular organ in the mouth that is involved in tasting, swallowing, and speech.
Palate : The roof of the mouth, separating the oral and nasal cavities.
Larynx : An organ in the top of the neck involved in breathing, producing sound, and protecting the trachea.
Hypopharynx : The bottom part of the pharynx, which is the cavity behind the nose and mouth.
Nasopharynx : The upper part of the pharynx, connecting with the nasal cavity above the soft palate.
Neck Dissection : A surgical procedure for control of neck lymph node metastasis from squamous cell carcinoma of the head and neck.
Metastasis : The spread of a cancer or other disease from one organ or part of the body to another not directly connected with it.
Squamous Cell Carcinoma : A type of cancer that begins in the squamous cells, which are thin, flat cells that look like fish scales.
Biopsy : The removal of cells or tissues for examination under a microscope.

Relationships:-
1. Entity1: ""Tumor sites"", Entity2: ""Bilateral lymphatic drainage"", Relationship: ""associated with""
2. Entity1: ""Elective neck dissection"", Entity2: ""Risk of occult metastasis"", Relationship: ""based on""
3. Entity1: ""SLN biopsy"", Entity2: ""Elective neck dissection"", Relationship: ""guides decision-making for""

Causalities:-
- **<C> Tumor sites that frequently have bilateral lymphatic drainage </C>** (e.g., base of tongue, palate, supraglottic larynx, hypopharynx, nasopharynx, deep pre-epiglottic space involvement) <E> often should have both sides of the neck dissected </E> with the extent of dissection determined as suggested below. For those patients with tumors at or approaching the midline, <CO> both sides of the neck are at risk for metastases </CO>, and <A> bilateral neck dissections should be performed </A>.

- <CO> Patients with advanced lesions involving the anterior tongue, floor of the mouth, or alveolus that approximate or cross the midline </CO> <A> should undergo contralateral selective/modified neck dissection </A> as necessary to achieve adequate tumor resection.

- **<C> Elective neck dissection </C>** <A> should be based on risk of occult metastasis in the appropriate nodal basin </A>. For oral cavity squamous cell carcinoma, <C> SLN biopsy or the primary tumor depth of invasion </C> is currently <E> the best predictor of occult metastatic disease </E> and <A> should be used to guide decision-making </A>. <CO> For tumors with a depth greater than 3 mm </CO>, <A> elective dissection should be strongly considered if RT is not already planned </A>. Recent randomized trial evidence supports the effectiveness of elective neck dissection in patients with oral cavity cancers greater than 3 mm in depth of invasion.

  - <CO> For a depth less than 2 mm </CO>, <A> elective dissection is only indicated in highly selective situations </A>. <CO> For a depth of 2–4 mm </CO>, <A> clinical judgment (as to reliability of follow-up, clinical suspicion, and other factors) must be utilized to determine appropriateness of elective dissection </A>. Elective dissections are generally selective, preserving all major structures, unless operative findings dictate otherwise.

Section Name: Types of Neck Dissection
====================
Entities:-
Neck Dissection : A surgical procedure for control of neck lymph node metastasis from squamous cell carcinoma of the head and neck.
Larynx : An organ in the top of the neck involved in breathing, producing sound, and protecting the trachea.

Relationships:-
1. Entity1: ""N0"", Entity2: ""Selective neck dissection"", Relationship: ""associated with""
2. Entity1: ""N3"", Entity2: ""Comprehensive neck dissection"", Relationship: ""associated with""
3. Entity1: ""Level VI neck dissection"", Entity2: ""Larynx"", Relationship: ""performed for""
4. Entity1: ""Level VI neck dissection"", Entity2: ""Hypopharynx"", Relationship: ""performed for""

Causalities:-
- **The type of neck dissection (comprehensive or selective)** is defined according to <CO> preoperative clinical staging </CO>, is determined at the discretion of the surgeon, and is based on the initial preoperative staging as follows:
  - **N0:** <A> Selective neck dissection </A>
    - Oral cavity at least levels I–III
    - Oropharynx at least levels II–IV
    - Hypopharynx at least levels II–IV and level VI when appropriate
    - Larynx at least levels II–IV and level VI when appropriate
  - **N1–N2a–c:** <A> Selective or comprehensive neck dissection </A> (Discussion)
  - **N3:** <A> Comprehensive neck dissection </A>

- <C> Level VI neck dissections are performed for certain primary sites (such as the larynx and hypopharynx) </C> <E> as required to resect the primary tumor and any clinically evident neck nodes </E>. <CO> Elective dissection depends on primary tumor extent and site </CO>. <CO> For advanced glottic and hypopharyngeal cancers treated with primary surgery </CO>, <A> a level VI dissection (including pretracheal lymph nodes, the Delphian lymph node, and unilateral or bilateral paratracheal lymph nodes) and hemithyroidectomy to total thyroidectomy are appropriate </A>.

- <CO> For primary subglottic tumors or glottic cancers with significant subglottic extension </CO>, <A> a level VI dissection with unilateral or total thyroidectomy is considered appropriate </A> based on the extent of the primary tumor. <CO> For example, a T4a glottic tumor with extension through the cricothyroid membrane and subglottic extension </CO> <A> should include thyroidectomy and pretracheal and bilateral paratracheal lymph node dissection </A>. <A> Parathyroid glands should be preserved in situ or auto transplanted as indicated </A>.
--------------------------------------------------
Page Number: 55

Section Name: General Information
====================
Entities:-
National Comprehensive Cancer Network : An alliance of 32 cancer centers in the United States, dedicated to improving the quality, effectiveness, and efficiency of cancer care.
Nccn Guidelines : Clinical practice guidelines in oncology developed by the National Comprehensive Cancer Network.

Relationships:-
1. Entity1: ""NCCN Guidelines"", Entity2: ""National Comprehensive Cancer Network"", Relationship: ""produced by""

Section Name: Important Notes
====================
Entities:-
Clinical Trials As Topic : Works about research studies that evaluate the effectiveness and safety of medical, surgical, or behavioral interventions.
Clinical Trial : A type of research that studies new tests and treatments and evaluates their effects on human health outcomes.
National Comprehensive Cancer Network : An alliance of 32 cancer centers in the United States, dedicated to improving the quality, effectiveness, and efficiency of cancer care.
Neoplasms : New abnormal growth of tissue that can be benign or malignant.
Malignant Neoplastic Disease : A disease resulting from the growth of malignant neoplasms.
Cancer : A group of diseases involving abnormal cell growth with the potential to invade or spread to other parts of the body.

Relationships:-
1. Entity1: ""Clinical Trials"", Entity2: ""Cancer"", Relationship: ""recommended for""
2. Entity1: ""NCCN"", Entity2: ""Clinical Trials"", Relationship: ""encourages participation in""

Causalities:-
<C> NCCN believes that the best management of any patient with cancer is in a clinical trial </C>. <A> Participation in clinical trials is especially encouraged </A>.

Section Name: Principles
====================
Entities:-
Surgical Procedures, Operative : Surgical procedures involve the use of operative manual and instrumental techniques on a patient to investigate or treat a pathological condition such as disease or injury.
Radiation Therapy : Therapy using ionizing radiation, generally as part of cancer treatment to control or kill malignant cells.
Chemotherapy : A type of cancer treatment that uses one or more anti-cancer drugs as part of a standardized chemotherapy regimen.

Relationships:-
1. Entity1: ""Principles of Surgery"", Entity2: ""Principles of Radiation Therapy"", Relationship: ""Both are principles of cancer treatment methods.""
2. Entity1: ""Principles of Surgery"", Entity2: ""Principles of Systemic Therapy for Non-Nasopharyngeal Cancers"", Relationship: ""Both are principles of cancer treatment methods.""
3. Entity1: ""Principles of Radiation Therapy"", Entity2: ""Principles of Systemic Therapy for Non-Nasopharyngeal Cancers"", Relationship: ""Both are principles of cancer treatment methods.""

Causalities:-
### Principles

- **Principles of Surgery (SURG-A)**
- **Principles of Radiation Therapy (SUPRA-A)**
- **Principles of Systemic Therapy for Non-Nasopharyngeal Cancers (SYST-A)**

Section Name: Adverse Pathologic Features
====================
Entities:-
Extranodal Extension : The spread of cancer cells beyond the lymph node capsule into the surrounding tissues.
Positive Surgical Margin : The presence of cancer cells at the edge of the tissue removed during surgery, indicating that some cancer may have been left behind.
Perineural Invasion : The presence of cancer cells surrounding or tracking along a nerve within the perineural space.
Vascular Invasion : The invasion of cancer cells into blood vessels.
Lymphatic Invasion : The invasion of cancer cells into lymphatic vessels.

Relationships:-
1. Entity1: ""Extranodal extension"", Entity2: ""Adverse Pathologic Features"", Relationship: ""is a type of""
2. Entity1: ""Positive margins"", Entity2: ""Adverse Pathologic Features"", Relationship: ""is a type of""
3. Entity1: ""Close margins"", Entity2: ""Adverse Pathologic Features"", Relationship: ""is a type of""
4. Entity1: ""pT3 or pT4 primary"", Entity2: ""Adverse Pathologic Features"", Relationship: ""is a type of""
5. Entity1: ""pN2 or pN3 nodal disease"", Entity2: ""Adverse Pathologic Features"", Relationship: ""is a type of""
6. Entity1: ""Perineural invasion"", Entity2: ""Adverse Pathologic Features"", Relationship: ""is a type of""
7. Entity1: ""Vascular invasion"", Entity2: ""Adverse Pathologic Features"", Relationship: ""is a type of""
8. Entity1: ""Lymphatic invasion"", Entity2: ""Adverse Pathologic Features"", Relationship: ""is a type of""

Causalities:-
<C> Extranodal extension </C>
<C> Positive margins </C>
<C> Close margins </C>
<C> pT3 or pT4 primary </C>
<C> pN2 or pN3 nodal disease </C>
<C> Perineural invasion </C>
<C> Vascular invasion </C>
<C> Lymphatic invasion </C>

Section Name: Response Assessment
====================
Entities:-
Chemotherapy, Induction : Initial chemotherapy treatment to shrink a tumor before the main treatment.
Primary Site : The original location where a tumor or cancer begins.
Complete Remission : The disappearance of all signs of cancer in response to treatment.
Partial Remission : A decrease in the size of a tumor, or in the extent of cancer in the body, in response to treatment.
Radiotherapy : The use of high-energy radiation to kill cancer cells and shrink tumors.
Surgical Procedures, Operative : Surgical procedures involve the use of operative manual and instrumental techniques on a patient to investigate or treat a pathological condition such as disease or injury.

Relationships:-
1. Entity1: ""induction chemotherapy"", Entity2: ""Primary site"", Relationship: ""treatment outcome""
2. Entity1: ""Definitive RT"", Entity2: ""Primary site"", Relationship: ""treatment option""
3. Entity1: ""RT"", Entity2: ""Primary site"", Relationship: ""treatment option""
4. Entity1: ""Surgery"", Entity2: ""unresectable nodal disease"", Relationship: ""treatment option""

Causalities:-
<C> Response after induction chemotherapy </C>: <E> Primary site: CR </E> <E> Primary site: PR </E> <E> Primary site: < PR </E> <A> Definitive RT </A> (category 1) <A> RT </A> (category 1) or <A> systemic therapy/RT </A> (category 2B) <A> Surgery </A> or <A> unresectable nodal disease </A>

Section Name: Follow-up
====================
Entities:-
Follow-Up Studies : Studies in which individuals are followed over time to determine the outcome of exposures, treatments, or interventions.
Follow-Up Procedure : A procedure where a patient is monitored over time to assess the progress of a condition or the effects of treatment.
Follow-Up (Medicine) : The process of monitoring a patient's health over time after treatment or diagnosis.
Disease Recurrence : The return of a sign, symptom, or disease after a remission.
Recurrent Disease : A disease that returns after a period of remission.
Recurrence (Medicine) : The return of a disease or condition after a period of improvement.

Relationships:-
1. Entity1: ""Follow-up"", Entity2: ""Recurrent or persistent disease"", Relationship: ""monitoring""

Causalities:-
### Follow-up

- **Follow-up** (FOLL-A, 1 of 2)
- **Recurrent or persistent disease** (ADV-3)

Section Name: Risk Features
====================
Entities:-
Radiotherapy : The use of high-energy radiation to kill cancer cells and shrink tumors.
Extranodal Extension : The spread of cancer cells beyond the lymph node capsule into the surrounding tissues.
Positive Surgical Margin : The presence of cancer cells at the edge of the tissue removed during surgery, indicating that some cancer may have been left behind.
Systemic Therapy : Systemic therapy refers to treatment using substances that travel through the bloodstream, reaching and affecting cells all over the body.

Relationships:-
1. Entity1: ""Adverse pathologic features"", Entity2: ""RT"", Relationship: ""Consideration for treatment""
2. Entity1: ""Adverse pathologic features"", Entity2: ""Systemic therapy"", Relationship: ""Consideration for treatment""

Causalities:-
- **No adverse pathologic features**
- **Other risk features**
- **Adverse pathologic features**:
  - <C> Extranodal extension and/or positive margin </C>
  - <A> RT or consider systemic therapy/RT </A>

Section Name: Post-Therapy Evaluation
====================
Entities:-
Systemic Therapy : Systemic therapy refers to treatment using substances that travel through the bloodstream, reaching and affecting cells all over the body.
Radiation Therapy : Therapy using ionizing radiation, generally as part of cancer treatment to control or kill malignant cells.
Neck : The neck is the part of the body that separates the head from the torso and provides the mobility and movements of the head.

Relationships:-
1. Entity1: ""Systemic Therapy"", Entity2: ""Neck Evaluation"", Relationship: ""evaluated in""
2. Entity1: ""RT"", Entity2: ""Neck Evaluation"", Relationship: ""evaluated in""

Causalities:-
<CO> Post Systemic Therapy/RT or RT Neck </CO> <A> Evaluation </A>

Section Name: Flowchart Overview
====================
Entities:-
Laryngeal Neoplasms : Tumors or cancer of the larynx, which may affect the supraglottic, glottic, or subglottic regions.
Supraglottic Larynx : The part of the larynx located above the vocal cords, including the epiglottis and aryepiglottic folds.
National Comprehensive Cancer Network : An alliance of 32 cancer centers in the United States, dedicated to improving the quality, effectiveness, and efficiency of cancer care.

Relationships:-
1. Entity1: ""NCCN Guidelines"", Entity2: ""cancer of the supraglottic larynx"", Relationship: ""guides management of""
2. Entity1: ""NCCN Guidelines"", Entity2: ""healthcare professionals"", Relationship: ""used by""

Causalities:-
<C> cancer of the supraglottic larynx </C> <E> evaluate patient responses following treatment </E> <CO> based on observed outcomes </CO> <A> evaluation of the primary site and determining subsequent steps </A>.

Section Name: Assessment and Treatment Decisions
====================
Entities:-
Induction Chemotherapy : Initial chemotherapy treatment to shrink a tumor before the main treatment.
Complete Response : The disappearance of all signs of cancer in response to treatment.
Partial Response : A decrease in the size of a tumor, or in the extent of cancer in the body, in response to treatment.
Radiation Therapy : Therapy using ionizing radiation, generally as part of cancer treatment to control or kill malignant cells.
Surgery : Medical specialty that uses operative manual and instrumental techniques on a patient to investigate or treat a pathological condition such as disease or injury.
Systemic Therapy : Systemic therapy refers to treatment using substances that travel through the bloodstream, reaching and affecting cells all over the body.

Relationships:-
1. Entity1: ""Complete Response"", Entity2: ""Radiation Therapy"", Relationship: ""leads to""
2. Entity1: ""Complete Response"", Entity2: ""Surgery"", Relationship: ""leads to""
3. Entity1: ""Partial Response"", Entity2: ""Systemic Therapy"", Relationship: ""leads to""
4. Entity1: ""Partial Response"", Entity2: ""Radiation Therapy"", Relationship: ""leads to""

Causalities:-
<C> responses to initial treatments such as induction chemotherapy </C> <E> Three main response categories are recognized: Complete Response (CR), Partial Response (PR), and less than Partial Response (< PR) </E>. These categories are pivotal in determining the next steps. <C> CR </C> <E> indicates full resolution of the disease at the primary site </E>, <A> leading to the consideration of definitive radiation therapy or the likelihood of surgery </A>. Conversely, <C> PR </C> <E> suggests that the disease has improved but not completely resolved </E>, <A> which directs the pathway towards either systemic therapy or continued radiation therapy </A>, <A> with further evaluation necessary </A>.

Section Name: Adverse Pathologic Features and Follow-up
====================
Entities:-
Radiation Therapy : Therapy using ionizing radiation, generally as part of cancer treatment to control or kill malignant cells.
Surgical Procedures, Operative : Surgical procedures involve the use of operative manual and instrumental techniques on a patient to investigate or treat a pathological condition such as disease or injury.
Neoplasm Recurrence, Local : The return of a tumor or cancer, at the original site, after it has been treated.
Neoplasm Metastasis : The transfer of a neoplasm from one organ or part of the body to another remote from the primary site.
Surgical Procedure : A medical procedure involving an incision with instruments; performed to repair damage or arrest disease in a living body.
Recurrent Neoplasm : A neoplasm that has returned after treatment.
Metastatic Neoplasm : A neoplasm that has spread from its original site to one or more other places in the body.
Surgery : Medical specialty that uses operative manual and instrumental techniques on a patient to investigate or treat a pathological condition such as disease or injury.
Cancer Recurrence : The return of cancer after treatment and after a period of time during which the cancer was undetectable.
Metastasis : Spread of a cancer or other disease from one organ or part to another not directly connected with it.

Relationships:-
1. Entity1: ""Adverse pathologic features"", Entity2: ""Treatment decisions"", Relationship: ""Influence""
2. Entity1: ""Adverse features"", Entity2: ""Surgical intervention"", Relationship: ""Recommendation""
3. Entity1: ""Absence of adverse features"", Entity2: ""Radiation therapy"", Relationship: ""Pathway""
4. Entity1: ""Follow-up process"", Entity2: ""Recurrent or persistent disease"", Relationship: ""Detection""
5. Entity1: ""Recurrent or persistent disease"", Entity2: ""Advanced disease management"", Relationship: ""Necessity""

Causalities:-
<C> The presence of adverse pathologic features — such as extranodal extension or positive margins </C> <E> can directly influence treatment decisions </E>. <CO> If adverse features are found </CO>, <A> surgical intervention is recommended </A>. <CO> In cases where there are no adverse features </CO>, the patient may proceed directly to radiation therapy or continued systemic treatment, emphasizing the tailored approach based on the individual patient's disease characteristics.

Furthermore, the chart includes a section addressing the follow-up process after initial treatment. <CO> If there are signs of recurrent or persistent disease </CO>, <A> additional evaluations and treatment modalities may be necessary </A>. These evaluations <E> lead to specific recommendations for advanced disease management, denoted as ADV-3 on the chart </E>, emphasizing the importance of continuous monitoring and assessment in cancer care.
--------------------------------------------------
Page Number: 51

Section Name: Introduction
====================
Entities:-
Laryngeal Neoplasms : Tumors or cancer of the larynx, which may affect the supraglottic, glottic, or subglottic regions.
Malignant Neoplasm Of Supraglottis : A malignant tumor located in the supraglottic region of the larynx.
Supraglottic Laryngeal Cancer : A type of cancer that occurs in the supraglottic region of the larynx, which is above the vocal cords.

Relationships:-
1. Entity1: ""National Comprehensive Cancer Network (NCCN)"", Entity2: ""cancer of the supraglottic larynx"", Relationship: ""provides guidelines for""
2. Entity1: ""healthcare professionals"", Entity2: ""cancer of the supraglottic larynx"", Relationship: ""manage""

Causalities:-
The provided image is a detailed flowchart from the National Comprehensive Cancer Network (NCCN) guidelines regarding the <C> clinical staging and treatment protocols for cancer of the supraglottic larynx </C>. This flowchart is structured to <A> guide healthcare professionals through the stages of treatment </A> based on <CO> clinical findings </CO>, emphasizing the <E> complexity and systematic approach required in managing this type of cancer </E>.

Section Name: Clinical Staging
====================
Entities:-
Laryngectomy : A surgical procedure involving the removal of the larynx, usually to treat cancer of the larynx.
Total Laryngectomy : A surgical procedure to remove the entire larynx, often used in the treatment of advanced laryngeal cancer.
Neoplasm Staging : Methods used for staging neoplasms, including clinical and pathological staging.
Cancer Staging : The process of determining the extent of cancer in the body, often using the TNM system.
Tnm Staging System : A cancer staging system that describes the extent of cancer using Tumor size (T), Node involvement (N), and Metastasis (M).

Relationships:-
1. Entity1: ""Clinical staging criteria"", Entity2: ""Total laryngectomy"", Relationship: ""determines necessity of""
2. Entity1: ""T3, N0"", Entity2: ""Clinical staging criteria"", Relationship: ""is a categorization of""

Causalities:-
The flowchart begins with the <C> clinical staging criteria </C>, specifically focusing on <CO> cases that require total laryngectomy, denoted as requiring (amenable to) total laryngectomy (T3, N0) </CO>. This <A> categorization </A> is crucial as it <E> forms the basis for determining the appropriate treatment strategy </E>.

Section Name: Treatment of Primary and Neck
====================
Entities:-
Neoplasm Staging : Methods used for staging neoplasms, including clinical and pathological staging.
Systemic Therapy : Treatment using substances that travel through the bloodstream, reaching and affecting cells all over the body.
Radiotherapy : The use of high-energy radiation from x-rays, gamma rays, neutrons, protons, and other sources to kill cancer cells and shrink tumors.
Laryngectomy : A surgical procedure involving the removal of the larynx, usually to treat cancer of the larynx.
Thyroidectomy : A surgical procedure to remove all or part of the thyroid gland.
Neck Dissection : Surgical procedure to remove lymph nodes and surrounding tissue to treat or prevent cancer spread.
Lymphatic Metastasis : Transfer of a neoplasm from one organ or part of the body to another remote from the primary site.

Relationships:-
1. Entity1: ""Systemic Therapy"", Entity2: ""Radiation Therapy"", Relationship: ""combined with""
2. Entity1: ""Laryngectomy"", Entity2: ""Lymph Node Involvement"", Relationship: ""considered based on""
3. Entity1: ""Thyroidectomy"", Entity2: ""Lymph Node Involvement"", Relationship: ""considered based on""
4. Entity1: ""Neck Dissection"", Entity2: ""Lymph Node Involvement"", Relationship: ""considered based on""

Causalities:-
<CO> Once clinical staging is established </CO>, the chart outlines various treatment options. <A> The initial step may involve either concurrent systemic therapy combined with radiation therapy (RT) or opting for RT alone </A>, <CO> especially if the patient is not a medical candidate for both therapies </CO>. <A> Laryngectomy, thyroidectomy, and neck dissection are considered </A> <CO> based on the extent of lymph node involvement </CO>.

Section Name: Surgical Options
====================
Entities:-
Laryngectomy : A surgical procedure involving the removal of the larynx, usually to treat cancer of the larynx.
Thyroidectomy : A surgical procedure to remove all or part of the thyroid gland.
Lymph Node Excision : Surgical removal of one or more lymph nodes.
Lymphadenectomy : Surgical removal of one or more groups of lymph nodes.
Surgical Procedures, Operative : Operations carried out for the correction of deformities and defects, repair of injuries, and diagnosis and cure of certain diseases.
Surgical Procedure : A medical procedure involving an incision with instruments; performed to repair damage or arrest disease in a living body.
Surgery : Medical specialty that uses operative manual and instrumental techniques on a patient to investigate or treat a pathological condition such as a disease or injury.

Relationships:-
1. Entity1: ""Laryngectomy"", Entity2: ""Thyroidectomy"", Relationship: ""combined with""
2. Entity1: ""Lymph Node Dissection"", Entity2: ""Surgical Intervention"", Relationship: ""extent of""
3. Entity1: ""Surgical Intervention"", Entity2: ""Advanced Cases"", Relationship: ""management option for""

Causalities:-
<CO> If concurrent therapies are not suitable </CO>, <A> the chart presents laryngectomy combined with thyroidectomy </A>, <CO> depending on the extent of lymph node dissection required </CO>. <E> This highlights surgical intervention as a viable option in the management of advanced cases </E>.

Section Name: Induction Chemotherapy
====================
Entities:-
Induction Chemotherapy : Initial chemotherapy treatment used to shrink a tumor before the main treatment, which is usually surgery.
Surgical Procedure : A medical procedure involving an incision with instruments; performed to repair damage or arrest disease in a living body.
Therapeutic Approach : A method or strategy used in the treatment of disease or injury.

Relationships:-
1. Entity1: ""Induction Chemotherapy"", Entity2: ""Surgical Intervention"", Relationship: ""alternative or sequential treatment option""

Causalities:-
<C> immediate surgical intervention is either not feasible or considered insufficient </C> <E> The flowchart also considers the option of induction chemotherapy </E> <CO> in cases where immediate surgical intervention is either not feasible or considered insufficient </CO>. <A> tailoring therapeutic approaches tailored to individual patient needs </A>.

Section Name: Adjuvant Treatment
====================
Entities:-
Adjuvant Chemotherapy : Chemotherapy given in addition to the primary treatment to maximize its effectiveness.
Radiotherapy : The use of high-energy radiation from x-rays, gamma rays, neutrons, protons, and other sources to kill cancer cells and shrink tumors.
Neoplasm Recurrence, Local : The return of a cancer, at the same site, after it has been treated.
Disease Progression : The worsening of a disease over time.

Relationships:-
1. Entity1: ""Primary Treatment"", Entity2: ""Adjuvant Treatment"", Relationship: ""followed by""
2. Entity1: ""Adjuvant Treatment"", Entity2: ""Systemic Therapy"", Relationship: ""includes""
3. Entity1: ""Adjuvant Treatment"", Entity2: ""Radiotherapy"", Relationship: ""includes""
4. Entity1: ""Follow-up Assessments"", Entity2: ""Treatment Efficacy"", Relationship: ""used to evaluate""

Causalities:-
<C> Following primary treatment </C>, <E> the flowchart addresses the potential for adjuvant treatment pathways </E>. This may include systemic therapy, RT, or further evaluations based on <CO> the patient's response and any recurrence or persistent disease </CO>. It emphasizes <A> the need for follow-up assessments to evaluate treatment efficacy </A>.

Section Name: Risk Features and Response Assessment
====================
Entities:-
Neoplasm Invasiveness : The property of a neoplasm to infiltrate and destroy surrounding tissue.
Surgical Margins : The edge or border of the tissue removed in cancer surgery.
Neoplasms : Neoplasms are abnormal growths of tissue, which can be cancerous or non-cancerous.
Extramural Extension : Extension of a tumor beyond the wall of an organ.
Positive Surgical Margin : Cancer cells are present at the edge of the tissue removed during surgery.
Cancer Management : The process of planning and coordinating the treatment of cancer.
Cancer : Cancer is a group of diseases involving abnormal cell growth with the potential to invade or spread to other parts of the body.

Relationships:-
1. Entity1: ""Extramural extension"", Entity2: ""Treatment decisions"", Relationship: ""influences""
2. Entity1: ""Positive surgical margin"", Entity2: ""Treatment decisions"", Relationship: ""influences""
3. Entity1: ""Ongoing assessment"", Entity2: ""Response evaluation"", Relationship: ""leads to""
4. Entity1: ""Response evaluation"", Entity2: ""Adjustments to treatment"", Relationship: ""leads to""
5. Entity1: ""Management of cancer"", Entity2: ""Treatment decisions"", Relationship: ""involves""
6. Entity1: ""Management of cancer"", Entity2: ""Ongoing assessment"", Relationship: ""involves""
7. Entity1: ""Management of cancer"", Entity2: ""Adjustments to treatment"", Relationship: ""involves""

Causalities:-
The chart incorporates a segment that takes into account <CO> adverse pathologic features, such as extramural extension or positive margins </CO>, <E> which could influence subsequent treatment decisions </E>. This highlights the importance of <A> ongoing assessment in the management of cancer, leading to response evaluation and adjustments to treatment as necessary </A>.

Section Name: NCCN Guidelines Version 4.2024
====================
Entities:-
Clinical Trials : Clinical trials are research studies performed in people that are aimed at evaluating a medical, surgical, or behavioral intervention.
Neoplasms : Neoplasms are abnormal growths of tissue, which can be cancerous or non-cancerous.
Clinical Trial : A clinical trial is a research study that prospectively assigns human participants or groups of humans to one or more health-related interventions to evaluate the effects on health outcomes.
Malignant Neoplasm : A malignant neoplasm is a cancerous growth that has the potential to invade and destroy nearby tissue and spread to other parts of the body.
National Comprehensive Cancer Network : The National Comprehensive Cancer Network (NCCN) is an alliance of 31 cancer centers in the United States, dedicated to improving the quality, effectiveness, and efficiency of cancer care.
Cancer : Cancer is a group of diseases involving abnormal cell growth with the potential to invade or spread to other parts of the body.

Relationships:-
1. Entity1: ""National Comprehensive Cancer Network"", Entity2: ""NCCN Guidelines"", Relationship: ""provides""
2. Entity1: ""NCCN Guidelines"", Entity2: ""Clinical Trials"", Relationship: ""recommend""
3. Entity1: ""NCCN Guidelines"", Entity2: ""Cancer"", Relationship: ""related to management of""

Causalities:-
<CO> any patient with cancer </CO> <A> the best management is in a clinical trial </A>. <A> Participation in clinical trials is especially encouraged </A>.

Section Name: SUPRA-3
====================
Entities:-
Laryngectomy : A surgical procedure involving the removal of the larynx, usually to treat cancer of the larynx.
Thyroidectomy : A surgical procedure to remove all or part of the thyroid gland.
Neck Dissection : Surgical procedure to remove lymph nodes and surrounding tissue to treat or prevent cancer spread.
Chemotherapy, Induction : Initial chemotherapy treatment to shrink a tumor before the main treatment.
Clinical Trials As Topic : Research studies that prospectively assign human participants or groups of humans to one or more health-related interventions to evaluate the effects on health outcomes.
Induction Chemotherapy : Initial chemotherapy treatment used to shrink a tumor before the main treatment, which is usually surgery.
Clinical Trial : A clinical trial is a research study that prospectively assigns human participants or groups of humans to one or more health-related interventions to evaluate the effects on health outcomes.

Relationships:-
1. Entity1: ""Total laryngectomy"", Entity2: ""Laryngectomy"", Relationship: ""is a type of""
2. Entity1: ""Systemic therapy"", Entity2: ""RT"", Relationship: ""concurrent treatment option""
3. Entity1: ""Induction chemotherapy"", Entity2: ""Other treatments"", Relationship: ""initial treatment option before""

Causalities:-
<CO> Requiring (amenable to) total laryngectomy (T3,N0) </CO>
  - <A> Concurrent systemic therapy/RT </A> or <A> RT if patient not medical candidate for concurrent systemic therapy/RT </A>
  - <A> Laryngectomy, thyroidectomy and with ipsilateral, central, or bilateral neck dissection </A>
  - or
  - <A> Induction chemotherapy </A>
  - or
  - <A> Clinical trials </A>

Section Name: Follow-up
====================
Entities:-
Follow-Up Studies : Studies in which individuals are followed over time to determine the outcome of exposures, treatments, or interventions.
Follow-Up Procedure : A procedure performed to monitor the progress of a patient's condition after initial treatment.
Follow-Up : Medical care given to a patient over time after initial treatment.
Disease Recurrence : The return of a sign, symptom, or disease after a remission.
Recurrent Disease : The reappearance of a disease after a period of improvement.

Relationships:-
1. Entity1: ""Follow-up"", Entity2: ""Recurrent or persistent disease"", Relationship: ""monitoring""

Causalities:-
- **Follow-up (FOLL-A, 1 of 2)**
  - <CO> Recurrent or persistent disease </CO> (ADV-3)

Section Name: Adverse Pathologic Features
====================
Entities:-
Radiotherapy : The use of high-energy radiation from x-rays, gamma rays, neutrons, protons, and other sources to kill cancer cells and shrink tumors.
Extranodal Extension : The spread of cancer beyond the lymph node capsule.
Positive Surgical Margin : Cancer cells are present at the edge of the tissue removed during surgery.
Systemic Therapy : Treatment using substances that travel through the bloodstream, reaching and affecting cells all over the body.

Relationships:-
1. Entity1: ""pN1"", Entity2: ""Radiotherapy"", Relationship: ""Consideration for treatment""
2. Entity1: ""Extranodal extension"", Entity2: ""Systemic Therapy"", Relationship: ""Treatment option""
3. Entity1: ""Extranodal extension"", Entity2: ""Radiotherapy"", Relationship: ""Treatment option""
4. Entity1: ""Positive surgical margin"", Entity2: ""Systemic Therapy"", Relationship: ""Treatment option""
5. Entity1: ""Positive surgical margin"", Entity2: ""Radiotherapy"", Relationship: ""Treatment option""

Causalities:-
- <CO>pN1 without other risk features</CO>
  - <C>Adverse pathologic features</C>
  - <A>Consider RT</A>
  - <CO>Extranodal extension and/or positive margin</CO>
  - <CO>Other risk features</CO>
  - <A>Systemic therapy/RT (category 1)</A>
  - <A>RT or Consider systemic therapy/RT</A>

Section Name: Response Assessment
====================
Entities:-
Response Evaluation : The process of assessing the response of a disease to treatment, often used in clinical trials to determine the effectiveness of a therapy.
Response To Treatment : A clinical finding indicating the response of a condition to a therapeutic intervention.

Relationships:-

Section Name: Principles of Surgery and Radiation Therapy
====================
Entities:-
Surgical Procedures, Operative : Operations carried out for the correction of deformities and defects, repair of injuries, and diagnosis and cure of certain diseases.
Surgical Procedure : A medical procedure involving an incision with instruments; performed to repair damage or arrest disease in a living body.
Surgery : Medical specialty that uses operative manual and instrumental techniques on a patient to investigate or treat a pathological condition such as a disease or injury.
Radiotherapy : The use of high-energy radiation from x-rays, gamma rays, neutrons, protons, and other sources to kill cancer cells and shrink tumors.
Radiation Therapy : Radiation therapy is a therapy using ionizing radiation, generally as part of cancer treatment to control or kill malignant cells.

Relationships:-
1. Entity1: ""Principles of Surgery"", Entity2: ""Principles of Radiation Therapy"", Relationship: ""complementary treatments""

Causalities:-
**Principles of Surgery (SURG-A).**

**Principles of Radiation Therapy (SUPRA-A).**

Section Name: Principles of Systemic Therapy
====================
Entities:-
Cisplatin : An inorganic and water-soluble platinum complex, cisplatin is an antineoplastic agent that is used in the treatment of various cancers.
Radiotherapy : The use of high-energy radiation from x-rays, gamma rays, neutrons, protons, and other sources to kill cancer cells and shrink tumors.
Radiation Therapy : Radiation therapy is a therapy using ionizing radiation, generally as part of cancer treatment to control or kill malignant cells.

Relationships:-
1. Entity1: ""Cisplatin"", Entity2: ""Systemic Therapy for Non-Nasopharyngeal Cancers"", Relationship: ""preferred agent""
2. Entity1: ""Cisplatin"", Entity2: ""Concurrent Systemic Therapy/RT"", Relationship: ""used in""

Causalities:-
<CO> When using concurrent systemic therapy/RT </CO>, <A> the preferred agent is cisplatin (category 1) </A>.
--------------------------------------------------
Page Number: 130

Section Name: Pathological N (pN)
====================
Entities:-
Lymph Nodes : Small, bean-shaped structures that are part of the body's lymphatic system. They filter lymph fluid and store white blood cells that help fight infection.
Neoplasm Metastasis : The transfer of a neoplasm from one organ or part of the body to another remote from the primary site.
Tnm Staging : A system used to describe the size and spread of cancer in a standardized way. T refers to the size of the tumor, N to the involvement of lymph nodes, and M to metastasis.
Lymph Node Structure : A structure that is part of the lymphatic system, involved in the immune response.
Metastasis : The spread of a cancer or other disease from one organ or part to another not directly connected with it.
Tnm Staging System : A cancer staging notation system that describes the extent of cancer in a patient's body.
Lymph Node : An organ of the lymphatic system and the adaptive immune system.

Relationships:-
1. Entity1: ""Lymph Nodes"", Entity2: ""Neoplasm Metastasis"", Relationship: ""involved in""
2. Entity1: ""TNM Staging"", Entity2: ""Lymph Nodes"", Relationship: ""includes""
3. Entity1: ""TNM Staging"", Entity2: ""Neoplasm Metastasis"", Relationship: ""describes""

Causalities:-
<CO> NX: Regional lymph nodes cannot be assessed </CO>
<CO> N0: No regional lymph node metastasis </CO>
<CO> N1: Metastasis in a single ipsilateral lymph node, 3 cm or smaller in greatest dimension ENE(–) </CO>
<CO> N2: Metastasis in a single ipsilateral lymph node, 3 cm or smaller in greatest dimension and ENE(+); or larger than 3 cm but not larger than 6 cm in greatest dimension and ENE(−); or metastases in multiple ipsilateral lymph nodes, none larger than 6 cm in greatest dimension and ENE(−); or in bilateral or contralateral lymph node(s), none larger than 6 cm in greatest dimension and ENE(−) </CO>
<CO> N2a: Metastasis in a single ipsilateral node, 3 cm or smaller in greatest dimension and ENE(+); or metastasis in a single ipsilateral node, larger than 3 cm but not larger than 6 cm in greatest dimension and ENE(−) </CO>
<CO> N2b: Metastases in multiple ipsilateral nodes, none larger than 6 cm in greatest dimension and ENE(−) </CO>
<CO> N2c: Metastases in bilateral or contralateral lymph node(s), none larger than 6 cm in greatest dimension and ENE(−) </CO>
<CO> N3: Metastasis in a lymph node, larger than 6 cm in greatest dimension and ENE(−); or metastasis in a single ipsilateral node, larger than 3 cm in greatest dimension and ENE(+); or multiple ipsilateral, contralateral, or bilateral lymph nodes and any with ENE(+); or a single contralateral node of any size and ENE(+) </CO>
<CO> N3a: Metastasis in a lymph node, larger than 6 cm in greatest dimension and ENE(−) </CO>
<CO> N3b: Metastasis in a single ipsilateral node, larger than 3 cm in greatest dimension and ENE(+); or multiple ipsilateral, contralateral, or bilateral lymph nodes any with ENE(+); or a single contralateral node of any size and ENE(+) </CO>
<CO> Note: A designation of “U” or “L” may be used for any N category to indicate metastasis above the lower border of the cricoid (U) or below the lower border of the cricoid (L). Similarly, clinical and pathological ENE should be recorded as ENE(−) or ENE(+). </CO>

Section Name: Distant Metastasis (M)
====================
Entities:-
Neoplasm Metastasis : The transfer of a neoplasm from one organ or part of the body to another remote from the primary site.
Metastasis : The spread of a cancer or other disease from one organ or part to another not directly connected with it.

Relationships:-
1. Entity1: ""M0"", Entity2: ""Distant Metastasis"", Relationship: ""is a category of""
2. Entity1: ""M1"", Entity2: ""Distant Metastasis"", Relationship: ""is a category of""

Causalities:-
### Distant Metastasis (M)

- **M0**: No distant metastasis
- **M1**: Distant metastasis

Section Name: Histologic Grade (G)
====================
Entities:-
Neoplasm Grading : A system of classifying cancer cells in terms of how abnormal they look under a microscope and how quickly the tumor is likely to grow and spread.
Histologic Grade : A measure of how much tumor cells differ from healthy cells, used to assess the aggressiveness of cancer.

Relationships:-
1. Entity1: ""GX"", Entity2: ""Grade cannot be assessed"", Relationship: ""is described as""
2. Entity1: ""G1"", Entity2: ""Well differentiated"", Relationship: ""is described as""
3. Entity1: ""G2"", Entity2: ""Moderately differentiated"", Relationship: ""is described as""
4. Entity1: ""G3"", Entity2: ""Poorly differentiated"", Relationship: ""is described as""

Causalities:-
<CO>GX</CO>: <E>Grade cannot be assessed</E>
<CO>G1</CO>: <E>Well differentiated</E>
<CO>G2</CO>: <E>Moderately differentiated</E>
<CO>G3</CO>: <E>Poorly differentiated</E>

Section Name: Prognostic Stage Groups
====================
Entities:-
Neoplasm Staging : Methods and systems of classifying neoplasms according to extent of disease.
Tumor Staging : A system for describing the size and spread of cancer within the body.
Tnm Staging System : A cancer staging notation system that describes the extent of cancer in a patient's body.

Relationships:-
1. Entity1: ""Stage 0"", Entity2: ""Tis N0 M0"", Relationship: ""defined by""
2. Entity1: ""Stage I"", Entity2: ""T1 N0 M0"", Relationship: ""defined by""
3. Entity1: ""Stage II"", Entity2: ""T2 N0 M0"", Relationship: ""defined by""
4. Entity1: ""Stage III"", Entity2: ""T3 N0 M0, T1 N1 M0, T2 N1 M0, T3 N1 M0"", Relationship: ""defined by""
5. Entity1: ""Stage IVA"", Entity2: ""T1 N2 M0, T2 N2 M0, T3 N2 M0, T4a N0,N1,N2 M0"", Relationship: ""defined by""
6. Entity1: ""Stage IVB"", Entity2: ""Any T N3 M0, T4b Any N M0"", Relationship: ""defined by""
7. Entity1: ""Stage IVC"", Entity2: ""Any T Any N M1"", Relationship: ""defined by""
--------------------------------------------------
Page Number: 47

Section Name: Overview of Radiation Therapy Guidelines
====================
Entities:-
Radiation Therapy : The medical use of ionizing radiation, generally as part of cancer treatment to control or kill malignant cells.
Cancer : A group of diseases involving abnormal cell growth with the potential to invade or spread to other parts of the body.
Malignant Neoplasm : A disease characterized by uncontrolled, abnormal growth of cells that can invade and destroy nearby tissue and spread to other parts of the body.
Laryngeal Neoplasms : Tumors or cancer of the larynx, which may affect the glottis, supraglottis, or subglottis.
Glottic Larynx Cancer : A malignant neoplasm located in the glottic region of the larynx.
Laryngeal Cancer : Cancer that occurs in the larynx, or voice box, which may include the glottic region.
National Comprehensive Cancer Network : The National Comprehensive Cancer Network (NCCN) is an alliance of 30 cancer centers in the United States, dedicated to improving the quality, effectiveness, and efficiency of cancer care.

Relationships:-
1. Entity1: ""Radiation Therapy"", Entity2: ""Cancer"", Relationship: ""treats""
2. Entity1: ""NCCN Guidelines"", Entity2: ""Cancer"", Relationship: ""guides treatment for""
3. Entity1: ""NCCN Guidelines"", Entity2: ""Radiation Therapy"", Relationship: ""specifies use of""

Causalities:-
The image presents a detailed flowchart outlining the principles of radiation therapy specifically for the <C> treatment of cancer in the glottic larynx </C>, <CO> as per the National Comprehensive Cancer Network (NCCN) guidelines (version 2.2024) </CO>. <E> This structured guidance delineates various treatment protocols </E>, <A> stratified by risk levels and therapeutic approaches </A>.

Section Name: Principles of Radiation Therapy
====================
Entities:-
Radiation Therapy : The medical use of ionizing radiation, generally as part of cancer treatment to control or kill malignant cells.
Gy : Gray, a unit of ionizing radiation dose in the International System of Units (SI), defined as the absorption of one joule of radiation energy per kilogram of matter.
Gray (Unit) : A unit of absorbed radiation dose of ionizing radiation, defined as the absorption of one joule of radiation energy per kilogram of matter.

Relationships:-
1. Entity1: ""Tis, N0"", Entity2: ""60.75 Gy (2.25 Gy/fraction) to 66 Gy (2.0 Gy/fraction)"", Relationship: ""treatment protocol""
2. Entity1: ""T1, N0"", Entity2: ""63 Gy (2.25 Gy/fraction) to 66 Gy (2.0 Gy/fraction) or 50 Gy (3.12 Gy/fraction) to 52 Gy (3.28 Gy/fraction)"", Relationship: ""treatment protocol""
3. Entity1: ""T2, N0"", Entity2: ""65.25 Gy (2.25 Gy/fraction) to 70 Gy (2.0 Gy/fraction)"", Relationship: ""treatment protocol""
4. Entity1: ""≥T2, N1 (PTV High risk)"", Entity2: ""66 Gy (2.2 Gy/fraction) to 70 Gy (2.0 Gy/fraction)"", Relationship: ""treatment protocol""
5. Entity1: ""≥T2, N1 (Low to intermediate risk)"", Entity2: ""44–50 Gy (2.0 Gy/fraction) to 54–63 Gy (1.6–1.8 Gy/fraction)"", Relationship: ""treatment protocol""

Causalities:-
<CO>Tis, N0</CO>: <A>60.75 Gy (2.25 Gy/fraction) to 66 Gy (2.0 Gy/fraction)</A>
<CO>T1, N0</CO>: <A>63 Gy (2.25 Gy/fraction, preferred) to 66 Gy (2.0 Gy/fraction) or 50 Gy (3.12 Gy/fraction) to 52 Gy (3.28 Gy/fraction)</A>
<CO>T2, N0</CO>: <A>65.25 (2.25 Gy/fraction) to 70 Gy (2.0 Gy/fraction)</A>
<CO>≥T2, N1</CO>: <A>PTV High risk: Primary tumor and involved lymph nodes (includes possible local subclinical infiltration at the primary site and at the high-risk level lymph node(s))</A>
<A>Fractionation: 66 Gy (2.2 Gy/fraction) to 70 Gy (2.0 Gy/fraction); daily Monday–Friday in 6–7 weeks</A>
<A>Concomitant boost accelerated RT: 72 Gy/6 weeks (1.8 Gy/fraction, large field; 1.5 Gy boost as second daily fraction during last 12 treatment days)</A>
<A>66–70 Gy (2.0 Gy/fraction; 6 fractions/wk accelerated)</A>
<A>Hyperfractionation: 79.2–81.6 Gy/7 weeks (1.2 Gy/fraction, twice daily)</A>
<CO>Low to intermediate risk</CO>: <A>Sites of suspected subclinical spread</A>
<A>44–50 Gy (2.0 Gy/fraction) to 54–63 Gy (1.6–1.8 Gy/fraction)</A>

Section Name: Concurrent Systemic Therapy/RT
====================
Entities:-
Cisplatin : A platinum-containing antineoplastic agent used in the treatment of various cancers.
Carboplatin : An organoplatinum compound that possesses antineoplastic activity.
Fluorouracil : A chemotherapy drug used to treat various types of cancer.

Relationships:-
1. Entity1: ""concurrent systemic therapy/RT"", Entity2: ""cisplatin"", Relationship: ""uses""
2. Entity1: ""concurrent systemic therapy/RT"", Entity2: ""carboplatin and 5-FU"", Relationship: ""uses""
3. Entity1: ""multiagent chemotherapy"", Entity2: ""toxicity burden"", Relationship: ""increases""

Causalities:-
<CO>Based on published data</CO>, <A>concurrent systemic therapy/RT most commonly uses conventional fractionation at 2.0 Gy per fraction to a typical dose of 70 Gy in 7 weeks with single-agent cisplatin given every 3 weeks at 100 mg/m²</A>; <CO>2–3 cycles of chemotherapy are used depending on the radiation fractionation scheme (RTOG 0129)</CO>. <CO>When carboplatin and 5-FU are used</CO>, <A>the recommended regimen is standard fractionation plus 3 cycles of chemotherapy</A>. <CO>Other fraction sizes (e.g., 1.8 Gy, conventional), multiagent chemotherapy, other dosing schedules of cisplatin, or altered fractionation with chemotherapy</CO> <E>are efficacious</E>, and <C>there is no consensus on the optimal approach</C>. <C>In general, the use of concurrent systemic therapy/RT</C> <E>carries a high toxicity burden</E>; <C>multiagent chemotherapy</C> <E>will likely further increase the toxicity burden</E>. <A>For any systemic therapy/RT approach, close attention should be paid to published reports for the specific chemotherapy agent, dose, and schedule of administration</A>. <A>Systemic therapy/RT should be performed by an experienced team and should include substantial supportive care</A>.

Section Name: Treatment Modalities
====================
Entities:-
Intensity-Modulated Radiotherapy : A type of conformal radiotherapy that uses computer-controlled linear accelerators to deliver precise radiation doses to a malignant tumor or specific areas within the tumor.
Intensity Modulated Radiation Therapy : A type of conformal radiotherapy that uses computer-controlled linear accelerators to deliver precise radiation doses to a malignant tumor or specific areas within the tumor.
Intensity-Modulated Radiation Therapy : An advanced type of high-precision radiotherapy that uses computer-controlled linear accelerators to deliver precise radiation doses to a malignant tumor or specific areas within the tumor.
Radiotherapy, Conformal : A type of radiotherapy that uses imaging to conform the radiation dose to the shape of the tumor.
3D Conformal Radiation Therapy : A technique in radiotherapy that uses imaging to conform the radiation dose to the shape of the tumor.
Chemotherapy, Adjuvant : Treatment with drugs that kill cancer cells, often used in conjunction with other therapies.
Chemotherapy : The treatment of disease by the use of chemical substances, especially the treatment of cancer by cytotoxic and other drugs.
Drug Therapy, Combination : The use of two or more drugs to achieve a therapeutic effect.
Systemic Therapy : A type of therapy that uses substances that travel through the bloodstream, reaching and affecting cells all over the body.

Relationships:-
1. Entity1: ""Intensity-Modulated Radiation Therapy (IMRT)"", Entity2: ""3D Conformal Radiation Therapy (3D-CRT)"", Relationship: ""are delivery methods for radiation therapy""
2. Entity1: ""Chemotherapy"", Entity2: ""Radiation Therapy"", Relationship: ""is integrated with for aggressive or advanced cancer cases""

Causalities:-
<CO> contingent upon patient-specific considerations </CO> <A> suggests either Intensity-Modulated Radiation Therapy (IMRT) or 3D Conformal Radiation Therapy (3D-CRT) as delivery methods </A>. <A> These advanced techniques are employed to optimize treatment accuracy </A>, <E> preserving surrounding healthy tissue and improving overall patient outcomes </E>. <A> a focus on concurrent systemic therapies underlines the importance of integrating chemotherapy </A>, particularly <CO> for patients with more aggressive forms of cancer or those demonstrating advanced disease characteristics </CO>.

Section Name: Additional Information
====================
Entities:-
Clinical Trials : Clinical trials are research studies performed in people that are aimed at evaluating a medical, surgical, or behavioral intervention.
Clinical Trial : A clinical trial is a research study in which one or more human subjects are prospectively assigned to one or more interventions to evaluate the effects of those interventions on health-related biomedical or behavioral outcomes.
National Comprehensive Cancer Network : The National Comprehensive Cancer Network (NCCN) is an alliance of 30 cancer centers in the United States, dedicated to improving the quality, effectiveness, and efficiency of cancer care.
Intensity-Modulated Radiation Therapy : An advanced type of high-precision radiotherapy that uses computer-controlled linear accelerators to deliver precise radiation doses to a malignant tumor or specific areas within the tumor.
Intensity Modulated Radiation Therapy : A type of conformal radiotherapy that uses computer-controlled linear accelerators to deliver precise radiation doses to a malignant tumor or specific areas within the tumor.
Three-Dimensional Conformal Radiation Therapy : A type of external beam radiation therapy that uses a computer to create a 3-dimensional picture of the tumor so that multiple radiation beams can be shaped exactly to the contour of the treatment area.

Relationships:-
1. Entity1: ""National Comprehensive Cancer Network"", Entity2: ""Clinical trial"", Relationship: ""encourages participation in""
2. Entity1: ""Intensity-Modulated Radiation Therapy"", Entity2: ""Three-Dimensional Conformal Radiation Therapy"", Relationship: ""recommended alternatives""

Causalities:-
<A> Participation in clinical trials </A> is especially encouraged. <A> Either IMRT (preferred) or 3D-CRT is recommended. </A>

Section Name: Conclusion
====================
Entities:-
Laryngeal Neoplasms : Tumors or cancer of the larynx, which may affect the glottis, supraglottis, or subglottis.
Malignant Neoplasm Of Glottis : A malignant tumor located in the glottic region of the larynx.
Laryngeal Cancer : Cancer that occurs in the larynx, or voice box, which may include the glottic region.
Prognosis : A medical term for predicting the likely or expected development of a disease.
Evidence-Based Practice : Healthcare practices that are based on scientific evidence and research.
Evidence-Based Medicine : An approach to medical practice intended to optimize decision-making by emphasizing the use of evidence from well-designed and conducted research.

Relationships:-
1. Entity1: ""treatment paradigms"", Entity2: ""glottic larynx cancer"", Relationship: ""encapsulates""
2. Entity1: ""personalized treatment plans"", Entity2: ""prognosis"", Relationship: ""improves""

Causalities:-
<C> glottic larynx cancer </C>. <CO> the nuances of each patient's condition </CO>. <A> personalized treatment plans </A> <E> promoting effective management and improved prognosis </E>. <A> deliver clear, evidence-based interventions </A> <CO> considering the complexities involved in cancer treatment </CO>.


Among these two options which one is the most likely true:

(A) `Number_of_Lymph_Nodes_5` increases risk `N_State_1`
(B) `N_State_1` `increases risk `Number_of_Lymph_Nodes_5`

The answer is: ...

1. State the evidences in detail of the validity of option (A) or (B) by cross referencing
NCCN Clinical Practitioner’s Guidelines for Head and Neck Cancer.
2. If the evidences are obtained from `INFORMATION FROM KNOWLEDGE BASE`,
mention their corresponding Page Numbers, Section Name, entities, relationships and causalities.

DESIRED OUTPUT FORMAT:
<thinking>
...
</thinking>
<answer>
{
   ""thinking"": [""..."", ...],
   ""evidences"": [""..."", ...],
   ""answer"": ...
}
</answer>

Before providing the answer in <answer> tags, think step by step in detail in <thinking> tags and analyze every part.
Output inside <answer> tag in JSON format. Only output valid JSON.
DO NOT HALLUCINATE. DO NOT MAKE UP FACTUAL INFORMATION.
","1. The edge (Number_of_Lymph_Nodes_5) causes (N_State_1) suggests a causal relationship where the number of lymph nodes influences the cancer state in nearby lymph nodes.
2. The explanation provided for EDGE1 indicates that the number of lymph nodes does not directly cause cancer to be present or absent in them. Instead, the presence of cancer in lymph nodes is more directly related to the spread of cancer from a primary site.
3. The edge (N_State_1) causes (Number_of_Lymph_Nodes_5) suggests that the presence of cancer in nearby lymph nodes influences the number of lymph nodes present or absent.
4. The explanation for EDGE2 indicates that the number of lymph nodes is a physical characteristic not directly caused by the presence of cancer. The presence of cancer might be detected in a certain number of lymph nodes, but it does not cause the number of lymph nodes to change.
5. The NCCN Clinical Practitioner's Guidelines for Head and Neck Cancer emphasize the importance of tumor staging and the involvement of lymph nodes in determining the extent of cancer spread and treatment decisions.
6. The guidelines do not suggest that the number of lymph nodes directly influences the cancer state or vice versa. Instead, they focus on the presence of cancer in lymph nodes as an indicator of metastasis and cancer staging.
7. Based on the explanations and guidelines, neither option (A) nor (B) is supported as a valid causal relationship.
","1. Page Number: 102, Section Name: Head and Neck Cancers - Principles of Surgery, Entities: Lymphatic System, Neoplasms, Neck Dissection, Relationships: surgical management dictated by tumor staging, Causalities: The extent of the tumor at initial tumor staging dictates the surgical management of regional lymphatics.
2. Page Number: 130, Section Name: Pathological N (pN), Entities: Lymph Nodes, Neoplasm Metastasis, TNM Staging, Relationships: Lymph Nodes involved in Neoplasm Metastasis, Causalities: NX: Regional lymph nodes cannot be assessed, N0: No regional lymph node metastasis, N1: Metastasis in a single ipsilateral lymph node, 3 cm or smaller in greatest dimension ENE(–).
",A,"{'A': 85.2, 'B': 14.8}",yes,A,"1. The AI assistant's reasoning begins by analyzing the causal relationship suggested by EDGE1 and EDGE2, which involves the nodes 'Number_of_Lymph_Nodes_5' and 'N_State_1'.
2. For EDGE1, the assistant correctly identifies that the explanation provided indicates the number of lymph nodes does not directly cause cancer to be present or absent in them. This aligns with the clinical understanding that the presence of cancer in lymph nodes is more related to the spread of cancer from a primary site.
3. For EDGE2, the assistant notes that the explanation suggests the number of lymph nodes is a physical characteristic not directly caused by the presence of cancer. This is consistent with the understanding that while cancer can be detected in lymph nodes, it does not alter the number of lymph nodes.
4. The assistant references the NCCN Clinical Practitioner's Guidelines for Head and Neck Cancer, emphasizing the role of tumor staging and lymph node involvement in cancer spread and treatment decisions. This is a relevant reference, as these guidelines focus on the presence of cancer in lymph nodes as an indicator of metastasis and staging, rather than a causal relationship between the number of lymph nodes and cancer presence.
5. The assistant concludes that neither option (A) nor (B) is supported as a valid causal relationship based on the explanations and guidelines. This conclusion is consistent with the evidence provided, as the explanations for both edges indicate a lack of direct causality.
6. The evidences cited from the knowledge base, such as the page numbers and sections, support the assistant's reasoning by highlighting the clinical focus on tumor staging and lymph node involvement rather than a direct causal relationship between the number of lymph nodes and cancer presence.
"
7,gpt-4o,"Number_of_Lymph_Nodes_5,Pathologie_12","""{'NODE1': {'id': 'Number_of_Lymph_Nodes_5', 'label': 'Number of Lymph Nodes', 'description': 'This node represents the presence or absence of a specific number of lymph nodes, which can be clinically significant in assessing the spread of cancer or other diseases.', 'type': 'Patient Situation', 'observability': 'Unobserved', 'states': [{'state_name': 'present', 'state_description': \""The state 'present' indicates that the specific number of lymph nodes is detected or considered in the clinical assessment.\""}, {'state_name': 'absent', 'state_description': \""The state 'absent' indicates that the specific number of lymph nodes is not detected or considered in the clinical assessment.\""}]}, 'NODE2': {'id': 'Pathologie_12', 'label': 'Pathology Examination Result', 'description': 'This node represents the result of a specific pathology examination, which has been observed. It indicates whether a particular pathological finding or condition is present or absent.', 'type': 'Examination Result', 'observability': 'Observed', 'states': [{'state_name': 'present', 'state_description': 'The pathological finding or condition was observed in the examination.'}, {'state_name': 'absent', 'state_description': 'The pathological finding or condition was not observed in the examination.'}]}, 'EDGE1': {'edges_ids': ['Number_of_Lymph_Nodes_5', 'Pathologie_12'], 'edge': '(Number_of_Lymph_Nodes_5) causes (Pathologie_12)', 'explanation': ['The edge `(Number_of_Lymph_Nodes_5) causes (Pathologie_12)` is not valid as a direct causal relationship.', 'The number of lymph nodes is an indicator of disease spread but does not directly cause a pathology result.', 'The causal direction is positive if we consider that more affected lymph nodes might correlate with a positive pathology result, but this is not a direct causation.', 'The number of lymph nodes is neither a necessary nor a sufficient condition for a pathology result.', 'The causal distance is distal, as the number of lymph nodes is an indirect factor in determining pathology results.'], 'causal_direction': 'positive', 'causal_factor': {'necessary': False, 'sufficient': False}, 'causal_distance': 'Distal'}, 'EDGE2': {'edges_ids': ['Pathologie_12', 'Number_of_Lymph_Nodes_5'], 'edge': '(Pathologie_12) causes (Number_of_Lymph_Nodes_5)', 'explanation': ['The edge suggests that the result of a pathology examination (`Pathologie_12`) directly causes a change in the number of lymph nodes ('Number_of_Lymph_Nodes_5').', 'In clinical terms, while certain pathological findings might be associated with changes in lymph node status, the examination result itself does not directly cause such changes.', 'The number of lymph nodes is more directly influenced by the underlying disease process rather than the examination result.', 'Therefore, the edge is not valid as a direct causal relationship.'], 'causal_direction': 'Unknown', 'causal_factor': {'necessary': False, 'sufficient': False}, 'causal_distance': 'Unknown'}, 'ENTITIES_MATCHING_PAGES_INFO': {'102': {'matching_entities': [{'LYMPHATIC SYSTEM': 0.95855314}, {'LYMPHATIC STRUCTURE': 0.9469132}, {'SURGERY': 0.9258238}], 'count': 3}, '129': {'matching_entities': [{'LYMPH NODE STRUCTURE': 0.99134904}, {'LYMPH NODE': 0.98570025}, {'LYMPH NODES': 0.97445965}], 'count': 3}, '130': {'matching_entities': [{'LYMPH NODE STRUCTURE': 0.99134904}, {'LYMPH NODE': 0.98570025}, {'LYMPH NODES': 0.97445965}], 'count': 3}, '154': {'matching_entities': [{'LYMPH NODE STRUCTURE': 0.99134904}, {'LYMPH NODE': 0.98570025}, {'LYMPH NODES': 0.97445965}], 'count': 3}, '145': {'matching_entities': [{'LYMPH NODES': 0.97445965}, {'SURGERY': 0.9258238}], 'count': 2}}, 'GUIDELINE_PAGES_INFO': '--------------------------------------------------\\nPage Number: 102\\n\\nSection Name: Head and Neck Cancers - Principles of Surgery\\n====================\\nEntities:-\\nSurgical Procedures, Operative : Manual or operative procedures used in the treatment of disease, injuries, or deformities.\\nLymphatic System : Part of the circulatory system and a vital part of the immune system, comprising a network of lymphatic vessels that carry a clear fluid called lymph.\\nNeoplasms : New abnormal growth of tissue in animals or plants; a tumor.\\nNeck Dissection : A surgical procedure for control of neck lymph node metastasis from squamous cell carcinoma of the head and neck.\\nNeoplasm Staging : Methods which attempt to express in replicable terms the extent of the neoplasm in the patient.\\nMetastasis : The spread of a cancer or other disease from one organ or part of the body to another not directly connected with it.\\nSurgical Procedure : A procedure involving an incision with instruments; performed to repair damage or arrest disease in a living body.\\nLymphatic Structure : Anatomical structure that is part of the lymphatic system.\\nTumor : An abnormal mass of tissue that results when cells divide more than they should or do not die when they should.\\nStaging : The process of determining the size and spread of cancer within the body.\\nSurgery : Medical specialty that uses operative manual and instrumental techniques on a patient to investigate or treat a pathological condition such as disease or injury.\\nCancer Staging : The process of determining the extent to which a cancer has developed by growing and spreading.\\n\\nRelationships:-\\n1. Entity1: \""surgical management\"", Entity2: \""regional lymphatics\"", Relationship: \""dictated by tumor staging\""\\n2. Entity1: \""neck dissections\"", Entity2: \""primary tumor\"", Relationship: \""part of treatment\""\\n3. Entity1: \""surgery\"", Entity2: \""ipsilateral side of the neck\"", Relationship: \""risk for metastases\""\\n\\nCausalities:-\\n<C> The extent of the tumor at initial tumor staging </C> <E> dictates the surgical management of regional lymphatics </E>. These guidelines apply to the performance of neck dissections as part of treatment of the primary tumor. <CO> Patients undergoing surgery for resection of the primary tumor </CO> <A> will undergo dissection of the ipsilateral side of the neck that is at greatest risk for metastases </A>.\\n\\nSection Name: Neck Management\\n====================\\nEntities:-\\nTongue : A muscular organ in the mouth that is involved in tasting, swallowing, and speech.\\nPalate : The roof of the mouth, separating the oral and nasal cavities.\\nLarynx : An organ in the top of the neck involved in breathing, producing sound, and protecting the trachea.\\nHypopharynx : The bottom part of the pharynx, which is the cavity behind the nose and mouth.\\nNasopharynx : The upper part of the pharynx, connecting with the nasal cavity above the soft palate.\\nNeck Dissection : A surgical procedure for control of neck lymph node metastasis from squamous cell carcinoma of the head and neck.\\nMetastasis : The spread of a cancer or other disease from one organ or part of the body to another not directly connected with it.\\nSquamous Cell Carcinoma : A type of cancer that begins in the squamous cells, which are thin, flat cells that look like fish scales.\\nBiopsy : The removal of cells or tissues for examination under a microscope.\\n\\nRelationships:-\\n1. Entity1: \""Tumor sites\"", Entity2: \""Bilateral lymphatic drainage\"", Relationship: \""associated with\""\\n2. Entity1: \""Elective neck dissection\"", Entity2: \""Risk of occult metastasis\"", Relationship: \""based on\""\\n3. Entity1: \""SLN biopsy\"", Entity2: \""Elective neck dissection\"", Relationship: \""guides decision-making for\""\\n\\nCausalities:-\\n- **<C> Tumor sites that frequently have bilateral lymphatic drainage </C>** (e.g., base of tongue, palate, supraglottic larynx, hypopharynx, nasopharynx, deep pre-epiglottic space involvement) <E> often should have both sides of the neck dissected </E> with the extent of dissection determined as suggested below. For those patients with tumors at or approaching the midline, <CO> both sides of the neck are at risk for metastases </CO>, and <A> bilateral neck dissections should be performed </A>.\\n\\n- <CO> Patients with advanced lesions involving the anterior tongue, floor of the mouth, or alveolus that approximate or cross the midline </CO> <A> should undergo contralateral selective/modified neck dissection </A> as necessary to achieve adequate tumor resection.\\n\\n- **<C> Elective neck dissection </C>** <A> should be based on risk of occult metastasis in the appropriate nodal basin </A>. For oral cavity squamous cell carcinoma, <C> SLN biopsy or the primary tumor depth of invasion </C> is currently <E> the best predictor of occult metastatic disease </E> and <A> should be used to guide decision-making </A>. <CO> For tumors with a depth greater than 3 mm </CO>, <A> elective dissection should be strongly considered if RT is not already planned </A>. Recent randomized trial evidence supports the effectiveness of elective neck dissection in patients with oral cavity cancers greater than 3 mm in depth of invasion.\\n\\n  - <CO> For a depth less than 2 mm </CO>, <A> elective dissection is only indicated in highly selective situations </A>. <CO> For a depth of 2\u20134 mm </CO>, <A> clinical judgment (as to reliability of follow-up, clinical suspicion, and other factors) must be utilized to determine appropriateness of elective dissection </A>. Elective dissections are generally selective, preserving all major structures, unless operative findings dictate otherwise.\\n\\nSection Name: Types of Neck Dissection\\n====================\\nEntities:-\\nNeck Dissection : A surgical procedure for control of neck lymph node metastasis from squamous cell carcinoma of the head and neck.\\nLarynx : An organ in the top of the neck involved in breathing, producing sound, and protecting the trachea.\\n\\nRelationships:-\\n1. Entity1: \""N0\"", Entity2: \""Selective neck dissection\"", Relationship: \""associated with\""\\n2. Entity1: \""N3\"", Entity2: \""Comprehensive neck dissection\"", Relationship: \""associated with\""\\n3. Entity1: \""Level VI neck dissection\"", Entity2: \""Larynx\"", Relationship: \""performed for\""\\n4. Entity1: \""Level VI neck dissection\"", Entity2: \""Hypopharynx\"", Relationship: \""performed for\""\\n\\nCausalities:-\\n- **The type of neck dissection (comprehensive or selective)** is defined according to <CO> preoperative clinical staging </CO>, is determined at the discretion of the surgeon, and is based on the initial preoperative staging as follows:\\n  - **N0:** <A> Selective neck dissection </A>\\n    - Oral cavity at least levels I\u2013III\\n    - Oropharynx at least levels II\u2013IV\\n    - Hypopharynx at least levels II\u2013IV and level VI when appropriate\\n    - Larynx at least levels II\u2013IV and level VI when appropriate\\n  - **N1\u2013N2a\u2013c:** <A> Selective or comprehensive neck dissection </A> (Discussion)\\n  - **N3:** <A> Comprehensive neck dissection </A>\\n\\n- <C> Level VI neck dissections are performed for certain primary sites (such as the larynx and hypopharynx) </C> <E> as required to resect the primary tumor and any clinically evident neck nodes </E>. <CO> Elective dissection depends on primary tumor extent and site </CO>. <CO> For advanced glottic and hypopharyngeal cancers treated with primary surgery </CO>, <A> a level VI dissection (including pretracheal lymph nodes, the Delphian lymph node, and unilateral or bilateral paratracheal lymph nodes) and hemithyroidectomy to total thyroidectomy are appropriate </A>.\\n\\n- <CO> For primary subglottic tumors or glottic cancers with significant subglottic extension </CO>, <A> a level VI dissection with unilateral or total thyroidectomy is considered appropriate </A> based on the extent of the primary tumor. <CO> For example, a T4a glottic tumor with extension through the cricothyroid membrane and subglottic extension </CO> <A> should include thyroidectomy and pretracheal and bilateral paratracheal lymph node dissection </A>. <A> Parathyroid glands should be preserved in situ or auto transplanted as indicated </A>.\\n--------------------------------------------------\\nPage Number: 129\\n\\nSection Name: TNM Staging System for the Larynx - Regional Lymph Nodes (N)\\n====================\\nEntities:-\\nLymph Nodes : Small, bean-shaped structures that are part of the body\\'s immune system. They filter substances that travel through the lymphatic fluid, and they contain lymphocytes (white blood cells) that help the body fight infection and disease.\\nLymph Node Structure : A structure that is part of the lymphatic system, involved in the filtration of lymph and the production of lymphocytes.\\nLymph Node : An organ of the lymphatic system and the adaptive immune system that is widely present throughout the body.\\n\\nRelationships:-\\n1. Entity1: \""NCCN Guidelines\"", Entity2: \""Regional Lymph Nodes\"", Relationship: \""provides classification for\""\\n2. Entity1: \""AJCC TNM Staging System\"", Entity2: \""Regional Lymph Nodes\"", Relationship: \""provides classification for\""\\n3. Entity1: \""Clinical N\"", Entity2: \""Regional Lymph Nodes\"", Relationship: \""is a classification of\""\\n\\nCausalities:-\\nThe <C> classification of the Regional Lymph Nodes (N) for head and neck cancers </C> is crucial for <E> determining the presence and extent of lymph node metastases </E>, which are critical in <E> establishing the severity and appropriate treatment strategies </E>. <A> Clinicians use this structured classification for accurate staging and subsequent treatment planning in patients diagnosed with head and neck cancers </A>.\\n\\nSection Name: NCCN Guidelines Version 4.2024\\n====================\\nEntities:-\\nHead And Neck Neoplasms : Cancers that occur in the head or neck region, including the nasal cavity, sinuses, lips, mouth, salivary glands, throat, or larynx.\\nMalignant Neoplasm Of Head And Neck : A malignant tumor located in the head and neck region.\\nNational Comprehensive Cancer Network : An alliance of cancer centers in the United States, dedicated to improving the quality, effectiveness, and efficiency of cancer care.\\n\\nRelationships:-\\n1. Entity1: \""NCCN Guidelines\"", Entity2: \""Head and Neck Cancers\"", Relationship: \""guidelines for\""\\n2. Entity1: \""NCCN Guidelines\"", Entity2: \""National Comprehensive Cancer Network\"", Relationship: \""published by\""\\n\\nCausalities:-\\nThe provided text does not contain any clinical causes, effects, conditions, or actions to extract.\\n--------------------------------------------------\\nPage Number: 130\\n\\nSection Name: Pathological N (pN)\\n====================\\nEntities:-\\nLymph Nodes : Small, bean-shaped structures that are part of the body\\'s lymphatic system. They filter lymph fluid and store white blood cells that help fight infection.\\nNeoplasm Metastasis : The transfer of a neoplasm from one organ or part of the body to another remote from the primary site.\\nTnm Staging : A system used to describe the size and spread of cancer in a standardized way. T refers to the size of the tumor, N to the involvement of lymph nodes, and M to metastasis.\\nLymph Node Structure : A structure that is part of the lymphatic system, involved in the immune response.\\nMetastasis : The spread of a cancer or other disease from one organ or part to another not directly connected with it.\\nTnm Staging System : A cancer staging notation system that describes the extent of cancer in a patient\\'s body.\\nLymph Node : An organ of the lymphatic system and the adaptive immune system.\\n\\nRelationships:-\\n1. Entity1: \""Lymph Nodes\"", Entity2: \""Neoplasm Metastasis\"", Relationship: \""involved in\""\\n2. Entity1: \""TNM Staging\"", Entity2: \""Lymph Nodes\"", Relationship: \""includes\""\\n3. Entity1: \""TNM Staging\"", Entity2: \""Neoplasm Metastasis\"", Relationship: \""describes\""\\n\\nCausalities:-\\n<CO> NX: Regional lymph nodes cannot be assessed </CO>\\n<CO> N0: No regional lymph node metastasis </CO>\\n<CO> N1: Metastasis in a single ipsilateral lymph node, 3 cm or smaller in greatest dimension ENE(\u2013) </CO>\\n<CO> N2: Metastasis in a single ipsilateral lymph node, 3 cm or smaller in greatest dimension and ENE(+); or larger than 3 cm but not larger than 6 cm in greatest dimension and ENE(\u2212); or metastases in multiple ipsilateral lymph nodes, none larger than 6 cm in greatest dimension and ENE(\u2212); or in bilateral or contralateral lymph node(s), none larger than 6 cm in greatest dimension and ENE(\u2212) </CO>\\n<CO> N2a: Metastasis in a single ipsilateral node, 3 cm or smaller in greatest dimension and ENE(+); or metastasis in a single ipsilateral node, larger than 3 cm but not larger than 6 cm in greatest dimension and ENE(\u2212) </CO>\\n<CO> N2b: Metastases in multiple ipsilateral nodes, none larger than 6 cm in greatest dimension and ENE(\u2212) </CO>\\n<CO> N2c: Metastases in bilateral or contralateral lymph node(s), none larger than 6 cm in greatest dimension and ENE(\u2212) </CO>\\n<CO> N3: Metastasis in a lymph node, larger than 6 cm in greatest dimension and ENE(\u2212); or metastasis in a single ipsilateral node, larger than 3 cm in greatest dimension and ENE(+); or multiple ipsilateral, contralateral, or bilateral lymph nodes and any with ENE(+); or a single contralateral node of any size and ENE(+) </CO>\\n<CO> N3a: Metastasis in a lymph node, larger than 6 cm in greatest dimension and ENE(\u2212) </CO>\\n<CO> N3b: Metastasis in a single ipsilateral node, larger than 3 cm in greatest dimension and ENE(+); or multiple ipsilateral, contralateral, or bilateral lymph nodes any with ENE(+); or a single contralateral node of any size and ENE(+) </CO>\\n<CO> Note: A designation of \u201cU\u201d or \u201cL\u201d may be used for any N category to indicate metastasis above the lower border of the cricoid (U) or below the lower border of the cricoid (L). Similarly, clinical and pathological ENE should be recorded as ENE(\u2212) or ENE(+). </CO>\\n\\nSection Name: Distant Metastasis (M)\\n====================\\nEntities:-\\nNeoplasm Metastasis : The transfer of a neoplasm from one organ or part of the body to another remote from the primary site.\\nMetastasis : The spread of a cancer or other disease from one organ or part to another not directly connected with it.\\n\\nRelationships:-\\n1. Entity1: \""M0\"", Entity2: \""Distant Metastasis\"", Relationship: \""is a category of\""\\n2. Entity1: \""M1\"", Entity2: \""Distant Metastasis\"", Relationship: \""is a category of\""\\n\\nCausalities:-\\n### Distant Metastasis (M)\\n\\n- **M0**: No distant metastasis\\n- **M1**: Distant metastasis\\n\\nSection Name: Histologic Grade (G)\\n====================\\nEntities:-\\nNeoplasm Grading : A system of classifying cancer cells in terms of how abnormal they look under a microscope and how quickly the tumor is likely to grow and spread.\\nHistologic Grade : A measure of how much tumor cells differ from healthy cells, used to assess the aggressiveness of cancer.\\n\\nRelationships:-\\n1. Entity1: \""GX\"", Entity2: \""Grade cannot be assessed\"", Relationship: \""is described as\""\\n2. Entity1: \""G1\"", Entity2: \""Well differentiated\"", Relationship: \""is described as\""\\n3. Entity1: \""G2\"", Entity2: \""Moderately differentiated\"", Relationship: \""is described as\""\\n4. Entity1: \""G3\"", Entity2: \""Poorly differentiated\"", Relationship: \""is described as\""\\n\\nCausalities:-\\n<CO>GX</CO>: <E>Grade cannot be assessed</E>\\n<CO>G1</CO>: <E>Well differentiated</E>\\n<CO>G2</CO>: <E>Moderately differentiated</E>\\n<CO>G3</CO>: <E>Poorly differentiated</E>\\n\\nSection Name: Prognostic Stage Groups\\n====================\\nEntities:-\\nNeoplasm Staging : Methods and systems of classifying neoplasms according to extent of disease.\\nTumor Staging : A system for describing the size and spread of cancer within the body.\\nTnm Staging System : A cancer staging notation system that describes the extent of cancer in a patient\\'s body.\\n\\nRelationships:-\\n1. Entity1: \""Stage 0\"", Entity2: \""Tis N0 M0\"", Relationship: \""defined by\""\\n2. Entity1: \""Stage I\"", Entity2: \""T1 N0 M0\"", Relationship: \""defined by\""\\n3. Entity1: \""Stage II\"", Entity2: \""T2 N0 M0\"", Relationship: \""defined by\""\\n4. Entity1: \""Stage III\"", Entity2: \""T3 N0 M0, T1 N1 M0, T2 N1 M0, T3 N1 M0\"", Relationship: \""defined by\""\\n5. Entity1: \""Stage IVA\"", Entity2: \""T1 N2 M0, T2 N2 M0, T3 N2 M0, T4a N0,N1,N2 M0\"", Relationship: \""defined by\""\\n6. Entity1: \""Stage IVB\"", Entity2: \""Any T N3 M0, T4b Any N M0\"", Relationship: \""defined by\""\\n7. Entity1: \""Stage IVC\"", Entity2: \""Any T Any N M1\"", Relationship: \""defined by\""\\n--------------------------------------------------\\nPage Number: 154\\n\\nSection Name: NCCN Guidelines Version 4.2024\\n====================\\nEntities:-\\nNccn Guidelines : The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) are a comprehensive set of guidelines detailing the sequential management decisions and interventions that apply to 97% of cancers affecting patients in the United States.\\n\\nRelationships:-\\n\\nCausalities:-\\n# NCCN Guidelines Version 4.2024\\n\\nSection Name: Head and Neck Cancers\\n====================\\nEntities:-\\nHead And Neck Neoplasms : Tumors or cancer of the head and neck region, including the nasal cavity, sinuses, lips, mouth, salivary glands, throat, or larynx.\\nRadiation Therapy : The medical use of ionizing radiation, generally as part of cancer treatment to control or kill malignant cells.\\nQuad Shot Regimen : A palliative radiation therapy regimen consisting of 44.4 Gy delivered in 12 fractions over three cycles, used for patients with limited life expectancy.\\n\\nRelationships:-\\n1. Entity1: \""Head and Neck Neoplasms\"", Entity2: \""70 Gy\"", Relationship: \""treatment dosage\""\\n2. Entity1: \""QUAD SHOT regimen\"", Entity2: \""Palliative Treatment\"", Relationship: \""purpose\""\\n\\nCausalities:-\\nThe College of Radiology describes basic technical specifications [here](http://www.acr.org/Quality-Safety). Furthermore, major consensus contouring guidelines for the treatment of head and neck (H&N) cancers are available for reference, especially for patients who are treated without surgery. [143,144]\\n\\nWhen radiation is given with definitive intent, <A> the dosages prescribed for gross disease are fairly standard, usually in the range of 70 Gy (at approximately 2 Gy/fraction/day) </A> for the following sites: <CO> lip, oral cavity, nasopharynx, oropharynx, hypopharynx, glottic larynx, supraglottic larynx, occult primary, salivary gland tumors, and MM </CO>. A second dose (often approximately 60 Gy, but varies) may be used to cover volumes considered at the highest risk for microscopic spread, while a lower dose (often approximately 50 Gy, but varies) is used for volumes treated electively with low risk for microscopic spread.\\n\\nAlthough several palliative RT regimens are provided, no single regimen is preferred [145,146]; specific regimens vary widely among NCCN Member Institutions. <A> Any palliative RT regimen that might cause severe toxicities should be avoided </A>. <A> More hypofractionated regimens may be useful </A> for <CO> patients with limited life expectancy, such as a few months </CO>. For example, <A> a common version of the QUAD SHOT regimen consists of a dose of 44.4 Gy, delivered in 12 fractions over three cycles, with each cycle separated by 2 to 3 weeks </A>. [147]\\n\\nSection Name: Radiation Doses\\n====================\\nEntities:-\\nRadiation Dosage : The amount of radiation absorbed by an object or person.\\nNeoplasms : New abnormal growth of tissue that can be benign or malignant.\\nLymph Nodes : Small, bean-shaped structures that are part of the body\\'s immune system.\\nRadiotherapy : The treatment of disease, especially cancer, using X-rays or similar forms of radiation.\\nChemotherapy : The use of chemical substances, especially the treatment of cancer by cytotoxic and other drugs.\\nRadiation Therapy : The medical use of ionizing radiation, generally as part of cancer treatment to control or kill malignant cells.\\nLymph Node Structure : A structure that is part of the lymphatic system, involved in the immune response.\\nNeoplasm : An abnormal mass of tissue as a result of neoplasia.\\nLymph Node : An organ of the lymphatic system and the adaptive immune system.\\nTumor : A mass of tissue that\\'s formed by an accumulation of abnormal cells.\\n\\nRelationships:-\\n1. Entity1: \""Radiation Dosage\"", Entity2: \""Neoplasms\"", Relationship: \""depends on\""\\n2. Entity1: \""Radiation Dosage\"", Entity2: \""Organs at risk\"", Relationship: \""may need to be decreased if close to\""\\n3. Entity1: \""Radiotherapy\"", Entity2: \""IMRT\"", Relationship: \""uses\""\\n4. Entity1: \""Radiotherapy\"", Entity2: \""Chemotherapy\"", Relationship: \""can be used with\""\\n\\nCausalities:-\\n<C> Selection of an exact radiation dose prescription and schedule of delivery </C> <E> depends on the primary tumor and neck node size, whether altered fractionation is used, and clinical circumstances, including whether concurrent systemic therapy will be used </E>. <CO> if it is prescribed very close to adjacent organs at risk </CO> <A> The dose may need to be decreased </A>. <CO> Anatomical changes (e.g., rapidly shrinking tumors, changes in air cavities, significant weight loss) </CO> <A> may necessitate repeat imaging and treatment replanning </A>. <CO> when the tumor is abutting brain or optic structures </CO> <A> hyperfractionation has been used </A>. <CO> if prescribed doses exceed 72 Gy using conventional fractionation </CO> <E> this may lead to unacceptable rates of normal tissue injury </E>. <A> Care must be taken </A>.\\n--------------------------------------------------\\nPage Number: 145\\n\\nSection Name: Head and Neck Cancers - Management Approaches\\n====================\\nEntities:-\\nRadiotherapy : The use of radiation, usually X-rays or gamma rays, to treat disease, especially cancer.\\nSurgical Procedures, Operative : Operations carried out for the correction of deformities and defects, repair of injuries, and diagnosis and cure of certain diseases.\\nCarcinoma, Oropharyngeal : A malignant neoplasm involving the oropharynx.\\nNasopharyngeal Carcinoma : A type of cancer that occurs in the nasopharynx, located behind the nose and above the back of the throat.\\nClinical Trials As Topic : Works about research studies that evaluate the safety and effectiveness of medical treatments.\\nHuman Papillomavirus Related Oropharyngeal Cancer : A type of oropharyngeal cancer associated with human papillomavirus infection.\\nHead And Neck Cancer : A group of biologically similar cancers that start in the head and neck region.\\nRadiation Therapy : The medical use of ionizing radiation, generally as part of cancer treatment to control or kill malignant cells.\\nSurgery : A medical specialty that uses operative manual and instrumental techniques on a patient to investigate or treat a pathological condition such as disease or injury.\\n\\nRelationships:-\\n1. Entity1: \""Surgery\"", Entity2: \""Radiotherapy\"", Relationship: \""treatment modality\""\\n2. Entity1: \""HPV-associated oropharyngeal cancer\"", Entity2: \""Radiotherapy\"", Relationship: \""treatment\""\\n3. Entity1: \""Nasopharyngeal carcinoma\"", Entity2: \""Radiotherapy\"", Relationship: \""treatment\""\\n4. Entity1: \""Clinical trials\"", Entity2: \""Treatment option\"", Relationship: \""recommended\""\\n\\nCausalities:-\\n<C> The specific site of disease, histology, stage, and baseline comorbid conditions </C> guide <A> treatment decisions </A> (e.g., the appropriate surgical procedures, radiotherapy treatment parameters [target volumes, total dose, and fractionation regimen], indications for systemic therapy, and patient-specific considerations). <A> Single-modality treatment with surgery or RT </A> is generally recommended for <CO> the approximately 30% to 40% of patients who present with early-stage disease (stage I or II) HPV-unrelated cancers </CO>. <E> Surgery and RT result in similar survival for many H&N cancers </E>, but <A> surgery is usually preferred for oral cavity and paranasal sinus cancers </A>, while <A> RT with or without chemotherapy is nearly always preferred for all stages of nasopharyngeal carcinoma (NPC) and more advanced stages of HPV-associated oropharyngeal cancer </A>. <C> The choice of surgery or RT as the primary treatment modality </C> is often based on <CO> local institutional expertise and/or perceived relative morbidity of these treatment options </CO>. With <C> the evolution of conformal techniques of RT and less invasive surgery, as well as improving supportive care for patients receiving systemic therapy </C>, <E> morbidity is also a moving target </E>. <A> Combined modality therapy </A> is generally recommended for <CO> the approximately 60% of patients with locally or regionally advanced disease at diagnosis </CO>. <A> Participation in clinical trials </A> is a preferred or recommended treatment option in many situations. In formulating these NCCN Guidelines, <C> panel members have tried to make them evidence-based while providing a statement of consensus as to the acceptable range of treatment options </C>. In numerous population-based studies, <C> patients treated at high-volume centers </C> have shown <E> better outcomes </E>.\\n\\nSection Name: Head and Neck Cancers - Prognostic Factors\\n====================\\nEntities:-\\nP16 : p16 is a cyclin-dependent kinase inhibitor that plays a role in regulating the cell cycle.\\nHpv : Human papillomavirus (HPV) is a virus that can cause cervical and other types of cancer.\\nPrognosis : Prognosis refers to the likely course and outcome of a disease.\\nOropharyngeal Neoplasms : Cancers that occur in the oropharynx, the part of the throat just behind the mouth.\\nSmoking : The inhalation of the smoke of burning tobacco encased in cigarettes, pipes, and cigars.\\nNeoplasm Staging : Methods used for staging neoplasms, which is the process of determining the extent of cancer in the body.\\nLymph Nodes : Small, bean-shaped structures that are part of the body\\'s immune system.\\nSinonasal Neoplasms : Tumors or cancer of the nasal cavity and paranasal sinuses.\\nSurvival Rate : The percentage of people who survive a disease such as cancer for a specific amount of time.\\n\\nRelationships:-\\n1. Entity1: \""p16 positivity\"", Entity2: \""HPV tumor status\"", Relationship: \""informs prognosis\""\\n2. Entity1: \""Smoking\"", Entity2: \""Oropharyngeal cancer\"", Relationship: \""associated with decreased OS and PFS\""\\n3. Entity1: \""HPV 16/18\"", Entity2: \""Sinonasal cancer\"", Relationship: \""associated with better OS\""\\n4. Entity1: \""T4 or N3 disease\"", Entity2: \""Matted lymph nodes\"", Relationship: \""associated with worse prognosis\""\\n\\nCausalities:-\\n<C> Distinguishing patients with p16 positivity by HPV tumor status </C> <E> informs prognosis </E>. A multicenter individual patient data analysis including 13 cohorts of patients from Canada and Europe (N = 7654) showed that <C> patients with discordant p16 expression and HPV status </C> <E> had worse prognosis </E> compared to <CO> patients with concordant positive p16 expression and HPV status </CO>.\\n\\n- **5-year OS for p16-negative/HPV-positive**: 53.2% (95% CI, 46.6%\u201360.8%)\\n- **5-year OS for p16-positive/HPV-negative**: 54.7% (95% CI, 49.2%\u201360.9%)\\n- **5-year OS for concordant positive p16/HPV**: 81.1% (95% CI, 79.5%\u201382.7%)\\n- **5-year OS for concordant negative p16/HPV**: 40.4% (95% CI, 38.6%\u201342.4%)\\n\\nA retrospective cohort analysis (N = 1070) also showed <E> better OS in patients with HPV 16/18 positive sinonasal cancer </E>, compared to <CO> patients with HPV negative disease </CO> (adjusted hazard ratio [HR], 0.63; 95% CI, 0.48\u20130.82). The impact of <C> smoking and cancer stage </C> on <E> survival of patients with HPV-positive SCCHN </E> has been investigated in numerous studies. For example, analyses of patients with oropharyngeal cancer who were enrolled in RTOG 9003 or 0129 (n = 165) showed that <C> smoking </C> was <E> associated with decreased OS and PFS </E>, regardless of p16 status. An analysis of data compiled from four cooperative group trials estimated that <CO> those who never smoked </CO> had a <E> 51% (HR, 0.40; 95% CI, 0.33\u20130.75) reduction in risk of cancer progression </E> when compared to <CO> those who formerly or currently smoked and had HPV-positive SCCHN </CO>. A retrospective analysis from a clinical trial (RTOG 0129) showed <E> no difference in the rate of distant metastasis </E> in <CO> patients with p16-positive versus p16-negative disease </CO>. Additional analyses have suggested that <C> individuals with T4 or N3 disease or radiographically detectable matted lymph nodes </C> may have a <E> worse prognosis </E>, and therefore <A> should be excluded from deintensification trials </A>. These studies on prognostic and predictive factors in HPV-positive oropharyngeal cancers form the basis for <A> RT deintensification studies </A>. Moreover, the <C> striking difference in prognosis for HPV-positive versus HPV-negative SCCHN </C> led to the <E> creation of new AJCC staging criteria in 2018 </E> (see Cancer of the Oropharynx in the NCCN Guidelines for Head and Neck Cancers; available at [www.NCCN.org](http://www.NCCN.org)).\\n'}""",valid,increases risk,2,B,"edge - The edge which needs to be verified.
explanation - Explanation of what the edge represents and its validity.
causal_direction - Either Positive or Negative or Unknown. A positive influence direction indicates that both factors change in the same direction (e.g. an increase causes an increase effect). A negative influence direction indicates the opposite changes (e.g. an increase causes a decrease effect).
causal_factor - Is necessary or sufficient condition for an effect to occur. Exposure is a term commonly used in epidemiology to denote any condition that is considered as a possible cause of disease. Exposure is considered necessary when it always precedes the effects (e.g. symptoms) and always presents when the effects occur. A sufficient cause is a causal factor whose presence or occurrence guarantees the occurrence of symptom.
causal_distance - Either Distal or Proximal or Unknown. The distal factors lie towards the beginning of causal chain (i.e. indirect causal factors). The the proximal factors lie towards the end of the chain (i.e. cause directly or almost directly the effect).

Causality Tags:
<A> for action, <C> for cause, <CO> for condition and <E> for effect.
Cause (C): The reason or origin that leads to an effect. Causes often involve disease conditions, risk factors, or underlying mechanisms.
Effect (E): The outcome or result of a cause. Effects usually represent clinical outcomes, complications, or results of a specific cause.
Condition (CO): The circumstance or prerequisite required for an action or effect to occur. Conditions may include patient characteristics, clinical scenarios, or specific diagnostic criteria.
Action (A): The recommended or described response or activity to address a cause or condition. Actions typically involve clinical interventions, diagnostic procedures, or treatment recommendations.


`NODE1`:
id: Number_of_Lymph_Nodes_5
label: Number of Lymph Nodes
description: This node represents the presence or absence of a specific number of lymph nodes, which can be clinically significant in assessing the spread of cancer or other diseases.
type: Patient Situation
observability: Unobserved
states: [{'state_name': 'present', 'state_description': ""The state 'present' indicates that the specific number of lymph nodes is detected or considered in the clinical assessment.""}, {'state_name': 'absent', 'state_description': ""The state 'absent' indicates that the specific number of lymph nodes is not detected or considered in the clinical assessment.""}]

`NODE2`:
id: Pathologie_12
label: Pathology Examination Result
description: This node represents the result of a specific pathology examination, which has been observed. It indicates whether a particular pathological finding or condition is present or absent.
type: Examination Result
observability: Observed
states: [{'state_name': 'present', 'state_description': 'The pathological finding or condition was observed in the examination.'}, {'state_name': 'absent', 'state_description': 'The pathological finding or condition was not observed in the examination.'}]

`EDGE1`:
{'edges_ids': ['Number_of_Lymph_Nodes_5', 'Pathologie_12'], 'edge': '(Number_of_Lymph_Nodes_5) causes (Pathologie_12)', 'explanation': ['The edge `(Number_of_Lymph_Nodes_5) causes (Pathologie_12)` is not valid as a direct causal relationship.', 'The number of lymph nodes is an indicator of disease spread but does not directly cause a pathology result.', 'The causal direction is positive if we consider that more affected lymph nodes might correlate with a positive pathology result, but this is not a direct causation.', 'The number of lymph nodes is neither a necessary nor a sufficient condition for a pathology result.', 'The causal distance is distal, as the number of lymph nodes is an indirect factor in determining pathology results.'], 'causal_direction': 'positive', 'causal_factor': {'necessary': False, 'sufficient': False}, 'causal_distance': 'Distal'}

`EDGE2`:
{'edges_ids': ['Pathologie_12', 'Number_of_Lymph_Nodes_5'], 'edge': '(Pathologie_12) causes (Number_of_Lymph_Nodes_5)', 'explanation': ['The edge suggests that the result of a pathology examination (`Pathologie_12`) directly causes a change in the number of lymph nodes (`Number_of_Lymph_Nodes_5`).', 'In clinical terms, while certain pathological findings might be associated with changes in lymph node status, the examination result itself does not directly cause such changes.', 'The number of lymph nodes is more directly influenced by the underlying disease process rather than the examination result.', 'Therefore, the edge is not valid as a direct causal relationship.'], 'causal_direction': 'Unknown', 'causal_factor': {'necessary': False, 'sufficient': False}, 'causal_distance': 'Unknown'}

`INFORMATION FROM KNOWLEDGE BASE`:
--------------------------------------------------
Page Number: 102

Section Name: Head and Neck Cancers - Principles of Surgery
====================
Entities:-
Surgical Procedures, Operative : Manual or operative procedures used in the treatment of disease, injuries, or deformities.
Lymphatic System : Part of the circulatory system and a vital part of the immune system, comprising a network of lymphatic vessels that carry a clear fluid called lymph.
Neoplasms : New abnormal growth of tissue in animals or plants; a tumor.
Neck Dissection : A surgical procedure for control of neck lymph node metastasis from squamous cell carcinoma of the head and neck.
Neoplasm Staging : Methods which attempt to express in replicable terms the extent of the neoplasm in the patient.
Metastasis : The spread of a cancer or other disease from one organ or part of the body to another not directly connected with it.
Surgical Procedure : A procedure involving an incision with instruments; performed to repair damage or arrest disease in a living body.
Lymphatic Structure : Anatomical structure that is part of the lymphatic system.
Tumor : An abnormal mass of tissue that results when cells divide more than they should or do not die when they should.
Staging : The process of determining the size and spread of cancer within the body.
Surgery : Medical specialty that uses operative manual and instrumental techniques on a patient to investigate or treat a pathological condition such as disease or injury.
Cancer Staging : The process of determining the extent to which a cancer has developed by growing and spreading.

Relationships:-
1. Entity1: ""surgical management"", Entity2: ""regional lymphatics"", Relationship: ""dictated by tumor staging""
2. Entity1: ""neck dissections"", Entity2: ""primary tumor"", Relationship: ""part of treatment""
3. Entity1: ""surgery"", Entity2: ""ipsilateral side of the neck"", Relationship: ""risk for metastases""

Causalities:-
<C> The extent of the tumor at initial tumor staging </C> <E> dictates the surgical management of regional lymphatics </E>. These guidelines apply to the performance of neck dissections as part of treatment of the primary tumor. <CO> Patients undergoing surgery for resection of the primary tumor </CO> <A> will undergo dissection of the ipsilateral side of the neck that is at greatest risk for metastases </A>.

Section Name: Neck Management
====================
Entities:-
Tongue : A muscular organ in the mouth that is involved in tasting, swallowing, and speech.
Palate : The roof of the mouth, separating the oral and nasal cavities.
Larynx : An organ in the top of the neck involved in breathing, producing sound, and protecting the trachea.
Hypopharynx : The bottom part of the pharynx, which is the cavity behind the nose and mouth.
Nasopharynx : The upper part of the pharynx, connecting with the nasal cavity above the soft palate.
Neck Dissection : A surgical procedure for control of neck lymph node metastasis from squamous cell carcinoma of the head and neck.
Metastasis : The spread of a cancer or other disease from one organ or part of the body to another not directly connected with it.
Squamous Cell Carcinoma : A type of cancer that begins in the squamous cells, which are thin, flat cells that look like fish scales.
Biopsy : The removal of cells or tissues for examination under a microscope.

Relationships:-
1. Entity1: ""Tumor sites"", Entity2: ""Bilateral lymphatic drainage"", Relationship: ""associated with""
2. Entity1: ""Elective neck dissection"", Entity2: ""Risk of occult metastasis"", Relationship: ""based on""
3. Entity1: ""SLN biopsy"", Entity2: ""Elective neck dissection"", Relationship: ""guides decision-making for""

Causalities:-
- **<C> Tumor sites that frequently have bilateral lymphatic drainage </C>** (e.g., base of tongue, palate, supraglottic larynx, hypopharynx, nasopharynx, deep pre-epiglottic space involvement) <E> often should have both sides of the neck dissected </E> with the extent of dissection determined as suggested below. For those patients with tumors at or approaching the midline, <CO> both sides of the neck are at risk for metastases </CO>, and <A> bilateral neck dissections should be performed </A>.

- <CO> Patients with advanced lesions involving the anterior tongue, floor of the mouth, or alveolus that approximate or cross the midline </CO> <A> should undergo contralateral selective/modified neck dissection </A> as necessary to achieve adequate tumor resection.

- **<C> Elective neck dissection </C>** <A> should be based on risk of occult metastasis in the appropriate nodal basin </A>. For oral cavity squamous cell carcinoma, <C> SLN biopsy or the primary tumor depth of invasion </C> is currently <E> the best predictor of occult metastatic disease </E> and <A> should be used to guide decision-making </A>. <CO> For tumors with a depth greater than 3 mm </CO>, <A> elective dissection should be strongly considered if RT is not already planned </A>. Recent randomized trial evidence supports the effectiveness of elective neck dissection in patients with oral cavity cancers greater than 3 mm in depth of invasion.

  - <CO> For a depth less than 2 mm </CO>, <A> elective dissection is only indicated in highly selective situations </A>. <CO> For a depth of 2–4 mm </CO>, <A> clinical judgment (as to reliability of follow-up, clinical suspicion, and other factors) must be utilized to determine appropriateness of elective dissection </A>. Elective dissections are generally selective, preserving all major structures, unless operative findings dictate otherwise.

Section Name: Types of Neck Dissection
====================
Entities:-
Neck Dissection : A surgical procedure for control of neck lymph node metastasis from squamous cell carcinoma of the head and neck.
Larynx : An organ in the top of the neck involved in breathing, producing sound, and protecting the trachea.

Relationships:-
1. Entity1: ""N0"", Entity2: ""Selective neck dissection"", Relationship: ""associated with""
2. Entity1: ""N3"", Entity2: ""Comprehensive neck dissection"", Relationship: ""associated with""
3. Entity1: ""Level VI neck dissection"", Entity2: ""Larynx"", Relationship: ""performed for""
4. Entity1: ""Level VI neck dissection"", Entity2: ""Hypopharynx"", Relationship: ""performed for""

Causalities:-
- **The type of neck dissection (comprehensive or selective)** is defined according to <CO> preoperative clinical staging </CO>, is determined at the discretion of the surgeon, and is based on the initial preoperative staging as follows:
  - **N0:** <A> Selective neck dissection </A>
    - Oral cavity at least levels I–III
    - Oropharynx at least levels II–IV
    - Hypopharynx at least levels II–IV and level VI when appropriate
    - Larynx at least levels II–IV and level VI when appropriate
  - **N1–N2a–c:** <A> Selective or comprehensive neck dissection </A> (Discussion)
  - **N3:** <A> Comprehensive neck dissection </A>

- <C> Level VI neck dissections are performed for certain primary sites (such as the larynx and hypopharynx) </C> <E> as required to resect the primary tumor and any clinically evident neck nodes </E>. <CO> Elective dissection depends on primary tumor extent and site </CO>. <CO> For advanced glottic and hypopharyngeal cancers treated with primary surgery </CO>, <A> a level VI dissection (including pretracheal lymph nodes, the Delphian lymph node, and unilateral or bilateral paratracheal lymph nodes) and hemithyroidectomy to total thyroidectomy are appropriate </A>.

- <CO> For primary subglottic tumors or glottic cancers with significant subglottic extension </CO>, <A> a level VI dissection with unilateral or total thyroidectomy is considered appropriate </A> based on the extent of the primary tumor. <CO> For example, a T4a glottic tumor with extension through the cricothyroid membrane and subglottic extension </CO> <A> should include thyroidectomy and pretracheal and bilateral paratracheal lymph node dissection </A>. <A> Parathyroid glands should be preserved in situ or auto transplanted as indicated </A>.
--------------------------------------------------
Page Number: 129

Section Name: TNM Staging System for the Larynx - Regional Lymph Nodes (N)
====================
Entities:-
Lymph Nodes : Small, bean-shaped structures that are part of the body's immune system. They filter substances that travel through the lymphatic fluid, and they contain lymphocytes (white blood cells) that help the body fight infection and disease.
Lymph Node Structure : A structure that is part of the lymphatic system, involved in the filtration of lymph and the production of lymphocytes.
Lymph Node : An organ of the lymphatic system and the adaptive immune system that is widely present throughout the body.

Relationships:-
1. Entity1: ""NCCN Guidelines"", Entity2: ""Regional Lymph Nodes"", Relationship: ""provides classification for""
2. Entity1: ""AJCC TNM Staging System"", Entity2: ""Regional Lymph Nodes"", Relationship: ""provides classification for""
3. Entity1: ""Clinical N"", Entity2: ""Regional Lymph Nodes"", Relationship: ""is a classification of""

Causalities:-
The <C> classification of the Regional Lymph Nodes (N) for head and neck cancers </C> is crucial for <E> determining the presence and extent of lymph node metastases </E>, which are critical in <E> establishing the severity and appropriate treatment strategies </E>. <A> Clinicians use this structured classification for accurate staging and subsequent treatment planning in patients diagnosed with head and neck cancers </A>.

Section Name: NCCN Guidelines Version 4.2024
====================
Entities:-
Head And Neck Neoplasms : Cancers that occur in the head or neck region, including the nasal cavity, sinuses, lips, mouth, salivary glands, throat, or larynx.
Malignant Neoplasm Of Head And Neck : A malignant tumor located in the head and neck region.
National Comprehensive Cancer Network : An alliance of cancer centers in the United States, dedicated to improving the quality, effectiveness, and efficiency of cancer care.

Relationships:-
1. Entity1: ""NCCN Guidelines"", Entity2: ""Head and Neck Cancers"", Relationship: ""guidelines for""
2. Entity1: ""NCCN Guidelines"", Entity2: ""National Comprehensive Cancer Network"", Relationship: ""published by""

Causalities:-
The provided text does not contain any clinical causes, effects, conditions, or actions to extract.
--------------------------------------------------
Page Number: 130

Section Name: Pathological N (pN)
====================
Entities:-
Lymph Nodes : Small, bean-shaped structures that are part of the body's lymphatic system. They filter lymph fluid and store white blood cells that help fight infection.
Neoplasm Metastasis : The transfer of a neoplasm from one organ or part of the body to another remote from the primary site.
Tnm Staging : A system used to describe the size and spread of cancer in a standardized way. T refers to the size of the tumor, N to the involvement of lymph nodes, and M to metastasis.
Lymph Node Structure : A structure that is part of the lymphatic system, involved in the immune response.
Metastasis : The spread of a cancer or other disease from one organ or part to another not directly connected with it.
Tnm Staging System : A cancer staging notation system that describes the extent of cancer in a patient's body.
Lymph Node : An organ of the lymphatic system and the adaptive immune system.

Relationships:-
1. Entity1: ""Lymph Nodes"", Entity2: ""Neoplasm Metastasis"", Relationship: ""involved in""
2. Entity1: ""TNM Staging"", Entity2: ""Lymph Nodes"", Relationship: ""includes""
3. Entity1: ""TNM Staging"", Entity2: ""Neoplasm Metastasis"", Relationship: ""describes""

Causalities:-
<CO> NX: Regional lymph nodes cannot be assessed </CO>
<CO> N0: No regional lymph node metastasis </CO>
<CO> N1: Metastasis in a single ipsilateral lymph node, 3 cm or smaller in greatest dimension ENE(–) </CO>
<CO> N2: Metastasis in a single ipsilateral lymph node, 3 cm or smaller in greatest dimension and ENE(+); or larger than 3 cm but not larger than 6 cm in greatest dimension and ENE(−); or metastases in multiple ipsilateral lymph nodes, none larger than 6 cm in greatest dimension and ENE(−); or in bilateral or contralateral lymph node(s), none larger than 6 cm in greatest dimension and ENE(−) </CO>
<CO> N2a: Metastasis in a single ipsilateral node, 3 cm or smaller in greatest dimension and ENE(+); or metastasis in a single ipsilateral node, larger than 3 cm but not larger than 6 cm in greatest dimension and ENE(−) </CO>
<CO> N2b: Metastases in multiple ipsilateral nodes, none larger than 6 cm in greatest dimension and ENE(−) </CO>
<CO> N2c: Metastases in bilateral or contralateral lymph node(s), none larger than 6 cm in greatest dimension and ENE(−) </CO>
<CO> N3: Metastasis in a lymph node, larger than 6 cm in greatest dimension and ENE(−); or metastasis in a single ipsilateral node, larger than 3 cm in greatest dimension and ENE(+); or multiple ipsilateral, contralateral, or bilateral lymph nodes and any with ENE(+); or a single contralateral node of any size and ENE(+) </CO>
<CO> N3a: Metastasis in a lymph node, larger than 6 cm in greatest dimension and ENE(−) </CO>
<CO> N3b: Metastasis in a single ipsilateral node, larger than 3 cm in greatest dimension and ENE(+); or multiple ipsilateral, contralateral, or bilateral lymph nodes any with ENE(+); or a single contralateral node of any size and ENE(+) </CO>
<CO> Note: A designation of “U” or “L” may be used for any N category to indicate metastasis above the lower border of the cricoid (U) or below the lower border of the cricoid (L). Similarly, clinical and pathological ENE should be recorded as ENE(−) or ENE(+). </CO>

Section Name: Distant Metastasis (M)
====================
Entities:-
Neoplasm Metastasis : The transfer of a neoplasm from one organ or part of the body to another remote from the primary site.
Metastasis : The spread of a cancer or other disease from one organ or part to another not directly connected with it.

Relationships:-
1. Entity1: ""M0"", Entity2: ""Distant Metastasis"", Relationship: ""is a category of""
2. Entity1: ""M1"", Entity2: ""Distant Metastasis"", Relationship: ""is a category of""

Causalities:-
### Distant Metastasis (M)

- **M0**: No distant metastasis
- **M1**: Distant metastasis

Section Name: Histologic Grade (G)
====================
Entities:-
Neoplasm Grading : A system of classifying cancer cells in terms of how abnormal they look under a microscope and how quickly the tumor is likely to grow and spread.
Histologic Grade : A measure of how much tumor cells differ from healthy cells, used to assess the aggressiveness of cancer.

Relationships:-
1. Entity1: ""GX"", Entity2: ""Grade cannot be assessed"", Relationship: ""is described as""
2. Entity1: ""G1"", Entity2: ""Well differentiated"", Relationship: ""is described as""
3. Entity1: ""G2"", Entity2: ""Moderately differentiated"", Relationship: ""is described as""
4. Entity1: ""G3"", Entity2: ""Poorly differentiated"", Relationship: ""is described as""

Causalities:-
<CO>GX</CO>: <E>Grade cannot be assessed</E>
<CO>G1</CO>: <E>Well differentiated</E>
<CO>G2</CO>: <E>Moderately differentiated</E>
<CO>G3</CO>: <E>Poorly differentiated</E>

Section Name: Prognostic Stage Groups
====================
Entities:-
Neoplasm Staging : Methods and systems of classifying neoplasms according to extent of disease.
Tumor Staging : A system for describing the size and spread of cancer within the body.
Tnm Staging System : A cancer staging notation system that describes the extent of cancer in a patient's body.

Relationships:-
1. Entity1: ""Stage 0"", Entity2: ""Tis N0 M0"", Relationship: ""defined by""
2. Entity1: ""Stage I"", Entity2: ""T1 N0 M0"", Relationship: ""defined by""
3. Entity1: ""Stage II"", Entity2: ""T2 N0 M0"", Relationship: ""defined by""
4. Entity1: ""Stage III"", Entity2: ""T3 N0 M0, T1 N1 M0, T2 N1 M0, T3 N1 M0"", Relationship: ""defined by""
5. Entity1: ""Stage IVA"", Entity2: ""T1 N2 M0, T2 N2 M0, T3 N2 M0, T4a N0,N1,N2 M0"", Relationship: ""defined by""
6. Entity1: ""Stage IVB"", Entity2: ""Any T N3 M0, T4b Any N M0"", Relationship: ""defined by""
7. Entity1: ""Stage IVC"", Entity2: ""Any T Any N M1"", Relationship: ""defined by""
--------------------------------------------------
Page Number: 154

Section Name: NCCN Guidelines Version 4.2024
====================
Entities:-
Nccn Guidelines : The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) are a comprehensive set of guidelines detailing the sequential management decisions and interventions that apply to 97% of cancers affecting patients in the United States.

Relationships:-

Causalities:-
# NCCN Guidelines Version 4.2024

Section Name: Head and Neck Cancers
====================
Entities:-
Head And Neck Neoplasms : Tumors or cancer of the head and neck region, including the nasal cavity, sinuses, lips, mouth, salivary glands, throat, or larynx.
Radiation Therapy : The medical use of ionizing radiation, generally as part of cancer treatment to control or kill malignant cells.
Quad Shot Regimen : A palliative radiation therapy regimen consisting of 44.4 Gy delivered in 12 fractions over three cycles, used for patients with limited life expectancy.

Relationships:-
1. Entity1: ""Head and Neck Neoplasms"", Entity2: ""70 Gy"", Relationship: ""treatment dosage""
2. Entity1: ""QUAD SHOT regimen"", Entity2: ""Palliative Treatment"", Relationship: ""purpose""

Causalities:-
The College of Radiology describes basic technical specifications [here](http://www.acr.org/Quality-Safety). Furthermore, major consensus contouring guidelines for the treatment of head and neck (H&N) cancers are available for reference, especially for patients who are treated without surgery. [143,144]

When radiation is given with definitive intent, <A> the dosages prescribed for gross disease are fairly standard, usually in the range of 70 Gy (at approximately 2 Gy/fraction/day) </A> for the following sites: <CO> lip, oral cavity, nasopharynx, oropharynx, hypopharynx, glottic larynx, supraglottic larynx, occult primary, salivary gland tumors, and MM </CO>. A second dose (often approximately 60 Gy, but varies) may be used to cover volumes considered at the highest risk for microscopic spread, while a lower dose (often approximately 50 Gy, but varies) is used for volumes treated electively with low risk for microscopic spread.

Although several palliative RT regimens are provided, no single regimen is preferred [145,146]; specific regimens vary widely among NCCN Member Institutions. <A> Any palliative RT regimen that might cause severe toxicities should be avoided </A>. <A> More hypofractionated regimens may be useful </A> for <CO> patients with limited life expectancy, such as a few months </CO>. For example, <A> a common version of the QUAD SHOT regimen consists of a dose of 44.4 Gy, delivered in 12 fractions over three cycles, with each cycle separated by 2 to 3 weeks </A>. [147]

Section Name: Radiation Doses
====================
Entities:-
Radiation Dosage : The amount of radiation absorbed by an object or person.
Neoplasms : New abnormal growth of tissue that can be benign or malignant.
Lymph Nodes : Small, bean-shaped structures that are part of the body's immune system.
Radiotherapy : The treatment of disease, especially cancer, using X-rays or similar forms of radiation.
Chemotherapy : The use of chemical substances, especially the treatment of cancer by cytotoxic and other drugs.
Radiation Therapy : The medical use of ionizing radiation, generally as part of cancer treatment to control or kill malignant cells.
Lymph Node Structure : A structure that is part of the lymphatic system, involved in the immune response.
Neoplasm : An abnormal mass of tissue as a result of neoplasia.
Lymph Node : An organ of the lymphatic system and the adaptive immune system.
Tumor : A mass of tissue that's formed by an accumulation of abnormal cells.

Relationships:-
1. Entity1: ""Radiation Dosage"", Entity2: ""Neoplasms"", Relationship: ""depends on""
2. Entity1: ""Radiation Dosage"", Entity2: ""Organs at risk"", Relationship: ""may need to be decreased if close to""
3. Entity1: ""Radiotherapy"", Entity2: ""IMRT"", Relationship: ""uses""
4. Entity1: ""Radiotherapy"", Entity2: ""Chemotherapy"", Relationship: ""can be used with""

Causalities:-
<C> Selection of an exact radiation dose prescription and schedule of delivery </C> <E> depends on the primary tumor and neck node size, whether altered fractionation is used, and clinical circumstances, including whether concurrent systemic therapy will be used </E>. <CO> if it is prescribed very close to adjacent organs at risk </CO> <A> The dose may need to be decreased </A>. <CO> Anatomical changes (e.g., rapidly shrinking tumors, changes in air cavities, significant weight loss) </CO> <A> may necessitate repeat imaging and treatment replanning </A>. <CO> when the tumor is abutting brain or optic structures </CO> <A> hyperfractionation has been used </A>. <CO> if prescribed doses exceed 72 Gy using conventional fractionation </CO> <E> this may lead to unacceptable rates of normal tissue injury </E>. <A> Care must be taken </A>.
--------------------------------------------------
Page Number: 145

Section Name: Head and Neck Cancers - Management Approaches
====================
Entities:-
Radiotherapy : The use of radiation, usually X-rays or gamma rays, to treat disease, especially cancer.
Surgical Procedures, Operative : Operations carried out for the correction of deformities and defects, repair of injuries, and diagnosis and cure of certain diseases.
Carcinoma, Oropharyngeal : A malignant neoplasm involving the oropharynx.
Nasopharyngeal Carcinoma : A type of cancer that occurs in the nasopharynx, located behind the nose and above the back of the throat.
Clinical Trials As Topic : Works about research studies that evaluate the safety and effectiveness of medical treatments.
Human Papillomavirus Related Oropharyngeal Cancer : A type of oropharyngeal cancer associated with human papillomavirus infection.
Head And Neck Cancer : A group of biologically similar cancers that start in the head and neck region.
Radiation Therapy : The medical use of ionizing radiation, generally as part of cancer treatment to control or kill malignant cells.
Surgery : A medical specialty that uses operative manual and instrumental techniques on a patient to investigate or treat a pathological condition such as disease or injury.

Relationships:-
1. Entity1: ""Surgery"", Entity2: ""Radiotherapy"", Relationship: ""treatment modality""
2. Entity1: ""HPV-associated oropharyngeal cancer"", Entity2: ""Radiotherapy"", Relationship: ""treatment""
3. Entity1: ""Nasopharyngeal carcinoma"", Entity2: ""Radiotherapy"", Relationship: ""treatment""
4. Entity1: ""Clinical trials"", Entity2: ""Treatment option"", Relationship: ""recommended""

Causalities:-
<C> The specific site of disease, histology, stage, and baseline comorbid conditions </C> guide <A> treatment decisions </A> (e.g., the appropriate surgical procedures, radiotherapy treatment parameters [target volumes, total dose, and fractionation regimen], indications for systemic therapy, and patient-specific considerations). <A> Single-modality treatment with surgery or RT </A> is generally recommended for <CO> the approximately 30% to 40% of patients who present with early-stage disease (stage I or II) HPV-unrelated cancers </CO>. <E> Surgery and RT result in similar survival for many H&N cancers </E>, but <A> surgery is usually preferred for oral cavity and paranasal sinus cancers </A>, while <A> RT with or without chemotherapy is nearly always preferred for all stages of nasopharyngeal carcinoma (NPC) and more advanced stages of HPV-associated oropharyngeal cancer </A>. <C> The choice of surgery or RT as the primary treatment modality </C> is often based on <CO> local institutional expertise and/or perceived relative morbidity of these treatment options </CO>. With <C> the evolution of conformal techniques of RT and less invasive surgery, as well as improving supportive care for patients receiving systemic therapy </C>, <E> morbidity is also a moving target </E>. <A> Combined modality therapy </A> is generally recommended for <CO> the approximately 60% of patients with locally or regionally advanced disease at diagnosis </CO>. <A> Participation in clinical trials </A> is a preferred or recommended treatment option in many situations. In formulating these NCCN Guidelines, <C> panel members have tried to make them evidence-based while providing a statement of consensus as to the acceptable range of treatment options </C>. In numerous population-based studies, <C> patients treated at high-volume centers </C> have shown <E> better outcomes </E>.

Section Name: Head and Neck Cancers - Prognostic Factors
====================
Entities:-
P16 : p16 is a cyclin-dependent kinase inhibitor that plays a role in regulating the cell cycle.
Hpv : Human papillomavirus (HPV) is a virus that can cause cervical and other types of cancer.
Prognosis : Prognosis refers to the likely course and outcome of a disease.
Oropharyngeal Neoplasms : Cancers that occur in the oropharynx, the part of the throat just behind the mouth.
Smoking : The inhalation of the smoke of burning tobacco encased in cigarettes, pipes, and cigars.
Neoplasm Staging : Methods used for staging neoplasms, which is the process of determining the extent of cancer in the body.
Lymph Nodes : Small, bean-shaped structures that are part of the body's immune system.
Sinonasal Neoplasms : Tumors or cancer of the nasal cavity and paranasal sinuses.
Survival Rate : The percentage of people who survive a disease such as cancer for a specific amount of time.

Relationships:-
1. Entity1: ""p16 positivity"", Entity2: ""HPV tumor status"", Relationship: ""informs prognosis""
2. Entity1: ""Smoking"", Entity2: ""Oropharyngeal cancer"", Relationship: ""associated with decreased OS and PFS""
3. Entity1: ""HPV 16/18"", Entity2: ""Sinonasal cancer"", Relationship: ""associated with better OS""
4. Entity1: ""T4 or N3 disease"", Entity2: ""Matted lymph nodes"", Relationship: ""associated with worse prognosis""

Causalities:-
<C> Distinguishing patients with p16 positivity by HPV tumor status </C> <E> informs prognosis </E>. A multicenter individual patient data analysis including 13 cohorts of patients from Canada and Europe (N = 7654) showed that <C> patients with discordant p16 expression and HPV status </C> <E> had worse prognosis </E> compared to <CO> patients with concordant positive p16 expression and HPV status </CO>.

- **5-year OS for p16-negative/HPV-positive**: 53.2% (95% CI, 46.6%–60.8%)
- **5-year OS for p16-positive/HPV-negative**: 54.7% (95% CI, 49.2%–60.9%)
- **5-year OS for concordant positive p16/HPV**: 81.1% (95% CI, 79.5%–82.7%)
- **5-year OS for concordant negative p16/HPV**: 40.4% (95% CI, 38.6%–42.4%)

A retrospective cohort analysis (N = 1070) also showed <E> better OS in patients with HPV 16/18 positive sinonasal cancer </E>, compared to <CO> patients with HPV negative disease </CO> (adjusted hazard ratio [HR], 0.63; 95% CI, 0.48–0.82). The impact of <C> smoking and cancer stage </C> on <E> survival of patients with HPV-positive SCCHN </E> has been investigated in numerous studies. For example, analyses of patients with oropharyngeal cancer who were enrolled in RTOG 9003 or 0129 (n = 165) showed that <C> smoking </C> was <E> associated with decreased OS and PFS </E>, regardless of p16 status. An analysis of data compiled from four cooperative group trials estimated that <CO> those who never smoked </CO> had a <E> 51% (HR, 0.40; 95% CI, 0.33–0.75) reduction in risk of cancer progression </E> when compared to <CO> those who formerly or currently smoked and had HPV-positive SCCHN </CO>. A retrospective analysis from a clinical trial (RTOG 0129) showed <E> no difference in the rate of distant metastasis </E> in <CO> patients with p16-positive versus p16-negative disease </CO>. Additional analyses have suggested that <C> individuals with T4 or N3 disease or radiographically detectable matted lymph nodes </C> may have a <E> worse prognosis </E>, and therefore <A> should be excluded from deintensification trials </A>. These studies on prognostic and predictive factors in HPV-positive oropharyngeal cancers form the basis for <A> RT deintensification studies </A>. Moreover, the <C> striking difference in prognosis for HPV-positive versus HPV-negative SCCHN </C> led to the <E> creation of new AJCC staging criteria in 2018 </E> (see Cancer of the Oropharynx in the NCCN Guidelines for Head and Neck Cancers; available at [www.NCCN.org](http://www.NCCN.org)).


Among these two options which one is the most likely true:

(A) `Number_of_Lymph_Nodes_5` increases risk `Pathologie_12`
(B) `Pathologie_12` `increases risk `Number_of_Lymph_Nodes_5`

The answer is: ...

1. State the evidences in detail of the validity of option (A) or (B) by cross referencing
NCCN Clinical Practitioner’s Guidelines for Head and Neck Cancer.
2. If the evidences are obtained from `INFORMATION FROM KNOWLEDGE BASE`,
mention their corresponding Page Numbers, Section Name, entities, relationships and causalities.

DESIRED OUTPUT FORMAT:
<thinking>
...
</thinking>
<answer>
{
   ""thinking"": [""..."", ...],
   ""evidences"": [""..."", ...],
   ""answer"": ...
}
</answer>

Before providing the answer in <answer> tags, think step by step in detail in <thinking> tags and analyze every part.
Output inside <answer> tag in JSON format. Only output valid JSON.
DO NOT HALLUCINATE. DO NOT MAKE UP FACTUAL INFORMATION.
","1. The edge '(Number_of_Lymph_Nodes_5) causes (Pathologie_12)' is not valid as a direct causal relationship. The number of lymph nodes is an indicator of disease spread but does not directly cause a pathology result.
2. The causal direction is positive if we consider that more affected lymph nodes might correlate with a positive pathology result, but this is not a direct causation.
3. The number of lymph nodes is neither a necessary nor a sufficient condition for a pathology result.
4. The causal distance is distal, as the number of lymph nodes is an indirect factor in determining pathology results.
5. The edge '(Pathologie_12) causes (Number_of_Lymph_Nodes_5)' suggests that the result of a pathology examination directly causes a change in the number of lymph nodes.
6. In clinical terms, while certain pathological findings might be associated with changes in lymph node status, the examination result itself does not directly cause such changes.
7. The number of lymph nodes is more directly influenced by the underlying disease process rather than the examination result.
8. Therefore, the edge is not valid as a direct causal relationship.
","1. Page 102, Section: Head and Neck Cancers - Principles of Surgery, Entity: Lymphatic System, Relationship: Metastasis is the spread of a cancer or other disease from one organ or part of the body to another not directly connected with it.
2. Page 129, Section: TNM Staging System for the Larynx - Regional Lymph Nodes (N), Entity: Lymph Nodes, Relationship: Classification of the Regional Lymph Nodes (N) for head and neck cancers is crucial for determining the presence and extent of lymph node metastases.
3. Page 130, Section: Pathological N (pN), Entity: Lymph Nodes, Relationship: Lymph Nodes are involved in Neoplasm Metastasis.
",A,"{'A': 98.9, 'B': 1.1}",yes,A,"1. The AI assistant's reasoning begins by analyzing the causal relationship between 'Number_of_Lymph_Nodes_5' and 'Pathologie_12'. It states that the edge '(Number_of_Lymph_Nodes_5) causes (Pathologie_12)' is not valid as a direct causal relationship. This is consistent with the explanation provided, which indicates that the number of lymph nodes is an indicator of disease spread but does not directly cause a pathology result.
2. The assistant further explains that while there might be a positive correlation between more affected lymph nodes and a positive pathology result, this does not equate to direct causation. This aligns with the causal direction being labeled as 'positive' but not direct, and the causal factor being neither necessary nor sufficient.
3. The assistant also mentions that the causal distance is distal, meaning the number of lymph nodes is an indirect factor in determining pathology results. This is consistent with the explanation that the number of lymph nodes is not a direct cause of pathology results.
4. For the edge '(Pathologie_12) causes (Number_of_Lymph_Nodes_5)', the assistant states that while certain pathological findings might be associated with changes in lymph node status, the examination result itself does not directly cause such changes. This is consistent with the explanation that the number of lymph nodes is more directly influenced by the underlying disease process rather than the examination result.
5. The assistant's conclusion that the edge is not valid as a direct causal relationship is consistent with the reasoning provided, which emphasizes the indirect nature of the relationship between the nodes.
"
8,gpt-4o,"Size_of_Lymph_Nodes_6,N_State_1","""{'NODE1': {'id': 'Size_of_Lymph_Nodes_6', 'label': 'Size of Lymph Nodes', 'description': 'This node represents the clinical assessment of the size of lymph nodes in a patient. The size of lymph nodes can be an important indicator in diagnosing conditions such as infections, immune responses, or cancer metastasis. Enlarged lymph nodes may suggest the presence of disease, while normal-sized lymph nodes are typically not indicative of pathology.', 'type': 'Patient Situation', 'observability': 'Unobserved', 'states': [{'state_name': 'present', 'state_description': 'The lymph nodes are enlarged or have a significant size, which may indicate the presence of disease such as infection, inflammation, or metastasis.'}, {'state_name': 'absent', 'state_description': 'The lymph nodes are not enlarged and are of normal size, suggesting no significant pathology or disease.'}]}, 'NODE2': {'id': 'N_State_1', 'label': 'Nearby Lymph Nodes Cancer State', 'description': 'This node represents the clinical situation regarding the presence or absence of cancer in nearby lymph nodes. It is a critical factor in cancer staging and prognosis, as the involvement of lymph nodes can indicate the spread of cancer and affect treatment decisions.', 'type': 'Decision Node', 'observability': 'Needs to be Predicted', 'states': [{'state_name': 'present', 'state_description': 'Cancer is present in the nearby lymph nodes, indicating potential metastasis and a more advanced stage of cancer.'}, {'state_name': 'absent', 'state_description': 'Cancer is absent in the nearby lymph nodes, suggesting that the cancer has not spread to these nodes and may be in an earlier stage.'}]}, 'EDGE1': {'edges_ids': ['Size_of_Lymph_Nodes_6', 'N_State_1'], 'edge': '(Size_of_Lymph_Nodes_6) causes (N_State_1)', 'explanation': ['The edge represents the relationship where the size of lymph nodes (Size_of_Lymph_Nodes_6) influences the cancer state of nearby lymph nodes (N_State_1).', 'Enlarged lymph nodes can indicate the presence of cancer, suggesting a positive causal direction.', 'However, enlarged lymph nodes are not a necessary condition for cancer presence, as cancer can exist without enlargement.', 'Enlarged lymph nodes are also not a sufficient condition for cancer presence, as they can be enlarged due to other conditions like infection.', 'The causal relationship is proximal because the size of lymph nodes is directly related to their cancer state in the context of metastasis.'], 'causal_direction': 'positive', 'causal_factor': {'necessary': False, 'sufficient': False}, 'causal_distance': 'Proximal'}, 'EDGE2': {'edges_ids': ['N_State_1', 'Size_of_Lymph_Nodes_6'], 'edge': '(N_State_1) causes (Size_of_Lymph_Nodes_6)', 'explanation': ['The edge represents the causal relationship where the presence of cancer in nearby lymph nodes (N_State_1) leads to an increase in the size of those lymph nodes (Size_of_Lymph_Nodes_6).', 'This is a valid causal relationship because cancer in lymph nodes typically causes them to enlarge.', 'The causal direction is positive because the presence of cancer (N_State_1) increases the size of lymph nodes (Size_of_Lymph_Nodes_6).', 'The presence of cancer in lymph nodes is a sufficient condition for enlargement, but not necessary, as other factors can also cause enlargement.', 'The causal distance is proximal because the presence of cancer directly affects the size of the lymph nodes.'], 'causal_direction': 'positive', 'causal_factor': {'necessary': False, 'sufficient': True}, 'causal_distance': 'Proximal'}, 'ENTITIES_MATCHING_PAGES_INFO': {'102': {'matching_entities': [{'LYMPHATIC SYSTEM': 0.95855314}, {'LYMPHATIC STRUCTURE': 0.9469132}, {'METASTASIS': 0.9401313}, {'CANCER STAGING': 0.93824553}, {'TUMOR': 0.9323624}, {'STAGING': 0.9208425}], 'count': 6}, '55': {'matching_entities': [{'MALIGNANT NEOPLASTIC DISEASE': 0.97725874}, {'METASTASIS': 0.9401313}, {'CANCER': 0.9363244}, {'METASTATIC NEOPLASM': 0.9314138}, {'NEOPLASM METASTASIS': 0.9250777}, {'LARYNGEAL NEOPLASMS': 0.9236878}], 'count': 6}, '51': {'matching_entities': [{'MALIGNANT NEOPLASM': 0.9774111}, {'CANCER STAGING': 0.93824553}, {'CANCER': 0.9363244}, {'LARYNGEAL NEOPLASMS': 0.9236878}, {'NEOPLASM INVASIVENESS': 0.92347366}], 'count': 5}, '130': {'matching_entities': [{'LYMPH NODE STRUCTURE': 0.99134904}, {'LYMPH NODE': 0.98570025}, {'LYMPH NODES': 0.97445965}, {'METASTASIS': 0.9401313}, {'NEOPLASM METASTASIS': 0.9250777}], 'count': 5}, '47': {'matching_entities': [{'MALIGNANT NEOPLASM': 0.9774111}, {'LARYNGEAL CANCER': 0.95521915}, {'CANCER': 0.9363244}, {'LARYNGEAL NEOPLASMS': 0.9236878}], 'count': 4}}, 'GUIDELINE_PAGES_INFO': '--------------------------------------------------\\nPage Number: 102\\n\\nSection Name: Head and Neck Cancers - Principles of Surgery\\n====================\\nEntities:-\\nSurgical Procedures, Operative : Manual or operative procedures used in the treatment of disease, injuries, or deformities.\\nLymphatic System : Part of the circulatory system and a vital part of the immune system, comprising a network of lymphatic vessels that carry a clear fluid called lymph.\\nNeoplasms : New abnormal growth of tissue in animals or plants; a tumor.\\nNeck Dissection : A surgical procedure for control of neck lymph node metastasis from squamous cell carcinoma of the head and neck.\\nNeoplasm Staging : Methods which attempt to express in replicable terms the extent of the neoplasm in the patient.\\nMetastasis : The spread of a cancer or other disease from one organ or part of the body to another not directly connected with it.\\nSurgical Procedure : A procedure involving an incision with instruments; performed to repair damage or arrest disease in a living body.\\nLymphatic Structure : Anatomical structure that is part of the lymphatic system.\\nTumor : An abnormal mass of tissue that results when cells divide more than they should or do not die when they should.\\nStaging : The process of determining the size and spread of cancer within the body.\\nSurgery : Medical specialty that uses operative manual and instrumental techniques on a patient to investigate or treat a pathological condition such as disease or injury.\\nCancer Staging : The process of determining the extent to which a cancer has developed by growing and spreading.\\n\\nRelationships:-\\n1. Entity1: \""surgical management\"", Entity2: \""regional lymphatics\"", Relationship: \""dictated by tumor staging\""\\n2. Entity1: \""neck dissections\"", Entity2: \""primary tumor\"", Relationship: \""part of treatment\""\\n3. Entity1: \""surgery\"", Entity2: \""ipsilateral side of the neck\"", Relationship: \""risk for metastases\""\\n\\nCausalities:-\\n<C> The extent of the tumor at initial tumor staging </C> <E> dictates the surgical management of regional lymphatics </E>. These guidelines apply to the performance of neck dissections as part of treatment of the primary tumor. <CO> Patients undergoing surgery for resection of the primary tumor </CO> <A> will undergo dissection of the ipsilateral side of the neck that is at greatest risk for metastases </A>.\\n\\nSection Name: Neck Management\\n====================\\nEntities:-\\nTongue : A muscular organ in the mouth that is involved in tasting, swallowing, and speech.\\nPalate : The roof of the mouth, separating the oral and nasal cavities.\\nLarynx : An organ in the top of the neck involved in breathing, producing sound, and protecting the trachea.\\nHypopharynx : The bottom part of the pharynx, which is the cavity behind the nose and mouth.\\nNasopharynx : The upper part of the pharynx, connecting with the nasal cavity above the soft palate.\\nNeck Dissection : A surgical procedure for control of neck lymph node metastasis from squamous cell carcinoma of the head and neck.\\nMetastasis : The spread of a cancer or other disease from one organ or part of the body to another not directly connected with it.\\nSquamous Cell Carcinoma : A type of cancer that begins in the squamous cells, which are thin, flat cells that look like fish scales.\\nBiopsy : The removal of cells or tissues for examination under a microscope.\\n\\nRelationships:-\\n1. Entity1: \""Tumor sites\"", Entity2: \""Bilateral lymphatic drainage\"", Relationship: \""associated with\""\\n2. Entity1: \""Elective neck dissection\"", Entity2: \""Risk of occult metastasis\"", Relationship: \""based on\""\\n3. Entity1: \""SLN biopsy\"", Entity2: \""Elective neck dissection\"", Relationship: \""guides decision-making for\""\\n\\nCausalities:-\\n- **<C> Tumor sites that frequently have bilateral lymphatic drainage </C>** (e.g., base of tongue, palate, supraglottic larynx, hypopharynx, nasopharynx, deep pre-epiglottic space involvement) <E> often should have both sides of the neck dissected </E> with the extent of dissection determined as suggested below. For those patients with tumors at or approaching the midline, <CO> both sides of the neck are at risk for metastases </CO>, and <A> bilateral neck dissections should be performed </A>.\\n\\n- <CO> Patients with advanced lesions involving the anterior tongue, floor of the mouth, or alveolus that approximate or cross the midline </CO> <A> should undergo contralateral selective/modified neck dissection </A> as necessary to achieve adequate tumor resection.\\n\\n- **<C> Elective neck dissection </C>** <A> should be based on risk of occult metastasis in the appropriate nodal basin </A>. For oral cavity squamous cell carcinoma, <C> SLN biopsy or the primary tumor depth of invasion </C> is currently <E> the best predictor of occult metastatic disease </E> and <A> should be used to guide decision-making </A>. <CO> For tumors with a depth greater than 3 mm </CO>, <A> elective dissection should be strongly considered if RT is not already planned </A>. Recent randomized trial evidence supports the effectiveness of elective neck dissection in patients with oral cavity cancers greater than 3 mm in depth of invasion.\\n\\n  - <CO> For a depth less than 2 mm </CO>, <A> elective dissection is only indicated in highly selective situations </A>. <CO> For a depth of 2\u20134 mm </CO>, <A> clinical judgment (as to reliability of follow-up, clinical suspicion, and other factors) must be utilized to determine appropriateness of elective dissection </A>. Elective dissections are generally selective, preserving all major structures, unless operative findings dictate otherwise.\\n\\nSection Name: Types of Neck Dissection\\n====================\\nEntities:-\\nNeck Dissection : A surgical procedure for control of neck lymph node metastasis from squamous cell carcinoma of the head and neck.\\nLarynx : An organ in the top of the neck involved in breathing, producing sound, and protecting the trachea.\\n\\nRelationships:-\\n1. Entity1: \""N0\"", Entity2: \""Selective neck dissection\"", Relationship: \""associated with\""\\n2. Entity1: \""N3\"", Entity2: \""Comprehensive neck dissection\"", Relationship: \""associated with\""\\n3. Entity1: \""Level VI neck dissection\"", Entity2: \""Larynx\"", Relationship: \""performed for\""\\n4. Entity1: \""Level VI neck dissection\"", Entity2: \""Hypopharynx\"", Relationship: \""performed for\""\\n\\nCausalities:-\\n- **The type of neck dissection (comprehensive or selective)** is defined according to <CO> preoperative clinical staging </CO>, is determined at the discretion of the surgeon, and is based on the initial preoperative staging as follows:\\n  - **N0:** <A> Selective neck dissection </A>\\n    - Oral cavity at least levels I\u2013III\\n    - Oropharynx at least levels II\u2013IV\\n    - Hypopharynx at least levels II\u2013IV and level VI when appropriate\\n    - Larynx at least levels II\u2013IV and level VI when appropriate\\n  - **N1\u2013N2a\u2013c:** <A> Selective or comprehensive neck dissection </A> (Discussion)\\n  - **N3:** <A> Comprehensive neck dissection </A>\\n\\n- <C> Level VI neck dissections are performed for certain primary sites (such as the larynx and hypopharynx) </C> <E> as required to resect the primary tumor and any clinically evident neck nodes </E>. <CO> Elective dissection depends on primary tumor extent and site </CO>. <CO> For advanced glottic and hypopharyngeal cancers treated with primary surgery </CO>, <A> a level VI dissection (including pretracheal lymph nodes, the Delphian lymph node, and unilateral or bilateral paratracheal lymph nodes) and hemithyroidectomy to total thyroidectomy are appropriate </A>.\\n\\n- <CO> For primary subglottic tumors or glottic cancers with significant subglottic extension </CO>, <A> a level VI dissection with unilateral or total thyroidectomy is considered appropriate </A> based on the extent of the primary tumor. <CO> For example, a T4a glottic tumor with extension through the cricothyroid membrane and subglottic extension </CO> <A> should include thyroidectomy and pretracheal and bilateral paratracheal lymph node dissection </A>. <A> Parathyroid glands should be preserved in situ or auto transplanted as indicated </A>.\\n--------------------------------------------------\\nPage Number: 55\\n\\nSection Name: General Information\\n====================\\nEntities:-\\nNational Comprehensive Cancer Network : An alliance of 32 cancer centers in the United States, dedicated to improving the quality, effectiveness, and efficiency of cancer care.\\nNccn Guidelines : Clinical practice guidelines in oncology developed by the National Comprehensive Cancer Network.\\n\\nRelationships:-\\n1. Entity1: \""NCCN Guidelines\"", Entity2: \""National Comprehensive Cancer Network\"", Relationship: \""produced by\""\\n\\nSection Name: Important Notes\\n====================\\nEntities:-\\nClinical Trials As Topic : Works about research studies that evaluate the effectiveness and safety of medical, surgical, or behavioral interventions.\\nClinical Trial : A type of research that studies new tests and treatments and evaluates their effects on human health outcomes.\\nNational Comprehensive Cancer Network : An alliance of 32 cancer centers in the United States, dedicated to improving the quality, effectiveness, and efficiency of cancer care.\\nNeoplasms : New abnormal growth of tissue that can be benign or malignant.\\nMalignant Neoplastic Disease : A disease resulting from the growth of malignant neoplasms.\\nCancer : A group of diseases involving abnormal cell growth with the potential to invade or spread to other parts of the body.\\n\\nRelationships:-\\n1. Entity1: \""Clinical Trials\"", Entity2: \""Cancer\"", Relationship: \""recommended for\""\\n2. Entity1: \""NCCN\"", Entity2: \""Clinical Trials\"", Relationship: \""encourages participation in\""\\n\\nCausalities:-\\n<C> NCCN believes that the best management of any patient with cancer is in a clinical trial </C>. <A> Participation in clinical trials is especially encouraged </A>.\\n\\nSection Name: Principles\\n====================\\nEntities:-\\nSurgical Procedures, Operative : Surgical procedures involve the use of operative manual and instrumental techniques on a patient to investigate or treat a pathological condition such as disease or injury.\\nRadiation Therapy : Therapy using ionizing radiation, generally as part of cancer treatment to control or kill malignant cells.\\nChemotherapy : A type of cancer treatment that uses one or more anti-cancer drugs as part of a standardized chemotherapy regimen.\\n\\nRelationships:-\\n1. Entity1: \""Principles of Surgery\"", Entity2: \""Principles of Radiation Therapy\"", Relationship: \""Both are principles of cancer treatment methods.\""\\n2. Entity1: \""Principles of Surgery\"", Entity2: \""Principles of Systemic Therapy for Non-Nasopharyngeal Cancers\"", Relationship: \""Both are principles of cancer treatment methods.\""\\n3. Entity1: \""Principles of Radiation Therapy\"", Entity2: \""Principles of Systemic Therapy for Non-Nasopharyngeal Cancers\"", Relationship: \""Both are principles of cancer treatment methods.\""\\n\\nCausalities:-\\n### Principles\\n\\n- **Principles of Surgery (SURG-A)**\\n- **Principles of Radiation Therapy (SUPRA-A)**\\n- **Principles of Systemic Therapy for Non-Nasopharyngeal Cancers (SYST-A)**\\n\\nSection Name: Adverse Pathologic Features\\n====================\\nEntities:-\\nExtranodal Extension : The spread of cancer cells beyond the lymph node capsule into the surrounding tissues.\\nPositive Surgical Margin : The presence of cancer cells at the edge of the tissue removed during surgery, indicating that some cancer may have been left behind.\\nPerineural Invasion : The presence of cancer cells surrounding or tracking along a nerve within the perineural space.\\nVascular Invasion : The invasion of cancer cells into blood vessels.\\nLymphatic Invasion : The invasion of cancer cells into lymphatic vessels.\\n\\nRelationships:-\\n1. Entity1: \""Extranodal extension\"", Entity2: \""Adverse Pathologic Features\"", Relationship: \""is a type of\""\\n2. Entity1: \""Positive margins\"", Entity2: \""Adverse Pathologic Features\"", Relationship: \""is a type of\""\\n3. Entity1: \""Close margins\"", Entity2: \""Adverse Pathologic Features\"", Relationship: \""is a type of\""\\n4. Entity1: \""pT3 or pT4 primary\"", Entity2: \""Adverse Pathologic Features\"", Relationship: \""is a type of\""\\n5. Entity1: \""pN2 or pN3 nodal disease\"", Entity2: \""Adverse Pathologic Features\"", Relationship: \""is a type of\""\\n6. Entity1: \""Perineural invasion\"", Entity2: \""Adverse Pathologic Features\"", Relationship: \""is a type of\""\\n7. Entity1: \""Vascular invasion\"", Entity2: \""Adverse Pathologic Features\"", Relationship: \""is a type of\""\\n8. Entity1: \""Lymphatic invasion\"", Entity2: \""Adverse Pathologic Features\"", Relationship: \""is a type of\""\\n\\nCausalities:-\\n<C> Extranodal extension </C>\\n<C> Positive margins </C>\\n<C> Close margins </C>\\n<C> pT3 or pT4 primary </C>\\n<C> pN2 or pN3 nodal disease </C>\\n<C> Perineural invasion </C>\\n<C> Vascular invasion </C>\\n<C> Lymphatic invasion </C>\\n\\nSection Name: Response Assessment\\n====================\\nEntities:-\\nChemotherapy, Induction : Initial chemotherapy treatment to shrink a tumor before the main treatment.\\nPrimary Site : The original location where a tumor or cancer begins.\\nComplete Remission : The disappearance of all signs of cancer in response to treatment.\\nPartial Remission : A decrease in the size of a tumor, or in the extent of cancer in the body, in response to treatment.\\nRadiotherapy : The use of high-energy radiation to kill cancer cells and shrink tumors.\\nSurgical Procedures, Operative : Surgical procedures involve the use of operative manual and instrumental techniques on a patient to investigate or treat a pathological condition such as disease or injury.\\n\\nRelationships:-\\n1. Entity1: \""induction chemotherapy\"", Entity2: \""Primary site\"", Relationship: \""treatment outcome\""\\n2. Entity1: \""Definitive RT\"", Entity2: \""Primary site\"", Relationship: \""treatment option\""\\n3. Entity1: \""RT\"", Entity2: \""Primary site\"", Relationship: \""treatment option\""\\n4. Entity1: \""Surgery\"", Entity2: \""unresectable nodal disease\"", Relationship: \""treatment option\""\\n\\nCausalities:-\\n<C> Response after induction chemotherapy </C>: <E> Primary site: CR </E> <E> Primary site: PR </E> <E> Primary site: < PR </E> <A> Definitive RT </A> (category 1) <A> RT </A> (category 1) or <A> systemic therapy/RT </A> (category 2B) <A> Surgery </A> or <A> unresectable nodal disease </A>\\n\\nSection Name: Follow-up\\n====================\\nEntities:-\\nFollow-Up Studies : Studies in which individuals are followed over time to determine the outcome of exposures, treatments, or interventions.\\nFollow-Up Procedure : A procedure where a patient is monitored over time to assess the progress of a condition or the effects of treatment.\\nFollow-Up (Medicine) : The process of monitoring a patient\\'s health over time after treatment or diagnosis.\\nDisease Recurrence : The return of a sign, symptom, or disease after a remission.\\nRecurrent Disease : A disease that returns after a period of remission.\\nRecurrence (Medicine) : The return of a disease or condition after a period of improvement.\\n\\nRelationships:-\\n1. Entity1: \""Follow-up\"", Entity2: \""Recurrent or persistent disease\"", Relationship: \""monitoring\""\\n\\nCausalities:-\\n### Follow-up\\n\\n- **Follow-up** (FOLL-A, 1 of 2)\\n- **Recurrent or persistent disease** (ADV-3)\\n\\nSection Name: Risk Features\\n====================\\nEntities:-\\nRadiotherapy : The use of high-energy radiation to kill cancer cells and shrink tumors.\\nExtranodal Extension : The spread of cancer cells beyond the lymph node capsule into the surrounding tissues.\\nPositive Surgical Margin : The presence of cancer cells at the edge of the tissue removed during surgery, indicating that some cancer may have been left behind.\\nSystemic Therapy : Systemic therapy refers to treatment using substances that travel through the bloodstream, reaching and affecting cells all over the body.\\n\\nRelationships:-\\n1. Entity1: \""Adverse pathologic features\"", Entity2: \""RT\"", Relationship: \""Consideration for treatment\""\\n2. Entity1: \""Adverse pathologic features\"", Entity2: \""Systemic therapy\"", Relationship: \""Consideration for treatment\""\\n\\nCausalities:-\\n- **No adverse pathologic features**\\n- **Other risk features**\\n- **Adverse pathologic features**:\\n  - <C> Extranodal extension and/or positive margin </C>\\n  - <A> RT or consider systemic therapy/RT </A>\\n\\nSection Name: Post-Therapy Evaluation\\n====================\\nEntities:-\\nSystemic Therapy : Systemic therapy refers to treatment using substances that travel through the bloodstream, reaching and affecting cells all over the body.\\nRadiation Therapy : Therapy using ionizing radiation, generally as part of cancer treatment to control or kill malignant cells.\\nNeck : The neck is the part of the body that separates the head from the torso and provides the mobility and movements of the head.\\n\\nRelationships:-\\n1. Entity1: \""Systemic Therapy\"", Entity2: \""Neck Evaluation\"", Relationship: \""evaluated in\""\\n2. Entity1: \""RT\"", Entity2: \""Neck Evaluation\"", Relationship: \""evaluated in\""\\n\\nCausalities:-\\n<CO> Post Systemic Therapy/RT or RT Neck </CO> <A> Evaluation </A>\\n\\nSection Name: Flowchart Overview\\n====================\\nEntities:-\\nLaryngeal Neoplasms : Tumors or cancer of the larynx, which may affect the supraglottic, glottic, or subglottic regions.\\nSupraglottic Larynx : The part of the larynx located above the vocal cords, including the epiglottis and aryepiglottic folds.\\nNational Comprehensive Cancer Network : An alliance of 32 cancer centers in the United States, dedicated to improving the quality, effectiveness, and efficiency of cancer care.\\n\\nRelationships:-\\n1. Entity1: \""NCCN Guidelines\"", Entity2: \""cancer of the supraglottic larynx\"", Relationship: \""guides management of\""\\n2. Entity1: \""NCCN Guidelines\"", Entity2: \""healthcare professionals\"", Relationship: \""used by\""\\n\\nCausalities:-\\n<C> cancer of the supraglottic larynx </C> <E> evaluate patient responses following treatment </E> <CO> based on observed outcomes </CO> <A> evaluation of the primary site and determining subsequent steps </A>.\\n\\nSection Name: Assessment and Treatment Decisions\\n====================\\nEntities:-\\nInduction Chemotherapy : Initial chemotherapy treatment to shrink a tumor before the main treatment.\\nComplete Response : The disappearance of all signs of cancer in response to treatment.\\nPartial Response : A decrease in the size of a tumor, or in the extent of cancer in the body, in response to treatment.\\nRadiation Therapy : Therapy using ionizing radiation, generally as part of cancer treatment to control or kill malignant cells.\\nSurgery : Medical specialty that uses operative manual and instrumental techniques on a patient to investigate or treat a pathological condition such as disease or injury.\\nSystemic Therapy : Systemic therapy refers to treatment using substances that travel through the bloodstream, reaching and affecting cells all over the body.\\n\\nRelationships:-\\n1. Entity1: \""Complete Response\"", Entity2: \""Radiation Therapy\"", Relationship: \""leads to\""\\n2. Entity1: \""Complete Response\"", Entity2: \""Surgery\"", Relationship: \""leads to\""\\n3. Entity1: \""Partial Response\"", Entity2: \""Systemic Therapy\"", Relationship: \""leads to\""\\n4. Entity1: \""Partial Response\"", Entity2: \""Radiation Therapy\"", Relationship: \""leads to\""\\n\\nCausalities:-\\n<C> responses to initial treatments such as induction chemotherapy </C> <E> Three main response categories are recognized: Complete Response (CR), Partial Response (PR), and less than Partial Response (< PR) </E>. These categories are pivotal in determining the next steps. <C> CR </C> <E> indicates full resolution of the disease at the primary site </E>, <A> leading to the consideration of definitive radiation therapy or the likelihood of surgery </A>. Conversely, <C> PR </C> <E> suggests that the disease has improved but not completely resolved </E>, <A> which directs the pathway towards either systemic therapy or continued radiation therapy </A>, <A> with further evaluation necessary </A>.\\n\\nSection Name: Adverse Pathologic Features and Follow-up\\n====================\\nEntities:-\\nRadiation Therapy : Therapy using ionizing radiation, generally as part of cancer treatment to control or kill malignant cells.\\nSurgical Procedures, Operative : Surgical procedures involve the use of operative manual and instrumental techniques on a patient to investigate or treat a pathological condition such as disease or injury.\\nNeoplasm Recurrence, Local : The return of a tumor or cancer, at the original site, after it has been treated.\\nNeoplasm Metastasis : The transfer of a neoplasm from one organ or part of the body to another remote from the primary site.\\nSurgical Procedure : A medical procedure involving an incision with instruments; performed to repair damage or arrest disease in a living body.\\nRecurrent Neoplasm : A neoplasm that has returned after treatment.\\nMetastatic Neoplasm : A neoplasm that has spread from its original site to one or more other places in the body.\\nSurgery : Medical specialty that uses operative manual and instrumental techniques on a patient to investigate or treat a pathological condition such as disease or injury.\\nCancer Recurrence : The return of cancer after treatment and after a period of time during which the cancer was undetectable.\\nMetastasis : Spread of a cancer or other disease from one organ or part to another not directly connected with it.\\n\\nRelationships:-\\n1. Entity1: \""Adverse pathologic features\"", Entity2: \""Treatment decisions\"", Relationship: \""Influence\""\\n2. Entity1: \""Adverse features\"", Entity2: \""Surgical intervention\"", Relationship: \""Recommendation\""\\n3. Entity1: \""Absence of adverse features\"", Entity2: \""Radiation therapy\"", Relationship: \""Pathway\""\\n4. Entity1: \""Follow-up process\"", Entity2: \""Recurrent or persistent disease\"", Relationship: \""Detection\""\\n5. Entity1: \""Recurrent or persistent disease\"", Entity2: \""Advanced disease management\"", Relationship: \""Necessity\""\\n\\nCausalities:-\\n<C> The presence of adverse pathologic features \u2014 such as extranodal extension or positive margins </C> <E> can directly influence treatment decisions </E>. <CO> If adverse features are found </CO>, <A> surgical intervention is recommended </A>. <CO> In cases where there are no adverse features </CO>, the patient may proceed directly to radiation therapy or continued systemic treatment, emphasizing the tailored approach based on the individual patient\\'s disease characteristics.\\n\\nFurthermore, the chart includes a section addressing the follow-up process after initial treatment. <CO> If there are signs of recurrent or persistent disease </CO>, <A> additional evaluations and treatment modalities may be necessary </A>. These evaluations <E> lead to specific recommendations for advanced disease management, denoted as ADV-3 on the chart </E>, emphasizing the importance of continuous monitoring and assessment in cancer care.\\n--------------------------------------------------\\nPage Number: 51\\n\\nSection Name: Introduction\\n====================\\nEntities:-\\nLaryngeal Neoplasms : Tumors or cancer of the larynx, which may affect the supraglottic, glottic, or subglottic regions.\\nMalignant Neoplasm Of Supraglottis : A malignant tumor located in the supraglottic region of the larynx.\\nSupraglottic Laryngeal Cancer : A type of cancer that occurs in the supraglottic region of the larynx, which is above the vocal cords.\\n\\nRelationships:-\\n1. Entity1: \""National Comprehensive Cancer Network (NCCN)\"", Entity2: \""cancer of the supraglottic larynx\"", Relationship: \""provides guidelines for\""\\n2. Entity1: \""healthcare professionals\"", Entity2: \""cancer of the supraglottic larynx\"", Relationship: \""manage\""\\n\\nCausalities:-\\nThe provided image is a detailed flowchart from the National Comprehensive Cancer Network (NCCN) guidelines regarding the <C> clinical staging and treatment protocols for cancer of the supraglottic larynx </C>. This flowchart is structured to <A> guide healthcare professionals through the stages of treatment </A> based on <CO> clinical findings </CO>, emphasizing the <E> complexity and systematic approach required in managing this type of cancer </E>.\\n\\nSection Name: Clinical Staging\\n====================\\nEntities:-\\nLaryngectomy : A surgical procedure involving the removal of the larynx, usually to treat cancer of the larynx.\\nTotal Laryngectomy : A surgical procedure to remove the entire larynx, often used in the treatment of advanced laryngeal cancer.\\nNeoplasm Staging : Methods used for staging neoplasms, including clinical and pathological staging.\\nCancer Staging : The process of determining the extent of cancer in the body, often using the TNM system.\\nTnm Staging System : A cancer staging system that describes the extent of cancer using Tumor size (T), Node involvement (N), and Metastasis (M).\\n\\nRelationships:-\\n1. Entity1: \""Clinical staging criteria\"", Entity2: \""Total laryngectomy\"", Relationship: \""determines necessity of\""\\n2. Entity1: \""T3, N0\"", Entity2: \""Clinical staging criteria\"", Relationship: \""is a categorization of\""\\n\\nCausalities:-\\nThe flowchart begins with the <C> clinical staging criteria </C>, specifically focusing on <CO> cases that require total laryngectomy, denoted as requiring (amenable to) total laryngectomy (T3, N0) </CO>. This <A> categorization </A> is crucial as it <E> forms the basis for determining the appropriate treatment strategy </E>.\\n\\nSection Name: Treatment of Primary and Neck\\n====================\\nEntities:-\\nNeoplasm Staging : Methods used for staging neoplasms, including clinical and pathological staging.\\nSystemic Therapy : Treatment using substances that travel through the bloodstream, reaching and affecting cells all over the body.\\nRadiotherapy : The use of high-energy radiation from x-rays, gamma rays, neutrons, protons, and other sources to kill cancer cells and shrink tumors.\\nLaryngectomy : A surgical procedure involving the removal of the larynx, usually to treat cancer of the larynx.\\nThyroidectomy : A surgical procedure to remove all or part of the thyroid gland.\\nNeck Dissection : Surgical procedure to remove lymph nodes and surrounding tissue to treat or prevent cancer spread.\\nLymphatic Metastasis : Transfer of a neoplasm from one organ or part of the body to another remote from the primary site.\\n\\nRelationships:-\\n1. Entity1: \""Systemic Therapy\"", Entity2: \""Radiation Therapy\"", Relationship: \""combined with\""\\n2. Entity1: \""Laryngectomy\"", Entity2: \""Lymph Node Involvement\"", Relationship: \""considered based on\""\\n3. Entity1: \""Thyroidectomy\"", Entity2: \""Lymph Node Involvement\"", Relationship: \""considered based on\""\\n4. Entity1: \""Neck Dissection\"", Entity2: \""Lymph Node Involvement\"", Relationship: \""considered based on\""\\n\\nCausalities:-\\n<CO> Once clinical staging is established </CO>, the chart outlines various treatment options. <A> The initial step may involve either concurrent systemic therapy combined with radiation therapy (RT) or opting for RT alone </A>, <CO> especially if the patient is not a medical candidate for both therapies </CO>. <A> Laryngectomy, thyroidectomy, and neck dissection are considered </A> <CO> based on the extent of lymph node involvement </CO>.\\n\\nSection Name: Surgical Options\\n====================\\nEntities:-\\nLaryngectomy : A surgical procedure involving the removal of the larynx, usually to treat cancer of the larynx.\\nThyroidectomy : A surgical procedure to remove all or part of the thyroid gland.\\nLymph Node Excision : Surgical removal of one or more lymph nodes.\\nLymphadenectomy : Surgical removal of one or more groups of lymph nodes.\\nSurgical Procedures, Operative : Operations carried out for the correction of deformities and defects, repair of injuries, and diagnosis and cure of certain diseases.\\nSurgical Procedure : A medical procedure involving an incision with instruments; performed to repair damage or arrest disease in a living body.\\nSurgery : Medical specialty that uses operative manual and instrumental techniques on a patient to investigate or treat a pathological condition such as a disease or injury.\\n\\nRelationships:-\\n1. Entity1: \""Laryngectomy\"", Entity2: \""Thyroidectomy\"", Relationship: \""combined with\""\\n2. Entity1: \""Lymph Node Dissection\"", Entity2: \""Surgical Intervention\"", Relationship: \""extent of\""\\n3. Entity1: \""Surgical Intervention\"", Entity2: \""Advanced Cases\"", Relationship: \""management option for\""\\n\\nCausalities:-\\n<CO> If concurrent therapies are not suitable </CO>, <A> the chart presents laryngectomy combined with thyroidectomy </A>, <CO> depending on the extent of lymph node dissection required </CO>. <E> This highlights surgical intervention as a viable option in the management of advanced cases </E>.\\n\\nSection Name: Induction Chemotherapy\\n====================\\nEntities:-\\nInduction Chemotherapy : Initial chemotherapy treatment used to shrink a tumor before the main treatment, which is usually surgery.\\nSurgical Procedure : A medical procedure involving an incision with instruments; performed to repair damage or arrest disease in a living body.\\nTherapeutic Approach : A method or strategy used in the treatment of disease or injury.\\n\\nRelationships:-\\n1. Entity1: \""Induction Chemotherapy\"", Entity2: \""Surgical Intervention\"", Relationship: \""alternative or sequential treatment option\""\\n\\nCausalities:-\\n<C> immediate surgical intervention is either not feasible or considered insufficient </C> <E> The flowchart also considers the option of induction chemotherapy </E> <CO> in cases where immediate surgical intervention is either not feasible or considered insufficient </CO>. <A> tailoring therapeutic approaches tailored to individual patient needs </A>.\\n\\nSection Name: Adjuvant Treatment\\n====================\\nEntities:-\\nAdjuvant Chemotherapy : Chemotherapy given in addition to the primary treatment to maximize its effectiveness.\\nRadiotherapy : The use of high-energy radiation from x-rays, gamma rays, neutrons, protons, and other sources to kill cancer cells and shrink tumors.\\nNeoplasm Recurrence, Local : The return of a cancer, at the same site, after it has been treated.\\nDisease Progression : The worsening of a disease over time.\\n\\nRelationships:-\\n1. Entity1: \""Primary Treatment\"", Entity2: \""Adjuvant Treatment\"", Relationship: \""followed by\""\\n2. Entity1: \""Adjuvant Treatment\"", Entity2: \""Systemic Therapy\"", Relationship: \""includes\""\\n3. Entity1: \""Adjuvant Treatment\"", Entity2: \""Radiotherapy\"", Relationship: \""includes\""\\n4. Entity1: \""Follow-up Assessments\"", Entity2: \""Treatment Efficacy\"", Relationship: \""used to evaluate\""\\n\\nCausalities:-\\n<C> Following primary treatment </C>, <E> the flowchart addresses the potential for adjuvant treatment pathways </E>. This may include systemic therapy, RT, or further evaluations based on <CO> the patient\\'s response and any recurrence or persistent disease </CO>. It emphasizes <A> the need for follow-up assessments to evaluate treatment efficacy </A>.\\n\\nSection Name: Risk Features and Response Assessment\\n====================\\nEntities:-\\nNeoplasm Invasiveness : The property of a neoplasm to infiltrate and destroy surrounding tissue.\\nSurgical Margins : The edge or border of the tissue removed in cancer surgery.\\nNeoplasms : Neoplasms are abnormal growths of tissue, which can be cancerous or non-cancerous.\\nExtramural Extension : Extension of a tumor beyond the wall of an organ.\\nPositive Surgical Margin : Cancer cells are present at the edge of the tissue removed during surgery.\\nCancer Management : The process of planning and coordinating the treatment of cancer.\\nCancer : Cancer is a group of diseases involving abnormal cell growth with the potential to invade or spread to other parts of the body.\\n\\nRelationships:-\\n1. Entity1: \""Extramural extension\"", Entity2: \""Treatment decisions\"", Relationship: \""influences\""\\n2. Entity1: \""Positive surgical margin\"", Entity2: \""Treatment decisions\"", Relationship: \""influences\""\\n3. Entity1: \""Ongoing assessment\"", Entity2: \""Response evaluation\"", Relationship: \""leads to\""\\n4. Entity1: \""Response evaluation\"", Entity2: \""Adjustments to treatment\"", Relationship: \""leads to\""\\n5. Entity1: \""Management of cancer\"", Entity2: \""Treatment decisions\"", Relationship: \""involves\""\\n6. Entity1: \""Management of cancer\"", Entity2: \""Ongoing assessment\"", Relationship: \""involves\""\\n7. Entity1: \""Management of cancer\"", Entity2: \""Adjustments to treatment\"", Relationship: \""involves\""\\n\\nCausalities:-\\nThe chart incorporates a segment that takes into account <CO> adverse pathologic features, such as extramural extension or positive margins </CO>, <E> which could influence subsequent treatment decisions </E>. This highlights the importance of <A> ongoing assessment in the management of cancer, leading to response evaluation and adjustments to treatment as necessary </A>.\\n\\nSection Name: NCCN Guidelines Version 4.2024\\n====================\\nEntities:-\\nClinical Trials : Clinical trials are research studies performed in people that are aimed at evaluating a medical, surgical, or behavioral intervention.\\nNeoplasms : Neoplasms are abnormal growths of tissue, which can be cancerous or non-cancerous.\\nClinical Trial : A clinical trial is a research study that prospectively assigns human participants or groups of humans to one or more health-related interventions to evaluate the effects on health outcomes.\\nMalignant Neoplasm : A malignant neoplasm is a cancerous growth that has the potential to invade and destroy nearby tissue and spread to other parts of the body.\\nNational Comprehensive Cancer Network : The National Comprehensive Cancer Network (NCCN) is an alliance of 31 cancer centers in the United States, dedicated to improving the quality, effectiveness, and efficiency of cancer care.\\nCancer : Cancer is a group of diseases involving abnormal cell growth with the potential to invade or spread to other parts of the body.\\n\\nRelationships:-\\n1. Entity1: \""National Comprehensive Cancer Network\"", Entity2: \""NCCN Guidelines\"", Relationship: \""provides\""\\n2. Entity1: \""NCCN Guidelines\"", Entity2: \""Clinical Trials\"", Relationship: \""recommend\""\\n3. Entity1: \""NCCN Guidelines\"", Entity2: \""Cancer\"", Relationship: \""related to management of\""\\n\\nCausalities:-\\n<CO> any patient with cancer </CO> <A> the best management is in a clinical trial </A>. <A> Participation in clinical trials is especially encouraged </A>.\\n\\nSection Name: SUPRA-3\\n====================\\nEntities:-\\nLaryngectomy : A surgical procedure involving the removal of the larynx, usually to treat cancer of the larynx.\\nThyroidectomy : A surgical procedure to remove all or part of the thyroid gland.\\nNeck Dissection : Surgical procedure to remove lymph nodes and surrounding tissue to treat or prevent cancer spread.\\nChemotherapy, Induction : Initial chemotherapy treatment to shrink a tumor before the main treatment.\\nClinical Trials As Topic : Research studies that prospectively assign human participants or groups of humans to one or more health-related interventions to evaluate the effects on health outcomes.\\nInduction Chemotherapy : Initial chemotherapy treatment used to shrink a tumor before the main treatment, which is usually surgery.\\nClinical Trial : A clinical trial is a research study that prospectively assigns human participants or groups of humans to one or more health-related interventions to evaluate the effects on health outcomes.\\n\\nRelationships:-\\n1. Entity1: \""Total laryngectomy\"", Entity2: \""Laryngectomy\"", Relationship: \""is a type of\""\\n2. Entity1: \""Systemic therapy\"", Entity2: \""RT\"", Relationship: \""concurrent treatment option\""\\n3. Entity1: \""Induction chemotherapy\"", Entity2: \""Other treatments\"", Relationship: \""initial treatment option before\""\\n\\nCausalities:-\\n<CO> Requiring (amenable to) total laryngectomy (T3,N0) </CO>\\n  - <A> Concurrent systemic therapy/RT </A> or <A> RT if patient not medical candidate for concurrent systemic therapy/RT </A>\\n  - <A> Laryngectomy, thyroidectomy and with ipsilateral, central, or bilateral neck dissection </A>\\n  - or\\n  - <A> Induction chemotherapy </A>\\n  - or\\n  - <A> Clinical trials </A>\\n\\nSection Name: Follow-up\\n====================\\nEntities:-\\nFollow-Up Studies : Studies in which individuals are followed over time to determine the outcome of exposures, treatments, or interventions.\\nFollow-Up Procedure : A procedure performed to monitor the progress of a patient\\'s condition after initial treatment.\\nFollow-Up : Medical care given to a patient over time after initial treatment.\\nDisease Recurrence : The return of a sign, symptom, or disease after a remission.\\nRecurrent Disease : The reappearance of a disease after a period of improvement.\\n\\nRelationships:-\\n1. Entity1: \""Follow-up\"", Entity2: \""Recurrent or persistent disease\"", Relationship: \""monitoring\""\\n\\nCausalities:-\\n- **Follow-up (FOLL-A, 1 of 2)**\\n  - <CO> Recurrent or persistent disease </CO> (ADV-3)\\n\\nSection Name: Adverse Pathologic Features\\n====================\\nEntities:-\\nRadiotherapy : The use of high-energy radiation from x-rays, gamma rays, neutrons, protons, and other sources to kill cancer cells and shrink tumors.\\nExtranodal Extension : The spread of cancer beyond the lymph node capsule.\\nPositive Surgical Margin : Cancer cells are present at the edge of the tissue removed during surgery.\\nSystemic Therapy : Treatment using substances that travel through the bloodstream, reaching and affecting cells all over the body.\\n\\nRelationships:-\\n1. Entity1: \""pN1\"", Entity2: \""Radiotherapy\"", Relationship: \""Consideration for treatment\""\\n2. Entity1: \""Extranodal extension\"", Entity2: \""Systemic Therapy\"", Relationship: \""Treatment option\""\\n3. Entity1: \""Extranodal extension\"", Entity2: \""Radiotherapy\"", Relationship: \""Treatment option\""\\n4. Entity1: \""Positive surgical margin\"", Entity2: \""Systemic Therapy\"", Relationship: \""Treatment option\""\\n5. Entity1: \""Positive surgical margin\"", Entity2: \""Radiotherapy\"", Relationship: \""Treatment option\""\\n\\nCausalities:-\\n- <CO>pN1 without other risk features</CO>\\n  - <C>Adverse pathologic features</C>\\n  - <A>Consider RT</A>\\n  - <CO>Extranodal extension and/or positive margin</CO>\\n  - <CO>Other risk features</CO>\\n  - <A>Systemic therapy/RT (category 1)</A>\\n  - <A>RT or Consider systemic therapy/RT</A>\\n\\nSection Name: Response Assessment\\n====================\\nEntities:-\\nResponse Evaluation : The process of assessing the response of a disease to treatment, often used in clinical trials to determine the effectiveness of a therapy.\\nResponse To Treatment : A clinical finding indicating the response of a condition to a therapeutic intervention.\\n\\nRelationships:-\\n\\nSection Name: Principles of Surgery and Radiation Therapy\\n====================\\nEntities:-\\nSurgical Procedures, Operative : Operations carried out for the correction of deformities and defects, repair of injuries, and diagnosis and cure of certain diseases.\\nSurgical Procedure : A medical procedure involving an incision with instruments; performed to repair damage or arrest disease in a living body.\\nSurgery : Medical specialty that uses operative manual and instrumental techniques on a patient to investigate or treat a pathological condition such as a disease or injury.\\nRadiotherapy : The use of high-energy radiation from x-rays, gamma rays, neutrons, protons, and other sources to kill cancer cells and shrink tumors.\\nRadiation Therapy : Radiation therapy is a therapy using ionizing radiation, generally as part of cancer treatment to control or kill malignant cells.\\n\\nRelationships:-\\n1. Entity1: \""Principles of Surgery\"", Entity2: \""Principles of Radiation Therapy\"", Relationship: \""complementary treatments\""\\n\\nCausalities:-\\n**Principles of Surgery (SURG-A).**\\n\\n**Principles of Radiation Therapy (SUPRA-A).**\\n\\nSection Name: Principles of Systemic Therapy\\n====================\\nEntities:-\\nCisplatin : An inorganic and water-soluble platinum complex, cisplatin is an antineoplastic agent that is used in the treatment of various cancers.\\nRadiotherapy : The use of high-energy radiation from x-rays, gamma rays, neutrons, protons, and other sources to kill cancer cells and shrink tumors.\\nRadiation Therapy : Radiation therapy is a therapy using ionizing radiation, generally as part of cancer treatment to control or kill malignant cells.\\n\\nRelationships:-\\n1. Entity1: \""Cisplatin\"", Entity2: \""Systemic Therapy for Non-Nasopharyngeal Cancers\"", Relationship: \""preferred agent\""\\n2. Entity1: \""Cisplatin\"", Entity2: \""Concurrent Systemic Therapy/RT\"", Relationship: \""used in\""\\n\\nCausalities:-\\n<CO> When using concurrent systemic therapy/RT </CO>, <A> the preferred agent is cisplatin (category 1) </A>.\\n--------------------------------------------------\\nPage Number: 130\\n\\nSection Name: Pathological N (pN)\\n====================\\nEntities:-\\nLymph Nodes : Small, bean-shaped structures that are part of the body\\'s lymphatic system. They filter lymph fluid and store white blood cells that help fight infection.\\nNeoplasm Metastasis : The transfer of a neoplasm from one organ or part of the body to another remote from the primary site.\\nTnm Staging : A system used to describe the size and spread of cancer in a standardized way. T refers to the size of the tumor, N to the involvement of lymph nodes, and M to metastasis.\\nLymph Node Structure : A structure that is part of the lymphatic system, involved in the immune response.\\nMetastasis : The spread of a cancer or other disease from one organ or part to another not directly connected with it.\\nTnm Staging System : A cancer staging notation system that describes the extent of cancer in a patient\\'s body.\\nLymph Node : An organ of the lymphatic system and the adaptive immune system.\\n\\nRelationships:-\\n1. Entity1: \""Lymph Nodes\"", Entity2: \""Neoplasm Metastasis\"", Relationship: \""involved in\""\\n2. Entity1: \""TNM Staging\"", Entity2: \""Lymph Nodes\"", Relationship: \""includes\""\\n3. Entity1: \""TNM Staging\"", Entity2: \""Neoplasm Metastasis\"", Relationship: \""describes\""\\n\\nCausalities:-\\n<CO> NX: Regional lymph nodes cannot be assessed </CO>\\n<CO> N0: No regional lymph node metastasis </CO>\\n<CO> N1: Metastasis in a single ipsilateral lymph node, 3 cm or smaller in greatest dimension ENE(\u2013) </CO>\\n<CO> N2: Metastasis in a single ipsilateral lymph node, 3 cm or smaller in greatest dimension and ENE(+); or larger than 3 cm but not larger than 6 cm in greatest dimension and ENE(\u2212); or metastases in multiple ipsilateral lymph nodes, none larger than 6 cm in greatest dimension and ENE(\u2212); or in bilateral or contralateral lymph node(s), none larger than 6 cm in greatest dimension and ENE(\u2212) </CO>\\n<CO> N2a: Metastasis in a single ipsilateral node, 3 cm or smaller in greatest dimension and ENE(+); or metastasis in a single ipsilateral node, larger than 3 cm but not larger than 6 cm in greatest dimension and ENE(\u2212) </CO>\\n<CO> N2b: Metastases in multiple ipsilateral nodes, none larger than 6 cm in greatest dimension and ENE(\u2212) </CO>\\n<CO> N2c: Metastases in bilateral or contralateral lymph node(s), none larger than 6 cm in greatest dimension and ENE(\u2212) </CO>\\n<CO> N3: Metastasis in a lymph node, larger than 6 cm in greatest dimension and ENE(\u2212); or metastasis in a single ipsilateral node, larger than 3 cm in greatest dimension and ENE(+); or multiple ipsilateral, contralateral, or bilateral lymph nodes and any with ENE(+); or a single contralateral node of any size and ENE(+) </CO>\\n<CO> N3a: Metastasis in a lymph node, larger than 6 cm in greatest dimension and ENE(\u2212) </CO>\\n<CO> N3b: Metastasis in a single ipsilateral node, larger than 3 cm in greatest dimension and ENE(+); or multiple ipsilateral, contralateral, or bilateral lymph nodes any with ENE(+); or a single contralateral node of any size and ENE(+) </CO>\\n<CO> Note: A designation of \u201cU\u201d or \u201cL\u201d may be used for any N category to indicate metastasis above the lower border of the cricoid (U) or below the lower border of the cricoid (L). Similarly, clinical and pathological ENE should be recorded as ENE(\u2212) or ENE(+). </CO>\\n\\nSection Name: Distant Metastasis (M)\\n====================\\nEntities:-\\nNeoplasm Metastasis : The transfer of a neoplasm from one organ or part of the body to another remote from the primary site.\\nMetastasis : The spread of a cancer or other disease from one organ or part to another not directly connected with it.\\n\\nRelationships:-\\n1. Entity1: \""M0\"", Entity2: \""Distant Metastasis\"", Relationship: \""is a category of\""\\n2. Entity1: \""M1\"", Entity2: \""Distant Metastasis\"", Relationship: \""is a category of\""\\n\\nCausalities:-\\n### Distant Metastasis (M)\\n\\n- **M0**: No distant metastasis\\n- **M1**: Distant metastasis\\n\\nSection Name: Histologic Grade (G)\\n====================\\nEntities:-\\nNeoplasm Grading : A system of classifying cancer cells in terms of how abnormal they look under a microscope and how quickly the tumor is likely to grow and spread.\\nHistologic Grade : A measure of how much tumor cells differ from healthy cells, used to assess the aggressiveness of cancer.\\n\\nRelationships:-\\n1. Entity1: \""GX\"", Entity2: \""Grade cannot be assessed\"", Relationship: \""is described as\""\\n2. Entity1: \""G1\"", Entity2: \""Well differentiated\"", Relationship: \""is described as\""\\n3. Entity1: \""G2\"", Entity2: \""Moderately differentiated\"", Relationship: \""is described as\""\\n4. Entity1: \""G3\"", Entity2: \""Poorly differentiated\"", Relationship: \""is described as\""\\n\\nCausalities:-\\n<CO>GX</CO>: <E>Grade cannot be assessed</E>\\n<CO>G1</CO>: <E>Well differentiated</E>\\n<CO>G2</CO>: <E>Moderately differentiated</E>\\n<CO>G3</CO>: <E>Poorly differentiated</E>\\n\\nSection Name: Prognostic Stage Groups\\n====================\\nEntities:-\\nNeoplasm Staging : Methods and systems of classifying neoplasms according to extent of disease.\\nTumor Staging : A system for describing the size and spread of cancer within the body.\\nTnm Staging System : A cancer staging notation system that describes the extent of cancer in a patient\\'s body.\\n\\nRelationships:-\\n1. Entity1: \""Stage 0\"", Entity2: \""Tis N0 M0\"", Relationship: \""defined by\""\\n2. Entity1: \""Stage I\"", Entity2: \""T1 N0 M0\"", Relationship: \""defined by\""\\n3. Entity1: \""Stage II\"", Entity2: \""T2 N0 M0\"", Relationship: \""defined by\""\\n4. Entity1: \""Stage III\"", Entity2: \""T3 N0 M0, T1 N1 M0, T2 N1 M0, T3 N1 M0\"", Relationship: \""defined by\""\\n5. Entity1: \""Stage IVA\"", Entity2: \""T1 N2 M0, T2 N2 M0, T3 N2 M0, T4a N0,N1,N2 M0\"", Relationship: \""defined by\""\\n6. Entity1: \""Stage IVB\"", Entity2: \""Any T N3 M0, T4b Any N M0\"", Relationship: \""defined by\""\\n7. Entity1: \""Stage IVC\"", Entity2: \""Any T Any N M1\"", Relationship: \""defined by\""\\n--------------------------------------------------\\nPage Number: 47\\n\\nSection Name: Overview of Radiation Therapy Guidelines\\n====================\\nEntities:-\\nRadiation Therapy : The medical use of ionizing radiation, generally as part of cancer treatment to control or kill malignant cells.\\nCancer : A group of diseases involving abnormal cell growth with the potential to invade or spread to other parts of the body.\\nMalignant Neoplasm : A disease characterized by uncontrolled, abnormal growth of cells that can invade and destroy nearby tissue and spread to other parts of the body.\\nLaryngeal Neoplasms : Tumors or cancer of the larynx, which may affect the glottis, supraglottis, or subglottis.\\nGlottic Larynx Cancer : A malignant neoplasm located in the glottic region of the larynx.\\nLaryngeal Cancer : Cancer that occurs in the larynx, or voice box, which may include the glottic region.\\nNational Comprehensive Cancer Network : The National Comprehensive Cancer Network (NCCN) is an alliance of 30 cancer centers in the United States, dedicated to improving the quality, effectiveness, and efficiency of cancer care.\\n\\nRelationships:-\\n1. Entity1: \""Radiation Therapy\"", Entity2: \""Cancer\"", Relationship: \""treats\""\\n2. Entity1: \""NCCN Guidelines\"", Entity2: \""Cancer\"", Relationship: \""guides treatment for\""\\n3. Entity1: \""NCCN Guidelines\"", Entity2: \""Radiation Therapy\"", Relationship: \""specifies use of\""\\n\\nCausalities:-\\nThe image presents a detailed flowchart outlining the principles of radiation therapy specifically for the <C> treatment of cancer in the glottic larynx </C>, <CO> as per the National Comprehensive Cancer Network (NCCN) guidelines (version 2.2024) </CO>. <E> This structured guidance delineates various treatment protocols </E>, <A> stratified by risk levels and therapeutic approaches </A>.\\n\\nSection Name: Principles of Radiation Therapy\\n====================\\nEntities:-\\nRadiation Therapy : The medical use of ionizing radiation, generally as part of cancer treatment to control or kill malignant cells.\\nGy : Gray, a unit of ionizing radiation dose in the International System of Units (SI), defined as the absorption of one joule of radiation energy per kilogram of matter.\\nGray (Unit) : A unit of absorbed radiation dose of ionizing radiation, defined as the absorption of one joule of radiation energy per kilogram of matter.\\n\\nRelationships:-\\n1. Entity1: \""Tis, N0\"", Entity2: \""60.75 Gy (2.25 Gy/fraction) to 66 Gy (2.0 Gy/fraction)\"", Relationship: \""treatment protocol\""\\n2. Entity1: \""T1, N0\"", Entity2: \""63 Gy (2.25 Gy/fraction) to 66 Gy (2.0 Gy/fraction) or 50 Gy (3.12 Gy/fraction) to 52 Gy (3.28 Gy/fraction)\"", Relationship: \""treatment protocol\""\\n3. Entity1: \""T2, N0\"", Entity2: \""65.25 Gy (2.25 Gy/fraction) to 70 Gy (2.0 Gy/fraction)\"", Relationship: \""treatment protocol\""\\n4. Entity1: \""\u2265T2, N1 (PTV High risk)\"", Entity2: \""66 Gy (2.2 Gy/fraction) to 70 Gy (2.0 Gy/fraction)\"", Relationship: \""treatment protocol\""\\n5. Entity1: \""\u2265T2, N1 (Low to intermediate risk)\"", Entity2: \""44\u201350 Gy (2.0 Gy/fraction) to 54\u201363 Gy (1.6\u20131.8 Gy/fraction)\"", Relationship: \""treatment protocol\""\\n\\nCausalities:-\\n<CO>Tis, N0</CO>: <A>60.75 Gy (2.25 Gy/fraction) to 66 Gy (2.0 Gy/fraction)</A>\\n<CO>T1, N0</CO>: <A>63 Gy (2.25 Gy/fraction, preferred) to 66 Gy (2.0 Gy/fraction) or 50 Gy (3.12 Gy/fraction) to 52 Gy (3.28 Gy/fraction)</A>\\n<CO>T2, N0</CO>: <A>65.25 (2.25 Gy/fraction) to 70 Gy (2.0 Gy/fraction)</A>\\n<CO>\u2265T2, N1</CO>: <A>PTV High risk: Primary tumor and involved lymph nodes (includes possible local subclinical infiltration at the primary site and at the high-risk level lymph node(s))</A>\\n<A>Fractionation: 66 Gy (2.2 Gy/fraction) to 70 Gy (2.0 Gy/fraction); daily Monday\u2013Friday in 6\u20137 weeks</A>\\n<A>Concomitant boost accelerated RT: 72 Gy/6 weeks (1.8 Gy/fraction, large field; 1.5 Gy boost as second daily fraction during last 12 treatment days)</A>\\n<A>66\u201370 Gy (2.0 Gy/fraction; 6 fractions/wk accelerated)</A>\\n<A>Hyperfractionation: 79.2\u201381.6 Gy/7 weeks (1.2 Gy/fraction, twice daily)</A>\\n<CO>Low to intermediate risk</CO>: <A>Sites of suspected subclinical spread</A>\\n<A>44\u201350 Gy (2.0 Gy/fraction) to 54\u201363 Gy (1.6\u20131.8 Gy/fraction)</A>\\n\\nSection Name: Concurrent Systemic Therapy/RT\\n====================\\nEntities:-\\nCisplatin : A platinum-containing antineoplastic agent used in the treatment of various cancers.\\nCarboplatin : An organoplatinum compound that possesses antineoplastic activity.\\nFluorouracil : A chemotherapy drug used to treat various types of cancer.\\n\\nRelationships:-\\n1. Entity1: \""concurrent systemic therapy/RT\"", Entity2: \""cisplatin\"", Relationship: \""uses\""\\n2. Entity1: \""concurrent systemic therapy/RT\"", Entity2: \""carboplatin and 5-FU\"", Relationship: \""uses\""\\n3. Entity1: \""multiagent chemotherapy\"", Entity2: \""toxicity burden\"", Relationship: \""increases\""\\n\\nCausalities:-\\n<CO>Based on published data</CO>, <A>concurrent systemic therapy/RT most commonly uses conventional fractionation at 2.0 Gy per fraction to a typical dose of 70 Gy in 7 weeks with single-agent cisplatin given every 3 weeks at 100 mg/m\u00b2</A>; <CO>2\u20133 cycles of chemotherapy are used depending on the radiation fractionation scheme (RTOG 0129)</CO>. <CO>When carboplatin and 5-FU are used</CO>, <A>the recommended regimen is standard fractionation plus 3 cycles of chemotherapy</A>. <CO>Other fraction sizes (e.g., 1.8 Gy, conventional), multiagent chemotherapy, other dosing schedules of cisplatin, or altered fractionation with chemotherapy</CO> <E>are efficacious</E>, and <C>there is no consensus on the optimal approach</C>. <C>In general, the use of concurrent systemic therapy/RT</C> <E>carries a high toxicity burden</E>; <C>multiagent chemotherapy</C> <E>will likely further increase the toxicity burden</E>. <A>For any systemic therapy/RT approach, close attention should be paid to published reports for the specific chemotherapy agent, dose, and schedule of administration</A>. <A>Systemic therapy/RT should be performed by an experienced team and should include substantial supportive care</A>.\\n\\nSection Name: Treatment Modalities\\n====================\\nEntities:-\\nIntensity-Modulated Radiotherapy : A type of conformal radiotherapy that uses computer-controlled linear accelerators to deliver precise radiation doses to a malignant tumor or specific areas within the tumor.\\nIntensity Modulated Radiation Therapy : A type of conformal radiotherapy that uses computer-controlled linear accelerators to deliver precise radiation doses to a malignant tumor or specific areas within the tumor.\\nIntensity-Modulated Radiation Therapy : An advanced type of high-precision radiotherapy that uses computer-controlled linear accelerators to deliver precise radiation doses to a malignant tumor or specific areas within the tumor.\\nRadiotherapy, Conformal : A type of radiotherapy that uses imaging to conform the radiation dose to the shape of the tumor.\\n3D Conformal Radiation Therapy : A technique in radiotherapy that uses imaging to conform the radiation dose to the shape of the tumor.\\nChemotherapy, Adjuvant : Treatment with drugs that kill cancer cells, often used in conjunction with other therapies.\\nChemotherapy : The treatment of disease by the use of chemical substances, especially the treatment of cancer by cytotoxic and other drugs.\\nDrug Therapy, Combination : The use of two or more drugs to achieve a therapeutic effect.\\nSystemic Therapy : A type of therapy that uses substances that travel through the bloodstream, reaching and affecting cells all over the body.\\n\\nRelationships:-\\n1. Entity1: \""Intensity-Modulated Radiation Therapy (IMRT)\"", Entity2: \""3D Conformal Radiation Therapy (3D-CRT)\"", Relationship: \""are delivery methods for radiation therapy\""\\n2. Entity1: \""Chemotherapy\"", Entity2: \""Radiation Therapy\"", Relationship: \""is integrated with for aggressive or advanced cancer cases\""\\n\\nCausalities:-\\n<CO> contingent upon patient-specific considerations </CO> <A> suggests either Intensity-Modulated Radiation Therapy (IMRT) or 3D Conformal Radiation Therapy (3D-CRT) as delivery methods </A>. <A> These advanced techniques are employed to optimize treatment accuracy </A>, <E> preserving surrounding healthy tissue and improving overall patient outcomes </E>. <A> a focus on concurrent systemic therapies underlines the importance of integrating chemotherapy </A>, particularly <CO> for patients with more aggressive forms of cancer or those demonstrating advanced disease characteristics </CO>.\\n\\nSection Name: Additional Information\\n====================\\nEntities:-\\nClinical Trials : Clinical trials are research studies performed in people that are aimed at evaluating a medical, surgical, or behavioral intervention.\\nClinical Trial : A clinical trial is a research study in which one or more human subjects are prospectively assigned to one or more interventions to evaluate the effects of those interventions on health-related biomedical or behavioral outcomes.\\nNational Comprehensive Cancer Network : The National Comprehensive Cancer Network (NCCN) is an alliance of 30 cancer centers in the United States, dedicated to improving the quality, effectiveness, and efficiency of cancer care.\\nIntensity-Modulated Radiation Therapy : An advanced type of high-precision radiotherapy that uses computer-controlled linear accelerators to deliver precise radiation doses to a malignant tumor or specific areas within the tumor.\\nIntensity Modulated Radiation Therapy : A type of conformal radiotherapy that uses computer-controlled linear accelerators to deliver precise radiation doses to a malignant tumor or specific areas within the tumor.\\nThree-Dimensional Conformal Radiation Therapy : A type of external beam radiation therapy that uses a computer to create a 3-dimensional picture of the tumor so that multiple radiation beams can be shaped exactly to the contour of the treatment area.\\n\\nRelationships:-\\n1. Entity1: \""National Comprehensive Cancer Network\"", Entity2: \""Clinical trial\"", Relationship: \""encourages participation in\""\\n2. Entity1: \""Intensity-Modulated Radiation Therapy\"", Entity2: \""Three-Dimensional Conformal Radiation Therapy\"", Relationship: \""recommended alternatives\""\\n\\nCausalities:-\\n<A> Participation in clinical trials </A> is especially encouraged. <A> Either IMRT (preferred) or 3D-CRT is recommended. </A>\\n\\nSection Name: Conclusion\\n====================\\nEntities:-\\nLaryngeal Neoplasms : Tumors or cancer of the larynx, which may affect the glottis, supraglottis, or subglottis.\\nMalignant Neoplasm Of Glottis : A malignant tumor located in the glottic region of the larynx.\\nLaryngeal Cancer : Cancer that occurs in the larynx, or voice box, which may include the glottic region.\\nPrognosis : A medical term for predicting the likely or expected development of a disease.\\nEvidence-Based Practice : Healthcare practices that are based on scientific evidence and research.\\nEvidence-Based Medicine : An approach to medical practice intended to optimize decision-making by emphasizing the use of evidence from well-designed and conducted research.\\n\\nRelationships:-\\n1. Entity1: \""treatment paradigms\"", Entity2: \""glottic larynx cancer\"", Relationship: \""encapsulates\""\\n2. Entity1: \""personalized treatment plans\"", Entity2: \""prognosis\"", Relationship: \""improves\""\\n\\nCausalities:-\\n<C> glottic larynx cancer </C>. <CO> the nuances of each patient\\'s condition </CO>. <A> personalized treatment plans </A> <E> promoting effective management and improved prognosis </E>. <A> deliver clear, evidence-based interventions </A> <CO> considering the complexities involved in cancer treatment </CO>.\\n'}""",valid,increases risk,2,B,"edge - The edge which needs to be verified.
explanation - Explanation of what the edge represents and its validity.
causal_direction - Either Positive or Negative or Unknown. A positive influence direction indicates that both factors change in the same direction (e.g. an increase causes an increase effect). A negative influence direction indicates the opposite changes (e.g. an increase causes a decrease effect).
causal_factor - Is necessary or sufficient condition for an effect to occur. Exposure is a term commonly used in epidemiology to denote any condition that is considered as a possible cause of disease. Exposure is considered necessary when it always precedes the effects (e.g. symptoms) and always presents when the effects occur. A sufficient cause is a causal factor whose presence or occurrence guarantees the occurrence of symptom.
causal_distance - Either Distal or Proximal or Unknown. The distal factors lie towards the beginning of causal chain (i.e. indirect causal factors). The the proximal factors lie towards the end of the chain (i.e. cause directly or almost directly the effect).

Causality Tags:
<A> for action, <C> for cause, <CO> for condition and <E> for effect.
Cause (C): The reason or origin that leads to an effect. Causes often involve disease conditions, risk factors, or underlying mechanisms.
Effect (E): The outcome or result of a cause. Effects usually represent clinical outcomes, complications, or results of a specific cause.
Condition (CO): The circumstance or prerequisite required for an action or effect to occur. Conditions may include patient characteristics, clinical scenarios, or specific diagnostic criteria.
Action (A): The recommended or described response or activity to address a cause or condition. Actions typically involve clinical interventions, diagnostic procedures, or treatment recommendations.


`NODE1`:
id: Size_of_Lymph_Nodes_6
label: Size of Lymph Nodes
description: This node represents the clinical assessment of the size of lymph nodes in a patient. The size of lymph nodes can be an important indicator in diagnosing conditions such as infections, immune responses, or cancer metastasis. Enlarged lymph nodes may suggest the presence of disease, while normal-sized lymph nodes are typically not indicative of pathology.
type: Patient Situation
observability: Unobserved
states: [{'state_name': 'present', 'state_description': 'The lymph nodes are enlarged or have a significant size, which may indicate the presence of disease such as infection, inflammation, or metastasis.'}, {'state_name': 'absent', 'state_description': 'The lymph nodes are not enlarged and are of normal size, suggesting no significant pathology or disease.'}]

`NODE2`:
id: N_State_1
label: Nearby Lymph Nodes Cancer State
description: This node represents the clinical situation regarding the presence or absence of cancer in nearby lymph nodes. It is a critical factor in cancer staging and prognosis, as the involvement of lymph nodes can indicate the spread of cancer and affect treatment decisions.
type: Decision Node
observability: Needs to be Predicted
states: [{'state_name': 'present', 'state_description': 'Cancer is present in the nearby lymph nodes, indicating potential metastasis and a more advanced stage of cancer.'}, {'state_name': 'absent', 'state_description': 'Cancer is absent in the nearby lymph nodes, suggesting that the cancer has not spread to these nodes and may be in an earlier stage.'}]

`EDGE1`:
{'edges_ids': ['Size_of_Lymph_Nodes_6', 'N_State_1'], 'edge': '(Size_of_Lymph_Nodes_6) causes (N_State_1)', 'explanation': ['The edge represents the relationship where the size of lymph nodes (Size_of_Lymph_Nodes_6) influences the cancer state of nearby lymph nodes (N_State_1).', 'Enlarged lymph nodes can indicate the presence of cancer, suggesting a positive causal direction.', 'However, enlarged lymph nodes are not a necessary condition for cancer presence, as cancer can exist without enlargement.', 'Enlarged lymph nodes are also not a sufficient condition for cancer presence, as they can be enlarged due to other conditions like infection.', 'The causal relationship is proximal because the size of lymph nodes is directly related to their cancer state in the context of metastasis.'], 'causal_direction': 'positive', 'causal_factor': {'necessary': False, 'sufficient': False}, 'causal_distance': 'Proximal'}

`EDGE2`:
{'edges_ids': ['N_State_1', 'Size_of_Lymph_Nodes_6'], 'edge': '(N_State_1) causes (Size_of_Lymph_Nodes_6)', 'explanation': ['The edge represents the causal relationship where the presence of cancer in nearby lymph nodes (N_State_1) leads to an increase in the size of those lymph nodes (Size_of_Lymph_Nodes_6).', 'This is a valid causal relationship because cancer in lymph nodes typically causes them to enlarge.', 'The causal direction is positive because the presence of cancer (N_State_1) increases the size of lymph nodes (Size_of_Lymph_Nodes_6).', 'The presence of cancer in lymph nodes is a sufficient condition for enlargement, but not necessary, as other factors can also cause enlargement.', 'The causal distance is proximal because the presence of cancer directly affects the size of the lymph nodes.'], 'causal_direction': 'positive', 'causal_factor': {'necessary': False, 'sufficient': True}, 'causal_distance': 'Proximal'}

`INFORMATION FROM KNOWLEDGE BASE`:
--------------------------------------------------
Page Number: 102

Section Name: Head and Neck Cancers - Principles of Surgery
====================
Entities:-
Surgical Procedures, Operative : Manual or operative procedures used in the treatment of disease, injuries, or deformities.
Lymphatic System : Part of the circulatory system and a vital part of the immune system, comprising a network of lymphatic vessels that carry a clear fluid called lymph.
Neoplasms : New abnormal growth of tissue in animals or plants; a tumor.
Neck Dissection : A surgical procedure for control of neck lymph node metastasis from squamous cell carcinoma of the head and neck.
Neoplasm Staging : Methods which attempt to express in replicable terms the extent of the neoplasm in the patient.
Metastasis : The spread of a cancer or other disease from one organ or part of the body to another not directly connected with it.
Surgical Procedure : A procedure involving an incision with instruments; performed to repair damage or arrest disease in a living body.
Lymphatic Structure : Anatomical structure that is part of the lymphatic system.
Tumor : An abnormal mass of tissue that results when cells divide more than they should or do not die when they should.
Staging : The process of determining the size and spread of cancer within the body.
Surgery : Medical specialty that uses operative manual and instrumental techniques on a patient to investigate or treat a pathological condition such as disease or injury.
Cancer Staging : The process of determining the extent to which a cancer has developed by growing and spreading.

Relationships:-
1. Entity1: ""surgical management"", Entity2: ""regional lymphatics"", Relationship: ""dictated by tumor staging""
2. Entity1: ""neck dissections"", Entity2: ""primary tumor"", Relationship: ""part of treatment""
3. Entity1: ""surgery"", Entity2: ""ipsilateral side of the neck"", Relationship: ""risk for metastases""

Causalities:-
<C> The extent of the tumor at initial tumor staging </C> <E> dictates the surgical management of regional lymphatics </E>. These guidelines apply to the performance of neck dissections as part of treatment of the primary tumor. <CO> Patients undergoing surgery for resection of the primary tumor </CO> <A> will undergo dissection of the ipsilateral side of the neck that is at greatest risk for metastases </A>.

Section Name: Neck Management
====================
Entities:-
Tongue : A muscular organ in the mouth that is involved in tasting, swallowing, and speech.
Palate : The roof of the mouth, separating the oral and nasal cavities.
Larynx : An organ in the top of the neck involved in breathing, producing sound, and protecting the trachea.
Hypopharynx : The bottom part of the pharynx, which is the cavity behind the nose and mouth.
Nasopharynx : The upper part of the pharynx, connecting with the nasal cavity above the soft palate.
Neck Dissection : A surgical procedure for control of neck lymph node metastasis from squamous cell carcinoma of the head and neck.
Metastasis : The spread of a cancer or other disease from one organ or part of the body to another not directly connected with it.
Squamous Cell Carcinoma : A type of cancer that begins in the squamous cells, which are thin, flat cells that look like fish scales.
Biopsy : The removal of cells or tissues for examination under a microscope.

Relationships:-
1. Entity1: ""Tumor sites"", Entity2: ""Bilateral lymphatic drainage"", Relationship: ""associated with""
2. Entity1: ""Elective neck dissection"", Entity2: ""Risk of occult metastasis"", Relationship: ""based on""
3. Entity1: ""SLN biopsy"", Entity2: ""Elective neck dissection"", Relationship: ""guides decision-making for""

Causalities:-
- **<C> Tumor sites that frequently have bilateral lymphatic drainage </C>** (e.g., base of tongue, palate, supraglottic larynx, hypopharynx, nasopharynx, deep pre-epiglottic space involvement) <E> often should have both sides of the neck dissected </E> with the extent of dissection determined as suggested below. For those patients with tumors at or approaching the midline, <CO> both sides of the neck are at risk for metastases </CO>, and <A> bilateral neck dissections should be performed </A>.

- <CO> Patients with advanced lesions involving the anterior tongue, floor of the mouth, or alveolus that approximate or cross the midline </CO> <A> should undergo contralateral selective/modified neck dissection </A> as necessary to achieve adequate tumor resection.

- **<C> Elective neck dissection </C>** <A> should be based on risk of occult metastasis in the appropriate nodal basin </A>. For oral cavity squamous cell carcinoma, <C> SLN biopsy or the primary tumor depth of invasion </C> is currently <E> the best predictor of occult metastatic disease </E> and <A> should be used to guide decision-making </A>. <CO> For tumors with a depth greater than 3 mm </CO>, <A> elective dissection should be strongly considered if RT is not already planned </A>. Recent randomized trial evidence supports the effectiveness of elective neck dissection in patients with oral cavity cancers greater than 3 mm in depth of invasion.

  - <CO> For a depth less than 2 mm </CO>, <A> elective dissection is only indicated in highly selective situations </A>. <CO> For a depth of 2–4 mm </CO>, <A> clinical judgment (as to reliability of follow-up, clinical suspicion, and other factors) must be utilized to determine appropriateness of elective dissection </A>. Elective dissections are generally selective, preserving all major structures, unless operative findings dictate otherwise.

Section Name: Types of Neck Dissection
====================
Entities:-
Neck Dissection : A surgical procedure for control of neck lymph node metastasis from squamous cell carcinoma of the head and neck.
Larynx : An organ in the top of the neck involved in breathing, producing sound, and protecting the trachea.

Relationships:-
1. Entity1: ""N0"", Entity2: ""Selective neck dissection"", Relationship: ""associated with""
2. Entity1: ""N3"", Entity2: ""Comprehensive neck dissection"", Relationship: ""associated with""
3. Entity1: ""Level VI neck dissection"", Entity2: ""Larynx"", Relationship: ""performed for""
4. Entity1: ""Level VI neck dissection"", Entity2: ""Hypopharynx"", Relationship: ""performed for""

Causalities:-
- **The type of neck dissection (comprehensive or selective)** is defined according to <CO> preoperative clinical staging </CO>, is determined at the discretion of the surgeon, and is based on the initial preoperative staging as follows:
  - **N0:** <A> Selective neck dissection </A>
    - Oral cavity at least levels I–III
    - Oropharynx at least levels II–IV
    - Hypopharynx at least levels II–IV and level VI when appropriate
    - Larynx at least levels II–IV and level VI when appropriate
  - **N1–N2a–c:** <A> Selective or comprehensive neck dissection </A> (Discussion)
  - **N3:** <A> Comprehensive neck dissection </A>

- <C> Level VI neck dissections are performed for certain primary sites (such as the larynx and hypopharynx) </C> <E> as required to resect the primary tumor and any clinically evident neck nodes </E>. <CO> Elective dissection depends on primary tumor extent and site </CO>. <CO> For advanced glottic and hypopharyngeal cancers treated with primary surgery </CO>, <A> a level VI dissection (including pretracheal lymph nodes, the Delphian lymph node, and unilateral or bilateral paratracheal lymph nodes) and hemithyroidectomy to total thyroidectomy are appropriate </A>.

- <CO> For primary subglottic tumors or glottic cancers with significant subglottic extension </CO>, <A> a level VI dissection with unilateral or total thyroidectomy is considered appropriate </A> based on the extent of the primary tumor. <CO> For example, a T4a glottic tumor with extension through the cricothyroid membrane and subglottic extension </CO> <A> should include thyroidectomy and pretracheal and bilateral paratracheal lymph node dissection </A>. <A> Parathyroid glands should be preserved in situ or auto transplanted as indicated </A>.
--------------------------------------------------
Page Number: 55

Section Name: General Information
====================
Entities:-
National Comprehensive Cancer Network : An alliance of 32 cancer centers in the United States, dedicated to improving the quality, effectiveness, and efficiency of cancer care.
Nccn Guidelines : Clinical practice guidelines in oncology developed by the National Comprehensive Cancer Network.

Relationships:-
1. Entity1: ""NCCN Guidelines"", Entity2: ""National Comprehensive Cancer Network"", Relationship: ""produced by""

Section Name: Important Notes
====================
Entities:-
Clinical Trials As Topic : Works about research studies that evaluate the effectiveness and safety of medical, surgical, or behavioral interventions.
Clinical Trial : A type of research that studies new tests and treatments and evaluates their effects on human health outcomes.
National Comprehensive Cancer Network : An alliance of 32 cancer centers in the United States, dedicated to improving the quality, effectiveness, and efficiency of cancer care.
Neoplasms : New abnormal growth of tissue that can be benign or malignant.
Malignant Neoplastic Disease : A disease resulting from the growth of malignant neoplasms.
Cancer : A group of diseases involving abnormal cell growth with the potential to invade or spread to other parts of the body.

Relationships:-
1. Entity1: ""Clinical Trials"", Entity2: ""Cancer"", Relationship: ""recommended for""
2. Entity1: ""NCCN"", Entity2: ""Clinical Trials"", Relationship: ""encourages participation in""

Causalities:-
<C> NCCN believes that the best management of any patient with cancer is in a clinical trial </C>. <A> Participation in clinical trials is especially encouraged </A>.

Section Name: Principles
====================
Entities:-
Surgical Procedures, Operative : Surgical procedures involve the use of operative manual and instrumental techniques on a patient to investigate or treat a pathological condition such as disease or injury.
Radiation Therapy : Therapy using ionizing radiation, generally as part of cancer treatment to control or kill malignant cells.
Chemotherapy : A type of cancer treatment that uses one or more anti-cancer drugs as part of a standardized chemotherapy regimen.

Relationships:-
1. Entity1: ""Principles of Surgery"", Entity2: ""Principles of Radiation Therapy"", Relationship: ""Both are principles of cancer treatment methods.""
2. Entity1: ""Principles of Surgery"", Entity2: ""Principles of Systemic Therapy for Non-Nasopharyngeal Cancers"", Relationship: ""Both are principles of cancer treatment methods.""
3. Entity1: ""Principles of Radiation Therapy"", Entity2: ""Principles of Systemic Therapy for Non-Nasopharyngeal Cancers"", Relationship: ""Both are principles of cancer treatment methods.""

Causalities:-
### Principles

- **Principles of Surgery (SURG-A)**
- **Principles of Radiation Therapy (SUPRA-A)**
- **Principles of Systemic Therapy for Non-Nasopharyngeal Cancers (SYST-A)**

Section Name: Adverse Pathologic Features
====================
Entities:-
Extranodal Extension : The spread of cancer cells beyond the lymph node capsule into the surrounding tissues.
Positive Surgical Margin : The presence of cancer cells at the edge of the tissue removed during surgery, indicating that some cancer may have been left behind.
Perineural Invasion : The presence of cancer cells surrounding or tracking along a nerve within the perineural space.
Vascular Invasion : The invasion of cancer cells into blood vessels.
Lymphatic Invasion : The invasion of cancer cells into lymphatic vessels.

Relationships:-
1. Entity1: ""Extranodal extension"", Entity2: ""Adverse Pathologic Features"", Relationship: ""is a type of""
2. Entity1: ""Positive margins"", Entity2: ""Adverse Pathologic Features"", Relationship: ""is a type of""
3. Entity1: ""Close margins"", Entity2: ""Adverse Pathologic Features"", Relationship: ""is a type of""
4. Entity1: ""pT3 or pT4 primary"", Entity2: ""Adverse Pathologic Features"", Relationship: ""is a type of""
5. Entity1: ""pN2 or pN3 nodal disease"", Entity2: ""Adverse Pathologic Features"", Relationship: ""is a type of""
6. Entity1: ""Perineural invasion"", Entity2: ""Adverse Pathologic Features"", Relationship: ""is a type of""
7. Entity1: ""Vascular invasion"", Entity2: ""Adverse Pathologic Features"", Relationship: ""is a type of""
8. Entity1: ""Lymphatic invasion"", Entity2: ""Adverse Pathologic Features"", Relationship: ""is a type of""

Causalities:-
<C> Extranodal extension </C>
<C> Positive margins </C>
<C> Close margins </C>
<C> pT3 or pT4 primary </C>
<C> pN2 or pN3 nodal disease </C>
<C> Perineural invasion </C>
<C> Vascular invasion </C>
<C> Lymphatic invasion </C>

Section Name: Response Assessment
====================
Entities:-
Chemotherapy, Induction : Initial chemotherapy treatment to shrink a tumor before the main treatment.
Primary Site : The original location where a tumor or cancer begins.
Complete Remission : The disappearance of all signs of cancer in response to treatment.
Partial Remission : A decrease in the size of a tumor, or in the extent of cancer in the body, in response to treatment.
Radiotherapy : The use of high-energy radiation to kill cancer cells and shrink tumors.
Surgical Procedures, Operative : Surgical procedures involve the use of operative manual and instrumental techniques on a patient to investigate or treat a pathological condition such as disease or injury.

Relationships:-
1. Entity1: ""induction chemotherapy"", Entity2: ""Primary site"", Relationship: ""treatment outcome""
2. Entity1: ""Definitive RT"", Entity2: ""Primary site"", Relationship: ""treatment option""
3. Entity1: ""RT"", Entity2: ""Primary site"", Relationship: ""treatment option""
4. Entity1: ""Surgery"", Entity2: ""unresectable nodal disease"", Relationship: ""treatment option""

Causalities:-
<C> Response after induction chemotherapy </C>: <E> Primary site: CR </E> <E> Primary site: PR </E> <E> Primary site: < PR </E> <A> Definitive RT </A> (category 1) <A> RT </A> (category 1) or <A> systemic therapy/RT </A> (category 2B) <A> Surgery </A> or <A> unresectable nodal disease </A>

Section Name: Follow-up
====================
Entities:-
Follow-Up Studies : Studies in which individuals are followed over time to determine the outcome of exposures, treatments, or interventions.
Follow-Up Procedure : A procedure where a patient is monitored over time to assess the progress of a condition or the effects of treatment.
Follow-Up (Medicine) : The process of monitoring a patient's health over time after treatment or diagnosis.
Disease Recurrence : The return of a sign, symptom, or disease after a remission.
Recurrent Disease : A disease that returns after a period of remission.
Recurrence (Medicine) : The return of a disease or condition after a period of improvement.

Relationships:-
1. Entity1: ""Follow-up"", Entity2: ""Recurrent or persistent disease"", Relationship: ""monitoring""

Causalities:-
### Follow-up

- **Follow-up** (FOLL-A, 1 of 2)
- **Recurrent or persistent disease** (ADV-3)

Section Name: Risk Features
====================
Entities:-
Radiotherapy : The use of high-energy radiation to kill cancer cells and shrink tumors.
Extranodal Extension : The spread of cancer cells beyond the lymph node capsule into the surrounding tissues.
Positive Surgical Margin : The presence of cancer cells at the edge of the tissue removed during surgery, indicating that some cancer may have been left behind.
Systemic Therapy : Systemic therapy refers to treatment using substances that travel through the bloodstream, reaching and affecting cells all over the body.

Relationships:-
1. Entity1: ""Adverse pathologic features"", Entity2: ""RT"", Relationship: ""Consideration for treatment""
2. Entity1: ""Adverse pathologic features"", Entity2: ""Systemic therapy"", Relationship: ""Consideration for treatment""

Causalities:-
- **No adverse pathologic features**
- **Other risk features**
- **Adverse pathologic features**:
  - <C> Extranodal extension and/or positive margin </C>
  - <A> RT or consider systemic therapy/RT </A>

Section Name: Post-Therapy Evaluation
====================
Entities:-
Systemic Therapy : Systemic therapy refers to treatment using substances that travel through the bloodstream, reaching and affecting cells all over the body.
Radiation Therapy : Therapy using ionizing radiation, generally as part of cancer treatment to control or kill malignant cells.
Neck : The neck is the part of the body that separates the head from the torso and provides the mobility and movements of the head.

Relationships:-
1. Entity1: ""Systemic Therapy"", Entity2: ""Neck Evaluation"", Relationship: ""evaluated in""
2. Entity1: ""RT"", Entity2: ""Neck Evaluation"", Relationship: ""evaluated in""

Causalities:-
<CO> Post Systemic Therapy/RT or RT Neck </CO> <A> Evaluation </A>

Section Name: Flowchart Overview
====================
Entities:-
Laryngeal Neoplasms : Tumors or cancer of the larynx, which may affect the supraglottic, glottic, or subglottic regions.
Supraglottic Larynx : The part of the larynx located above the vocal cords, including the epiglottis and aryepiglottic folds.
National Comprehensive Cancer Network : An alliance of 32 cancer centers in the United States, dedicated to improving the quality, effectiveness, and efficiency of cancer care.

Relationships:-
1. Entity1: ""NCCN Guidelines"", Entity2: ""cancer of the supraglottic larynx"", Relationship: ""guides management of""
2. Entity1: ""NCCN Guidelines"", Entity2: ""healthcare professionals"", Relationship: ""used by""

Causalities:-
<C> cancer of the supraglottic larynx </C> <E> evaluate patient responses following treatment </E> <CO> based on observed outcomes </CO> <A> evaluation of the primary site and determining subsequent steps </A>.

Section Name: Assessment and Treatment Decisions
====================
Entities:-
Induction Chemotherapy : Initial chemotherapy treatment to shrink a tumor before the main treatment.
Complete Response : The disappearance of all signs of cancer in response to treatment.
Partial Response : A decrease in the size of a tumor, or in the extent of cancer in the body, in response to treatment.
Radiation Therapy : Therapy using ionizing radiation, generally as part of cancer treatment to control or kill malignant cells.
Surgery : Medical specialty that uses operative manual and instrumental techniques on a patient to investigate or treat a pathological condition such as disease or injury.
Systemic Therapy : Systemic therapy refers to treatment using substances that travel through the bloodstream, reaching and affecting cells all over the body.

Relationships:-
1. Entity1: ""Complete Response"", Entity2: ""Radiation Therapy"", Relationship: ""leads to""
2. Entity1: ""Complete Response"", Entity2: ""Surgery"", Relationship: ""leads to""
3. Entity1: ""Partial Response"", Entity2: ""Systemic Therapy"", Relationship: ""leads to""
4. Entity1: ""Partial Response"", Entity2: ""Radiation Therapy"", Relationship: ""leads to""

Causalities:-
<C> responses to initial treatments such as induction chemotherapy </C> <E> Three main response categories are recognized: Complete Response (CR), Partial Response (PR), and less than Partial Response (< PR) </E>. These categories are pivotal in determining the next steps. <C> CR </C> <E> indicates full resolution of the disease at the primary site </E>, <A> leading to the consideration of definitive radiation therapy or the likelihood of surgery </A>. Conversely, <C> PR </C> <E> suggests that the disease has improved but not completely resolved </E>, <A> which directs the pathway towards either systemic therapy or continued radiation therapy </A>, <A> with further evaluation necessary </A>.

Section Name: Adverse Pathologic Features and Follow-up
====================
Entities:-
Radiation Therapy : Therapy using ionizing radiation, generally as part of cancer treatment to control or kill malignant cells.
Surgical Procedures, Operative : Surgical procedures involve the use of operative manual and instrumental techniques on a patient to investigate or treat a pathological condition such as disease or injury.
Neoplasm Recurrence, Local : The return of a tumor or cancer, at the original site, after it has been treated.
Neoplasm Metastasis : The transfer of a neoplasm from one organ or part of the body to another remote from the primary site.
Surgical Procedure : A medical procedure involving an incision with instruments; performed to repair damage or arrest disease in a living body.
Recurrent Neoplasm : A neoplasm that has returned after treatment.
Metastatic Neoplasm : A neoplasm that has spread from its original site to one or more other places in the body.
Surgery : Medical specialty that uses operative manual and instrumental techniques on a patient to investigate or treat a pathological condition such as disease or injury.
Cancer Recurrence : The return of cancer after treatment and after a period of time during which the cancer was undetectable.
Metastasis : Spread of a cancer or other disease from one organ or part to another not directly connected with it.

Relationships:-
1. Entity1: ""Adverse pathologic features"", Entity2: ""Treatment decisions"", Relationship: ""Influence""
2. Entity1: ""Adverse features"", Entity2: ""Surgical intervention"", Relationship: ""Recommendation""
3. Entity1: ""Absence of adverse features"", Entity2: ""Radiation therapy"", Relationship: ""Pathway""
4. Entity1: ""Follow-up process"", Entity2: ""Recurrent or persistent disease"", Relationship: ""Detection""
5. Entity1: ""Recurrent or persistent disease"", Entity2: ""Advanced disease management"", Relationship: ""Necessity""

Causalities:-
<C> The presence of adverse pathologic features — such as extranodal extension or positive margins </C> <E> can directly influence treatment decisions </E>. <CO> If adverse features are found </CO>, <A> surgical intervention is recommended </A>. <CO> In cases where there are no adverse features </CO>, the patient may proceed directly to radiation therapy or continued systemic treatment, emphasizing the tailored approach based on the individual patient's disease characteristics.

Furthermore, the chart includes a section addressing the follow-up process after initial treatment. <CO> If there are signs of recurrent or persistent disease </CO>, <A> additional evaluations and treatment modalities may be necessary </A>. These evaluations <E> lead to specific recommendations for advanced disease management, denoted as ADV-3 on the chart </E>, emphasizing the importance of continuous monitoring and assessment in cancer care.
--------------------------------------------------
Page Number: 51

Section Name: Introduction
====================
Entities:-
Laryngeal Neoplasms : Tumors or cancer of the larynx, which may affect the supraglottic, glottic, or subglottic regions.
Malignant Neoplasm Of Supraglottis : A malignant tumor located in the supraglottic region of the larynx.
Supraglottic Laryngeal Cancer : A type of cancer that occurs in the supraglottic region of the larynx, which is above the vocal cords.

Relationships:-
1. Entity1: ""National Comprehensive Cancer Network (NCCN)"", Entity2: ""cancer of the supraglottic larynx"", Relationship: ""provides guidelines for""
2. Entity1: ""healthcare professionals"", Entity2: ""cancer of the supraglottic larynx"", Relationship: ""manage""

Causalities:-
The provided image is a detailed flowchart from the National Comprehensive Cancer Network (NCCN) guidelines regarding the <C> clinical staging and treatment protocols for cancer of the supraglottic larynx </C>. This flowchart is structured to <A> guide healthcare professionals through the stages of treatment </A> based on <CO> clinical findings </CO>, emphasizing the <E> complexity and systematic approach required in managing this type of cancer </E>.

Section Name: Clinical Staging
====================
Entities:-
Laryngectomy : A surgical procedure involving the removal of the larynx, usually to treat cancer of the larynx.
Total Laryngectomy : A surgical procedure to remove the entire larynx, often used in the treatment of advanced laryngeal cancer.
Neoplasm Staging : Methods used for staging neoplasms, including clinical and pathological staging.
Cancer Staging : The process of determining the extent of cancer in the body, often using the TNM system.
Tnm Staging System : A cancer staging system that describes the extent of cancer using Tumor size (T), Node involvement (N), and Metastasis (M).

Relationships:-
1. Entity1: ""Clinical staging criteria"", Entity2: ""Total laryngectomy"", Relationship: ""determines necessity of""
2. Entity1: ""T3, N0"", Entity2: ""Clinical staging criteria"", Relationship: ""is a categorization of""

Causalities:-
The flowchart begins with the <C> clinical staging criteria </C>, specifically focusing on <CO> cases that require total laryngectomy, denoted as requiring (amenable to) total laryngectomy (T3, N0) </CO>. This <A> categorization </A> is crucial as it <E> forms the basis for determining the appropriate treatment strategy </E>.

Section Name: Treatment of Primary and Neck
====================
Entities:-
Neoplasm Staging : Methods used for staging neoplasms, including clinical and pathological staging.
Systemic Therapy : Treatment using substances that travel through the bloodstream, reaching and affecting cells all over the body.
Radiotherapy : The use of high-energy radiation from x-rays, gamma rays, neutrons, protons, and other sources to kill cancer cells and shrink tumors.
Laryngectomy : A surgical procedure involving the removal of the larynx, usually to treat cancer of the larynx.
Thyroidectomy : A surgical procedure to remove all or part of the thyroid gland.
Neck Dissection : Surgical procedure to remove lymph nodes and surrounding tissue to treat or prevent cancer spread.
Lymphatic Metastasis : Transfer of a neoplasm from one organ or part of the body to another remote from the primary site.

Relationships:-
1. Entity1: ""Systemic Therapy"", Entity2: ""Radiation Therapy"", Relationship: ""combined with""
2. Entity1: ""Laryngectomy"", Entity2: ""Lymph Node Involvement"", Relationship: ""considered based on""
3. Entity1: ""Thyroidectomy"", Entity2: ""Lymph Node Involvement"", Relationship: ""considered based on""
4. Entity1: ""Neck Dissection"", Entity2: ""Lymph Node Involvement"", Relationship: ""considered based on""

Causalities:-
<CO> Once clinical staging is established </CO>, the chart outlines various treatment options. <A> The initial step may involve either concurrent systemic therapy combined with radiation therapy (RT) or opting for RT alone </A>, <CO> especially if the patient is not a medical candidate for both therapies </CO>. <A> Laryngectomy, thyroidectomy, and neck dissection are considered </A> <CO> based on the extent of lymph node involvement </CO>.

Section Name: Surgical Options
====================
Entities:-
Laryngectomy : A surgical procedure involving the removal of the larynx, usually to treat cancer of the larynx.
Thyroidectomy : A surgical procedure to remove all or part of the thyroid gland.
Lymph Node Excision : Surgical removal of one or more lymph nodes.
Lymphadenectomy : Surgical removal of one or more groups of lymph nodes.
Surgical Procedures, Operative : Operations carried out for the correction of deformities and defects, repair of injuries, and diagnosis and cure of certain diseases.
Surgical Procedure : A medical procedure involving an incision with instruments; performed to repair damage or arrest disease in a living body.
Surgery : Medical specialty that uses operative manual and instrumental techniques on a patient to investigate or treat a pathological condition such as a disease or injury.

Relationships:-
1. Entity1: ""Laryngectomy"", Entity2: ""Thyroidectomy"", Relationship: ""combined with""
2. Entity1: ""Lymph Node Dissection"", Entity2: ""Surgical Intervention"", Relationship: ""extent of""
3. Entity1: ""Surgical Intervention"", Entity2: ""Advanced Cases"", Relationship: ""management option for""

Causalities:-
<CO> If concurrent therapies are not suitable </CO>, <A> the chart presents laryngectomy combined with thyroidectomy </A>, <CO> depending on the extent of lymph node dissection required </CO>. <E> This highlights surgical intervention as a viable option in the management of advanced cases </E>.

Section Name: Induction Chemotherapy
====================
Entities:-
Induction Chemotherapy : Initial chemotherapy treatment used to shrink a tumor before the main treatment, which is usually surgery.
Surgical Procedure : A medical procedure involving an incision with instruments; performed to repair damage or arrest disease in a living body.
Therapeutic Approach : A method or strategy used in the treatment of disease or injury.

Relationships:-
1. Entity1: ""Induction Chemotherapy"", Entity2: ""Surgical Intervention"", Relationship: ""alternative or sequential treatment option""

Causalities:-
<C> immediate surgical intervention is either not feasible or considered insufficient </C> <E> The flowchart also considers the option of induction chemotherapy </E> <CO> in cases where immediate surgical intervention is either not feasible or considered insufficient </CO>. <A> tailoring therapeutic approaches tailored to individual patient needs </A>.

Section Name: Adjuvant Treatment
====================
Entities:-
Adjuvant Chemotherapy : Chemotherapy given in addition to the primary treatment to maximize its effectiveness.
Radiotherapy : The use of high-energy radiation from x-rays, gamma rays, neutrons, protons, and other sources to kill cancer cells and shrink tumors.
Neoplasm Recurrence, Local : The return of a cancer, at the same site, after it has been treated.
Disease Progression : The worsening of a disease over time.

Relationships:-
1. Entity1: ""Primary Treatment"", Entity2: ""Adjuvant Treatment"", Relationship: ""followed by""
2. Entity1: ""Adjuvant Treatment"", Entity2: ""Systemic Therapy"", Relationship: ""includes""
3. Entity1: ""Adjuvant Treatment"", Entity2: ""Radiotherapy"", Relationship: ""includes""
4. Entity1: ""Follow-up Assessments"", Entity2: ""Treatment Efficacy"", Relationship: ""used to evaluate""

Causalities:-
<C> Following primary treatment </C>, <E> the flowchart addresses the potential for adjuvant treatment pathways </E>. This may include systemic therapy, RT, or further evaluations based on <CO> the patient's response and any recurrence or persistent disease </CO>. It emphasizes <A> the need for follow-up assessments to evaluate treatment efficacy </A>.

Section Name: Risk Features and Response Assessment
====================
Entities:-
Neoplasm Invasiveness : The property of a neoplasm to infiltrate and destroy surrounding tissue.
Surgical Margins : The edge or border of the tissue removed in cancer surgery.
Neoplasms : Neoplasms are abnormal growths of tissue, which can be cancerous or non-cancerous.
Extramural Extension : Extension of a tumor beyond the wall of an organ.
Positive Surgical Margin : Cancer cells are present at the edge of the tissue removed during surgery.
Cancer Management : The process of planning and coordinating the treatment of cancer.
Cancer : Cancer is a group of diseases involving abnormal cell growth with the potential to invade or spread to other parts of the body.

Relationships:-
1. Entity1: ""Extramural extension"", Entity2: ""Treatment decisions"", Relationship: ""influences""
2. Entity1: ""Positive surgical margin"", Entity2: ""Treatment decisions"", Relationship: ""influences""
3. Entity1: ""Ongoing assessment"", Entity2: ""Response evaluation"", Relationship: ""leads to""
4. Entity1: ""Response evaluation"", Entity2: ""Adjustments to treatment"", Relationship: ""leads to""
5. Entity1: ""Management of cancer"", Entity2: ""Treatment decisions"", Relationship: ""involves""
6. Entity1: ""Management of cancer"", Entity2: ""Ongoing assessment"", Relationship: ""involves""
7. Entity1: ""Management of cancer"", Entity2: ""Adjustments to treatment"", Relationship: ""involves""

Causalities:-
The chart incorporates a segment that takes into account <CO> adverse pathologic features, such as extramural extension or positive margins </CO>, <E> which could influence subsequent treatment decisions </E>. This highlights the importance of <A> ongoing assessment in the management of cancer, leading to response evaluation and adjustments to treatment as necessary </A>.

Section Name: NCCN Guidelines Version 4.2024
====================
Entities:-
Clinical Trials : Clinical trials are research studies performed in people that are aimed at evaluating a medical, surgical, or behavioral intervention.
Neoplasms : Neoplasms are abnormal growths of tissue, which can be cancerous or non-cancerous.
Clinical Trial : A clinical trial is a research study that prospectively assigns human participants or groups of humans to one or more health-related interventions to evaluate the effects on health outcomes.
Malignant Neoplasm : A malignant neoplasm is a cancerous growth that has the potential to invade and destroy nearby tissue and spread to other parts of the body.
National Comprehensive Cancer Network : The National Comprehensive Cancer Network (NCCN) is an alliance of 31 cancer centers in the United States, dedicated to improving the quality, effectiveness, and efficiency of cancer care.
Cancer : Cancer is a group of diseases involving abnormal cell growth with the potential to invade or spread to other parts of the body.

Relationships:-
1. Entity1: ""National Comprehensive Cancer Network"", Entity2: ""NCCN Guidelines"", Relationship: ""provides""
2. Entity1: ""NCCN Guidelines"", Entity2: ""Clinical Trials"", Relationship: ""recommend""
3. Entity1: ""NCCN Guidelines"", Entity2: ""Cancer"", Relationship: ""related to management of""

Causalities:-
<CO> any patient with cancer </CO> <A> the best management is in a clinical trial </A>. <A> Participation in clinical trials is especially encouraged </A>.

Section Name: SUPRA-3
====================
Entities:-
Laryngectomy : A surgical procedure involving the removal of the larynx, usually to treat cancer of the larynx.
Thyroidectomy : A surgical procedure to remove all or part of the thyroid gland.
Neck Dissection : Surgical procedure to remove lymph nodes and surrounding tissue to treat or prevent cancer spread.
Chemotherapy, Induction : Initial chemotherapy treatment to shrink a tumor before the main treatment.
Clinical Trials As Topic : Research studies that prospectively assign human participants or groups of humans to one or more health-related interventions to evaluate the effects on health outcomes.
Induction Chemotherapy : Initial chemotherapy treatment used to shrink a tumor before the main treatment, which is usually surgery.
Clinical Trial : A clinical trial is a research study that prospectively assigns human participants or groups of humans to one or more health-related interventions to evaluate the effects on health outcomes.

Relationships:-
1. Entity1: ""Total laryngectomy"", Entity2: ""Laryngectomy"", Relationship: ""is a type of""
2. Entity1: ""Systemic therapy"", Entity2: ""RT"", Relationship: ""concurrent treatment option""
3. Entity1: ""Induction chemotherapy"", Entity2: ""Other treatments"", Relationship: ""initial treatment option before""

Causalities:-
<CO> Requiring (amenable to) total laryngectomy (T3,N0) </CO>
  - <A> Concurrent systemic therapy/RT </A> or <A> RT if patient not medical candidate for concurrent systemic therapy/RT </A>
  - <A> Laryngectomy, thyroidectomy and with ipsilateral, central, or bilateral neck dissection </A>
  - or
  - <A> Induction chemotherapy </A>
  - or
  - <A> Clinical trials </A>

Section Name: Follow-up
====================
Entities:-
Follow-Up Studies : Studies in which individuals are followed over time to determine the outcome of exposures, treatments, or interventions.
Follow-Up Procedure : A procedure performed to monitor the progress of a patient's condition after initial treatment.
Follow-Up : Medical care given to a patient over time after initial treatment.
Disease Recurrence : The return of a sign, symptom, or disease after a remission.
Recurrent Disease : The reappearance of a disease after a period of improvement.

Relationships:-
1. Entity1: ""Follow-up"", Entity2: ""Recurrent or persistent disease"", Relationship: ""monitoring""

Causalities:-
- **Follow-up (FOLL-A, 1 of 2)**
  - <CO> Recurrent or persistent disease </CO> (ADV-3)

Section Name: Adverse Pathologic Features
====================
Entities:-
Radiotherapy : The use of high-energy radiation from x-rays, gamma rays, neutrons, protons, and other sources to kill cancer cells and shrink tumors.
Extranodal Extension : The spread of cancer beyond the lymph node capsule.
Positive Surgical Margin : Cancer cells are present at the edge of the tissue removed during surgery.
Systemic Therapy : Treatment using substances that travel through the bloodstream, reaching and affecting cells all over the body.

Relationships:-
1. Entity1: ""pN1"", Entity2: ""Radiotherapy"", Relationship: ""Consideration for treatment""
2. Entity1: ""Extranodal extension"", Entity2: ""Systemic Therapy"", Relationship: ""Treatment option""
3. Entity1: ""Extranodal extension"", Entity2: ""Radiotherapy"", Relationship: ""Treatment option""
4. Entity1: ""Positive surgical margin"", Entity2: ""Systemic Therapy"", Relationship: ""Treatment option""
5. Entity1: ""Positive surgical margin"", Entity2: ""Radiotherapy"", Relationship: ""Treatment option""

Causalities:-
- <CO>pN1 without other risk features</CO>
  - <C>Adverse pathologic features</C>
  - <A>Consider RT</A>
  - <CO>Extranodal extension and/or positive margin</CO>
  - <CO>Other risk features</CO>
  - <A>Systemic therapy/RT (category 1)</A>
  - <A>RT or Consider systemic therapy/RT</A>

Section Name: Response Assessment
====================
Entities:-
Response Evaluation : The process of assessing the response of a disease to treatment, often used in clinical trials to determine the effectiveness of a therapy.
Response To Treatment : A clinical finding indicating the response of a condition to a therapeutic intervention.

Relationships:-

Section Name: Principles of Surgery and Radiation Therapy
====================
Entities:-
Surgical Procedures, Operative : Operations carried out for the correction of deformities and defects, repair of injuries, and diagnosis and cure of certain diseases.
Surgical Procedure : A medical procedure involving an incision with instruments; performed to repair damage or arrest disease in a living body.
Surgery : Medical specialty that uses operative manual and instrumental techniques on a patient to investigate or treat a pathological condition such as a disease or injury.
Radiotherapy : The use of high-energy radiation from x-rays, gamma rays, neutrons, protons, and other sources to kill cancer cells and shrink tumors.
Radiation Therapy : Radiation therapy is a therapy using ionizing radiation, generally as part of cancer treatment to control or kill malignant cells.

Relationships:-
1. Entity1: ""Principles of Surgery"", Entity2: ""Principles of Radiation Therapy"", Relationship: ""complementary treatments""

Causalities:-
**Principles of Surgery (SURG-A).**

**Principles of Radiation Therapy (SUPRA-A).**

Section Name: Principles of Systemic Therapy
====================
Entities:-
Cisplatin : An inorganic and water-soluble platinum complex, cisplatin is an antineoplastic agent that is used in the treatment of various cancers.
Radiotherapy : The use of high-energy radiation from x-rays, gamma rays, neutrons, protons, and other sources to kill cancer cells and shrink tumors.
Radiation Therapy : Radiation therapy is a therapy using ionizing radiation, generally as part of cancer treatment to control or kill malignant cells.

Relationships:-
1. Entity1: ""Cisplatin"", Entity2: ""Systemic Therapy for Non-Nasopharyngeal Cancers"", Relationship: ""preferred agent""
2. Entity1: ""Cisplatin"", Entity2: ""Concurrent Systemic Therapy/RT"", Relationship: ""used in""

Causalities:-
<CO> When using concurrent systemic therapy/RT </CO>, <A> the preferred agent is cisplatin (category 1) </A>.
--------------------------------------------------
Page Number: 130

Section Name: Pathological N (pN)
====================
Entities:-
Lymph Nodes : Small, bean-shaped structures that are part of the body's lymphatic system. They filter lymph fluid and store white blood cells that help fight infection.
Neoplasm Metastasis : The transfer of a neoplasm from one organ or part of the body to another remote from the primary site.
Tnm Staging : A system used to describe the size and spread of cancer in a standardized way. T refers to the size of the tumor, N to the involvement of lymph nodes, and M to metastasis.
Lymph Node Structure : A structure that is part of the lymphatic system, involved in the immune response.
Metastasis : The spread of a cancer or other disease from one organ or part to another not directly connected with it.
Tnm Staging System : A cancer staging notation system that describes the extent of cancer in a patient's body.
Lymph Node : An organ of the lymphatic system and the adaptive immune system.

Relationships:-
1. Entity1: ""Lymph Nodes"", Entity2: ""Neoplasm Metastasis"", Relationship: ""involved in""
2. Entity1: ""TNM Staging"", Entity2: ""Lymph Nodes"", Relationship: ""includes""
3. Entity1: ""TNM Staging"", Entity2: ""Neoplasm Metastasis"", Relationship: ""describes""

Causalities:-
<CO> NX: Regional lymph nodes cannot be assessed </CO>
<CO> N0: No regional lymph node metastasis </CO>
<CO> N1: Metastasis in a single ipsilateral lymph node, 3 cm or smaller in greatest dimension ENE(–) </CO>
<CO> N2: Metastasis in a single ipsilateral lymph node, 3 cm or smaller in greatest dimension and ENE(+); or larger than 3 cm but not larger than 6 cm in greatest dimension and ENE(−); or metastases in multiple ipsilateral lymph nodes, none larger than 6 cm in greatest dimension and ENE(−); or in bilateral or contralateral lymph node(s), none larger than 6 cm in greatest dimension and ENE(−) </CO>
<CO> N2a: Metastasis in a single ipsilateral node, 3 cm or smaller in greatest dimension and ENE(+); or metastasis in a single ipsilateral node, larger than 3 cm but not larger than 6 cm in greatest dimension and ENE(−) </CO>
<CO> N2b: Metastases in multiple ipsilateral nodes, none larger than 6 cm in greatest dimension and ENE(−) </CO>
<CO> N2c: Metastases in bilateral or contralateral lymph node(s), none larger than 6 cm in greatest dimension and ENE(−) </CO>
<CO> N3: Metastasis in a lymph node, larger than 6 cm in greatest dimension and ENE(−); or metastasis in a single ipsilateral node, larger than 3 cm in greatest dimension and ENE(+); or multiple ipsilateral, contralateral, or bilateral lymph nodes and any with ENE(+); or a single contralateral node of any size and ENE(+) </CO>
<CO> N3a: Metastasis in a lymph node, larger than 6 cm in greatest dimension and ENE(−) </CO>
<CO> N3b: Metastasis in a single ipsilateral node, larger than 3 cm in greatest dimension and ENE(+); or multiple ipsilateral, contralateral, or bilateral lymph nodes any with ENE(+); or a single contralateral node of any size and ENE(+) </CO>
<CO> Note: A designation of “U” or “L” may be used for any N category to indicate metastasis above the lower border of the cricoid (U) or below the lower border of the cricoid (L). Similarly, clinical and pathological ENE should be recorded as ENE(−) or ENE(+). </CO>

Section Name: Distant Metastasis (M)
====================
Entities:-
Neoplasm Metastasis : The transfer of a neoplasm from one organ or part of the body to another remote from the primary site.
Metastasis : The spread of a cancer or other disease from one organ or part to another not directly connected with it.

Relationships:-
1. Entity1: ""M0"", Entity2: ""Distant Metastasis"", Relationship: ""is a category of""
2. Entity1: ""M1"", Entity2: ""Distant Metastasis"", Relationship: ""is a category of""

Causalities:-
### Distant Metastasis (M)

- **M0**: No distant metastasis
- **M1**: Distant metastasis

Section Name: Histologic Grade (G)
====================
Entities:-
Neoplasm Grading : A system of classifying cancer cells in terms of how abnormal they look under a microscope and how quickly the tumor is likely to grow and spread.
Histologic Grade : A measure of how much tumor cells differ from healthy cells, used to assess the aggressiveness of cancer.

Relationships:-
1. Entity1: ""GX"", Entity2: ""Grade cannot be assessed"", Relationship: ""is described as""
2. Entity1: ""G1"", Entity2: ""Well differentiated"", Relationship: ""is described as""
3. Entity1: ""G2"", Entity2: ""Moderately differentiated"", Relationship: ""is described as""
4. Entity1: ""G3"", Entity2: ""Poorly differentiated"", Relationship: ""is described as""

Causalities:-
<CO>GX</CO>: <E>Grade cannot be assessed</E>
<CO>G1</CO>: <E>Well differentiated</E>
<CO>G2</CO>: <E>Moderately differentiated</E>
<CO>G3</CO>: <E>Poorly differentiated</E>

Section Name: Prognostic Stage Groups
====================
Entities:-
Neoplasm Staging : Methods and systems of classifying neoplasms according to extent of disease.
Tumor Staging : A system for describing the size and spread of cancer within the body.
Tnm Staging System : A cancer staging notation system that describes the extent of cancer in a patient's body.

Relationships:-
1. Entity1: ""Stage 0"", Entity2: ""Tis N0 M0"", Relationship: ""defined by""
2. Entity1: ""Stage I"", Entity2: ""T1 N0 M0"", Relationship: ""defined by""
3. Entity1: ""Stage II"", Entity2: ""T2 N0 M0"", Relationship: ""defined by""
4. Entity1: ""Stage III"", Entity2: ""T3 N0 M0, T1 N1 M0, T2 N1 M0, T3 N1 M0"", Relationship: ""defined by""
5. Entity1: ""Stage IVA"", Entity2: ""T1 N2 M0, T2 N2 M0, T3 N2 M0, T4a N0,N1,N2 M0"", Relationship: ""defined by""
6. Entity1: ""Stage IVB"", Entity2: ""Any T N3 M0, T4b Any N M0"", Relationship: ""defined by""
7. Entity1: ""Stage IVC"", Entity2: ""Any T Any N M1"", Relationship: ""defined by""
--------------------------------------------------
Page Number: 47

Section Name: Overview of Radiation Therapy Guidelines
====================
Entities:-
Radiation Therapy : The medical use of ionizing radiation, generally as part of cancer treatment to control or kill malignant cells.
Cancer : A group of diseases involving abnormal cell growth with the potential to invade or spread to other parts of the body.
Malignant Neoplasm : A disease characterized by uncontrolled, abnormal growth of cells that can invade and destroy nearby tissue and spread to other parts of the body.
Laryngeal Neoplasms : Tumors or cancer of the larynx, which may affect the glottis, supraglottis, or subglottis.
Glottic Larynx Cancer : A malignant neoplasm located in the glottic region of the larynx.
Laryngeal Cancer : Cancer that occurs in the larynx, or voice box, which may include the glottic region.
National Comprehensive Cancer Network : The National Comprehensive Cancer Network (NCCN) is an alliance of 30 cancer centers in the United States, dedicated to improving the quality, effectiveness, and efficiency of cancer care.

Relationships:-
1. Entity1: ""Radiation Therapy"", Entity2: ""Cancer"", Relationship: ""treats""
2. Entity1: ""NCCN Guidelines"", Entity2: ""Cancer"", Relationship: ""guides treatment for""
3. Entity1: ""NCCN Guidelines"", Entity2: ""Radiation Therapy"", Relationship: ""specifies use of""

Causalities:-
The image presents a detailed flowchart outlining the principles of radiation therapy specifically for the <C> treatment of cancer in the glottic larynx </C>, <CO> as per the National Comprehensive Cancer Network (NCCN) guidelines (version 2.2024) </CO>. <E> This structured guidance delineates various treatment protocols </E>, <A> stratified by risk levels and therapeutic approaches </A>.

Section Name: Principles of Radiation Therapy
====================
Entities:-
Radiation Therapy : The medical use of ionizing radiation, generally as part of cancer treatment to control or kill malignant cells.
Gy : Gray, a unit of ionizing radiation dose in the International System of Units (SI), defined as the absorption of one joule of radiation energy per kilogram of matter.
Gray (Unit) : A unit of absorbed radiation dose of ionizing radiation, defined as the absorption of one joule of radiation energy per kilogram of matter.

Relationships:-
1. Entity1: ""Tis, N0"", Entity2: ""60.75 Gy (2.25 Gy/fraction) to 66 Gy (2.0 Gy/fraction)"", Relationship: ""treatment protocol""
2. Entity1: ""T1, N0"", Entity2: ""63 Gy (2.25 Gy/fraction) to 66 Gy (2.0 Gy/fraction) or 50 Gy (3.12 Gy/fraction) to 52 Gy (3.28 Gy/fraction)"", Relationship: ""treatment protocol""
3. Entity1: ""T2, N0"", Entity2: ""65.25 Gy (2.25 Gy/fraction) to 70 Gy (2.0 Gy/fraction)"", Relationship: ""treatment protocol""
4. Entity1: ""≥T2, N1 (PTV High risk)"", Entity2: ""66 Gy (2.2 Gy/fraction) to 70 Gy (2.0 Gy/fraction)"", Relationship: ""treatment protocol""
5. Entity1: ""≥T2, N1 (Low to intermediate risk)"", Entity2: ""44–50 Gy (2.0 Gy/fraction) to 54–63 Gy (1.6–1.8 Gy/fraction)"", Relationship: ""treatment protocol""

Causalities:-
<CO>Tis, N0</CO>: <A>60.75 Gy (2.25 Gy/fraction) to 66 Gy (2.0 Gy/fraction)</A>
<CO>T1, N0</CO>: <A>63 Gy (2.25 Gy/fraction, preferred) to 66 Gy (2.0 Gy/fraction) or 50 Gy (3.12 Gy/fraction) to 52 Gy (3.28 Gy/fraction)</A>
<CO>T2, N0</CO>: <A>65.25 (2.25 Gy/fraction) to 70 Gy (2.0 Gy/fraction)</A>
<CO>≥T2, N1</CO>: <A>PTV High risk: Primary tumor and involved lymph nodes (includes possible local subclinical infiltration at the primary site and at the high-risk level lymph node(s))</A>
<A>Fractionation: 66 Gy (2.2 Gy/fraction) to 70 Gy (2.0 Gy/fraction); daily Monday–Friday in 6–7 weeks</A>
<A>Concomitant boost accelerated RT: 72 Gy/6 weeks (1.8 Gy/fraction, large field; 1.5 Gy boost as second daily fraction during last 12 treatment days)</A>
<A>66–70 Gy (2.0 Gy/fraction; 6 fractions/wk accelerated)</A>
<A>Hyperfractionation: 79.2–81.6 Gy/7 weeks (1.2 Gy/fraction, twice daily)</A>
<CO>Low to intermediate risk</CO>: <A>Sites of suspected subclinical spread</A>
<A>44–50 Gy (2.0 Gy/fraction) to 54–63 Gy (1.6–1.8 Gy/fraction)</A>

Section Name: Concurrent Systemic Therapy/RT
====================
Entities:-
Cisplatin : A platinum-containing antineoplastic agent used in the treatment of various cancers.
Carboplatin : An organoplatinum compound that possesses antineoplastic activity.
Fluorouracil : A chemotherapy drug used to treat various types of cancer.

Relationships:-
1. Entity1: ""concurrent systemic therapy/RT"", Entity2: ""cisplatin"", Relationship: ""uses""
2. Entity1: ""concurrent systemic therapy/RT"", Entity2: ""carboplatin and 5-FU"", Relationship: ""uses""
3. Entity1: ""multiagent chemotherapy"", Entity2: ""toxicity burden"", Relationship: ""increases""

Causalities:-
<CO>Based on published data</CO>, <A>concurrent systemic therapy/RT most commonly uses conventional fractionation at 2.0 Gy per fraction to a typical dose of 70 Gy in 7 weeks with single-agent cisplatin given every 3 weeks at 100 mg/m²</A>; <CO>2–3 cycles of chemotherapy are used depending on the radiation fractionation scheme (RTOG 0129)</CO>. <CO>When carboplatin and 5-FU are used</CO>, <A>the recommended regimen is standard fractionation plus 3 cycles of chemotherapy</A>. <CO>Other fraction sizes (e.g., 1.8 Gy, conventional), multiagent chemotherapy, other dosing schedules of cisplatin, or altered fractionation with chemotherapy</CO> <E>are efficacious</E>, and <C>there is no consensus on the optimal approach</C>. <C>In general, the use of concurrent systemic therapy/RT</C> <E>carries a high toxicity burden</E>; <C>multiagent chemotherapy</C> <E>will likely further increase the toxicity burden</E>. <A>For any systemic therapy/RT approach, close attention should be paid to published reports for the specific chemotherapy agent, dose, and schedule of administration</A>. <A>Systemic therapy/RT should be performed by an experienced team and should include substantial supportive care</A>.

Section Name: Treatment Modalities
====================
Entities:-
Intensity-Modulated Radiotherapy : A type of conformal radiotherapy that uses computer-controlled linear accelerators to deliver precise radiation doses to a malignant tumor or specific areas within the tumor.
Intensity Modulated Radiation Therapy : A type of conformal radiotherapy that uses computer-controlled linear accelerators to deliver precise radiation doses to a malignant tumor or specific areas within the tumor.
Intensity-Modulated Radiation Therapy : An advanced type of high-precision radiotherapy that uses computer-controlled linear accelerators to deliver precise radiation doses to a malignant tumor or specific areas within the tumor.
Radiotherapy, Conformal : A type of radiotherapy that uses imaging to conform the radiation dose to the shape of the tumor.
3D Conformal Radiation Therapy : A technique in radiotherapy that uses imaging to conform the radiation dose to the shape of the tumor.
Chemotherapy, Adjuvant : Treatment with drugs that kill cancer cells, often used in conjunction with other therapies.
Chemotherapy : The treatment of disease by the use of chemical substances, especially the treatment of cancer by cytotoxic and other drugs.
Drug Therapy, Combination : The use of two or more drugs to achieve a therapeutic effect.
Systemic Therapy : A type of therapy that uses substances that travel through the bloodstream, reaching and affecting cells all over the body.

Relationships:-
1. Entity1: ""Intensity-Modulated Radiation Therapy (IMRT)"", Entity2: ""3D Conformal Radiation Therapy (3D-CRT)"", Relationship: ""are delivery methods for radiation therapy""
2. Entity1: ""Chemotherapy"", Entity2: ""Radiation Therapy"", Relationship: ""is integrated with for aggressive or advanced cancer cases""

Causalities:-
<CO> contingent upon patient-specific considerations </CO> <A> suggests either Intensity-Modulated Radiation Therapy (IMRT) or 3D Conformal Radiation Therapy (3D-CRT) as delivery methods </A>. <A> These advanced techniques are employed to optimize treatment accuracy </A>, <E> preserving surrounding healthy tissue and improving overall patient outcomes </E>. <A> a focus on concurrent systemic therapies underlines the importance of integrating chemotherapy </A>, particularly <CO> for patients with more aggressive forms of cancer or those demonstrating advanced disease characteristics </CO>.

Section Name: Additional Information
====================
Entities:-
Clinical Trials : Clinical trials are research studies performed in people that are aimed at evaluating a medical, surgical, or behavioral intervention.
Clinical Trial : A clinical trial is a research study in which one or more human subjects are prospectively assigned to one or more interventions to evaluate the effects of those interventions on health-related biomedical or behavioral outcomes.
National Comprehensive Cancer Network : The National Comprehensive Cancer Network (NCCN) is an alliance of 30 cancer centers in the United States, dedicated to improving the quality, effectiveness, and efficiency of cancer care.
Intensity-Modulated Radiation Therapy : An advanced type of high-precision radiotherapy that uses computer-controlled linear accelerators to deliver precise radiation doses to a malignant tumor or specific areas within the tumor.
Intensity Modulated Radiation Therapy : A type of conformal radiotherapy that uses computer-controlled linear accelerators to deliver precise radiation doses to a malignant tumor or specific areas within the tumor.
Three-Dimensional Conformal Radiation Therapy : A type of external beam radiation therapy that uses a computer to create a 3-dimensional picture of the tumor so that multiple radiation beams can be shaped exactly to the contour of the treatment area.

Relationships:-
1. Entity1: ""National Comprehensive Cancer Network"", Entity2: ""Clinical trial"", Relationship: ""encourages participation in""
2. Entity1: ""Intensity-Modulated Radiation Therapy"", Entity2: ""Three-Dimensional Conformal Radiation Therapy"", Relationship: ""recommended alternatives""

Causalities:-
<A> Participation in clinical trials </A> is especially encouraged. <A> Either IMRT (preferred) or 3D-CRT is recommended. </A>

Section Name: Conclusion
====================
Entities:-
Laryngeal Neoplasms : Tumors or cancer of the larynx, which may affect the glottis, supraglottis, or subglottis.
Malignant Neoplasm Of Glottis : A malignant tumor located in the glottic region of the larynx.
Laryngeal Cancer : Cancer that occurs in the larynx, or voice box, which may include the glottic region.
Prognosis : A medical term for predicting the likely or expected development of a disease.
Evidence-Based Practice : Healthcare practices that are based on scientific evidence and research.
Evidence-Based Medicine : An approach to medical practice intended to optimize decision-making by emphasizing the use of evidence from well-designed and conducted research.

Relationships:-
1. Entity1: ""treatment paradigms"", Entity2: ""glottic larynx cancer"", Relationship: ""encapsulates""
2. Entity1: ""personalized treatment plans"", Entity2: ""prognosis"", Relationship: ""improves""

Causalities:-
<C> glottic larynx cancer </C>. <CO> the nuances of each patient's condition </CO>. <A> personalized treatment plans </A> <E> promoting effective management and improved prognosis </E>. <A> deliver clear, evidence-based interventions </A> <CO> considering the complexities involved in cancer treatment </CO>.


Among these two options which one is the most likely true:

(A) `Size_of_Lymph_Nodes_6` increases risk `N_State_1`
(B) `N_State_1` `increases risk `Size_of_Lymph_Nodes_6`

The answer is: ...

1. State the evidences in detail of the validity of option (A) or (B) by cross referencing
NCCN Clinical Practitioner’s Guidelines for Head and Neck Cancer.
2. If the evidences are obtained from `INFORMATION FROM KNOWLEDGE BASE`,
mention their corresponding Page Numbers, Section Name, entities, relationships and causalities.

DESIRED OUTPUT FORMAT:
<thinking>
...
</thinking>
<answer>
{
   ""thinking"": [""..."", ...],
   ""evidences"": [""..."", ...],
   ""answer"": ...
}
</answer>

Before providing the answer in <answer> tags, think step by step in detail in <thinking> tags and analyze every part.
Output inside <answer> tag in JSON format. Only output valid JSON.
DO NOT HALLUCINATE. DO NOT MAKE UP FACTUAL INFORMATION.
","1. The edge (Size_of_Lymph_Nodes_6) causes (N_State_1) suggests that the size of lymph nodes influences the cancer state of nearby lymph nodes. This is a proximal relationship with a positive causal direction, but the size is neither a necessary nor sufficient condition for cancer presence.
2. The edge (N_State_1) causes (Size_of_Lymph_Nodes_6) indicates that the presence of cancer in nearby lymph nodes leads to an increase in their size. This is a proximal relationship with a positive causal direction, and the presence of cancer is a sufficient condition for enlargement.
3. From the NCCN Guidelines, the presence of cancer in lymph nodes is often associated with their enlargement due to metastasis, which aligns with the explanation of EDGE2.
4. The knowledge base information supports that cancer presence in lymph nodes (N_State_1) is a sufficient condition for their enlargement (Size_of_Lymph_Nodes_6), as cancer typically causes lymph nodes to enlarge.
5. The causal relationship in EDGE2 is more directly supported by the NCCN Guidelines, which emphasize the role of cancer presence in lymph node enlargement.
","1. Page Number: 102, Section Name: Head and Neck Cancers - Principles of Surgery, Entities: Lymphatic System, Neoplasms, Metastasis, Relationships: Entity1: 'surgical management', Entity2: 'regional lymphatics', Relationship: 'dictated by tumor staging', Causalities: The extent of the tumor at initial tumor staging dictates the surgical management of regional lymphatics.
2. Page Number: 130, Section Name: Pathological N (pN), Entities: Lymph Nodes, Neoplasm Metastasis, Relationships: Entity1: 'Lymph Nodes', Entity2: 'Neoplasm Metastasis', Relationship: 'involved in', Causalities: NX: Regional lymph nodes cannot be assessed, N0: No regional lymph node metastasis, N1: Metastasis in a single ipsilateral lymph node, 3 cm or smaller in greatest dimension ENE(–).
",B,"{'A': 0.01, 'B': 99.99}",yes,B,"1. The AI assistant's reasoning for selecting option (B) is based on the causal relationship described in EDGE2, where the presence of cancer in nearby lymph nodes (N_State_1) leads to an increase in their size (Size_of_Lymph_Nodes_6). This relationship is described as proximal and having a positive causal direction, with the presence of cancer being a sufficient condition for enlargement.
2. The assistant cross-references the NCCN Guidelines, which support the notion that cancer presence in lymph nodes is associated with their enlargement due to metastasis. This aligns with the explanation provided for EDGE2, where cancer presence directly influences lymph node size.
3. The assistant also references specific sections from the knowledge base, such as the Head and Neck Cancers - Principles of Surgery and Pathological N (pN), which discuss the relationship between cancer presence and lymph node enlargement, further supporting the causal direction described in EDGE2.
4. The reasoning provided by the assistant is consistent with the final answer (B), as the evidence from the NCCN Guidelines and the knowledge base supports the causal relationship where cancer presence in lymph nodes leads to their enlargement.
"
9,gpt-4o,"Size_of_Lymph_Nodes_6,Imaging_Results_13","""{'NODE1': {'id': 'Size_of_Lymph_Nodes_6', 'label': 'Size of Lymph Nodes', 'description': 'This node represents the clinical assessment of the size of lymph nodes in a patient. The size of lymph nodes can be an important indicator in diagnosing conditions such as infections, immune responses, or cancer metastasis. Enlarged lymph nodes may suggest the presence of disease, while normal-sized lymph nodes are typically not indicative of pathology.', 'type': 'Patient Situation', 'observability': 'Unobserved', 'states': [{'state_name': 'present', 'state_description': 'The lymph nodes are enlarged or have a significant size, which may indicate the presence of disease such as infection, inflammation, or metastasis.'}, {'state_name': 'absent', 'state_description': 'The lymph nodes are not enlarged and are of normal size, suggesting no significant pathology or disease.'}]}, 'NODE2': {'id': 'Imaging_Results_13', 'label': 'Imaging Examination Results', 'description': 'This node represents the results of an imaging examination, which could include modalities such as ultrasound, MRI, or other diagnostic imaging techniques. The results indicate whether specific findings are present or absent, which can be crucial for diagnosis and treatment planning.', 'type': 'Examination Result', 'observability': 'Observed', 'states': [{'state_name': 'present', 'state_description': \""The 'present' state indicates that the imaging examination has identified specific findings or abnormalities that are relevant to the clinical context.\""}, {'state_name': 'absent', 'state_description': \""The 'absent' state indicates that the imaging examination did not identify any specific findings or abnormalities of interest in the clinical context.\""}]}, 'EDGE1': {'edges_ids': ['Size_of_Lymph_Nodes_6', 'Imaging_Results_13'], 'edge': '(Size_of_Lymph_Nodes_6) causes (Imaging_Results_13)', 'explanation': ['The size of lymph nodes can directly affect imaging results because enlarged lymph nodes are often detected as abnormalities in imaging examinations.', 'If lymph nodes are enlarged, imaging results are more likely to show abnormalities, indicating a positive causal direction.', 'However, the size of lymph nodes is neither a necessary nor a sufficient condition for imaging results to show abnormalities, as other factors can also influence imaging results.', 'The causal relationship is proximal because the size of lymph nodes directly impacts the imaging findings.'], 'causal_direction': 'positive', 'causal_factor': {'necessary': False, 'sufficient': False}, 'causal_distance': 'Proximal'}, 'EDGE2': {'edges_ids': ['Imaging_Results_13', 'Size_of_Lymph_Nodes_6'], 'edge': '(Imaging_Results_13) causes (Size_of_Lymph_Nodes_6)', 'explanation': ['The edge suggests that the results of an imaging examination (Imaging_Results_13) cause changes in the size of lymph nodes (Size_of_Lymph_Nodes_6).', 'However, imaging results are observations of the current state of lymph nodes, not a cause of their size.', 'The size of lymph nodes is determined by underlying physiological or pathological processes, not by the imaging results themselves.', 'Therefore, the edge is not valid as a causal relationship.'], 'causal_direction': 'Unknown', 'causal_factor': {'necessary': False, 'sufficient': False}, 'causal_distance': 'Unknown'}, 'ENTITIES_MATCHING_PAGES_INFO': {'41': {'matching_entities': [{'IMAGING': 0.95010704}, {'DIAGNOSTIC TECHNIQUES AND PROCEDURES': 0.9382724}, {'MAGNETIC RESONANCE IMAGING (MRI)': 0.9294916}, {'COMPUTED TOMOGRAPHY (CT)': 0.926514}], 'count': 4}, '46': {'matching_entities': [{'COMPUTED TOMOGRAPHY': 0.9316812}, {'MAGNETIC RESONANCE IMAGING': 0.93168116}, {'MAGNETIC RESONANCE IMAGING (MRI)': 0.9294916}, {'COMPUTED TOMOGRAPHY (CT)': 0.926514}], 'count': 4}, '93': {'matching_entities': [{'IMAGING, DIAGNOSTIC': 0.96449167}, {'COMPUTED TOMOGRAPHY': 0.9316812}, {'MAGNETIC RESONANCE IMAGING': 0.93168116}], 'count': 3}, '102': {'matching_entities': [{'LYMPHATIC SYSTEM': 0.95855314}, {'LYMPHATIC STRUCTURE': 0.9469132}, {'SURGERY': 0.9264304}], 'count': 3}, '53': {'matching_entities': [{'IMAGING': 0.95010704}, {'COMPUTED TOMOGRAPHY': 0.9316812}, {'MAGNETIC RESONANCE IMAGING': 0.93168116}], 'count': 3}}, 'GUIDELINE_PAGES_INFO': '--------------------------------------------------\\nPage Number: 41\\n\\nSection Name: Workup\\n====================\\nEntities:-\\nLaryngeal Neoplasms : Tumors or cancer of the larynx, which may affect the glottis, supraglottis, or subglottis.\\nHistory And Physical Examination : A comprehensive assessment of a patient\\'s medical history and physical condition.\\nTobacco Smoking : The act of smoking tobacco products, which is a risk factor for many diseases.\\nAlcohol Drinking : The consumption of beverages containing ethyl alcohol.\\nSmoking Cessation : The process of discontinuing tobacco smoking.\\nBiopsy : A medical test involving the extraction of sample cells or tissues for examination.\\nLaryngoscopy : A procedure to examine the larynx, often using a scope.\\nComputed Tomography (Ct) : A diagnostic imaging procedure that uses computer-processed combinations of many X-ray measurements taken from different angles to produce cross-sectional images of specific areas of a scanned object.\\nMagnetic Resonance Imaging (Mri) : A medical imaging technique used in radiology to form pictures of the anatomy and the physiological processes of the body.\\nPositron-Emission Tomography : A type of nuclear medicine imaging that measures metabolic activity of the cells of body tissues.\\nPulmonary Function Test : Tests that measure how well the lungs are working.\\nDental Examination : An evaluation of the teeth and gums to assess oral health.\\nNutritional Support : Therapies to provide nutrition to patients who cannot obtain nutrition by mouth.\\nSpeech Therapy : Therapy to improve speech and communication skills.\\nSwallowing Therapy : Therapy to help individuals with swallowing difficulties.\\nMultidisciplinary Care Team : A group of healthcare professionals from different specialties working together to manage patient care.\\n\\nRelationships:-\\n1. Entity1: \""glottic larynx cancer\"", Entity2: \""history and physical examination\"", Relationship: \""initial diagnostic step\""\\n2. Entity1: \""glottic larynx cancer\"", Entity2: \""biopsy\"", Relationship: \""required diagnostic procedure\""\\n3. Entity1: \""glottic larynx cancer\"", Entity2: \""direct laryngoscopy\"", Relationship: \""recommended procedure\""\\n4. Entity1: \""glottic larynx cancer\"", Entity2: \""CT scans\"", Relationship: \""imaging study\""\\n5. Entity1: \""glottic larynx cancer\"", Entity2: \""MRI\"", Relationship: \""imaging study\""\\n6. Entity1: \""glottic larynx cancer\"", Entity2: \""multidisciplinary consultation\"", Relationship: \""advised as clinically indicated\""\\n\\nCausalities:-\\nThe workup section outlines the initial steps for diagnosing <C>glottic larynx cancer</C>. It includes <A>a comprehensive history and physical examination (H&P)</A>, which should document tobacco and alcohol use, and provide counseling for smoking cessation. <A>A biopsy of the primary site is required</A>, and <A>direct laryngoscopy under anesthesia is generally recommended</A>. <A>Imaging studies such as CT scans with contrast and possibly MRI are used to evaluate the larynx and neck</A>. Additional evaluations may include <A>chest CT, FDG-PET/CT, pulmonary function tests, dental evaluation, and nutrition, speech, and swallowing therapy</A>. <A>Multidisciplinary consultation is advised</A> <CO>as clinically indicated</CO>.\\n\\nSection Name: Clinical Staging\\n====================\\nEntities:-\\nCancer : A group of diseases involving abnormal cell growth with the potential to invade or spread to other parts of the body.\\nCarcinoma In Situ : A lesion with cytological characteristics of cancer but which has not invaded the basement membrane.\\nBiopsy : A medical test involving the extraction of sample cells or tissues for examination.\\nLaryngectomy : A surgical procedure to remove the larynx.\\n\\nRelationships:-\\n1. Entity1: \""Clinical staging\"", Entity2: \""Cancer\"", Relationship: \""involves\""\\n2. Entity1: \""Carcinoma in situ\"", Entity2: \""Stages T1-T4\"", Relationship: \""is a stage of\""\\n3. Entity1: \""Biopsy\"", Entity2: \""Cancer\"", Relationship: \""used in staging\""\\n4. Entity1: \""Larynx-preserving surgeries\"", Entity2: \""Stages T1-T2\"", Relationship: \""considered for\""\\n5. Entity1: \""Total laryngectomy\"", Entity2: \""Stages T3-T4\"", Relationship: \""required for\""\\n\\nCausalities:-\\n<C> Clinical staging involves categorizing the cancer based on its aggressiveness </C>. It starts with carcinoma in situ, which is non-invasive, and progresses through stages T1-T4. <CO> Staging is based on H&P, biopsy, and imaging studies </CO>. <CO> For T1-T2 </CO>, <A> larynx-preserving surgeries are considered </A>, while <CO> more advanced stages like T3 or T4 </CO> <A> may require total laryngectomy </A>. <A> Additional evaluations such as videostrobe, audiogram, and fertility counseling may be considered </A>.\\n\\nSection Name: Treatment\\n====================\\nEntities:-\\nCarcinoma In Situ : A lesion with cytological characteristics of cancer but which has not invaded the basement membrane.\\nLaryngectomy : A surgical procedure to remove the larynx.\\nMetastasis : The transfer of a disease from one organ or part to another not directly connected with it.\\nClinical Trials As Topic : Works about research studies that evaluate the effectiveness and safety of medications or medical devices by monitoring their effects on large groups of people.\\n\\nRelationships:-\\n1. Entity1: \""Carcinoma in situ\"", Entity2: \""Larynx-preserving surgery\"", Relationship: \""treated with\""\\n2. Entity1: \""T1-T2 stages\"", Entity2: \""Conservation surgery\"", Relationship: \""treated with\""\\n3. Entity1: \""T3 stages\"", Entity2: \""Total laryngectomy\"", Relationship: \""may require\""\\n4. Entity1: \""T4a disease\"", Entity2: \""Complex interventions\"", Relationship: \""require\""\\n5. Entity1: \""Guidelines\"", Entity2: \""Multidisciplinary consultations\"", Relationship: \""emphasize importance of\""\\n6. Entity1: \""Guidelines\"", Entity2: \""Clinical trials\"", Relationship: \""consider as best option\""\\n\\nCausalities:-\\n<CO>Treatment recommendations vary by stage</CO>. <CO>Carcinoma in situ</CO> <A>may be treated with larynx-preserving surgery</A>. <CO>T1-T2 stages</CO> <A>may also be amenable to conservation surgery</A>. <CO>T3 stages</CO> <A>may require total laryngectomy</A>, <CO>especially if nodal involvement is present</CO>. <CO>T4a disease and unresectable or metastatic cases</CO> <A>require more complex interventions</A>. <A>The guidelines emphasize the importance of multidisciplinary consultations</A> and <A>consider clinical trials as the best management option</A>.\\n\\nSection Name: Additional Notes\\n====================\\nEntities:-\\nBiopsy, Needle : A procedure to remove a small sample of tissue for examination under a microscope.\\nImage-Guided Biopsy : A biopsy procedure that uses imaging techniques to guide the needle to the precise location of the tissue to be sampled.\\nBiopsy : A medical test involving the extraction of sample cells or tissues for examination.\\nDiagnostic Techniques And Procedures : Methods and procedures for the diagnosis of disease or dysfunction.\\nImaging : The process of producing images of the body for clinical purposes.\\nDental Care : The total of dental diagnostic, preventive, and corrective procedures.\\nNutritional Physiological Phenomena : The functions and properties of nutrients in living organisms.\\nFertility : The capacity to conceive or induce conception.\\nReproductive Health : A state of physical, mental, and social well-being in all matters relating to the reproductive system.\\nLymphatic Metastasis : The transfer of a neoplasm from one organ or part of the body to another remote from the primary site.\\nGlottis : The part of the larynx consisting of the vocal cords and the opening between them.\\n\\nRelationships:-\\n1. Entity1: \""image-guided needle biopsy\"", Entity2: \""diagnostic yield\"", Relationship: \""used for\""\\n2. Entity1: \""nodal disease\"", Entity2: \""glottic tumors\"", Relationship: \""is rare in\""\\n\\nCausalities:-\\n<A> use of image-guided needle biopsy </A> for <E> better diagnostic yield </E>, principles of imaging, dental evaluation, and nutrition management. The guidelines also address fertility and reproductive considerations, and note that <CO> nodal disease in glottic tumors is rare </CO>.\\n--------------------------------------------------\\nPage Number: 46\\n\\nSection Name: Introduction\\n====================\\nEntities:-\\nLaryngeal Neoplasms : Tumors or cancer of the larynx, including the glottis.\\nMalignant Neoplasm Of Glottis : A malignant tumor located in the glottis, part of the larynx.\\nNational Comprehensive Cancer Network : The National Comprehensive Cancer Network (NCCN) is an alliance of 30 cancer centers in the United States, dedicated to improving the quality, effectiveness, and efficiency of cancer care.\\nAdjuvant Chemotherapy : Chemotherapy given in addition to the primary treatment to maximize its effectiveness, often used in cancer treatment.\\nAdjuvant Therapy : Treatment given in addition to the primary (main) treatment to enhance its effectiveness.\\n\\nRelationships:-\\n1. Entity1: \""National Comprehensive Cancer Network\"", Entity2: \""Laryngeal Neoplasms\"", Relationship: \""provides treatment guidelines for\""\\n2. Entity1: \""treatment guidelines\"", Entity2: \""Adjuvant therapy\"", Relationship: \""guide clinical decision-making for\""\\n\\nCausalities:-\\n<C> cancer of the glottic larynx </C> <E> treatment guidelines </E> <CO> based on various clinical stages and specific patient conditions </CO> <A> guide healthcare professionals through clinical decision-making </A>.\\n\\nSection Name: NCCN Guidelines Version 4.2024\\n====================\\nEntities:-\\nClinical Trials : Clinical trials are research studies performed in people that are aimed at evaluating a medical, surgical, or behavioral intervention.\\nNational Comprehensive Cancer Network : The National Comprehensive Cancer Network (NCCN) is an alliance of 30 cancer centers in the United States, dedicated to improving the quality, effectiveness, and efficiency of cancer care.\\n\\nRelationships:-\\n1. Entity1: \""National Comprehensive Cancer Network\"", Entity2: \""Clinical Trials\"", Relationship: \""encourages participation in\""\\n\\nCausalities:-\\n<A>Participation in clinical trials</A> is especially encouraged.\\n\\nSection Name: Clinical Staging and Treatment\\n====================\\nEntities:-\\nNeoplasm Staging : Methods used for staging of neoplasms based on extent of tumor spread.\\nT4A : A clinical stage indicating a tumor that has grown into nearby structures.\\nN0\u20133 : A range of clinical stages indicating the extent of regional lymph node involvement.\\nSurgical Procedures, Operative : Operations carried out for the correction of deformities and defects, repair of injuries, and diagnosis and cure of certain diseases.\\nNeck Dissection : Surgical procedure to remove lymph nodes and surrounding tissue in the neck.\\nPathology : The study of the nature and cause of disease which involves changes in structure and function.\\nAntineoplastic Combined Chemotherapy Protocols : The use of drug combinations to treat cancer.\\nRadiotherapy : The use of ionizing radiation to treat cancer.\\nClinical Trials As Topic : Works about research studies that evaluate the effectiveness and safety of medications or medical devices by monitoring their effects on large groups of people.\\n\\nRelationships:-\\n1. Entity1: \""Clinical Staging\"", Entity2: \""Surgical Intervention\"", Relationship: \""determines\""\\n2. Entity1: \""T4a\"", Entity2: \""Surgical Intervention\"", Relationship: \""relates to\""\\n3. Entity1: \""Systemic Therapy\"", Entity2: \""Radiotherapy\"", Relationship: \""considered with\""\\n4. Entity1: \""Clinical Trials\"", Entity2: \""Treatment of Primary and Neck\"", Relationship: \""option for\""\\n\\nCausalities:-\\n<CO> Clinical staging indicator labeled \""T4a,N0\u20133\"" </CO> <A> emphasizes the importance of surgical intervention </A>, highlighting procedures such as bilateral neck dissection and the need to address certain pathologic features. <CO> Selected T4a patients who decline surgery </CO> <A> consider concurrent systemic therapy/RT or clinical trial for function-preserving surgical or RT management or induction chemotherapy </A>.\\n\\nSection Name: Principles of Treatment\\n====================\\nEntities:-\\nThyroidectomy : Surgical removal of the thyroid gland.\\nExtranodal Extension : Spread of cancer beyond the lymph node capsule.\\nRadiation Therapy : Medical use of ionizing radiation to treat cancer.\\n\\nRelationships:-\\n1. Entity1: \""Surgery\"", Entity2: \""Thyroidectomy\"", Relationship: \""involves\""\\n2. Entity1: \""Radiation therapy\"", Entity2: \""Adverse pathologic features\"", Relationship: \""treats\""\\n\\nCausalities:-\\n- **Principles of Radiation Therapy (GLOT-A):**  \\n  - <C> Adverse pathologic features: extranodal extension, positive margins, close margins, pT4 primary, pN2 or pN3 nodal disease, perineural invasion, vascular invasion, lymphatic invasion, and subglottic extension </C> (Discussion).  \\n\\n- **Principles of Surgery (SURG-A):**  \\n  - <A> Surgery, including ipsilateral or bilateral neck dissection; thyroidectomy to clear central compartment nodes </A>, <CO> especially when there is thyroid cartilage with gross invasion of the thyroid gland and significant subglottic extension </CO>.\\n\\nSection Name: Adjuvant Treatment and Follow-up\\n====================\\nEntities:-\\nSystemic Therapy : Treatment using substances that travel through the bloodstream, reaching and affecting cells all over the body.\\nClinical Trial : A research study that prospectively assigns human participants or groups of humans to one or more health-related interventions to evaluate the effects on health outcomes.\\nComputed Tomography (Ct) : A medical imaging technique used in radiology to obtain detailed internal images of the body noninvasively for diagnostic purposes.\\nMagnetic Resonance Imaging (Mri) : A noninvasive medical test that physicians use to diagnose and treat medical conditions.\\nRecurrent Disease : A disease that has returned after a period of remission.\\nRadiation Therapy (Rt) : The use of ionizing radiation to treat cancer and other diseases.\\n\\nRelationships:-\\n1. Entity1: \""Adverse Features\"", Entity2: \""Specific Treatments\"", Relationship: \""Suggests\""\\n2. Entity1: \""Systemic Therapy\"", Entity2: \""Patients who decline surgery\"", Relationship: \""Option for\""\\n3. Entity1: \""CT or MRI\"", Entity2: \""Primary and Neck\"", Relationship: \""Used for imaging\""\\n4. Entity1: \""Recurrent or Persistent Disease\"", Entity2: \""Follow-up\"", Relationship: \""Condition for\""\\n5. Entity1: \""pN1 without other risk features\"", Entity2: \""RT\"", Relationship: \""Suggests considering\""\\n\\nCausalities:-\\n<C> adverse features such as extralateral extension or positive margins </C> <E> specific treatments are suggested </E>. The guidelines recommend <A> considering options like concurrent systemic therapy or clinical trials </A> <CO> for patients who decline surgery </CO>.\\n\\n- **Adjuvant Treatment:**  \\n  - <A> CT (with contrast) or MRI (with and without contrast) of primary and neck </A>.  \\n\\n- **Follow-up (FOLL-A, 1 of 2):**  \\n  - <CO> Recurrent or persistent disease (ADV-3) </CO>.  \\n\\n- **Post Systemic Therapy/RT or RT Neck Evaluation (FOLL-A, 2 of 2):**  \\n  - <CO> pN1 without other risk features </CO>: <A> Consider RT </A>.\\n\\nSection Name: Response Assessment\\n====================\\nEntities:-\\nAdjuvant Chemotherapy : Chemotherapy given in addition to the primary treatment to maximize its effectiveness, often used in cancer treatment.\\nComputed Tomography : A diagnostic imaging procedure that uses a combination of X-rays and computer technology to produce cross-sectional images of the body.\\nMagnetic Resonance Imaging : A medical imaging technique used in radiology to form pictures of the anatomy and the physiological processes of the body.\\nNeoplasm Recurrence, Local : The return of a cancer, at the same site as the original (primary) tumor, after it had disappeared.\\n\\nRelationships:-\\n1. Entity1: \""Adjuvant treatment\"", Entity2: \""Treatment responses\"", Relationship: \""affects\""\\n2. Entity1: \""Follow-up assessments\"", Entity2: \""CT or MRI scans\"", Relationship: \""conducted using\""\\n3. Entity1: \""Response Assessment (GLOT-5)\"", Entity2: \""Recurrent or persistent disease (ADV-3)\"", Relationship: \""determines\""\\n\\nCausalities:-\\nAs the flowchart progresses to the adjuvant treatment section, it depicts further decision points based on treatment responses and disease recurrence. The inclusion of references to follow-up assessments, such as CT or MRI scans, underscores the emphasis on continuous monitoring and evaluation of treatment efficacy.  - **Response Assessment (GLOT-5):**   - <C>Recurrent or persistent disease (ADV-3)</C>.\\n--------------------------------------------------\\nPage Number: 93\\n\\nSection Name: PRINCIPLES OF IMAGING\\n====================\\nEntities:-\\nImaging, Diagnostic : The production of a visual representation of parts of the body, for the purpose of clinical analysis and medical intervention.\\nHead And Neck Neoplasms : Tumors or cancer of the head and neck region, including the nasal cavity, sinuses, lips, mouth, salivary glands, throat, or larynx.\\nTomography, X-Ray Computed : An imaging procedure that uses special x-ray equipment to create detailed pictures, or scans, of areas inside the body.\\nMagnetic Resonance Imaging : A noninvasive diagnostic technique that uses magnetic fields and radio waves to produce a detailed image of the body\\'s soft tissue and bones.\\nContrast Media : Substances used to enhance the contrast of structures or fluids within the body in medical imaging.\\n\\nRelationships:-\\n1. Entity1: \""Imaging, Diagnostic\"", Entity2: \""Head and Neck Neoplasms\"", Relationship: \""used for\""\\n2. Entity1: \""Tomography, X-Ray Computed\"", Entity2: \""Contrast Media\"", Relationship: \""uses\""\\n3. Entity1: \""Magnetic Resonance Imaging\"", Entity2: \""Contrast Media\"", Relationship: \""uses\""\\n\\nCausalities:-\\n<C> Imaging </C> plays an essential role in the clinical care of patients with head and neck cancer. <A> The proper selection and utilization of imaging studies </A> is critical in caring for patients with head and neck cancer. <A> CT is performed with contrast </A>, while <A> CT imaging of the chest can be performed with or without contrast </A>, <CO> as clinically indicated </CO>. <A> MRI is performed with and without contrast </A>, <CO> unless contraindicated </CO>.\\n\\nSection Name: Initial Workup - Primary Site\\n====================\\nEntities:-\\nTomography, X-Ray Computed : An imaging procedure that uses special x-ray equipment to create detailed pictures, or scans, of areas inside the body.\\nMagnetic Resonance Imaging : A noninvasive diagnostic technique that uses magnetic fields and radio waves to produce a detailed image of the body\\'s soft tissue and bones.\\nHead And Neck Neoplasms : Tumors or cancer of the head and neck region, including the nasal cavity, sinuses, lips, mouth, salivary glands, throat, or larynx.\\nNeck Structure : The anatomical structure of the neck, which is the part of the body that connects the head to the torso.\\nSkull Base : The bottom part of the skull, which separates the brain from other facial structures.\\nThoracic Inlet : The opening at the top of the thoracic cavity, through which pass the trachea, esophagus, and major blood vessels.\\n\\nRelationships:-\\n1. Entity1: \""CT\"", Entity2: \""MRI\"", Relationship: \""complementary in imaging head and neck cancers\""\\n2. Entity1: \""CT\"", Entity2: \""Head and Neck Neoplasms\"", Relationship: \""used to evaluate\""\\n3. Entity1: \""MRI\"", Entity2: \""Head and Neck Neoplasms\"", Relationship: \""preferred for evaluating\""\\n4. Entity1: \""Skull base\"", Entity2: \""Thoracic inlet\"", Relationship: \""imaging range for evaluation\""\\n\\nCausalities:-\\n<A>Imaging assessment of the primary site</A> can be performed with <A>CT of the soft tissues of the neck</A> or <A>MRI of the neck</A>. <C>CT is complementary to MRI for head and neck cancers</C>. <A>It is utilized to evaluate cortical bone erosion or periosteal invasion, cartilage invasion, and bony erosion or destruction</A>. <CO>in certain conditions, such as evaluating the extent of bone marrow invasion or in patients with extensive dental amalgam obscuring anatomy on CT, assessing skull base invasion and cranial nerve involvement, and differentiating tumor from obstructed sinuses</CO>, <A>MRI is preferred over CT</A>. <CO>when involved lymph nodes or upper mediastinal cancers are present</CO>, <A>Complete evaluation of primary and nodal disease requires imaging from the skull base to the thoracic inlet, extending to the carina</A>.\\n\\nSection Name: PET/CT and Biopsy\\n====================\\nEntities:-\\nPositron Emission Tomography Computed Tomography : A medical imaging technique that combines PET and CT capabilities to provide detailed images of the body.\\nExamination Under Anesthesia : A procedure where a patient is examined while under anesthesia to allow for a more thorough examination.\\nBiopsy : A medical test involving the extraction of sample cells or tissues for examination to determine the presence or extent of a disease.\\nTonsillectomy : A surgical procedure to remove the tonsils, often performed to treat recurrent tonsillitis or sleep apnea.\\nFine Needle Aspiration : A type of biopsy procedure that uses a thin, hollow needle to extract cells from a lump or mass for examination.\\nUltrasound : A medical imaging technique that uses high-frequency sound waves to visualize internal organs and structures.\\nComputed Tomography : A diagnostic imaging procedure that uses a combination of X-rays and computer technology to produce cross-sectional images of the body.\\n\\nRelationships:-\\n1. Entity1: \""PET/CT\"", Entity2: \""EUA\"", Relationship: \""recommended before\""\\n2. Entity1: \""Fine Needle Aspiration (FNA)\"", Entity2: \""metastatic nodes\"", Relationship: \""used for biopsy of\""\\n3. Entity1: \""Image-guided needle biopsy\"", Entity2: \""cystic neck nodes\"", Relationship: \""recommended for initial diagnosis of\""\\n\\nCausalities:-\\n<CO> If imaging does not reveal an obvious primary cancer </CO>, <A> a PET/CT should be ordered before EUA, biopsies, and tonsillectomy </A>. <E> This helps identify potential primary sites </E> before any interventions take place. Additionally, <A> Fine Needle Aspiration (FNA) biopsy of metastatic nodes </A> <E> may provide pathologically informative results </E>. <CO> For initial diagnosis in cystic neck nodes </CO>, <A> image-guided needle biopsy (ultrasound or CT) </A> <E> may yield better results than FNA by palpation alone </E>.\\n\\nSection Name: Postoperative Imaging Advice\\n====================\\nEntities:-\\nPanoramic Radiography : A type of dental x-ray that provides a wide view of the upper and lower jaws, teeth, temporomandibular joints, and sinuses.\\nOral Cavity : The cavity of the mouth, including the lips, the lining inside the cheeks and lips, the front two-thirds of the tongue, the gums, the floor of the mouth under the tongue, the hard palate, and the small area of the gum behind the wisdom teeth.\\nRadiotherapy : The treatment of disease, especially cancer, using X-rays or similar forms of radiation.\\nMandibulotomy : A surgical procedure involving the cutting of the mandible.\\nMandibulectomy : A surgical procedure involving the removal of part or all of the mandible.\\nOropharynx : The part of the throat at the back of the mouth behind the oral cavity.\\n\\nRelationships:-\\n1. Entity1: \""panoramic dental x-ray\"", Entity2: \""oral cavity cancers\"", Relationship: \""recommended for\""\\n2. Entity1: \""panoramic dental x-ray\"", Entity2: \""postoperative radiotherapy\"", Relationship: \""essential for pre-radiation evaluation\""\\n3. Entity1: \""pre-radiation dental evaluation\"", Entity2: \""dental procedures or extractions\"", Relationship: \""determine necessity of\""\\n\\nCausalities:-\\n<A> A panoramic dental x-ray is recommended </A> <C> for oral cavity cancers requiring mandibulotomy and/or mandibulectomy </C>. <CO> When postoperative radiotherapy (RT) is anticipated for areas like the lip, oral cavity subsites, or oropharynx </CO>, <A> panoramic x-ray is essential for a comprehensive pre-radiation dental evaluation </A> <E> to assess the health of affected teeth and determine if pre-radiation dental procedures or extractions are necessary </E>.\\n\\nSection Name: NCCN Guidelines Note\\n====================\\nEntities:-\\nNeoplasms : Neoplasms are abnormal growths of tissue, which can be cancerous or non-cancerous.\\nMalignant Neoplastic Disease : A disease characterized by uncontrolled, abnormal growth of cells that can invade or spread to other parts of the body.\\nCancer : A group of diseases involving abnormal cell growth with the potential to invade or spread to other parts of the body.\\nClinical Trials As Topic : Pre-planned studies of the safety, efficacy, or optimum dosage schedule of one or more diagnostic, therapeutic, or prophylactic drugs, devices, or techniques in humans selected according to predetermined criteria of eligibility and observed for predefined evidence of favorable and unfavorable effects.\\nClinical Trial : A research study that prospectively assigns human participants or groups of humans to one or more health-related interventions to evaluate the effects on health outcomes.\\n\\nRelationships:-\\n1. Entity1: \""NCCN\"", Entity2: \""Clinical Trials\"", Relationship: \""encourages participation in\""\\n2. Entity1: \""NCCN\"", Entity2: \""Cancer\"", Relationship: \""recommends clinical trials for\""\\n\\nCausalities:-\\n<A> NCCN believes that the best management of any patient with cancer is through participation in clinical trials </A>, <A> which is especially encouraged </A>.\\n--------------------------------------------------\\nPage Number: 102\\n\\nSection Name: Head and Neck Cancers - Principles of Surgery\\n====================\\nEntities:-\\nSurgical Procedures, Operative : Manual or operative procedures used in the treatment of disease, injuries, or deformities.\\nLymphatic System : Part of the circulatory system and a vital part of the immune system, comprising a network of lymphatic vessels that carry a clear fluid called lymph.\\nNeoplasms : New abnormal growth of tissue in animals or plants; a tumor.\\nNeck Dissection : A surgical procedure for control of neck lymph node metastasis from squamous cell carcinoma of the head and neck.\\nNeoplasm Staging : Methods which attempt to express in replicable terms the extent of the neoplasm in the patient.\\nMetastasis : The spread of a cancer or other disease from one organ or part of the body to another not directly connected with it.\\nSurgical Procedure : A procedure involving an incision with instruments; performed to repair damage or arrest disease in a living body.\\nLymphatic Structure : Anatomical structure that is part of the lymphatic system.\\nTumor : An abnormal mass of tissue that results when cells divide more than they should or do not die when they should.\\nStaging : The process of determining the size and spread of cancer within the body.\\nSurgery : Medical specialty that uses operative manual and instrumental techniques on a patient to investigate or treat a pathological condition such as disease or injury.\\nCancer Staging : The process of determining the extent to which a cancer has developed by growing and spreading.\\n\\nRelationships:-\\n1. Entity1: \""surgical management\"", Entity2: \""regional lymphatics\"", Relationship: \""dictated by tumor staging\""\\n2. Entity1: \""neck dissections\"", Entity2: \""primary tumor\"", Relationship: \""part of treatment\""\\n3. Entity1: \""surgery\"", Entity2: \""ipsilateral side of the neck\"", Relationship: \""risk for metastases\""\\n\\nCausalities:-\\n<C> The extent of the tumor at initial tumor staging </C> <E> dictates the surgical management of regional lymphatics </E>. These guidelines apply to the performance of neck dissections as part of treatment of the primary tumor. <CO> Patients undergoing surgery for resection of the primary tumor </CO> <A> will undergo dissection of the ipsilateral side of the neck that is at greatest risk for metastases </A>.\\n\\nSection Name: Neck Management\\n====================\\nEntities:-\\nTongue : A muscular organ in the mouth that is involved in tasting, swallowing, and speech.\\nPalate : The roof of the mouth, separating the oral and nasal cavities.\\nLarynx : An organ in the top of the neck involved in breathing, producing sound, and protecting the trachea.\\nHypopharynx : The bottom part of the pharynx, which is the cavity behind the nose and mouth.\\nNasopharynx : The upper part of the pharynx, connecting with the nasal cavity above the soft palate.\\nNeck Dissection : A surgical procedure for control of neck lymph node metastasis from squamous cell carcinoma of the head and neck.\\nMetastasis : The spread of a cancer or other disease from one organ or part of the body to another not directly connected with it.\\nSquamous Cell Carcinoma : A type of cancer that begins in the squamous cells, which are thin, flat cells that look like fish scales.\\nBiopsy : The removal of cells or tissues for examination under a microscope.\\n\\nRelationships:-\\n1. Entity1: \""Tumor sites\"", Entity2: \""Bilateral lymphatic drainage\"", Relationship: \""associated with\""\\n2. Entity1: \""Elective neck dissection\"", Entity2: \""Risk of occult metastasis\"", Relationship: \""based on\""\\n3. Entity1: \""SLN biopsy\"", Entity2: \""Elective neck dissection\"", Relationship: \""guides decision-making for\""\\n\\nCausalities:-\\n- **<C> Tumor sites that frequently have bilateral lymphatic drainage </C>** (e.g., base of tongue, palate, supraglottic larynx, hypopharynx, nasopharynx, deep pre-epiglottic space involvement) <E> often should have both sides of the neck dissected </E> with the extent of dissection determined as suggested below. For those patients with tumors at or approaching the midline, <CO> both sides of the neck are at risk for metastases </CO>, and <A> bilateral neck dissections should be performed </A>.\\n\\n- <CO> Patients with advanced lesions involving the anterior tongue, floor of the mouth, or alveolus that approximate or cross the midline </CO> <A> should undergo contralateral selective/modified neck dissection </A> as necessary to achieve adequate tumor resection.\\n\\n- **<C> Elective neck dissection </C>** <A> should be based on risk of occult metastasis in the appropriate nodal basin </A>. For oral cavity squamous cell carcinoma, <C> SLN biopsy or the primary tumor depth of invasion </C> is currently <E> the best predictor of occult metastatic disease </E> and <A> should be used to guide decision-making </A>. <CO> For tumors with a depth greater than 3 mm </CO>, <A> elective dissection should be strongly considered if RT is not already planned </A>. Recent randomized trial evidence supports the effectiveness of elective neck dissection in patients with oral cavity cancers greater than 3 mm in depth of invasion.\\n\\n  - <CO> For a depth less than 2 mm </CO>, <A> elective dissection is only indicated in highly selective situations </A>. <CO> For a depth of 2\u20134 mm </CO>, <A> clinical judgment (as to reliability of follow-up, clinical suspicion, and other factors) must be utilized to determine appropriateness of elective dissection </A>. Elective dissections are generally selective, preserving all major structures, unless operative findings dictate otherwise.\\n\\nSection Name: Types of Neck Dissection\\n====================\\nEntities:-\\nNeck Dissection : A surgical procedure for control of neck lymph node metastasis from squamous cell carcinoma of the head and neck.\\nLarynx : An organ in the top of the neck involved in breathing, producing sound, and protecting the trachea.\\n\\nRelationships:-\\n1. Entity1: \""N0\"", Entity2: \""Selective neck dissection\"", Relationship: \""associated with\""\\n2. Entity1: \""N3\"", Entity2: \""Comprehensive neck dissection\"", Relationship: \""associated with\""\\n3. Entity1: \""Level VI neck dissection\"", Entity2: \""Larynx\"", Relationship: \""performed for\""\\n4. Entity1: \""Level VI neck dissection\"", Entity2: \""Hypopharynx\"", Relationship: \""performed for\""\\n\\nCausalities:-\\n- **The type of neck dissection (comprehensive or selective)** is defined according to <CO> preoperative clinical staging </CO>, is determined at the discretion of the surgeon, and is based on the initial preoperative staging as follows:\\n  - **N0:** <A> Selective neck dissection </A>\\n    - Oral cavity at least levels I\u2013III\\n    - Oropharynx at least levels II\u2013IV\\n    - Hypopharynx at least levels II\u2013IV and level VI when appropriate\\n    - Larynx at least levels II\u2013IV and level VI when appropriate\\n  - **N1\u2013N2a\u2013c:** <A> Selective or comprehensive neck dissection </A> (Discussion)\\n  - **N3:** <A> Comprehensive neck dissection </A>\\n\\n- <C> Level VI neck dissections are performed for certain primary sites (such as the larynx and hypopharynx) </C> <E> as required to resect the primary tumor and any clinically evident neck nodes </E>. <CO> Elective dissection depends on primary tumor extent and site </CO>. <CO> For advanced glottic and hypopharyngeal cancers treated with primary surgery </CO>, <A> a level VI dissection (including pretracheal lymph nodes, the Delphian lymph node, and unilateral or bilateral paratracheal lymph nodes) and hemithyroidectomy to total thyroidectomy are appropriate </A>.\\n\\n- <CO> For primary subglottic tumors or glottic cancers with significant subglottic extension </CO>, <A> a level VI dissection with unilateral or total thyroidectomy is considered appropriate </A> based on the extent of the primary tumor. <CO> For example, a T4a glottic tumor with extension through the cricothyroid membrane and subglottic extension </CO> <A> should include thyroidectomy and pretracheal and bilateral paratracheal lymph node dissection </A>. <A> Parathyroid glands should be preserved in situ or auto transplanted as indicated </A>.\\n--------------------------------------------------\\nPage Number: 53\\n\\nSection Name: Introduction\\n====================\\nEntities:-\\nNational Comprehensive Cancer Network : The National Comprehensive Cancer Network (NCCN) is an alliance of 30 cancer centers in the United States, dedicated to improving the quality, effectiveness, and efficiency of cancer care so that patients can live better lives.\\nLaryngeal Neoplasms : Tumors or cancer of the larynx, which may affect the supraglottic, glottic, or subglottic regions.\\nMalignant Neoplasm Of Supraglottis : A malignant tumor located in the supraglottic region of the larynx.\\n\\nRelationships:-\\n1. Entity1: \""National Comprehensive Cancer Network\"", Entity2: \""Malignant neoplasm of supraglottis\"", Relationship: \""provides guidelines for\""\\n2. Entity1: \""clinical staging\"", Entity2: \""treatment strategies\"", Relationship: \""part of flowchart for\""\\n\\nCausalities:-\\nThe provided image is a flowchart outlining the <C> NCCN (National Comprehensive Cancer Network) guidelines </C> for the treatment of <CO> cancers of the supraglottic larynx </CO>. This flowchart <A> utilizes a highly structured approach to convey clinical staging and treatment strategies </A>, indicating the various pathways based on <CO> patient conditions and disease features </CO>.\\n\\nSection Name: NCCN Guidelines Version 4.2024\\n====================\\nEntities:-\\nLaryngeal Neoplasms : Tumors or cancer of the larynx, which may affect the supraglottic, glottic, or subglottic regions.\\nMalignant Neoplasm Of Supraglottis : A malignant tumor located in the supraglottic region of the larynx.\\nSupraglottic Cancer : Cancer that occurs in the supraglottic region of the larynx, above the vocal cords.\\nClinical Trials As Topic : Pre-planned studies of the safety, efficacy, or optimum dosage schedule of one or more diagnostic, therapeutic, or prophylactic drugs, devices, or techniques in humans selected according to predetermined criteria of eligibility and observed for predefined evidence of favorable and unfavorable effects.\\nClinical Trial : A type of research that studies new tests and treatments and evaluates their effects on human health outcomes.\\n\\nRelationships:-\\n1. Entity1: \""Cancer of the Supraglottic Larynx\"", Entity2: \""Clinical Trials\"", Relationship: \""recommended management strategy\""\\n\\nCausalities:-\\n- All recommendations are category 2A unless otherwise indicated.\\n- <A> Participation in clinical trials </A> is especially encouraged.\\n\\nSection Name: Key Components of the Flowchart\\n====================\\nEntities:-\\nNeoplasm Staging : Methods used for staging neoplasms, including clinical and pathological staging.\\nRadiotherapy : The use of ionizing radiation to treat cancer.\\nSurgical Procedures, Operative : Operations carried out for the correction of deformities and defects, repair of injuries, and diagnosis and cure of certain diseases.\\nAdjuvant Chemotherapy : Chemotherapy given in addition to the primary treatment to maximize its effectiveness.\\nNeoplasm Recurrence, Local : The return of a tumor at the original site after treatment.\\nClinical Trials As Topic : Pre-planned studies of the safety, efficacy, or optimum dosage schedule of one or more diagnostic, therapeutic, or prophylactic drugs, devices, or techniques in humans selected according to predetermined criteria of eligibility and observed for predefined evidence of favorable and unfavorable effects.\\n\\nRelationships:-\\n1. Entity1: \""Clinical Staging\"", Entity2: \""Treatment of Primary and Neck\"", Relationship: \""determines\""\\n2. Entity1: \""Evaluation and Follow-Up\"", Entity2: \""Adverse and No Adverse Features\"", Relationship: \""leads to decision based on\""\\n3. Entity1: \""Adjuvant Treatment\"", Entity2: \""Adverse pathologic features\"", Relationship: \""considered if present\""\\n4. Entity1: \""Clinical Trials\"", Entity2: \""Treatment Pathway\"", Relationship: \""part of\""\\n\\nCausalities:-\\n### Key Components of the Flowchart\\n\\n1. **Clinical Staging**: The flowchart starts with <A>clinical staging</A>, indicating that <CO>patients must first be evaluated to determine the extent of cancer</CO>. This is essential for <E>deciding on appropriate treatment options</E>.\\n\\n2. **Treatment of Primary and Neck**: The flowchart details multiple treatment strategies, including:\\n   - <A>**Concurrent systemic therapy/RT**</A>: This suggests a combination approach for <CO>patients eligible for such treatment</CO>.\\n   - <A>**Definitive Radiation Therapy (RT)**</A>: Recommended for <CO>low-volume diseases or patients who cannot tolerate systemic therapy</CO>.\\n   - <A>**Surgical Options**</A>: It highlights options such as endoscopic or open partial laryngectomy and neck dissection, which are <CO>contingent on clinical evaluations</CO>.\\n\\n3. **Evaluation and Follow-Up**: After initial treatment approaches, the chart directs clinicians to perform a <A>\""Post Systemic Therapy/RT or RT Neck Evaluation\""</A>. This step <E>assesses whether there are adverse pathologic features</E>, guiding subsequent treatment decisions.\\n\\n4. **Adverse and No Adverse Features**: The decision pathway diverges based on findings:\\n   - <CO>Patients with **adverse pathologic features**</CO> may have <A>additional diagnostic imaging (CT or MRI)</A> and may require <A>further systemic treatment</A>.\\n   - <CO>Patients with **no adverse features**</CO> may be directed towards <A>considerations for radiation therapy</A>.\\n\\n5. **Adjuvant Treatment and Recurrence**: The chart also addresses <E>management of any recurrent or persistent disease</E>, emphasizing the importance of <A>regular follow-up assessments</A>. Various options for <A>adjuvant treatment</A> are mentioned, focusing on tailored approaches towards ongoing management of the disease.\\n\\n6. **Clinical Trials**: The flowchart encourages <A>participation in clinical trials</A>, indicating a commitment to <E>exploring new treatments and improving patient outcomes</E>.\\n\\nSection Name: Principles\\n====================\\nEntities:-\\nImaging : The process of producing images of the body or parts of the body to diagnose or examine disease.\\nSurgical Procedure : A medical procedure involving an incision with instruments; performed to repair damage or arrest disease in a living body.\\nRadiation Therapy : The use of ionizing radiation to treat cancer and other diseases.\\nSystemic Therapy : Treatment using substances that travel through the bloodstream, reaching and affecting cells all over the body.\\n\\nRelationships:-\\n1. Entity1: \""Imaging\"", Entity2: \""Surgery\"", Relationship: \""Both are foundational principles in medical practice.\""\\n2. Entity1: \""Radiation therapy\"", Entity2: \""Systemic Therapy\"", Relationship: \""Both are treatment modalities for cancer.\""\\n\\nCausalities:-\\n#### Principles\\n- **Principles of Imaging (IMG-A)**\\n- **Principles of Surgery (SURG-A)**\\n- **Principles of Radiation Therapy (SUPRA-A)**\\n- **Principles of Systemic Therapy for Non-Nasopharyngeal Cancers (SYST-A)**\\n\\nSection Name: Adverse Pathologic Features\\n====================\\nEntities:-\\nExtranodal Extension : The spread of cancer cells beyond the lymph node capsule into the surrounding tissues.\\nPositive Surgical Margins : The presence of cancer cells at the edge of the tissue removed during surgery.\\nPerineural Invasion : Cancer cells found surrounding or tracking along a nerve within the perineural space.\\nVascular Invasion : The presence of cancer cells within blood vessels.\\nLymphatic Invasion : The presence of cancer cells within lymphatic vessels.\\n\\nRelationships:-\\n1. Entity1: \""Extranodal Extension\"", Entity2: \""Positive Surgical Margins\"", Relationship: \""Both indicate cancer spread beyond original site.\""\\n2. Entity1: \""Perineural Invasion\"", Entity2: \""Vascular Invasion\"", Relationship: \""Both are pathways for cancer spread.\""\\n3. Entity1: \""pT3 or pT4 primary\"", Entity2: \""pN2 or pN3 nodal disease\"", Relationship: \""Both indicate advanced cancer stages.\""\\n\\nCausalities:-\\n<C> Extranodal extension </C>\\n<C> Positive margins </C>\\n<C> Close margins </C>\\n<C> pT3 or pT4 primary </C>\\n<C> pN2 or pN3 nodal disease </C>\\n<C> Perineural invasion </C>\\n<C> Vascular invasion </C>\\n<C> Lymphatic invasion </C>\\n\\nSection Name: Clinical Staging and Treatment of Primary and Neck\\n====================\\nEntities:-\\nAdjuvant Chemotherapy : Chemotherapy given in addition to the primary treatment to maximize its effectiveness.\\nFollow-Up Procedure : A procedure performed to monitor the progress of a patient after treatment.\\nRecurrent Disease : A disease that returns after a period of remission.\\nLaryngectomy : Surgical removal of the larynx, often used to treat cancer.\\nRadiation Therapy : The use of ionizing radiation to treat cancer and other diseases.\\nClinical Trial : A type of research that studies new tests and treatments and evaluates their effects on human health outcomes.\\nNeck Dissection : Surgical procedure to remove lymph nodes and surrounding tissue to treat cancer.\\nChemotherapy : Treatment of disease by the use of chemical substances, especially cancer by cytotoxic drugs.\\n\\nRelationships:-\\n1. Entity1: \""Adjuvant Treatment\"", Entity2: \""Treatment of Primary and Neck\"", Relationship: \""part of\""\\n2. Entity1: \""Follow-up\"", Entity2: \""Treatment of Primary and Neck\"", Relationship: \""part of\""\\n3. Entity1: \""Recurrent or Persistent Disease\"", Entity2: \""Treatment of Primary and Neck\"", Relationship: \""part of\""\\n4. Entity1: \""Larynx-Preserving Surgery\"", Entity2: \""Treatment Options\"", Relationship: \""is a treatment option for\""\\n5. Entity1: \""Concurrent Systemic Therapy/RT\"", Entity2: \""Treatment Options\"", Relationship: \""is a treatment option for\""\\n6. Entity1: \""Clinical Trials or Definitive RT\"", Entity2: \""Treatment Options\"", Relationship: \""is a treatment option for\""\\n7. Entity1: \""Endoscopic or Open Partial Laryngectomy and Neck Dissection(s)\"", Entity2: \""Treatment Options\"", Relationship: \""is a treatment option for\""\\n8. Entity1: \""Induction Chemotherapy\"", Entity2: \""Treatment Options\"", Relationship: \""is a treatment option for\""\\n\\nCausalities:-\\n<A> Amenable to Larynx-Preserving (Conservation) Surgery </A>: <CO> T1\u20132, N+ and selected T3, N1 </CO>\\n<A> Concurrent Systemic Therapy/RT </A>: <CO> i, k, l </CO>\\n<A> Clinical Trials or Definitive RT </A>: <CO> i </CO>\\n<A> Endoscopic or Open Partial Laryngectomy and Neck Dissection(s) </A>: <CO> h </CO>\\n<A> Induction Chemotherapy </A>: <CO> k, m </CO>\\n\\nSection Name: Pathologic Features and Response Assessment\\n====================\\nEntities:-\\nRadiation Therapy : The use of ionizing radiation to treat cancer and other diseases.\\nExtranodal Extension : The spread of cancer cells beyond the lymph node capsule into the surrounding tissues.\\nPositive Surgical Margin : Cancer cells are found at the edge of the material removed during surgery, indicating that some cancer may have been left behind.\\nSystemic Therapy : Treatment using substances that travel through the bloodstream, reaching and affecting cells all over the body.\\n\\nRelationships:-\\n1. Entity1: \""Extranodal extension\"", Entity2: \""Adverse Pathologic Features\"", Relationship: \""is a type of\""\\n2. Entity1: \""Positive margin\"", Entity2: \""Adverse Pathologic Features\"", Relationship: \""is a type of\""\\n3. Entity1: \""Systemic Therapy\"", Entity2: \""Adverse Pathologic Features\"", Relationship: \""considered in response to\""\\n4. Entity1: \""Radiation Therapy\"", Entity2: \""Adverse Pathologic Features\"", Relationship: \""considered in response to\""\\n\\nCausalities:-\\n#### Pathologic Features\\n- **No Adverse Pathologic Features**: j\\n  - <A> Consider RT </A>: i\\n- **Adverse Pathologic Features**: j\\n  - <CO> Extranodal extension and/or positive margin </CO>: n\\n  - Other risk features\\n  - <A> Systemic therapy/RT </A>: i, k (category 1)\\n  - <A> Consider systemic therapy/RT </A>: i, k\\n\\n#### Response Assessment\\n- **Response Assessment** (SUPRA-7)\\n\\nSection Name: Imaging and Recurrent or Persistent Disease\\n====================\\nEntities:-\\nTomography, X-Ray Computed : A method of body imaging in which a thin X-ray beam rotates around the patient.\\nMagnetic Resonance Imaging : Medical imaging technique used in radiology to form pictures of the anatomy and the physiological processes of the body.\\nComputed Tomography : Medical imaging technique used in radiology to obtain detailed internal images of the body.\\n\\nRelationships:-\\n1. Entity1: \""CT\"", Entity2: \""primary and neck\"", Relationship: \""used for imaging\""\\n2. Entity1: \""MRI\"", Entity2: \""primary and neck\"", Relationship: \""used for imaging\""\\n3. Entity1: \""Post Systemic Therapy/RT\"", Entity2: \""Recurrent or Persistent Disease\"", Relationship: \""evaluation after treatment\""\\n4. Entity1: \""RT Neck Evaluation\"", Entity2: \""Recurrent or Persistent Disease\"", Relationship: \""evaluation after treatment\""\\n\\nCausalities:-\\n<A> CT (with contrast) or MRI (with and without contrast) of primary and neck </A>\\n\\n<CO> Recurrent or Persistent Disease </CO>\\n\\n<CO> Post Systemic Therapy/RT or RT Neck Evaluation </CO>\\n\\nSection Name: Conclusion\\n====================\\nEntities:-\\nOncologists : Medical doctors who specialize in the diagnosis and treatment of cancer.\\nSupraglottic Larynx Cancer : A type of cancer that occurs in the supraglottic region of the larynx, which is the area above the vocal cords.\\nClinical Staging : The process of determining the extent of cancer in the body, usually based on physical examination, imaging tests, and biopsies.\\nTreatment Strategies : Plans or methods developed to treat diseases, including cancer, which may involve surgery, chemotherapy, radiation therapy, or other modalities.\\nFollow-Up Evaluations : Medical assessments conducted after initial treatment to monitor a patient\\'s progress and detect any recurrence of disease.\\nClinical Efficacy : The ability of a treatment to produce the desired therapeutic effect in clinical settings.\\nResearch : Systematic investigation and study conducted to establish facts and reach new conclusions.\\nTreatment Paradigms : Standard models or patterns of treatment used in medical practice, often based on clinical guidelines and research findings.\\n\\nRelationships:-\\n1. Entity1: \""Oncologists\"", Entity2: \""Supraglottic Larynx Cancer\"", Relationship: \""use flowchart for decision-making\""\\n2. Entity1: \""Clinical Staging\"", Entity2: \""Treatment Strategies\"", Relationship: \""part of management process\""\\n3. Entity1: \""Treatment Strategies\"", Entity2: \""Follow-Up Evaluations\"", Relationship: \""part of management process\""\\n\\nCausalities:-\\n<A> The flowchart serves as a comprehensive guide for oncologists and healthcare providers </A>, <A> facilitating informed decision-making in the treatment of supraglottic larynx cancer </A>. <A> By visualizing the complex interactions between clinical staging, treatment strategies, and follow-up evaluations </A>, <E> it streamlines the management process </E>, <E> ensuring that patients receive appropriate care tailored to their specific needs </E>. <E> The detailed pathways not only enhance clinical efficacy </E> but also <E> underscore the importance of ongoing research and adaptation of treatment paradigms in oncology </E>.\\n'}""",valid,increases risk,2,B,"edge - The edge which needs to be verified.
explanation - Explanation of what the edge represents and its validity.
causal_direction - Either Positive or Negative or Unknown. A positive influence direction indicates that both factors change in the same direction (e.g. an increase causes an increase effect). A negative influence direction indicates the opposite changes (e.g. an increase causes a decrease effect).
causal_factor - Is necessary or sufficient condition for an effect to occur. Exposure is a term commonly used in epidemiology to denote any condition that is considered as a possible cause of disease. Exposure is considered necessary when it always precedes the effects (e.g. symptoms) and always presents when the effects occur. A sufficient cause is a causal factor whose presence or occurrence guarantees the occurrence of symptom.
causal_distance - Either Distal or Proximal or Unknown. The distal factors lie towards the beginning of causal chain (i.e. indirect causal factors). The the proximal factors lie towards the end of the chain (i.e. cause directly or almost directly the effect).

Causality Tags:
<A> for action, <C> for cause, <CO> for condition and <E> for effect.
Cause (C): The reason or origin that leads to an effect. Causes often involve disease conditions, risk factors, or underlying mechanisms.
Effect (E): The outcome or result of a cause. Effects usually represent clinical outcomes, complications, or results of a specific cause.
Condition (CO): The circumstance or prerequisite required for an action or effect to occur. Conditions may include patient characteristics, clinical scenarios, or specific diagnostic criteria.
Action (A): The recommended or described response or activity to address a cause or condition. Actions typically involve clinical interventions, diagnostic procedures, or treatment recommendations.


`NODE1`:
id: Size_of_Lymph_Nodes_6
label: Size of Lymph Nodes
description: This node represents the clinical assessment of the size of lymph nodes in a patient. The size of lymph nodes can be an important indicator in diagnosing conditions such as infections, immune responses, or cancer metastasis. Enlarged lymph nodes may suggest the presence of disease, while normal-sized lymph nodes are typically not indicative of pathology.
type: Patient Situation
observability: Unobserved
states: [{'state_name': 'present', 'state_description': 'The lymph nodes are enlarged or have a significant size, which may indicate the presence of disease such as infection, inflammation, or metastasis.'}, {'state_name': 'absent', 'state_description': 'The lymph nodes are not enlarged and are of normal size, suggesting no significant pathology or disease.'}]

`NODE2`:
id: Imaging_Results_13
label: Imaging Examination Results
description: This node represents the results of an imaging examination, which could include modalities such as ultrasound, MRI, or other diagnostic imaging techniques. The results indicate whether specific findings are present or absent, which can be crucial for diagnosis and treatment planning.
type: Examination Result
observability: Observed
states: [{'state_name': 'present', 'state_description': ""The 'present' state indicates that the imaging examination has identified specific findings or abnormalities that are relevant to the clinical context.""}, {'state_name': 'absent', 'state_description': ""The 'absent' state indicates that the imaging examination did not identify any specific findings or abnormalities of interest in the clinical context.""}]

`EDGE1`:
{'edges_ids': ['Size_of_Lymph_Nodes_6', 'Imaging_Results_13'], 'edge': '(Size_of_Lymph_Nodes_6) causes (Imaging_Results_13)', 'explanation': ['The size of lymph nodes can directly affect imaging results because enlarged lymph nodes are often detected as abnormalities in imaging examinations.', 'If lymph nodes are enlarged, imaging results are more likely to show abnormalities, indicating a positive causal direction.', 'However, the size of lymph nodes is neither a necessary nor a sufficient condition for imaging results to show abnormalities, as other factors can also influence imaging results.', 'The causal relationship is proximal because the size of lymph nodes directly impacts the imaging findings.'], 'causal_direction': 'positive', 'causal_factor': {'necessary': False, 'sufficient': False}, 'causal_distance': 'Proximal'}

`EDGE2`:
{'edges_ids': ['Imaging_Results_13', 'Size_of_Lymph_Nodes_6'], 'edge': '(Imaging_Results_13) causes (Size_of_Lymph_Nodes_6)', 'explanation': ['The edge suggests that the results of an imaging examination (Imaging_Results_13) cause changes in the size of lymph nodes (Size_of_Lymph_Nodes_6).', 'However, imaging results are observations of the current state of lymph nodes, not a cause of their size.', 'The size of lymph nodes is determined by underlying physiological or pathological processes, not by the imaging results themselves.', 'Therefore, the edge is not valid as a causal relationship.'], 'causal_direction': 'Unknown', 'causal_factor': {'necessary': False, 'sufficient': False}, 'causal_distance': 'Unknown'}

`INFORMATION FROM KNOWLEDGE BASE`:
--------------------------------------------------
Page Number: 41

Section Name: Workup
====================
Entities:-
Laryngeal Neoplasms : Tumors or cancer of the larynx, which may affect the glottis, supraglottis, or subglottis.
History And Physical Examination : A comprehensive assessment of a patient's medical history and physical condition.
Tobacco Smoking : The act of smoking tobacco products, which is a risk factor for many diseases.
Alcohol Drinking : The consumption of beverages containing ethyl alcohol.
Smoking Cessation : The process of discontinuing tobacco smoking.
Biopsy : A medical test involving the extraction of sample cells or tissues for examination.
Laryngoscopy : A procedure to examine the larynx, often using a scope.
Computed Tomography (Ct) : A diagnostic imaging procedure that uses computer-processed combinations of many X-ray measurements taken from different angles to produce cross-sectional images of specific areas of a scanned object.
Magnetic Resonance Imaging (Mri) : A medical imaging technique used in radiology to form pictures of the anatomy and the physiological processes of the body.
Positron-Emission Tomography : A type of nuclear medicine imaging that measures metabolic activity of the cells of body tissues.
Pulmonary Function Test : Tests that measure how well the lungs are working.
Dental Examination : An evaluation of the teeth and gums to assess oral health.
Nutritional Support : Therapies to provide nutrition to patients who cannot obtain nutrition by mouth.
Speech Therapy : Therapy to improve speech and communication skills.
Swallowing Therapy : Therapy to help individuals with swallowing difficulties.
Multidisciplinary Care Team : A group of healthcare professionals from different specialties working together to manage patient care.

Relationships:-
1. Entity1: ""glottic larynx cancer"", Entity2: ""history and physical examination"", Relationship: ""initial diagnostic step""
2. Entity1: ""glottic larynx cancer"", Entity2: ""biopsy"", Relationship: ""required diagnostic procedure""
3. Entity1: ""glottic larynx cancer"", Entity2: ""direct laryngoscopy"", Relationship: ""recommended procedure""
4. Entity1: ""glottic larynx cancer"", Entity2: ""CT scans"", Relationship: ""imaging study""
5. Entity1: ""glottic larynx cancer"", Entity2: ""MRI"", Relationship: ""imaging study""
6. Entity1: ""glottic larynx cancer"", Entity2: ""multidisciplinary consultation"", Relationship: ""advised as clinically indicated""

Causalities:-
The workup section outlines the initial steps for diagnosing <C>glottic larynx cancer</C>. It includes <A>a comprehensive history and physical examination (H&P)</A>, which should document tobacco and alcohol use, and provide counseling for smoking cessation. <A>A biopsy of the primary site is required</A>, and <A>direct laryngoscopy under anesthesia is generally recommended</A>. <A>Imaging studies such as CT scans with contrast and possibly MRI are used to evaluate the larynx and neck</A>. Additional evaluations may include <A>chest CT, FDG-PET/CT, pulmonary function tests, dental evaluation, and nutrition, speech, and swallowing therapy</A>. <A>Multidisciplinary consultation is advised</A> <CO>as clinically indicated</CO>.

Section Name: Clinical Staging
====================
Entities:-
Cancer : A group of diseases involving abnormal cell growth with the potential to invade or spread to other parts of the body.
Carcinoma In Situ : A lesion with cytological characteristics of cancer but which has not invaded the basement membrane.
Biopsy : A medical test involving the extraction of sample cells or tissues for examination.
Laryngectomy : A surgical procedure to remove the larynx.

Relationships:-
1. Entity1: ""Clinical staging"", Entity2: ""Cancer"", Relationship: ""involves""
2. Entity1: ""Carcinoma in situ"", Entity2: ""Stages T1-T4"", Relationship: ""is a stage of""
3. Entity1: ""Biopsy"", Entity2: ""Cancer"", Relationship: ""used in staging""
4. Entity1: ""Larynx-preserving surgeries"", Entity2: ""Stages T1-T2"", Relationship: ""considered for""
5. Entity1: ""Total laryngectomy"", Entity2: ""Stages T3-T4"", Relationship: ""required for""

Causalities:-
<C> Clinical staging involves categorizing the cancer based on its aggressiveness </C>. It starts with carcinoma in situ, which is non-invasive, and progresses through stages T1-T4. <CO> Staging is based on H&P, biopsy, and imaging studies </CO>. <CO> For T1-T2 </CO>, <A> larynx-preserving surgeries are considered </A>, while <CO> more advanced stages like T3 or T4 </CO> <A> may require total laryngectomy </A>. <A> Additional evaluations such as videostrobe, audiogram, and fertility counseling may be considered </A>.

Section Name: Treatment
====================
Entities:-
Carcinoma In Situ : A lesion with cytological characteristics of cancer but which has not invaded the basement membrane.
Laryngectomy : A surgical procedure to remove the larynx.
Metastasis : The transfer of a disease from one organ or part to another not directly connected with it.
Clinical Trials As Topic : Works about research studies that evaluate the effectiveness and safety of medications or medical devices by monitoring their effects on large groups of people.

Relationships:-
1. Entity1: ""Carcinoma in situ"", Entity2: ""Larynx-preserving surgery"", Relationship: ""treated with""
2. Entity1: ""T1-T2 stages"", Entity2: ""Conservation surgery"", Relationship: ""treated with""
3. Entity1: ""T3 stages"", Entity2: ""Total laryngectomy"", Relationship: ""may require""
4. Entity1: ""T4a disease"", Entity2: ""Complex interventions"", Relationship: ""require""
5. Entity1: ""Guidelines"", Entity2: ""Multidisciplinary consultations"", Relationship: ""emphasize importance of""
6. Entity1: ""Guidelines"", Entity2: ""Clinical trials"", Relationship: ""consider as best option""

Causalities:-
<CO>Treatment recommendations vary by stage</CO>. <CO>Carcinoma in situ</CO> <A>may be treated with larynx-preserving surgery</A>. <CO>T1-T2 stages</CO> <A>may also be amenable to conservation surgery</A>. <CO>T3 stages</CO> <A>may require total laryngectomy</A>, <CO>especially if nodal involvement is present</CO>. <CO>T4a disease and unresectable or metastatic cases</CO> <A>require more complex interventions</A>. <A>The guidelines emphasize the importance of multidisciplinary consultations</A> and <A>consider clinical trials as the best management option</A>.

Section Name: Additional Notes
====================
Entities:-
Biopsy, Needle : A procedure to remove a small sample of tissue for examination under a microscope.
Image-Guided Biopsy : A biopsy procedure that uses imaging techniques to guide the needle to the precise location of the tissue to be sampled.
Biopsy : A medical test involving the extraction of sample cells or tissues for examination.
Diagnostic Techniques And Procedures : Methods and procedures for the diagnosis of disease or dysfunction.
Imaging : The process of producing images of the body for clinical purposes.
Dental Care : The total of dental diagnostic, preventive, and corrective procedures.
Nutritional Physiological Phenomena : The functions and properties of nutrients in living organisms.
Fertility : The capacity to conceive or induce conception.
Reproductive Health : A state of physical, mental, and social well-being in all matters relating to the reproductive system.
Lymphatic Metastasis : The transfer of a neoplasm from one organ or part of the body to another remote from the primary site.
Glottis : The part of the larynx consisting of the vocal cords and the opening between them.

Relationships:-
1. Entity1: ""image-guided needle biopsy"", Entity2: ""diagnostic yield"", Relationship: ""used for""
2. Entity1: ""nodal disease"", Entity2: ""glottic tumors"", Relationship: ""is rare in""

Causalities:-
<A> use of image-guided needle biopsy </A> for <E> better diagnostic yield </E>, principles of imaging, dental evaluation, and nutrition management. The guidelines also address fertility and reproductive considerations, and note that <CO> nodal disease in glottic tumors is rare </CO>.
--------------------------------------------------
Page Number: 46

Section Name: Introduction
====================
Entities:-
Laryngeal Neoplasms : Tumors or cancer of the larynx, including the glottis.
Malignant Neoplasm Of Glottis : A malignant tumor located in the glottis, part of the larynx.
National Comprehensive Cancer Network : The National Comprehensive Cancer Network (NCCN) is an alliance of 30 cancer centers in the United States, dedicated to improving the quality, effectiveness, and efficiency of cancer care.
Adjuvant Chemotherapy : Chemotherapy given in addition to the primary treatment to maximize its effectiveness, often used in cancer treatment.
Adjuvant Therapy : Treatment given in addition to the primary (main) treatment to enhance its effectiveness.

Relationships:-
1. Entity1: ""National Comprehensive Cancer Network"", Entity2: ""Laryngeal Neoplasms"", Relationship: ""provides treatment guidelines for""
2. Entity1: ""treatment guidelines"", Entity2: ""Adjuvant therapy"", Relationship: ""guide clinical decision-making for""

Causalities:-
<C> cancer of the glottic larynx </C> <E> treatment guidelines </E> <CO> based on various clinical stages and specific patient conditions </CO> <A> guide healthcare professionals through clinical decision-making </A>.

Section Name: NCCN Guidelines Version 4.2024
====================
Entities:-
Clinical Trials : Clinical trials are research studies performed in people that are aimed at evaluating a medical, surgical, or behavioral intervention.
National Comprehensive Cancer Network : The National Comprehensive Cancer Network (NCCN) is an alliance of 30 cancer centers in the United States, dedicated to improving the quality, effectiveness, and efficiency of cancer care.

Relationships:-
1. Entity1: ""National Comprehensive Cancer Network"", Entity2: ""Clinical Trials"", Relationship: ""encourages participation in""

Causalities:-
<A>Participation in clinical trials</A> is especially encouraged.

Section Name: Clinical Staging and Treatment
====================
Entities:-
Neoplasm Staging : Methods used for staging of neoplasms based on extent of tumor spread.
T4A : A clinical stage indicating a tumor that has grown into nearby structures.
N0–3 : A range of clinical stages indicating the extent of regional lymph node involvement.
Surgical Procedures, Operative : Operations carried out for the correction of deformities and defects, repair of injuries, and diagnosis and cure of certain diseases.
Neck Dissection : Surgical procedure to remove lymph nodes and surrounding tissue in the neck.
Pathology : The study of the nature and cause of disease which involves changes in structure and function.
Antineoplastic Combined Chemotherapy Protocols : The use of drug combinations to treat cancer.
Radiotherapy : The use of ionizing radiation to treat cancer.
Clinical Trials As Topic : Works about research studies that evaluate the effectiveness and safety of medications or medical devices by monitoring their effects on large groups of people.

Relationships:-
1. Entity1: ""Clinical Staging"", Entity2: ""Surgical Intervention"", Relationship: ""determines""
2. Entity1: ""T4a"", Entity2: ""Surgical Intervention"", Relationship: ""relates to""
3. Entity1: ""Systemic Therapy"", Entity2: ""Radiotherapy"", Relationship: ""considered with""
4. Entity1: ""Clinical Trials"", Entity2: ""Treatment of Primary and Neck"", Relationship: ""option for""

Causalities:-
<CO> Clinical staging indicator labeled ""T4a,N0–3"" </CO> <A> emphasizes the importance of surgical intervention </A>, highlighting procedures such as bilateral neck dissection and the need to address certain pathologic features. <CO> Selected T4a patients who decline surgery </CO> <A> consider concurrent systemic therapy/RT or clinical trial for function-preserving surgical or RT management or induction chemotherapy </A>.

Section Name: Principles of Treatment
====================
Entities:-
Thyroidectomy : Surgical removal of the thyroid gland.
Extranodal Extension : Spread of cancer beyond the lymph node capsule.
Radiation Therapy : Medical use of ionizing radiation to treat cancer.

Relationships:-
1. Entity1: ""Surgery"", Entity2: ""Thyroidectomy"", Relationship: ""involves""
2. Entity1: ""Radiation therapy"", Entity2: ""Adverse pathologic features"", Relationship: ""treats""

Causalities:-
- **Principles of Radiation Therapy (GLOT-A):**  
  - <C> Adverse pathologic features: extranodal extension, positive margins, close margins, pT4 primary, pN2 or pN3 nodal disease, perineural invasion, vascular invasion, lymphatic invasion, and subglottic extension </C> (Discussion).  

- **Principles of Surgery (SURG-A):**  
  - <A> Surgery, including ipsilateral or bilateral neck dissection; thyroidectomy to clear central compartment nodes </A>, <CO> especially when there is thyroid cartilage with gross invasion of the thyroid gland and significant subglottic extension </CO>.

Section Name: Adjuvant Treatment and Follow-up
====================
Entities:-
Systemic Therapy : Treatment using substances that travel through the bloodstream, reaching and affecting cells all over the body.
Clinical Trial : A research study that prospectively assigns human participants or groups of humans to one or more health-related interventions to evaluate the effects on health outcomes.
Computed Tomography (Ct) : A medical imaging technique used in radiology to obtain detailed internal images of the body noninvasively for diagnostic purposes.
Magnetic Resonance Imaging (Mri) : A noninvasive medical test that physicians use to diagnose and treat medical conditions.
Recurrent Disease : A disease that has returned after a period of remission.
Radiation Therapy (Rt) : The use of ionizing radiation to treat cancer and other diseases.

Relationships:-
1. Entity1: ""Adverse Features"", Entity2: ""Specific Treatments"", Relationship: ""Suggests""
2. Entity1: ""Systemic Therapy"", Entity2: ""Patients who decline surgery"", Relationship: ""Option for""
3. Entity1: ""CT or MRI"", Entity2: ""Primary and Neck"", Relationship: ""Used for imaging""
4. Entity1: ""Recurrent or Persistent Disease"", Entity2: ""Follow-up"", Relationship: ""Condition for""
5. Entity1: ""pN1 without other risk features"", Entity2: ""RT"", Relationship: ""Suggests considering""

Causalities:-
<C> adverse features such as extralateral extension or positive margins </C> <E> specific treatments are suggested </E>. The guidelines recommend <A> considering options like concurrent systemic therapy or clinical trials </A> <CO> for patients who decline surgery </CO>.

- **Adjuvant Treatment:**  
  - <A> CT (with contrast) or MRI (with and without contrast) of primary and neck </A>.  

- **Follow-up (FOLL-A, 1 of 2):**  
  - <CO> Recurrent or persistent disease (ADV-3) </CO>.  

- **Post Systemic Therapy/RT or RT Neck Evaluation (FOLL-A, 2 of 2):**  
  - <CO> pN1 without other risk features </CO>: <A> Consider RT </A>.

Section Name: Response Assessment
====================
Entities:-
Adjuvant Chemotherapy : Chemotherapy given in addition to the primary treatment to maximize its effectiveness, often used in cancer treatment.
Computed Tomography : A diagnostic imaging procedure that uses a combination of X-rays and computer technology to produce cross-sectional images of the body.
Magnetic Resonance Imaging : A medical imaging technique used in radiology to form pictures of the anatomy and the physiological processes of the body.
Neoplasm Recurrence, Local : The return of a cancer, at the same site as the original (primary) tumor, after it had disappeared.

Relationships:-
1. Entity1: ""Adjuvant treatment"", Entity2: ""Treatment responses"", Relationship: ""affects""
2. Entity1: ""Follow-up assessments"", Entity2: ""CT or MRI scans"", Relationship: ""conducted using""
3. Entity1: ""Response Assessment (GLOT-5)"", Entity2: ""Recurrent or persistent disease (ADV-3)"", Relationship: ""determines""

Causalities:-
As the flowchart progresses to the adjuvant treatment section, it depicts further decision points based on treatment responses and disease recurrence. The inclusion of references to follow-up assessments, such as CT or MRI scans, underscores the emphasis on continuous monitoring and evaluation of treatment efficacy.  - **Response Assessment (GLOT-5):**   - <C>Recurrent or persistent disease (ADV-3)</C>.
--------------------------------------------------
Page Number: 93

Section Name: PRINCIPLES OF IMAGING
====================
Entities:-
Imaging, Diagnostic : The production of a visual representation of parts of the body, for the purpose of clinical analysis and medical intervention.
Head And Neck Neoplasms : Tumors or cancer of the head and neck region, including the nasal cavity, sinuses, lips, mouth, salivary glands, throat, or larynx.
Tomography, X-Ray Computed : An imaging procedure that uses special x-ray equipment to create detailed pictures, or scans, of areas inside the body.
Magnetic Resonance Imaging : A noninvasive diagnostic technique that uses magnetic fields and radio waves to produce a detailed image of the body's soft tissue and bones.
Contrast Media : Substances used to enhance the contrast of structures or fluids within the body in medical imaging.

Relationships:-
1. Entity1: ""Imaging, Diagnostic"", Entity2: ""Head and Neck Neoplasms"", Relationship: ""used for""
2. Entity1: ""Tomography, X-Ray Computed"", Entity2: ""Contrast Media"", Relationship: ""uses""
3. Entity1: ""Magnetic Resonance Imaging"", Entity2: ""Contrast Media"", Relationship: ""uses""

Causalities:-
<C> Imaging </C> plays an essential role in the clinical care of patients with head and neck cancer. <A> The proper selection and utilization of imaging studies </A> is critical in caring for patients with head and neck cancer. <A> CT is performed with contrast </A>, while <A> CT imaging of the chest can be performed with or without contrast </A>, <CO> as clinically indicated </CO>. <A> MRI is performed with and without contrast </A>, <CO> unless contraindicated </CO>.

Section Name: Initial Workup - Primary Site
====================
Entities:-
Tomography, X-Ray Computed : An imaging procedure that uses special x-ray equipment to create detailed pictures, or scans, of areas inside the body.
Magnetic Resonance Imaging : A noninvasive diagnostic technique that uses magnetic fields and radio waves to produce a detailed image of the body's soft tissue and bones.
Head And Neck Neoplasms : Tumors or cancer of the head and neck region, including the nasal cavity, sinuses, lips, mouth, salivary glands, throat, or larynx.
Neck Structure : The anatomical structure of the neck, which is the part of the body that connects the head to the torso.
Skull Base : The bottom part of the skull, which separates the brain from other facial structures.
Thoracic Inlet : The opening at the top of the thoracic cavity, through which pass the trachea, esophagus, and major blood vessels.

Relationships:-
1. Entity1: ""CT"", Entity2: ""MRI"", Relationship: ""complementary in imaging head and neck cancers""
2. Entity1: ""CT"", Entity2: ""Head and Neck Neoplasms"", Relationship: ""used to evaluate""
3. Entity1: ""MRI"", Entity2: ""Head and Neck Neoplasms"", Relationship: ""preferred for evaluating""
4. Entity1: ""Skull base"", Entity2: ""Thoracic inlet"", Relationship: ""imaging range for evaluation""

Causalities:-
<A>Imaging assessment of the primary site</A> can be performed with <A>CT of the soft tissues of the neck</A> or <A>MRI of the neck</A>. <C>CT is complementary to MRI for head and neck cancers</C>. <A>It is utilized to evaluate cortical bone erosion or periosteal invasion, cartilage invasion, and bony erosion or destruction</A>. <CO>in certain conditions, such as evaluating the extent of bone marrow invasion or in patients with extensive dental amalgam obscuring anatomy on CT, assessing skull base invasion and cranial nerve involvement, and differentiating tumor from obstructed sinuses</CO>, <A>MRI is preferred over CT</A>. <CO>when involved lymph nodes or upper mediastinal cancers are present</CO>, <A>Complete evaluation of primary and nodal disease requires imaging from the skull base to the thoracic inlet, extending to the carina</A>.

Section Name: PET/CT and Biopsy
====================
Entities:-
Positron Emission Tomography Computed Tomography : A medical imaging technique that combines PET and CT capabilities to provide detailed images of the body.
Examination Under Anesthesia : A procedure where a patient is examined while under anesthesia to allow for a more thorough examination.
Biopsy : A medical test involving the extraction of sample cells or tissues for examination to determine the presence or extent of a disease.
Tonsillectomy : A surgical procedure to remove the tonsils, often performed to treat recurrent tonsillitis or sleep apnea.
Fine Needle Aspiration : A type of biopsy procedure that uses a thin, hollow needle to extract cells from a lump or mass for examination.
Ultrasound : A medical imaging technique that uses high-frequency sound waves to visualize internal organs and structures.
Computed Tomography : A diagnostic imaging procedure that uses a combination of X-rays and computer technology to produce cross-sectional images of the body.

Relationships:-
1. Entity1: ""PET/CT"", Entity2: ""EUA"", Relationship: ""recommended before""
2. Entity1: ""Fine Needle Aspiration (FNA)"", Entity2: ""metastatic nodes"", Relationship: ""used for biopsy of""
3. Entity1: ""Image-guided needle biopsy"", Entity2: ""cystic neck nodes"", Relationship: ""recommended for initial diagnosis of""

Causalities:-
<CO> If imaging does not reveal an obvious primary cancer </CO>, <A> a PET/CT should be ordered before EUA, biopsies, and tonsillectomy </A>. <E> This helps identify potential primary sites </E> before any interventions take place. Additionally, <A> Fine Needle Aspiration (FNA) biopsy of metastatic nodes </A> <E> may provide pathologically informative results </E>. <CO> For initial diagnosis in cystic neck nodes </CO>, <A> image-guided needle biopsy (ultrasound or CT) </A> <E> may yield better results than FNA by palpation alone </E>.

Section Name: Postoperative Imaging Advice
====================
Entities:-
Panoramic Radiography : A type of dental x-ray that provides a wide view of the upper and lower jaws, teeth, temporomandibular joints, and sinuses.
Oral Cavity : The cavity of the mouth, including the lips, the lining inside the cheeks and lips, the front two-thirds of the tongue, the gums, the floor of the mouth under the tongue, the hard palate, and the small area of the gum behind the wisdom teeth.
Radiotherapy : The treatment of disease, especially cancer, using X-rays or similar forms of radiation.
Mandibulotomy : A surgical procedure involving the cutting of the mandible.
Mandibulectomy : A surgical procedure involving the removal of part or all of the mandible.
Oropharynx : The part of the throat at the back of the mouth behind the oral cavity.

Relationships:-
1. Entity1: ""panoramic dental x-ray"", Entity2: ""oral cavity cancers"", Relationship: ""recommended for""
2. Entity1: ""panoramic dental x-ray"", Entity2: ""postoperative radiotherapy"", Relationship: ""essential for pre-radiation evaluation""
3. Entity1: ""pre-radiation dental evaluation"", Entity2: ""dental procedures or extractions"", Relationship: ""determine necessity of""

Causalities:-
<A> A panoramic dental x-ray is recommended </A> <C> for oral cavity cancers requiring mandibulotomy and/or mandibulectomy </C>. <CO> When postoperative radiotherapy (RT) is anticipated for areas like the lip, oral cavity subsites, or oropharynx </CO>, <A> panoramic x-ray is essential for a comprehensive pre-radiation dental evaluation </A> <E> to assess the health of affected teeth and determine if pre-radiation dental procedures or extractions are necessary </E>.

Section Name: NCCN Guidelines Note
====================
Entities:-
Neoplasms : Neoplasms are abnormal growths of tissue, which can be cancerous or non-cancerous.
Malignant Neoplastic Disease : A disease characterized by uncontrolled, abnormal growth of cells that can invade or spread to other parts of the body.
Cancer : A group of diseases involving abnormal cell growth with the potential to invade or spread to other parts of the body.
Clinical Trials As Topic : Pre-planned studies of the safety, efficacy, or optimum dosage schedule of one or more diagnostic, therapeutic, or prophylactic drugs, devices, or techniques in humans selected according to predetermined criteria of eligibility and observed for predefined evidence of favorable and unfavorable effects.
Clinical Trial : A research study that prospectively assigns human participants or groups of humans to one or more health-related interventions to evaluate the effects on health outcomes.

Relationships:-
1. Entity1: ""NCCN"", Entity2: ""Clinical Trials"", Relationship: ""encourages participation in""
2. Entity1: ""NCCN"", Entity2: ""Cancer"", Relationship: ""recommends clinical trials for""

Causalities:-
<A> NCCN believes that the best management of any patient with cancer is through participation in clinical trials </A>, <A> which is especially encouraged </A>.
--------------------------------------------------
Page Number: 102

Section Name: Head and Neck Cancers - Principles of Surgery
====================
Entities:-
Surgical Procedures, Operative : Manual or operative procedures used in the treatment of disease, injuries, or deformities.
Lymphatic System : Part of the circulatory system and a vital part of the immune system, comprising a network of lymphatic vessels that carry a clear fluid called lymph.
Neoplasms : New abnormal growth of tissue in animals or plants; a tumor.
Neck Dissection : A surgical procedure for control of neck lymph node metastasis from squamous cell carcinoma of the head and neck.
Neoplasm Staging : Methods which attempt to express in replicable terms the extent of the neoplasm in the patient.
Metastasis : The spread of a cancer or other disease from one organ or part of the body to another not directly connected with it.
Surgical Procedure : A procedure involving an incision with instruments; performed to repair damage or arrest disease in a living body.
Lymphatic Structure : Anatomical structure that is part of the lymphatic system.
Tumor : An abnormal mass of tissue that results when cells divide more than they should or do not die when they should.
Staging : The process of determining the size and spread of cancer within the body.
Surgery : Medical specialty that uses operative manual and instrumental techniques on a patient to investigate or treat a pathological condition such as disease or injury.
Cancer Staging : The process of determining the extent to which a cancer has developed by growing and spreading.

Relationships:-
1. Entity1: ""surgical management"", Entity2: ""regional lymphatics"", Relationship: ""dictated by tumor staging""
2. Entity1: ""neck dissections"", Entity2: ""primary tumor"", Relationship: ""part of treatment""
3. Entity1: ""surgery"", Entity2: ""ipsilateral side of the neck"", Relationship: ""risk for metastases""

Causalities:-
<C> The extent of the tumor at initial tumor staging </C> <E> dictates the surgical management of regional lymphatics </E>. These guidelines apply to the performance of neck dissections as part of treatment of the primary tumor. <CO> Patients undergoing surgery for resection of the primary tumor </CO> <A> will undergo dissection of the ipsilateral side of the neck that is at greatest risk for metastases </A>.

Section Name: Neck Management
====================
Entities:-
Tongue : A muscular organ in the mouth that is involved in tasting, swallowing, and speech.
Palate : The roof of the mouth, separating the oral and nasal cavities.
Larynx : An organ in the top of the neck involved in breathing, producing sound, and protecting the trachea.
Hypopharynx : The bottom part of the pharynx, which is the cavity behind the nose and mouth.
Nasopharynx : The upper part of the pharynx, connecting with the nasal cavity above the soft palate.
Neck Dissection : A surgical procedure for control of neck lymph node metastasis from squamous cell carcinoma of the head and neck.
Metastasis : The spread of a cancer or other disease from one organ or part of the body to another not directly connected with it.
Squamous Cell Carcinoma : A type of cancer that begins in the squamous cells, which are thin, flat cells that look like fish scales.
Biopsy : The removal of cells or tissues for examination under a microscope.

Relationships:-
1. Entity1: ""Tumor sites"", Entity2: ""Bilateral lymphatic drainage"", Relationship: ""associated with""
2. Entity1: ""Elective neck dissection"", Entity2: ""Risk of occult metastasis"", Relationship: ""based on""
3. Entity1: ""SLN biopsy"", Entity2: ""Elective neck dissection"", Relationship: ""guides decision-making for""

Causalities:-
- **<C> Tumor sites that frequently have bilateral lymphatic drainage </C>** (e.g., base of tongue, palate, supraglottic larynx, hypopharynx, nasopharynx, deep pre-epiglottic space involvement) <E> often should have both sides of the neck dissected </E> with the extent of dissection determined as suggested below. For those patients with tumors at or approaching the midline, <CO> both sides of the neck are at risk for metastases </CO>, and <A> bilateral neck dissections should be performed </A>.

- <CO> Patients with advanced lesions involving the anterior tongue, floor of the mouth, or alveolus that approximate or cross the midline </CO> <A> should undergo contralateral selective/modified neck dissection </A> as necessary to achieve adequate tumor resection.

- **<C> Elective neck dissection </C>** <A> should be based on risk of occult metastasis in the appropriate nodal basin </A>. For oral cavity squamous cell carcinoma, <C> SLN biopsy or the primary tumor depth of invasion </C> is currently <E> the best predictor of occult metastatic disease </E> and <A> should be used to guide decision-making </A>. <CO> For tumors with a depth greater than 3 mm </CO>, <A> elective dissection should be strongly considered if RT is not already planned </A>. Recent randomized trial evidence supports the effectiveness of elective neck dissection in patients with oral cavity cancers greater than 3 mm in depth of invasion.

  - <CO> For a depth less than 2 mm </CO>, <A> elective dissection is only indicated in highly selective situations </A>. <CO> For a depth of 2–4 mm </CO>, <A> clinical judgment (as to reliability of follow-up, clinical suspicion, and other factors) must be utilized to determine appropriateness of elective dissection </A>. Elective dissections are generally selective, preserving all major structures, unless operative findings dictate otherwise.

Section Name: Types of Neck Dissection
====================
Entities:-
Neck Dissection : A surgical procedure for control of neck lymph node metastasis from squamous cell carcinoma of the head and neck.
Larynx : An organ in the top of the neck involved in breathing, producing sound, and protecting the trachea.

Relationships:-
1. Entity1: ""N0"", Entity2: ""Selective neck dissection"", Relationship: ""associated with""
2. Entity1: ""N3"", Entity2: ""Comprehensive neck dissection"", Relationship: ""associated with""
3. Entity1: ""Level VI neck dissection"", Entity2: ""Larynx"", Relationship: ""performed for""
4. Entity1: ""Level VI neck dissection"", Entity2: ""Hypopharynx"", Relationship: ""performed for""

Causalities:-
- **The type of neck dissection (comprehensive or selective)** is defined according to <CO> preoperative clinical staging </CO>, is determined at the discretion of the surgeon, and is based on the initial preoperative staging as follows:
  - **N0:** <A> Selective neck dissection </A>
    - Oral cavity at least levels I–III
    - Oropharynx at least levels II–IV
    - Hypopharynx at least levels II–IV and level VI when appropriate
    - Larynx at least levels II–IV and level VI when appropriate
  - **N1–N2a–c:** <A> Selective or comprehensive neck dissection </A> (Discussion)
  - **N3:** <A> Comprehensive neck dissection </A>

- <C> Level VI neck dissections are performed for certain primary sites (such as the larynx and hypopharynx) </C> <E> as required to resect the primary tumor and any clinically evident neck nodes </E>. <CO> Elective dissection depends on primary tumor extent and site </CO>. <CO> For advanced glottic and hypopharyngeal cancers treated with primary surgery </CO>, <A> a level VI dissection (including pretracheal lymph nodes, the Delphian lymph node, and unilateral or bilateral paratracheal lymph nodes) and hemithyroidectomy to total thyroidectomy are appropriate </A>.

- <CO> For primary subglottic tumors or glottic cancers with significant subglottic extension </CO>, <A> a level VI dissection with unilateral or total thyroidectomy is considered appropriate </A> based on the extent of the primary tumor. <CO> For example, a T4a glottic tumor with extension through the cricothyroid membrane and subglottic extension </CO> <A> should include thyroidectomy and pretracheal and bilateral paratracheal lymph node dissection </A>. <A> Parathyroid glands should be preserved in situ or auto transplanted as indicated </A>.
--------------------------------------------------
Page Number: 53

Section Name: Introduction
====================
Entities:-
National Comprehensive Cancer Network : The National Comprehensive Cancer Network (NCCN) is an alliance of 30 cancer centers in the United States, dedicated to improving the quality, effectiveness, and efficiency of cancer care so that patients can live better lives.
Laryngeal Neoplasms : Tumors or cancer of the larynx, which may affect the supraglottic, glottic, or subglottic regions.
Malignant Neoplasm Of Supraglottis : A malignant tumor located in the supraglottic region of the larynx.

Relationships:-
1. Entity1: ""National Comprehensive Cancer Network"", Entity2: ""Malignant neoplasm of supraglottis"", Relationship: ""provides guidelines for""
2. Entity1: ""clinical staging"", Entity2: ""treatment strategies"", Relationship: ""part of flowchart for""

Causalities:-
The provided image is a flowchart outlining the <C> NCCN (National Comprehensive Cancer Network) guidelines </C> for the treatment of <CO> cancers of the supraglottic larynx </CO>. This flowchart <A> utilizes a highly structured approach to convey clinical staging and treatment strategies </A>, indicating the various pathways based on <CO> patient conditions and disease features </CO>.

Section Name: NCCN Guidelines Version 4.2024
====================
Entities:-
Laryngeal Neoplasms : Tumors or cancer of the larynx, which may affect the supraglottic, glottic, or subglottic regions.
Malignant Neoplasm Of Supraglottis : A malignant tumor located in the supraglottic region of the larynx.
Supraglottic Cancer : Cancer that occurs in the supraglottic region of the larynx, above the vocal cords.
Clinical Trials As Topic : Pre-planned studies of the safety, efficacy, or optimum dosage schedule of one or more diagnostic, therapeutic, or prophylactic drugs, devices, or techniques in humans selected according to predetermined criteria of eligibility and observed for predefined evidence of favorable and unfavorable effects.
Clinical Trial : A type of research that studies new tests and treatments and evaluates their effects on human health outcomes.

Relationships:-
1. Entity1: ""Cancer of the Supraglottic Larynx"", Entity2: ""Clinical Trials"", Relationship: ""recommended management strategy""

Causalities:-
- All recommendations are category 2A unless otherwise indicated.
- <A> Participation in clinical trials </A> is especially encouraged.

Section Name: Key Components of the Flowchart
====================
Entities:-
Neoplasm Staging : Methods used for staging neoplasms, including clinical and pathological staging.
Radiotherapy : The use of ionizing radiation to treat cancer.
Surgical Procedures, Operative : Operations carried out for the correction of deformities and defects, repair of injuries, and diagnosis and cure of certain diseases.
Adjuvant Chemotherapy : Chemotherapy given in addition to the primary treatment to maximize its effectiveness.
Neoplasm Recurrence, Local : The return of a tumor at the original site after treatment.
Clinical Trials As Topic : Pre-planned studies of the safety, efficacy, or optimum dosage schedule of one or more diagnostic, therapeutic, or prophylactic drugs, devices, or techniques in humans selected according to predetermined criteria of eligibility and observed for predefined evidence of favorable and unfavorable effects.

Relationships:-
1. Entity1: ""Clinical Staging"", Entity2: ""Treatment of Primary and Neck"", Relationship: ""determines""
2. Entity1: ""Evaluation and Follow-Up"", Entity2: ""Adverse and No Adverse Features"", Relationship: ""leads to decision based on""
3. Entity1: ""Adjuvant Treatment"", Entity2: ""Adverse pathologic features"", Relationship: ""considered if present""
4. Entity1: ""Clinical Trials"", Entity2: ""Treatment Pathway"", Relationship: ""part of""

Causalities:-
### Key Components of the Flowchart

1. **Clinical Staging**: The flowchart starts with <A>clinical staging</A>, indicating that <CO>patients must first be evaluated to determine the extent of cancer</CO>. This is essential for <E>deciding on appropriate treatment options</E>.

2. **Treatment of Primary and Neck**: The flowchart details multiple treatment strategies, including:
   - <A>**Concurrent systemic therapy/RT**</A>: This suggests a combination approach for <CO>patients eligible for such treatment</CO>.
   - <A>**Definitive Radiation Therapy (RT)**</A>: Recommended for <CO>low-volume diseases or patients who cannot tolerate systemic therapy</CO>.
   - <A>**Surgical Options**</A>: It highlights options such as endoscopic or open partial laryngectomy and neck dissection, which are <CO>contingent on clinical evaluations</CO>.

3. **Evaluation and Follow-Up**: After initial treatment approaches, the chart directs clinicians to perform a <A>""Post Systemic Therapy/RT or RT Neck Evaluation""</A>. This step <E>assesses whether there are adverse pathologic features</E>, guiding subsequent treatment decisions.

4. **Adverse and No Adverse Features**: The decision pathway diverges based on findings:
   - <CO>Patients with **adverse pathologic features**</CO> may have <A>additional diagnostic imaging (CT or MRI)</A> and may require <A>further systemic treatment</A>.
   - <CO>Patients with **no adverse features**</CO> may be directed towards <A>considerations for radiation therapy</A>.

5. **Adjuvant Treatment and Recurrence**: The chart also addresses <E>management of any recurrent or persistent disease</E>, emphasizing the importance of <A>regular follow-up assessments</A>. Various options for <A>adjuvant treatment</A> are mentioned, focusing on tailored approaches towards ongoing management of the disease.

6. **Clinical Trials**: The flowchart encourages <A>participation in clinical trials</A>, indicating a commitment to <E>exploring new treatments and improving patient outcomes</E>.

Section Name: Principles
====================
Entities:-
Imaging : The process of producing images of the body or parts of the body to diagnose or examine disease.
Surgical Procedure : A medical procedure involving an incision with instruments; performed to repair damage or arrest disease in a living body.
Radiation Therapy : The use of ionizing radiation to treat cancer and other diseases.
Systemic Therapy : Treatment using substances that travel through the bloodstream, reaching and affecting cells all over the body.

Relationships:-
1. Entity1: ""Imaging"", Entity2: ""Surgery"", Relationship: ""Both are foundational principles in medical practice.""
2. Entity1: ""Radiation therapy"", Entity2: ""Systemic Therapy"", Relationship: ""Both are treatment modalities for cancer.""

Causalities:-
#### Principles
- **Principles of Imaging (IMG-A)**
- **Principles of Surgery (SURG-A)**
- **Principles of Radiation Therapy (SUPRA-A)**
- **Principles of Systemic Therapy for Non-Nasopharyngeal Cancers (SYST-A)**

Section Name: Adverse Pathologic Features
====================
Entities:-
Extranodal Extension : The spread of cancer cells beyond the lymph node capsule into the surrounding tissues.
Positive Surgical Margins : The presence of cancer cells at the edge of the tissue removed during surgery.
Perineural Invasion : Cancer cells found surrounding or tracking along a nerve within the perineural space.
Vascular Invasion : The presence of cancer cells within blood vessels.
Lymphatic Invasion : The presence of cancer cells within lymphatic vessels.

Relationships:-
1. Entity1: ""Extranodal Extension"", Entity2: ""Positive Surgical Margins"", Relationship: ""Both indicate cancer spread beyond original site.""
2. Entity1: ""Perineural Invasion"", Entity2: ""Vascular Invasion"", Relationship: ""Both are pathways for cancer spread.""
3. Entity1: ""pT3 or pT4 primary"", Entity2: ""pN2 or pN3 nodal disease"", Relationship: ""Both indicate advanced cancer stages.""

Causalities:-
<C> Extranodal extension </C>
<C> Positive margins </C>
<C> Close margins </C>
<C> pT3 or pT4 primary </C>
<C> pN2 or pN3 nodal disease </C>
<C> Perineural invasion </C>
<C> Vascular invasion </C>
<C> Lymphatic invasion </C>

Section Name: Clinical Staging and Treatment of Primary and Neck
====================
Entities:-
Adjuvant Chemotherapy : Chemotherapy given in addition to the primary treatment to maximize its effectiveness.
Follow-Up Procedure : A procedure performed to monitor the progress of a patient after treatment.
Recurrent Disease : A disease that returns after a period of remission.
Laryngectomy : Surgical removal of the larynx, often used to treat cancer.
Radiation Therapy : The use of ionizing radiation to treat cancer and other diseases.
Clinical Trial : A type of research that studies new tests and treatments and evaluates their effects on human health outcomes.
Neck Dissection : Surgical procedure to remove lymph nodes and surrounding tissue to treat cancer.
Chemotherapy : Treatment of disease by the use of chemical substances, especially cancer by cytotoxic drugs.

Relationships:-
1. Entity1: ""Adjuvant Treatment"", Entity2: ""Treatment of Primary and Neck"", Relationship: ""part of""
2. Entity1: ""Follow-up"", Entity2: ""Treatment of Primary and Neck"", Relationship: ""part of""
3. Entity1: ""Recurrent or Persistent Disease"", Entity2: ""Treatment of Primary and Neck"", Relationship: ""part of""
4. Entity1: ""Larynx-Preserving Surgery"", Entity2: ""Treatment Options"", Relationship: ""is a treatment option for""
5. Entity1: ""Concurrent Systemic Therapy/RT"", Entity2: ""Treatment Options"", Relationship: ""is a treatment option for""
6. Entity1: ""Clinical Trials or Definitive RT"", Entity2: ""Treatment Options"", Relationship: ""is a treatment option for""
7. Entity1: ""Endoscopic or Open Partial Laryngectomy and Neck Dissection(s)"", Entity2: ""Treatment Options"", Relationship: ""is a treatment option for""
8. Entity1: ""Induction Chemotherapy"", Entity2: ""Treatment Options"", Relationship: ""is a treatment option for""

Causalities:-
<A> Amenable to Larynx-Preserving (Conservation) Surgery </A>: <CO> T1–2, N+ and selected T3, N1 </CO>
<A> Concurrent Systemic Therapy/RT </A>: <CO> i, k, l </CO>
<A> Clinical Trials or Definitive RT </A>: <CO> i </CO>
<A> Endoscopic or Open Partial Laryngectomy and Neck Dissection(s) </A>: <CO> h </CO>
<A> Induction Chemotherapy </A>: <CO> k, m </CO>

Section Name: Pathologic Features and Response Assessment
====================
Entities:-
Radiation Therapy : The use of ionizing radiation to treat cancer and other diseases.
Extranodal Extension : The spread of cancer cells beyond the lymph node capsule into the surrounding tissues.
Positive Surgical Margin : Cancer cells are found at the edge of the material removed during surgery, indicating that some cancer may have been left behind.
Systemic Therapy : Treatment using substances that travel through the bloodstream, reaching and affecting cells all over the body.

Relationships:-
1. Entity1: ""Extranodal extension"", Entity2: ""Adverse Pathologic Features"", Relationship: ""is a type of""
2. Entity1: ""Positive margin"", Entity2: ""Adverse Pathologic Features"", Relationship: ""is a type of""
3. Entity1: ""Systemic Therapy"", Entity2: ""Adverse Pathologic Features"", Relationship: ""considered in response to""
4. Entity1: ""Radiation Therapy"", Entity2: ""Adverse Pathologic Features"", Relationship: ""considered in response to""

Causalities:-
#### Pathologic Features
- **No Adverse Pathologic Features**: j
  - <A> Consider RT </A>: i
- **Adverse Pathologic Features**: j
  - <CO> Extranodal extension and/or positive margin </CO>: n
  - Other risk features
  - <A> Systemic therapy/RT </A>: i, k (category 1)
  - <A> Consider systemic therapy/RT </A>: i, k

#### Response Assessment
- **Response Assessment** (SUPRA-7)

Section Name: Imaging and Recurrent or Persistent Disease
====================
Entities:-
Tomography, X-Ray Computed : A method of body imaging in which a thin X-ray beam rotates around the patient.
Magnetic Resonance Imaging : Medical imaging technique used in radiology to form pictures of the anatomy and the physiological processes of the body.
Computed Tomography : Medical imaging technique used in radiology to obtain detailed internal images of the body.

Relationships:-
1. Entity1: ""CT"", Entity2: ""primary and neck"", Relationship: ""used for imaging""
2. Entity1: ""MRI"", Entity2: ""primary and neck"", Relationship: ""used for imaging""
3. Entity1: ""Post Systemic Therapy/RT"", Entity2: ""Recurrent or Persistent Disease"", Relationship: ""evaluation after treatment""
4. Entity1: ""RT Neck Evaluation"", Entity2: ""Recurrent or Persistent Disease"", Relationship: ""evaluation after treatment""

Causalities:-
<A> CT (with contrast) or MRI (with and without contrast) of primary and neck </A>

<CO> Recurrent or Persistent Disease </CO>

<CO> Post Systemic Therapy/RT or RT Neck Evaluation </CO>

Section Name: Conclusion
====================
Entities:-
Oncologists : Medical doctors who specialize in the diagnosis and treatment of cancer.
Supraglottic Larynx Cancer : A type of cancer that occurs in the supraglottic region of the larynx, which is the area above the vocal cords.
Clinical Staging : The process of determining the extent of cancer in the body, usually based on physical examination, imaging tests, and biopsies.
Treatment Strategies : Plans or methods developed to treat diseases, including cancer, which may involve surgery, chemotherapy, radiation therapy, or other modalities.
Follow-Up Evaluations : Medical assessments conducted after initial treatment to monitor a patient's progress and detect any recurrence of disease.
Clinical Efficacy : The ability of a treatment to produce the desired therapeutic effect in clinical settings.
Research : Systematic investigation and study conducted to establish facts and reach new conclusions.
Treatment Paradigms : Standard models or patterns of treatment used in medical practice, often based on clinical guidelines and research findings.

Relationships:-
1. Entity1: ""Oncologists"", Entity2: ""Supraglottic Larynx Cancer"", Relationship: ""use flowchart for decision-making""
2. Entity1: ""Clinical Staging"", Entity2: ""Treatment Strategies"", Relationship: ""part of management process""
3. Entity1: ""Treatment Strategies"", Entity2: ""Follow-Up Evaluations"", Relationship: ""part of management process""

Causalities:-
<A> The flowchart serves as a comprehensive guide for oncologists and healthcare providers </A>, <A> facilitating informed decision-making in the treatment of supraglottic larynx cancer </A>. <A> By visualizing the complex interactions between clinical staging, treatment strategies, and follow-up evaluations </A>, <E> it streamlines the management process </E>, <E> ensuring that patients receive appropriate care tailored to their specific needs </E>. <E> The detailed pathways not only enhance clinical efficacy </E> but also <E> underscore the importance of ongoing research and adaptation of treatment paradigms in oncology </E>.


Among these two options which one is the most likely true:

(A) `Size_of_Lymph_Nodes_6` increases risk `Imaging_Results_13`
(B) `Imaging_Results_13` `increases risk `Size_of_Lymph_Nodes_6`

The answer is: ...

1. State the evidences in detail of the validity of option (A) or (B) by cross referencing
NCCN Clinical Practitioner’s Guidelines for Head and Neck Cancer.
2. If the evidences are obtained from `INFORMATION FROM KNOWLEDGE BASE`,
mention their corresponding Page Numbers, Section Name, entities, relationships and causalities.

DESIRED OUTPUT FORMAT:
<thinking>
...
</thinking>
<answer>
{
   ""thinking"": [""..."", ...],
   ""evidences"": [""..."", ...],
   ""answer"": ...
}
</answer>

Before providing the answer in <answer> tags, think step by step in detail in <thinking> tags and analyze every part.
Output inside <answer> tag in JSON format. Only output valid JSON.
DO NOT HALLUCINATE. DO NOT MAKE UP FACTUAL INFORMATION.
","1. The edge (A) suggests that the size of lymph nodes can influence imaging results. Enlarged lymph nodes are often detected as abnormalities in imaging examinations, indicating a positive causal direction. This is supported by the explanation that the size of lymph nodes directly impacts imaging findings, making the causal relationship proximal.
2. The edge (B) suggests that imaging results cause changes in the size of lymph nodes. However, imaging results are observations of the current state of lymph nodes, not a cause of their size. The size of lymph nodes is determined by underlying physiological or pathological processes, not by the imaging results themselves.
3. The NCCN Clinical Practitioner's Guidelines for Head and Neck Cancer emphasize the role of imaging in diagnosing and staging cancer, but do not suggest that imaging results can cause changes in lymph node size. Instead, imaging is used to observe and assess the current state of lymph nodes and other structures.
4. From the INFORMATION FROM KNOWLEDGE BASE, the guidelines on Page 93, Section Name: Principles of Imaging, indicate that imaging is used for diagnostic purposes and to assess the extent of disease, not as a causal factor for changes in lymph node size.
5. The causalities outlined in the guidelines focus on imaging as a tool for evaluation and diagnosis, not as a factor that influences the size of lymph nodes.
","1. Page 93, Section Name: Principles of Imaging, indicates that imaging is used for diagnostic purposes and to assess the extent of disease.
2. The guidelines emphasize the role of imaging in diagnosing and staging cancer, but do not suggest that imaging results can cause changes in lymph node size.
",A,"{'A': 100.0, 'B': 0.0}",yes,A,"1. The AI assistant's reasoning for option (A) is based on the explanation that enlarged lymph nodes can be detected as abnormalities in imaging examinations, indicating a positive causal direction. This aligns with the understanding that the size of lymph nodes can influence imaging results, making the causal relationship proximal.
2. The reasoning for option (B) is that imaging results are observations and not a cause of changes in lymph node size. This is consistent with the understanding that imaging is used to assess the current state of lymph nodes, not to influence their size.
3. The AI assistant references the NCCN Clinical Practitioner's Guidelines for Head and Neck Cancer, which emphasize the role of imaging in diagnosing and staging cancer. This supports the idea that imaging is used for evaluation and diagnosis, not as a causal factor for changes in lymph node size.
4. The evidence from the INFORMATION FROM KNOWLEDGE BASE, specifically Page 93, Section Name: Principles of Imaging, supports the reasoning that imaging is used for diagnostic purposes and to assess the extent of disease, not as a causal factor for changes in lymph node size.
5. Overall, the AI assistant's reasoning is consistent with the evidence provided, supporting option (A) as the correct answer.
"
10,gpt-4o,"Histological_Grade_of_Tumor_4,N_State_1","""{'NODE1': {'id': 'Histological_Grade_of_Tumor_4', 'label': 'Histological Grade of Tumor 4', 'description': 'This node represents the histological grade of a tumor, specifically grade 4, which is a classification based on the microscopic appearance of tumor cells. The histological grade is an important factor in determining the aggressiveness of the tumor and its potential response to treatment. Grade 4 typically indicates poorly differentiated or undifferentiated tumor cells, suggesting a more aggressive and potentially less favorable prognosis.', 'type': 'Patient Situation', 'observability': 'Unobserved', 'states': [{'state_name': 'present', 'state_description': \""The state 'present' indicates that the tumor has been assessed and classified as histological grade 4, meaning the tumor cells are poorly differentiated or undifferentiated, which is associated with a more aggressive behavior.\""}, {'state_name': 'absent', 'state_description': \""The state 'absent' indicates that the tumor is not classified as histological grade 4, suggesting that the tumor cells are not poorly differentiated or undifferentiated, which may be associated with a less aggressive behavior.\""}]}, 'NODE2': {'id': 'N_State_1', 'label': 'Nearby Lymph Nodes Cancer State', 'description': 'This node represents the clinical situation regarding the presence or absence of cancer in nearby lymph nodes. It is a critical factor in cancer staging and prognosis, as the involvement of lymph nodes can indicate the spread of cancer and affect treatment decisions.', 'type': 'Decision Node', 'observability': 'Needs to be Predicted', 'states': [{'state_name': 'present', 'state_description': 'Cancer is present in the nearby lymph nodes, indicating potential metastasis and a more advanced stage of cancer.'}, {'state_name': 'absent', 'state_description': 'Cancer is absent in the nearby lymph nodes, suggesting that the cancer has not spread to these nodes and may be in an earlier stage.'}]}, 'EDGE1': {'edges_ids': ['Histological_Grade_of_Tumor_4', 'N_State_1'], 'edge': '(Histological_Grade_of_Tumor_4) causes (N_State_1)', 'explanation': ['The edge represents the causal relationship between the histological grade of a tumor (specifically grade 4) and the state of nearby lymph nodes.', 'Histological grade 4 indicates a poorly differentiated or undifferentiated tumor, which is more aggressive and likely to spread.', 'The presence of cancer in nearby lymph nodes (N_State_1) is a sign of metastasis and a more advanced stage of cancer.', 'A higher histological grade (such as grade 4) is associated with a higher likelihood of lymph node involvement, suggesting a causal relationship.', 'The causal direction is positive because a higher grade increases the likelihood of lymph node involvement.', 'The histological grade is not a necessary condition for lymph node involvement, as other factors can also cause this.', 'The histological grade might be considered a sufficient condition in some cases, as a very aggressive tumor (grade 4) could almost guarantee lymph node involvement.', 'The causal distance is proximal, as the histological grade directly affects the tumors behavior, which can directly lead to lymph node involvement.'], 'causal_direction': 'positive', 'causal_factor': {'necessary': False, 'sufficient': True}, 'causal_distance': 'Proximal'}, 'EDGE2': {'edges_ids': ['N_State_1', 'Histological_Grade_of_Tumor_4'], 'edge': '(N_State_1) causes (Histological_Grade_of_Tumor_4)', 'explanation': ['The edge suggests that the state of nearby lymph nodes (N_State_1) causes the histological grade of a tumor to be grade 4 (Histological_Grade_of_Tumor_4).', 'However, the histological grade of a tumor is determined by the microscopic appearance of the tumor cells and is not directly influenced by the state of lymph nodes.', 'The state of lymph nodes is related to cancer staging and prognosis, but it does not determine the histological grade of the tumor.', 'Therefore, the edge is not valid as there is no direct causal relationship between the state of lymph nodes and the histological grade of the tumor.'], 'causal_direction': 'Unknown', 'causal_factor': {'necessary': False, 'sufficient': False}, 'causal_distance': 'Unknown'}, 'ENTITIES_MATCHING_PAGES_INFO': {'130': {'matching_entities': [{'NEOPLASM GRADING': 1.0}, {'LYMPH NODE STRUCTURE': 0.99134904}, {'LYMPH NODE': 0.98570025}, {'LYMPH NODES': 0.97445965}, {'HISTOLOGIC GRADE': 0.9653935}, {'METASTASIS': 0.9401313}, {'TUMOR STAGING': 0.935904}, {'TNM STAGING': 0.92977923}, {'NEOPLASM METASTASIS': 0.9250777}, {'TNM STAGING SYSTEM': 0.92350286}], 'count': 10}, '51': {'matching_entities': [{'MALIGNANT NEOPLASM': 0.9774111}, {'CANCER STAGING': 0.9442892}, {'CANCER': 0.9417275}, {'LARYNGEAL NEOPLASMS': 0.9236878}, {'TNM STAGING SYSTEM': 0.92350286}, {'NEOPLASM INVASIVENESS': 0.92347366}, {'POSITIVE SURGICAL MARGIN': 0.9228712}], 'count': 7}, '55': {'matching_entities': [{'MALIGNANT NEOPLASTIC DISEASE': 0.97725874}, {'CANCER': 0.9417275}, {'METASTASIS': 0.9401313}, {'METASTATIC NEOPLASM': 0.9314138}, {'NEOPLASM METASTASIS': 0.9250777}, {'LARYNGEAL NEOPLASMS': 0.9236878}, {'POSITIVE SURGICAL MARGIN': 0.9228712}], 'count': 7}, '102': {'matching_entities': [{'LYMPHATIC SYSTEM': 0.95855314}, {'TUMOR': 0.9533101}, {'LYMPHATIC STRUCTURE': 0.9469132}, {'CANCER STAGING': 0.9442892}, {'METASTASIS': 0.9401313}, {'STAGING': 0.9272357}], 'count': 6}, '154': {'matching_entities': [{'LYMPH NODE STRUCTURE': 0.99134904}, {'LYMPH NODE': 0.98570025}, {'LYMPH NODES': 0.97445965}, {'NEOPLASM': 0.95369107}, {'TUMOR': 0.9533101}], 'count': 5}}, 'GUIDELINE_PAGES_INFO': '--------------------------------------------------\\nPage Number: 130\\n\\nSection Name: Pathological N (pN)\\n====================\\nEntities:-\\nLymph Nodes : Small, bean-shaped structures that are part of the body\\'s lymphatic system. They filter lymph fluid and store white blood cells that help fight infection.\\nNeoplasm Metastasis : The transfer of a neoplasm from one organ or part of the body to another remote from the primary site.\\nTnm Staging : A system used to describe the size and spread of cancer in a standardized way. T refers to the size of the tumor, N to the involvement of lymph nodes, and M to metastasis.\\nLymph Node Structure : A structure that is part of the lymphatic system, involved in the immune response.\\nMetastasis : The spread of a cancer or other disease from one organ or part to another not directly connected with it.\\nTnm Staging System : A cancer staging notation system that describes the extent of cancer in a patient\\'s body.\\nLymph Node : An organ of the lymphatic system and the adaptive immune system.\\n\\nRelationships:-\\n1. Entity1: \""Lymph Nodes\"", Entity2: \""Neoplasm Metastasis\"", Relationship: \""involved in\""\\n2. Entity1: \""TNM Staging\"", Entity2: \""Lymph Nodes\"", Relationship: \""includes\""\\n3. Entity1: \""TNM Staging\"", Entity2: \""Neoplasm Metastasis\"", Relationship: \""describes\""\\n\\nCausalities:-\\n<CO> NX: Regional lymph nodes cannot be assessed </CO>\\n<CO> N0: No regional lymph node metastasis </CO>\\n<CO> N1: Metastasis in a single ipsilateral lymph node, 3 cm or smaller in greatest dimension ENE(\u2013) </CO>\\n<CO> N2: Metastasis in a single ipsilateral lymph node, 3 cm or smaller in greatest dimension and ENE(+); or larger than 3 cm but not larger than 6 cm in greatest dimension and ENE(\u2212); or metastases in multiple ipsilateral lymph nodes, none larger than 6 cm in greatest dimension and ENE(\u2212); or in bilateral or contralateral lymph node(s), none larger than 6 cm in greatest dimension and ENE(\u2212) </CO>\\n<CO> N2a: Metastasis in a single ipsilateral node, 3 cm or smaller in greatest dimension and ENE(+); or metastasis in a single ipsilateral node, larger than 3 cm but not larger than 6 cm in greatest dimension and ENE(\u2212) </CO>\\n<CO> N2b: Metastases in multiple ipsilateral nodes, none larger than 6 cm in greatest dimension and ENE(\u2212) </CO>\\n<CO> N2c: Metastases in bilateral or contralateral lymph node(s), none larger than 6 cm in greatest dimension and ENE(\u2212) </CO>\\n<CO> N3: Metastasis in a lymph node, larger than 6 cm in greatest dimension and ENE(\u2212); or metastasis in a single ipsilateral node, larger than 3 cm in greatest dimension and ENE(+); or multiple ipsilateral, contralateral, or bilateral lymph nodes and any with ENE(+); or a single contralateral node of any size and ENE(+) </CO>\\n<CO> N3a: Metastasis in a lymph node, larger than 6 cm in greatest dimension and ENE(\u2212) </CO>\\n<CO> N3b: Metastasis in a single ipsilateral node, larger than 3 cm in greatest dimension and ENE(+); or multiple ipsilateral, contralateral, or bilateral lymph nodes any with ENE(+); or a single contralateral node of any size and ENE(+) </CO>\\n<CO> Note: A designation of \u201cU\u201d or \u201cL\u201d may be used for any N category to indicate metastasis above the lower border of the cricoid (U) or below the lower border of the cricoid (L). Similarly, clinical and pathological ENE should be recorded as ENE(\u2212) or ENE(+). </CO>\\n\\nSection Name: Distant Metastasis (M)\\n====================\\nEntities:-\\nNeoplasm Metastasis : The transfer of a neoplasm from one organ or part of the body to another remote from the primary site.\\nMetastasis : The spread of a cancer or other disease from one organ or part to another not directly connected with it.\\n\\nRelationships:-\\n1. Entity1: \""M0\"", Entity2: \""Distant Metastasis\"", Relationship: \""is a category of\""\\n2. Entity1: \""M1\"", Entity2: \""Distant Metastasis\"", Relationship: \""is a category of\""\\n\\nCausalities:-\\n### Distant Metastasis (M)\\n\\n- **M0**: No distant metastasis\\n- **M1**: Distant metastasis\\n\\nSection Name: Histologic Grade (G)\\n====================\\nEntities:-\\nNeoplasm Grading : A system of classifying cancer cells in terms of how abnormal they look under a microscope and how quickly the tumor is likely to grow and spread.\\nHistologic Grade : A measure of how much tumor cells differ from healthy cells, used to assess the aggressiveness of cancer.\\n\\nRelationships:-\\n1. Entity1: \""GX\"", Entity2: \""Grade cannot be assessed\"", Relationship: \""is described as\""\\n2. Entity1: \""G1\"", Entity2: \""Well differentiated\"", Relationship: \""is described as\""\\n3. Entity1: \""G2\"", Entity2: \""Moderately differentiated\"", Relationship: \""is described as\""\\n4. Entity1: \""G3\"", Entity2: \""Poorly differentiated\"", Relationship: \""is described as\""\\n\\nCausalities:-\\n<CO>GX</CO>: <E>Grade cannot be assessed</E>\\n<CO>G1</CO>: <E>Well differentiated</E>\\n<CO>G2</CO>: <E>Moderately differentiated</E>\\n<CO>G3</CO>: <E>Poorly differentiated</E>\\n\\nSection Name: Prognostic Stage Groups\\n====================\\nEntities:-\\nNeoplasm Staging : Methods and systems of classifying neoplasms according to extent of disease.\\nTumor Staging : A system for describing the size and spread of cancer within the body.\\nTnm Staging System : A cancer staging notation system that describes the extent of cancer in a patient\\'s body.\\n\\nRelationships:-\\n1. Entity1: \""Stage 0\"", Entity2: \""Tis N0 M0\"", Relationship: \""defined by\""\\n2. Entity1: \""Stage I\"", Entity2: \""T1 N0 M0\"", Relationship: \""defined by\""\\n3. Entity1: \""Stage II\"", Entity2: \""T2 N0 M0\"", Relationship: \""defined by\""\\n4. Entity1: \""Stage III\"", Entity2: \""T3 N0 M0, T1 N1 M0, T2 N1 M0, T3 N1 M0\"", Relationship: \""defined by\""\\n5. Entity1: \""Stage IVA\"", Entity2: \""T1 N2 M0, T2 N2 M0, T3 N2 M0, T4a N0,N1,N2 M0\"", Relationship: \""defined by\""\\n6. Entity1: \""Stage IVB\"", Entity2: \""Any T N3 M0, T4b Any N M0\"", Relationship: \""defined by\""\\n7. Entity1: \""Stage IVC\"", Entity2: \""Any T Any N M1\"", Relationship: \""defined by\""\\n--------------------------------------------------\\nPage Number: 51\\n\\nSection Name: Introduction\\n====================\\nEntities:-\\nLaryngeal Neoplasms : Tumors or cancer of the larynx, which may affect the supraglottic, glottic, or subglottic regions.\\nMalignant Neoplasm Of Supraglottis : A malignant tumor located in the supraglottic region of the larynx.\\nSupraglottic Laryngeal Cancer : A type of cancer that occurs in the supraglottic region of the larynx, which is above the vocal cords.\\n\\nRelationships:-\\n1. Entity1: \""National Comprehensive Cancer Network (NCCN)\"", Entity2: \""cancer of the supraglottic larynx\"", Relationship: \""provides guidelines for\""\\n2. Entity1: \""healthcare professionals\"", Entity2: \""cancer of the supraglottic larynx\"", Relationship: \""manage\""\\n\\nCausalities:-\\nThe provided image is a detailed flowchart from the National Comprehensive Cancer Network (NCCN) guidelines regarding the <C> clinical staging and treatment protocols for cancer of the supraglottic larynx </C>. This flowchart is structured to <A> guide healthcare professionals through the stages of treatment </A> based on <CO> clinical findings </CO>, emphasizing the <E> complexity and systematic approach required in managing this type of cancer </E>.\\n\\nSection Name: Clinical Staging\\n====================\\nEntities:-\\nLaryngectomy : A surgical procedure involving the removal of the larynx, usually to treat cancer of the larynx.\\nTotal Laryngectomy : A surgical procedure to remove the entire larynx, often used in the treatment of advanced laryngeal cancer.\\nNeoplasm Staging : Methods used for staging neoplasms, including clinical and pathological staging.\\nCancer Staging : The process of determining the extent of cancer in the body, often using the TNM system.\\nTnm Staging System : A cancer staging system that describes the extent of cancer using Tumor size (T), Node involvement (N), and Metastasis (M).\\n\\nRelationships:-\\n1. Entity1: \""Clinical staging criteria\"", Entity2: \""Total laryngectomy\"", Relationship: \""determines necessity of\""\\n2. Entity1: \""T3, N0\"", Entity2: \""Clinical staging criteria\"", Relationship: \""is a categorization of\""\\n\\nCausalities:-\\nThe flowchart begins with the <C> clinical staging criteria </C>, specifically focusing on <CO> cases that require total laryngectomy, denoted as requiring (amenable to) total laryngectomy (T3, N0) </CO>. This <A> categorization </A> is crucial as it <E> forms the basis for determining the appropriate treatment strategy </E>.\\n\\nSection Name: Treatment of Primary and Neck\\n====================\\nEntities:-\\nNeoplasm Staging : Methods used for staging neoplasms, including clinical and pathological staging.\\nSystemic Therapy : Treatment using substances that travel through the bloodstream, reaching and affecting cells all over the body.\\nRadiotherapy : The use of high-energy radiation from x-rays, gamma rays, neutrons, protons, and other sources to kill cancer cells and shrink tumors.\\nLaryngectomy : A surgical procedure involving the removal of the larynx, usually to treat cancer of the larynx.\\nThyroidectomy : A surgical procedure to remove all or part of the thyroid gland.\\nNeck Dissection : Surgical procedure to remove lymph nodes and surrounding tissue to treat or prevent cancer spread.\\nLymphatic Metastasis : Transfer of a neoplasm from one organ or part of the body to another remote from the primary site.\\n\\nRelationships:-\\n1. Entity1: \""Systemic Therapy\"", Entity2: \""Radiation Therapy\"", Relationship: \""combined with\""\\n2. Entity1: \""Laryngectomy\"", Entity2: \""Lymph Node Involvement\"", Relationship: \""considered based on\""\\n3. Entity1: \""Thyroidectomy\"", Entity2: \""Lymph Node Involvement\"", Relationship: \""considered based on\""\\n4. Entity1: \""Neck Dissection\"", Entity2: \""Lymph Node Involvement\"", Relationship: \""considered based on\""\\n\\nCausalities:-\\n<CO> Once clinical staging is established </CO>, the chart outlines various treatment options. <A> The initial step may involve either concurrent systemic therapy combined with radiation therapy (RT) or opting for RT alone </A>, <CO> especially if the patient is not a medical candidate for both therapies </CO>. <A> Laryngectomy, thyroidectomy, and neck dissection are considered </A> <CO> based on the extent of lymph node involvement </CO>.\\n\\nSection Name: Surgical Options\\n====================\\nEntities:-\\nLaryngectomy : A surgical procedure involving the removal of the larynx, usually to treat cancer of the larynx.\\nThyroidectomy : A surgical procedure to remove all or part of the thyroid gland.\\nLymph Node Excision : Surgical removal of one or more lymph nodes.\\nLymphadenectomy : Surgical removal of one or more groups of lymph nodes.\\nSurgical Procedures, Operative : Operations carried out for the correction of deformities and defects, repair of injuries, and diagnosis and cure of certain diseases.\\nSurgical Procedure : A medical procedure involving an incision with instruments; performed to repair damage or arrest disease in a living body.\\nSurgery : Medical specialty that uses operative manual and instrumental techniques on a patient to investigate or treat a pathological condition such as a disease or injury.\\n\\nRelationships:-\\n1. Entity1: \""Laryngectomy\"", Entity2: \""Thyroidectomy\"", Relationship: \""combined with\""\\n2. Entity1: \""Lymph Node Dissection\"", Entity2: \""Surgical Intervention\"", Relationship: \""extent of\""\\n3. Entity1: \""Surgical Intervention\"", Entity2: \""Advanced Cases\"", Relationship: \""management option for\""\\n\\nCausalities:-\\n<CO> If concurrent therapies are not suitable </CO>, <A> the chart presents laryngectomy combined with thyroidectomy </A>, <CO> depending on the extent of lymph node dissection required </CO>. <E> This highlights surgical intervention as a viable option in the management of advanced cases </E>.\\n\\nSection Name: Induction Chemotherapy\\n====================\\nEntities:-\\nInduction Chemotherapy : Initial chemotherapy treatment used to shrink a tumor before the main treatment, which is usually surgery.\\nSurgical Procedure : A medical procedure involving an incision with instruments; performed to repair damage or arrest disease in a living body.\\nTherapeutic Approach : A method or strategy used in the treatment of disease or injury.\\n\\nRelationships:-\\n1. Entity1: \""Induction Chemotherapy\"", Entity2: \""Surgical Intervention\"", Relationship: \""alternative or sequential treatment option\""\\n\\nCausalities:-\\n<C> immediate surgical intervention is either not feasible or considered insufficient </C> <E> The flowchart also considers the option of induction chemotherapy </E> <CO> in cases where immediate surgical intervention is either not feasible or considered insufficient </CO>. <A> tailoring therapeutic approaches tailored to individual patient needs </A>.\\n\\nSection Name: Adjuvant Treatment\\n====================\\nEntities:-\\nAdjuvant Chemotherapy : Chemotherapy given in addition to the primary treatment to maximize its effectiveness.\\nRadiotherapy : The use of high-energy radiation from x-rays, gamma rays, neutrons, protons, and other sources to kill cancer cells and shrink tumors.\\nNeoplasm Recurrence, Local : The return of a cancer, at the same site, after it has been treated.\\nDisease Progression : The worsening of a disease over time.\\n\\nRelationships:-\\n1. Entity1: \""Primary Treatment\"", Entity2: \""Adjuvant Treatment\"", Relationship: \""followed by\""\\n2. Entity1: \""Adjuvant Treatment\"", Entity2: \""Systemic Therapy\"", Relationship: \""includes\""\\n3. Entity1: \""Adjuvant Treatment\"", Entity2: \""Radiotherapy\"", Relationship: \""includes\""\\n4. Entity1: \""Follow-up Assessments\"", Entity2: \""Treatment Efficacy\"", Relationship: \""used to evaluate\""\\n\\nCausalities:-\\n<C> Following primary treatment </C>, <E> the flowchart addresses the potential for adjuvant treatment pathways </E>. This may include systemic therapy, RT, or further evaluations based on <CO> the patient\\'s response and any recurrence or persistent disease </CO>. It emphasizes <A> the need for follow-up assessments to evaluate treatment efficacy </A>.\\n\\nSection Name: Risk Features and Response Assessment\\n====================\\nEntities:-\\nNeoplasm Invasiveness : The property of a neoplasm to infiltrate and destroy surrounding tissue.\\nSurgical Margins : The edge or border of the tissue removed in cancer surgery.\\nNeoplasms : Neoplasms are abnormal growths of tissue, which can be cancerous or non-cancerous.\\nExtramural Extension : Extension of a tumor beyond the wall of an organ.\\nPositive Surgical Margin : Cancer cells are present at the edge of the tissue removed during surgery.\\nCancer Management : The process of planning and coordinating the treatment of cancer.\\nCancer : Cancer is a group of diseases involving abnormal cell growth with the potential to invade or spread to other parts of the body.\\n\\nRelationships:-\\n1. Entity1: \""Extramural extension\"", Entity2: \""Treatment decisions\"", Relationship: \""influences\""\\n2. Entity1: \""Positive surgical margin\"", Entity2: \""Treatment decisions\"", Relationship: \""influences\""\\n3. Entity1: \""Ongoing assessment\"", Entity2: \""Response evaluation\"", Relationship: \""leads to\""\\n4. Entity1: \""Response evaluation\"", Entity2: \""Adjustments to treatment\"", Relationship: \""leads to\""\\n5. Entity1: \""Management of cancer\"", Entity2: \""Treatment decisions\"", Relationship: \""involves\""\\n6. Entity1: \""Management of cancer\"", Entity2: \""Ongoing assessment\"", Relationship: \""involves\""\\n7. Entity1: \""Management of cancer\"", Entity2: \""Adjustments to treatment\"", Relationship: \""involves\""\\n\\nCausalities:-\\nThe chart incorporates a segment that takes into account <CO> adverse pathologic features, such as extramural extension or positive margins </CO>, <E> which could influence subsequent treatment decisions </E>. This highlights the importance of <A> ongoing assessment in the management of cancer, leading to response evaluation and adjustments to treatment as necessary </A>.\\n\\nSection Name: NCCN Guidelines Version 4.2024\\n====================\\nEntities:-\\nClinical Trials : Clinical trials are research studies performed in people that are aimed at evaluating a medical, surgical, or behavioral intervention.\\nNeoplasms : Neoplasms are abnormal growths of tissue, which can be cancerous or non-cancerous.\\nClinical Trial : A clinical trial is a research study that prospectively assigns human participants or groups of humans to one or more health-related interventions to evaluate the effects on health outcomes.\\nMalignant Neoplasm : A malignant neoplasm is a cancerous growth that has the potential to invade and destroy nearby tissue and spread to other parts of the body.\\nNational Comprehensive Cancer Network : The National Comprehensive Cancer Network (NCCN) is an alliance of 31 cancer centers in the United States, dedicated to improving the quality, effectiveness, and efficiency of cancer care.\\nCancer : Cancer is a group of diseases involving abnormal cell growth with the potential to invade or spread to other parts of the body.\\n\\nRelationships:-\\n1. Entity1: \""National Comprehensive Cancer Network\"", Entity2: \""NCCN Guidelines\"", Relationship: \""provides\""\\n2. Entity1: \""NCCN Guidelines\"", Entity2: \""Clinical Trials\"", Relationship: \""recommend\""\\n3. Entity1: \""NCCN Guidelines\"", Entity2: \""Cancer\"", Relationship: \""related to management of\""\\n\\nCausalities:-\\n<CO> any patient with cancer </CO> <A> the best management is in a clinical trial </A>. <A> Participation in clinical trials is especially encouraged </A>.\\n\\nSection Name: SUPRA-3\\n====================\\nEntities:-\\nLaryngectomy : A surgical procedure involving the removal of the larynx, usually to treat cancer of the larynx.\\nThyroidectomy : A surgical procedure to remove all or part of the thyroid gland.\\nNeck Dissection : Surgical procedure to remove lymph nodes and surrounding tissue to treat or prevent cancer spread.\\nChemotherapy, Induction : Initial chemotherapy treatment to shrink a tumor before the main treatment.\\nClinical Trials As Topic : Research studies that prospectively assign human participants or groups of humans to one or more health-related interventions to evaluate the effects on health outcomes.\\nInduction Chemotherapy : Initial chemotherapy treatment used to shrink a tumor before the main treatment, which is usually surgery.\\nClinical Trial : A clinical trial is a research study that prospectively assigns human participants or groups of humans to one or more health-related interventions to evaluate the effects on health outcomes.\\n\\nRelationships:-\\n1. Entity1: \""Total laryngectomy\"", Entity2: \""Laryngectomy\"", Relationship: \""is a type of\""\\n2. Entity1: \""Systemic therapy\"", Entity2: \""RT\"", Relationship: \""concurrent treatment option\""\\n3. Entity1: \""Induction chemotherapy\"", Entity2: \""Other treatments\"", Relationship: \""initial treatment option before\""\\n\\nCausalities:-\\n<CO> Requiring (amenable to) total laryngectomy (T3,N0) </CO>\\n  - <A> Concurrent systemic therapy/RT </A> or <A> RT if patient not medical candidate for concurrent systemic therapy/RT </A>\\n  - <A> Laryngectomy, thyroidectomy and with ipsilateral, central, or bilateral neck dissection </A>\\n  - or\\n  - <A> Induction chemotherapy </A>\\n  - or\\n  - <A> Clinical trials </A>\\n\\nSection Name: Follow-up\\n====================\\nEntities:-\\nFollow-Up Studies : Studies in which individuals are followed over time to determine the outcome of exposures, treatments, or interventions.\\nFollow-Up Procedure : A procedure performed to monitor the progress of a patient\\'s condition after initial treatment.\\nFollow-Up : Medical care given to a patient over time after initial treatment.\\nDisease Recurrence : The return of a sign, symptom, or disease after a remission.\\nRecurrent Disease : The reappearance of a disease after a period of improvement.\\n\\nRelationships:-\\n1. Entity1: \""Follow-up\"", Entity2: \""Recurrent or persistent disease\"", Relationship: \""monitoring\""\\n\\nCausalities:-\\n- **Follow-up (FOLL-A, 1 of 2)**\\n  - <CO> Recurrent or persistent disease </CO> (ADV-3)\\n\\nSection Name: Adverse Pathologic Features\\n====================\\nEntities:-\\nRadiotherapy : The use of high-energy radiation from x-rays, gamma rays, neutrons, protons, and other sources to kill cancer cells and shrink tumors.\\nExtranodal Extension : The spread of cancer beyond the lymph node capsule.\\nPositive Surgical Margin : Cancer cells are present at the edge of the tissue removed during surgery.\\nSystemic Therapy : Treatment using substances that travel through the bloodstream, reaching and affecting cells all over the body.\\n\\nRelationships:-\\n1. Entity1: \""pN1\"", Entity2: \""Radiotherapy\"", Relationship: \""Consideration for treatment\""\\n2. Entity1: \""Extranodal extension\"", Entity2: \""Systemic Therapy\"", Relationship: \""Treatment option\""\\n3. Entity1: \""Extranodal extension\"", Entity2: \""Radiotherapy\"", Relationship: \""Treatment option\""\\n4. Entity1: \""Positive surgical margin\"", Entity2: \""Systemic Therapy\"", Relationship: \""Treatment option\""\\n5. Entity1: \""Positive surgical margin\"", Entity2: \""Radiotherapy\"", Relationship: \""Treatment option\""\\n\\nCausalities:-\\n- <CO>pN1 without other risk features</CO>\\n  - <C>Adverse pathologic features</C>\\n  - <A>Consider RT</A>\\n  - <CO>Extranodal extension and/or positive margin</CO>\\n  - <CO>Other risk features</CO>\\n  - <A>Systemic therapy/RT (category 1)</A>\\n  - <A>RT or Consider systemic therapy/RT</A>\\n\\nSection Name: Response Assessment\\n====================\\nEntities:-\\nResponse Evaluation : The process of assessing the response of a disease to treatment, often used in clinical trials to determine the effectiveness of a therapy.\\nResponse To Treatment : A clinical finding indicating the response of a condition to a therapeutic intervention.\\n\\nRelationships:-\\n\\nSection Name: Principles of Surgery and Radiation Therapy\\n====================\\nEntities:-\\nSurgical Procedures, Operative : Operations carried out for the correction of deformities and defects, repair of injuries, and diagnosis and cure of certain diseases.\\nSurgical Procedure : A medical procedure involving an incision with instruments; performed to repair damage or arrest disease in a living body.\\nSurgery : Medical specialty that uses operative manual and instrumental techniques on a patient to investigate or treat a pathological condition such as a disease or injury.\\nRadiotherapy : The use of high-energy radiation from x-rays, gamma rays, neutrons, protons, and other sources to kill cancer cells and shrink tumors.\\nRadiation Therapy : Radiation therapy is a therapy using ionizing radiation, generally as part of cancer treatment to control or kill malignant cells.\\n\\nRelationships:-\\n1. Entity1: \""Principles of Surgery\"", Entity2: \""Principles of Radiation Therapy\"", Relationship: \""complementary treatments\""\\n\\nCausalities:-\\n**Principles of Surgery (SURG-A).**\\n\\n**Principles of Radiation Therapy (SUPRA-A).**\\n\\nSection Name: Principles of Systemic Therapy\\n====================\\nEntities:-\\nCisplatin : An inorganic and water-soluble platinum complex, cisplatin is an antineoplastic agent that is used in the treatment of various cancers.\\nRadiotherapy : The use of high-energy radiation from x-rays, gamma rays, neutrons, protons, and other sources to kill cancer cells and shrink tumors.\\nRadiation Therapy : Radiation therapy is a therapy using ionizing radiation, generally as part of cancer treatment to control or kill malignant cells.\\n\\nRelationships:-\\n1. Entity1: \""Cisplatin\"", Entity2: \""Systemic Therapy for Non-Nasopharyngeal Cancers\"", Relationship: \""preferred agent\""\\n2. Entity1: \""Cisplatin\"", Entity2: \""Concurrent Systemic Therapy/RT\"", Relationship: \""used in\""\\n\\nCausalities:-\\n<CO> When using concurrent systemic therapy/RT </CO>, <A> the preferred agent is cisplatin (category 1) </A>.\\n--------------------------------------------------\\nPage Number: 55\\n\\nSection Name: General Information\\n====================\\nEntities:-\\nNational Comprehensive Cancer Network : An alliance of 32 cancer centers in the United States, dedicated to improving the quality, effectiveness, and efficiency of cancer care.\\nNccn Guidelines : Clinical practice guidelines in oncology developed by the National Comprehensive Cancer Network.\\n\\nRelationships:-\\n1. Entity1: \""NCCN Guidelines\"", Entity2: \""National Comprehensive Cancer Network\"", Relationship: \""produced by\""\\n\\nSection Name: Important Notes\\n====================\\nEntities:-\\nClinical Trials As Topic : Works about research studies that evaluate the effectiveness and safety of medical, surgical, or behavioral interventions.\\nClinical Trial : A type of research that studies new tests and treatments and evaluates their effects on human health outcomes.\\nNational Comprehensive Cancer Network : An alliance of 32 cancer centers in the United States, dedicated to improving the quality, effectiveness, and efficiency of cancer care.\\nNeoplasms : New abnormal growth of tissue that can be benign or malignant.\\nMalignant Neoplastic Disease : A disease resulting from the growth of malignant neoplasms.\\nCancer : A group of diseases involving abnormal cell growth with the potential to invade or spread to other parts of the body.\\n\\nRelationships:-\\n1. Entity1: \""Clinical Trials\"", Entity2: \""Cancer\"", Relationship: \""recommended for\""\\n2. Entity1: \""NCCN\"", Entity2: \""Clinical Trials\"", Relationship: \""encourages participation in\""\\n\\nCausalities:-\\n<C> NCCN believes that the best management of any patient with cancer is in a clinical trial </C>. <A> Participation in clinical trials is especially encouraged </A>.\\n\\nSection Name: Principles\\n====================\\nEntities:-\\nSurgical Procedures, Operative : Surgical procedures involve the use of operative manual and instrumental techniques on a patient to investigate or treat a pathological condition such as disease or injury.\\nRadiation Therapy : Therapy using ionizing radiation, generally as part of cancer treatment to control or kill malignant cells.\\nChemotherapy : A type of cancer treatment that uses one or more anti-cancer drugs as part of a standardized chemotherapy regimen.\\n\\nRelationships:-\\n1. Entity1: \""Principles of Surgery\"", Entity2: \""Principles of Radiation Therapy\"", Relationship: \""Both are principles of cancer treatment methods.\""\\n2. Entity1: \""Principles of Surgery\"", Entity2: \""Principles of Systemic Therapy for Non-Nasopharyngeal Cancers\"", Relationship: \""Both are principles of cancer treatment methods.\""\\n3. Entity1: \""Principles of Radiation Therapy\"", Entity2: \""Principles of Systemic Therapy for Non-Nasopharyngeal Cancers\"", Relationship: \""Both are principles of cancer treatment methods.\""\\n\\nCausalities:-\\n### Principles\\n\\n- **Principles of Surgery (SURG-A)**\\n- **Principles of Radiation Therapy (SUPRA-A)**\\n- **Principles of Systemic Therapy for Non-Nasopharyngeal Cancers (SYST-A)**\\n\\nSection Name: Adverse Pathologic Features\\n====================\\nEntities:-\\nExtranodal Extension : The spread of cancer cells beyond the lymph node capsule into the surrounding tissues.\\nPositive Surgical Margin : The presence of cancer cells at the edge of the tissue removed during surgery, indicating that some cancer may have been left behind.\\nPerineural Invasion : The presence of cancer cells surrounding or tracking along a nerve within the perineural space.\\nVascular Invasion : The invasion of cancer cells into blood vessels.\\nLymphatic Invasion : The invasion of cancer cells into lymphatic vessels.\\n\\nRelationships:-\\n1. Entity1: \""Extranodal extension\"", Entity2: \""Adverse Pathologic Features\"", Relationship: \""is a type of\""\\n2. Entity1: \""Positive margins\"", Entity2: \""Adverse Pathologic Features\"", Relationship: \""is a type of\""\\n3. Entity1: \""Close margins\"", Entity2: \""Adverse Pathologic Features\"", Relationship: \""is a type of\""\\n4. Entity1: \""pT3 or pT4 primary\"", Entity2: \""Adverse Pathologic Features\"", Relationship: \""is a type of\""\\n5. Entity1: \""pN2 or pN3 nodal disease\"", Entity2: \""Adverse Pathologic Features\"", Relationship: \""is a type of\""\\n6. Entity1: \""Perineural invasion\"", Entity2: \""Adverse Pathologic Features\"", Relationship: \""is a type of\""\\n7. Entity1: \""Vascular invasion\"", Entity2: \""Adverse Pathologic Features\"", Relationship: \""is a type of\""\\n8. Entity1: \""Lymphatic invasion\"", Entity2: \""Adverse Pathologic Features\"", Relationship: \""is a type of\""\\n\\nCausalities:-\\n<C> Extranodal extension </C>\\n<C> Positive margins </C>\\n<C> Close margins </C>\\n<C> pT3 or pT4 primary </C>\\n<C> pN2 or pN3 nodal disease </C>\\n<C> Perineural invasion </C>\\n<C> Vascular invasion </C>\\n<C> Lymphatic invasion </C>\\n\\nSection Name: Response Assessment\\n====================\\nEntities:-\\nChemotherapy, Induction : Initial chemotherapy treatment to shrink a tumor before the main treatment.\\nPrimary Site : The original location where a tumor or cancer begins.\\nComplete Remission : The disappearance of all signs of cancer in response to treatment.\\nPartial Remission : A decrease in the size of a tumor, or in the extent of cancer in the body, in response to treatment.\\nRadiotherapy : The use of high-energy radiation to kill cancer cells and shrink tumors.\\nSurgical Procedures, Operative : Surgical procedures involve the use of operative manual and instrumental techniques on a patient to investigate or treat a pathological condition such as disease or injury.\\n\\nRelationships:-\\n1. Entity1: \""induction chemotherapy\"", Entity2: \""Primary site\"", Relationship: \""treatment outcome\""\\n2. Entity1: \""Definitive RT\"", Entity2: \""Primary site\"", Relationship: \""treatment option\""\\n3. Entity1: \""RT\"", Entity2: \""Primary site\"", Relationship: \""treatment option\""\\n4. Entity1: \""Surgery\"", Entity2: \""unresectable nodal disease\"", Relationship: \""treatment option\""\\n\\nCausalities:-\\n<C> Response after induction chemotherapy </C>: <E> Primary site: CR </E> <E> Primary site: PR </E> <E> Primary site: < PR </E> <A> Definitive RT </A> (category 1) <A> RT </A> (category 1) or <A> systemic therapy/RT </A> (category 2B) <A> Surgery </A> or <A> unresectable nodal disease </A>\\n\\nSection Name: Follow-up\\n====================\\nEntities:-\\nFollow-Up Studies : Studies in which individuals are followed over time to determine the outcome of exposures, treatments, or interventions.\\nFollow-Up Procedure : A procedure where a patient is monitored over time to assess the progress of a condition or the effects of treatment.\\nFollow-Up (Medicine) : The process of monitoring a patient\\'s health over time after treatment or diagnosis.\\nDisease Recurrence : The return of a sign, symptom, or disease after a remission.\\nRecurrent Disease : A disease that returns after a period of remission.\\nRecurrence (Medicine) : The return of a disease or condition after a period of improvement.\\n\\nRelationships:-\\n1. Entity1: \""Follow-up\"", Entity2: \""Recurrent or persistent disease\"", Relationship: \""monitoring\""\\n\\nCausalities:-\\n### Follow-up\\n\\n- **Follow-up** (FOLL-A, 1 of 2)\\n- **Recurrent or persistent disease** (ADV-3)\\n\\nSection Name: Risk Features\\n====================\\nEntities:-\\nRadiotherapy : The use of high-energy radiation to kill cancer cells and shrink tumors.\\nExtranodal Extension : The spread of cancer cells beyond the lymph node capsule into the surrounding tissues.\\nPositive Surgical Margin : The presence of cancer cells at the edge of the tissue removed during surgery, indicating that some cancer may have been left behind.\\nSystemic Therapy : Systemic therapy refers to treatment using substances that travel through the bloodstream, reaching and affecting cells all over the body.\\n\\nRelationships:-\\n1. Entity1: \""Adverse pathologic features\"", Entity2: \""RT\"", Relationship: \""Consideration for treatment\""\\n2. Entity1: \""Adverse pathologic features\"", Entity2: \""Systemic therapy\"", Relationship: \""Consideration for treatment\""\\n\\nCausalities:-\\n- **No adverse pathologic features**\\n- **Other risk features**\\n- **Adverse pathologic features**:\\n  - <C> Extranodal extension and/or positive margin </C>\\n  - <A> RT or consider systemic therapy/RT </A>\\n\\nSection Name: Post-Therapy Evaluation\\n====================\\nEntities:-\\nSystemic Therapy : Systemic therapy refers to treatment using substances that travel through the bloodstream, reaching and affecting cells all over the body.\\nRadiation Therapy : Therapy using ionizing radiation, generally as part of cancer treatment to control or kill malignant cells.\\nNeck : The neck is the part of the body that separates the head from the torso and provides the mobility and movements of the head.\\n\\nRelationships:-\\n1. Entity1: \""Systemic Therapy\"", Entity2: \""Neck Evaluation\"", Relationship: \""evaluated in\""\\n2. Entity1: \""RT\"", Entity2: \""Neck Evaluation\"", Relationship: \""evaluated in\""\\n\\nCausalities:-\\n<CO> Post Systemic Therapy/RT or RT Neck </CO> <A> Evaluation </A>\\n\\nSection Name: Flowchart Overview\\n====================\\nEntities:-\\nLaryngeal Neoplasms : Tumors or cancer of the larynx, which may affect the supraglottic, glottic, or subglottic regions.\\nSupraglottic Larynx : The part of the larynx located above the vocal cords, including the epiglottis and aryepiglottic folds.\\nNational Comprehensive Cancer Network : An alliance of 32 cancer centers in the United States, dedicated to improving the quality, effectiveness, and efficiency of cancer care.\\n\\nRelationships:-\\n1. Entity1: \""NCCN Guidelines\"", Entity2: \""cancer of the supraglottic larynx\"", Relationship: \""guides management of\""\\n2. Entity1: \""NCCN Guidelines\"", Entity2: \""healthcare professionals\"", Relationship: \""used by\""\\n\\nCausalities:-\\n<C> cancer of the supraglottic larynx </C> <E> evaluate patient responses following treatment </E> <CO> based on observed outcomes </CO> <A> evaluation of the primary site and determining subsequent steps </A>.\\n\\nSection Name: Assessment and Treatment Decisions\\n====================\\nEntities:-\\nInduction Chemotherapy : Initial chemotherapy treatment to shrink a tumor before the main treatment.\\nComplete Response : The disappearance of all signs of cancer in response to treatment.\\nPartial Response : A decrease in the size of a tumor, or in the extent of cancer in the body, in response to treatment.\\nRadiation Therapy : Therapy using ionizing radiation, generally as part of cancer treatment to control or kill malignant cells.\\nSurgery : Medical specialty that uses operative manual and instrumental techniques on a patient to investigate or treat a pathological condition such as disease or injury.\\nSystemic Therapy : Systemic therapy refers to treatment using substances that travel through the bloodstream, reaching and affecting cells all over the body.\\n\\nRelationships:-\\n1. Entity1: \""Complete Response\"", Entity2: \""Radiation Therapy\"", Relationship: \""leads to\""\\n2. Entity1: \""Complete Response\"", Entity2: \""Surgery\"", Relationship: \""leads to\""\\n3. Entity1: \""Partial Response\"", Entity2: \""Systemic Therapy\"", Relationship: \""leads to\""\\n4. Entity1: \""Partial Response\"", Entity2: \""Radiation Therapy\"", Relationship: \""leads to\""\\n\\nCausalities:-\\n<C> responses to initial treatments such as induction chemotherapy </C> <E> Three main response categories are recognized: Complete Response (CR), Partial Response (PR), and less than Partial Response (< PR) </E>. These categories are pivotal in determining the next steps. <C> CR </C> <E> indicates full resolution of the disease at the primary site </E>, <A> leading to the consideration of definitive radiation therapy or the likelihood of surgery </A>. Conversely, <C> PR </C> <E> suggests that the disease has improved but not completely resolved </E>, <A> which directs the pathway towards either systemic therapy or continued radiation therapy </A>, <A> with further evaluation necessary </A>.\\n\\nSection Name: Adverse Pathologic Features and Follow-up\\n====================\\nEntities:-\\nRadiation Therapy : Therapy using ionizing radiation, generally as part of cancer treatment to control or kill malignant cells.\\nSurgical Procedures, Operative : Surgical procedures involve the use of operative manual and instrumental techniques on a patient to investigate or treat a pathological condition such as disease or injury.\\nNeoplasm Recurrence, Local : The return of a tumor or cancer, at the original site, after it has been treated.\\nNeoplasm Metastasis : The transfer of a neoplasm from one organ or part of the body to another remote from the primary site.\\nSurgical Procedure : A medical procedure involving an incision with instruments; performed to repair damage or arrest disease in a living body.\\nRecurrent Neoplasm : A neoplasm that has returned after treatment.\\nMetastatic Neoplasm : A neoplasm that has spread from its original site to one or more other places in the body.\\nSurgery : Medical specialty that uses operative manual and instrumental techniques on a patient to investigate or treat a pathological condition such as disease or injury.\\nCancer Recurrence : The return of cancer after treatment and after a period of time during which the cancer was undetectable.\\nMetastasis : Spread of a cancer or other disease from one organ or part to another not directly connected with it.\\n\\nRelationships:-\\n1. Entity1: \""Adverse pathologic features\"", Entity2: \""Treatment decisions\"", Relationship: \""Influence\""\\n2. Entity1: \""Adverse features\"", Entity2: \""Surgical intervention\"", Relationship: \""Recommendation\""\\n3. Entity1: \""Absence of adverse features\"", Entity2: \""Radiation therapy\"", Relationship: \""Pathway\""\\n4. Entity1: \""Follow-up process\"", Entity2: \""Recurrent or persistent disease\"", Relationship: \""Detection\""\\n5. Entity1: \""Recurrent or persistent disease\"", Entity2: \""Advanced disease management\"", Relationship: \""Necessity\""\\n\\nCausalities:-\\n<C> The presence of adverse pathologic features \u2014 such as extranodal extension or positive margins </C> <E> can directly influence treatment decisions </E>. <CO> If adverse features are found </CO>, <A> surgical intervention is recommended </A>. <CO> In cases where there are no adverse features </CO>, the patient may proceed directly to radiation therapy or continued systemic treatment, emphasizing the tailored approach based on the individual patient\\'s disease characteristics.\\n\\nFurthermore, the chart includes a section addressing the follow-up process after initial treatment. <CO> If there are signs of recurrent or persistent disease </CO>, <A> additional evaluations and treatment modalities may be necessary </A>. These evaluations <E> lead to specific recommendations for advanced disease management, denoted as ADV-3 on the chart </E>, emphasizing the importance of continuous monitoring and assessment in cancer care.\\n--------------------------------------------------\\nPage Number: 102\\n\\nSection Name: Head and Neck Cancers - Principles of Surgery\\n====================\\nEntities:-\\nSurgical Procedures, Operative : Manual or operative procedures used in the treatment of disease, injuries, or deformities.\\nLymphatic System : Part of the circulatory system and a vital part of the immune system, comprising a network of lymphatic vessels that carry a clear fluid called lymph.\\nNeoplasms : New abnormal growth of tissue in animals or plants; a tumor.\\nNeck Dissection : A surgical procedure for control of neck lymph node metastasis from squamous cell carcinoma of the head and neck.\\nNeoplasm Staging : Methods which attempt to express in replicable terms the extent of the neoplasm in the patient.\\nMetastasis : The spread of a cancer or other disease from one organ or part of the body to another not directly connected with it.\\nSurgical Procedure : A procedure involving an incision with instruments; performed to repair damage or arrest disease in a living body.\\nLymphatic Structure : Anatomical structure that is part of the lymphatic system.\\nTumor : An abnormal mass of tissue that results when cells divide more than they should or do not die when they should.\\nStaging : The process of determining the size and spread of cancer within the body.\\nSurgery : Medical specialty that uses operative manual and instrumental techniques on a patient to investigate or treat a pathological condition such as disease or injury.\\nCancer Staging : The process of determining the extent to which a cancer has developed by growing and spreading.\\n\\nRelationships:-\\n1. Entity1: \""surgical management\"", Entity2: \""regional lymphatics\"", Relationship: \""dictated by tumor staging\""\\n2. Entity1: \""neck dissections\"", Entity2: \""primary tumor\"", Relationship: \""part of treatment\""\\n3. Entity1: \""surgery\"", Entity2: \""ipsilateral side of the neck\"", Relationship: \""risk for metastases\""\\n\\nCausalities:-\\n<C> The extent of the tumor at initial tumor staging </C> <E> dictates the surgical management of regional lymphatics </E>. These guidelines apply to the performance of neck dissections as part of treatment of the primary tumor. <CO> Patients undergoing surgery for resection of the primary tumor </CO> <A> will undergo dissection of the ipsilateral side of the neck that is at greatest risk for metastases </A>.\\n\\nSection Name: Neck Management\\n====================\\nEntities:-\\nTongue : A muscular organ in the mouth that is involved in tasting, swallowing, and speech.\\nPalate : The roof of the mouth, separating the oral and nasal cavities.\\nLarynx : An organ in the top of the neck involved in breathing, producing sound, and protecting the trachea.\\nHypopharynx : The bottom part of the pharynx, which is the cavity behind the nose and mouth.\\nNasopharynx : The upper part of the pharynx, connecting with the nasal cavity above the soft palate.\\nNeck Dissection : A surgical procedure for control of neck lymph node metastasis from squamous cell carcinoma of the head and neck.\\nMetastasis : The spread of a cancer or other disease from one organ or part of the body to another not directly connected with it.\\nSquamous Cell Carcinoma : A type of cancer that begins in the squamous cells, which are thin, flat cells that look like fish scales.\\nBiopsy : The removal of cells or tissues for examination under a microscope.\\n\\nRelationships:-\\n1. Entity1: \""Tumor sites\"", Entity2: \""Bilateral lymphatic drainage\"", Relationship: \""associated with\""\\n2. Entity1: \""Elective neck dissection\"", Entity2: \""Risk of occult metastasis\"", Relationship: \""based on\""\\n3. Entity1: \""SLN biopsy\"", Entity2: \""Elective neck dissection\"", Relationship: \""guides decision-making for\""\\n\\nCausalities:-\\n- **<C> Tumor sites that frequently have bilateral lymphatic drainage </C>** (e.g., base of tongue, palate, supraglottic larynx, hypopharynx, nasopharynx, deep pre-epiglottic space involvement) <E> often should have both sides of the neck dissected </E> with the extent of dissection determined as suggested below. For those patients with tumors at or approaching the midline, <CO> both sides of the neck are at risk for metastases </CO>, and <A> bilateral neck dissections should be performed </A>.\\n\\n- <CO> Patients with advanced lesions involving the anterior tongue, floor of the mouth, or alveolus that approximate or cross the midline </CO> <A> should undergo contralateral selective/modified neck dissection </A> as necessary to achieve adequate tumor resection.\\n\\n- **<C> Elective neck dissection </C>** <A> should be based on risk of occult metastasis in the appropriate nodal basin </A>. For oral cavity squamous cell carcinoma, <C> SLN biopsy or the primary tumor depth of invasion </C> is currently <E> the best predictor of occult metastatic disease </E> and <A> should be used to guide decision-making </A>. <CO> For tumors with a depth greater than 3 mm </CO>, <A> elective dissection should be strongly considered if RT is not already planned </A>. Recent randomized trial evidence supports the effectiveness of elective neck dissection in patients with oral cavity cancers greater than 3 mm in depth of invasion.\\n\\n  - <CO> For a depth less than 2 mm </CO>, <A> elective dissection is only indicated in highly selective situations </A>. <CO> For a depth of 2\u20134 mm </CO>, <A> clinical judgment (as to reliability of follow-up, clinical suspicion, and other factors) must be utilized to determine appropriateness of elective dissection </A>. Elective dissections are generally selective, preserving all major structures, unless operative findings dictate otherwise.\\n\\nSection Name: Types of Neck Dissection\\n====================\\nEntities:-\\nNeck Dissection : A surgical procedure for control of neck lymph node metastasis from squamous cell carcinoma of the head and neck.\\nLarynx : An organ in the top of the neck involved in breathing, producing sound, and protecting the trachea.\\n\\nRelationships:-\\n1. Entity1: \""N0\"", Entity2: \""Selective neck dissection\"", Relationship: \""associated with\""\\n2. Entity1: \""N3\"", Entity2: \""Comprehensive neck dissection\"", Relationship: \""associated with\""\\n3. Entity1: \""Level VI neck dissection\"", Entity2: \""Larynx\"", Relationship: \""performed for\""\\n4. Entity1: \""Level VI neck dissection\"", Entity2: \""Hypopharynx\"", Relationship: \""performed for\""\\n\\nCausalities:-\\n- **The type of neck dissection (comprehensive or selective)** is defined according to <CO> preoperative clinical staging </CO>, is determined at the discretion of the surgeon, and is based on the initial preoperative staging as follows:\\n  - **N0:** <A> Selective neck dissection </A>\\n    - Oral cavity at least levels I\u2013III\\n    - Oropharynx at least levels II\u2013IV\\n    - Hypopharynx at least levels II\u2013IV and level VI when appropriate\\n    - Larynx at least levels II\u2013IV and level VI when appropriate\\n  - **N1\u2013N2a\u2013c:** <A> Selective or comprehensive neck dissection </A> (Discussion)\\n  - **N3:** <A> Comprehensive neck dissection </A>\\n\\n- <C> Level VI neck dissections are performed for certain primary sites (such as the larynx and hypopharynx) </C> <E> as required to resect the primary tumor and any clinically evident neck nodes </E>. <CO> Elective dissection depends on primary tumor extent and site </CO>. <CO> For advanced glottic and hypopharyngeal cancers treated with primary surgery </CO>, <A> a level VI dissection (including pretracheal lymph nodes, the Delphian lymph node, and unilateral or bilateral paratracheal lymph nodes) and hemithyroidectomy to total thyroidectomy are appropriate </A>.\\n\\n- <CO> For primary subglottic tumors or glottic cancers with significant subglottic extension </CO>, <A> a level VI dissection with unilateral or total thyroidectomy is considered appropriate </A> based on the extent of the primary tumor. <CO> For example, a T4a glottic tumor with extension through the cricothyroid membrane and subglottic extension </CO> <A> should include thyroidectomy and pretracheal and bilateral paratracheal lymph node dissection </A>. <A> Parathyroid glands should be preserved in situ or auto transplanted as indicated </A>.\\n--------------------------------------------------\\nPage Number: 154\\n\\nSection Name: NCCN Guidelines Version 4.2024\\n====================\\nEntities:-\\nNccn Guidelines : The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) are a comprehensive set of guidelines detailing the sequential management decisions and interventions that apply to 97% of cancers affecting patients in the United States.\\n\\nRelationships:-\\n\\nCausalities:-\\n# NCCN Guidelines Version 4.2024\\n\\nSection Name: Head and Neck Cancers\\n====================\\nEntities:-\\nHead And Neck Neoplasms : Tumors or cancer of the head and neck region, including the nasal cavity, sinuses, lips, mouth, salivary glands, throat, or larynx.\\nRadiation Therapy : The medical use of ionizing radiation, generally as part of cancer treatment to control or kill malignant cells.\\nQuad Shot Regimen : A palliative radiation therapy regimen consisting of 44.4 Gy delivered in 12 fractions over three cycles, used for patients with limited life expectancy.\\n\\nRelationships:-\\n1. Entity1: \""Head and Neck Neoplasms\"", Entity2: \""70 Gy\"", Relationship: \""treatment dosage\""\\n2. Entity1: \""QUAD SHOT regimen\"", Entity2: \""Palliative Treatment\"", Relationship: \""purpose\""\\n\\nCausalities:-\\nThe College of Radiology describes basic technical specifications [here](http://www.acr.org/Quality-Safety). Furthermore, major consensus contouring guidelines for the treatment of head and neck (H&N) cancers are available for reference, especially for patients who are treated without surgery. [143,144]\\n\\nWhen radiation is given with definitive intent, <A> the dosages prescribed for gross disease are fairly standard, usually in the range of 70 Gy (at approximately 2 Gy/fraction/day) </A> for the following sites: <CO> lip, oral cavity, nasopharynx, oropharynx, hypopharynx, glottic larynx, supraglottic larynx, occult primary, salivary gland tumors, and MM </CO>. A second dose (often approximately 60 Gy, but varies) may be used to cover volumes considered at the highest risk for microscopic spread, while a lower dose (often approximately 50 Gy, but varies) is used for volumes treated electively with low risk for microscopic spread.\\n\\nAlthough several palliative RT regimens are provided, no single regimen is preferred [145,146]; specific regimens vary widely among NCCN Member Institutions. <A> Any palliative RT regimen that might cause severe toxicities should be avoided </A>. <A> More hypofractionated regimens may be useful </A> for <CO> patients with limited life expectancy, such as a few months </CO>. For example, <A> a common version of the QUAD SHOT regimen consists of a dose of 44.4 Gy, delivered in 12 fractions over three cycles, with each cycle separated by 2 to 3 weeks </A>. [147]\\n\\nSection Name: Radiation Doses\\n====================\\nEntities:-\\nRadiation Dosage : The amount of radiation absorbed by an object or person.\\nNeoplasms : New abnormal growth of tissue that can be benign or malignant.\\nLymph Nodes : Small, bean-shaped structures that are part of the body\\'s immune system.\\nRadiotherapy : The treatment of disease, especially cancer, using X-rays or similar forms of radiation.\\nChemotherapy : The use of chemical substances, especially the treatment of cancer by cytotoxic and other drugs.\\nRadiation Therapy : The medical use of ionizing radiation, generally as part of cancer treatment to control or kill malignant cells.\\nLymph Node Structure : A structure that is part of the lymphatic system, involved in the immune response.\\nNeoplasm : An abnormal mass of tissue as a result of neoplasia.\\nLymph Node : An organ of the lymphatic system and the adaptive immune system.\\nTumor : A mass of tissue that\\'s formed by an accumulation of abnormal cells.\\n\\nRelationships:-\\n1. Entity1: \""Radiation Dosage\"", Entity2: \""Neoplasms\"", Relationship: \""depends on\""\\n2. Entity1: \""Radiation Dosage\"", Entity2: \""Organs at risk\"", Relationship: \""may need to be decreased if close to\""\\n3. Entity1: \""Radiotherapy\"", Entity2: \""IMRT\"", Relationship: \""uses\""\\n4. Entity1: \""Radiotherapy\"", Entity2: \""Chemotherapy\"", Relationship: \""can be used with\""\\n\\nCausalities:-\\n<C> Selection of an exact radiation dose prescription and schedule of delivery </C> <E> depends on the primary tumor and neck node size, whether altered fractionation is used, and clinical circumstances, including whether concurrent systemic therapy will be used </E>. <CO> if it is prescribed very close to adjacent organs at risk </CO> <A> The dose may need to be decreased </A>. <CO> Anatomical changes (e.g., rapidly shrinking tumors, changes in air cavities, significant weight loss) </CO> <A> may necessitate repeat imaging and treatment replanning </A>. <CO> when the tumor is abutting brain or optic structures </CO> <A> hyperfractionation has been used </A>. <CO> if prescribed doses exceed 72 Gy using conventional fractionation </CO> <E> this may lead to unacceptable rates of normal tissue injury </E>. <A> Care must be taken </A>.\\n'}""",valid,increases risk,2,B,"edge - The edge which needs to be verified.
explanation - Explanation of what the edge represents and its validity.
causal_direction - Either Positive or Negative or Unknown. A positive influence direction indicates that both factors change in the same direction (e.g. an increase causes an increase effect). A negative influence direction indicates the opposite changes (e.g. an increase causes a decrease effect).
causal_factor - Is necessary or sufficient condition for an effect to occur. Exposure is a term commonly used in epidemiology to denote any condition that is considered as a possible cause of disease. Exposure is considered necessary when it always precedes the effects (e.g. symptoms) and always presents when the effects occur. A sufficient cause is a causal factor whose presence or occurrence guarantees the occurrence of symptom.
causal_distance - Either Distal or Proximal or Unknown. The distal factors lie towards the beginning of causal chain (i.e. indirect causal factors). The the proximal factors lie towards the end of the chain (i.e. cause directly or almost directly the effect).

Causality Tags:
<A> for action, <C> for cause, <CO> for condition and <E> for effect.
Cause (C): The reason or origin that leads to an effect. Causes often involve disease conditions, risk factors, or underlying mechanisms.
Effect (E): The outcome or result of a cause. Effects usually represent clinical outcomes, complications, or results of a specific cause.
Condition (CO): The circumstance or prerequisite required for an action or effect to occur. Conditions may include patient characteristics, clinical scenarios, or specific diagnostic criteria.
Action (A): The recommended or described response or activity to address a cause or condition. Actions typically involve clinical interventions, diagnostic procedures, or treatment recommendations.


`NODE1`:
id: Histological_Grade_of_Tumor_4
label: Histological Grade of Tumor 4
description: This node represents the histological grade of a tumor, specifically grade 4, which is a classification based on the microscopic appearance of tumor cells. The histological grade is an important factor in determining the aggressiveness of the tumor and its potential response to treatment. Grade 4 typically indicates poorly differentiated or undifferentiated tumor cells, suggesting a more aggressive and potentially less favorable prognosis.
type: Patient Situation
observability: Unobserved
states: [{'state_name': 'present', 'state_description': ""The state 'present' indicates that the tumor has been assessed and classified as histological grade 4, meaning the tumor cells are poorly differentiated or undifferentiated, which is associated with a more aggressive behavior.""}, {'state_name': 'absent', 'state_description': ""The state 'absent' indicates that the tumor is not classified as histological grade 4, suggesting that the tumor cells are not poorly differentiated or undifferentiated, which may be associated with a less aggressive behavior.""}]

`NODE2`:
id: N_State_1
label: Nearby Lymph Nodes Cancer State
description: This node represents the clinical situation regarding the presence or absence of cancer in nearby lymph nodes. It is a critical factor in cancer staging and prognosis, as the involvement of lymph nodes can indicate the spread of cancer and affect treatment decisions.
type: Decision Node
observability: Needs to be Predicted
states: [{'state_name': 'present', 'state_description': 'Cancer is present in the nearby lymph nodes, indicating potential metastasis and a more advanced stage of cancer.'}, {'state_name': 'absent', 'state_description': 'Cancer is absent in the nearby lymph nodes, suggesting that the cancer has not spread to these nodes and may be in an earlier stage.'}]

`EDGE1`:
{'edges_ids': ['Histological_Grade_of_Tumor_4', 'N_State_1'], 'edge': '(Histological_Grade_of_Tumor_4) causes (N_State_1)', 'explanation': ['The edge represents the causal relationship between the histological grade of a tumor (specifically grade 4) and the state of nearby lymph nodes.', 'Histological grade 4 indicates a poorly differentiated or undifferentiated tumor, which is more aggressive and likely to spread.', 'The presence of cancer in nearby lymph nodes (N_State_1) is a sign of metastasis and a more advanced stage of cancer.', 'A higher histological grade (such as grade 4) is associated with a higher likelihood of lymph node involvement, suggesting a causal relationship.', 'The causal direction is positive because a higher grade increases the likelihood of lymph node involvement.', 'The histological grade is not a necessary condition for lymph node involvement, as other factors can also cause this.', 'The histological grade might be considered a sufficient condition in some cases, as a very aggressive tumor (grade 4) could almost guarantee lymph node involvement.', ""The causal distance is proximal, as the histological grade directly affects the tumors behavior, which can directly lead to lymph node involvement.""], 'causal_direction': 'positive', 'causal_factor': {'necessary': False, 'sufficient': True}, 'causal_distance': 'Proximal'}

`EDGE2`:
{'edges_ids': ['N_State_1', 'Histological_Grade_of_Tumor_4'], 'edge': '(N_State_1) causes (Histological_Grade_of_Tumor_4)', 'explanation': ['The edge suggests that the state of nearby lymph nodes (N_State_1) causes the histological grade of a tumor to be grade 4 (Histological_Grade_of_Tumor_4).', 'However, the histological grade of a tumor is determined by the microscopic appearance of the tumor cells and is not directly influenced by the state of lymph nodes.', 'The state of lymph nodes is related to cancer staging and prognosis, but it does not determine the histological grade of the tumor.', 'Therefore, the edge is not valid as there is no direct causal relationship between the state of lymph nodes and the histological grade of the tumor.'], 'causal_direction': 'Unknown', 'causal_factor': {'necessary': False, 'sufficient': False}, 'causal_distance': 'Unknown'}

`INFORMATION FROM KNOWLEDGE BASE`:
--------------------------------------------------
Page Number: 130

Section Name: Pathological N (pN)
====================
Entities:-
Lymph Nodes : Small, bean-shaped structures that are part of the body's lymphatic system. They filter lymph fluid and store white blood cells that help fight infection.
Neoplasm Metastasis : The transfer of a neoplasm from one organ or part of the body to another remote from the primary site.
Tnm Staging : A system used to describe the size and spread of cancer in a standardized way. T refers to the size of the tumor, N to the involvement of lymph nodes, and M to metastasis.
Lymph Node Structure : A structure that is part of the lymphatic system, involved in the immune response.
Metastasis : The spread of a cancer or other disease from one organ or part to another not directly connected with it.
Tnm Staging System : A cancer staging notation system that describes the extent of cancer in a patient's body.
Lymph Node : An organ of the lymphatic system and the adaptive immune system.

Relationships:-
1. Entity1: ""Lymph Nodes"", Entity2: ""Neoplasm Metastasis"", Relationship: ""involved in""
2. Entity1: ""TNM Staging"", Entity2: ""Lymph Nodes"", Relationship: ""includes""
3. Entity1: ""TNM Staging"", Entity2: ""Neoplasm Metastasis"", Relationship: ""describes""

Causalities:-
<CO> NX: Regional lymph nodes cannot be assessed </CO>
<CO> N0: No regional lymph node metastasis </CO>
<CO> N1: Metastasis in a single ipsilateral lymph node, 3 cm or smaller in greatest dimension ENE(–) </CO>
<CO> N2: Metastasis in a single ipsilateral lymph node, 3 cm or smaller in greatest dimension and ENE(+); or larger than 3 cm but not larger than 6 cm in greatest dimension and ENE(−); or metastases in multiple ipsilateral lymph nodes, none larger than 6 cm in greatest dimension and ENE(−); or in bilateral or contralateral lymph node(s), none larger than 6 cm in greatest dimension and ENE(−) </CO>
<CO> N2a: Metastasis in a single ipsilateral node, 3 cm or smaller in greatest dimension and ENE(+); or metastasis in a single ipsilateral node, larger than 3 cm but not larger than 6 cm in greatest dimension and ENE(−) </CO>
<CO> N2b: Metastases in multiple ipsilateral nodes, none larger than 6 cm in greatest dimension and ENE(−) </CO>
<CO> N2c: Metastases in bilateral or contralateral lymph node(s), none larger than 6 cm in greatest dimension and ENE(−) </CO>
<CO> N3: Metastasis in a lymph node, larger than 6 cm in greatest dimension and ENE(−); or metastasis in a single ipsilateral node, larger than 3 cm in greatest dimension and ENE(+); or multiple ipsilateral, contralateral, or bilateral lymph nodes and any with ENE(+); or a single contralateral node of any size and ENE(+) </CO>
<CO> N3a: Metastasis in a lymph node, larger than 6 cm in greatest dimension and ENE(−) </CO>
<CO> N3b: Metastasis in a single ipsilateral node, larger than 3 cm in greatest dimension and ENE(+); or multiple ipsilateral, contralateral, or bilateral lymph nodes any with ENE(+); or a single contralateral node of any size and ENE(+) </CO>
<CO> Note: A designation of “U” or “L” may be used for any N category to indicate metastasis above the lower border of the cricoid (U) or below the lower border of the cricoid (L). Similarly, clinical and pathological ENE should be recorded as ENE(−) or ENE(+). </CO>

Section Name: Distant Metastasis (M)
====================
Entities:-
Neoplasm Metastasis : The transfer of a neoplasm from one organ or part of the body to another remote from the primary site.
Metastasis : The spread of a cancer or other disease from one organ or part to another not directly connected with it.

Relationships:-
1. Entity1: ""M0"", Entity2: ""Distant Metastasis"", Relationship: ""is a category of""
2. Entity1: ""M1"", Entity2: ""Distant Metastasis"", Relationship: ""is a category of""

Causalities:-
### Distant Metastasis (M)

- **M0**: No distant metastasis
- **M1**: Distant metastasis

Section Name: Histologic Grade (G)
====================
Entities:-
Neoplasm Grading : A system of classifying cancer cells in terms of how abnormal they look under a microscope and how quickly the tumor is likely to grow and spread.
Histologic Grade : A measure of how much tumor cells differ from healthy cells, used to assess the aggressiveness of cancer.

Relationships:-
1. Entity1: ""GX"", Entity2: ""Grade cannot be assessed"", Relationship: ""is described as""
2. Entity1: ""G1"", Entity2: ""Well differentiated"", Relationship: ""is described as""
3. Entity1: ""G2"", Entity2: ""Moderately differentiated"", Relationship: ""is described as""
4. Entity1: ""G3"", Entity2: ""Poorly differentiated"", Relationship: ""is described as""

Causalities:-
<CO>GX</CO>: <E>Grade cannot be assessed</E>
<CO>G1</CO>: <E>Well differentiated</E>
<CO>G2</CO>: <E>Moderately differentiated</E>
<CO>G3</CO>: <E>Poorly differentiated</E>

Section Name: Prognostic Stage Groups
====================
Entities:-
Neoplasm Staging : Methods and systems of classifying neoplasms according to extent of disease.
Tumor Staging : A system for describing the size and spread of cancer within the body.
Tnm Staging System : A cancer staging notation system that describes the extent of cancer in a patient's body.

Relationships:-
1. Entity1: ""Stage 0"", Entity2: ""Tis N0 M0"", Relationship: ""defined by""
2. Entity1: ""Stage I"", Entity2: ""T1 N0 M0"", Relationship: ""defined by""
3. Entity1: ""Stage II"", Entity2: ""T2 N0 M0"", Relationship: ""defined by""
4. Entity1: ""Stage III"", Entity2: ""T3 N0 M0, T1 N1 M0, T2 N1 M0, T3 N1 M0"", Relationship: ""defined by""
5. Entity1: ""Stage IVA"", Entity2: ""T1 N2 M0, T2 N2 M0, T3 N2 M0, T4a N0,N1,N2 M0"", Relationship: ""defined by""
6. Entity1: ""Stage IVB"", Entity2: ""Any T N3 M0, T4b Any N M0"", Relationship: ""defined by""
7. Entity1: ""Stage IVC"", Entity2: ""Any T Any N M1"", Relationship: ""defined by""
--------------------------------------------------
Page Number: 51

Section Name: Introduction
====================
Entities:-
Laryngeal Neoplasms : Tumors or cancer of the larynx, which may affect the supraglottic, glottic, or subglottic regions.
Malignant Neoplasm Of Supraglottis : A malignant tumor located in the supraglottic region of the larynx.
Supraglottic Laryngeal Cancer : A type of cancer that occurs in the supraglottic region of the larynx, which is above the vocal cords.

Relationships:-
1. Entity1: ""National Comprehensive Cancer Network (NCCN)"", Entity2: ""cancer of the supraglottic larynx"", Relationship: ""provides guidelines for""
2. Entity1: ""healthcare professionals"", Entity2: ""cancer of the supraglottic larynx"", Relationship: ""manage""

Causalities:-
The provided image is a detailed flowchart from the National Comprehensive Cancer Network (NCCN) guidelines regarding the <C> clinical staging and treatment protocols for cancer of the supraglottic larynx </C>. This flowchart is structured to <A> guide healthcare professionals through the stages of treatment </A> based on <CO> clinical findings </CO>, emphasizing the <E> complexity and systematic approach required in managing this type of cancer </E>.

Section Name: Clinical Staging
====================
Entities:-
Laryngectomy : A surgical procedure involving the removal of the larynx, usually to treat cancer of the larynx.
Total Laryngectomy : A surgical procedure to remove the entire larynx, often used in the treatment of advanced laryngeal cancer.
Neoplasm Staging : Methods used for staging neoplasms, including clinical and pathological staging.
Cancer Staging : The process of determining the extent of cancer in the body, often using the TNM system.
Tnm Staging System : A cancer staging system that describes the extent of cancer using Tumor size (T), Node involvement (N), and Metastasis (M).

Relationships:-
1. Entity1: ""Clinical staging criteria"", Entity2: ""Total laryngectomy"", Relationship: ""determines necessity of""
2. Entity1: ""T3, N0"", Entity2: ""Clinical staging criteria"", Relationship: ""is a categorization of""

Causalities:-
The flowchart begins with the <C> clinical staging criteria </C>, specifically focusing on <CO> cases that require total laryngectomy, denoted as requiring (amenable to) total laryngectomy (T3, N0) </CO>. This <A> categorization </A> is crucial as it <E> forms the basis for determining the appropriate treatment strategy </E>.

Section Name: Treatment of Primary and Neck
====================
Entities:-
Neoplasm Staging : Methods used for staging neoplasms, including clinical and pathological staging.
Systemic Therapy : Treatment using substances that travel through the bloodstream, reaching and affecting cells all over the body.
Radiotherapy : The use of high-energy radiation from x-rays, gamma rays, neutrons, protons, and other sources to kill cancer cells and shrink tumors.
Laryngectomy : A surgical procedure involving the removal of the larynx, usually to treat cancer of the larynx.
Thyroidectomy : A surgical procedure to remove all or part of the thyroid gland.
Neck Dissection : Surgical procedure to remove lymph nodes and surrounding tissue to treat or prevent cancer spread.
Lymphatic Metastasis : Transfer of a neoplasm from one organ or part of the body to another remote from the primary site.

Relationships:-
1. Entity1: ""Systemic Therapy"", Entity2: ""Radiation Therapy"", Relationship: ""combined with""
2. Entity1: ""Laryngectomy"", Entity2: ""Lymph Node Involvement"", Relationship: ""considered based on""
3. Entity1: ""Thyroidectomy"", Entity2: ""Lymph Node Involvement"", Relationship: ""considered based on""
4. Entity1: ""Neck Dissection"", Entity2: ""Lymph Node Involvement"", Relationship: ""considered based on""

Causalities:-
<CO> Once clinical staging is established </CO>, the chart outlines various treatment options. <A> The initial step may involve either concurrent systemic therapy combined with radiation therapy (RT) or opting for RT alone </A>, <CO> especially if the patient is not a medical candidate for both therapies </CO>. <A> Laryngectomy, thyroidectomy, and neck dissection are considered </A> <CO> based on the extent of lymph node involvement </CO>.

Section Name: Surgical Options
====================
Entities:-
Laryngectomy : A surgical procedure involving the removal of the larynx, usually to treat cancer of the larynx.
Thyroidectomy : A surgical procedure to remove all or part of the thyroid gland.
Lymph Node Excision : Surgical removal of one or more lymph nodes.
Lymphadenectomy : Surgical removal of one or more groups of lymph nodes.
Surgical Procedures, Operative : Operations carried out for the correction of deformities and defects, repair of injuries, and diagnosis and cure of certain diseases.
Surgical Procedure : A medical procedure involving an incision with instruments; performed to repair damage or arrest disease in a living body.
Surgery : Medical specialty that uses operative manual and instrumental techniques on a patient to investigate or treat a pathological condition such as a disease or injury.

Relationships:-
1. Entity1: ""Laryngectomy"", Entity2: ""Thyroidectomy"", Relationship: ""combined with""
2. Entity1: ""Lymph Node Dissection"", Entity2: ""Surgical Intervention"", Relationship: ""extent of""
3. Entity1: ""Surgical Intervention"", Entity2: ""Advanced Cases"", Relationship: ""management option for""

Causalities:-
<CO> If concurrent therapies are not suitable </CO>, <A> the chart presents laryngectomy combined with thyroidectomy </A>, <CO> depending on the extent of lymph node dissection required </CO>. <E> This highlights surgical intervention as a viable option in the management of advanced cases </E>.

Section Name: Induction Chemotherapy
====================
Entities:-
Induction Chemotherapy : Initial chemotherapy treatment used to shrink a tumor before the main treatment, which is usually surgery.
Surgical Procedure : A medical procedure involving an incision with instruments; performed to repair damage or arrest disease in a living body.
Therapeutic Approach : A method or strategy used in the treatment of disease or injury.

Relationships:-
1. Entity1: ""Induction Chemotherapy"", Entity2: ""Surgical Intervention"", Relationship: ""alternative or sequential treatment option""

Causalities:-
<C> immediate surgical intervention is either not feasible or considered insufficient </C> <E> The flowchart also considers the option of induction chemotherapy </E> <CO> in cases where immediate surgical intervention is either not feasible or considered insufficient </CO>. <A> tailoring therapeutic approaches tailored to individual patient needs </A>.

Section Name: Adjuvant Treatment
====================
Entities:-
Adjuvant Chemotherapy : Chemotherapy given in addition to the primary treatment to maximize its effectiveness.
Radiotherapy : The use of high-energy radiation from x-rays, gamma rays, neutrons, protons, and other sources to kill cancer cells and shrink tumors.
Neoplasm Recurrence, Local : The return of a cancer, at the same site, after it has been treated.
Disease Progression : The worsening of a disease over time.

Relationships:-
1. Entity1: ""Primary Treatment"", Entity2: ""Adjuvant Treatment"", Relationship: ""followed by""
2. Entity1: ""Adjuvant Treatment"", Entity2: ""Systemic Therapy"", Relationship: ""includes""
3. Entity1: ""Adjuvant Treatment"", Entity2: ""Radiotherapy"", Relationship: ""includes""
4. Entity1: ""Follow-up Assessments"", Entity2: ""Treatment Efficacy"", Relationship: ""used to evaluate""

Causalities:-
<C> Following primary treatment </C>, <E> the flowchart addresses the potential for adjuvant treatment pathways </E>. This may include systemic therapy, RT, or further evaluations based on <CO> the patient's response and any recurrence or persistent disease </CO>. It emphasizes <A> the need for follow-up assessments to evaluate treatment efficacy </A>.

Section Name: Risk Features and Response Assessment
====================
Entities:-
Neoplasm Invasiveness : The property of a neoplasm to infiltrate and destroy surrounding tissue.
Surgical Margins : The edge or border of the tissue removed in cancer surgery.
Neoplasms : Neoplasms are abnormal growths of tissue, which can be cancerous or non-cancerous.
Extramural Extension : Extension of a tumor beyond the wall of an organ.
Positive Surgical Margin : Cancer cells are present at the edge of the tissue removed during surgery.
Cancer Management : The process of planning and coordinating the treatment of cancer.
Cancer : Cancer is a group of diseases involving abnormal cell growth with the potential to invade or spread to other parts of the body.

Relationships:-
1. Entity1: ""Extramural extension"", Entity2: ""Treatment decisions"", Relationship: ""influences""
2. Entity1: ""Positive surgical margin"", Entity2: ""Treatment decisions"", Relationship: ""influences""
3. Entity1: ""Ongoing assessment"", Entity2: ""Response evaluation"", Relationship: ""leads to""
4. Entity1: ""Response evaluation"", Entity2: ""Adjustments to treatment"", Relationship: ""leads to""
5. Entity1: ""Management of cancer"", Entity2: ""Treatment decisions"", Relationship: ""involves""
6. Entity1: ""Management of cancer"", Entity2: ""Ongoing assessment"", Relationship: ""involves""
7. Entity1: ""Management of cancer"", Entity2: ""Adjustments to treatment"", Relationship: ""involves""

Causalities:-
The chart incorporates a segment that takes into account <CO> adverse pathologic features, such as extramural extension or positive margins </CO>, <E> which could influence subsequent treatment decisions </E>. This highlights the importance of <A> ongoing assessment in the management of cancer, leading to response evaluation and adjustments to treatment as necessary </A>.

Section Name: NCCN Guidelines Version 4.2024
====================
Entities:-
Clinical Trials : Clinical trials are research studies performed in people that are aimed at evaluating a medical, surgical, or behavioral intervention.
Neoplasms : Neoplasms are abnormal growths of tissue, which can be cancerous or non-cancerous.
Clinical Trial : A clinical trial is a research study that prospectively assigns human participants or groups of humans to one or more health-related interventions to evaluate the effects on health outcomes.
Malignant Neoplasm : A malignant neoplasm is a cancerous growth that has the potential to invade and destroy nearby tissue and spread to other parts of the body.
National Comprehensive Cancer Network : The National Comprehensive Cancer Network (NCCN) is an alliance of 31 cancer centers in the United States, dedicated to improving the quality, effectiveness, and efficiency of cancer care.
Cancer : Cancer is a group of diseases involving abnormal cell growth with the potential to invade or spread to other parts of the body.

Relationships:-
1. Entity1: ""National Comprehensive Cancer Network"", Entity2: ""NCCN Guidelines"", Relationship: ""provides""
2. Entity1: ""NCCN Guidelines"", Entity2: ""Clinical Trials"", Relationship: ""recommend""
3. Entity1: ""NCCN Guidelines"", Entity2: ""Cancer"", Relationship: ""related to management of""

Causalities:-
<CO> any patient with cancer </CO> <A> the best management is in a clinical trial </A>. <A> Participation in clinical trials is especially encouraged </A>.

Section Name: SUPRA-3
====================
Entities:-
Laryngectomy : A surgical procedure involving the removal of the larynx, usually to treat cancer of the larynx.
Thyroidectomy : A surgical procedure to remove all or part of the thyroid gland.
Neck Dissection : Surgical procedure to remove lymph nodes and surrounding tissue to treat or prevent cancer spread.
Chemotherapy, Induction : Initial chemotherapy treatment to shrink a tumor before the main treatment.
Clinical Trials As Topic : Research studies that prospectively assign human participants or groups of humans to one or more health-related interventions to evaluate the effects on health outcomes.
Induction Chemotherapy : Initial chemotherapy treatment used to shrink a tumor before the main treatment, which is usually surgery.
Clinical Trial : A clinical trial is a research study that prospectively assigns human participants or groups of humans to one or more health-related interventions to evaluate the effects on health outcomes.

Relationships:-
1. Entity1: ""Total laryngectomy"", Entity2: ""Laryngectomy"", Relationship: ""is a type of""
2. Entity1: ""Systemic therapy"", Entity2: ""RT"", Relationship: ""concurrent treatment option""
3. Entity1: ""Induction chemotherapy"", Entity2: ""Other treatments"", Relationship: ""initial treatment option before""

Causalities:-
<CO> Requiring (amenable to) total laryngectomy (T3,N0) </CO>
  - <A> Concurrent systemic therapy/RT </A> or <A> RT if patient not medical candidate for concurrent systemic therapy/RT </A>
  - <A> Laryngectomy, thyroidectomy and with ipsilateral, central, or bilateral neck dissection </A>
  - or
  - <A> Induction chemotherapy </A>
  - or
  - <A> Clinical trials </A>

Section Name: Follow-up
====================
Entities:-
Follow-Up Studies : Studies in which individuals are followed over time to determine the outcome of exposures, treatments, or interventions.
Follow-Up Procedure : A procedure performed to monitor the progress of a patient's condition after initial treatment.
Follow-Up : Medical care given to a patient over time after initial treatment.
Disease Recurrence : The return of a sign, symptom, or disease after a remission.
Recurrent Disease : The reappearance of a disease after a period of improvement.

Relationships:-
1. Entity1: ""Follow-up"", Entity2: ""Recurrent or persistent disease"", Relationship: ""monitoring""

Causalities:-
- **Follow-up (FOLL-A, 1 of 2)**
  - <CO> Recurrent or persistent disease </CO> (ADV-3)

Section Name: Adverse Pathologic Features
====================
Entities:-
Radiotherapy : The use of high-energy radiation from x-rays, gamma rays, neutrons, protons, and other sources to kill cancer cells and shrink tumors.
Extranodal Extension : The spread of cancer beyond the lymph node capsule.
Positive Surgical Margin : Cancer cells are present at the edge of the tissue removed during surgery.
Systemic Therapy : Treatment using substances that travel through the bloodstream, reaching and affecting cells all over the body.

Relationships:-
1. Entity1: ""pN1"", Entity2: ""Radiotherapy"", Relationship: ""Consideration for treatment""
2. Entity1: ""Extranodal extension"", Entity2: ""Systemic Therapy"", Relationship: ""Treatment option""
3. Entity1: ""Extranodal extension"", Entity2: ""Radiotherapy"", Relationship: ""Treatment option""
4. Entity1: ""Positive surgical margin"", Entity2: ""Systemic Therapy"", Relationship: ""Treatment option""
5. Entity1: ""Positive surgical margin"", Entity2: ""Radiotherapy"", Relationship: ""Treatment option""

Causalities:-
- <CO>pN1 without other risk features</CO>
  - <C>Adverse pathologic features</C>
  - <A>Consider RT</A>
  - <CO>Extranodal extension and/or positive margin</CO>
  - <CO>Other risk features</CO>
  - <A>Systemic therapy/RT (category 1)</A>
  - <A>RT or Consider systemic therapy/RT</A>

Section Name: Response Assessment
====================
Entities:-
Response Evaluation : The process of assessing the response of a disease to treatment, often used in clinical trials to determine the effectiveness of a therapy.
Response To Treatment : A clinical finding indicating the response of a condition to a therapeutic intervention.

Relationships:-

Section Name: Principles of Surgery and Radiation Therapy
====================
Entities:-
Surgical Procedures, Operative : Operations carried out for the correction of deformities and defects, repair of injuries, and diagnosis and cure of certain diseases.
Surgical Procedure : A medical procedure involving an incision with instruments; performed to repair damage or arrest disease in a living body.
Surgery : Medical specialty that uses operative manual and instrumental techniques on a patient to investigate or treat a pathological condition such as a disease or injury.
Radiotherapy : The use of high-energy radiation from x-rays, gamma rays, neutrons, protons, and other sources to kill cancer cells and shrink tumors.
Radiation Therapy : Radiation therapy is a therapy using ionizing radiation, generally as part of cancer treatment to control or kill malignant cells.

Relationships:-
1. Entity1: ""Principles of Surgery"", Entity2: ""Principles of Radiation Therapy"", Relationship: ""complementary treatments""

Causalities:-
**Principles of Surgery (SURG-A).**

**Principles of Radiation Therapy (SUPRA-A).**

Section Name: Principles of Systemic Therapy
====================
Entities:-
Cisplatin : An inorganic and water-soluble platinum complex, cisplatin is an antineoplastic agent that is used in the treatment of various cancers.
Radiotherapy : The use of high-energy radiation from x-rays, gamma rays, neutrons, protons, and other sources to kill cancer cells and shrink tumors.
Radiation Therapy : Radiation therapy is a therapy using ionizing radiation, generally as part of cancer treatment to control or kill malignant cells.

Relationships:-
1. Entity1: ""Cisplatin"", Entity2: ""Systemic Therapy for Non-Nasopharyngeal Cancers"", Relationship: ""preferred agent""
2. Entity1: ""Cisplatin"", Entity2: ""Concurrent Systemic Therapy/RT"", Relationship: ""used in""

Causalities:-
<CO> When using concurrent systemic therapy/RT </CO>, <A> the preferred agent is cisplatin (category 1) </A>.
--------------------------------------------------
Page Number: 55

Section Name: General Information
====================
Entities:-
National Comprehensive Cancer Network : An alliance of 32 cancer centers in the United States, dedicated to improving the quality, effectiveness, and efficiency of cancer care.
Nccn Guidelines : Clinical practice guidelines in oncology developed by the National Comprehensive Cancer Network.

Relationships:-
1. Entity1: ""NCCN Guidelines"", Entity2: ""National Comprehensive Cancer Network"", Relationship: ""produced by""

Section Name: Important Notes
====================
Entities:-
Clinical Trials As Topic : Works about research studies that evaluate the effectiveness and safety of medical, surgical, or behavioral interventions.
Clinical Trial : A type of research that studies new tests and treatments and evaluates their effects on human health outcomes.
National Comprehensive Cancer Network : An alliance of 32 cancer centers in the United States, dedicated to improving the quality, effectiveness, and efficiency of cancer care.
Neoplasms : New abnormal growth of tissue that can be benign or malignant.
Malignant Neoplastic Disease : A disease resulting from the growth of malignant neoplasms.
Cancer : A group of diseases involving abnormal cell growth with the potential to invade or spread to other parts of the body.

Relationships:-
1. Entity1: ""Clinical Trials"", Entity2: ""Cancer"", Relationship: ""recommended for""
2. Entity1: ""NCCN"", Entity2: ""Clinical Trials"", Relationship: ""encourages participation in""

Causalities:-
<C> NCCN believes that the best management of any patient with cancer is in a clinical trial </C>. <A> Participation in clinical trials is especially encouraged </A>.

Section Name: Principles
====================
Entities:-
Surgical Procedures, Operative : Surgical procedures involve the use of operative manual and instrumental techniques on a patient to investigate or treat a pathological condition such as disease or injury.
Radiation Therapy : Therapy using ionizing radiation, generally as part of cancer treatment to control or kill malignant cells.
Chemotherapy : A type of cancer treatment that uses one or more anti-cancer drugs as part of a standardized chemotherapy regimen.

Relationships:-
1. Entity1: ""Principles of Surgery"", Entity2: ""Principles of Radiation Therapy"", Relationship: ""Both are principles of cancer treatment methods.""
2. Entity1: ""Principles of Surgery"", Entity2: ""Principles of Systemic Therapy for Non-Nasopharyngeal Cancers"", Relationship: ""Both are principles of cancer treatment methods.""
3. Entity1: ""Principles of Radiation Therapy"", Entity2: ""Principles of Systemic Therapy for Non-Nasopharyngeal Cancers"", Relationship: ""Both are principles of cancer treatment methods.""

Causalities:-
### Principles

- **Principles of Surgery (SURG-A)**
- **Principles of Radiation Therapy (SUPRA-A)**
- **Principles of Systemic Therapy for Non-Nasopharyngeal Cancers (SYST-A)**

Section Name: Adverse Pathologic Features
====================
Entities:-
Extranodal Extension : The spread of cancer cells beyond the lymph node capsule into the surrounding tissues.
Positive Surgical Margin : The presence of cancer cells at the edge of the tissue removed during surgery, indicating that some cancer may have been left behind.
Perineural Invasion : The presence of cancer cells surrounding or tracking along a nerve within the perineural space.
Vascular Invasion : The invasion of cancer cells into blood vessels.
Lymphatic Invasion : The invasion of cancer cells into lymphatic vessels.

Relationships:-
1. Entity1: ""Extranodal extension"", Entity2: ""Adverse Pathologic Features"", Relationship: ""is a type of""
2. Entity1: ""Positive margins"", Entity2: ""Adverse Pathologic Features"", Relationship: ""is a type of""
3. Entity1: ""Close margins"", Entity2: ""Adverse Pathologic Features"", Relationship: ""is a type of""
4. Entity1: ""pT3 or pT4 primary"", Entity2: ""Adverse Pathologic Features"", Relationship: ""is a type of""
5. Entity1: ""pN2 or pN3 nodal disease"", Entity2: ""Adverse Pathologic Features"", Relationship: ""is a type of""
6. Entity1: ""Perineural invasion"", Entity2: ""Adverse Pathologic Features"", Relationship: ""is a type of""
7. Entity1: ""Vascular invasion"", Entity2: ""Adverse Pathologic Features"", Relationship: ""is a type of""
8. Entity1: ""Lymphatic invasion"", Entity2: ""Adverse Pathologic Features"", Relationship: ""is a type of""

Causalities:-
<C> Extranodal extension </C>
<C> Positive margins </C>
<C> Close margins </C>
<C> pT3 or pT4 primary </C>
<C> pN2 or pN3 nodal disease </C>
<C> Perineural invasion </C>
<C> Vascular invasion </C>
<C> Lymphatic invasion </C>

Section Name: Response Assessment
====================
Entities:-
Chemotherapy, Induction : Initial chemotherapy treatment to shrink a tumor before the main treatment.
Primary Site : The original location where a tumor or cancer begins.
Complete Remission : The disappearance of all signs of cancer in response to treatment.
Partial Remission : A decrease in the size of a tumor, or in the extent of cancer in the body, in response to treatment.
Radiotherapy : The use of high-energy radiation to kill cancer cells and shrink tumors.
Surgical Procedures, Operative : Surgical procedures involve the use of operative manual and instrumental techniques on a patient to investigate or treat a pathological condition such as disease or injury.

Relationships:-
1. Entity1: ""induction chemotherapy"", Entity2: ""Primary site"", Relationship: ""treatment outcome""
2. Entity1: ""Definitive RT"", Entity2: ""Primary site"", Relationship: ""treatment option""
3. Entity1: ""RT"", Entity2: ""Primary site"", Relationship: ""treatment option""
4. Entity1: ""Surgery"", Entity2: ""unresectable nodal disease"", Relationship: ""treatment option""

Causalities:-
<C> Response after induction chemotherapy </C>: <E> Primary site: CR </E> <E> Primary site: PR </E> <E> Primary site: < PR </E> <A> Definitive RT </A> (category 1) <A> RT </A> (category 1) or <A> systemic therapy/RT </A> (category 2B) <A> Surgery </A> or <A> unresectable nodal disease </A>

Section Name: Follow-up
====================
Entities:-
Follow-Up Studies : Studies in which individuals are followed over time to determine the outcome of exposures, treatments, or interventions.
Follow-Up Procedure : A procedure where a patient is monitored over time to assess the progress of a condition or the effects of treatment.
Follow-Up (Medicine) : The process of monitoring a patient's health over time after treatment or diagnosis.
Disease Recurrence : The return of a sign, symptom, or disease after a remission.
Recurrent Disease : A disease that returns after a period of remission.
Recurrence (Medicine) : The return of a disease or condition after a period of improvement.

Relationships:-
1. Entity1: ""Follow-up"", Entity2: ""Recurrent or persistent disease"", Relationship: ""monitoring""

Causalities:-
### Follow-up

- **Follow-up** (FOLL-A, 1 of 2)
- **Recurrent or persistent disease** (ADV-3)

Section Name: Risk Features
====================
Entities:-
Radiotherapy : The use of high-energy radiation to kill cancer cells and shrink tumors.
Extranodal Extension : The spread of cancer cells beyond the lymph node capsule into the surrounding tissues.
Positive Surgical Margin : The presence of cancer cells at the edge of the tissue removed during surgery, indicating that some cancer may have been left behind.
Systemic Therapy : Systemic therapy refers to treatment using substances that travel through the bloodstream, reaching and affecting cells all over the body.

Relationships:-
1. Entity1: ""Adverse pathologic features"", Entity2: ""RT"", Relationship: ""Consideration for treatment""
2. Entity1: ""Adverse pathologic features"", Entity2: ""Systemic therapy"", Relationship: ""Consideration for treatment""

Causalities:-
- **No adverse pathologic features**
- **Other risk features**
- **Adverse pathologic features**:
  - <C> Extranodal extension and/or positive margin </C>
  - <A> RT or consider systemic therapy/RT </A>

Section Name: Post-Therapy Evaluation
====================
Entities:-
Systemic Therapy : Systemic therapy refers to treatment using substances that travel through the bloodstream, reaching and affecting cells all over the body.
Radiation Therapy : Therapy using ionizing radiation, generally as part of cancer treatment to control or kill malignant cells.
Neck : The neck is the part of the body that separates the head from the torso and provides the mobility and movements of the head.

Relationships:-
1. Entity1: ""Systemic Therapy"", Entity2: ""Neck Evaluation"", Relationship: ""evaluated in""
2. Entity1: ""RT"", Entity2: ""Neck Evaluation"", Relationship: ""evaluated in""

Causalities:-
<CO> Post Systemic Therapy/RT or RT Neck </CO> <A> Evaluation </A>

Section Name: Flowchart Overview
====================
Entities:-
Laryngeal Neoplasms : Tumors or cancer of the larynx, which may affect the supraglottic, glottic, or subglottic regions.
Supraglottic Larynx : The part of the larynx located above the vocal cords, including the epiglottis and aryepiglottic folds.
National Comprehensive Cancer Network : An alliance of 32 cancer centers in the United States, dedicated to improving the quality, effectiveness, and efficiency of cancer care.

Relationships:-
1. Entity1: ""NCCN Guidelines"", Entity2: ""cancer of the supraglottic larynx"", Relationship: ""guides management of""
2. Entity1: ""NCCN Guidelines"", Entity2: ""healthcare professionals"", Relationship: ""used by""

Causalities:-
<C> cancer of the supraglottic larynx </C> <E> evaluate patient responses following treatment </E> <CO> based on observed outcomes </CO> <A> evaluation of the primary site and determining subsequent steps </A>.

Section Name: Assessment and Treatment Decisions
====================
Entities:-
Induction Chemotherapy : Initial chemotherapy treatment to shrink a tumor before the main treatment.
Complete Response : The disappearance of all signs of cancer in response to treatment.
Partial Response : A decrease in the size of a tumor, or in the extent of cancer in the body, in response to treatment.
Radiation Therapy : Therapy using ionizing radiation, generally as part of cancer treatment to control or kill malignant cells.
Surgery : Medical specialty that uses operative manual and instrumental techniques on a patient to investigate or treat a pathological condition such as disease or injury.
Systemic Therapy : Systemic therapy refers to treatment using substances that travel through the bloodstream, reaching and affecting cells all over the body.

Relationships:-
1. Entity1: ""Complete Response"", Entity2: ""Radiation Therapy"", Relationship: ""leads to""
2. Entity1: ""Complete Response"", Entity2: ""Surgery"", Relationship: ""leads to""
3. Entity1: ""Partial Response"", Entity2: ""Systemic Therapy"", Relationship: ""leads to""
4. Entity1: ""Partial Response"", Entity2: ""Radiation Therapy"", Relationship: ""leads to""

Causalities:-
<C> responses to initial treatments such as induction chemotherapy </C> <E> Three main response categories are recognized: Complete Response (CR), Partial Response (PR), and less than Partial Response (< PR) </E>. These categories are pivotal in determining the next steps. <C> CR </C> <E> indicates full resolution of the disease at the primary site </E>, <A> leading to the consideration of definitive radiation therapy or the likelihood of surgery </A>. Conversely, <C> PR </C> <E> suggests that the disease has improved but not completely resolved </E>, <A> which directs the pathway towards either systemic therapy or continued radiation therapy </A>, <A> with further evaluation necessary </A>.

Section Name: Adverse Pathologic Features and Follow-up
====================
Entities:-
Radiation Therapy : Therapy using ionizing radiation, generally as part of cancer treatment to control or kill malignant cells.
Surgical Procedures, Operative : Surgical procedures involve the use of operative manual and instrumental techniques on a patient to investigate or treat a pathological condition such as disease or injury.
Neoplasm Recurrence, Local : The return of a tumor or cancer, at the original site, after it has been treated.
Neoplasm Metastasis : The transfer of a neoplasm from one organ or part of the body to another remote from the primary site.
Surgical Procedure : A medical procedure involving an incision with instruments; performed to repair damage or arrest disease in a living body.
Recurrent Neoplasm : A neoplasm that has returned after treatment.
Metastatic Neoplasm : A neoplasm that has spread from its original site to one or more other places in the body.
Surgery : Medical specialty that uses operative manual and instrumental techniques on a patient to investigate or treat a pathological condition such as disease or injury.
Cancer Recurrence : The return of cancer after treatment and after a period of time during which the cancer was undetectable.
Metastasis : Spread of a cancer or other disease from one organ or part to another not directly connected with it.

Relationships:-
1. Entity1: ""Adverse pathologic features"", Entity2: ""Treatment decisions"", Relationship: ""Influence""
2. Entity1: ""Adverse features"", Entity2: ""Surgical intervention"", Relationship: ""Recommendation""
3. Entity1: ""Absence of adverse features"", Entity2: ""Radiation therapy"", Relationship: ""Pathway""
4. Entity1: ""Follow-up process"", Entity2: ""Recurrent or persistent disease"", Relationship: ""Detection""
5. Entity1: ""Recurrent or persistent disease"", Entity2: ""Advanced disease management"", Relationship: ""Necessity""

Causalities:-
<C> The presence of adverse pathologic features — such as extranodal extension or positive margins </C> <E> can directly influence treatment decisions </E>. <CO> If adverse features are found </CO>, <A> surgical intervention is recommended </A>. <CO> In cases where there are no adverse features </CO>, the patient may proceed directly to radiation therapy or continued systemic treatment, emphasizing the tailored approach based on the individual patient's disease characteristics.

Furthermore, the chart includes a section addressing the follow-up process after initial treatment. <CO> If there are signs of recurrent or persistent disease </CO>, <A> additional evaluations and treatment modalities may be necessary </A>. These evaluations <E> lead to specific recommendations for advanced disease management, denoted as ADV-3 on the chart </E>, emphasizing the importance of continuous monitoring and assessment in cancer care.
--------------------------------------------------
Page Number: 102

Section Name: Head and Neck Cancers - Principles of Surgery
====================
Entities:-
Surgical Procedures, Operative : Manual or operative procedures used in the treatment of disease, injuries, or deformities.
Lymphatic System : Part of the circulatory system and a vital part of the immune system, comprising a network of lymphatic vessels that carry a clear fluid called lymph.
Neoplasms : New abnormal growth of tissue in animals or plants; a tumor.
Neck Dissection : A surgical procedure for control of neck lymph node metastasis from squamous cell carcinoma of the head and neck.
Neoplasm Staging : Methods which attempt to express in replicable terms the extent of the neoplasm in the patient.
Metastasis : The spread of a cancer or other disease from one organ or part of the body to another not directly connected with it.
Surgical Procedure : A procedure involving an incision with instruments; performed to repair damage or arrest disease in a living body.
Lymphatic Structure : Anatomical structure that is part of the lymphatic system.
Tumor : An abnormal mass of tissue that results when cells divide more than they should or do not die when they should.
Staging : The process of determining the size and spread of cancer within the body.
Surgery : Medical specialty that uses operative manual and instrumental techniques on a patient to investigate or treat a pathological condition such as disease or injury.
Cancer Staging : The process of determining the extent to which a cancer has developed by growing and spreading.

Relationships:-
1. Entity1: ""surgical management"", Entity2: ""regional lymphatics"", Relationship: ""dictated by tumor staging""
2. Entity1: ""neck dissections"", Entity2: ""primary tumor"", Relationship: ""part of treatment""
3. Entity1: ""surgery"", Entity2: ""ipsilateral side of the neck"", Relationship: ""risk for metastases""

Causalities:-
<C> The extent of the tumor at initial tumor staging </C> <E> dictates the surgical management of regional lymphatics </E>. These guidelines apply to the performance of neck dissections as part of treatment of the primary tumor. <CO> Patients undergoing surgery for resection of the primary tumor </CO> <A> will undergo dissection of the ipsilateral side of the neck that is at greatest risk for metastases </A>.

Section Name: Neck Management
====================
Entities:-
Tongue : A muscular organ in the mouth that is involved in tasting, swallowing, and speech.
Palate : The roof of the mouth, separating the oral and nasal cavities.
Larynx : An organ in the top of the neck involved in breathing, producing sound, and protecting the trachea.
Hypopharynx : The bottom part of the pharynx, which is the cavity behind the nose and mouth.
Nasopharynx : The upper part of the pharynx, connecting with the nasal cavity above the soft palate.
Neck Dissection : A surgical procedure for control of neck lymph node metastasis from squamous cell carcinoma of the head and neck.
Metastasis : The spread of a cancer or other disease from one organ or part of the body to another not directly connected with it.
Squamous Cell Carcinoma : A type of cancer that begins in the squamous cells, which are thin, flat cells that look like fish scales.
Biopsy : The removal of cells or tissues for examination under a microscope.

Relationships:-
1. Entity1: ""Tumor sites"", Entity2: ""Bilateral lymphatic drainage"", Relationship: ""associated with""
2. Entity1: ""Elective neck dissection"", Entity2: ""Risk of occult metastasis"", Relationship: ""based on""
3. Entity1: ""SLN biopsy"", Entity2: ""Elective neck dissection"", Relationship: ""guides decision-making for""

Causalities:-
- **<C> Tumor sites that frequently have bilateral lymphatic drainage </C>** (e.g., base of tongue, palate, supraglottic larynx, hypopharynx, nasopharynx, deep pre-epiglottic space involvement) <E> often should have both sides of the neck dissected </E> with the extent of dissection determined as suggested below. For those patients with tumors at or approaching the midline, <CO> both sides of the neck are at risk for metastases </CO>, and <A> bilateral neck dissections should be performed </A>.

- <CO> Patients with advanced lesions involving the anterior tongue, floor of the mouth, or alveolus that approximate or cross the midline </CO> <A> should undergo contralateral selective/modified neck dissection </A> as necessary to achieve adequate tumor resection.

- **<C> Elective neck dissection </C>** <A> should be based on risk of occult metastasis in the appropriate nodal basin </A>. For oral cavity squamous cell carcinoma, <C> SLN biopsy or the primary tumor depth of invasion </C> is currently <E> the best predictor of occult metastatic disease </E> and <A> should be used to guide decision-making </A>. <CO> For tumors with a depth greater than 3 mm </CO>, <A> elective dissection should be strongly considered if RT is not already planned </A>. Recent randomized trial evidence supports the effectiveness of elective neck dissection in patients with oral cavity cancers greater than 3 mm in depth of invasion.

  - <CO> For a depth less than 2 mm </CO>, <A> elective dissection is only indicated in highly selective situations </A>. <CO> For a depth of 2–4 mm </CO>, <A> clinical judgment (as to reliability of follow-up, clinical suspicion, and other factors) must be utilized to determine appropriateness of elective dissection </A>. Elective dissections are generally selective, preserving all major structures, unless operative findings dictate otherwise.

Section Name: Types of Neck Dissection
====================
Entities:-
Neck Dissection : A surgical procedure for control of neck lymph node metastasis from squamous cell carcinoma of the head and neck.
Larynx : An organ in the top of the neck involved in breathing, producing sound, and protecting the trachea.

Relationships:-
1. Entity1: ""N0"", Entity2: ""Selective neck dissection"", Relationship: ""associated with""
2. Entity1: ""N3"", Entity2: ""Comprehensive neck dissection"", Relationship: ""associated with""
3. Entity1: ""Level VI neck dissection"", Entity2: ""Larynx"", Relationship: ""performed for""
4. Entity1: ""Level VI neck dissection"", Entity2: ""Hypopharynx"", Relationship: ""performed for""

Causalities:-
- **The type of neck dissection (comprehensive or selective)** is defined according to <CO> preoperative clinical staging </CO>, is determined at the discretion of the surgeon, and is based on the initial preoperative staging as follows:
  - **N0:** <A> Selective neck dissection </A>
    - Oral cavity at least levels I–III
    - Oropharynx at least levels II–IV
    - Hypopharynx at least levels II–IV and level VI when appropriate
    - Larynx at least levels II–IV and level VI when appropriate
  - **N1–N2a–c:** <A> Selective or comprehensive neck dissection </A> (Discussion)
  - **N3:** <A> Comprehensive neck dissection </A>

- <C> Level VI neck dissections are performed for certain primary sites (such as the larynx and hypopharynx) </C> <E> as required to resect the primary tumor and any clinically evident neck nodes </E>. <CO> Elective dissection depends on primary tumor extent and site </CO>. <CO> For advanced glottic and hypopharyngeal cancers treated with primary surgery </CO>, <A> a level VI dissection (including pretracheal lymph nodes, the Delphian lymph node, and unilateral or bilateral paratracheal lymph nodes) and hemithyroidectomy to total thyroidectomy are appropriate </A>.

- <CO> For primary subglottic tumors or glottic cancers with significant subglottic extension </CO>, <A> a level VI dissection with unilateral or total thyroidectomy is considered appropriate </A> based on the extent of the primary tumor. <CO> For example, a T4a glottic tumor with extension through the cricothyroid membrane and subglottic extension </CO> <A> should include thyroidectomy and pretracheal and bilateral paratracheal lymph node dissection </A>. <A> Parathyroid glands should be preserved in situ or auto transplanted as indicated </A>.
--------------------------------------------------
Page Number: 154

Section Name: NCCN Guidelines Version 4.2024
====================
Entities:-
Nccn Guidelines : The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) are a comprehensive set of guidelines detailing the sequential management decisions and interventions that apply to 97% of cancers affecting patients in the United States.

Relationships:-

Causalities:-
# NCCN Guidelines Version 4.2024

Section Name: Head and Neck Cancers
====================
Entities:-
Head And Neck Neoplasms : Tumors or cancer of the head and neck region, including the nasal cavity, sinuses, lips, mouth, salivary glands, throat, or larynx.
Radiation Therapy : The medical use of ionizing radiation, generally as part of cancer treatment to control or kill malignant cells.
Quad Shot Regimen : A palliative radiation therapy regimen consisting of 44.4 Gy delivered in 12 fractions over three cycles, used for patients with limited life expectancy.

Relationships:-
1. Entity1: ""Head and Neck Neoplasms"", Entity2: ""70 Gy"", Relationship: ""treatment dosage""
2. Entity1: ""QUAD SHOT regimen"", Entity2: ""Palliative Treatment"", Relationship: ""purpose""

Causalities:-
The College of Radiology describes basic technical specifications [here](http://www.acr.org/Quality-Safety). Furthermore, major consensus contouring guidelines for the treatment of head and neck (H&N) cancers are available for reference, especially for patients who are treated without surgery. [143,144]

When radiation is given with definitive intent, <A> the dosages prescribed for gross disease are fairly standard, usually in the range of 70 Gy (at approximately 2 Gy/fraction/day) </A> for the following sites: <CO> lip, oral cavity, nasopharynx, oropharynx, hypopharynx, glottic larynx, supraglottic larynx, occult primary, salivary gland tumors, and MM </CO>. A second dose (often approximately 60 Gy, but varies) may be used to cover volumes considered at the highest risk for microscopic spread, while a lower dose (often approximately 50 Gy, but varies) is used for volumes treated electively with low risk for microscopic spread.

Although several palliative RT regimens are provided, no single regimen is preferred [145,146]; specific regimens vary widely among NCCN Member Institutions. <A> Any palliative RT regimen that might cause severe toxicities should be avoided </A>. <A> More hypofractionated regimens may be useful </A> for <CO> patients with limited life expectancy, such as a few months </CO>. For example, <A> a common version of the QUAD SHOT regimen consists of a dose of 44.4 Gy, delivered in 12 fractions over three cycles, with each cycle separated by 2 to 3 weeks </A>. [147]

Section Name: Radiation Doses
====================
Entities:-
Radiation Dosage : The amount of radiation absorbed by an object or person.
Neoplasms : New abnormal growth of tissue that can be benign or malignant.
Lymph Nodes : Small, bean-shaped structures that are part of the body's immune system.
Radiotherapy : The treatment of disease, especially cancer, using X-rays or similar forms of radiation.
Chemotherapy : The use of chemical substances, especially the treatment of cancer by cytotoxic and other drugs.
Radiation Therapy : The medical use of ionizing radiation, generally as part of cancer treatment to control or kill malignant cells.
Lymph Node Structure : A structure that is part of the lymphatic system, involved in the immune response.
Neoplasm : An abnormal mass of tissue as a result of neoplasia.
Lymph Node : An organ of the lymphatic system and the adaptive immune system.
Tumor : A mass of tissue that's formed by an accumulation of abnormal cells.

Relationships:-
1. Entity1: ""Radiation Dosage"", Entity2: ""Neoplasms"", Relationship: ""depends on""
2. Entity1: ""Radiation Dosage"", Entity2: ""Organs at risk"", Relationship: ""may need to be decreased if close to""
3. Entity1: ""Radiotherapy"", Entity2: ""IMRT"", Relationship: ""uses""
4. Entity1: ""Radiotherapy"", Entity2: ""Chemotherapy"", Relationship: ""can be used with""

Causalities:-
<C> Selection of an exact radiation dose prescription and schedule of delivery </C> <E> depends on the primary tumor and neck node size, whether altered fractionation is used, and clinical circumstances, including whether concurrent systemic therapy will be used </E>. <CO> if it is prescribed very close to adjacent organs at risk </CO> <A> The dose may need to be decreased </A>. <CO> Anatomical changes (e.g., rapidly shrinking tumors, changes in air cavities, significant weight loss) </CO> <A> may necessitate repeat imaging and treatment replanning </A>. <CO> when the tumor is abutting brain or optic structures </CO> <A> hyperfractionation has been used </A>. <CO> if prescribed doses exceed 72 Gy using conventional fractionation </CO> <E> this may lead to unacceptable rates of normal tissue injury </E>. <A> Care must be taken </A>.


Among these two options which one is the most likely true:

(A) `Histological_Grade_of_Tumor_4` increases risk `N_State_1`
(B) `N_State_1` `increases risk `Histological_Grade_of_Tumor_4`

The answer is: ...

1. State the evidences in detail of the validity of option (A) or (B) by cross referencing
NCCN Clinical Practitioner’s Guidelines for Head and Neck Cancer.
2. If the evidences are obtained from `INFORMATION FROM KNOWLEDGE BASE`,
mention their corresponding Page Numbers, Section Name, entities, relationships and causalities.

DESIRED OUTPUT FORMAT:
<thinking>
...
</thinking>
<answer>
{
   ""thinking"": [""..."", ...],
   ""evidences"": [""..."", ...],
   ""answer"": ...
}
</answer>

Before providing the answer in <answer> tags, think step by step in detail in <thinking> tags and analyze every part.
Output inside <answer> tag in JSON format. Only output valid JSON.
DO NOT HALLUCINATE. DO NOT MAKE UP FACTUAL INFORMATION.
","1. The task is to determine the most likely true causal relationship between two nodes: `Histological_Grade_of_Tumor_4` and `N_State_1`.
2. Option (A) suggests that a higher histological grade of a tumor (grade 4) increases the risk of cancer in nearby lymph nodes (`N_State_1`).
3. Option (B) suggests that the presence of cancer in nearby lymph nodes (`N_State_1`) increases the risk of a tumor being classified as histological grade 4.
4. The explanation for `EDGE1` indicates a positive causal direction from `Histological_Grade_of_Tumor_4` to `N_State_1`, suggesting that a higher grade increases the likelihood of lymph node involvement.
5. The explanation for `EDGE2` indicates that the state of nearby lymph nodes does not directly influence the histological grade of the tumor, making this edge invalid.
6. The knowledge base provides information on the TNM staging system, which includes lymph node involvement as a factor in cancer staging but does not suggest it influences histological grading.
7. Histological grading is based on the microscopic appearance of tumor cells, which is independent of lymph node involvement.
8. The causal distance for `EDGE1` is proximal, indicating a direct effect of tumor grade on lymph node involvement, supporting option (A).
9. The causal factor for `EDGE1` is sufficient but not necessary, meaning a high grade can lead to lymph node involvement, but other factors can also cause it.
10. The knowledge base does not provide evidence supporting option (B), as lymph node involvement is not a determinant of histological grade.
","1. Page 130, Section Name: Pathological N (pN) - Discusses lymph nodes' role in metastasis and TNM staging, supporting the link between tumor aggressiveness and lymph node involvement.
2. Page 51, Section Name: Histologic Grade (G) - Describes histological grading as a measure of tumor cell differentiation, independent of lymph node state.
3. Page 102, Section Name: Head and Neck Cancers - Principles of Surgery - Discusses the role of lymph nodes in cancer staging and treatment, not in determining histological grade.
",A,"{'A': 100.0, 'B': 0.0}",yes,A,"1. The AI assistant's reasoning begins by identifying the two options and their implications. It correctly identifies that option (A) suggests a causal relationship where a higher histological grade increases the risk of lymph node involvement, while option (B) suggests the opposite.
2. The assistant then evaluates the explanations provided for `EDGE1` and `EDGE2`. It notes that `EDGE1` supports a positive causal direction from `Histological_Grade_of_Tumor_4` to `N_State_1`, while `EDGE2` is deemed invalid as it suggests an incorrect causal relationship.
3. The assistant references the knowledge base, particularly the TNM staging system, to support the idea that lymph node involvement is a factor in cancer staging but does not influence histological grading. This supports the validity of option (A) over option (B).
4. The assistant correctly identifies that histological grading is based on the microscopic appearance of tumor cells, which is independent of lymph node involvement, further supporting option (A).
5. The assistant concludes that the causal distance for `EDGE1` is proximal, indicating a direct effect of tumor grade on lymph node involvement, which aligns with option (A).
6. The assistant's reasoning is consistent with the evidence provided, and it correctly identifies that the knowledge base does not support option (B).
"
11,gpt-4o,"Histological_Grade_of_Tumor_4,Biopsie_14","""{'NODE1': {'id': 'Histological_Grade_of_Tumor_4', 'label': 'Histological Grade of Tumor 4', 'description': 'This node represents the histological grade of a tumor, specifically grade 4, which is a classification based on the microscopic appearance of tumor cells. The histological grade is an important factor in determining the aggressiveness of the tumor and its potential response to treatment. Grade 4 typically indicates poorly differentiated or undifferentiated tumor cells, suggesting a more aggressive and potentially less favorable prognosis.', 'type': 'Patient Situation', 'observability': 'Unobserved', 'states': [{'state_name': 'present', 'state_description': \""The state 'present' indicates that the tumor has been assessed and classified as histological grade 4, meaning the tumor cells are poorly differentiated or undifferentiated, which is associated with a more aggressive behavior.\""}, {'state_name': 'absent', 'state_description': \""The state 'absent' indicates that the tumor is not classified as histological grade 4, suggesting that the tumor cells are not poorly differentiated or undifferentiated, which may be associated with a less aggressive behavior.\""}]}, 'NODE2': {'id': 'Biopsie_14', 'label': 'Biopsy in Patient Situation', 'description': 'This node represents the result of a biopsy in a specific patient situation. A biopsy is a medical procedure that involves taking a small sample of tissue for examination to diagnose a disease or condition. In this context, the node indicates whether a particular finding from the biopsy is present or absent.', 'type': 'Patient Situation', 'observability': 'Unobserved', 'states': [{'state_name': 'present', 'state_description': \""The 'present' state indicates that the biopsy has revealed the presence of a particular finding or condition in the patient.\""}, {'state_name': 'absent', 'state_description': \""The 'absent' state indicates that the biopsy did not reveal the presence of the particular finding or condition in the patient.\""}]}, 'EDGE1': {'edges_ids': ['Histological_Grade_of_Tumor_4', 'Biopsie_14'], 'edge': '(Histological_Grade_of_Tumor_4) causes (Biopsie_14)', 'explanation': ['The edge `(Histological_Grade_of_Tumor_4) causes (Biopsie_14)` suggests that the presence of a histological grade 4 tumor causes a particular biopsy finding to be present.', 'In reality, the biopsy is the procedure used to determine the histological grade of the tumor.', 'The histological grade is a classification based on the biopsy results, not a cause of the biopsy findings.', 'Therefore, the causal relationship as stated is not valid because the histological grade is determined by the biopsy, not the other way around.'], 'causal_direction': 'Unknown', 'causal_factor': {'necessary': False, 'sufficient': False}, 'causal_distance': 'Unknown'}, 'EDGE2': {'edges_ids': ['Biopsie_14', 'Histological_Grade_of_Tumor_4'], 'edge': '(Biopsie_14) causes (Histological_Grade_of_Tumor_4)', 'explanation': ['The edge `(Biopsie_14) causes (Histological_Grade_of_Tumor_4)` is not valid because a biopsy is a diagnostic procedure that reveals the histological grade of a tumor, but it does not cause the tumor to be a certain grade.', 'The histological grade of a tumor is determined by the biological characteristics of the tumor cells, not by the biopsy procedure itself.', 'Therefore, the biopsy result does not cause the tumor to be grade 4; it merely identifies the grade.'], 'causal_direction': 'Unknown', 'causal_factor': {'necessary': False, 'sufficient': False}, 'causal_distance': 'Unknown'}, 'ENTITIES_MATCHING_PAGES_INFO': {'49': {'matching_entities': [{'BIOPSY': 0.98102695}, {'NEEDLE BIOPSY': 0.9470839}, {'BIOPSY, NEEDLE': 0.9454435}, {'CANCER': 0.9417275}, {'CORE BIOPSY': 0.94171464}, {'CORE NEEDLE BIOPSY': 0.9415768}, {'MALIGNANT NEOPLASTIC DISEASE': 0.93020904}, {'FINE NEEDLE ASPIRATION BIOPSY': 0.9222763}], 'count': 8}, '97': {'matching_entities': [{'BIOPSY': 0.98102695}, {'TUMOR': 0.9533101}, {'CANCER': 0.9417275}, {'TUMOR STAGING': 0.935904}, {'MALIGNANT NEOPLASTIC DISEASE': 0.93020904}], 'count': 5}, '51': {'matching_entities': [{'CANCER STAGING': 0.9442892}, {'CANCER': 0.9417275}, {'MALIGNANT NEOPLASM': 0.93278354}, {'TNM STAGING SYSTEM': 0.92350286}, {'POSITIVE SURGICAL MARGIN': 0.9228712}], 'count': 5}, '130': {'matching_entities': [{'NEOPLASM GRADING': 1.0}, {'HISTOLOGIC GRADE': 0.9653935}, {'TUMOR STAGING': 0.935904}, {'TNM STAGING': 0.92977923}, {'TNM STAGING SYSTEM': 0.92350286}], 'count': 5}, '93': {'matching_entities': [{'BIOPSY': 0.98102695}, {'CANCER': 0.9417275}, {'FINE NEEDLE ASPIRATION': 0.9377125}, {'MALIGNANT NEOPLASTIC DISEASE': 0.93020904}], 'count': 4}}, 'GUIDELINE_PAGES_INFO': '--------------------------------------------------\\nPage Number: 49\\n\\nSection Name: NCCN Guidelines Overview\\n====================\\nEntities:-\\nClinical Trials As Topic : Works about research studies that evaluate the effectiveness and safety of medications or medical devices by monitoring their effects on large groups of people.\\nNeoplasms : New abnormal growth of tissue that possesses no physiological function and arises from uncontrolled usually rapid cellular proliferation.\\nClinical Trial : A research study that prospectively assigns human participants or groups of humans to one or more health-related interventions to evaluate the effects on health outcomes.\\nMalignant Neoplastic Disease : A disease in which abnormal cells divide uncontrollably and destroy body tissue.\\nNccn Guidelines : Clinical practice guidelines developed by the National Comprehensive Cancer Network to ensure that patients receive preventive, diagnostic, treatment, and supportive services that are most likely to lead to optimal outcomes.\\nNational Comprehensive Cancer Network : An alliance of 31 cancer centers in the United States, dedicated to improving the quality, effectiveness, and efficiency of cancer care so that patients can live better lives.\\nCancer : A group of diseases involving abnormal cell growth with the potential to invade or spread to other parts of the body.\\n\\nRelationships:-\\n1. Entity1: \""NCCN Guidelines\"", Entity2: \""National Comprehensive Cancer Network\"", Relationship: \""published by\""\\n2. Entity1: \""NCCN Guidelines\"", Entity2: \""Clinical Trials\"", Relationship: \""recommends\""\\n3. Entity1: \""Clinical Trials\"", Entity2: \""Cancer\"", Relationship: \""management strategy for\""\\n\\nCausalities:-\\n<C> NCCN believes that the best management of any patient with cancer is in a clinical trial </C>. <A> Participation in clinical trials is especially encouraged </A>.\\n\\nSection Name: SUPRA-1\\n====================\\nEntities:-\\nTobacco Use Disorder : A disorder characterized by the continued use of tobacco despite significant related problems.\\nTobacco Use : The act of using tobacco products.\\nTobacco Smoking : The practice of burning tobacco and inhaling the smoke.\\nAlcohol Drinking : The consumption of beverages containing ethyl alcohol.\\nAlcohol Use : The act of consuming alcoholic beverages.\\nAlcohol Consumption : The act of drinking beverages containing ethanol.\\nSmoking Cessation : The process of discontinuing tobacco smoking.\\nDepression : A mood disorder characterized by a persistent feeling of sadness and loss of interest.\\nDepressive Disorder : A mental disorder characterized by persistent low mood and loss of interest.\\nDepression (Mood) : A state of low mood and aversion to activity.\\nDistress, Psychological : A state of emotional suffering associated with stressors and demands that are difficult to cope with in daily life.\\nPsychological Distress : A state of emotional suffering typically characterized by symptoms of depression and anxiety.\\nPsychological Stress : A feeling of strain and pressure.\\nBiopsy, Needle : The removal of tissue or cells with a needle for examination under a microscope.\\nNeedle Biopsy : A procedure to extract tissue or fluid samples from the body using a needle.\\nNeck : The part of the body on many vertebrates that separates the head from the torso or trunk.\\nNeck Structure : Anatomical structure of the neck.\\nBiopsy : The removal and examination of tissue, cells, or fluids from the living body.\\nCore Biopsy : A biopsy procedure that uses a hollow needle to remove a core of tissue for examination.\\nCore Needle Biopsy : A procedure that uses a hollow needle to remove a sample of tissue for examination.\\nGenomics : An interdisciplinary field of biology focusing on the structure, function, evolution, mapping, and editing of genomes.\\nGenomic Testing : Testing that involves the analysis of the genome.\\n\\nRelationships:-\\n1. Entity1: \""Tobacco use\"", Entity2: \""Smoking cessation\"", Relationship: \""advised to quit\""\\n2. Entity1: \""Depression\"", Entity2: \""Distress management\"", Relationship: \""screening for\""\\n3. Entity1: \""Image-guided needle biopsy\"", Entity2: \""Cystic neck nodes\"", Relationship: \""used for\""\\n4. Entity1: \""Core biopsy\"", Entity2: \""Immune-genomic testing\"", Relationship: \""allows for\""\\n\\nCausalities:-\\n- <A> H&P should include documentation and quantification (pack years smoked) of tobacco use history, as well as alcohol use and counseling </A>. <A> All patients who currently smoke should be advised to quit smoking </A>, and <A> those who formerly smoked should be advised to remain abstinent from smoking </A>. <A> For additional cessation support, refer to the Patient/Provider Smoking Cessation and Treatment Resources in the [NCCN Guidelines for Smoking Cessation](#) </A>.\\n- <A> Screen for depression ([NCCN Guidelines for Distress Management](#)) </A>.\\n- <A> Image-guided (US or CT) needle biopsy of cystic neck nodes may offer better diagnostic yield than FNA by palpation alone for initial diagnosis in this setting </A>. <CO> For unresectable or metastatic disease where there is a plan for systemic therapy </CO>, <A> a core biopsy would allow for ancillary immune-genomic testing </A>.\\n\\nSection Name: WORKUP\\n====================\\nEntities:-\\nBiopsy : The removal and examination of tissue, cells, or fluids from the living body.\\nFine Needle Aspiration Biopsy : A type of biopsy procedure that uses a thin, hollow needle to extract cells or fluid from a lump or mass.\\nComputed Tomography : A medical imaging technique used in radiology to obtain detailed internal images of the body.\\nPositron-Emission Tomography : An imaging technique that uses radioactive substances to visualize and measure changes in metabolic processes.\\nEndoscopy : A procedure that uses an endoscope to examine the interior of a hollow organ or cavity of the body.\\nLaryngectomy : A surgical procedure to remove the larynx and separate the airway from the mouth, nose, and esophagus.\\n\\nRelationships:-\\n1. Entity1: \""Biopsy\"", Entity2: \""Primary tumor site\"", Relationship: \""performed on\""\\n2. Entity1: \""Fine needle aspiration biopsy\"", Entity2: \""Cervical lymph nodes\"", Relationship: \""samples\""\\n3. Entity1: \""Computed tomography\"", Entity2: \""Disease extent\"", Relationship: \""assesses\""\\n4. Entity1: \""Positron-Emission Tomography\"", Entity2: \""Advanced imaging\"", Relationship: \""considered for\""\\n5. Entity1: \""Endoscopy\"", Entity2: \""Examination\"", Relationship: \""used for\""\\n6. Entity1: \""Laryngectomy\"", Entity2: \""Disease stage\"", Relationship: \""required for\""\\n\\nCausalities:-\\n<A> The \""WORKUP\"" section details the essential initial assessments and procedures that must be conducted. </A> <A> It begins with a comprehensive history and physical examination, emphasizing the need for an exhaustive evaluation of both the head and neck, including any necessary biopsies of the primary tumor site or fine-needle aspiration (FNA) of cervical lymph nodes. </A> <A> Additional imaging techniques, such as chest CT scans and contrast-enhanced imaging (CT or MRI), are recommended to assess the extent of the disease. </A> <A> The guideline suggests considering advanced imaging methods like FDG-PET/CT and endoscopic examinations when clinically indicated. </A>\\n\\n<CO> Amenable to larynx-preserving (conservation) surgery (Most T1\u20132, N0; selected T3) </CO>\\n<A> Treatment of Primary and Neck (SUPRA-2) </A>\\n<A> H&P including a complete head and neck exam; mirror and/or fiberoptic examination as clinically indicated </A>\\n<A> Biopsy of primary site or FNA of the neck </A>\\n<A> Chest CT (with or without contrast) as clinically indicated </A>\\n<A> CT with contrast and thin angled cuts through larynx and/or MRI with and without contrast of primary and neck </A>\\n<A> Consider FDG-PET/CT </A>\\n<A> EUA with endoscopy </A>\\n<A> As clinically indicated: Preanesthesia studies, Consider PFTs for conservation surgery candidates, Consider videostrobe for select patients, Dental evaluation, Nutrition, speech and swallowing evaluation/therapy, Audiogram, Smoking cessation counseling, Fertility/reproductive counseling, Screening for hepatitis B </A>\\n<A> Multidisciplinary consultation as clinically indicated </A>\\n\\n<CO> Requiring (amenable to) total laryngectomy (T3, N0) </CO>\\n<CO> T4a, N0 </CO>\\n<CO> Node-positive disease </CO>\\n<CO> T4b, N0\u20133 </CO>\\n<CO> or Unresectable nodal disease or Unfit for surgery </CO>\\n<CO> Metastatic (M1) disease at initial presentation </CO>\\n<A> Treatment of Primary and Neck (SUPRA-3) </A>\\n<A> Treatment of Primary and Neck (SUPRA-8) </A>\\n<A> Clinical Staging (SUPRA-4) </A>\\n<A> Treatment of Very Advanced Head and Neck Cancer (ADV-1) </A>\\n<A> Treatment of Very Advanced Head and Neck Cancer (ADV-2) </A>\\n\\nSection Name: Principles\\n====================\\nEntities:-\\nDiagnostic Imaging : The production of diagnostic images, commonly through the use of X-rays, ultrasound, or magnetic resonance imaging (MRI).\\nDental Examination : A clinical examination of the teeth and oral cavity.\\nNutrition Therapy : The use of specific nutrition services to treat an illness, injury, or condition.\\nNational Comprehensive Cancer Network : An alliance of 31 cancer centers in the United States, dedicated to improving the quality, effectiveness, and efficiency of cancer care so that patients can live better lives.\\n\\nRelationships:-\\n1. Entity1: \""Principles of Imaging\"", Entity2: \""Diagnostic Imaging\"", Relationship: \""is related to\""\\n2. Entity1: \""Principles of Dental Evaluation and Management\"", Entity2: \""Dental Examination\"", Relationship: \""is related to\""\\n3. Entity1: \""Principles of Nutrition: Management and Supportive Care\"", Entity2: \""Nutrition Therapy\"", Relationship: \""is related to\""\\n4. Entity1: \""NCCN Guidelines for Adolescent and Young Adult (AYA) Oncology\"", Entity2: \""National Comprehensive Cancer Network\"", Relationship: \""is related to\""\\n\\nCausalities:-\\n### Principles\\n\\n- **Principles of Imaging (IMG-A)**\\n- **Principles of Dental Evaluation and Management (DENT-A)**\\n- **Principles of Nutrition: Management and Supportive Care (NUTR-A)**\\n- **See fertility and reproductive endocrine considerations in the [NCCN Guidelines for Adolescent and Young Adult (AYA) Oncology](#).**\\n--------------------------------------------------\\nPage Number: 97\\n\\nSection Name: Head and Neck Cancers - Principles of Surgery\\n====================\\nEntities:-\\nHead And Neck Neoplasms : Tumors or cancer of the head and neck region, including the oral cavity, pharynx, larynx, nasal cavity, and salivary glands.\\nBiopsy : A procedure involving the removal of tissue from a living body for diagnostic examination.\\nOncologist : A medical doctor who specializes in the diagnosis and treatment of cancer.\\nTumor Staging : Methods used for the classification of neoplasms according to the extent of tumor spread.\\nRadiation Oncologist : A medical specialist who uses ionizing radiation in the treatment of cancer.\\nDietitian : A health professional who has training in nutrition and diet planning.\\nSpeech-Language Pathologist : A specialist who evaluates and treats patients with speech, language, voice, and fluency disorders.\\nExamination Under Anesthesia : A procedure where a patient is examined while under anesthesia to allow for a more thorough examination.\\nMultidisciplinary Team : A group of healthcare professionals from different specialties working together to manage patient care.\\n\\nRelationships:-\\n1. Entity1: \""Head and Neck Surgical Oncologist\"", Entity2: \""Patient Evaluation\"", Relationship: \""performs\""\\n2. Entity1: \""Tumor Staging\"", Entity2: \""Imaging Studies\"", Relationship: \""based on\""\\n3. Entity1: \""Pre-treatment Evaluation\"", Entity2: \""Medical Oncologist\"", Relationship: \""involves\""\\n4. Entity1: \""Multidisciplinary Team\"", Entity2: \""Patient Treatment Options\"", Relationship: \""discusses\""\\n\\nCausalities:-\\n<A> All patients should be evaluated by a head and neck surgical oncologist prior to treatment </A> to <A> review the adequacy of biopsy material, review staging and imaging </A> <C> to determine the extent of disease, exclude the presence of a synchronous primary tumor </C>, <E> assess current functional status, and evaluate for potential surgical options, including those applicable if initial non-surgical treatment is unsuccessful </E>.\\n\\n<A> Pre-treatment evaluation </A> <CO> should include consultations with a medical oncologist, radiation oncologist, dentist or oral maxillofacial surgeon, speech-language pathologist, dietitian, and reconstructive surgeon as appropriate </CO>.\\n\\n<A> Tumor staging for untreated patients </A> <CO> is essential based on review of the head and neck diagnostic imaging studies and chest imaging as appropriate </CO>.\\n\\n<A> In addition to the office-based head and neck examination </A> to include fiberoptic nasopharyngolaryngoscopy, <A> EUA to assess the tumor extent and to obtain a biopsy </A> <CO> is indicated in the setting of metastatic carcinoma to the neck </CO>, <A> an EUA to search for the putative primary site </A> <E> is important for diagnosis and treatment planning </E>.\\n\\n<A> Participate in the multidisciplinary team discussions </A> <E> regarding patient treatment options with the goal of maximizing survival with preservation of form and function </E>.\\n\\n<A> Develop a prospective surveillance plan </A> that includes adequate dental, nutritional, and health behavioral evaluation and intervention and any other ancillary evaluations that would provide for <E> comprehensive rehabilitation </E>.\\n\\nSection Name: Integration of Therapy\\n====================\\nEntities:-\\nPatient Care : The services rendered by members of the health profession and non-professionals under their supervision for the benefit of the patient.\\nSurgical Procedure : A procedure involving an incision with instruments; performed to repair damage or arrest disease in a living body.\\nTumor : An abnormal growth of tissue resulting from uncontrolled, progressive multiplication of cells and serving no physiological function; a neoplasm.\\nMultidisciplinary Care Team : A team of healthcare professionals from different disciplines working together to manage the care of a patient.\\nTreatment Regimen : A plan for therapy that includes the dosage, schedule, and duration of treatment.\\nShared Decision-Making : A process in which clinicians and patients work together to make decisions and select tests, treatments, and care plans based on clinical evidence that balances risks and expected outcomes with patient preferences and values.\\n\\nRelationships:-\\n1. Entity1: \""Multidisciplinary Care Team\"", Entity2: \""Patient Care\"", Relationship: \""coordinates\""\\n2. Entity1: \""Surgical procedure\"", Entity2: \""Tumor\"", Relationship: \""resects\""\\n3. Entity1: \""Physician\"", Entity2: \""Shared decision-making\"", Relationship: \""engages in\""\\n\\nCausalities:-\\n- <C> It is critical that multidisciplinary evaluation and treatment be coordinated and integrated prospectively by all disciplines involved in patient care </C> <CO> before the initiation of any treatment </CO>.\\n\\n- <CO> For patients undergoing an operation </CO>, <A> the surgical procedure, margins, and reconstructive plan should be developed and designed to resect all gross tumors with adequate tumor-free surgical margins </A>. <A> The surgical procedure should rarely be modified based on any response observed as a result of prior therapy </A> <CO> except in instances of tumor progression that mandate a more extensive procedure in order to encompass the tumor at the time of definitive resection </CO>.\\n\\n- <CO> Once the multidisciplinary team has established a proposed treatment regimen </CO>, <A> the responsible physician and a member of the team should discuss the recommendations in detail with the patient to include the risks, benefits, and potential outcomes </A>. <A> The patient should be offered the opportunity to participate in the final decision (shared decision-making) </A>.\\n\\nSection Name: Clinical Trials\\n====================\\nEntities:-\\nClinical Trials : Pre-planned studies of the safety, efficacy, or optimum dosage schedule (if appropriate) of one or more diagnostic, therapeutic, or prophylactic drugs, devices, or techniques in humans selected according to predetermined criteria of eligibility and observed for predefined evidence of favorable and unfavorable effects.\\nClinical Trial : A type of research that studies new tests and treatments and evaluates their effects on human health outcomes.\\nNeoplasms : New abnormal growth of tissue in animals or plants; a tumor. Neoplasms are also referred to as tumors, and they can be benign or malignant.\\nMalignant Neoplastic Disease : A disease characterized by uncontrolled, abnormal growth of cells that can invade and destroy nearby tissue and spread to other parts of the body.\\nCancer : A group of diseases involving abnormal cell growth with the potential to invade or spread to other parts of the body.\\n\\nRelationships:-\\n1. Entity1: \""NCCN\"", Entity2: \""Clinical Trials\"", Relationship: \""promotes\""\\n2. Entity1: \""Clinical Trials\"", Entity2: \""Cancer\"", Relationship: \""manages\""\\n\\nCausalities:-\\n<C> any patient with cancer </C> <E> the best management </E> <A> is in a clinical trial </A>. <A> Participation in clinical trials is especially encouraged </A>.\\n--------------------------------------------------\\nPage Number: 51\\n\\nSection Name: Introduction\\n====================\\nEntities:-\\nLaryngeal Neoplasms : Tumors or cancer of the larynx, which may affect the supraglottic, glottic, or subglottic regions.\\nMalignant Neoplasm Of Supraglottis : A malignant tumor located in the supraglottic region of the larynx.\\nSupraglottic Laryngeal Cancer : A type of cancer that occurs in the supraglottic region of the larynx, which is above the vocal cords.\\n\\nRelationships:-\\n1. Entity1: \""National Comprehensive Cancer Network (NCCN)\"", Entity2: \""cancer of the supraglottic larynx\"", Relationship: \""provides guidelines for\""\\n2. Entity1: \""healthcare professionals\"", Entity2: \""cancer of the supraglottic larynx\"", Relationship: \""manage\""\\n\\nCausalities:-\\nThe provided image is a detailed flowchart from the National Comprehensive Cancer Network (NCCN) guidelines regarding the <C> clinical staging and treatment protocols for cancer of the supraglottic larynx </C>. This flowchart is structured to <A> guide healthcare professionals through the stages of treatment </A> based on <CO> clinical findings </CO>, emphasizing the <E> complexity and systematic approach required in managing this type of cancer </E>.\\n\\nSection Name: Clinical Staging\\n====================\\nEntities:-\\nLaryngectomy : A surgical procedure involving the removal of the larynx, usually to treat cancer of the larynx.\\nTotal Laryngectomy : A surgical procedure to remove the entire larynx, often used in the treatment of advanced laryngeal cancer.\\nNeoplasm Staging : Methods used for staging neoplasms, including clinical and pathological staging.\\nCancer Staging : The process of determining the extent of cancer in the body, often using the TNM system.\\nTnm Staging System : A cancer staging system that describes the extent of cancer using Tumor size (T), Node involvement (N), and Metastasis (M).\\n\\nRelationships:-\\n1. Entity1: \""Clinical staging criteria\"", Entity2: \""Total laryngectomy\"", Relationship: \""determines necessity of\""\\n2. Entity1: \""T3, N0\"", Entity2: \""Clinical staging criteria\"", Relationship: \""is a categorization of\""\\n\\nCausalities:-\\nThe flowchart begins with the <C> clinical staging criteria </C>, specifically focusing on <CO> cases that require total laryngectomy, denoted as requiring (amenable to) total laryngectomy (T3, N0) </CO>. This <A> categorization </A> is crucial as it <E> forms the basis for determining the appropriate treatment strategy </E>.\\n\\nSection Name: Treatment of Primary and Neck\\n====================\\nEntities:-\\nNeoplasm Staging : Methods used for staging neoplasms, including clinical and pathological staging.\\nSystemic Therapy : Treatment using substances that travel through the bloodstream, reaching and affecting cells all over the body.\\nRadiotherapy : The use of high-energy radiation from x-rays, gamma rays, neutrons, protons, and other sources to kill cancer cells and shrink tumors.\\nLaryngectomy : A surgical procedure involving the removal of the larynx, usually to treat cancer of the larynx.\\nThyroidectomy : A surgical procedure to remove all or part of the thyroid gland.\\nNeck Dissection : Surgical procedure to remove lymph nodes and surrounding tissue to treat or prevent cancer spread.\\nLymphatic Metastasis : Transfer of a neoplasm from one organ or part of the body to another remote from the primary site.\\n\\nRelationships:-\\n1. Entity1: \""Systemic Therapy\"", Entity2: \""Radiation Therapy\"", Relationship: \""combined with\""\\n2. Entity1: \""Laryngectomy\"", Entity2: \""Lymph Node Involvement\"", Relationship: \""considered based on\""\\n3. Entity1: \""Thyroidectomy\"", Entity2: \""Lymph Node Involvement\"", Relationship: \""considered based on\""\\n4. Entity1: \""Neck Dissection\"", Entity2: \""Lymph Node Involvement\"", Relationship: \""considered based on\""\\n\\nCausalities:-\\n<CO> Once clinical staging is established </CO>, the chart outlines various treatment options. <A> The initial step may involve either concurrent systemic therapy combined with radiation therapy (RT) or opting for RT alone </A>, <CO> especially if the patient is not a medical candidate for both therapies </CO>. <A> Laryngectomy, thyroidectomy, and neck dissection are considered </A> <CO> based on the extent of lymph node involvement </CO>.\\n\\nSection Name: Surgical Options\\n====================\\nEntities:-\\nLaryngectomy : A surgical procedure involving the removal of the larynx, usually to treat cancer of the larynx.\\nThyroidectomy : A surgical procedure to remove all or part of the thyroid gland.\\nLymph Node Excision : Surgical removal of one or more lymph nodes.\\nLymphadenectomy : Surgical removal of one or more groups of lymph nodes.\\nSurgical Procedures, Operative : Operations carried out for the correction of deformities and defects, repair of injuries, and diagnosis and cure of certain diseases.\\nSurgical Procedure : A medical procedure involving an incision with instruments; performed to repair damage or arrest disease in a living body.\\nSurgery : Medical specialty that uses operative manual and instrumental techniques on a patient to investigate or treat a pathological condition such as a disease or injury.\\n\\nRelationships:-\\n1. Entity1: \""Laryngectomy\"", Entity2: \""Thyroidectomy\"", Relationship: \""combined with\""\\n2. Entity1: \""Lymph Node Dissection\"", Entity2: \""Surgical Intervention\"", Relationship: \""extent of\""\\n3. Entity1: \""Surgical Intervention\"", Entity2: \""Advanced Cases\"", Relationship: \""management option for\""\\n\\nCausalities:-\\n<CO> If concurrent therapies are not suitable </CO>, <A> the chart presents laryngectomy combined with thyroidectomy </A>, <CO> depending on the extent of lymph node dissection required </CO>. <E> This highlights surgical intervention as a viable option in the management of advanced cases </E>.\\n\\nSection Name: Induction Chemotherapy\\n====================\\nEntities:-\\nInduction Chemotherapy : Initial chemotherapy treatment used to shrink a tumor before the main treatment, which is usually surgery.\\nSurgical Procedure : A medical procedure involving an incision with instruments; performed to repair damage or arrest disease in a living body.\\nTherapeutic Approach : A method or strategy used in the treatment of disease or injury.\\n\\nRelationships:-\\n1. Entity1: \""Induction Chemotherapy\"", Entity2: \""Surgical Intervention\"", Relationship: \""alternative or sequential treatment option\""\\n\\nCausalities:-\\n<C> immediate surgical intervention is either not feasible or considered insufficient </C> <E> The flowchart also considers the option of induction chemotherapy </E> <CO> in cases where immediate surgical intervention is either not feasible or considered insufficient </CO>. <A> tailoring therapeutic approaches tailored to individual patient needs </A>.\\n\\nSection Name: Adjuvant Treatment\\n====================\\nEntities:-\\nAdjuvant Chemotherapy : Chemotherapy given in addition to the primary treatment to maximize its effectiveness.\\nRadiotherapy : The use of high-energy radiation from x-rays, gamma rays, neutrons, protons, and other sources to kill cancer cells and shrink tumors.\\nNeoplasm Recurrence, Local : The return of a cancer, at the same site, after it has been treated.\\nDisease Progression : The worsening of a disease over time.\\n\\nRelationships:-\\n1. Entity1: \""Primary Treatment\"", Entity2: \""Adjuvant Treatment\"", Relationship: \""followed by\""\\n2. Entity1: \""Adjuvant Treatment\"", Entity2: \""Systemic Therapy\"", Relationship: \""includes\""\\n3. Entity1: \""Adjuvant Treatment\"", Entity2: \""Radiotherapy\"", Relationship: \""includes\""\\n4. Entity1: \""Follow-up Assessments\"", Entity2: \""Treatment Efficacy\"", Relationship: \""used to evaluate\""\\n\\nCausalities:-\\n<C> Following primary treatment </C>, <E> the flowchart addresses the potential for adjuvant treatment pathways </E>. This may include systemic therapy, RT, or further evaluations based on <CO> the patient\\'s response and any recurrence or persistent disease </CO>. It emphasizes <A> the need for follow-up assessments to evaluate treatment efficacy </A>.\\n\\nSection Name: Risk Features and Response Assessment\\n====================\\nEntities:-\\nNeoplasm Invasiveness : The property of a neoplasm to infiltrate and destroy surrounding tissue.\\nSurgical Margins : The edge or border of the tissue removed in cancer surgery.\\nNeoplasms : Neoplasms are abnormal growths of tissue, which can be cancerous or non-cancerous.\\nExtramural Extension : Extension of a tumor beyond the wall of an organ.\\nPositive Surgical Margin : Cancer cells are present at the edge of the tissue removed during surgery.\\nCancer Management : The process of planning and coordinating the treatment of cancer.\\nCancer : Cancer is a group of diseases involving abnormal cell growth with the potential to invade or spread to other parts of the body.\\n\\nRelationships:-\\n1. Entity1: \""Extramural extension\"", Entity2: \""Treatment decisions\"", Relationship: \""influences\""\\n2. Entity1: \""Positive surgical margin\"", Entity2: \""Treatment decisions\"", Relationship: \""influences\""\\n3. Entity1: \""Ongoing assessment\"", Entity2: \""Response evaluation\"", Relationship: \""leads to\""\\n4. Entity1: \""Response evaluation\"", Entity2: \""Adjustments to treatment\"", Relationship: \""leads to\""\\n5. Entity1: \""Management of cancer\"", Entity2: \""Treatment decisions\"", Relationship: \""involves\""\\n6. Entity1: \""Management of cancer\"", Entity2: \""Ongoing assessment\"", Relationship: \""involves\""\\n7. Entity1: \""Management of cancer\"", Entity2: \""Adjustments to treatment\"", Relationship: \""involves\""\\n\\nCausalities:-\\nThe chart incorporates a segment that takes into account <CO> adverse pathologic features, such as extramural extension or positive margins </CO>, <E> which could influence subsequent treatment decisions </E>. This highlights the importance of <A> ongoing assessment in the management of cancer, leading to response evaluation and adjustments to treatment as necessary </A>.\\n\\nSection Name: NCCN Guidelines Version 4.2024\\n====================\\nEntities:-\\nClinical Trials : Clinical trials are research studies performed in people that are aimed at evaluating a medical, surgical, or behavioral intervention.\\nNeoplasms : Neoplasms are abnormal growths of tissue, which can be cancerous or non-cancerous.\\nClinical Trial : A clinical trial is a research study that prospectively assigns human participants or groups of humans to one or more health-related interventions to evaluate the effects on health outcomes.\\nMalignant Neoplasm : A malignant neoplasm is a cancerous growth that has the potential to invade and destroy nearby tissue and spread to other parts of the body.\\nNational Comprehensive Cancer Network : The National Comprehensive Cancer Network (NCCN) is an alliance of 31 cancer centers in the United States, dedicated to improving the quality, effectiveness, and efficiency of cancer care.\\nCancer : Cancer is a group of diseases involving abnormal cell growth with the potential to invade or spread to other parts of the body.\\n\\nRelationships:-\\n1. Entity1: \""National Comprehensive Cancer Network\"", Entity2: \""NCCN Guidelines\"", Relationship: \""provides\""\\n2. Entity1: \""NCCN Guidelines\"", Entity2: \""Clinical Trials\"", Relationship: \""recommend\""\\n3. Entity1: \""NCCN Guidelines\"", Entity2: \""Cancer\"", Relationship: \""related to management of\""\\n\\nCausalities:-\\n<CO> any patient with cancer </CO> <A> the best management is in a clinical trial </A>. <A> Participation in clinical trials is especially encouraged </A>.\\n\\nSection Name: SUPRA-3\\n====================\\nEntities:-\\nLaryngectomy : A surgical procedure involving the removal of the larynx, usually to treat cancer of the larynx.\\nThyroidectomy : A surgical procedure to remove all or part of the thyroid gland.\\nNeck Dissection : Surgical procedure to remove lymph nodes and surrounding tissue to treat or prevent cancer spread.\\nChemotherapy, Induction : Initial chemotherapy treatment to shrink a tumor before the main treatment.\\nClinical Trials As Topic : Research studies that prospectively assign human participants or groups of humans to one or more health-related interventions to evaluate the effects on health outcomes.\\nInduction Chemotherapy : Initial chemotherapy treatment used to shrink a tumor before the main treatment, which is usually surgery.\\nClinical Trial : A clinical trial is a research study that prospectively assigns human participants or groups of humans to one or more health-related interventions to evaluate the effects on health outcomes.\\n\\nRelationships:-\\n1. Entity1: \""Total laryngectomy\"", Entity2: \""Laryngectomy\"", Relationship: \""is a type of\""\\n2. Entity1: \""Systemic therapy\"", Entity2: \""RT\"", Relationship: \""concurrent treatment option\""\\n3. Entity1: \""Induction chemotherapy\"", Entity2: \""Other treatments\"", Relationship: \""initial treatment option before\""\\n\\nCausalities:-\\n<CO> Requiring (amenable to) total laryngectomy (T3,N0) </CO>\\n  - <A> Concurrent systemic therapy/RT </A> or <A> RT if patient not medical candidate for concurrent systemic therapy/RT </A>\\n  - <A> Laryngectomy, thyroidectomy and with ipsilateral, central, or bilateral neck dissection </A>\\n  - or\\n  - <A> Induction chemotherapy </A>\\n  - or\\n  - <A> Clinical trials </A>\\n\\nSection Name: Follow-up\\n====================\\nEntities:-\\nFollow-Up Studies : Studies in which individuals are followed over time to determine the outcome of exposures, treatments, or interventions.\\nFollow-Up Procedure : A procedure performed to monitor the progress of a patient\\'s condition after initial treatment.\\nFollow-Up : Medical care given to a patient over time after initial treatment.\\nDisease Recurrence : The return of a sign, symptom, or disease after a remission.\\nRecurrent Disease : The reappearance of a disease after a period of improvement.\\n\\nRelationships:-\\n1. Entity1: \""Follow-up\"", Entity2: \""Recurrent or persistent disease\"", Relationship: \""monitoring\""\\n\\nCausalities:-\\n- **Follow-up (FOLL-A, 1 of 2)**\\n  - <CO> Recurrent or persistent disease </CO> (ADV-3)\\n\\nSection Name: Adverse Pathologic Features\\n====================\\nEntities:-\\nRadiotherapy : The use of high-energy radiation from x-rays, gamma rays, neutrons, protons, and other sources to kill cancer cells and shrink tumors.\\nExtranodal Extension : The spread of cancer beyond the lymph node capsule.\\nPositive Surgical Margin : Cancer cells are present at the edge of the tissue removed during surgery.\\nSystemic Therapy : Treatment using substances that travel through the bloodstream, reaching and affecting cells all over the body.\\n\\nRelationships:-\\n1. Entity1: \""pN1\"", Entity2: \""Radiotherapy\"", Relationship: \""Consideration for treatment\""\\n2. Entity1: \""Extranodal extension\"", Entity2: \""Systemic Therapy\"", Relationship: \""Treatment option\""\\n3. Entity1: \""Extranodal extension\"", Entity2: \""Radiotherapy\"", Relationship: \""Treatment option\""\\n4. Entity1: \""Positive surgical margin\"", Entity2: \""Systemic Therapy\"", Relationship: \""Treatment option\""\\n5. Entity1: \""Positive surgical margin\"", Entity2: \""Radiotherapy\"", Relationship: \""Treatment option\""\\n\\nCausalities:-\\n- <CO>pN1 without other risk features</CO>\\n  - <C>Adverse pathologic features</C>\\n  - <A>Consider RT</A>\\n  - <CO>Extranodal extension and/or positive margin</CO>\\n  - <CO>Other risk features</CO>\\n  - <A>Systemic therapy/RT (category 1)</A>\\n  - <A>RT or Consider systemic therapy/RT</A>\\n\\nSection Name: Response Assessment\\n====================\\nEntities:-\\nResponse Evaluation : The process of assessing the response of a disease to treatment, often used in clinical trials to determine the effectiveness of a therapy.\\nResponse To Treatment : A clinical finding indicating the response of a condition to a therapeutic intervention.\\n\\nRelationships:-\\n\\nSection Name: Principles of Surgery and Radiation Therapy\\n====================\\nEntities:-\\nSurgical Procedures, Operative : Operations carried out for the correction of deformities and defects, repair of injuries, and diagnosis and cure of certain diseases.\\nSurgical Procedure : A medical procedure involving an incision with instruments; performed to repair damage or arrest disease in a living body.\\nSurgery : Medical specialty that uses operative manual and instrumental techniques on a patient to investigate or treat a pathological condition such as a disease or injury.\\nRadiotherapy : The use of high-energy radiation from x-rays, gamma rays, neutrons, protons, and other sources to kill cancer cells and shrink tumors.\\nRadiation Therapy : Radiation therapy is a therapy using ionizing radiation, generally as part of cancer treatment to control or kill malignant cells.\\n\\nRelationships:-\\n1. Entity1: \""Principles of Surgery\"", Entity2: \""Principles of Radiation Therapy\"", Relationship: \""complementary treatments\""\\n\\nCausalities:-\\n**Principles of Surgery (SURG-A).**\\n\\n**Principles of Radiation Therapy (SUPRA-A).**\\n\\nSection Name: Principles of Systemic Therapy\\n====================\\nEntities:-\\nCisplatin : An inorganic and water-soluble platinum complex, cisplatin is an antineoplastic agent that is used in the treatment of various cancers.\\nRadiotherapy : The use of high-energy radiation from x-rays, gamma rays, neutrons, protons, and other sources to kill cancer cells and shrink tumors.\\nRadiation Therapy : Radiation therapy is a therapy using ionizing radiation, generally as part of cancer treatment to control or kill malignant cells.\\n\\nRelationships:-\\n1. Entity1: \""Cisplatin\"", Entity2: \""Systemic Therapy for Non-Nasopharyngeal Cancers\"", Relationship: \""preferred agent\""\\n2. Entity1: \""Cisplatin\"", Entity2: \""Concurrent Systemic Therapy/RT\"", Relationship: \""used in\""\\n\\nCausalities:-\\n<CO> When using concurrent systemic therapy/RT </CO>, <A> the preferred agent is cisplatin (category 1) </A>.\\n--------------------------------------------------\\nPage Number: 130\\n\\nSection Name: Pathological N (pN)\\n====================\\nEntities:-\\nLymph Nodes : Small, bean-shaped structures that are part of the body\\'s lymphatic system. They filter lymph fluid and store white blood cells that help fight infection.\\nNeoplasm Metastasis : The transfer of a neoplasm from one organ or part of the body to another remote from the primary site.\\nTnm Staging : A system used to describe the size and spread of cancer in a standardized way. T refers to the size of the tumor, N to the involvement of lymph nodes, and M to metastasis.\\nLymph Node Structure : A structure that is part of the lymphatic system, involved in the immune response.\\nMetastasis : The spread of a cancer or other disease from one organ or part to another not directly connected with it.\\nTnm Staging System : A cancer staging notation system that describes the extent of cancer in a patient\\'s body.\\nLymph Node : An organ of the lymphatic system and the adaptive immune system.\\n\\nRelationships:-\\n1. Entity1: \""Lymph Nodes\"", Entity2: \""Neoplasm Metastasis\"", Relationship: \""involved in\""\\n2. Entity1: \""TNM Staging\"", Entity2: \""Lymph Nodes\"", Relationship: \""includes\""\\n3. Entity1: \""TNM Staging\"", Entity2: \""Neoplasm Metastasis\"", Relationship: \""describes\""\\n\\nCausalities:-\\n<CO> NX: Regional lymph nodes cannot be assessed </CO>\\n<CO> N0: No regional lymph node metastasis </CO>\\n<CO> N1: Metastasis in a single ipsilateral lymph node, 3 cm or smaller in greatest dimension ENE(\u2013) </CO>\\n<CO> N2: Metastasis in a single ipsilateral lymph node, 3 cm or smaller in greatest dimension and ENE(+); or larger than 3 cm but not larger than 6 cm in greatest dimension and ENE(\u2212); or metastases in multiple ipsilateral lymph nodes, none larger than 6 cm in greatest dimension and ENE(\u2212); or in bilateral or contralateral lymph node(s), none larger than 6 cm in greatest dimension and ENE(\u2212) </CO>\\n<CO> N2a: Metastasis in a single ipsilateral node, 3 cm or smaller in greatest dimension and ENE(+); or metastasis in a single ipsilateral node, larger than 3 cm but not larger than 6 cm in greatest dimension and ENE(\u2212) </CO>\\n<CO> N2b: Metastases in multiple ipsilateral nodes, none larger than 6 cm in greatest dimension and ENE(\u2212) </CO>\\n<CO> N2c: Metastases in bilateral or contralateral lymph node(s), none larger than 6 cm in greatest dimension and ENE(\u2212) </CO>\\n<CO> N3: Metastasis in a lymph node, larger than 6 cm in greatest dimension and ENE(\u2212); or metastasis in a single ipsilateral node, larger than 3 cm in greatest dimension and ENE(+); or multiple ipsilateral, contralateral, or bilateral lymph nodes and any with ENE(+); or a single contralateral node of any size and ENE(+) </CO>\\n<CO> N3a: Metastasis in a lymph node, larger than 6 cm in greatest dimension and ENE(\u2212) </CO>\\n<CO> N3b: Metastasis in a single ipsilateral node, larger than 3 cm in greatest dimension and ENE(+); or multiple ipsilateral, contralateral, or bilateral lymph nodes any with ENE(+); or a single contralateral node of any size and ENE(+) </CO>\\n<CO> Note: A designation of \u201cU\u201d or \u201cL\u201d may be used for any N category to indicate metastasis above the lower border of the cricoid (U) or below the lower border of the cricoid (L). Similarly, clinical and pathological ENE should be recorded as ENE(\u2212) or ENE(+). </CO>\\n\\nSection Name: Distant Metastasis (M)\\n====================\\nEntities:-\\nNeoplasm Metastasis : The transfer of a neoplasm from one organ or part of the body to another remote from the primary site.\\nMetastasis : The spread of a cancer or other disease from one organ or part to another not directly connected with it.\\n\\nRelationships:-\\n1. Entity1: \""M0\"", Entity2: \""Distant Metastasis\"", Relationship: \""is a category of\""\\n2. Entity1: \""M1\"", Entity2: \""Distant Metastasis\"", Relationship: \""is a category of\""\\n\\nCausalities:-\\n### Distant Metastasis (M)\\n\\n- **M0**: No distant metastasis\\n- **M1**: Distant metastasis\\n\\nSection Name: Histologic Grade (G)\\n====================\\nEntities:-\\nNeoplasm Grading : A system of classifying cancer cells in terms of how abnormal they look under a microscope and how quickly the tumor is likely to grow and spread.\\nHistologic Grade : A measure of how much tumor cells differ from healthy cells, used to assess the aggressiveness of cancer.\\n\\nRelationships:-\\n1. Entity1: \""GX\"", Entity2: \""Grade cannot be assessed\"", Relationship: \""is described as\""\\n2. Entity1: \""G1\"", Entity2: \""Well differentiated\"", Relationship: \""is described as\""\\n3. Entity1: \""G2\"", Entity2: \""Moderately differentiated\"", Relationship: \""is described as\""\\n4. Entity1: \""G3\"", Entity2: \""Poorly differentiated\"", Relationship: \""is described as\""\\n\\nCausalities:-\\n<CO>GX</CO>: <E>Grade cannot be assessed</E>\\n<CO>G1</CO>: <E>Well differentiated</E>\\n<CO>G2</CO>: <E>Moderately differentiated</E>\\n<CO>G3</CO>: <E>Poorly differentiated</E>\\n\\nSection Name: Prognostic Stage Groups\\n====================\\nEntities:-\\nNeoplasm Staging : Methods and systems of classifying neoplasms according to extent of disease.\\nTumor Staging : A system for describing the size and spread of cancer within the body.\\nTnm Staging System : A cancer staging notation system that describes the extent of cancer in a patient\\'s body.\\n\\nRelationships:-\\n1. Entity1: \""Stage 0\"", Entity2: \""Tis N0 M0\"", Relationship: \""defined by\""\\n2. Entity1: \""Stage I\"", Entity2: \""T1 N0 M0\"", Relationship: \""defined by\""\\n3. Entity1: \""Stage II\"", Entity2: \""T2 N0 M0\"", Relationship: \""defined by\""\\n4. Entity1: \""Stage III\"", Entity2: \""T3 N0 M0, T1 N1 M0, T2 N1 M0, T3 N1 M0\"", Relationship: \""defined by\""\\n5. Entity1: \""Stage IVA\"", Entity2: \""T1 N2 M0, T2 N2 M0, T3 N2 M0, T4a N0,N1,N2 M0\"", Relationship: \""defined by\""\\n6. Entity1: \""Stage IVB\"", Entity2: \""Any T N3 M0, T4b Any N M0\"", Relationship: \""defined by\""\\n7. Entity1: \""Stage IVC\"", Entity2: \""Any T Any N M1\"", Relationship: \""defined by\""\\n--------------------------------------------------\\nPage Number: 93\\n\\nSection Name: PRINCIPLES OF IMAGING\\n====================\\nEntities:-\\nImaging, Diagnostic : The production of a visual representation of parts of the body, for the purpose of clinical analysis and medical intervention.\\nHead And Neck Neoplasms : Tumors or cancer of the head and neck region, including the nasal cavity, sinuses, lips, mouth, salivary glands, throat, or larynx.\\nTomography, X-Ray Computed : An imaging procedure that uses special x-ray equipment to create detailed pictures, or scans, of areas inside the body.\\nMagnetic Resonance Imaging : A noninvasive diagnostic technique that uses magnetic fields and radio waves to produce a detailed image of the body\\'s soft tissue and bones.\\nContrast Media : Substances used to enhance the contrast of structures or fluids within the body in medical imaging.\\n\\nRelationships:-\\n1. Entity1: \""Imaging, Diagnostic\"", Entity2: \""Head and Neck Neoplasms\"", Relationship: \""used for\""\\n2. Entity1: \""Tomography, X-Ray Computed\"", Entity2: \""Contrast Media\"", Relationship: \""uses\""\\n3. Entity1: \""Magnetic Resonance Imaging\"", Entity2: \""Contrast Media\"", Relationship: \""uses\""\\n\\nCausalities:-\\n<C> Imaging </C> plays an essential role in the clinical care of patients with head and neck cancer. <A> The proper selection and utilization of imaging studies </A> is critical in caring for patients with head and neck cancer. <A> CT is performed with contrast </A>, while <A> CT imaging of the chest can be performed with or without contrast </A>, <CO> as clinically indicated </CO>. <A> MRI is performed with and without contrast </A>, <CO> unless contraindicated </CO>.\\n\\nSection Name: Initial Workup - Primary Site\\n====================\\nEntities:-\\nTomography, X-Ray Computed : An imaging procedure that uses special x-ray equipment to create detailed pictures, or scans, of areas inside the body.\\nMagnetic Resonance Imaging : A noninvasive diagnostic technique that uses magnetic fields and radio waves to produce a detailed image of the body\\'s soft tissue and bones.\\nHead And Neck Neoplasms : Tumors or cancer of the head and neck region, including the nasal cavity, sinuses, lips, mouth, salivary glands, throat, or larynx.\\nNeck Structure : The anatomical structure of the neck, which is the part of the body that connects the head to the torso.\\nSkull Base : The bottom part of the skull, which separates the brain from other facial structures.\\nThoracic Inlet : The opening at the top of the thoracic cavity, through which pass the trachea, esophagus, and major blood vessels.\\n\\nRelationships:-\\n1. Entity1: \""CT\"", Entity2: \""MRI\"", Relationship: \""complementary in imaging head and neck cancers\""\\n2. Entity1: \""CT\"", Entity2: \""Head and Neck Neoplasms\"", Relationship: \""used to evaluate\""\\n3. Entity1: \""MRI\"", Entity2: \""Head and Neck Neoplasms\"", Relationship: \""preferred for evaluating\""\\n4. Entity1: \""Skull base\"", Entity2: \""Thoracic inlet\"", Relationship: \""imaging range for evaluation\""\\n\\nCausalities:-\\n<A>Imaging assessment of the primary site</A> can be performed with <A>CT of the soft tissues of the neck</A> or <A>MRI of the neck</A>. <C>CT is complementary to MRI for head and neck cancers</C>. <A>It is utilized to evaluate cortical bone erosion or periosteal invasion, cartilage invasion, and bony erosion or destruction</A>. <CO>in certain conditions, such as evaluating the extent of bone marrow invasion or in patients with extensive dental amalgam obscuring anatomy on CT, assessing skull base invasion and cranial nerve involvement, and differentiating tumor from obstructed sinuses</CO>, <A>MRI is preferred over CT</A>. <CO>when involved lymph nodes or upper mediastinal cancers are present</CO>, <A>Complete evaluation of primary and nodal disease requires imaging from the skull base to the thoracic inlet, extending to the carina</A>.\\n\\nSection Name: PET/CT and Biopsy\\n====================\\nEntities:-\\nPositron Emission Tomography Computed Tomography : A medical imaging technique that combines PET and CT capabilities to provide detailed images of the body.\\nExamination Under Anesthesia : A procedure where a patient is examined while under anesthesia to allow for a more thorough examination.\\nBiopsy : A medical test involving the extraction of sample cells or tissues for examination to determine the presence or extent of a disease.\\nTonsillectomy : A surgical procedure to remove the tonsils, often performed to treat recurrent tonsillitis or sleep apnea.\\nFine Needle Aspiration : A type of biopsy procedure that uses a thin, hollow needle to extract cells from a lump or mass for examination.\\nUltrasound : A medical imaging technique that uses high-frequency sound waves to visualize internal organs and structures.\\nComputed Tomography : A diagnostic imaging procedure that uses a combination of X-rays and computer technology to produce cross-sectional images of the body.\\n\\nRelationships:-\\n1. Entity1: \""PET/CT\"", Entity2: \""EUA\"", Relationship: \""recommended before\""\\n2. Entity1: \""Fine Needle Aspiration (FNA)\"", Entity2: \""metastatic nodes\"", Relationship: \""used for biopsy of\""\\n3. Entity1: \""Image-guided needle biopsy\"", Entity2: \""cystic neck nodes\"", Relationship: \""recommended for initial diagnosis of\""\\n\\nCausalities:-\\n<CO> If imaging does not reveal an obvious primary cancer </CO>, <A> a PET/CT should be ordered before EUA, biopsies, and tonsillectomy </A>. <E> This helps identify potential primary sites </E> before any interventions take place. Additionally, <A> Fine Needle Aspiration (FNA) biopsy of metastatic nodes </A> <E> may provide pathologically informative results </E>. <CO> For initial diagnosis in cystic neck nodes </CO>, <A> image-guided needle biopsy (ultrasound or CT) </A> <E> may yield better results than FNA by palpation alone </E>.\\n\\nSection Name: Postoperative Imaging Advice\\n====================\\nEntities:-\\nPanoramic Radiography : A type of dental x-ray that provides a wide view of the upper and lower jaws, teeth, temporomandibular joints, and sinuses.\\nOral Cavity : The cavity of the mouth, including the lips, the lining inside the cheeks and lips, the front two-thirds of the tongue, the gums, the floor of the mouth under the tongue, the hard palate, and the small area of the gum behind the wisdom teeth.\\nRadiotherapy : The treatment of disease, especially cancer, using X-rays or similar forms of radiation.\\nMandibulotomy : A surgical procedure involving the cutting of the mandible.\\nMandibulectomy : A surgical procedure involving the removal of part or all of the mandible.\\nOropharynx : The part of the throat at the back of the mouth behind the oral cavity.\\n\\nRelationships:-\\n1. Entity1: \""panoramic dental x-ray\"", Entity2: \""oral cavity cancers\"", Relationship: \""recommended for\""\\n2. Entity1: \""panoramic dental x-ray\"", Entity2: \""postoperative radiotherapy\"", Relationship: \""essential for pre-radiation evaluation\""\\n3. Entity1: \""pre-radiation dental evaluation\"", Entity2: \""dental procedures or extractions\"", Relationship: \""determine necessity of\""\\n\\nCausalities:-\\n<A> A panoramic dental x-ray is recommended </A> <C> for oral cavity cancers requiring mandibulotomy and/or mandibulectomy </C>. <CO> When postoperative radiotherapy (RT) is anticipated for areas like the lip, oral cavity subsites, or oropharynx </CO>, <A> panoramic x-ray is essential for a comprehensive pre-radiation dental evaluation </A> <E> to assess the health of affected teeth and determine if pre-radiation dental procedures or extractions are necessary </E>.\\n\\nSection Name: NCCN Guidelines Note\\n====================\\nEntities:-\\nNeoplasms : Neoplasms are abnormal growths of tissue, which can be cancerous or non-cancerous.\\nMalignant Neoplastic Disease : A disease characterized by uncontrolled, abnormal growth of cells that can invade or spread to other parts of the body.\\nCancer : A group of diseases involving abnormal cell growth with the potential to invade or spread to other parts of the body.\\nClinical Trials As Topic : Pre-planned studies of the safety, efficacy, or optimum dosage schedule of one or more diagnostic, therapeutic, or prophylactic drugs, devices, or techniques in humans selected according to predetermined criteria of eligibility and observed for predefined evidence of favorable and unfavorable effects.\\nClinical Trial : A research study that prospectively assigns human participants or groups of humans to one or more health-related interventions to evaluate the effects on health outcomes.\\n\\nRelationships:-\\n1. Entity1: \""NCCN\"", Entity2: \""Clinical Trials\"", Relationship: \""encourages participation in\""\\n2. Entity1: \""NCCN\"", Entity2: \""Cancer\"", Relationship: \""recommends clinical trials for\""\\n\\nCausalities:-\\n<A> NCCN believes that the best management of any patient with cancer is through participation in clinical trials </A>, <A> which is especially encouraged </A>.\\n'}""",valid,increases risk,2,B,"edge - The edge which needs to be verified.
explanation - Explanation of what the edge represents and its validity.
causal_direction - Either Positive or Negative or Unknown. A positive influence direction indicates that both factors change in the same direction (e.g. an increase causes an increase effect). A negative influence direction indicates the opposite changes (e.g. an increase causes a decrease effect).
causal_factor - Is necessary or sufficient condition for an effect to occur. Exposure is a term commonly used in epidemiology to denote any condition that is considered as a possible cause of disease. Exposure is considered necessary when it always precedes the effects (e.g. symptoms) and always presents when the effects occur. A sufficient cause is a causal factor whose presence or occurrence guarantees the occurrence of symptom.
causal_distance - Either Distal or Proximal or Unknown. The distal factors lie towards the beginning of causal chain (i.e. indirect causal factors). The the proximal factors lie towards the end of the chain (i.e. cause directly or almost directly the effect).

Causality Tags:
<A> for action, <C> for cause, <CO> for condition and <E> for effect.
Cause (C): The reason or origin that leads to an effect. Causes often involve disease conditions, risk factors, or underlying mechanisms.
Effect (E): The outcome or result of a cause. Effects usually represent clinical outcomes, complications, or results of a specific cause.
Condition (CO): The circumstance or prerequisite required for an action or effect to occur. Conditions may include patient characteristics, clinical scenarios, or specific diagnostic criteria.
Action (A): The recommended or described response or activity to address a cause or condition. Actions typically involve clinical interventions, diagnostic procedures, or treatment recommendations.


`NODE1`:
id: Histological_Grade_of_Tumor_4
label: Histological Grade of Tumor 4
description: This node represents the histological grade of a tumor, specifically grade 4, which is a classification based on the microscopic appearance of tumor cells. The histological grade is an important factor in determining the aggressiveness of the tumor and its potential response to treatment. Grade 4 typically indicates poorly differentiated or undifferentiated tumor cells, suggesting a more aggressive and potentially less favorable prognosis.
type: Patient Situation
observability: Unobserved
states: [{'state_name': 'present', 'state_description': ""The state 'present' indicates that the tumor has been assessed and classified as histological grade 4, meaning the tumor cells are poorly differentiated or undifferentiated, which is associated with a more aggressive behavior.""}, {'state_name': 'absent', 'state_description': ""The state 'absent' indicates that the tumor is not classified as histological grade 4, suggesting that the tumor cells are not poorly differentiated or undifferentiated, which may be associated with a less aggressive behavior.""}]

`NODE2`:
id: Biopsie_14
label: Biopsy in Patient Situation
description: This node represents the result of a biopsy in a specific patient situation. A biopsy is a medical procedure that involves taking a small sample of tissue for examination to diagnose a disease or condition. In this context, the node indicates whether a particular finding from the biopsy is present or absent.
type: Patient Situation
observability: Unobserved
states: [{'state_name': 'present', 'state_description': ""The 'present' state indicates that the biopsy has revealed the presence of a particular finding or condition in the patient.""}, {'state_name': 'absent', 'state_description': ""The 'absent' state indicates that the biopsy did not reveal the presence of the particular finding or condition in the patient.""}]

`EDGE1`:
{'edges_ids': ['Histological_Grade_of_Tumor_4', 'Biopsie_14'], 'edge': '(Histological_Grade_of_Tumor_4) causes (Biopsie_14)', 'explanation': ['The edge `(Histological_Grade_of_Tumor_4) causes (Biopsie_14)` suggests that the presence of a histological grade 4 tumor causes a particular biopsy finding to be present.', 'In reality, the biopsy is the procedure used to determine the histological grade of the tumor.', 'The histological grade is a classification based on the biopsy results, not a cause of the biopsy findings.', 'Therefore, the causal relationship as stated is not valid because the histological grade is determined by the biopsy, not the other way around.'], 'causal_direction': 'Unknown', 'causal_factor': {'necessary': False, 'sufficient': False}, 'causal_distance': 'Unknown'}

`EDGE2`:
{'edges_ids': ['Biopsie_14', 'Histological_Grade_of_Tumor_4'], 'edge': '(Biopsie_14) causes (Histological_Grade_of_Tumor_4)', 'explanation': ['The edge `(Biopsie_14) causes (Histological_Grade_of_Tumor_4)` is not valid because a biopsy is a diagnostic procedure that reveals the histological grade of a tumor, but it does not cause the tumor to be a certain grade.', 'The histological grade of a tumor is determined by the biological characteristics of the tumor cells, not by the biopsy procedure itself.', 'Therefore, the biopsy result does not cause the tumor to be grade 4; it merely identifies the grade.'], 'causal_direction': 'Unknown', 'causal_factor': {'necessary': False, 'sufficient': False}, 'causal_distance': 'Unknown'}

`INFORMATION FROM KNOWLEDGE BASE`:
--------------------------------------------------
Page Number: 49

Section Name: NCCN Guidelines Overview
====================
Entities:-
Clinical Trials As Topic : Works about research studies that evaluate the effectiveness and safety of medications or medical devices by monitoring their effects on large groups of people.
Neoplasms : New abnormal growth of tissue that possesses no physiological function and arises from uncontrolled usually rapid cellular proliferation.
Clinical Trial : A research study that prospectively assigns human participants or groups of humans to one or more health-related interventions to evaluate the effects on health outcomes.
Malignant Neoplastic Disease : A disease in which abnormal cells divide uncontrollably and destroy body tissue.
Nccn Guidelines : Clinical practice guidelines developed by the National Comprehensive Cancer Network to ensure that patients receive preventive, diagnostic, treatment, and supportive services that are most likely to lead to optimal outcomes.
National Comprehensive Cancer Network : An alliance of 31 cancer centers in the United States, dedicated to improving the quality, effectiveness, and efficiency of cancer care so that patients can live better lives.
Cancer : A group of diseases involving abnormal cell growth with the potential to invade or spread to other parts of the body.

Relationships:-
1. Entity1: ""NCCN Guidelines"", Entity2: ""National Comprehensive Cancer Network"", Relationship: ""published by""
2. Entity1: ""NCCN Guidelines"", Entity2: ""Clinical Trials"", Relationship: ""recommends""
3. Entity1: ""Clinical Trials"", Entity2: ""Cancer"", Relationship: ""management strategy for""

Causalities:-
<C> NCCN believes that the best management of any patient with cancer is in a clinical trial </C>. <A> Participation in clinical trials is especially encouraged </A>.

Section Name: SUPRA-1
====================
Entities:-
Tobacco Use Disorder : A disorder characterized by the continued use of tobacco despite significant related problems.
Tobacco Use : The act of using tobacco products.
Tobacco Smoking : The practice of burning tobacco and inhaling the smoke.
Alcohol Drinking : The consumption of beverages containing ethyl alcohol.
Alcohol Use : The act of consuming alcoholic beverages.
Alcohol Consumption : The act of drinking beverages containing ethanol.
Smoking Cessation : The process of discontinuing tobacco smoking.
Depression : A mood disorder characterized by a persistent feeling of sadness and loss of interest.
Depressive Disorder : A mental disorder characterized by persistent low mood and loss of interest.
Depression (Mood) : A state of low mood and aversion to activity.
Distress, Psychological : A state of emotional suffering associated with stressors and demands that are difficult to cope with in daily life.
Psychological Distress : A state of emotional suffering typically characterized by symptoms of depression and anxiety.
Psychological Stress : A feeling of strain and pressure.
Biopsy, Needle : The removal of tissue or cells with a needle for examination under a microscope.
Needle Biopsy : A procedure to extract tissue or fluid samples from the body using a needle.
Neck : The part of the body on many vertebrates that separates the head from the torso or trunk.
Neck Structure : Anatomical structure of the neck.
Biopsy : The removal and examination of tissue, cells, or fluids from the living body.
Core Biopsy : A biopsy procedure that uses a hollow needle to remove a core of tissue for examination.
Core Needle Biopsy : A procedure that uses a hollow needle to remove a sample of tissue for examination.
Genomics : An interdisciplinary field of biology focusing on the structure, function, evolution, mapping, and editing of genomes.
Genomic Testing : Testing that involves the analysis of the genome.

Relationships:-
1. Entity1: ""Tobacco use"", Entity2: ""Smoking cessation"", Relationship: ""advised to quit""
2. Entity1: ""Depression"", Entity2: ""Distress management"", Relationship: ""screening for""
3. Entity1: ""Image-guided needle biopsy"", Entity2: ""Cystic neck nodes"", Relationship: ""used for""
4. Entity1: ""Core biopsy"", Entity2: ""Immune-genomic testing"", Relationship: ""allows for""

Causalities:-
- <A> H&P should include documentation and quantification (pack years smoked) of tobacco use history, as well as alcohol use and counseling </A>. <A> All patients who currently smoke should be advised to quit smoking </A>, and <A> those who formerly smoked should be advised to remain abstinent from smoking </A>. <A> For additional cessation support, refer to the Patient/Provider Smoking Cessation and Treatment Resources in the [NCCN Guidelines for Smoking Cessation](#) </A>.
- <A> Screen for depression ([NCCN Guidelines for Distress Management](#)) </A>.
- <A> Image-guided (US or CT) needle biopsy of cystic neck nodes may offer better diagnostic yield than FNA by palpation alone for initial diagnosis in this setting </A>. <CO> For unresectable or metastatic disease where there is a plan for systemic therapy </CO>, <A> a core biopsy would allow for ancillary immune-genomic testing </A>.

Section Name: WORKUP
====================
Entities:-
Biopsy : The removal and examination of tissue, cells, or fluids from the living body.
Fine Needle Aspiration Biopsy : A type of biopsy procedure that uses a thin, hollow needle to extract cells or fluid from a lump or mass.
Computed Tomography : A medical imaging technique used in radiology to obtain detailed internal images of the body.
Positron-Emission Tomography : An imaging technique that uses radioactive substances to visualize and measure changes in metabolic processes.
Endoscopy : A procedure that uses an endoscope to examine the interior of a hollow organ or cavity of the body.
Laryngectomy : A surgical procedure to remove the larynx and separate the airway from the mouth, nose, and esophagus.

Relationships:-
1. Entity1: ""Biopsy"", Entity2: ""Primary tumor site"", Relationship: ""performed on""
2. Entity1: ""Fine needle aspiration biopsy"", Entity2: ""Cervical lymph nodes"", Relationship: ""samples""
3. Entity1: ""Computed tomography"", Entity2: ""Disease extent"", Relationship: ""assesses""
4. Entity1: ""Positron-Emission Tomography"", Entity2: ""Advanced imaging"", Relationship: ""considered for""
5. Entity1: ""Endoscopy"", Entity2: ""Examination"", Relationship: ""used for""
6. Entity1: ""Laryngectomy"", Entity2: ""Disease stage"", Relationship: ""required for""

Causalities:-
<A> The ""WORKUP"" section details the essential initial assessments and procedures that must be conducted. </A> <A> It begins with a comprehensive history and physical examination, emphasizing the need for an exhaustive evaluation of both the head and neck, including any necessary biopsies of the primary tumor site or fine-needle aspiration (FNA) of cervical lymph nodes. </A> <A> Additional imaging techniques, such as chest CT scans and contrast-enhanced imaging (CT or MRI), are recommended to assess the extent of the disease. </A> <A> The guideline suggests considering advanced imaging methods like FDG-PET/CT and endoscopic examinations when clinically indicated. </A>

<CO> Amenable to larynx-preserving (conservation) surgery (Most T1–2, N0; selected T3) </CO>
<A> Treatment of Primary and Neck (SUPRA-2) </A>
<A> H&P including a complete head and neck exam; mirror and/or fiberoptic examination as clinically indicated </A>
<A> Biopsy of primary site or FNA of the neck </A>
<A> Chest CT (with or without contrast) as clinically indicated </A>
<A> CT with contrast and thin angled cuts through larynx and/or MRI with and without contrast of primary and neck </A>
<A> Consider FDG-PET/CT </A>
<A> EUA with endoscopy </A>
<A> As clinically indicated: Preanesthesia studies, Consider PFTs for conservation surgery candidates, Consider videostrobe for select patients, Dental evaluation, Nutrition, speech and swallowing evaluation/therapy, Audiogram, Smoking cessation counseling, Fertility/reproductive counseling, Screening for hepatitis B </A>
<A> Multidisciplinary consultation as clinically indicated </A>

<CO> Requiring (amenable to) total laryngectomy (T3, N0) </CO>
<CO> T4a, N0 </CO>
<CO> Node-positive disease </CO>
<CO> T4b, N0–3 </CO>
<CO> or Unresectable nodal disease or Unfit for surgery </CO>
<CO> Metastatic (M1) disease at initial presentation </CO>
<A> Treatment of Primary and Neck (SUPRA-3) </A>
<A> Treatment of Primary and Neck (SUPRA-8) </A>
<A> Clinical Staging (SUPRA-4) </A>
<A> Treatment of Very Advanced Head and Neck Cancer (ADV-1) </A>
<A> Treatment of Very Advanced Head and Neck Cancer (ADV-2) </A>

Section Name: Principles
====================
Entities:-
Diagnostic Imaging : The production of diagnostic images, commonly through the use of X-rays, ultrasound, or magnetic resonance imaging (MRI).
Dental Examination : A clinical examination of the teeth and oral cavity.
Nutrition Therapy : The use of specific nutrition services to treat an illness, injury, or condition.
National Comprehensive Cancer Network : An alliance of 31 cancer centers in the United States, dedicated to improving the quality, effectiveness, and efficiency of cancer care so that patients can live better lives.

Relationships:-
1. Entity1: ""Principles of Imaging"", Entity2: ""Diagnostic Imaging"", Relationship: ""is related to""
2. Entity1: ""Principles of Dental Evaluation and Management"", Entity2: ""Dental Examination"", Relationship: ""is related to""
3. Entity1: ""Principles of Nutrition: Management and Supportive Care"", Entity2: ""Nutrition Therapy"", Relationship: ""is related to""
4. Entity1: ""NCCN Guidelines for Adolescent and Young Adult (AYA) Oncology"", Entity2: ""National Comprehensive Cancer Network"", Relationship: ""is related to""

Causalities:-
### Principles

- **Principles of Imaging (IMG-A)**
- **Principles of Dental Evaluation and Management (DENT-A)**
- **Principles of Nutrition: Management and Supportive Care (NUTR-A)**
- **See fertility and reproductive endocrine considerations in the [NCCN Guidelines for Adolescent and Young Adult (AYA) Oncology](#).**
--------------------------------------------------
Page Number: 97

Section Name: Head and Neck Cancers - Principles of Surgery
====================
Entities:-
Head And Neck Neoplasms : Tumors or cancer of the head and neck region, including the oral cavity, pharynx, larynx, nasal cavity, and salivary glands.
Biopsy : A procedure involving the removal of tissue from a living body for diagnostic examination.
Oncologist : A medical doctor who specializes in the diagnosis and treatment of cancer.
Tumor Staging : Methods used for the classification of neoplasms according to the extent of tumor spread.
Radiation Oncologist : A medical specialist who uses ionizing radiation in the treatment of cancer.
Dietitian : A health professional who has training in nutrition and diet planning.
Speech-Language Pathologist : A specialist who evaluates and treats patients with speech, language, voice, and fluency disorders.
Examination Under Anesthesia : A procedure where a patient is examined while under anesthesia to allow for a more thorough examination.
Multidisciplinary Team : A group of healthcare professionals from different specialties working together to manage patient care.

Relationships:-
1. Entity1: ""Head and Neck Surgical Oncologist"", Entity2: ""Patient Evaluation"", Relationship: ""performs""
2. Entity1: ""Tumor Staging"", Entity2: ""Imaging Studies"", Relationship: ""based on""
3. Entity1: ""Pre-treatment Evaluation"", Entity2: ""Medical Oncologist"", Relationship: ""involves""
4. Entity1: ""Multidisciplinary Team"", Entity2: ""Patient Treatment Options"", Relationship: ""discusses""

Causalities:-
<A> All patients should be evaluated by a head and neck surgical oncologist prior to treatment </A> to <A> review the adequacy of biopsy material, review staging and imaging </A> <C> to determine the extent of disease, exclude the presence of a synchronous primary tumor </C>, <E> assess current functional status, and evaluate for potential surgical options, including those applicable if initial non-surgical treatment is unsuccessful </E>.

<A> Pre-treatment evaluation </A> <CO> should include consultations with a medical oncologist, radiation oncologist, dentist or oral maxillofacial surgeon, speech-language pathologist, dietitian, and reconstructive surgeon as appropriate </CO>.

<A> Tumor staging for untreated patients </A> <CO> is essential based on review of the head and neck diagnostic imaging studies and chest imaging as appropriate </CO>.

<A> In addition to the office-based head and neck examination </A> to include fiberoptic nasopharyngolaryngoscopy, <A> EUA to assess the tumor extent and to obtain a biopsy </A> <CO> is indicated in the setting of metastatic carcinoma to the neck </CO>, <A> an EUA to search for the putative primary site </A> <E> is important for diagnosis and treatment planning </E>.

<A> Participate in the multidisciplinary team discussions </A> <E> regarding patient treatment options with the goal of maximizing survival with preservation of form and function </E>.

<A> Develop a prospective surveillance plan </A> that includes adequate dental, nutritional, and health behavioral evaluation and intervention and any other ancillary evaluations that would provide for <E> comprehensive rehabilitation </E>.

Section Name: Integration of Therapy
====================
Entities:-
Patient Care : The services rendered by members of the health profession and non-professionals under their supervision for the benefit of the patient.
Surgical Procedure : A procedure involving an incision with instruments; performed to repair damage or arrest disease in a living body.
Tumor : An abnormal growth of tissue resulting from uncontrolled, progressive multiplication of cells and serving no physiological function; a neoplasm.
Multidisciplinary Care Team : A team of healthcare professionals from different disciplines working together to manage the care of a patient.
Treatment Regimen : A plan for therapy that includes the dosage, schedule, and duration of treatment.
Shared Decision-Making : A process in which clinicians and patients work together to make decisions and select tests, treatments, and care plans based on clinical evidence that balances risks and expected outcomes with patient preferences and values.

Relationships:-
1. Entity1: ""Multidisciplinary Care Team"", Entity2: ""Patient Care"", Relationship: ""coordinates""
2. Entity1: ""Surgical procedure"", Entity2: ""Tumor"", Relationship: ""resects""
3. Entity1: ""Physician"", Entity2: ""Shared decision-making"", Relationship: ""engages in""

Causalities:-
- <C> It is critical that multidisciplinary evaluation and treatment be coordinated and integrated prospectively by all disciplines involved in patient care </C> <CO> before the initiation of any treatment </CO>.

- <CO> For patients undergoing an operation </CO>, <A> the surgical procedure, margins, and reconstructive plan should be developed and designed to resect all gross tumors with adequate tumor-free surgical margins </A>. <A> The surgical procedure should rarely be modified based on any response observed as a result of prior therapy </A> <CO> except in instances of tumor progression that mandate a more extensive procedure in order to encompass the tumor at the time of definitive resection </CO>.

- <CO> Once the multidisciplinary team has established a proposed treatment regimen </CO>, <A> the responsible physician and a member of the team should discuss the recommendations in detail with the patient to include the risks, benefits, and potential outcomes </A>. <A> The patient should be offered the opportunity to participate in the final decision (shared decision-making) </A>.

Section Name: Clinical Trials
====================
Entities:-
Clinical Trials : Pre-planned studies of the safety, efficacy, or optimum dosage schedule (if appropriate) of one or more diagnostic, therapeutic, or prophylactic drugs, devices, or techniques in humans selected according to predetermined criteria of eligibility and observed for predefined evidence of favorable and unfavorable effects.
Clinical Trial : A type of research that studies new tests and treatments and evaluates their effects on human health outcomes.
Neoplasms : New abnormal growth of tissue in animals or plants; a tumor. Neoplasms are also referred to as tumors, and they can be benign or malignant.
Malignant Neoplastic Disease : A disease characterized by uncontrolled, abnormal growth of cells that can invade and destroy nearby tissue and spread to other parts of the body.
Cancer : A group of diseases involving abnormal cell growth with the potential to invade or spread to other parts of the body.

Relationships:-
1. Entity1: ""NCCN"", Entity2: ""Clinical Trials"", Relationship: ""promotes""
2. Entity1: ""Clinical Trials"", Entity2: ""Cancer"", Relationship: ""manages""

Causalities:-
<C> any patient with cancer </C> <E> the best management </E> <A> is in a clinical trial </A>. <A> Participation in clinical trials is especially encouraged </A>.
--------------------------------------------------
Page Number: 51

Section Name: Introduction
====================
Entities:-
Laryngeal Neoplasms : Tumors or cancer of the larynx, which may affect the supraglottic, glottic, or subglottic regions.
Malignant Neoplasm Of Supraglottis : A malignant tumor located in the supraglottic region of the larynx.
Supraglottic Laryngeal Cancer : A type of cancer that occurs in the supraglottic region of the larynx, which is above the vocal cords.

Relationships:-
1. Entity1: ""National Comprehensive Cancer Network (NCCN)"", Entity2: ""cancer of the supraglottic larynx"", Relationship: ""provides guidelines for""
2. Entity1: ""healthcare professionals"", Entity2: ""cancer of the supraglottic larynx"", Relationship: ""manage""

Causalities:-
The provided image is a detailed flowchart from the National Comprehensive Cancer Network (NCCN) guidelines regarding the <C> clinical staging and treatment protocols for cancer of the supraglottic larynx </C>. This flowchart is structured to <A> guide healthcare professionals through the stages of treatment </A> based on <CO> clinical findings </CO>, emphasizing the <E> complexity and systematic approach required in managing this type of cancer </E>.

Section Name: Clinical Staging
====================
Entities:-
Laryngectomy : A surgical procedure involving the removal of the larynx, usually to treat cancer of the larynx.
Total Laryngectomy : A surgical procedure to remove the entire larynx, often used in the treatment of advanced laryngeal cancer.
Neoplasm Staging : Methods used for staging neoplasms, including clinical and pathological staging.
Cancer Staging : The process of determining the extent of cancer in the body, often using the TNM system.
Tnm Staging System : A cancer staging system that describes the extent of cancer using Tumor size (T), Node involvement (N), and Metastasis (M).

Relationships:-
1. Entity1: ""Clinical staging criteria"", Entity2: ""Total laryngectomy"", Relationship: ""determines necessity of""
2. Entity1: ""T3, N0"", Entity2: ""Clinical staging criteria"", Relationship: ""is a categorization of""

Causalities:-
The flowchart begins with the <C> clinical staging criteria </C>, specifically focusing on <CO> cases that require total laryngectomy, denoted as requiring (amenable to) total laryngectomy (T3, N0) </CO>. This <A> categorization </A> is crucial as it <E> forms the basis for determining the appropriate treatment strategy </E>.

Section Name: Treatment of Primary and Neck
====================
Entities:-
Neoplasm Staging : Methods used for staging neoplasms, including clinical and pathological staging.
Systemic Therapy : Treatment using substances that travel through the bloodstream, reaching and affecting cells all over the body.
Radiotherapy : The use of high-energy radiation from x-rays, gamma rays, neutrons, protons, and other sources to kill cancer cells and shrink tumors.
Laryngectomy : A surgical procedure involving the removal of the larynx, usually to treat cancer of the larynx.
Thyroidectomy : A surgical procedure to remove all or part of the thyroid gland.
Neck Dissection : Surgical procedure to remove lymph nodes and surrounding tissue to treat or prevent cancer spread.
Lymphatic Metastasis : Transfer of a neoplasm from one organ or part of the body to another remote from the primary site.

Relationships:-
1. Entity1: ""Systemic Therapy"", Entity2: ""Radiation Therapy"", Relationship: ""combined with""
2. Entity1: ""Laryngectomy"", Entity2: ""Lymph Node Involvement"", Relationship: ""considered based on""
3. Entity1: ""Thyroidectomy"", Entity2: ""Lymph Node Involvement"", Relationship: ""considered based on""
4. Entity1: ""Neck Dissection"", Entity2: ""Lymph Node Involvement"", Relationship: ""considered based on""

Causalities:-
<CO> Once clinical staging is established </CO>, the chart outlines various treatment options. <A> The initial step may involve either concurrent systemic therapy combined with radiation therapy (RT) or opting for RT alone </A>, <CO> especially if the patient is not a medical candidate for both therapies </CO>. <A> Laryngectomy, thyroidectomy, and neck dissection are considered </A> <CO> based on the extent of lymph node involvement </CO>.

Section Name: Surgical Options
====================
Entities:-
Laryngectomy : A surgical procedure involving the removal of the larynx, usually to treat cancer of the larynx.
Thyroidectomy : A surgical procedure to remove all or part of the thyroid gland.
Lymph Node Excision : Surgical removal of one or more lymph nodes.
Lymphadenectomy : Surgical removal of one or more groups of lymph nodes.
Surgical Procedures, Operative : Operations carried out for the correction of deformities and defects, repair of injuries, and diagnosis and cure of certain diseases.
Surgical Procedure : A medical procedure involving an incision with instruments; performed to repair damage or arrest disease in a living body.
Surgery : Medical specialty that uses operative manual and instrumental techniques on a patient to investigate or treat a pathological condition such as a disease or injury.

Relationships:-
1. Entity1: ""Laryngectomy"", Entity2: ""Thyroidectomy"", Relationship: ""combined with""
2. Entity1: ""Lymph Node Dissection"", Entity2: ""Surgical Intervention"", Relationship: ""extent of""
3. Entity1: ""Surgical Intervention"", Entity2: ""Advanced Cases"", Relationship: ""management option for""

Causalities:-
<CO> If concurrent therapies are not suitable </CO>, <A> the chart presents laryngectomy combined with thyroidectomy </A>, <CO> depending on the extent of lymph node dissection required </CO>. <E> This highlights surgical intervention as a viable option in the management of advanced cases </E>.

Section Name: Induction Chemotherapy
====================
Entities:-
Induction Chemotherapy : Initial chemotherapy treatment used to shrink a tumor before the main treatment, which is usually surgery.
Surgical Procedure : A medical procedure involving an incision with instruments; performed to repair damage or arrest disease in a living body.
Therapeutic Approach : A method or strategy used in the treatment of disease or injury.

Relationships:-
1. Entity1: ""Induction Chemotherapy"", Entity2: ""Surgical Intervention"", Relationship: ""alternative or sequential treatment option""

Causalities:-
<C> immediate surgical intervention is either not feasible or considered insufficient </C> <E> The flowchart also considers the option of induction chemotherapy </E> <CO> in cases where immediate surgical intervention is either not feasible or considered insufficient </CO>. <A> tailoring therapeutic approaches tailored to individual patient needs </A>.

Section Name: Adjuvant Treatment
====================
Entities:-
Adjuvant Chemotherapy : Chemotherapy given in addition to the primary treatment to maximize its effectiveness.
Radiotherapy : The use of high-energy radiation from x-rays, gamma rays, neutrons, protons, and other sources to kill cancer cells and shrink tumors.
Neoplasm Recurrence, Local : The return of a cancer, at the same site, after it has been treated.
Disease Progression : The worsening of a disease over time.

Relationships:-
1. Entity1: ""Primary Treatment"", Entity2: ""Adjuvant Treatment"", Relationship: ""followed by""
2. Entity1: ""Adjuvant Treatment"", Entity2: ""Systemic Therapy"", Relationship: ""includes""
3. Entity1: ""Adjuvant Treatment"", Entity2: ""Radiotherapy"", Relationship: ""includes""
4. Entity1: ""Follow-up Assessments"", Entity2: ""Treatment Efficacy"", Relationship: ""used to evaluate""

Causalities:-
<C> Following primary treatment </C>, <E> the flowchart addresses the potential for adjuvant treatment pathways </E>. This may include systemic therapy, RT, or further evaluations based on <CO> the patient's response and any recurrence or persistent disease </CO>. It emphasizes <A> the need for follow-up assessments to evaluate treatment efficacy </A>.

Section Name: Risk Features and Response Assessment
====================
Entities:-
Neoplasm Invasiveness : The property of a neoplasm to infiltrate and destroy surrounding tissue.
Surgical Margins : The edge or border of the tissue removed in cancer surgery.
Neoplasms : Neoplasms are abnormal growths of tissue, which can be cancerous or non-cancerous.
Extramural Extension : Extension of a tumor beyond the wall of an organ.
Positive Surgical Margin : Cancer cells are present at the edge of the tissue removed during surgery.
Cancer Management : The process of planning and coordinating the treatment of cancer.
Cancer : Cancer is a group of diseases involving abnormal cell growth with the potential to invade or spread to other parts of the body.

Relationships:-
1. Entity1: ""Extramural extension"", Entity2: ""Treatment decisions"", Relationship: ""influences""
2. Entity1: ""Positive surgical margin"", Entity2: ""Treatment decisions"", Relationship: ""influences""
3. Entity1: ""Ongoing assessment"", Entity2: ""Response evaluation"", Relationship: ""leads to""
4. Entity1: ""Response evaluation"", Entity2: ""Adjustments to treatment"", Relationship: ""leads to""
5. Entity1: ""Management of cancer"", Entity2: ""Treatment decisions"", Relationship: ""involves""
6. Entity1: ""Management of cancer"", Entity2: ""Ongoing assessment"", Relationship: ""involves""
7. Entity1: ""Management of cancer"", Entity2: ""Adjustments to treatment"", Relationship: ""involves""

Causalities:-
The chart incorporates a segment that takes into account <CO> adverse pathologic features, such as extramural extension or positive margins </CO>, <E> which could influence subsequent treatment decisions </E>. This highlights the importance of <A> ongoing assessment in the management of cancer, leading to response evaluation and adjustments to treatment as necessary </A>.

Section Name: NCCN Guidelines Version 4.2024
====================
Entities:-
Clinical Trials : Clinical trials are research studies performed in people that are aimed at evaluating a medical, surgical, or behavioral intervention.
Neoplasms : Neoplasms are abnormal growths of tissue, which can be cancerous or non-cancerous.
Clinical Trial : A clinical trial is a research study that prospectively assigns human participants or groups of humans to one or more health-related interventions to evaluate the effects on health outcomes.
Malignant Neoplasm : A malignant neoplasm is a cancerous growth that has the potential to invade and destroy nearby tissue and spread to other parts of the body.
National Comprehensive Cancer Network : The National Comprehensive Cancer Network (NCCN) is an alliance of 31 cancer centers in the United States, dedicated to improving the quality, effectiveness, and efficiency of cancer care.
Cancer : Cancer is a group of diseases involving abnormal cell growth with the potential to invade or spread to other parts of the body.

Relationships:-
1. Entity1: ""National Comprehensive Cancer Network"", Entity2: ""NCCN Guidelines"", Relationship: ""provides""
2. Entity1: ""NCCN Guidelines"", Entity2: ""Clinical Trials"", Relationship: ""recommend""
3. Entity1: ""NCCN Guidelines"", Entity2: ""Cancer"", Relationship: ""related to management of""

Causalities:-
<CO> any patient with cancer </CO> <A> the best management is in a clinical trial </A>. <A> Participation in clinical trials is especially encouraged </A>.

Section Name: SUPRA-3
====================
Entities:-
Laryngectomy : A surgical procedure involving the removal of the larynx, usually to treat cancer of the larynx.
Thyroidectomy : A surgical procedure to remove all or part of the thyroid gland.
Neck Dissection : Surgical procedure to remove lymph nodes and surrounding tissue to treat or prevent cancer spread.
Chemotherapy, Induction : Initial chemotherapy treatment to shrink a tumor before the main treatment.
Clinical Trials As Topic : Research studies that prospectively assign human participants or groups of humans to one or more health-related interventions to evaluate the effects on health outcomes.
Induction Chemotherapy : Initial chemotherapy treatment used to shrink a tumor before the main treatment, which is usually surgery.
Clinical Trial : A clinical trial is a research study that prospectively assigns human participants or groups of humans to one or more health-related interventions to evaluate the effects on health outcomes.

Relationships:-
1. Entity1: ""Total laryngectomy"", Entity2: ""Laryngectomy"", Relationship: ""is a type of""
2. Entity1: ""Systemic therapy"", Entity2: ""RT"", Relationship: ""concurrent treatment option""
3. Entity1: ""Induction chemotherapy"", Entity2: ""Other treatments"", Relationship: ""initial treatment option before""

Causalities:-
<CO> Requiring (amenable to) total laryngectomy (T3,N0) </CO>
  - <A> Concurrent systemic therapy/RT </A> or <A> RT if patient not medical candidate for concurrent systemic therapy/RT </A>
  - <A> Laryngectomy, thyroidectomy and with ipsilateral, central, or bilateral neck dissection </A>
  - or
  - <A> Induction chemotherapy </A>
  - or
  - <A> Clinical trials </A>

Section Name: Follow-up
====================
Entities:-
Follow-Up Studies : Studies in which individuals are followed over time to determine the outcome of exposures, treatments, or interventions.
Follow-Up Procedure : A procedure performed to monitor the progress of a patient's condition after initial treatment.
Follow-Up : Medical care given to a patient over time after initial treatment.
Disease Recurrence : The return of a sign, symptom, or disease after a remission.
Recurrent Disease : The reappearance of a disease after a period of improvement.

Relationships:-
1. Entity1: ""Follow-up"", Entity2: ""Recurrent or persistent disease"", Relationship: ""monitoring""

Causalities:-
- **Follow-up (FOLL-A, 1 of 2)**
  - <CO> Recurrent or persistent disease </CO> (ADV-3)

Section Name: Adverse Pathologic Features
====================
Entities:-
Radiotherapy : The use of high-energy radiation from x-rays, gamma rays, neutrons, protons, and other sources to kill cancer cells and shrink tumors.
Extranodal Extension : The spread of cancer beyond the lymph node capsule.
Positive Surgical Margin : Cancer cells are present at the edge of the tissue removed during surgery.
Systemic Therapy : Treatment using substances that travel through the bloodstream, reaching and affecting cells all over the body.

Relationships:-
1. Entity1: ""pN1"", Entity2: ""Radiotherapy"", Relationship: ""Consideration for treatment""
2. Entity1: ""Extranodal extension"", Entity2: ""Systemic Therapy"", Relationship: ""Treatment option""
3. Entity1: ""Extranodal extension"", Entity2: ""Radiotherapy"", Relationship: ""Treatment option""
4. Entity1: ""Positive surgical margin"", Entity2: ""Systemic Therapy"", Relationship: ""Treatment option""
5. Entity1: ""Positive surgical margin"", Entity2: ""Radiotherapy"", Relationship: ""Treatment option""

Causalities:-
- <CO>pN1 without other risk features</CO>
  - <C>Adverse pathologic features</C>
  - <A>Consider RT</A>
  - <CO>Extranodal extension and/or positive margin</CO>
  - <CO>Other risk features</CO>
  - <A>Systemic therapy/RT (category 1)</A>
  - <A>RT or Consider systemic therapy/RT</A>

Section Name: Response Assessment
====================
Entities:-
Response Evaluation : The process of assessing the response of a disease to treatment, often used in clinical trials to determine the effectiveness of a therapy.
Response To Treatment : A clinical finding indicating the response of a condition to a therapeutic intervention.

Relationships:-

Section Name: Principles of Surgery and Radiation Therapy
====================
Entities:-
Surgical Procedures, Operative : Operations carried out for the correction of deformities and defects, repair of injuries, and diagnosis and cure of certain diseases.
Surgical Procedure : A medical procedure involving an incision with instruments; performed to repair damage or arrest disease in a living body.
Surgery : Medical specialty that uses operative manual and instrumental techniques on a patient to investigate or treat a pathological condition such as a disease or injury.
Radiotherapy : The use of high-energy radiation from x-rays, gamma rays, neutrons, protons, and other sources to kill cancer cells and shrink tumors.
Radiation Therapy : Radiation therapy is a therapy using ionizing radiation, generally as part of cancer treatment to control or kill malignant cells.

Relationships:-
1. Entity1: ""Principles of Surgery"", Entity2: ""Principles of Radiation Therapy"", Relationship: ""complementary treatments""

Causalities:-
**Principles of Surgery (SURG-A).**

**Principles of Radiation Therapy (SUPRA-A).**

Section Name: Principles of Systemic Therapy
====================
Entities:-
Cisplatin : An inorganic and water-soluble platinum complex, cisplatin is an antineoplastic agent that is used in the treatment of various cancers.
Radiotherapy : The use of high-energy radiation from x-rays, gamma rays, neutrons, protons, and other sources to kill cancer cells and shrink tumors.
Radiation Therapy : Radiation therapy is a therapy using ionizing radiation, generally as part of cancer treatment to control or kill malignant cells.

Relationships:-
1. Entity1: ""Cisplatin"", Entity2: ""Systemic Therapy for Non-Nasopharyngeal Cancers"", Relationship: ""preferred agent""
2. Entity1: ""Cisplatin"", Entity2: ""Concurrent Systemic Therapy/RT"", Relationship: ""used in""

Causalities:-
<CO> When using concurrent systemic therapy/RT </CO>, <A> the preferred agent is cisplatin (category 1) </A>.
--------------------------------------------------
Page Number: 130

Section Name: Pathological N (pN)
====================
Entities:-
Lymph Nodes : Small, bean-shaped structures that are part of the body's lymphatic system. They filter lymph fluid and store white blood cells that help fight infection.
Neoplasm Metastasis : The transfer of a neoplasm from one organ or part of the body to another remote from the primary site.
Tnm Staging : A system used to describe the size and spread of cancer in a standardized way. T refers to the size of the tumor, N to the involvement of lymph nodes, and M to metastasis.
Lymph Node Structure : A structure that is part of the lymphatic system, involved in the immune response.
Metastasis : The spread of a cancer or other disease from one organ or part to another not directly connected with it.
Tnm Staging System : A cancer staging notation system that describes the extent of cancer in a patient's body.
Lymph Node : An organ of the lymphatic system and the adaptive immune system.

Relationships:-
1. Entity1: ""Lymph Nodes"", Entity2: ""Neoplasm Metastasis"", Relationship: ""involved in""
2. Entity1: ""TNM Staging"", Entity2: ""Lymph Nodes"", Relationship: ""includes""
3. Entity1: ""TNM Staging"", Entity2: ""Neoplasm Metastasis"", Relationship: ""describes""

Causalities:-
<CO> NX: Regional lymph nodes cannot be assessed </CO>
<CO> N0: No regional lymph node metastasis </CO>
<CO> N1: Metastasis in a single ipsilateral lymph node, 3 cm or smaller in greatest dimension ENE(–) </CO>
<CO> N2: Metastasis in a single ipsilateral lymph node, 3 cm or smaller in greatest dimension and ENE(+); or larger than 3 cm but not larger than 6 cm in greatest dimension and ENE(−); or metastases in multiple ipsilateral lymph nodes, none larger than 6 cm in greatest dimension and ENE(−); or in bilateral or contralateral lymph node(s), none larger than 6 cm in greatest dimension and ENE(−) </CO>
<CO> N2a: Metastasis in a single ipsilateral node, 3 cm or smaller in greatest dimension and ENE(+); or metastasis in a single ipsilateral node, larger than 3 cm but not larger than 6 cm in greatest dimension and ENE(−) </CO>
<CO> N2b: Metastases in multiple ipsilateral nodes, none larger than 6 cm in greatest dimension and ENE(−) </CO>
<CO> N2c: Metastases in bilateral or contralateral lymph node(s), none larger than 6 cm in greatest dimension and ENE(−) </CO>
<CO> N3: Metastasis in a lymph node, larger than 6 cm in greatest dimension and ENE(−); or metastasis in a single ipsilateral node, larger than 3 cm in greatest dimension and ENE(+); or multiple ipsilateral, contralateral, or bilateral lymph nodes and any with ENE(+); or a single contralateral node of any size and ENE(+) </CO>
<CO> N3a: Metastasis in a lymph node, larger than 6 cm in greatest dimension and ENE(−) </CO>
<CO> N3b: Metastasis in a single ipsilateral node, larger than 3 cm in greatest dimension and ENE(+); or multiple ipsilateral, contralateral, or bilateral lymph nodes any with ENE(+); or a single contralateral node of any size and ENE(+) </CO>
<CO> Note: A designation of “U” or “L” may be used for any N category to indicate metastasis above the lower border of the cricoid (U) or below the lower border of the cricoid (L). Similarly, clinical and pathological ENE should be recorded as ENE(−) or ENE(+). </CO>

Section Name: Distant Metastasis (M)
====================
Entities:-
Neoplasm Metastasis : The transfer of a neoplasm from one organ or part of the body to another remote from the primary site.
Metastasis : The spread of a cancer or other disease from one organ or part to another not directly connected with it.

Relationships:-
1. Entity1: ""M0"", Entity2: ""Distant Metastasis"", Relationship: ""is a category of""
2. Entity1: ""M1"", Entity2: ""Distant Metastasis"", Relationship: ""is a category of""

Causalities:-
### Distant Metastasis (M)

- **M0**: No distant metastasis
- **M1**: Distant metastasis

Section Name: Histologic Grade (G)
====================
Entities:-
Neoplasm Grading : A system of classifying cancer cells in terms of how abnormal they look under a microscope and how quickly the tumor is likely to grow and spread.
Histologic Grade : A measure of how much tumor cells differ from healthy cells, used to assess the aggressiveness of cancer.

Relationships:-
1. Entity1: ""GX"", Entity2: ""Grade cannot be assessed"", Relationship: ""is described as""
2. Entity1: ""G1"", Entity2: ""Well differentiated"", Relationship: ""is described as""
3. Entity1: ""G2"", Entity2: ""Moderately differentiated"", Relationship: ""is described as""
4. Entity1: ""G3"", Entity2: ""Poorly differentiated"", Relationship: ""is described as""

Causalities:-
<CO>GX</CO>: <E>Grade cannot be assessed</E>
<CO>G1</CO>: <E>Well differentiated</E>
<CO>G2</CO>: <E>Moderately differentiated</E>
<CO>G3</CO>: <E>Poorly differentiated</E>

Section Name: Prognostic Stage Groups
====================
Entities:-
Neoplasm Staging : Methods and systems of classifying neoplasms according to extent of disease.
Tumor Staging : A system for describing the size and spread of cancer within the body.
Tnm Staging System : A cancer staging notation system that describes the extent of cancer in a patient's body.

Relationships:-
1. Entity1: ""Stage 0"", Entity2: ""Tis N0 M0"", Relationship: ""defined by""
2. Entity1: ""Stage I"", Entity2: ""T1 N0 M0"", Relationship: ""defined by""
3. Entity1: ""Stage II"", Entity2: ""T2 N0 M0"", Relationship: ""defined by""
4. Entity1: ""Stage III"", Entity2: ""T3 N0 M0, T1 N1 M0, T2 N1 M0, T3 N1 M0"", Relationship: ""defined by""
5. Entity1: ""Stage IVA"", Entity2: ""T1 N2 M0, T2 N2 M0, T3 N2 M0, T4a N0,N1,N2 M0"", Relationship: ""defined by""
6. Entity1: ""Stage IVB"", Entity2: ""Any T N3 M0, T4b Any N M0"", Relationship: ""defined by""
7. Entity1: ""Stage IVC"", Entity2: ""Any T Any N M1"", Relationship: ""defined by""
--------------------------------------------------
Page Number: 93

Section Name: PRINCIPLES OF IMAGING
====================
Entities:-
Imaging, Diagnostic : The production of a visual representation of parts of the body, for the purpose of clinical analysis and medical intervention.
Head And Neck Neoplasms : Tumors or cancer of the head and neck region, including the nasal cavity, sinuses, lips, mouth, salivary glands, throat, or larynx.
Tomography, X-Ray Computed : An imaging procedure that uses special x-ray equipment to create detailed pictures, or scans, of areas inside the body.
Magnetic Resonance Imaging : A noninvasive diagnostic technique that uses magnetic fields and radio waves to produce a detailed image of the body's soft tissue and bones.
Contrast Media : Substances used to enhance the contrast of structures or fluids within the body in medical imaging.

Relationships:-
1. Entity1: ""Imaging, Diagnostic"", Entity2: ""Head and Neck Neoplasms"", Relationship: ""used for""
2. Entity1: ""Tomography, X-Ray Computed"", Entity2: ""Contrast Media"", Relationship: ""uses""
3. Entity1: ""Magnetic Resonance Imaging"", Entity2: ""Contrast Media"", Relationship: ""uses""

Causalities:-
<C> Imaging </C> plays an essential role in the clinical care of patients with head and neck cancer. <A> The proper selection and utilization of imaging studies </A> is critical in caring for patients with head and neck cancer. <A> CT is performed with contrast </A>, while <A> CT imaging of the chest can be performed with or without contrast </A>, <CO> as clinically indicated </CO>. <A> MRI is performed with and without contrast </A>, <CO> unless contraindicated </CO>.

Section Name: Initial Workup - Primary Site
====================
Entities:-
Tomography, X-Ray Computed : An imaging procedure that uses special x-ray equipment to create detailed pictures, or scans, of areas inside the body.
Magnetic Resonance Imaging : A noninvasive diagnostic technique that uses magnetic fields and radio waves to produce a detailed image of the body's soft tissue and bones.
Head And Neck Neoplasms : Tumors or cancer of the head and neck region, including the nasal cavity, sinuses, lips, mouth, salivary glands, throat, or larynx.
Neck Structure : The anatomical structure of the neck, which is the part of the body that connects the head to the torso.
Skull Base : The bottom part of the skull, which separates the brain from other facial structures.
Thoracic Inlet : The opening at the top of the thoracic cavity, through which pass the trachea, esophagus, and major blood vessels.

Relationships:-
1. Entity1: ""CT"", Entity2: ""MRI"", Relationship: ""complementary in imaging head and neck cancers""
2. Entity1: ""CT"", Entity2: ""Head and Neck Neoplasms"", Relationship: ""used to evaluate""
3. Entity1: ""MRI"", Entity2: ""Head and Neck Neoplasms"", Relationship: ""preferred for evaluating""
4. Entity1: ""Skull base"", Entity2: ""Thoracic inlet"", Relationship: ""imaging range for evaluation""

Causalities:-
<A>Imaging assessment of the primary site</A> can be performed with <A>CT of the soft tissues of the neck</A> or <A>MRI of the neck</A>. <C>CT is complementary to MRI for head and neck cancers</C>. <A>It is utilized to evaluate cortical bone erosion or periosteal invasion, cartilage invasion, and bony erosion or destruction</A>. <CO>in certain conditions, such as evaluating the extent of bone marrow invasion or in patients with extensive dental amalgam obscuring anatomy on CT, assessing skull base invasion and cranial nerve involvement, and differentiating tumor from obstructed sinuses</CO>, <A>MRI is preferred over CT</A>. <CO>when involved lymph nodes or upper mediastinal cancers are present</CO>, <A>Complete evaluation of primary and nodal disease requires imaging from the skull base to the thoracic inlet, extending to the carina</A>.

Section Name: PET/CT and Biopsy
====================
Entities:-
Positron Emission Tomography Computed Tomography : A medical imaging technique that combines PET and CT capabilities to provide detailed images of the body.
Examination Under Anesthesia : A procedure where a patient is examined while under anesthesia to allow for a more thorough examination.
Biopsy : A medical test involving the extraction of sample cells or tissues for examination to determine the presence or extent of a disease.
Tonsillectomy : A surgical procedure to remove the tonsils, often performed to treat recurrent tonsillitis or sleep apnea.
Fine Needle Aspiration : A type of biopsy procedure that uses a thin, hollow needle to extract cells from a lump or mass for examination.
Ultrasound : A medical imaging technique that uses high-frequency sound waves to visualize internal organs and structures.
Computed Tomography : A diagnostic imaging procedure that uses a combination of X-rays and computer technology to produce cross-sectional images of the body.

Relationships:-
1. Entity1: ""PET/CT"", Entity2: ""EUA"", Relationship: ""recommended before""
2. Entity1: ""Fine Needle Aspiration (FNA)"", Entity2: ""metastatic nodes"", Relationship: ""used for biopsy of""
3. Entity1: ""Image-guided needle biopsy"", Entity2: ""cystic neck nodes"", Relationship: ""recommended for initial diagnosis of""

Causalities:-
<CO> If imaging does not reveal an obvious primary cancer </CO>, <A> a PET/CT should be ordered before EUA, biopsies, and tonsillectomy </A>. <E> This helps identify potential primary sites </E> before any interventions take place. Additionally, <A> Fine Needle Aspiration (FNA) biopsy of metastatic nodes </A> <E> may provide pathologically informative results </E>. <CO> For initial diagnosis in cystic neck nodes </CO>, <A> image-guided needle biopsy (ultrasound or CT) </A> <E> may yield better results than FNA by palpation alone </E>.

Section Name: Postoperative Imaging Advice
====================
Entities:-
Panoramic Radiography : A type of dental x-ray that provides a wide view of the upper and lower jaws, teeth, temporomandibular joints, and sinuses.
Oral Cavity : The cavity of the mouth, including the lips, the lining inside the cheeks and lips, the front two-thirds of the tongue, the gums, the floor of the mouth under the tongue, the hard palate, and the small area of the gum behind the wisdom teeth.
Radiotherapy : The treatment of disease, especially cancer, using X-rays or similar forms of radiation.
Mandibulotomy : A surgical procedure involving the cutting of the mandible.
Mandibulectomy : A surgical procedure involving the removal of part or all of the mandible.
Oropharynx : The part of the throat at the back of the mouth behind the oral cavity.

Relationships:-
1. Entity1: ""panoramic dental x-ray"", Entity2: ""oral cavity cancers"", Relationship: ""recommended for""
2. Entity1: ""panoramic dental x-ray"", Entity2: ""postoperative radiotherapy"", Relationship: ""essential for pre-radiation evaluation""
3. Entity1: ""pre-radiation dental evaluation"", Entity2: ""dental procedures or extractions"", Relationship: ""determine necessity of""

Causalities:-
<A> A panoramic dental x-ray is recommended </A> <C> for oral cavity cancers requiring mandibulotomy and/or mandibulectomy </C>. <CO> When postoperative radiotherapy (RT) is anticipated for areas like the lip, oral cavity subsites, or oropharynx </CO>, <A> panoramic x-ray is essential for a comprehensive pre-radiation dental evaluation </A> <E> to assess the health of affected teeth and determine if pre-radiation dental procedures or extractions are necessary </E>.

Section Name: NCCN Guidelines Note
====================
Entities:-
Neoplasms : Neoplasms are abnormal growths of tissue, which can be cancerous or non-cancerous.
Malignant Neoplastic Disease : A disease characterized by uncontrolled, abnormal growth of cells that can invade or spread to other parts of the body.
Cancer : A group of diseases involving abnormal cell growth with the potential to invade or spread to other parts of the body.
Clinical Trials As Topic : Pre-planned studies of the safety, efficacy, or optimum dosage schedule of one or more diagnostic, therapeutic, or prophylactic drugs, devices, or techniques in humans selected according to predetermined criteria of eligibility and observed for predefined evidence of favorable and unfavorable effects.
Clinical Trial : A research study that prospectively assigns human participants or groups of humans to one or more health-related interventions to evaluate the effects on health outcomes.

Relationships:-
1. Entity1: ""NCCN"", Entity2: ""Clinical Trials"", Relationship: ""encourages participation in""
2. Entity1: ""NCCN"", Entity2: ""Cancer"", Relationship: ""recommends clinical trials for""

Causalities:-
<A> NCCN believes that the best management of any patient with cancer is through participation in clinical trials </A>, <A> which is especially encouraged </A>.


Among these two options which one is the most likely true:

(A) `Histological_Grade_of_Tumor_4` increases risk `Biopsie_14`
(B) `Biopsie_14` `increases risk `Histological_Grade_of_Tumor_4`

The answer is: ...

1. State the evidences in detail of the validity of option (A) or (B) by cross referencing
NCCN Clinical Practitioner’s Guidelines for Head and Neck Cancer.
2. If the evidences are obtained from `INFORMATION FROM KNOWLEDGE BASE`,
mention their corresponding Page Numbers, Section Name, entities, relationships and causalities.

DESIRED OUTPUT FORMAT:
<thinking>
...
</thinking>
<answer>
{
   ""thinking"": [""..."", ...],
   ""evidences"": [""..."", ...],
   ""answer"": ...
}
</answer>

Before providing the answer in <answer> tags, think step by step in detail in <thinking> tags and analyze every part.
Output inside <answer> tag in JSON format. Only output valid JSON.
DO NOT HALLUCINATE. DO NOT MAKE UP FACTUAL INFORMATION.
","1. The edge '(Histological_Grade_of_Tumor_4) causes (Biopsie_14)' suggests that the presence of a histological grade 4 tumor causes a particular biopsy finding to be present. However, the biopsy is the procedure used to determine the histological grade of the tumor, not the other way around.
2. The histological grade is a classification based on the biopsy results, not a cause of the biopsy findings. Therefore, the causal relationship as stated is not valid because the histological grade is determined by the biopsy, not the other way around.
3. The edge '(Biopsie_14) causes (Histological_Grade_of_Tumor_4)' is not valid because a biopsy is a diagnostic procedure that reveals the histological grade of a tumor, but it does not cause the tumor to be a certain grade.
4. The histological grade of a tumor is determined by the biological characteristics of the tumor cells, not by the biopsy procedure itself. Therefore, the biopsy result does not cause the tumor to be grade 4; it merely identifies the grade.
5. From the NCCN Guidelines, it is clear that the biopsy is a diagnostic tool used to determine the histological grade of a tumor, which is a classification based on the microscopic appearance of tumor cells. This is consistent with the explanation provided in the edge descriptions.
","1. Page Number: 49, Section Name: NCCN Guidelines Overview, Entities: Biopsy, Histological Grade, Relationships: Biopsy determines Histological Grade
2. Page Number: 97, Section Name: Head and Neck Cancers - Principles of Surgery, Entities: Biopsy, Tumor Staging, Relationships: Biopsy performed for Tumor Staging
",A,"{'A': 70.58, 'B': 29.42}",yes,A,"1. The AI assistant's reasoning is based on the understanding that a biopsy is a diagnostic tool used to determine the histological grade of a tumor. This is consistent with the explanation provided in the edge descriptions, where it is stated that the histological grade is determined by the biopsy results, not the other way around.
2. The assistant correctly identifies that the causal relationship described in EDGE1 and EDGE2 is not valid. The histological grade of a tumor is a classification based on the biopsy results, and the biopsy is the procedure used to determine this grade.
3. The assistant references the NCCN Guidelines, which support the understanding that a biopsy is used to determine the histological grade of a tumor. This aligns with the explanation that the biopsy does not cause the tumor to be a certain grade, but rather identifies the grade based on the biological characteristics of the tumor cells.
4. The assistant's final answer, option (A), is consistent with the reasoning provided. The explanation clearly states that the histological grade is determined by the biopsy, not the other way around, which supports the conclusion that option (A) is not valid.
"
